1	When	O
2	CSF	O
3	[	O
4	HCO3	O
5	-]	O
6	is	O
7	shown	O
8	as	O
9	a	O
10	function	O
11	of	O
12	CSF	O
13	PCO2	O
14	the	O
15	data	O
16	of	O
17	K	O
18	-	O
19	depleted	O
20	rats	O
21	are	O
22	no	O
23	longer	O
24	displaced	O
25	when	O
26	compared	O
27	to	O
28	controls	O
29	but	O
30	still	O
31	have	O
32	a	O
33	significantly	O
34	greater	O
35	slope	O
36	(	O
37	1	O
38	.	O
39	21	O
40	+/-	O
41	0	O
42	.	O
43	23	O
44	vs	O
45	.	O
1	Colorectal	O
2	polyps	O
3	should	O
4	be	O
5	removed	O
6	endoscopically	O
7	whenever	O
8	possible	O
9	.	O
1	By	O
2	contrast	O
3	,	O
4	secretory	B
5	HI	I
6	antibodies	I
7	were	O
8	not	O
9	demonstrated	O
10	at	O
11	the	O
12	onset	O
13	of	O
14	illness	O
15	in	O
16	any	O
17	of	O
18	the	O
19	patients	O
20	,	O
21	but	O
22	their	O
23	formation	O
24	started	O
25	early	O
26	and	O
27	the	O
28	antibodies	O
29	reached	O
30	maximal	O
31	levels	O
32	about	O
33	10	O
34	days	O
35	after	O
36	onset	O
37	of	O
38	illness	O
39	.	O
1	With	O
2	the	O
3	exception	O
4	of	O
5	virus	O
6	assay	O
7	and	O
8	quantitation	O
9	,	O
10	these	O
11	methods	O
12	are	O
13	simple	O
14	and	O
15	inexpensive	O
16	enough	O
17	to	O
18	be	O
19	done	O
20	in	O
21	typical	O
22	shellfish	O
23	microbiology	O
24	laboratories	O
25	.	O
1	Selective	O
2	stimulation	O
3	of	O
4	central	O
5	alpha	B
6	-	I
7	autoreceptors	I
8	following	O
9	treatment	O
10	with	O
11	alpha	O
12	-	O
13	methyldopa	O
14	and	O
15	FLA	O
16	136	O
17	.	O
1	Abstracts	O
2	.	O
1	Prenatal	O
2	diagnosis	O
3	of	O
4	galactosaemia	O
5	.	O
1	Serum	O
2	-	O
3	ferritin	B
4	in	O
5	diagnosis	O
6	of	O
7	haemochromatosis	O
8	.	O
1	Albumin	B
2	and	O
3	cyclic	O
4	AMP	O
5	levels	O
6	in	O
7	peritoneal	O
8	fluids	O
9	in	O
10	the	O
11	child	O
1	Thirty	O
2	-	O
3	five	O
4	strains	O
5	of	O
6	Legionnaires	O
7	'	O
8	disease	O
9	bacteria	O
10	were	O
11	shown	O
12	to	O
13	belong	O
14	in	O
15	four	O
16	distinct	O
17	serologic	O
18	groups	O
19	on	O
20	the	O
21	basis	O
22	of	O
23	findings	O
24	obtained	O
25	with	O
26	direct	O
27	fluorescent	O
28	antibody	O
29	testing	O
30	.	O
1	A	O
2	three	O
3	-	O
4	phased	O
5	analysis	O
6	of	O
7	treatment	O
8	plans	O
9	for	O
10	45	O
11	patients	O
12	was	O
13	undertaken	O
14	.	O
1	Several	O
2	demographic	O
3	indices	O
4	of	O
5	isolated	O
6	populations	O
7	in	O
8	Uzbekistan	O
1	The	O
2	Southern	O
3	technique	O
4	allowed	O
5	a	O
6	further	O
7	localization	O
8	of	O
9	the	O
10	region	O
11	of	O
12	most	O
13	extensive	O
14	transcription	O
15	to	O
16	a	O
17	1	O
18	.	O
19	8	O
20	kb	O
21	HindIII	B
22	-	O
23	EcoRI	B
24	fragment	O
25	.	O
1	Molecular	O
2	neurochemistry	O
3	of	O
4	addictive	O
5	drugs	O
6	.	O
1	Efforts	O
2	were	O
3	made	O
4	to	O
5	determine	O
6	the	O
7	amount	O
8	of	O
9	time	O
10	required	O
11	for	O
12	kidney	O
13	lesions	O
14	to	O
15	develop	O
16	and	O
17	,	O
18	if	O
19	possible	O
20	,	O
21	to	O
22	delineate	O
23	the	O
24	potential	O
25	site	O
26	of	O
27	action	O
28	of	O
29	PBB	O
30	.	O
1	Effect	O
2	of	O
3	succimer	O
4	on	O
5	the	O
6	intensity	O
7	of	O
8	tricarboxylic	B
9	acid	I
10	dehydrogenase	I
11	reactions	O
12	in	O
13	the	O
14	brain	O
15	of	O
16	rats	O
17	poisoned	O
18	with	O
19	mercuric	O
20	chloride	O
1	Distribution	O
2	and	O
3	correlations	O
4	of	O
5	serum	O
6	uric	O
7	-	O
8	acid	O
9	in	O
10	two	O
11	French	O
12	adult	O
13	populations	O
14	:	O
15	13	O
16	,	O
17	885	O
18	men	O
19	and	O
20	6	O
21	,	O
22	861	O
23	women	O
1	Technetium	O
2	-	O
3	99m	O
4	stannous	O
5	pyrophosphate	O
6	myocardial	O
7	scintigrams	O
8	were	O
9	obtained	O
10	in	O
11	138	O
12	clinically	O
13	stable	O
14	patients	O
15	32	O
16	.	O
17	7	O
18	+/-	O
19	47	O
20	.	O
21	3	O
22	weeks	O
23	(	O
24	range	O
25	6	O
26	to	O
27	260	O
28	)	O
29	after	O
30	acute	O
31	myocardial	O
32	infarction	O
33	.	O
1	A	O
2	gas	O
3	-	O
4	liquid	O
5	chromatographic	O
6	method	O
7	for	O
8	the	O
9	determination	O
10	of	O
11	p	O
12	-	O
13	chlorophenoxyisobutyric	O
14	(	O
15	CPIB	O
16	)	O
17	acid	O
18	in	O
19	blood	O
20	plasma	O
21	is	O
22	described	O
23	.	O
1	V	O
2	.	O
1	In	O
2	patients	O
3	who	O
4	were	O
5	not	O
6	vented	O
7	,	O
8	there	O
9	was	O
10	overall	O
11	significant	O
12	depression	O
13	of	O
14	function	O
15	(	O
16	67	O
17	+/-	O
18	5	O
19	%	O
20	of	O
21	control	O
22	;	O
23	range	O
24	,	O
25	91	O
26	--	O
27	45	O
28	%,	O
29	p	O
30	less	O
31	than	O
32	0	O
33	.	O
34	01	O
35	).	O
1	A	O
2	total	O
3	of	O
4	26	O
5	BCG	O
6	strains	O
7	,	O
8	out	O
9	of	O
10	them	O
11	10	O
12	Czechoslovak	O
13	strains	O
14	(	O
15	2	O
16	lyophilized	O
17	cultures	O
18	of	O
19	BCG	O
20	of	O
21	different	O
22	batch	O
23	,	O
24	6	O
25	strains	O
26	isolated	O
27	from	O
28	abscesses	O
29	of	O
30	children	O
31	after	O
32	BCG	O
33	-	O
34	vaccination	O
35	and	O
36	2	O
37	strains	O
38	from	O
39	fatal	O
40	cases	O
41	after	O
42	BCG	O
43	-	O
44	vaccination	O
45	)	O
46	and	O
47	16	O
48	strains	O
49	obtained	O
50	from	O
51	foreign	O
52	laboratories	O
53	,	O
54	were	O
55	used	O
56	.	O
1	255	O
2	-	O
3	61	O
4	.	O
1	Most	O
2	of	O
3	the	O
4	phenomena	O
5	of	O
6	azotaemic	O
7	osteodystrophy	O
8	are	O
9	encountered	O
10	in	O
11	simple	O
12	vitamin	O
13	D	O
14	deficiency	O
15	;	O
16	as	O
17	in	O
18	that	O
19	condition	O
20	,	O
21	deficiency	O
22	of	O
23	1	O
24	,	O
25	25	O
26	-	O
27	dihydroxycholecalciferol	O
28	may	O
29	be	O
30	of	O
31	primary	O
32	significance	O
33	in	O
34	causing	O
35	secondary	O
36	hyperparathyroidism	O
37	in	O
38	renal	O
39	failure	O
40	.	O
1	Renin	B
2	studies	O
3	performed	O
4	in	O
5	34	O
6	hypertensive	O
7	patients	O
8	and	O
9	in	O
10	a	O
11	control	O
12	group	O
13	of	O
14	11	O
15	recipients	O
16	showed	O
17	that	O
18	elevation	O
19	of	O
20	plasma	B
21	renin	I
22	activity	O
23	and	O
24	of	O
25	plasma	O
26	aldosterone	O
27	level	O
28	is	O
29	frequent	O
30	but	O
31	difficult	O
32	to	O
33	interpret	O
34	,	O
35	particularly	O
36	when	O
37	a	O
38	renal	O
39	artery	O
40	stenosis	O
41	is	O
42	observed	O
43	.	O
1	202	O
2	-	O
3	8	O
4	.	O
1	Neomycin	O
2	is	O
3	fairly	O
4	effective	O
5	against	O
6	staphylococci	O
7	,	O
8	less	O
9	effective	O
10	against	O
11	streptococci	O
12	,	O
13	and	O
14	fairly	O
15	effective	O
16	against	O
17	gram	O
18	-	O
19	negative	O
20	intestinal	O
21	organisms	O
22	.	O
1	40	O
2	patients	O
3	with	O
4	chronic	O
5	osteomyelitis	O
6	were	O
7	treated	O
8	per	O
9	os	O
10	with	O
11	the	O
12	bactericidal	O
13	beta	O
14	-	O
15	lactam	O
16	-	O
17	antibiotic	O
18	cephalexin	O
19	during	O
20	3	O
21	to	O
22	60	O
23	weeks	O
24	.	O
1	Ultimate	O
2	strengthes	O
3	seem	O
4	to	O
5	be	O
6	reached	O
7	for	O
8	cast	O
9	cobalt	O
10	alloys	O
11	,	O
12	whereas	O
13	titanium	O
14	alloys	O
15	,	O
16	such	O
17	as	O
18	Ta	O
19	6	O
20	V	O
21	,	O
22	present	O
23	very	O
24	high	O
25	fatigue	O
26	limit	O
27	under	O
28	corrosion	O
29	.	O
1	In	O
2	the	O
3	8	O
4	patients	O
5	the	O
6	difference	O
7	betweent	O
8	he	O
9	mean	O
10	diastolic	O
11	values	O
12	of	O
13	delta	O
14	PU	O
15	and	O
16	delta	O
17	PM	O
18	was	O
19	-	O
20	0	O
21	.	O
22	54	O
23	+/-	O
24	1	O
25	.	O
26	0	O
27	(	O
28	SD	O
29	)	O
30	mmHg	O
31	.	O
1	A	O
2	rise	O
3	of	O
4	hemoglobin	B
5	concentration	O
6	accompanied	O
7	by	O
8	an	O
9	increase	O
10	of	O
11	the	O
12	total	O
13	iron	O
14	in	O
15	the	O
16	blood	O
17	serum	O
18	of	O
19	white	O
20	mice	O
21	was	O
22	found	O
23	under	O
24	oxygen	O
25	pressure	O
26	of	O
27	4	O
28	atm	O
29	for	O
30	an	O
31	hour	O
32	(	O
33	preconvulsive	O
34	state	O
35	)	O
36	and	O
37	6	O
38	atm	O
39	(	O
40	convulsive	O
41	state	O
42	).	O
1	Nernst	O
2	--	O
3	Planck	O
4	analog	O
5	equations	O
6	and	O
7	stationary	O
8	state	O
9	membrane	O
10	electric	O
11	potentials	O
12	.	O
1	Effect	O
2	of	O
3	intraventricular	O
4	administration	O
5	of	O
6	streptolysin	B
7	O	I
8	on	O
9	the	O
10	electroencephalogram	O
11	of	O
12	rabbits	O
13	.	O
1	These	O
2	data	O
3	confirm	O
4	the	O
5	existence	O
6	of	O
7	hyperlipemic	O
8	abdominal	O
9	crisis	O
10	as	O
11	a	O
12	distinct	O
13	entity	O
14	and	O
15	testify	O
16	to	O
17	the	O
18	importance	O
19	of	O
20	recognizing	O
21	this	O
22	syndrome	O
23	in	O
24	order	O
25	to	O
26	avoid	O
27	the	O
28	occurrence	O
29	of	O
30	acute	O
31	pancreatitis	O
32	and	O
33	the	O
34	performance	O
35	of	O
36	unnecessary	O
37	and	O
38	potentially	O
39	harmful	O
40	surgery	O
41	.	O
1	It	O
2	has	O
3	come	O
4	out	O
5	that	O
6	CAEC	O
7	is	O
8	between	O
9	CC	O
10	and	O
11	CIEC	O
12	and	O
13	that	O
14	attacks	O
15	of	O
16	biliary	O
17	fever	O
18	and	O
19	high	O
20	levels	O
21	of	O
22	alkaline	B
23	phosphatase	I
24	and	O
25	transaminases	O
26	in	O
27	the	O
28	serum	O
29	are	O
30	the	O
31	helpful	O
32	findings	O
33	for	O
34	preoperative	O
35	diagnosis	O
36	.	O
1	All	O
2	13	O
3	patients	O
4	showed	O
5	endoscopic	O
6	evidence	O
7	of	O
8	oesophagitis	O
9	,	O
10	moderate	O
11	in	O
12	4	O
13	and	O
14	severe	O
15	in	O
16	9	O
17	.	O
1	Both	O
2	reduced	O
3	spontaneous	O
4	locomotor	O
5	activity	O
6	in	O
7	mice	O
8	,	O
9	protected	O
10	them	O
11	from	O
12	death	O
13	from	O
14	amphetamine	O
15	induced	O
16	toxicity	O
17	,	O
18	prolonged	O
19	hexobarbitone	O
20	sleeping	O
21	time	O
22	and	O
23	caused	O
24	a	O
25	depletion	O
26	of	O
27	catecholamines	O
28	from	O
29	various	O
30	organs	O
31	of	O
32	the	O
33	rat	O
34	.	O
1	With	O
2	certain	O
3	exceptions	O
4	the	O
5	method	O
6	was	O
7	considered	O
8	suitable	O
9	in	O
10	the	O
11	routine	O
12	intravenous	O
13	cholangiography	O
14	.	O
1	The	O
2	six	O
3	commonest	O
4	causes	O
5	of	O
6	death	O
7	varied	O
8	in	O
9	the	O
10	three	O
11	ethnic	O
12	groups	O
13	.	O
1	Of	O
2	the	O
3	compounds	O
4	tested	O
5	,	O
6	alpha	O
7	-(	O
8	3	O
9	-	O
10	methyl	O
11	-	O
12	2	O
13	-	O
14	quinoxalinyl	O
15	)-	O
16	N	O
17	-	O
18	methylnitrone	O
19	1	O
20	,	O
21	4	O
22	-	O
23	dioxide	O
24	(	O
25	2	O
26	)	O
27	was	O
28	the	O
29	most	O
30	active	O
31	agent	O
32	in	O
33	vivo	O
34	against	O
35	the	O
36	gram	O
37	-	O
38	negative	O
39	and	O
40	the	O
41	gram	O
42	-	O
43	positive	O
44	organisms	O
45	.	O
1	Changes	O
2	in	O
3	ionic	O
4	content	O
5	of	O
6	the	O
7	mucous	O
8	suggest	O
9	that	O
10	cholinergic	O
11	mechanisms	O
12	affect	O
13	pressure	O
14	in	O
15	the	O
16	excretory	O
17	duct	O
18	of	O
19	the	O
20	gland	O
21	.	O
1	Although	O
2	it	O
3	has	O
4	been	O
5	shown	O
6	that	O
7	it	O
8	is	O
9	possible	O
10	to	O
11	use	O
12	orally	O
13	administered	O
14	testosterone	O
15	to	O
16	maintain	O
17	se	O
18	-	O
19	T	O
20	levels	O
21	in	O
22	the	O
23	normal	O
24	male	O
25	range	O
26	,	O
27	the	O
28	convenience	O
29	to	O
30	the	O
31	patient	O
32	must	O
33	be	O
34	balanced	O
35	against	O
36	the	O
37	cost	O
38	and	O
39	possible	O
40	side	O
41	effects	O
42	of	O
43	the	O
44	large	O
45	doses	O
46	required	O
47	.	O
1	One	O
2	-	O
3	third	O
4	of	O
5	the	O
6	men	O
7	with	O
8	azoospermia	O
9	and	O
10	with	O
11	sperm	O
12	density	O
13	of	O
14	less	O
15	than	O
16	10	O
17	million	O
18	had	O
19	marked	O
20	FSH	B
21	elevation	O
22	and	O
23	our	O
24	experience	O
25	confirms	O
26	the	O
27	work	O
28	of	O
29	others	O
30	that	O
31	this	O
32	indicates	O
33	a	O
34	poor	O
35	prognosis	O
36	.	O
1	2	O
2	cases	O
3	of	O
4	toxic	O
5	lymphomononucleosis	O
1	Experimental	O
2	ischemic	O
3	heart	O
4	disease	O
5	induced	O
6	by	O
7	thromboxane	O
8	A2	O
9	in	O
10	rabbits	O
11	.	O
1	This	O
2	implies	O
3	that	O
4	the	O
5	groups	O
6	do	O
7	not	O
8	just	O
9	differ	O
10	along	O
11	one	O
12	dimension	O
13	,	O
14	but	O
15	along	O
16	three	O
17	dimensions	O
18	.	O
1	These	O
2	show	O
3	that	O
4	the	O
5	collagen	B
6	in	O
7	this	O
8	tissue	O
9	is	O
10	modified	O
11	compared	O
12	with	O
13	that	O
14	in	O
15	tendon	O
16	.	O
1	The	O
2	malignity	O
3	of	O
4	nevoid	O
5	lentigo	O
6	.	O
1	Internally	O
2	oriented	O
3	patients	O
4	'	O
5	scores	O
6	on	O
7	Rotter	O
8	'	O
9	s	O
10	Internal	O
11	-	O
12	External	O
13	Locus	O
14	of	O
15	Control	O
16	Scale	O
17	remained	O
18	the	O
19	same	O
20	over	O
21	treatment	O
22	but	O
23	those	O
24	of	O
25	externally	O
26	oriented	O
27	patients	O
28	shifted	O
29	toward	O
30	greater	O
31	internal	O
32	control	O
33	.	O
1	Potency	O
2	of	O
3	enflurane	O
4	in	O
5	dogs	O
6	:	O
7	comparison	O
8	with	O
9	halothane	O
10	and	O
11	isoflurane	O
12	.	O
1	Radionuclide	O
2	angiography	O
3	and	O
4	static	O
5	whole	O
6	body	O
7	imaging	O
8	performed	O
9	with	O
10	technetium	O
11	-	O
12	99m	O
13	-	O
14	labeled	O
15	particulates	O
16	can	O
17	clearly	O
18	demonstrate	O
19	differential	O
20	shunting	O
21	in	O
22	patients	O
23	with	O
24	patent	O
25	ductus	O
26	arteriosus	O
27	(	O
28	PDA	O
29	)	O
30	with	O
31	Eisenmenger	O
32	physiology	O
33	.	O
1	Silicosis	O
2	mortality	O
1	Thromboplastic	O
2	and	O
3	fibrynolytic	O
4	activity	O
5	of	O
6	the	O
7	blood	O
8	after	O
9	administration	O
10	of	O
11	intralipid	O
12	in	O
13	men	O
14	with	O
15	history	O
16	of	O
17	myocardial	O
18	infarction	O
19	up	O
20	to	O
21	45	O
22	year	O
23	of	O
24	life	O
1	Synovial	O
2	cysts	O
3	of	O
4	the	O
5	hip	O
6	joint	O
1	Effect	O
2	of	O
3	time	O
4	and	O
5	dose	O
6	on	O
7	alterations	O
8	following	O
9	inhalation	O
10	of	O
11	plutonium	O
12	-	O
13	239	O
14	dioxide	O
15	aerosol	O
16	in	O
17	rat	O
18	.	O
1	Thyroid	O
2	disease	O
3	and	O
4	pregnancy	O
5	.	O
1	Residues	O
2	removed	O
3	from	O
4	transcripts	O
5	by	O
6	splicing	O
7	were	O
8	identified	O
9	.	O
1	Two	O
2	out	O
3	of	O
4	five	O
5	patients	O
6	undergoing	O
7	selective	O
8	spinal	O
9	arteriography	O
10	developed	O
11	transient	O
12	neurological	O
13	complications	O
14	during	O
15	the	O
16	injection	O
17	of	O
18	Urografin	O
19	310	O
20	M	O
21	.	O
1	A	O
2	--	O
3	A	O
4	natural	O
5	hydrostatic	O
6	phenomenon	O
7	,	O
8	at	O
9	the	O
10	level	O
11	of	O
12	the	O
13	ends	O
14	of	O
15	the	O
16	plantar	O
17	arcs	O
18	,	O
19	diffuses	O
20	body	O
21	weight	O
22	,	O
23	as	O
24	PAIN	O
25	plays	O
26	the	O
27	role	O
28	of	O
29	outsentry	O
30	(	O
31	fig	O
32	.--	O
33	1	O
34	)	O
35	(	O
36	5	O
37	);	O
38	B	O
39	--	O
40	Plantar	O
41	perforating	O
42	ulceration	O
43	(	O
44	PPU	O
45	)	O
46	is	O
47	caused	O
48	by	O
49	a	O
50	combination	O
51	of	O
52	INSENSITIVITY	O
53	and	O
54	TRAUMATIS	O
55	(	O
56	1	O
57	);	O
58	C	O
59	--	O
60	The	O
61	patient	O
62	reposing	O
63	,	O
64	as	O
65	body	O
66	weight	O
67	(	O
68	traumatism	O
69	)	O
70	effects	O
71	disappear	O
72	,	O
73	cicatrization	O
74	process	O
75	can	O
76	be	O
77	easily	O
78	observed	O
79	;	O
80	D	O
81	--	O
82	PNEUMATIC	O
83	INSOLE	O
84	,	O
85	being	O
86	elastic	O
87	,	O
88	diffuses	O
89	localized	O
90	compression	O
91	at	O
92	the	O
93	ends	O
94	of	O
95	the	O
96	plantar	O
97	arcs	O
98	,	O
99	reduces	O
100	attrition	O
101	,	O
102	makes	O
103	easier	O
104	blood	O
105	circulation	O
106	,	O
107	as	O
108	well	O
109	as	O
110	cure	O
111	and	O
112	prophylaxis	O
113	of	O
114	PPU	O
115	(	O
116	fig	O
117	.--	O
118	6	O
119	)	O
120	(	O
121	3	O
122	).	O
1	Dietetics	O
2	of	O
3	childhood	O
4	-	O
5	and	O
6	juvenile	O
7	diabetes	O
1	Avian	O
2	reproductive	O
3	system	O
4	:	O
5	daily	O
6	variations	O
7	in	O
8	responses	O
9	to	O
10	hormones	O
11	.	O
1	Biological	O
2	properties	O
3	of	O
4	sumithion	O
5	.	O
1	Dialyzable	O
2	transfer	B
3	factor	I
4	.	O
1	Up	O
2	to	O
3	now	O
4	the	O
5	number	O
6	of	O
7	patients	O
8	examined	O
9	is	O
10	about	O
11	300	O
12	,	O
13	additionally	O
14	6	O
15	persons	O
16	who	O
17	underwent	O
18	binephrectomy	O
19	.	O
1	The	O
2	responsiveness	O
3	of	O
4	visual	O
5	cortex	O
6	(	O
7	VC	O
8	)	O
9	and	O
10	superior	O
11	colliculus	O
12	(	O
13	SC	O
14	)	O
15	was	O
16	simultaneously	O
17	compared	O
18	following	O
19	conditioning	O
20	""""	O
21	ON	O
22	""""	O
23	or	O
24	""""	O
25	OFF	O
26	""""	O
27	stimulation	O
28	,	O
29	in	O
30	the	O
31	rabbit	O
32	.	O
1	The	O
2	background	O
3	processes	O
4	depending	O
5	on	O
6	the	O
7	etiological	O
8	factor	O
9	and	O
10	the	O
11	character	O
12	of	O
13	lesion	O
14	of	O
15	the	O
16	epithelium	O
17	are	O
18	divided	O
19	into	O
20	dyshormonal	O
21	,	O
22	inflammatory	O
23	,	O
24	and	O
25	posttraumatic	O
26	.	O
1	A	O
2	follow	O
3	-	O
4	up	O
5	study	O
6	of	O
7	22	O
8	patients	O
9	with	O
10	Ebstein	O
11	'	O
12	s	O
13	anomaly	O
14	has	O
15	been	O
16	performed	O
17	.	O
1	Deaths	O
2	stopped	O
3	11	O
4	hours	O
5	after	O
6	copper	O
7	concentrations	O
8	decreased	O
9	below	O
10	0	O
11	.	O
12	2	O
13	ppm	O
14	and	O
15	signs	O
16	of	O
17	distress	O
18	stopped	O
19	in	O
20	surviving	O
21	pinfish	O
22	by	O
23	approximately	O
24	6	O
25	hours	O
26	after	O
27	the	O
28	last	O
29	death	O
30	.	O
1	Amikacin	O
2	was	O
3	used	O
4	in	O
5	the	O
6	treatment	O
7	of	O
8	56	O
9	serious	O
10	gram	O
11	-	O
12	negative	O
13	infections	O
14	in	O
15	54	O
16	patients	O
17	of	O
18	whom	O
19	47	O
20	survived	O
21	.	O
1	Estimation	O
2	of	O
3	L	O
4	-	O
5	alanine	O
6	in	O
7	serum	O
8	or	O
9	plasma	O
10	using	O
11	the	O
12	LKB	O
13	reaction	O
14	rate	O
15	analyser	O
16	.	O
1	The	O
2	morphological	O
3	effects	O
4	of	O
5	two	O
6	snake	O
7	venoms	O
8	,	O
9	N	O
10	.	O
11	naja	O
12	and	O
13	A	O
14	.	O
15	piscivorus	O
16	,	O
17	and	O
18	of	O
19	the	O
20	Direct	B
21	Lytic	I
22	Factor	I
23	and	O
24	Phospholipase	B
25	-	I
26	A	I
27	,	O
28	compounds	O
29	purified	O
30	from	O
31	N	O
32	.	O
33	naja	O
34	crude	O
35	venom	O
36	,	O
37	were	O
38	investigated	O
39	on	O
40	lung	O
41	and	O
42	cremaster	O
43	vessels	O
44	of	O
45	rats	O
46	.	O
1	The	O
2	sera	O
3	and	O
4	nasal	O
5	secretions	O
6	of	O
7	142	O
8	patients	O
9	,	O
10	who	O
11	were	O
12	positive	O
13	in	O
14	HD	O
15	or	O
16	mites	O
17	skin	O
18	test	O
19	,	O
20	were	O
21	subjected	O
22	to	O
23	a	O
24	radioallergosorbent	O
25	test	O
26	(	O
27	RAST	O
28	)	O
29	for	O
30	estimating	O
31	the	O
32	specific	O
33	IgE	B
34	antibody	I
35	activity	O
36	to	O
37	mites	O
38	.	O
1	Does	O
2	afferent	O
3	loop	O
4	syndrome	O
5	exist	O
6	?]	O
7	It	O
8	is	O
9	the	O
10	author	O
11	'	O
12	s	O
13	opinion	O
14	that	O
15	diagnosis	O
16	of	O
17	the	O
18	""""	O
19	adducent	O
20	loop	O
21	syndrome	O
22	""""	O
23	is	O
24	unlikely	O
25	to	O
26	be	O
27	correct	O
28	in	O
29	patients	O
30	subjected	O
31	to	O
32	Billroth	O
33	-	O
34	II	O
35	gastrectomy	O
36	.	O
1	Batch	O
2	cultures	O
3	of	O
4	S	O
5	.	O
6	mutans	O
7	serotype	O
8	a	O
9	demonstrated	O
10	no	O
11	growth	O
12	on	O
13	MSB	O
14	agar	O
15	.	O
1	Crisis	O
2	of	O
3	the	O
4	therapeutic	O
5	community	O
6	in	O
7	Great	O
8	Britain	O
1	It	O
2	is	O
3	possible	O
4	that	O
5	cyclic	O
6	variations	O
7	in	O
8	heme	O
9	turnover	O
10	are	O
11	related	O
12	to	O
13	changes	O
14	in	O
15	erythrocyte	O
16	characteristics	O
17	during	O
18	the	O
19	progesterone	O
20	phase	O
21	.	O
1	Toward	O
2	absolute	O
3	methods	O
4	in	O
5	clinical	O
6	chemistry	O
7	:	O
8	application	O
9	of	O
10	mass	O
11	fragmentography	O
12	to	O
13	high	O
14	-	O
15	accuracy	O
16	analyses	O
17	.	O
1	All	O
2	Cu	O
3	values	O
4	obtained	O
5	from	O
6	the	O
7	organs	O
8	investigated	O
9	had	O
10	reached	O
11	a	O
12	saturation	O
13	level	O
14	at	O
15	8	O
16	mug	O
17	Cu	O
18	/	O
19	g	O
20	diet	O
21	with	O
22	the	O
23	exception	O
24	of	O
25	the	O
26	values	O
27	for	O
28	body	O
29	Cu	O
30	found	O
31	in	O
32	the	O
33	dams	O
34	that	O
35	were	O
36	killed	O
37	on	O
38	the	O
39	day	O
40	of	O
41	delivery	O
42	.	O
1	Compared	O
2	to	O
3	controls	O
4	,	O
5	both	O
6	UB	O
7	and	O
8	OCS	O
9	rats	O
10	showed	O
11	a	O
12	small	O
13	but	O
14	significant	O
15	post	O
16	-	O
17	operative	O
18	reduction	O
19	in	O
20	the	O
21	nocturnality	O
22	of	O
23	drinking	O
24	.	O
1	Dual	O
2	innervation	O
3	of	O
4	fast	O
5	fibers	O
6	in	O
7	trunk	O
8	muscles	O
9	of	O
10	lamprey	O
11	larvae	O
1	Is	O
2	criticism	O
3	of	O
4	patient	O
5	care	O
6	justified	O
7	and	O
8	does	O
9	it	O
10	have	O
11	educational	O
12	value	O
13	?	O
14	Patients	O
15	'	O
16	criticism	O
17	contributes	O
18	to	O
19	improved	O
20	patient	O
21	care	O
1	Improvement	O
2	of	O
3	nursing	O
4	instruction	O
5	to	O
6	be	O
7	given	O
8	at	O
9	the	O
10	time	O
11	of	O
12	discharge	O
13	from	O
14	the	O
15	ward	O
16	for	O
17	premature	O
18	infants	O
1	No	O
2	difference	O
3	in	O
4	the	O
5	clinical	O
6	acceptability	O
7	could	O
8	be	O
9	ascertained	O
10	between	O
11	the	O
12	two	O
13	groups	O
14	.	O
1	Evidence	O
2	is	O
3	presented	O
4	that	O
5	Leber	O
6	'	O
7	s	O
8	military	O
9	aneurysm	O
10	retinitis	O
11	is	O
12	not	O
13	a	O
14	separate	O
15	entity	O
16	but	O
17	a	O
18	special	O
19	form	O
20	of	O
21	Coats	O
22	'	O
23	disease	O
24	.	O
1	A	O
2	newly	O
3	synthesized	O
4	anti	O
5	-	O
6	inflammatory	O
7	agent	O
8	,	O
9	Y	O
10	-	O
11	8004	O
12	demonstrated	O
13	a	O
14	greater	O
15	inhibition	O
16	than	O
17	did	O
18	indomethacin	O
19	(	O
20	IM	O
21	).	O
22	on	O
23	inflammatory	O
24	response	O
25	such	O
26	as	O
27	ultraviolet	O
28	erythema	O
29	in	O
30	guinea	O
31	pigs	O
32	,	O
33	carrageenin	O
34	edema	O
35	,	O
36	evans	O
37	blue	O
38	and	O
39	carrageenin	O
40	-	O
41	induced	O
42	pleuritis	O
43	and	O
44	acetic	O
45	acid	O
46	-	O
47	induced	O
48	peritonitis	O
49	in	O
50	rats	O
51	.	O
1	Lymphocyte	O
2	subpopulations	O
3	,	O
4	serum	B
5	IgE	I
6	and	O
7	total	O
8	eosinophil	O
9	counts	O
10	in	O
11	patients	O
12	with	O
13	bronchial	O
14	asthma	O
15	.	O
1	Technique	O
2	for	O
3	obtaining	O
4	refined	O
5	ceramics	O
6	with	O
7	dense	O
8	mass	O
1	The	O
2	correcting	O
3	action	O
4	of	O
5	tropatepine	O
6	hydrochloride	O
7	upon	O
8	the	O
9	extrapyramidal	O
10	effects	O
11	induced	O
12	by	O
13	neuroleptics	O
14	has	O
15	been	O
16	studied	O
17	in	O
18	32	O
19	acute	O
20	psychotic	O
21	states	O
22	.	O
1	Two	O
2	patients	O
3	were	O
4	treated	O
5	with	O
6	both	O
7	regimens	O
8	.	O
1	Results	O
2	obtained	O
3	for	O
4	chloramphenicol	O
5	-	O
6	containing	O
7	preparations	O
8	are	O
9	presented	O
10	,	O
11	and	O
12	both	O
13	dissolution	O
14	curves	O
15	and	O
16	cup	O
17	-	O
18	plate	O
19	assays	O
20	demonstrate	O
21	that	O
22	chloramphenicol	O
23	has	O
24	far	O
25	superior	O
26	release	O
27	(	O
28	and	O
29	hence	O
30	activity	O
31	)	O
32	from	O
33	creams	O
34	than	O
35	from	O
36	ophthalmic	O
37	ointments	O
38	.	O
1	The	O
2	data	O
3	support	O
4	the	O
5	notion	O
6	that	O
7	suppression	O
8	of	O
9	images	O
10	during	O
11	binocular	O
12	rivalry	O
13	is	O
14	independent	O
15	in	O
16	both	O
17	eyes	O
18	.	O
1	Glycogen	O
2	utilization	O
3	was	O
4	increased	O
5	,	O
6	but	O
7	tissue	O
8	levels	O
9	of	O
10	creatine	O
11	phosphate	O
12	,	O
13	ATP	O
14	,	O
15	and	O
16	lactate	O
17	were	O
18	similar	O
19	to	O
20	those	O
21	in	O
22	hearts	O
23	receiving	O
24	normal	O
25	flow	O
26	.	O
1	With	O
2	0	O
3	.	O
4	5	O
5	vol	O
6	.-%,	O
7	the	O
8	corresponding	O
9	values	O
10	were	O
11	345	O
12	mumol	O
13	/	O
14	1	O
15	(	O
16	5	O
17	.	O
18	72	O
19	mg	O
20	/	O
21	100	O
22	ml	O
23	)	O
24	and	O
25	137	O
26	mumol	O
27	/	O
28	1	O
29	(	O
30	2	O
31	.	O
32	25	O
33	mg	O
34	/	O
35	100	O
36	ml	O
37	)	O
38	respectively	O
39	.	O
1	Vitrectomy	O
2	with	O
3	an	O
4	alternative	O
5	instrument	O
6	system	O
7	.	O
1	Editorial	O
2	:	O
3	Low	O
4	-	O
5	dose	O
6	heparin	O
7	and	O
8	the	O
9	prevention	O
10	of	O
11	venous	O
12	thromboembolic	O
13	disease	O
14	.	O
1	At	O
2	the	O
3	very	O
4	high	O
5	dose	O
6	levels	O
7	used	O
8	,	O
9	sodium	O
10	saccharin	O
11	and	O
12	sodium	O
13	cyclamate	O
14	were	O
15	weak	O
16	solitary	O
17	carcinogens	O
18	producing	O
19	4	O
20	/	O
21	253	O
22	and	O
23	3	O
24	/	O
25	228	O
26	bladder	O
27	tumours	O
28	respectively	O
29	,	O
30	and	O
31	the	O
32	first	O
33	of	O
34	these	O
35	tumours	O
36	did	O
37	not	O
38	appear	O
39	for	O
40	more	O
41	than	O
42	80	O
43	weeks	O
44	.	O
1	Prostaglandins	O
2	F	O
3	(	O
4	PGF	O
5	)	O
6	were	O
7	measured	O
8	in	O
9	uterine	O
10	vein	O
11	,	O
12	ovarian	O
13	artery	O
14	,	O
15	and	O
16	jugular	O
17	vein	O
18	plasma	O
19	and	O
20	in	O
21	the	O
22	endometrial	O
23	tissues	O
24	at	O
25	various	O
26	times	O
27	during	O
28	the	O
29	bovine	O
30	estrous	O
31	cycle	O
32	,	O
33	and	O
34	were	O
35	compared	O
36	to	O
37	peripheral	O
38	plasma	O
39	progesterone	O
40	levels	O
41	.	O
1	Letter	O
2	:	O
3	Lactose	O
4	tolerance	O
5	tests	O
6	as	O
7	a	O
8	predictor	O
9	of	O
10	milk	O
11	tolerance	O
12	.	O
1	Like	O
2	pineal	O
3	melatonin	O
4	,	O
5	serum	O
6	melatonin	O
7	was	O
8	high	O
9	at	O
10	mid	O
11	-	O
12	dark	O
13	and	O
14	low	O
15	at	O
16	mid	O
17	-	O
18	light	O
19	.	O
1	The	O
2	authors	O
3	concluded	O
4	that	O
5	ultrasonic	O
6	Doppler	O
7	-	O
8	cardiography	O
9	can	O
10	be	O
11	used	O
12	for	O
13	measuring	O
14	the	O
15	relative	O
16	changes	O
17	in	O
18	the	O
19	stroke	O
20	volume	O
21	.	O
1	The	O
2	attainment	O
3	of	O
4	sexual	O
5	maturity	O
6	in	O
7	terms	O
8	of	O
9	secondary	O
10	sexual	O
11	characteristics	O
12	,	O
13	the	O
14	production	O
15	of	O
16	spermatozoa	O
17	in	O
18	the	O
19	male	O
20	,	O
21	and	O
22	the	O
23	cyclical	O
24	female	O
25	pattern	O
26	with	O
27	release	O
28	of	O
29	ova	O
30	are	O
31	end	O
32	-	O
33	points	O
34	of	O
35	the	O
36	developmental	O
37	process	O
38	.	O
1	Caution	O
2	should	O
3	be	O
4	exercised	O
5	in	O
6	the	O
7	use	O
8	of	O
9	these	O
10	dyes	O
11	for	O
12	lymphograms	O
13	.	O
1	In	O
2	about	O
3	one	O
4	third	O
5	of	O
6	the	O
7	cases	O
8	this	O
9	operation	O
10	results	O
11	in	O
12	tonal	O
13	and	O
14	vocal	O
15	improvement	O
16	for	O
17	patients	O
18	suffering	O
19	from	O
20	progressive	O
21	perceptive	O
22	deafness	O
23	.	O
1	Demonstration	O
2	of	O
3	the	O
4	agent	O
5	was	O
6	performed	O
7	from	O
8	the	O
9	6th	O
10	to	O
11	the	O
12	11th	O
13	day	O
14	p	O
15	.	O
16	i	O
17	.	O
18	by	O
19	direct	O
20	microscopic	O
21	methods	O
22	(	O
23	Stamp	O
24	and	O
25	auramine	O
26	staining	O
27	,	O
28	fluorescent	O
29	antibody	O
30	technique	O
31	);	O
32	the	O
33	Coxiella	O
34	content	O
35	was	O
36	determined	O
37	by	O
38	titration	O
39	in	O
40	embryonated	O
41	hen	O
42	'	O
43	s	O
44	eggs	O
45	.	O
1	The	O
2	alterations	O
3	of	O
4	5	O
5	-	O
6	HT	O
7	and	O
8	5	O
9	-	O
10	HIAA	O
11	levels	O
12	in	O
13	several	O
14	regions	O
15	of	O
16	the	O
17	brain	O
18	under	O
19	the	O
20	conditions	O
21	examined	O
22	may	O
23	indicate	O
24	that	O
25	IDPN	O
26	'	O
27	s	O
28	neurotoxicity	O
29	primarily	O
30	affects	O
31	5	O
32	-	O
33	HT	O
34	-	O
35	containing	O
36	neurones	O
37	.	O
1	The	O
2	results	O
3	indicate	O
4	that	O
5	increased	O
6	pulmonary	O
7	blood	O
8	flow	O
9	and	O
10	decreased	O
11	pulmonary	O
12	vascular	O
13	resistance	O
14	with	O
15	advancing	O
16	gestation	O
17	are	O
18	due	O
19	to	O
20	an	O
21	increase	O
22	in	O
23	the	O
24	total	O
25	number	O
26	of	O
27	vessels	O
28	and	O
29	increased	O
30	vasomotor	O
31	reactivity	O
32	is	O
33	related	O
34	to	O
35	an	O
36	increase	O
37	in	O
38	the	O
39	total	O
40	amount	O
41	of	O
42	smooth	O
43	muscle	O
44	while	O
45	the	O
46	thickness	O
47	of	O
48	muscle	O
49	in	O
50	individual	O
51	vessels	O
52	remains	O
53	constant	O
54	.	O
1	A	O
2	late	O
3	diagnosis	O
4	of	O
5	retinoblastoma	O
6	is	O
7	an	O
8	unquestionable	O
9	fact	O
10	that	O
11	allows	O
12	its	O
13	growth	O
14	and	O
15	leads	O
16	to	O
17	a	O
18	deterioration	O
19	in	O
20	the	O
21	outlook	O
22	.	O
1	A	O
2	note	O
3	on	O
4	the	O
5	phase	O
6	-	O
7	plane	O
8	technique	O
9	representation	O
10	of	O
11	cardiac	O
12	action	O
13	potentials	O
14	.	O
1	The	O
2	concept	O
3	of	O
4	""""	O
5	structural	O
6	identifiability	O
7	""""	O
8	is	O
9	employed	O
10	in	O
11	this	O
12	analysis	O
13	to	O
14	determine	O
15	which	O
16	model	O
17	parameters	O
18	can	O
19	be	O
20	and	O
21	which	O
22	cannot	O
23	be	O
24	determined	O
25	""""	O
26	uniquely	O
27	""""	O
28	from	O
29	given	O
30	input	O
31	-	O
32	output	O
33	data	O
34	;	O
35	a	O
36	step	O
37	-	O
38	by	O
39	-	O
40	step	O
41	procedure	O
42	based	O
43	on	O
44	an	O
45	extension	O
46	of	O
47	this	O
48	concept	O
49	is	O
50	presented	O
51	for	O
52	adapting	O
53	the	O
54	overall	O
55	approach	O
56	to	O
57	the	O
58	experimental	O
59	design	O
60	problem	O
61	.	O
1	One	O
2	site	O
3	,	O
4	PAL	B
5	,	O
6	occurs	O
7	within	O
8	the	O
9	10	O
10	bp	O
11	sequence	O
12	GGGGAGGAGG	O
13	.	O
1	A	O
2	significant	O
3	direct	O
4	relationship	O
5	was	O
6	observed	O
7	between	O
8	the	O
9	percent	O
10	area	O
11	density	O
12	of	O
13	smooth	O
14	muscle	O
15	and	O
16	the	O
17	percent	O
18	change	O
19	in	O
20	peak	O
21	urinary	O
22	flow	O
23	rate	O
24	.	O
1	Prospects	O
2	for	O
3	controlled	O
4	-	O
5	delivery	O
6	systems	O
7	.	O
1	The	O
2	two	O
3	drugs	O
4	increase	O
5	the	O
6	rate	O
7	of	O
8	early	O
9	diastolic	O
10	filling	O
11	.	O
1	This	O
2	analysis	O
3	,	O
4	together	O
5	with	O
6	a	O
7	consideration	O
8	of	O
9	the	O
10	SCBs	O
11	found	O
12	upstream	O
13	of	O
14	known	O
15	SWI4	B
16	,	I
17	6	I
18	-	O
19	dependent	O
20	genes	O
21	,	O
22	leads	O
23	to	O
24	the	O
25	proposal	O
26	of	O
27	a	O
28	revised	O
29	consensus	O
30	sequence	O
31	for	O
32	this	O
33	important	O
34	regulatory	O
35	element	O
36	.	O
1	Mutational	O
2	analysis	O
3	of	O
4	a	O
5	DNA	O
6	sequence	O
7	involved	O
8	in	O
9	linking	O
10	gene	O
11	expression	O
12	to	O
13	the	O
14	cell	O
15	cycle	O
16	.	O
1	The	O
2	cellular	O
3	sequences	O
4	5	O
5	'	O
6	to	O
7	the	O
8	viral	O
9	integration	O
10	site	O
11	exhibited	O
12	85	O
13	to	O
14	97	O
15	%	O
16	identity	O
17	to	O
18	several	O
19	sequences	O
20	belonging	O
21	to	O
22	the	O
23	mouse	B
24	L1	I
25	family	I
26	of	O
27	long	O
28	interspersed	O
29	repetitive	O
30	sequences	O
31	.	O
1	Nucleotide	O
2	sequence	O
3	analysis	O
4	revealed	O
5	that	O
6	TAR	B
7	-	I
8	binding	I
9	protein	I
10	is	O
11	very	O
12	similar	O
13	to	O
14	the	O
15	CREB2	B
16	protein	I
17	.	O
1	The	O
2	JS78	O
3	mutation	O
4	changes	O
5	Gln243	O
6	in	O
7	gp0	O
8	.	O
9	7	O
10	to	O
11	an	O
12	amber	O
13	codon	O
14	,	O
15	which	O
16	explains	O
17	the	O
18	production	O
19	of	O
20	the	O
21	truncated	O
22	,	O
23	30	B
24	-	I
25	kDa	I
26	gp0	I
27	.	I
28	7	I
29	-	I
30	related	I
31	polypeptide	I
32	,	O
33	and	O
34	implicates	O
35	the	O
36	11	O
37	-	O
38	kDa	O
39	C	O
40	-	O
41	terminal	O
42	domain	O
43	in	O
44	host	O
45	transcription	O
46	shut	O
47	-	O
48	off	O
49	.	O
1	Analysis	O
2	of	O
3	the	O
4	entire	O
5	16	O
6	.	O
7	7	O
8	-	O
9	kb	O
10	mt	O
11	genome	O
12	determined	O
13	that	O
14	a	O
15	MDP1	B
16	mediates	O
17	cleavage	O
18	of	O
19	chick	O
20	mtDNA	O
21	in	O
22	vitro	O
23	at	O
24	three	O
25	H	O
26	-	O
27	and	O
28	two	O
29	L	O
30	-	O
31	strand	O
32	sequence	O
33	-	O
34	specific	O
35	target	O
36	sites	O
37	located	O
38	within	O
39	a	O
40	90	O
41	-	O
42	bp	O
43	A	O
44	+	O
45	T	O
46	-	O
47	rich	O
48	genomic	O
49	tract	O
50	,	O
51	theoretically	O
52	capable	O
53	of	O
54	forming	O
55	stable	O
56	secondary	O
57	structures	O
58	,	O
59	approximately	O
60	200	O
61	bases	O
62	upstream	O
63	from	O
64	the	O
65	H	O
66	-	O
67	strand	O
68	origin	O
69	(	O
70	OH	O
71	)	O
72	of	O
73	replication	O
74	.	O
1	A	O
2	rather	O
3	similar	O
4	pattern	O
5	of	O
6	results	O
7	was	O
8	obtained	O
9	with	O
10	respect	O
11	to	O
12	LMP2B	B
13	mRNA	I
14	expression	O
15	,	O
16	such	O
17	transcripts	O
18	being	O
19	detectable	O
20	only	O
21	in	O
22	a	O
23	subset	O
24	of	O
25	tumors	O
26	,	O
27	and	O
28	then	O
29	at	O
30	apparently	O
31	low	O
32	levels	O
33	.	O
1	Treatment	O
2	with	O
3	MK	O
4	-	O
5	801	O
6	induced	O
7	a	O
8	burst	O
9	suppression	O
10	in	O
11	the	O
12	EEG	O
13	and	O
14	a	O
15	transient	O
16	drop	O
17	(	O
18	11	O
19	.	O
20	4	O
21	+/-	O
22	6	O
23	.	O
24	5	O
25	mm	O
26	Hg	O
27	)	O
28	in	O
29	the	O
30	mean	O
31	arterial	O
32	pressure	O
33	.	O
1	The	O
2	experiment	O
3	results	O
4	showed	O
5	:	O
6	(	O
7	i	O
8	)	O
9	not	O
10	only	O
11	1O2	O
12	,	O
13	but	O
14	also	O
15	free	O
16	radicals	O
17	(	O
18	O2	O
19	-.	O
20	.	O
21	OH	O
22	and	O
23	YHPD	O
24	-.)	O
25	can	O
26	be	O
27	formed	O
28	by	O
29	the	O
30	aid	O
31	of	O
32	YHPD	O
33	;	O
34	and	O
35	(	O
36	ii	O
37	)	O
38	as	O
39	to	O
40	the	O
41	ability	O
42	of	O
43	producing	O
44	1O2	O
45	,	O
46	YHPD	O
47	less	O
48	than	O
49	BHPD	O
50	,	O
51	while	O
52	for	O
53	generating	O
54	O2	O
55	-.	O
56	and	O
57	.	O
58	OH	O
59	,	O
60	YHPD	O
61	greater	O
62	than	O
63	BHPD	O
64	.	O
1	Two	O
2	points	O
3	are	O
4	indicated	O
5	:	O
6	first	O
7	,	O
8	the	O
9	photosensitized	O
10	damage	O
11	of	O
12	YHPD	O
13	is	O
14	interrelated	O
15	to	O
16	not	O
17	only	O
18	1O2	O
19	,	O
20	but	O
21	also	O
22	free	O
23	radicals	O
24	(	O
25	O2	O
26	-.	O
27	.	O
28	OH	O
29	and	O
30	YHPD	O
31	-.);	O
32	second	O
33	,	O
34	although	O
35	the	O
36	photosensitized	O
37	damage	O
38	of	O
39	YHPD	O
40	is	O
41	stronger	O
42	than	O
43	that	O
44	of	O
45	BHPD	O
46	,	O
47	yet	O
48	the	O
49	photosensitized	O
50	damage	O
51	is	O
52	negatively	O
53	correlated	O
54	to	O
55	the	O
56	yield	O
57	of	O
58	1O2	O
59	but	O
60	positively	O
61	correlated	O
62	to	O
63	those	O
64	of	O
65	O2	O
66	-.	O
67	and	O
68	OH	O
69	.	O
1	The	O
2	unphosphorylated	O
3	form	O
4	of	O
5	RNA	B
6	polymerase	I
7	II	I
8	is	O
9	designated	O
10	IIA	O
11	,	O
12	whereas	O
13	the	O
14	phosphorylated	O
15	form	O
16	is	O
17	designated	O
18	IIO	O
19	.	O
1	RNA	B
2	polymerase	I
3	IIA	I
4	was	O
5	recovered	O
6	in	O
7	transcriptionally	O
8	active	O
9	complexes	O
10	in	O
11	reactions	O
12	in	O
13	which	O
14	the	O
15	input	O
16	enzyme	O
17	was	O
18	RNA	B
19	polymerase	I
20	IIA	I
21	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	an	O
6	internal	O
7	short	O
8	element	O
9	located	O
10	at	O
11	the	O
12	very	O
13	5	O
14	'	O
15	terminal	O
16	of	O
17	L1	B
18	sequence	I
19	and	O
20	the	O
21	nuclear	O
22	factor	O
23	binding	O
24	to	O
25	the	O
26	element	O
27	play	O
28	a	O
29	crucial	O
30	role	O
31	in	O
32	the	O
33	transcription	O
34	of	O
35	human	B
36	L1	I
37	.	O
1	ROS	B
2	x	O
3	SRC	B
4	(	O
5	R	B
6	)	O
7	contains	O
8	a	O
9	16	O
10	-	O
11	amino	O
12	-	O
13	acid	O
14	deletion	O
15	that	O
16	includes	O
17	the	O
18	3	O
19	'	O
20	half	O
21	of	O
22	the	O
23	transmembrane	O
24	domain	O
25	of	O
26	ros	B
27	.	O
1	The	O
2	enhancer	O
3	region	O
4	of	O
5	Akv	O
6	murine	O
7	leukemia	O
8	virus	O
9	contains	O
10	the	O
11	sequence	O
12	motif	O
13	ACAGATGG	O
14	.	O
1	As	O
2	was	O
3	observed	O
4	previously	O
5	for	O
6	MATa	B
7	cna1	I
8	cna2	I
9	double	O
10	mutants	O
11	,	O
12	MATa	B
13	cnb1	I
14	mutants	I
15	were	O
16	defective	O
17	in	O
18	their	O
19	ability	O
20	to	O
21	recover	O
22	from	O
23	alpha	B
24	-	I
25	factor	I
26	-	O
27	induced	O
28	growth	O
29	arrest	O
30	.	O
1	METHODS	O
2	:	O
3	IgG	B
4	antibodies	I
5	vs	O
6	HHV	O
7	-	O
8	6	O
9	(	O
10	anti	B
11	-	I
12	HHV	I
13	-	I
14	6	I
15	-	I
16	IgG	I
17	)	O
18	were	O
19	determined	O
20	by	O
21	indirect	O
22	immunofluorescence	O
23	in	O
24	100	O
25	IVDA	O
26	(	O
27	29	O
28	seronegative	O
29	and	O
30	71	O
31	seropositive	O
32	for	O
33	HIV	O
34	-	O
35	1	O
36	of	O
37	which	O
38	45	O
39	were	O
40	in	O
41	stage	O
42	II	O
43	and	O
44	26	O
45	in	O
46	IV	O
47	-	O
48	C1	O
49	of	O
50	CDC	O
51	)	O
52	as	O
53	well	O
54	as	O
55	in	O
56	100	O
57	healthy	O
58	subjects	O
59	of	O
60	a	O
61	similar	O
62	age	O
63	(	O
64	control	O
65	group	O
66	).	O
1	Insertional	O
2	inactivation	O
3	of	O
4	sms	B
5	led	O
6	to	O
7	increased	O
8	sensitivity	O
9	to	O
10	the	O
11	alkylating	O
12	agent	O
13	methylmethane	O
14	sulfonate	O
15	,	O
16	but	O
17	not	O
18	to	O
19	a	O
20	requirement	O
21	for	O
22	serine	O
23	or	O
24	other	O
25	metabolites	O
26	.	O
1	NSCL	B
2	-	I
3	1	I
4	is	O
5	expressed	O
6	in	O
7	a	O
8	larger	O
9	number	O
10	of	O
11	these	O
12	cell	O
13	lines	O
14	.	O
1	Truncation	O
2	variants	O
3	of	O
4	peptides	O
5	isolated	O
6	from	O
7	MHC	B
8	class	I
9	II	I
10	molecules	I
11	suggest	O
12	sequence	O
13	motifs	O
14	.	O
1	Although	O
2	the	O
3	E	O
4	-	O
5	box	O
6	consensus	O
7	is	O
8	minimally	O
9	defined	O
10	as	O
11	CANNTG	O
12	,	O
13	the	O
14	adjacent	O
15	nucleotides	O
16	of	O
17	functional	O
18	E	O
19	-	O
20	boxes	O
21	are	O
22	variable	O
23	for	O
24	genes	O
25	regulated	O
26	by	O
27	the	O
28	bHLH	B
29	proteins	I
30	.	O
1	Intermediate	O
2	levels	O
3	of	O
4	gene	O
5	activity	O
6	were	O
7	observed	O
8	for	O
9	TnI	B
10	enhancers	I
11	containing	O
12	E	O
13	-	O
14	boxes	O
15	derived	O
16	from	O
17	the	O
18	MCK	B
19	left	I
20	E	I
21	-	I
22	box	I
23	site	I
24	or	O
25	from	O
26	the	O
27	Ig	B
28	kappa	I
29	E2	I
30	E	I
31	-	I
32	box	I
33	.	O
1	A	O
2	major	O
3	mechanism	O
4	whereby	O
5	steroid	B
6	hydroxylase	I
7	gene	I
8	transcription	O
9	is	O
10	regulated	O
11	in	O
12	the	O
13	adrenal	O
14	cortex	O
15	requires	O
16	the	O
17	pituitary	O
18	peptide	O
19	hormone	O
20	,	O
21	ACTH	B
22	,	O
23	which	O
24	acts	O
25	via	O
26	cAMP	O
27	.	O
1	A	O
2	combination	O
3	of	O
4	comparative	O
5	sequence	O
6	analysis	O
7	and	O
8	thermodynamic	O
9	methods	O
10	reveals	O
11	the	O
12	conservation	O
13	of	O
14	tertiary	O
15	structure	O
16	elements	O
17	in	O
18	the	O
19	5	O
20	'	O
21	untranslated	O
22	region	O
23	(	O
24	UTR	O
25	)	O
26	of	O
27	human	O
28	enteroviruses	O
29	and	O
30	rhinoviruses	O
31	.	O
1	The	O
2	-	O
3	64	O
4	/-	O
5	37	O
6	region	O
7	interacted	O
8	with	O
9	purified	O
10	Sp1	B
11	and	O
12	an	O
13	unidentified	O
14	protein	O
15	(	O
16	s	O
17	),	O
18	proximal	B
19	regulatory	I
20	factor	I
21	(	I
22	s	I
23	)	I
24	I	I
25	(	O
26	PRF	B
27	-	I
28	I	I
29	).	O
1	Strategies	O
2	for	O
3	blood	O
4	screening	O
5	for	O
6	the	O
7	hepatitis	O
8	C	O
9	virus	O
10	and	O
11	for	O
12	the	O
13	human	O
14	immunodeficiency	O
15	virus	O
16	in	O
17	high	O
18	risk	O
19	groups	O
20	.	O
1	Laboratory	O
2	studies	O
3	using	O
4	Ca45	O
5	labeled	O
6	teeth	O
7	and	O
8	biologically	O
9	stained	O
10	teeth	O
11	confirmed	O
12	that	O
13	the	O
14	dentifrice	O
15	did	O
16	not	O
17	decalcify	O
18	enamel	O
19	or	O
20	bleach	O
21	teeth	O
22	.	O
1	Some	O
2	research	O
3	studies	O
4	have	O
5	related	O
6	this	O
7	kind	O
8	of	O
9	tumors	O
10	with	O
11	prolonged	O
12	ingestion	O
13	of	O
14	H2	O
15	inhibitors	O
16	and	O
17	others	O
18	antacid	O
19	.	O
1	Characterization	O
2	of	O
3	the	O
4	regulon	O
5	controlled	O
6	by	O
7	the	O
8	leucine	B
9	-	I
10	responsive	I
11	regulatory	I
12	protein	I
13	in	O
14	Escherichia	O
15	coli	O
16	.	O
1	The	O
2	rationale	O
3	for	O
4	continuous	O
5	dopaminergic	O
6	stimulation	O
7	in	O
8	patients	O
9	with	O
10	Parkinson	O
11	'	O
12	s	O
13	disease	O
14	.	O
1	In	O
2	a	O
3	retrospective	O
4	analysis	O
5	of	O
6	data	O
7	from	O
8	35	O
9	cases	O
10	with	O
11	malignant	O
12	lymphoma	O
13	from	O
14	a	O
15	cohort	O
16	of	O
17	2017	O
18	HIV	O
19	-	O
20	infected	O
21	patients	O
22	,	O
23	the	O
24	stage	O
25	of	O
26	HIV	O
27	-	O
28	disease	O
29	,	O
30	the	O
31	CD4	B
32	counts	O
33	at	O
34	the	O
35	time	O
36	of	O
37	diagnosis	O
38	,	O
39	and	O
40	the	O
41	use	O
42	of	O
43	antineoplastic	O
44	agents	O
45	or	O
46	radiotherapy	O
47	were	O
48	correlated	O
49	with	O
50	outcome	O
51	.	O
1	1	O
2	.	O
1	Effects	O
2	of	O
3	dioxins	O
4	on	O
5	thyroid	O
6	function	O
7	in	O
8	newborn	O
9	babies	O
10	.	O
1	Interaction	O
2	of	O
3	H	B
4	-	I
5	2Eb	I
6	with	O
7	an	O
8	IAP	B
9	retrotransposon	I
10	in	O
11	the	O
12	A20	O
13	/	O
14	2J	O
15	B	O
16	cell	O
17	lymphoma	O
18	.	O
1	Substitution	O
2	of	O
3	the	O
4	DR1	B
5	beta	I
6	chain	I
7	with	O
8	H	B
9	-	I
10	2E	I
11	beta	I
12	k	I
13	led	O
14	to	O
15	a	O
16	dramatic	O
17	loss	O
18	of	O
19	recognition	O
20	;	O
21	alpha	O
22	chain	O
23	substitution	O
24	had	O
25	a	O
26	less	O
27	marked	O
28	effect	O
29	.	O
1	This	O
2	negative	O
3	regulatory	O
4	pathway	O
5	may	O
6	be	O
7	important	O
8	for	O
9	determining	O
10	cell	O
11	fate	O
12	or	O
13	maintaining	O
14	an	O
15	inducible	O
16	state	O
17	in	O
18	the	O
19	ventroposterior	O
20	region	O
21	of	O
22	the	O
23	embryo	O
24	.	O
1	This	O
2	computation	O
3	is	O
4	performed	O
5	by	O
6	a	O
7	parallel	O
8	network	O
9	of	O
10	locally	O
11	connected	O
12	neuron	O
13	-	O
14	like	O
15	elements	O
16	.	O
1	We	O
2	also	O
3	report	O
4	here	O
5	the	O
6	complete	O
7	structural	O
8	organization	O
9	of	O
10	the	O
11	goat	B
12	alpha	I
13	s1	I
14	-	I
15	casein	I
16	transcription	I
17	unit	I
18	,	O
19	deduced	O
20	from	O
21	polymerase	O
22	chain	O
23	reaction	O
24	experiments	O
25	.	O
1	The	O
2	chick	O
3	axon	O
4	-	O
5	associated	O
6	surface	O
7	glycoprotein	O
8	neurofascin	B
9	is	O
10	implicated	O
11	in	O
12	axonal	O
13	growth	O
14	and	O
15	fasciculation	O
16	as	O
17	revealed	O
18	by	O
19	antibody	O
20	perturbation	O
21	experiments	O
22	.	O
1	In	O
2	contrast	O
3	,	O
4	tobacco	B
5	GS	I
6	-	I
7	2	I
8	is	O
9	composed	O
10	of	O
11	subunits	O
12	of	O
13	identical	O
14	size	O
15	in	O
16	all	O
17	organs	O
18	examined	O
19	.	O
1	Between	O
2	acoR	B
3	and	O
4	acoXABC	B
5	,	O
6	two	O
7	different	O
8	types	O
9	of	O
10	sequences	O
11	with	O
12	dual	O
13	rotational	O
14	symmetry	O
15	[	O
16	CAC	O
17	-(	O
18	N11	O
19	to	O
20	N18	O
21	)-	O
22	GTG	O
23	and	O
24	TGT	O
25	-(	O
26	N10	O
27	to	O
28	N14	O
29	)-	O
30	ACA	O
31	]	O
32	were	O
33	found	O
34	;	O
35	these	O
36	sequences	O
37	are	O
38	similar	O
39	to	O
40	NtrC	B
41	and	O
42	NifA	B
43	upstream	I
44	activator	I
45	sequences	I
46	,	O
47	respectively	O
48	.	O
1	Thirty	O
2	percent	O
3	of	O
4	patients	O
5	were	O
6	tapered	O
7	off	O
8	all	O
9	steroids	O
10	,	O
11	and	O
12	the	O
13	average	O
14	steroid	O
15	dose	O
16	in	O
17	the	O
18	group	O
19	who	O
20	received	O
21	steroids	O
22	was	O
23	8	O
24	.	O
25	6	O
26	mg	O
27	of	O
28	prednisone	O
29	per	O
30	day	O
31	.	O
1	We	O
2	analyzed	O
3	an	O
4	EBV	O
5	B	O
6	-	O
7	cell	O
8	clone	O
9	,	O
10	E29	O
11	.	O
12	1	O
13	,	O
14	derived	O
15	from	O
16	an	O
17	11	O
18	week	O
19	-	O
20	old	O
21	embryo	O
22	,	O
23	and	O
24	secreting	O
25	both	O
26	IgM	B
27	kappa	I
28	and	O
29	IgM	B
30	lambda	I
31	.	O
1	To	O
2	study	O
3	a	O
4	possible	O
5	functional	O
6	role	O
7	of	O
8	this	O
9	putative	O
10	chicken	O
11	ICS	B
12	,	O
13	an	O
14	oligonucleotide	O
15	spanning	O
16	the	O
17	upstream	O
18	sequences	O
19	of	O
20	the	O
21	BF	B
22	-	I
23	IV	I
24	gene	I
25	(-	O
26	174	O
27	/-	O
28	194	O
29	)	O
30	was	O
31	cloned	O
32	singly	O
33	or	O
34	in	O
35	multiple	O
36	copies	O
37	before	O
38	the	O
39	herpes	O
40	TK	B
41	promoter	I
42	controlling	O
43	the	O
44	chloramphenicol	B
45	acetyl	I
46	transferase	I
47	(	O
48	CAT	B
49	)	O
50	gene	O
51	(	O
52	pBLCAT2	B
53	).	O
1	Urease	B
2	activity	O
3	,	O
4	judged	O
5	as	O
6	the	O
7	amount	O
8	of	O
9	ammonia	O
10	production	O
11	from	O
12	urea	O
13	,	O
14	could	O
15	be	O
16	measured	O
17	at	O
18	25	O
19	ng	O
20	per	O
21	tube	O
22	(	O
23	S	O
24	/	O
25	N	O
26	=	O
27	1	O
28	.	O
29	5	O
30	)	O
31	with	O
32	Jack	B
33	bean	I
34	meal	I
35	urease	I
36	.	O
1	These	O
2	results	O
3	lead	O
4	us	O
5	to	O
6	hypothesize	O
7	that	O
8	a	O
9	single	O
10	multisubunit	B
11	TFIID	I
12	protein	I
13	supports	O
14	transcriptional	O
15	stimulation	O
16	by	O
17	diverse	O
18	activation	O
19	domains	O
20	and	O
21	from	O
22	a	O
23	TATA	O
24	-	O
25	less	O
26	promoter	O
27	.	O
1	The	O
2	gene	O
3	sequence	O
4	also	O
5	identified	O
6	a	O
7	340	O
8	-	O
9	nucleotide	O
10	RNA	O
11	in	O
12	total	O
13	yeast	O
14	RNA	O
15	and	O
16	in	O
17	purified	O
18	RNase	B
19	MRP	I
20	enzyme	I
21	preparations	O
22	.	O
1	Cleavage	O
2	by	O
3	the	O
4	intron	O
5	-	O
6	encoded	O
7	enzyme	O
8	(	O
9	I	B
10	-	I
11	CreI	I
12	)	O
13	occurs	O
14	5	O
15	bp	O
16	and	O
17	1	O
18	bp	O
19	3	O
20	'	O
21	to	O
22	the	O
23	intron	O
24	insertion	O
25	site	O
26	(	O
27	in	O
28	the	O
29	3	O
30	'-	O
31	exon	O
32	)	O
33	in	O
34	the	O
35	top	O
36	(/)	O
37	and	O
38	bottom	O
39	(,)	O
40	strands	O
41	,	O
42	respectively	O
43	,	O
44	resulting	O
45	in	O
46	4	O
47	-	O
48	nt	O
49	single	O
50	-	O
51	stranded	O
52	overhangs	O
53	with	O
54	3	O
55	'-	O
56	OH	O
57	termini	O
58	.	O
1	In	O
2	humans	O
3	,	O
4	four	O
5	AMP	B
6	deaminase	I
7	variants	I
8	,	O
9	termed	O
10	M	B
11	(	O
12	muscle	O
13	),	O
14	L	B
15	(	O
16	liver	O
17	),	O
18	E1	B
19	,	O
20	and	O
21	E2	B
22	(	O
23	erythrocyte	O
24	)	O
25	can	O
26	be	O
27	distinguished	O
28	by	O
29	a	O
30	variety	O
31	of	O
32	biochemical	O
33	and	O
34	immunological	O
35	criteria	O
36	.	O
1	Chronic	O
2	hepatitis	O
3	B	O
4	in	O
5	adopted	O
6	Romanian	O
7	children	O
8	.	O
1	PaO2	O
2	threshold	O
3	was	O
4	determined	O
5	through	O
6	an	O
7	indwelling	O
8	O2	O
9	sensor	O
10	catheter	O
11	.	O
1	We	O
2	couldn	O
3	'	O
4	t	O
5	detect	O
6	any	O
7	effect	O
8	of	O
9	n	O
10	-	O
11	3	O
12	FA	O
13	supplementation	O
14	on	O
15	total	O
16	cholesterol	O
17	,	O
18	HDL	B
19	cholesterol	I
20	,	O
21	LDL	B
22	cholesterol	I
23	,	O
24	apo	B
25	A1	I
26	,	O
27	Lp	O
28	(	O
29	a	O
30	),	O
31	HbA1C	B
32	,	O
33	glucose	O
34	,	O
35	fibrinogen	B
36	,	O
37	factor	B
38	VIII	I
39	,	O
40	antithrombin	B
41	III	I
42	,	O
43	plasminogen	B
44	activator	I
45	inhibitor	I
46	,	O
47	tissue	B
48	plasminogen	I
49	activator	I
50	and	O
51	von	B
52	Willebrand	I
53	factor	I
54	concentration	O
55	,	O
56	on	O
57	bleeding	O
58	time	O
59	or	O
60	on	O
61	systolic	O
62	or	O
63	diastolic	O
64	blood	O
65	pressure	O
66	.	O
1	The	O
2	IgG	B
3	subclass	O
4	profile	O
5	of	O
6	untreated	O
7	coeliac	O
8	disease	O
9	was	O
10	found	O
11	to	O
12	be	O
13	the	O
14	same	O
15	as	O
16	in	O
17	healthy	O
18	controls	O
19	(	O
20	IgG1	B
21	approximately	O
22	IgG2	B
23	>	O
24	IgG3	B
25	>	O
26	IgG4	B
27	),	O
28	with	O
29	only	O
30	the	O
31	magnitude	O
32	of	O
33	the	O
34	individual	O
35	subclass	O
36	responses	O
37	being	O
38	increased	O
39	in	O
40	coeliac	O
41	patients	O
42	.	O
1	The	O
2	effects	O
3	of	O
4	two	O
5	levels	O
6	of	O
7	caffeine	O
8	ingestion	O
9	on	O
10	excess	O
11	postexercise	O
12	oxygen	O
13	consumption	O
14	in	O
15	untrained	O
16	women	O
17	.	O
1	4	O
2	.	O
1	In	O
2	a	O
3	prospective	O
4	,	O
5	randomized	O
6	clinical	O
7	trial	O
8	we	O
9	compared	O
10	the	O
11	efficacy	O
12	of	O
13	subcutaneously	O
14	(	O
15	SC	O
16	)	O
17	administered	O
18	(	O
19	every	O
20	8	O
21	h	O
22	)	O
23	calcium	O
24	heparin	O
25	to	O
26	intravenous	O
27	(	O
28	IV	O
29	)	O
30	sodium	O
31	heparin	O
32	in	O
33	the	O
34	treatment	O
35	of	O
36	proximal	O
37	deep	O
38	-	O
39	vein	O
40	thrombosis	O
41	(	O
42	DVT	O
43	).	O
1	Nucleotide	O
2	sequence	O
3	and	O
4	transcriptional	O
5	analysis	O
6	of	O
7	the	O
8	polyhedrin	B
9	gene	I
10	of	O
11	Spodoptera	O
12	exigua	O
13	nuclear	O
14	polyhedrosis	O
15	virus	O
16	.	O
1	As	O
2	a	O
3	consequence	O
4	of	O
5	dark	O
6	rearing	O
7	,	O
8	the	O
9	numerical	O
10	density	O
11	of	O
12	cortical	O
13	neurons	O
14	in	O
15	area	O
16	17	O
17	amounted	O
18	to	O
19	about	O
20	double	O
21	of	O
22	the	O
23	value	O
24	observed	O
25	in	O
26	normally	O
27	reared	O
28	kittens	O
29	and	O
30	was	O
31	also	O
32	significantly	O
33	higher	O
34	in	O
35	area	O
36	18	O
37	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	decreased	O
6	class	O
7	I	O
8	enhancer	O
9	activity	O
10	in	O
11	Ad12	O
12	-	O
13	transformed	O
14	cells	O
15	may	O
16	,	O
17	at	O
18	least	O
19	in	O
20	part	O
21	,	O
22	be	O
23	due	O
24	to	O
25	the	O
26	higher	O
27	levels	O
28	of	O
29	an	O
30	enhancer	O
31	-	O
32	specific	O
33	factor	O
34	,	O
35	possibly	O
36	acting	O
37	as	O
38	a	O
39	repressor	O
40	.	O
1	Purification	O
2	and	O
3	cloning	O
4	of	O
5	a	O
6	novel	O
7	serine	B
8	protease	I
9	,	O
10	RNK	B
11	-	I
12	Met	I
13	-	I
14	1	I
15	,	O
16	from	O
17	the	O
18	granules	O
19	of	O
20	a	O
21	rat	O
22	natural	O
23	killer	O
24	cell	O
25	leukemia	O
26	.	O
1	Comparisons	O
2	with	O
3	the	O
4	available	O
5	amino	O
6	acid	O
7	residue	O
8	(	O
9	aa	O
10	)	O
11	sequence	O
12	information	O
13	from	O
14	the	O
15	complete	O
16	CPMV	B
17	RNA	I
18	1	I
19	sequence	I
20	and	O
21	the	O
22	partial	O
23	sequence	O
24	of	O
25	red	B
26	clover	I
27	mottle	I
28	virus	I
29	RNA	I
30	1	I
31	suggest	O
32	that	O
33	CPSMV	B
34	RNA	I
35	1	I
36	specifies	O
37	the	O
38	expected	O
39	set	O
40	of	O
41	five	O
42	mature	O
43	proteins	O
44	:	O
45	32K	B
46	proteinase	I
47	cofactor	I
48	,	O
49	58K	B
50	presumed	I
51	helicase	I
52	,	O
53	VPg	B
54	5	I
55	'-	I
56	linked	I
57	protein	I
58	of	O
59	the	O
60	genomic	O
61	RNAs	O
62	,	O
63	24K	B
64	proteinase	I
65	,	O
66	and	O
67	87K	B
68	presumed	I
69	polymerase	I
70	,	O
71	separated	O
72	by	O
73	four	O
74	cleavage	O
75	sites	O
76	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	utility	O
6	of	O
7	beta	B
8	2	I
9	transferrin	I
10	assay	O
11	in	O
12	the	O
13	diagnosis	O
14	of	O
15	cerebrospinal	O
16	fluid	O
17	otorrhea	O
18	is	O
19	presented	O
20	.	O
1	The	O
2	addition	O
3	of	O
4	diatrizoate	O
5	to	O
6	the	O
7	IPRK	O
8	led	O
9	to	O
10	a	O
11	dose	O
12	-	O
13	dependent	O
14	biphasic	O
15	change	O
16	in	O
17	RPF	O
18	and	O
19	GFR	O
20	characterized	O
21	by	O
22	an	O
23	initial	O
24	transient	O
25	increase	O
26	followed	O
27	by	O
28	a	O
29	marked	O
30	and	O
31	sustained	O
32	decrease	O
33	.	O
1	Laboratory	O
2	studies	O
3	showed	O
4	that	O
5	the	O
6	direct	O
7	fluorescent	O
8	-	O
9	antibody	O
10	kits	O
11	were	O
12	the	O
13	least	O
14	sensitive	O
15	in	O
16	this	O
17	case	O
18	and	O
19	did	O
20	not	O
21	detect	O
22	fewer	O
23	than	O
24	10	O
25	(	O
26	4	O
27	)	O
28	elementary	O
29	bodies	O
30	per	O
31	ml	O
32	,	O
33	while	O
34	most	O
35	ELISA	O
36	kits	O
37	detected	O
38	between	O
39	130	O
40	and	O
41	600	O
42	elementary	O
43	bodies	O
44	per	O
45	ml	O
46	.	O
1	GAL4	B
2	-	O
3	VP16	B
4	-	O
5	mediated	O
6	antirepression	O
7	required	O
8	an	O
9	auxiliary	O
10	factor	O
11	,	O
12	denoted	O
13	as	O
14	a	O
15	co	O
16	-	O
17	antirepressor	O
18	,	O
19	which	O
20	was	O
21	partially	O
22	purified	O
23	from	O
24	Drosophila	O
25	embryos	O
26	.	O
1	Four	O
2	ruminally	O
3	and	O
4	duodenally	O
5	cannulated	O
6	Hampshire	O
7	wethers	O
8	were	O
9	used	O
10	in	O
11	a	O
12	4	O
13	x	O
14	4	O
15	Latin	O
16	square	O
17	experiment	O
18	to	O
19	determine	O
20	whether	O
21	linoleoyl	O
22	methionine	O
23	and	O
24	calcium	O
25	linoleate	O
26	would	O
27	increase	O
28	duodenal	O
29	flow	O
30	of	O
31	unsaturated	O
32	fatty	O
33	acids	O
34	(	O
35	C18	O
36	:	O
37	2	O
38	+	O
39	cis	O
40	C18	O
41	:	O
42	1	O
43	).	O
1	Comparable	O
2	amounts	O
3	of	O
4	alpha	B
5	5	I
6	beta	I
7	1	I
8	integrin	I
9	were	O
10	isolated	O
11	from	O
12	these	O
13	cells	O
14	by	O
15	chromatography	O
16	of	O
17	detergent	O
18	extracts	O
19	on	O
20	a	O
21	fibronectin	B
22	cell	O
23	-	O
24	binding	O
25	fragment	O
26	affinity	O
27	column	O
28	and	O
29	elution	O
30	with	O
31	EDTA	O
32	.	O
1	Among	O
2	these	O
3	,	O
4	ACT1	B
5	was	O
6	isolated	O
7	four	O
8	times	O
9	,	O
10	and	O
11	NSR1	B
12	three	O
13	times	O
14	.	O
1	Since	O
2	CENP	B
3	-	I
4	B	I
5	gene	I
6	is	O
7	conserved	O
8	in	O
9	mammalian	O
10	species	O
11	and	O
12	CENP	B
13	-	I
14	B	I
15	boxes	I
16	are	O
17	found	O
18	also	O
19	in	O
20	mouse	O
21	centromere	O
22	satellite	O
23	DNA	O
24	(	O
25	minor	O
26	satellite	O
27	),	O
28	this	O
29	sequence	O
30	-	O
31	specific	O
32	DNA	O
33	-	O
34	protein	O
35	interaction	O
36	may	O
37	be	O
38	important	O
39	for	O
40	some	O
41	kind	O
42	of	O
43	common	O
44	centromere	O
45	function	O
46	.	O
1	However	O
2	,	O
3	in	O
4	the	O
5	subgroup	O
6	with	O
7	normal	O
8	Ht	O
9	(<	O
10	0	O
11	.	O
12	45	O
13	l	O
14	/	O
15	l	O
16	;	O
17	n	O
18	=	O
19	201	O
20	)	O
21	there	O
22	was	O
23	a	O
24	significant	O
25	reduction	O
26	(	O
27	p	O
28	<	O
29	0	O
30	.	O
31	05	O
32	)	O
33	of	O
34	the	O
35	mortality	O
36	after	O
37	3	O
38	months	O
39	(	O
40	27	O
41	%	O
42	and	O
43	16	O
44	%,	O
45	respectively	O
46	)	O
47	and	O
48	an	O
49	increase	O
50	of	O
51	independence	O
52	at	O
53	home	O
54	(	O
55	35	O
56	%	O
57	and	O
58	48	O
59	%,	O
60	respectively	O
61	)	O
62	due	O
63	to	O
64	a	O
65	reduction	O
66	of	O
67	the	O
68	viscosity	O
69	by	O
70	means	O
71	of	O
72	haemodilution	O
73	with	O
74	albumin	B
75	(	O
76	a	O
77	specific	O
78	viscosity	O
79	effect	O
80	in	O
81	the	O
82	normovolaemic	O
83	group	O
84	).	O
1	RESULTS	O
2	:	O
3	In	O
4	the	O
5	AGA	O
6	group	O
7	,	O
8	both	O
9	fetal	O
10	and	O
11	maternal	O
12	serum	O
13	prolactin	B
14	concentration	O
15	increased	O
16	significantly	O
17	with	O
18	gestation	O
19	(	O
20	P	O
21	<	O
22	0	O
23	.	O
24	001	O
25	and	O
26	P	O
27	<	O
28	0	O
29	.	O
30	01	O
31	,	O
32	respectively	O
33	).	O
1	Therefore	O
2	,	O
3	the	O
4	molecular	O
5	mechanisms	O
6	of	O
7	the	O
8	estrogen	O
9	action	O
10	that	O
11	govern	O
12	the	O
13	lactoferrin	B
14	gene	I
15	expression	O
16	differ	O
17	between	O
18	mouse	O
19	and	O
20	human	O
21	.	O
1	The	O
2	CEM	O
3	receives	O
4	registration	O
5	updates	O
6	via	O
7	an	O
8	HL7	O
9	message	O
10	and	O
11	evaluates	O
12	data	O
13	dependencies	O
14	in	O
15	rules	O
16	via	O
17	an	O
18	interface	O
19	to	O
20	the	O
21	relational	O
22	database	O
23	.	O
1	Patients	O
2	receiving	O
3	VPA	O
4	showed	O
5	differences	O
6	in	O
7	attention	O
8	,	O
9	visuomotor	O
10	performance	O
11	,	O
12	verbal	O
13	span	O
14	and	O
15	sensory	O
16	discrimination	O
17	tasks	O
18	at	O
19	T1	O
20	,	O
21	in	O
22	visuomotor	O
23	performance	O
24	at	O
25	T2	O
26	and	O
27	in	O
28	spatial	O
29	span	O
30	at	O
31	T3	O
32	,	O
33	whereas	O
34	no	O
35	differences	O
36	were	O
37	detected	O
38	at	O
39	T4	O
40	.	O
1	We	O
2	found	O
3	that	O
4	the	O
5	gene	O
6	segment	O
7	containing	O
8	the	O
9	mu	O
10	m	O
11	poly	O
12	(	O
13	A	O
14	)	O
15	signals	O
16	,	O
17	along	O
18	with	O
19	536	O
20	bp	O
21	of	O
22	downstream	O
23	flanking	O
24	sequence	O
25	,	O
26	acted	O
27	as	O
28	a	O
29	transcription	O
30	terminator	O
31	in	O
32	both	O
33	myeloma	O
34	cells	O
35	and	O
36	L	O
37	cell	O
38	fibroblasts	O
39	.	O
1	The	O
2	results	O
3	of	O
4	this	O
5	study	O
6	demonstrate	O
7	that	O
8	strongyloidiasis	O
9	was	O
10	the	O
11	cause	O
12	of	O
13	sudden	O
14	death	O
15	.	O
1	The	O
2	case	O
3	described	O
4	is	O
5	that	O
6	of	O
7	a	O
8	72	O
9	-	O
10	year	O
11	-	O
12	old	O
13	man	O
14	with	O
15	ochronosis	O
16	who	O
17	suffered	O
18	a	O
19	hyperextension	O
20	injury	O
21	to	O
22	his	O
23	spine	O
24	in	O
25	a	O
26	fall	O
27	,	O
28	resulting	O
29	in	O
30	a	O
31	fracture	O
32	through	O
33	an	O
34	ankylosed	O
35	L2	O
36	-	O
37	L3	O
38	disk	O
39	space	O
40	.	O
1	The	O
2	mean	O
3	blood	O
4	flow	O
5	in	O
6	the	O
7	penile	O
8	foreskin	O
9	was	O
10	estimated	O
11	to	O
12	be	O
13	15	O
14	ml	O
15	/	O
16	min	O
17	/	O
18	100	O
19	g	O
20	and	O
21	it	O
22	increased	O
23	to	O
24	150	O
25	-	O
26	200	O
27	%	O
28	after	O
29	the	O
30	induction	O
31	of	O
32	anesthesia	O
33	,	O
34	and	O
35	then	O
36	decreased	O
37	to	O
38	72	O
39	%	O
40	at	O
41	the	O
42	tip	O
43	of	O
44	the	O
45	created	O
46	parameatal	O
47	foreskin	O
48	flap	O
49	.	O
1	ME1a1	B
2	,	O
3	a	O
4	16	O
5	-	O
6	base	O
7	-	O
8	pair	O
9	nuclear	O
10	factor	O
11	binding	O
12	site	O
13	residing	O
14	between	O
15	the	O
16	c	B
17	-	I
18	MYC	I
19	P1	I
20	and	I
21	P2	I
22	transcription	I
23	initiation	I
24	sites	I
25	,	O
26	is	O
27	required	O
28	for	O
29	P2	O
30	activity	O
31	.	O
1	The	O
2	next	O
3	twenty	O
4	years	O
5	of	O
6	prevention	O
7	in	O
8	Indian	O
9	country	O
10	:	O
11	visionary	O
12	,	O
13	complex	O
14	,	O
15	and	O
16	practical	O
17	.	O
1	Replacing	O
2	the	O
3	aspartic	O
4	acid	O
5	with	O
6	a	O
7	lysine	O
8	but	O
9	not	O
10	with	O
11	an	O
12	alanine	O
13	or	O
14	valine	O
15	residue	O
16	allowed	O
17	formation	O
18	of	O
19	disulfide	O
20	-	O
21	linked	O
22	dimers	O
23	.	O
1	We	O
2	show	O
3	that	O
4	LexA	B
5	-	O
6	GAL4	B
7	and	O
8	LexA	B
9	-	O
10	Bicoid	B
11	fusion	O
12	proteins	O
13	are	O
14	both	O
15	dependent	O
16	on	O
17	SNF2	B
18	,	O
19	SNF5	B
20	,	O
21	and	O
22	SNF6	B
23	for	O
24	activation	O
25	of	O
26	target	O
27	genes	O
28	containing	O
29	one	O
30	or	O
31	multiple	O
32	lexA	B
33	operators	I
34	.	O
1	A	O
2	lambda	O
3	gt10	O
4	cDNA	O
5	library	O
6	was	O
7	constructed	O
8	from	O
9	poly	O
10	(	O
11	A	O
12	)+	O
13	RNA	O
14	of	O
15	young	O
16	green	O
17	leaves	O
18	of	O
19	spinach	O
20	.	O
1	Exon	O
2	-	O
3	intron	O
4	junctions	O
5	in	O
6	the	O
7	human	O
8	and	O
9	rat	B
10	AdoMet	I
11	decarboxylase	I
12	genes	I
13	were	O
14	in	O
15	identical	O
16	positions	O
17	except	O
18	that	O
19	exons	O
20	6	O
21	and	O
22	7	O
23	of	O
24	the	O
25	human	O
26	gene	O
27	formed	O
28	a	O
29	single	O
30	exon	O
31	in	O
32	the	O
33	rat	O
34	gene	O
35	.	O
1	Thus	O
2	,	O
3	this	O
4	study	O
5	provides	O
6	evidence	O
7	that	O
8	a	O
9	novel	O
10	,	O
11	ubiquitous	O
12	factor	O
13	(	O
14	HF	B
15	-	I
16	1a	I
17	)	O
18	and	O
19	a	O
20	muscle	O
21	factor	O
22	(	O
23	HF	B
24	-	I
25	1b	I
26	/	O
27	MEF	B
28	-	I
29	2	I
30	)	O
31	can	O
32	form	O
33	a	O
34	novel	O
35	,	O
36	E	O
37	-	O
38	box	O
39	-	O
40	independent	O
41	pathway	O
42	for	O
43	muscle	O
44	-	O
45	specific	O
46	expression	O
47	in	O
48	ventricular	O
49	cardiac	O
50	muscle	O
51	cells	O
52	.	O
1	Using	O
2	bovine	B
3	and	I
4	murine	I
5	c	I
6	-	I
7	myb	I
8	clones	O
9	,	O
10	no	O
11	change	O
12	in	O
13	the	O
14	rate	O
15	of	O
16	c	B
17	-	I
18	myb	I
19	gene	I
20	transcription	O
21	or	O
22	mRNA	O
23	stability	O
24	was	O
25	detected	O
26	during	O
27	the	O
28	cell	O
29	cycle	O
30	.	O
1	A	O
2	13	O
3	base	O
4	-	O
5	pair	O
6	oligonucleotide	O
7	spanning	O
8	nucleotides	O
9	+	O
10	80	O
11	to	O
12	+	O
13	92	O
14	of	O
15	the	O
16	5	B
17	S	I
18	RNA	I
19	gene	I
20	retained	O
21	specific	O
22	and	O
23	high	O
24	-	O
25	affinity	O
26	binding	O
27	,	O
28	although	O
29	the	O
30	latter	O
31	was	O
32	reduced	O
33	sixfold	O
34	relative	O
35	to	O
36	longer	O
37	DNA	O
38	fragments	O
39	.	O
1	The	O
2	p130	B
3	and	O
4	p62	B
5	tyrosine	O
6	-	O
7	phosphorylated	O
8	proteins	O
9	that	O
10	complexed	O
11	v	B
12	-	I
13	Src	I
14	SH2	I
15	in	O
16	vitro	O
17	also	O
18	associated	O
19	with	O
20	v	B
21	-	I
22	Src	I
23	in	O
24	v	B
25	-	I
26	src	I
27	-	O
28	transformed	O
29	Rat	O
30	-	O
31	2	O
32	cells	O
33	;	O
34	this	O
35	in	O
36	vivo	O
37	binding	O
38	was	O
39	dependent	O
40	on	O
41	the	O
42	v	B
43	-	I
44	Src	I
45	SH2	I
46	domain	O
47	.	O
1	These	O
2	data	O
3	support	O
4	a	O
5	possible	O
6	biological	O
7	significance	O
8	of	O
9	the	O
10	frameshift	O
11	to	O
12	occur	O
13	at	O
14	this	O
15	position	O
16	of	O
17	the	O
18	large	O
19	overlap	O
20	by	O
21	including	O
22	the	O
23	putative	O
24	RNA	O
25	template	O
26	-	O
27	binding	O
28	site	O
29	of	O
30	the	O
31	PLRV	B
32	replicase	I
33	in	O
34	the	O
35	ORF2a	B
36	/	I
37	ORF2b	I
38	transframe	I
39	protein	I
40	.	O
1	Proprotein	O
2	processing	O
3	occurs	O
4	intracellularly	O
5	.	O
1	Previous	O
2	transactivation	O
3	experiments	O
4	indicated	O
5	that	O
6	three	O
7	amino	O
8	acids	O
9	residing	O
10	in	O
11	this	O
12	region	O
13	,	O
14	Gly	O
15	,	O
16	Ser	O
17	and	O
18	Val	O
19	,	O
20	appear	O
21	to	O
22	be	O
23	critical	O
24	for	O
25	target	O
26	-	O
27	site	O
28	discrimination	O
29	.	O
1	This	O
2	vector	O
3	transfected	O
4	into	O
5	the	O
6	yeast	O
7	Saccharomyces	O
8	cerevisiae	O
9	directs	O
10	expression	O
11	of	O
12	a	O
13	secreted	O
14	mature	O
15	protein	O
16	at	O
17	levels	O
18	up	O
19	to	O
20	200	O
21	mg	O
22	of	O
23	LAPP	O
24	/	O
25	liter	O
26	of	O
27	culture	O
28	medium	O
29	.	O
1	OBJECTIVE	O
2	:	O
3	The	O
4	study	O
5	was	O
6	designed	O
7	to	O
8	investigate	O
9	the	O
10	frequency	O
11	of	O
12	alterations	O
13	in	O
14	serum	O
15	creatinine	O
16	in	O
17	patients	O
18	with	O
19	psoriasis	O
20	receiving	O
21	5	O
22	mg	O
23	/	O
24	kg	O
25	/	O
26	day	O
27	of	O
28	cyclosporine	O
29	.	O
1	Electromagnetic	O
2	blood	O
3	flow	O
4	(	O
5	BF	O
6	)	O
7	probe	O
8	was	O
9	applied	O
10	on	O
11	the	O
12	left	O
13	anterior	O
14	descending	O
15	artery	O
16	(	O
17	LAD	O
18	).	O
1	Thus	O
2	,	O
3	the	O
4	human	B
5	D1A	I
6	gene	I
7	belongs	O
8	to	O
9	the	O
10	category	O
11	of	O
12	tissue	O
13	-	O
14	specific	O
15	,	O
16	regulated	O
17	genes	O
18	that	O
19	have	O
20	housekeeping	O
21	-	O
22	type	O
23	promoters	O
24	.	O
1	To	O
2	determine	O
3	the	O
4	genetic	O
5	basis	O
6	for	O
7	the	O
8	differences	O
9	between	O
10	the	O
11	cardiac	O
12	and	O
13	brain	B
14	AE3	I
15	variants	I
16	,	O
17	we	O
18	isolated	O
19	and	O
20	characterized	O
21	the	O
22	rat	O
23	gene	O
24	.	O
1	Lac	B
2	operators	O
3	were	O
4	introduced	O
5	into	O
6	several	O
7	positions	O
8	within	O
9	the	O
10	CAB	B
11	promoter	I
12	and	O
13	operator	O
14	-	O
15	free	O
16	plasmid	O
17	was	O
18	used	O
19	as	O
20	control	O
21	.	O
1	Twenty	O
2	-	O
3	eight	O
4	(	O
5	7	O
6	.	O
7	0	O
8	%)	O
9	infants	O
10	without	O
11	periventricular	O
12	hemorrhage	O
13	were	O
14	revealed	O
15	as	O
16	having	O
17	spastic	O
18	cerebral	O
19	palsy	O
20	by	O
21	neurodevelopmental	O
22	evaluation	O
23	in	O
24	later	O
25	infancy	O
26	.	O
1	Here	O
2	,	O
3	we	O
4	present	O
5	evidence	O
6	for	O
7	a	O
8	model	O
9	in	O
10	which	O
11	mRNA	O
12	sequences	O
13	up	O
14	to	O
15	around	O
16	100	O
17	nucleotides	O
18	downstream	O
19	from	O
20	the	O
21	start	O
22	codon	O
23	of	O
24	21K	O
25	fold	O
26	back	O
27	and	O
28	base	O
29	-	O
30	pair	O
31	to	O
32	the	O
33	21K	O
34	translation	O
35	initiation	O
36	region	O
37	,	O
38	thereby	O
39	decreasing	O
40	the	O
41	translation	O
42	initiation	O
43	frequency	O
44	.	O
1	PSI	B
2	-	I
3	G	I
4	and	O
5	PSI	B
6	-	I
7	K	I
8	probably	O
9	have	O
10	evolved	O
11	from	O
12	a	O
13	gene	O
14	duplication	O
15	of	O
16	an	O
17	ancestral	O
18	gene	O
19	.	O
1	At	O
2	the	O
3	C	O
4	-	O
5	terminus	O
6	of	O
7	the	O
8	protein	O
9	is	O
10	a	O
11	domain	O
12	that	O
13	contains	O
14	sequences	O
15	very	O
16	similar	O
17	to	O
18	those	O
19	found	O
20	in	O
21	the	O
22	breakpoint	O
23	cluster	O
24	region	O
25	gene	O
26	product	O
27	,	O
28	n	B
29	-	I
30	chimerin	I
31	,	O
32	and	O
33	rho	B
34	GAP	I
35	,	O
36	all	O
37	of	O
38	which	O
39	have	O
40	been	O
41	shown	O
42	to	O
43	possess	O
44	intrinsic	O
45	GAP	B
46	activity	O
47	on	O
48	small	B
49	GTPases	I
50	.	O
1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	revealed	O
6	that	O
7	two	O
8	clusters	O
9	of	O
10	basic	O
11	amino	O
12	acids	O
13	within	O
14	a	O
15	conserved	O
16	basic	O
17	region	O
18	and	O
19	two	O
20	amphipathic	O
21	helices	O
22	within	O
23	the	O
24	adjacent	O
25	HLH	O
26	domain	O
27	are	O
28	essential	O
29	for	O
30	sequence	O
31	-	O
32	specific	O
33	DNA	O
34	binding	O
35	and	O
36	hetero	O
37	-	O
38	oligomerization	O
39	,	O
40	respectively	O
41	.	O
1	The	O
2	circadian	O
3	rhythmicity	O
4	of	O
5	sleep	O
6	was	O
7	pronounced	O
8	.	O
1	Neural	O
2	-	O
3	specific	O
4	expression	O
5	,	O
6	genomic	O
7	structure	O
8	,	O
9	and	O
10	chromosomal	O
11	localization	O
12	of	O
13	the	O
14	gene	O
15	encoding	O
16	the	O
17	zinc	B
18	-	I
19	finger	I
20	transcription	I
21	factor	I
22	NGFI	I
23	-	I
24	C	I
25	.	O
1	The	O
2	sequence	O
3	data	O
4	now	O
5	permit	O
6	a	O
7	detailed	O
8	interpretation	O
9	of	O
10	the	O
11	X	O
12	-	O
13	ray	O
14	crystallographic	O
15	structure	O
16	of	O
17	the	O
18	enzyme	O
19	and	O
20	the	O
21	cloning	O
22	and	O
23	expression	O
24	of	O
25	the	O
26	clostridial	O
27	gene	O
28	will	O
29	facilitate	O
30	site	O
31	-	O
32	directed	O
33	mutagenesis	O
34	.	O
1	A	O
2	reduction	O
3	in	O
4	blood	O
5	pressure	O
6	was	O
7	only	O
8	observed	O
9	at	O
10	the	O
11	end	O
12	of	O
13	the	O
14	study	O
15	,	O
16	from	O
17	142	O
18	+/-	O
19	17	O
20	/	O
21	86	O
22	.	O
23	6	O
24	+/-	O
25	9	O
26	.	O
27	1	O
28	to	O
29	139	O
30	+/-	O
31	13	O
32	/	O
33	82	O
34	.	O
35	9	O
36	+/-	O
37	8	O
38	.	O
39	9	O
40	mmHg	O
41	(	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	05	O
48	for	O
49	DBP	O
50	).	O
1	A	O
2	gene	O
3	homologous	O
4	to	O
5	the	O
6	Escherichia	B
7	coli	I
8	dnaA	I
9	gene	I
10	was	O
11	isolated	O
12	from	O
13	Pseudomonas	O
14	putida	O
15	and	O
16	its	O
17	transcription	O
18	was	O
19	investigated	O
20	in	O
21	E	O
22	.	O
23	coli	O
24	as	O
25	well	O
26	as	O
27	in	O
28	P	O
29	.	O
30	putida	O
31	.	O
1	STP1	B
2	is	O
3	an	O
4	unessential	O
5	yeast	O
6	gene	O
7	involved	O
8	in	O
9	the	O
10	removal	O
11	of	O
12	intervening	O
13	sequences	O
14	from	O
15	some	O
16	,	O
17	but	O
18	not	O
19	all	O
20	,	O
21	families	O
22	of	O
23	intervening	O
24	sequence	O
25	-	O
26	containing	O
27	pre	O
28	-	O
29	tRNAs	O
30	.	O
1	Recent	O
2	investigations	O
3	have	O
4	detailed	O
5	a	O
6	selective	O
7	dye	O
8	release	O
9	technique	O
10	in	O
11	which	O
12	a	O
13	pulse	O
14	of	O
15	laser	O
16	light	O
17	induces	O
18	the	O
19	release	O
20	of	O
21	a	O
22	fluorescent	O
23	dye	O
24	from	O
25	temperature	O
26	-	O
27	sensitive	O
28	liposomes	O
29	circulating	O
30	in	O
31	the	O
32	retinal	O
33	vasculature	O
34	.	O
1	And	O
2	the	O
3	natural	O
4	barriers	O
5	?	O
1	Three	O
2	pyridoxine	O
3	derivatives	O
4	have	O
5	been	O
6	isolated	O
7	from	O
8	the	O
9	fresh	O
10	stem	O
11	bark	O
12	of	O
13	Albizzia	O
14	julibrissin	O
15	DURAZZ	O
16	..	O
1	The	O
2	coating	O
3	materials	O
4	were	O
5	poloxamine	O
6	904	O
7	,	O
8	poloxamine	O
9	908	O
10	,	O
11	poloxamine	O
12	1508	O
13	,	O
14	poloxamer	O
15	338	O
16	,	O
17	and	O
18	Brij	O
19	35	O
20	.	O
1	The	O
2	eating	O
3	and	O
4	drinking	O
5	patterns	O
6	of	O
7	pygmy	O
8	goats	O
9	fed	O
10	ad	O
11	lib	O
12	and	O
13	kept	O
14	on	O
15	a	O
16	12	O
17	h	O
18	light	O
19	/	O
20	12	O
21	h	O
22	dark	O
23	cycle	O
24	were	O
25	recorded	O
26	and	O
27	analyzed	O
28	.	O
1	Argatroban	O
2	may	O
3	be	O
4	more	O
5	effective	O
6	under	O
7	low	O
8	HC	B
9	II	I
10	conditions	O
11	because	O
12	of	O
13	its	O
14	potent	O
15	inhibition	O
16	of	O
17	thrombin	B
18	activity	O
19	at	O
20	sites	O
21	of	O
22	vascular	O
23	wall	O
24	damage	O
25	.	O
1	These	O
2	results	O
3	support	O
4	the	O
5	diagnostic	O
6	validity	O
7	of	O
8	NFPD	O
9	in	O
10	CP	O
11	/	O
12	NCA	O
13	patients	O
14	,	O
15	because	O
16	such	O
17	patients	O
18	had	O
19	a	O
20	family	O
21	history	O
22	of	O
23	panic	O
24	disorder	O
25	similar	O
26	to	O
27	patients	O
28	with	O
29	a	O
30	more	O
31	classical	O
32	panic	O
33	disorder	O
34	presentation	O
35	.	O
1	Furthermore	O
2	,	O
3	no	O
4	transcripts	O
5	of	O
6	the	O
7	same	O
8	size	O
9	and	O
10	having	O
11	the	O
12	same	O
13	developmental	O
14	profile	O
15	as	O
16	those	O
17	generated	O
18	by	O
19	the	O
20	wild	B
21	-	I
22	type	I
23	E10	I
24	fragment	I
25	were	O
26	identified	O
27	by	O
28	probes	O
29	covering	O
30	the	O
31	remainder	O
32	of	O
33	the	O
34	cloned	O
35	region	O
36	.	O
1	In	O
2	conclusion	O
3	,	O
4	to	O
5	study	O
6	and	O
7	overcome	O
8	TI	O
9	region	O
10	-	O
11	based	O
12	expression	O
13	problems	O
14	it	O
15	is	O
16	worthwhile	O
17	to	O
18	start	O
19	out	O
20	with	O
21	a	O
22	versatile	O
23	vector	O
24	containing	O
25	exhaustive	O
26	mutations	O
27	in	O
28	the	O
29	periShine	O
30	-	O
31	Dalgarno	O
32	sequences	O
33	;	O
34	as	O
35	a	O
36	rule	O
37	the	O
38	coding	O
39	MTI	O
40	subregion	O
41	can	O
42	be	O
43	kept	O
44	unchanged	O
45	.	O
1	Incidence	O
2	rate	O
3	ranging	O
4	between	O
5	122	O
6	/	O
7	100	O
8	,	O
9	000	O
10	/	O
11	year	O
12	and	O
13	190	O
14	/	O
15	100	O
16	,	O
17	000	O
18	/	O
19	year	O
20	were	O
21	found	O
22	(	O
23	minimum	O
24	,	O
25	estimated	O
26	and	O
27	raw	O
28	datasets	O
29	).	O
1	A	O
2	38	O
3	-	O
4	bp	O
5	poly	O
6	(	O
7	dA	O
8	-	O
9	dT	O
10	)	O
11	region	O
12	was	O
13	found	O
14	to	O
15	be	O
16	a	O
17	positive	O
18	regulator	O
19	of	O
20	Act1	B
21	promoter	I
22	activity	O
23	.	O
1	We	O
2	report	O
3	a	O
4	patient	O
5	developing	O
6	factor	B
7	VII	I
8	inhibitor	I
9	possibly	O
10	as	O
11	a	O
12	reaction	O
13	to	O
14	penicillin	O
15	administration	O
16	;	O
17	it	O
18	gave	O
19	rise	O
20	to	O
21	fatal	O
22	haemorrhage	O
23	.	O
1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	carbon	O
7	-	O
8	perfused	O
9	areas	O
10	and	O
11	MBF	O
12	in	O
13	the	O
14	liver	O
15	,	O
16	renal	O
17	cortex	O
18	,	O
19	spleen	O
20	,	O
21	and	O
22	small	O
23	intestinal	O
24	serosa	O
25	(	O
26	only	O
27	MBF	O
28	)	O
29	increased	O
30	significantly	O
31	5	O
32	h	O
33	after	O
34	CLP	O
35	.	O
1	Recently	O
2	,	O
3	the	O
4	3	B
5	.	I
6	6	I
7	-	I
8	kb	I
9	full	I
10	-	I
11	length	I
12	alpha	I
13	-	I
14	GalNAc	I
15	cDNA	I
16	sequence	I
17	was	O
18	isolated	O
19	and	O
20	found	O
21	to	O
22	have	O
23	remarkable	O
24	nucleotide	O
25	and	O
26	predicted	O
27	amino	O
28	acid	O
29	homology	O
30	(	O
31	55	O
32	.	O
33	8	O
34	and	O
35	46	O
36	.	O
37	9	O
38	%,	O
39	respectively	O
40	)	O
41	with	O
42	the	O
43	human	B
44	alpha	I
45	-	I
46	galactosidase	I
47	A	I
48	(	O
49	alpha	B
50	-	I
51	Gal	I
52	A	I
53	)	O
54	cDNA	O
55	.	O
1	Patients	O
2	with	O
3	an	O
4	enzymatic	O
5	activity	O
6	below	O
7	X	O
8	--	O
9	1	O
10	manifested	O
11	a	O
12	decrease	O
13	of	O
14	the	O
15	content	O
16	of	O
17	IgA	B
18	,	O
19	IgG	B
20	,	O
21	IgM	B
22	,	O
23	T	O
24	and	O
25	B	O
26	lymphocytes	O
27	,	O
28	and	O
29	of	O
30	phagocytic	O
31	activity	O
32	of	O
33	neutrophils	O
34	as	O
35	compared	O
36	to	O
37	patients	O
38	exhibiting	O
39	a	O
40	high	O
41	enzymatic	O
42	activity	O
43	.	O
1	The	O
2	reason	O
3	that	O
4	nitrous	O
5	oxide	O
6	does	O
7	not	O
8	produce	O
9	hydroxyl	O
10	radicals	O
11	readily	O
12	might	O
13	be	O
14	that	O
15	the	O
16	one	O
17	-	O
18	electron	O
19	reduction	O
20	proceeds	O
21	through	O
22	an	O
23	N2O	O
24	-	O
25	intermediate	O
26	which	O
27	is	O
28	energetically	O
29	very	O
30	unfavourable	O
31	:	O
32	EO	O
33	(	O
34	N2O	O
35	/	O
36	N2O	O
37	-)	O
38	=	O
39	-	O
40	1	O
41	.	O
42	1	O
43	V	O
44	.	O
1	We	O
2	identify	O
3	the	O
4	""""	O
5	M	O
6	region	O
7	""""	O
8	of	O
9	the	O
10	muscle	B
11	-	I
12	specific	I
13	Xenopus	I
14	cardiac	I
15	actin	I
16	gene	I
17	promoter	I
18	from	O
19	-	O
20	282	O
21	to	O
22	-	O
23	348	O
24	as	O
25	necessary	O
26	for	O
27	the	O
28	embryonic	O
29	expression	O
30	of	O
31	a	O
32	cardiac	O
33	actin	B
34	-	O
35	beta	B
36	-	I
37	globin	I
38	reporter	O
39	gene	O
40	injected	O
41	into	O
42	fertilized	O
43	eggs	O
44	.	O
1	EBNA	B
2	-	I
3	2	I
4	and	O
5	the	O
6	cis	O
7	-	O
8	acting	O
9	CD23	B
10	element	I
11	increased	O
12	TK	B
13	-	O
14	promoted	O
15	mRNA	O
16	and	O
17	did	O
18	not	O
19	alter	O
20	the	O
21	herpes	B
22	simplex	I
23	virus	I
24	TK	I
25	promoter	I
26	transcription	I
27	start	I
28	site	I
29	.	O
1	The	O
2	initial	O
3	phase	O
4	of	O
5	increased	O
6	vascular	O
7	permeability	O
8	in	O
9	the	O
10	peritoneal	O
11	cavity	O
12	and	O
13	LTB4	O
14	production	O
15	was	O
16	dose	O
17	dependently	O
18	inhibited	O
19	by	O
20	the	O
21	5	O
22	-	O
23	LO	O
24	inhibitors	O
25	phenidone	O
26	,	O
27	BW	O
28	A4C	O
29	,	O
30	A63162	O
31	,	O
32	and	O
33	ICI	O
34	207	O
35	968	O
36	but	O
37	not	O
38	by	O
39	dexamethasone	O
40	or	O
41	colchicine	O
42	.	O
1	We	O
2	have	O
3	identified	O
4	SWI5	B
5	'	O
6	s	O
7	nuclear	O
8	localization	O
9	signal	O
10	(	O
11	NLS	O
12	)	O
13	and	O
14	show	O
15	that	O
16	it	O
17	can	O
18	confer	O
19	cell	O
20	cycle	O
21	-	O
22	dependent	O
23	nuclear	O
24	entry	O
25	to	O
26	a	O
27	heterologous	O
28	protein	O
29	.	O
1	Two	O
2	putative	O
3	12	O
4	-	O
5	O	O
6	-	O
7	tetradecanoyl	O
8	-	O
9	phorbol	O
10	-	O
11	13	O
12	-	O
13	acetate	O
14	(	O
15	TPA	O
16	)	O
17	response	O
18	elements	O
19	,	O
20	that	O
21	might	O
22	serve	O
23	as	O
24	binding	O
25	sites	O
26	for	O
27	the	O
28	transcription	B
29	factor	I
30	AP	I
31	-	I
32	1	I
33	and	O
34	a	O
35	consensus	O
36	sequence	O
37	of	O
38	a	O
39	transforming	B
40	growth	I
41	factor	I
42	beta	I
43	1	I
44	(	O
45	TGF	B
46	-	I
47	beta	I
48	1	I
49	)	O
50	inhibitory	O
51	element	O
52	were	O
53	found	O
54	in	O
55	the	O
56	promoter	O
57	region	O
58	.	O
1	axl	O
2	,	O
3	a	O
4	transforming	O
5	gene	O
6	isolated	O
7	from	O
8	primary	O
9	human	O
10	myeloid	O
11	leukemia	O
12	cells	O
13	,	O
14	encodes	O
15	a	O
16	novel	O
17	receptor	B
18	tyrosine	I
19	kinase	I
20	.	O
1	However	O
2	,	O
3	alterations	O
4	in	O
5	electrostatic	O
6	and	O
7	hydrophobic	O
8	interactions	O
9	created	O
10	by	O
11	the	O
12	three	O
13	amino	O
14	acid	O
15	substitutions	O
16	prevent	O
17	the	O
18	conformational	O
19	change	O
20	in	O
21	the	O
22	enzyme	O
23	usually	O
24	produced	O
25	by	O
26	calmodulin	B
27	binding	O
28	.	O
1	No	O
2	homology	O
3	was	O
4	found	O
5	between	O
6	RNA14	B
7	and	O
8	RNA15	B
9	or	O
10	between	O
11	RNA14	B
12	and	O
13	other	O
14	proteins	O
15	contained	O
16	in	O
17	data	O
18	banks	O
19	.	O
1	Mutations	O
2	in	O
3	the	O
4	yeast	B
5	RNA14	I
6	and	O
7	RNA15	B
8	genes	I
9	result	O
10	in	O
11	an	O
12	abnormal	O
13	mRNA	O
14	decay	O
15	rate	O
16	;	O
17	sequence	O
18	analysis	O
19	reveals	O
20	an	O
21	RNA	O
22	-	O
23	binding	O
24	domain	O
25	in	O
26	the	O
27	RNA15	B
28	protein	I
29	.	O
1	Diagnostic	O
2	value	O
3	of	O
4	cerebrospinal	B
5	fluid	I
6	immunoglobulin	I
7	G	I
8	(	O
9	IgG	B
10	)	O
11	in	O
12	pediatric	O
13	neurological	O
14	diseases	O
15	.	O
1	Both	O
2	genes	O
3	comprise	O
4	three	O
5	exons	O
6	,	O
7	two	O
8	introns	O
9	and	O
10	an	O
11	unusually	O
12	long	O
13	3	O
14	'-	O
15	untranslated	O
16	region	O
17	(	O
18	3	O
19	.	O
20	2	O
21	kilobase	O
22	pairs	O
23	),	O
24	specificying	O
25	a	O
26	mRNA	O
27	of	O
28	approximately	O
29	4	O
30	.	O
31	1	O
32	kilobases	O
33	.	O
1	Stable	O
2	expression	O
3	of	O
4	the	O
5	chimeric	O
6	alpha	B
7	i	I
8	(	I
9	54	I
10	)/	I
11	s	I
12	polypeptide	O
13	in	O
14	Chinese	O
15	hamster	O
16	ovary	O
17	(	O
18	CHO	O
19	)	O
20	cells	O
21	constitutively	O
22	increased	O
23	both	O
24	cAMP	O
25	synthesis	O
26	and	O
27	cAMP	B
28	-	I
29	dependent	I
30	protein	I
31	kinase	I
32	activity	O
33	.	O
1	A	O
2	new	O
3	,	O
4	flexible	O
5	fiberoptic	O
6	ventriculoscope	O
7	for	O
8	observation	O
9	of	O
10	the	O
11	ventricles	O
12	and	O
13	major	O
14	cisterns	O
15	is	O
16	reported	O
17	.	O
1	Platelet	O
2	aggregation	O
3	and	O
4	metabolic	O
5	control	O
6	are	O
7	not	O
8	affected	O
9	by	O
10	calcium	O
11	antagonist	O
12	treatment	O
13	in	O
14	type	O
15	II	O
16	diabetes	O
17	mellitus	O
18	.	O
1	(	O
2	1988	O
3	)	O
4	J	O
5	.	O
1	These	O
2	results	O
3	strongly	O
4	suggested	O
5	that	O
6	similar	O
7	,	O
8	if	O
9	not	O
10	identical	O
11	,	O
12	the	O
13	CArG	B
14	box	I
15	binding	I
16	proteins	I
17	interact	O
18	with	O
19	the	O
20	functionally	O
21	different	O
22	promoter	O
23	element	O
24	in	O
25	the	O
26	VLC1	B
27	,	O
28	cardiac	B
29	alpha	I
30	-	I
31	actin	I
32	,	O
33	and	O
34	c	B
35	-	I
36	fos	I
37	genes	I
38	.	O
1	Recently	O
2	,	O
3	studies	O
4	of	O
5	agents	O
6	that	O
7	disrupt	O
8	collagen	B
9	synthesis	O
10	and	O
11	deposition	O
12	have	O
13	yielded	O
14	several	O
15	new	O
16	angiogenesis	O
17	inhibitors	O
18	.	O
1	Since	O
2	the	O
3	5	O
4	'-	O
5	flanking	O
6	region	O
7	of	O
8	this	O
9	gene	O
10	is	O
11	likely	O
12	involved	O
13	in	O
14	hormonal	O
15	regulation	O
16	of	O
17	its	O
18	expression	O
19	,	O
20	we	O
21	have	O
22	isolated	O
23	and	O
24	partially	O
25	characterized	O
26	an	O
27	avian	O
28	fatty	B
29	acid	I
30	synthase	I
31	gene	O
32	.	O
1	Lymphoproliferative	O
2	disorders	O
3	arising	O
4	under	O
5	immunosuppression	O
6	with	O
7	FK	O
8	506	O
9	:	O
10	initial	O
11	observations	O
12	in	O
13	a	O
14	large	O
15	transplant	O
16	population	O
17	.	O
1	It	O
2	is	O
3	,	O
4	however	O
5	,	O
6	extremely	O
7	homologous	O
8	to	O
9	a	O
10	third	O
11	'	O
12	non	O
13	-	O
14	classical	O
15	'	O
16	gene	O
17	,	O
18	HLA	B
19	-	I
20	5	I
21	.	I
22	4	I
23	,	O
24	and	O
25	to	O
26	the	O
27	chimpanzee	O
28	gene	O
29	,	O
30	Ch28	B
31	.	O
1	The	O
2	DNA	O
3	sequence	O
4	conferring	O
5	AP	B
6	-	I
7	1	I
8	activity	O
9	was	O
10	located	O
11	in	O
12	the	O
13	proximal	O
14	promoter	O
15	region	O
16	.	O
1	The	O
2	SH2	B
3	and	O
4	SH3	B
5	domains	I
6	of	O
7	pp60src	B
8	direct	O
9	stable	O
10	association	O
11	with	O
12	tyrosine	O
13	phosphorylated	O
14	proteins	O
15	p130	B
16	and	O
17	p110	B
18	.	O
1	The	O
2	10	O
3	kDa	O
4	polypeptide	O
5	was	O
6	phosphorylated	O
7	in	O
8	vitro	O
9	by	O
10	incubating	O
11	wheat	O
12	etioplast	O
13	membranes	O
14	with	O
15	[	O
16	gamma	O
17	32P	O
18	]	O
19	ATP	O
20	.	O
1	In	O
2	addition	O
3	to	O
4	targeting	O
5	partially	O
6	assembled	O
7	Ti	B
8	alpha	I
9	-	I
10	beta	I
11	CD3	I
12	gamma	I
13	delta	I
14	epsilon	I
15	TCR	I
16	complexes	I
17	to	O
18	the	O
19	cell	O
20	surface	O
21	,	O
22	CD3	B
23	zeta	I
24	appears	O
25	to	O
26	be	O
27	essential	O
28	for	O
29	interleukin	B
30	-	I
31	2	I
32	production	O
33	after	O
34	TCR	B
35	stimulation	O
36	with	O
37	antigen	B
38	/	I
39	major	I
40	histocompatibility	I
41	complex	I
42	.	O
1	When	O
2	desipramine	O
3	was	O
4	injected	O
5	16	O
6	hrs	O
7	after	O
8	fluoxetine	O
9	injection	O
10	,	O
11	brain	O
12	levels	O
13	of	O
14	desipramine	O
15	were	O
16	no	O
17	longer	O
18	elevated	O
19	.	O
1	Opposite	O
2	effects	O
3	of	O
4	CYP1	B
5	are	O
6	observed	O
7	in	O
8	aerobic	O
9	,	O
10	heme	O
11	-	O
12	sufficient	O
13	cells	O
14	.	O
1	Finally	O
2	,	O
3	some	O
4	point	O
5	mutations	O
6	in	O
7	the	O
8	Gag	B
9	-	O
10	Pol	B
11	PR	O
12	domain	O
13	inhibited	O
14	activation	O
15	of	O
16	RT	B
17	in	O
18	trans	O
19	by	O
20	a	O
21	wild	O
22	-	O
23	type	O
24	PR	B
25	,	O
26	suggesting	O
27	that	O
28	the	O
29	correct	O
30	conformation	O
31	of	O
32	the	O
33	PR	B
34	domain	O
35	in	O
36	Gag	B
37	-	O
38	Pol	B
39	is	O
40	prerequisite	O
41	for	O
42	activation	O
43	of	O
44	RT	B
45	.	O
1	Cloning	O
2	of	O
3	a	O
4	human	O
5	cDNA	O
6	encoding	O
7	a	O
8	CDC2	B
9	-	I
10	related	I
11	kinase	I
12	by	O
13	complementation	O
14	of	O
15	a	O
16	budding	B
17	yeast	I
18	cdc28	I
19	mutation	O
20	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	sulfhydryl	O
7	group	O
8	of	O
9	certain	O
10	angiotensin	B
11	converting	I
12	enzyme	I
13	inhibitors	O
14	can	O
15	potentiate	O
16	their	O
17	effect	O
18	on	O
19	the	O
20	endogenous	O
21	nitrovasodilator	O
22	EDRF	B
23	.	O
1	Pharmacokinetics	O
2	of	O
3	FK	O
4	506	O
5	in	O
6	transplant	O
7	patients	O
8	.	O
1	The	O
2	reduced	O
3	rate	O
4	of	O
5	F	O
6	absorption	O
7	and	O
8	slower	O
9	rise	O
10	in	O
11	plasma	O
12	F	O
13	concentration	O
14	accompanying	O
15	delayed	O
16	gastric	O
17	emptying	O
18	indicate	O
19	that	O
20	passage	O
21	of	O
22	F	O
23	into	O
24	the	O
25	small	O
26	intestine	O
27	is	O
28	the	O
29	major	O
30	factor	O
31	in	O
32	rapid	O
33	F	O
34	absorption	O
35	.	O
1	Vaccinia	O
2	virus	O
3	(	O
4	VV	O
5	)	O
6	is	O
7	a	O
8	potent	O
9	immunogen	O
10	,	O
11	but	O
12	the	O
13	nature	O
14	of	O
15	VV	O
16	proteins	O
17	involved	O
18	in	O
19	the	O
20	activation	O
21	of	O
22	the	O
23	immune	O
24	response	O
25	of	O
26	the	O
27	host	O
28	is	O
29	not	O
30	yet	O
31	known	O
32	.	O
1	Substitutions	O
2	introduced	O
3	at	O
4	bases	O
5	surrounding	O
6	the	O
7	ICR2	B
8	motif	I
9	yielded	O
10	levels	O
11	of	O
12	pRNA	O
13	replication	O
14	that	O
15	differed	O
16	,	O
17	depending	O
18	on	O
19	the	O
20	maintenance	O
21	of	O
22	a	O
23	putative	O
24	5	O
25	'	O
26	stem	O
27	-	O
28	loop	O
29	structure	O
30	in	O
31	the	O
32	positive	O
33	strand	O
34	of	O
35	the	O
36	viral	O
37	genome	O
38	.	O
1	Zn	O
2	(	O
3	II	O
4	)	O
5	coordination	O
6	domain	O
7	mutants	O
8	of	O
9	T4	O
10	gene	B
11	32	I
12	protein	O
13	.	O
1	The	O
2	tissue	O
3	specificity	O
4	of	O
5	gene	O
6	expression	O
7	was	O
8	identical	O
9	to	O
10	that	O
11	described	O
12	previously	O
13	for	O
14	the	O
15	CaMV	B
16	35S	I
17	domain	I
18	B	I
19	enhancer	I
20	element	I
21	.	O
1	The	O
2	pathophysiology	O
3	and	O
4	clinical	O
5	management	O
6	of	O
7	acute	O
8	brain	O
9	injury	O
10	in	O
11	infancy	O
12	and	O
13	childhood	O
14	are	O
15	presented	O
16	using	O
17	acute	O
18	traumatic	O
19	brain	O
20	injury	O
21	as	O
22	a	O
23	model	O
24	.	O
1	Thus	O
2	,	O
3	the	O
4	active	O
5	-	O
6	site	O
7	mutation	O
8	prevents	O
9	the	O
10	wild	O
11	-	O
12	type	O
13	processing	O
14	of	O
15	the	O
16	N	O
17	-	O
18	glycosylated	O
19	73	O
20	-	O
21	kDa	O
22	precursor	O
23	of	O
24	PrB	B
25	to	O
26	the	O
27	41	B
28	.	I
29	5	I
30	kDa	I
31	pro	I
32	-	I
33	PrB	I
34	in	O
35	the	O
36	endoplasmic	O
37	reticulum	O
38	.	O
1	SETTING	O
2	--	O
3	Women	O
4	,	O
5	Infants	O
6	,	O
7	and	O
8	Children	O
9	clinics	O
10	in	O
11	Minneapolis	O
12	,	O
13	Minn	O
14	.	O
1	The	O
2	upstream	O
3	delta	O
4	-	O
5	alpha	O
6	breakpoint	O
7	is	O
8	flanked	O
9	by	O
10	the	O
11	direct	O
12	repeats	O
13	of	O
14	the	O
15	acceptor	O
16	splice	O
17	site	O
18	,	O
19	whereas	O
20	the	O
21	down	O
22	-	O
23	stream	O
24	alpha	O
25	-	O
26	delta	O
27	breakpoint	O
28	is	O
29	located	O
30	in	O
31	the	O
32	adjacent	O
33	intron	O
34	.	O
1	Management	O
2	often	O
3	involves	O
4	beta	O
5	-	O
6	and	O
7	calcium	O
8	channel	O
9	blocking	O
10	drugs	O
11	or	O
12	type	O
13	IC	O
14	antiarrhythmic	O
15	drugs	O
16	.	O
1	To	O
2	overcome	O
3	this	O
4	problem	O
5	,	O
6	we	O
7	have	O
8	overexpressed	O
9	Kex2p	B
10	using	O
11	the	O
12	baculovirus	O
13	/	O
14	insect	O
15	cell	O
16	expression	O
17	system	O
18	.	O
1	W	O
2	.	O
3	G	O
4	.	O
1	This	O
2	study	O
3	confirms	O
4	,	O
5	although	O
6	individual	O
7	reaction	O
8	is	O
9	remarkably	O
10	different	O
11	,	O
12	transportation	O
13	as	O
14	a	O
15	potent	O
16	stressor	O
17	for	O
18	Beagle	O
19	dogs	O
20	.	O
1	RESULTS	O
2	:	O
3	Plasma	B
4	AVP	I
5	responses	O
6	to	O
7	osmotic	O
8	stimulation	O
9	,	O
10	and	O
11	non	O
12	-	O
13	osmotic	O
14	inhibition	O
15	by	O
16	drinking	O
17	,	O
18	were	O
19	normal	O
20	in	O
21	patients	O
22	with	O
23	compulsive	O
24	water	O
25	drinking	O
26	.	O
1	The	O
2	csbA	B
3	fusion	I
4	was	O
5	maximally	O
6	expressed	O
7	during	O
8	early	O
9	stationary	O
10	phase	O
11	in	O
12	cells	O
13	grown	O
14	in	O
15	Luria	O
16	broth	O
17	containing	O
18	5	O
19	%	O
20	glucose	O
21	and	O
22	0	O
23	.	O
24	2	O
25	%	O
26	glutamine	O
27	.	O
1	In	O
2	this	O
3	report	O
4	,	O
5	almost	O
6	6	O
7	kb	O
8	of	O
9	DNA	O
10	sequence	O
11	is	O
12	presented	O
13	,	O
14	including	O
15	1251	O
16	bp	O
17	5	O
18	'	O
19	to	O
20	the	O
21	gene	O
22	,	O
23	over	O
24	4	O
25	kb	O
26	of	O
27	exon	O
28	and	O
29	exon	O
30	-	O
31	intron	O
32	junctions	O
33	,	O
34	and	O
35	583	O
36	bp	O
37	3	O
38	'	O
39	to	O
40	the	O
41	gene	O
42	.	O
1	Auditory	O
2	threshold	O
3	shifts	O
4	,	O
5	as	O
6	measured	O
7	by	O
8	the	O
9	auditory	O
10	evoked	O
11	brainstem	O
12	response	O
13	,	O
14	were	O
15	measured	O
16	at	O
17	2	O
18	,	O
19	4	O
20	,	O
21	8	O
22	,	O
23	12	O
24	,	O
25	16	O
26	,	O
27	20	O
28	and	O
29	24	O
30	kHz	O
31	.	O
1	Adverse	O
2	foetal	O
3	outcome	O
4	in	O
5	specific	O
6	IgM	B
7	positive	O
8	Chlamydia	O
9	trachomatis	O
10	infection	O
11	in	O
12	pregnancy	O
13	.	O
1	In	O
2	a	O
3	second	O
4	patient	O
5	the	O
6	VT	O
7	became	O
8	nonsustained	O
9	.	O
1	First	O
2	,	O
3	the	O
4	finding	O
5	of	O
6	a	O
7	monomeric	O
8	Alu	B
9	family	O
10	repeat	O
11	at	O
12	the	O
13	junction	O
14	between	O
15	nonhomology	O
16	block	O
17	I	O
18	and	O
19	homology	O
20	block	O
21	Y	O
22	of	O
23	the	O
24	alpha	B
25	2	I
26	gene	I
27	-	I
28	containing	I
29	unit	I
30	in	I
31	rhesus	I
32	macaque	I
33	suggests	O
34	that	O
35	the	O
36	dimeric	O
37	Alu	B
38	family	O
39	repeat	O
40	,	O
41	Alu	B
42	3	I
43	,	O
44	at	O
45	the	O
46	orthologous	O
47	position	O
48	in	O
49	human	O
50	was	O
51	generated	O
52	by	O
53	insertion	O
54	of	O
55	a	O
56	monomeric	O
57	Alu	B
58	family	O
59	repeat	O
60	into	O
61	the	O
62	3	O
63	'	O
64	end	O
65	of	O
66	another	O
67	preexisting	O
68	Alu	B
69	family	O
70	repeat	O
71	.	O
1	Ten	O
2	out	O
3	of	O
4	10	O
5	patients	O
6	with	O
7	progressive	O
8	disease	O
9	had	O
10	mast	O
11	cells	O
12	greater	O
13	than	O
14	or	O
15	equal	O
16	to	O
17	0	O
18	.	O
19	5	O
20	%,	O
21	hyaluronan	O
22	greater	O
23	than	O
24	or	O
25	equal	O
26	to	O
27	50	O
28	micrograms	O
29	.	O
30	l	O
31	-	O
32	1	O
33	and	O
34	fibronectin	B
35	greater	O
36	than	O
37	or	O
38	equal	O
39	to	O
40	350	O
41	micrograms	O
42	.	O
43	l	O
44	-	O
45	1	O
46	compared	O
47	to	O
48	eight	O
49	out	O
50	of	O
51	41	O
52	patients	O
53	with	O
54	stable	O
55	or	O
56	regressive	O
57	disease	O
58	.(	O
59	ABSTRACT	O
60	TRUNCATED	O
61	AT	O
62	250	O
63	WORDS	O
64	)	O
1	RU486	O
2	and	O
3	ONO	O
4	802	O
5	in	O
6	combination	O
7	have	O
8	been	O
9	shown	O
10	to	O
11	be	O
12	effective	O
13	in	O
14	early	O
15	termination	O
16	of	O
17	pregnancy	O
18	.	O
1	Many	O
2	cells	O
3	were	O
4	negative	O
5	for	O
6	endothelial	O
7	-	O
8	cell	O
9	markers	O
10	,	O
11	and	O
12	they	O
13	reacted	O
14	with	O
15	a	O
16	monoclonal	O
17	antibody	O
18	against	O
19	muscle	O
20	actin	B
21	.	O
1	So	O
2	far	O
3	15	O
4	children	O
5	have	O
6	been	O
7	studied	O
8	.	O
1	Different	O
2	doses	O
3	of	O
4	15	O
5	-	O
6	methyl	O
7	-	O
8	PGF2	O
9	alpha	O
10	(	O
11	0	O
12	.	O
13	125	O
14	-	O
15	10	O
16	mg	O
17	)	O
18	were	O
19	used	O
20	to	O
21	induce	O
22	luteolysis	O
23	and	O
24	oestrus	O
25	in	O
26	7	O
27	heifers	O
28	with	O
29	28	O
30	treatments	O
31	on	O
32	day	O
33	8	O
34	-	O
35	12	O
36	of	O
37	the	O
38	oestrous	O
39	cycle	O
40	.	O
1	Maize	B
2	rbcS	I
3	promoter	I
4	activity	O
5	depends	O
6	on	O
7	sequence	O
8	elements	O
9	not	O
10	found	O
11	in	O
12	dicot	B
13	rbcS	I
14	promoters	I
15	.	O
1	The	O
2	gene	O
3	is	O
4	1	O
5	,	O
6	139	O
7	base	O
8	pairs	O
9	(	O
10	bp	O
11	)	O
12	long	O
13	,	O
14	and	O
15	,	O
16	like	O
17	other	O
18	members	O
19	of	O
20	the	O
21	SIG	B
22	family	I
23	,	O
24	the	O
25	beta	B
26	TG	I
27	gene	I
28	is	O
29	divided	O
30	into	O
31	3	O
32	exons	O
33	.	O
1	The	O
2	pp90rsk	B
3	-	I
4	protein	I
5	kinase	I
6	activity	O
7	(	O
8	referred	O
9	to	O
10	as	O
11	rsk	B
12	-	I
13	kinase	I
14	)	O
15	is	O
16	also	O
17	not	O
18	related	O
19	to	O
20	cofactor	O
21	-	O
22	dependent	O
23	signal	O
24	transducing	O
25	protein	O
26	kinases	O
27	such	O
28	as	O
29	the	O
30	cyclic	B
31	AMP	I
32	-	I
33	dependent	I
34	protein	I
35	kinases	I
36	,	O
37	members	O
38	of	O
39	the	O
40	protein	B
41	kinase	I
42	C	I
43	family	I
44	,	O
45	or	O
46	other	O
47	Ca2	B
48	(+)-	I
49	dependent	I
50	protein	I
51	kinases	I
52	.	O
1	The	O
2	abundance	O
3	of	O
4	transcripts	O
5	from	O
6	several	O
7	unrelated	O
8	genes	O
9	is	O
10	decreased	O
11	in	O
12	cdc68	B
13	-	I
14	1	I
15	mutant	I
16	cells	O
17	after	O
18	transfer	O
19	to	O
20	the	O
21	restrictive	O
22	temperature	O
23	,	O
24	while	O
25	at	O
26	least	O
27	one	O
28	transcript	O
29	,	O
30	from	O
31	the	O
32	HSP82	B
33	gene	I
34	,	O
35	persists	O
36	in	O
37	an	O
38	aberrant	O
39	fashion	O
40	.	O
1	The	O
2	spectrum	O
3	of	O
4	histologically	O
5	diagnosed	O
6	malignant	O
7	neoplasms	O
8	in	O
9	Sabah	O
10	,	O
11	1983	O
12	-	O
13	1988	O
14	.	O
1	This	O
2	result	O
3	suggests	O
4	that	O
5	phosphorylation	O
6	of	O
7	Thr	O
8	14	O
9	and	O
10	/	O
11	or	O
12	Tyr	O
13	15	O
14	inhibits	O
15	p34cdc2	B
16	kinase	I
17	activity	O
18	,	O
19	in	O
20	line	O
21	with	O
22	the	O
23	location	O
24	of	O
25	these	O
26	residues	O
27	within	O
28	the	O
29	putative	O
30	ATP	O
31	binding	O
32	site	O
33	of	O
34	the	O
35	kinase	O
36	.	O
1	The	O
2	findings	O
3	are	O
4	compatible	O
5	with	O
6	the	O
7	idea	O
8	that	O
9	the	O
10	genes	O
11	encoding	O
12	PDGF	B
13	receptors	I
14	in	O
15	glioma	O
16	cells	O
17	are	O
18	regulated	O
19	in	O
20	concert	O
21	with	O
22	other	O
23	genes	O
24	,	O
25	the	O
26	expression	O
27	of	O
28	which	O
29	may	O
30	reflect	O
31	the	O
32	developmental	O
33	program	O
34	of	O
35	normal	O
36	glia	O
37	cell	O
38	lineages	O
39	.	O
1	To	O
2	determine	O
3	the	O
4	relationship	O
5	of	O
6	these	O
7	viruses	O
8	,	O
9	the	O
10	complete	O
11	DNA	O
12	sequence	O
13	of	O
14	KV	O
15	consisting	O
16	of	O
17	4754	O
18	bp	O
19	was	O
20	determined	O
21	.	O
1	Heterodimers	O
2	of	O
3	myogenin	B
4	and	O
5	E12	B
6	(	O
7	or	O
8	MyoD	B
9	and	O
10	E12	B
11	)	O
12	specifically	O
13	bound	O
14	a	O
15	restriction	O
16	fragment	O
17	extending	O
18	from	O
19	-	O
20	200	O
21	to	O
22	-	O
23	103	O
24	relative	O
25	to	O
26	the	O
27	start	O
28	of	O
29	cardiac	B
30	alpha	I
31	-	I
32	actin	I
33	transcription	O
34	.	O
1	The	O
2	promoter	O
3	activity	O
4	of	O
5	the	O
6	gene	B
7	encoding	I
8	Alzheimer	I
9	beta	I
10	-	I
11	amyloid	I
12	precursor	I
13	protein	I
14	(	O
15	APP	B
16	)	O
17	is	O
18	regulated	O
19	by	O
20	two	O
21	blocks	O
22	of	O
23	upstream	O
24	sequences	O
25	.	O
1	The	O
2	patient	O
3	was	O
4	a	O
5	78	O
6	-	O
7	year	O
8	-	O
9	old	O
10	male	O
11	in	O
12	whom	O
13	skin	O
14	lesions	O
15	preceded	O
16	the	O
17	diagnosis	O
18	of	O
19	myelofibrosis	O
20	.	O
1	Linear	O
2	regression	O
3	analysis	O
4	was	O
5	performed	O
6	and	O
7	the	O
8	following	O
9	result	O
10	was	O
11	obtained	O
12	:	O
13	clearance	O
14	(	O
15	HMPAO	O
16	)	O
17	=	O
18	0	O
19	.	O
20	07	O
21	+	O
22	0	O
23	.	O
24	43	O
25	.	O
26	rCBF	O
27	with	O
28	a	O
29	high	O
30	significance	O
31	(	O
32	p	O
33	less	O
34	than	O
35	0	O
36	.	O
37	001	O
38	).	O
1	Saccharomyces	O
2	cerevisiae	O
3	has	O
4	been	O
5	used	O
6	widely	O
7	both	O
8	as	O
9	a	O
10	model	O
11	system	O
12	for	O
13	unraveling	O
14	the	O
15	biochemical	O
16	,	O
17	genetic	O
18	,	O
19	and	O
20	molecular	O
21	details	O
22	of	O
23	gene	O
24	expression	O
25	and	O
26	the	O
27	secretion	O
28	process	O
29	,	O
30	and	O
31	as	O
32	a	O
33	host	O
34	for	O
35	the	O
36	production	O
37	of	O
38	heterologous	O
39	proteins	O
40	of	O
41	biotechnological	O
42	interest	O
43	.	O
1	The	O
2	domains	O
3	involved	O
4	in	O
5	superactivation	O
6	appear	O
7	to	O
8	be	O
9	a	O
10	subset	O
11	of	O
12	those	O
13	necessary	O
14	to	O
15	achieve	O
16	synergistic	O
17	activation	O
18	.	O
1	J	O
2	.	O
1	3	O
2	cases	O
1	Infarct	O
2	regional	O
3	ejection	O
4	fraction	O
5	improved	O
6	by	O
7	10	O
8	.	O
9	1	O
10	+/-	O
11	2	O
12	.	O
13	1	O
14	%	O
15	between	O
16	early	O
17	and	O
18	late	O
19	studies	O
20	when	O
21	the	O
22	infarct	O
23	-	O
24	related	O
25	artery	O
26	was	O
27	patent	O
28	and	O
29	by	O
30	4	O
31	.	O
32	8	O
33	+/-	O
34	1	O
35	.	O
36	4	O
37	%	O
38	if	O
39	it	O
40	was	O
41	occluded	O
42	(	O
43	p	O
44	=	O
45	0	O
46	.	O
47	048	O
48	);	O
49	changes	O
50	in	O
51	global	O
52	and	O
53	noninfarct	O
54	regional	O
55	ejection	O
56	fraction	O
57	were	O
58	similar	O
59	irrespective	O
60	of	O
61	perfusion	O
62	status	O
63	.	O
1	The	O
2	ORF	O
3	was	O
4	analyzed	O
5	for	O
6	secondary	O
7	structural	O
8	features	O
9	,	O
10	and	O
11	the	O
12	sequence	O
13	data	O
14	bases	O
15	were	O
16	searched	O
17	for	O
18	homologies	O
19	.	O
1	Mitomycin	O
2	-	O
3	C	O
4	can	O
5	cause	O
6	severe	O
7	necrosis	O
8	and	O
9	ulceration	O
10	when	O
11	extravasated	O
12	inadvertently	O
13	into	O
14	skin	O
15	and	O
16	soft	O
17	tissues	O
18	following	O
19	IV	O
20	drug	O
21	administration	O
22	.	O
1	Sequence	O
2	analysis	O
3	reveals	O
4	that	O
5	the	O
6	DNA	O
7	binding	O
8	domain	O
9	of	O
10	ILF	B
11	has	O
12	strong	O
13	homology	O
14	to	O
15	the	O
16	recently	O
17	described	O
18	fork	B
19	head	I
20	DNA	I
21	binding	I
22	domain	I
23	found	O
24	in	O
25	the	O
26	Drosophila	B
27	homeotic	I
28	protein	I
29	fork	I
30	head	I
31	and	O
32	a	O
33	family	O
34	of	O
35	hepatocyte	B
36	nuclear	I
37	factors	I
38	,	O
39	HNF	B
40	-	I
41	3	I
42	.	O
1	In	O
2	study	O
3	2	O
4	,	O
5	the	O
6	correlation	O
7	coefficients	O
8	between	O
9	the	O
10	ISO2	O
11	measurements	O
12	obtained	O
13	at	O
14	the	O
15	ulcer	O
16	margin	O
17	and	O
18	at	O
19	the	O
20	adjacent	O
21	normal	O
22	mucosa	O
23	,	O
24	and	O
25	delta	O
26	ISO2	O
27	obtained	O
28	by	O
29	the	O
30	experienced	O
31	observer	O
32	and	O
33	one	O
34	of	O
35	the	O
36	three	O
37	learners	O
38	were	O
39	0	O
40	.	O
41	94	O
42	,	O
43	0	O
44	.	O
45	97	O
46	,	O
47	and	O
48	0	O
49	.	O
50	94	O
51	,	O
52	respectively	O
53	.	O
1	It	O
2	was	O
3	found	O
4	that	O
5	the	O
6	ROSP	O
7	undergoes	O
8	a	O
9	number	O
10	of	O
11	fluctuations	O
12	in	O
13	the	O
14	negative	O
15	and	O
16	positive	O
17	directions	O
18	with	O
19	a	O
20	gradually	O
21	decreasing	O
22	amplitude	O
23	in	O
24	the	O
25	course	O
26	of	O
27	5	O
28	-	O
29	25	O
30	days	O
31	following	O
32	the	O
33	operation	O
34	,	O
35	after	O
36	which	O
37	relatively	O
38	stable	O
39	negative	O
40	values	O
41	of	O
42	the	O
43	ROSP	O
44	are	O
45	established	O
46	on	O
47	the	O
48	average	O
49	in	O
50	electrodes	O
51	implanted	O
52	to	O
53	the	O
54	level	O
55	of	O
56	the	O
57	dura	O
58	mater	O
59	,	O
60	and	O
61	positive	O
62	values	O
63	in	O
64	electrodes	O
65	implanted	O
66	to	O
67	the	O
68	level	O
69	of	O
70	the	O
71	pia	O
72	mater	O
73	.	O
1	In	O
2	the	O
3	yeast	O
4	Saccharomyces	O
5	cerevisiae	O
6	,	O
7	copper	O
8	levels	O
9	exert	O
10	some	O
11	control	O
12	over	O
13	the	O
14	level	O
15	of	O
16	SOD1	B
17	expression	O
18	.	O
1	Neuro	O
2	-	O
3	otological	O
4	examinations	O
5	revealed	O
6	spontaneous	O
7	downbeat	O
8	nystagmus	O
9	,	O
10	bilateral	O
11	gaze	O
12	nystagmus	O
13	and	O
14	rebound	O
15	nystagmus	O
16	.	O
1	To	O
2	lower	O
3	the	O
4	current	O
5	high	O
6	incidence	O
7	of	O
8	NANB	O
9	-	O
10	induced	O
11	PTH	O
12	,	O
13	in	O
14	1986	O
15	,	O
16	the	O
17	American	O
18	Association	O
19	of	O
20	Blood	O
21	Banks	O
22	(	O
23	AABB	O
24	)	O
25	recommended	O
26	testing	O
27	for	O
28	these	O
29	PTH	O
30	-	O
31	associated	O
32	""""	O
33	surrogate	O
34	""""	O
35	markers	O
36	on	O
37	all	O
38	donated	O
39	units	O
40	of	O
41	blood	O
42	.	O
1	Skeletal	O
2	muscle	O
3	metaboreceptor	O
4	exercise	O
5	responses	O
6	are	O
7	attenuated	O
8	in	O
9	heart	O
10	failure	O
11	.	O
1	The	O
2	examinations	O
3	were	O
4	performed	O
5	on	O
6	two	O
7	groups	O
8	of	O
9	20	O
10	(	O
11	using	O
12	AmF	O
13	/	O
14	SnF2	O
15	)-,	O
16	resp	O
17	.	O
1	The	O
2	vaccine	O
3	used	O
4	was	O
5	known	O
6	to	O
7	be	O
8	immunogenic	O
9	for	O
10	older	O
11	children	O
12	and	O
13	adults	O
14	.	O
1	Applications	O
2	of	O
3	three	O
4	-	O
5	dimensional	O
6	analysis	O
7	to	O
8	the	O
9	auditory	O
10	P300	O
11	.	O
1	The	O
2	construct	O
3	was	O
4	introduced	O
5	into	O
6	BW2001	O
7	(	O
8	xth	O
9	-	O
10	11	O
11	,	O
12	nfo	O
13	-	O
14	2	O
15	)	O
16	strain	O
17	cells	O
18	of	O
19	Escherichia	O
20	coli	O
21	.	O
1	Only	O
2	after	O
3	a	O
4	pretreatment	O
5	aimed	O
6	at	O
7	increasing	O
8	its	O
9	oxide	O
10	surface	O
11	layer	O
12	was	O
13	titanium	O
14	powder	O
15	found	O
16	to	O
17	accelerate	O
18	the	O
19	precipitation	O
20	from	O
21	solutions	O
22	containing	O
23	2	O
24	mmol	O
25	/	O
26	L	O
27	CaCl2	O
28	,	O
29	2	O
30	mmol	O
31	/	O
32	L	O
33	KH2PO4	O
34	,	O
35	50	O
36	mmol	O
37	/	O
38	L	O
39	Hepes	O
40	,	O
41	pH	O
42	7	O
43	.	O
44	2	O
45	,	O
46	and	O
47	to	O
48	induce	O
49	precipitation	O
50	from	O
51	metastable	O
52	solutions	O
53	containing	O
54	1	O
55	.	O
56	2	O
57	mmol	O
58	/	O
59	L	O
60	CaCl2	O
61	,	O
62	1	O
63	.	O
64	2	O
65	mmol	O
66	/	O
67	L	O
68	KH2PO4	O
69	,	O
70	50	O
71	mmol	O
72	/	O
73	L	O
74	Hepes	O
75	,	O
76	pH	O
77	7	O
78	.	O
79	2	O
80	,	O
81	at	O
82	37	O
83	degrees	O
84	C	O
85	.	O
1	Endothelial	O
2	cells	O
3	stored	O
4	with	O
5	University	O
6	of	O
7	Wisconsin	O
8	solution	O
9	excluded	O
10	trypan	O
11	blue	O
12	better	O
13	(	O
14	1	O
15	.	O
16	0	O
17	%	O
18	+/-	O
19	0	O
20	.	O
21	5	O
22	%	O
23	cells	O
24	stained	O
25	,	O
26	p	O
27	less	O
28	than	O
29	0	O
30	.	O
31	001	O
32	.	O
1	A	O
2	herpesvirus	O
3	proteinase	O
4	activity	O
5	has	O
6	been	O
7	identified	O
8	and	O
9	partially	O
10	characterized	O
11	by	O
12	using	O
13	the	O
14	cloned	O
15	enzyme	O
16	and	O
17	substrate	O
18	genes	O
19	in	O
20	transient	O
21	transfection	O
22	assays	O
23	.	O
1	The	O
2	1489	O
3	-	O
4	base	O
5	pair	O
6	EFIA	B
7	cDNA	O
8	encodes	O
9	a	O
10	322	O
11	-	O
12	amino	O
13	acid	O
14	protein	O
15	which	O
16	is	O
17	nearly	O
18	identical	O
19	to	O
20	two	O
21	previously	O
22	described	O
23	human	O
24	DNA	O
25	binding	O
26	proteins	O
27	.	O
1	Sci	O
2	.	O
1	Translational	O
2	fusions	O
3	of	O
4	the	O
5	aroF	B
6	regulatory	I
7	regions	I
8	to	O
9	lacZ	B
10	were	O
11	constructed	O
12	and	O
13	then	O
14	introduced	O
15	in	O
16	single	O
17	copy	O
18	into	O
19	the	O
20	E	O
21	.	O
22	coli	O
23	chromosome	O
24	.	O
25	beta	B
26	-	I
27	Galactosidase	I
28	assays	O
29	for	O
30	tyrR	O
31	-	O
32	mediated	O
33	regulation	O
34	of	O
35	aroF	B
36	-	O
37	lacZ	B
38	expression	O
39	revealed	O
40	that	O
41	the	O
42	E	B
43	.	I
44	coli	I
45	TyrR	I
46	repressor	I
47	apparently	O
48	recognizes	O
49	the	O
50	operators	O
51	of	O
52	both	O
53	organisms	O
54	with	O
55	about	O
56	equal	O
57	efficiency	O
58	.	O
1	Along	O
2	with	O
3	previously	O
4	mapped	O
5	genes	O
6	including	O
7	Ly	B
8	-	I
9	1	I
10	and	O
11	CD20	B
12	,	O
13	OSBP	B
14	defines	O
15	a	O
16	new	O
17	conserved	O
18	syntenic	O
19	group	O
20	on	O
21	the	O
22	long	O
23	arm	O
24	of	O
25	chromosome	O
26	11	O
27	in	O
28	the	O
29	human	O
30	and	O
31	the	O
32	proximal	O
33	end	O
34	of	O
35	chromosome	O
36	19	O
37	in	O
38	the	O
39	mouse	O
40	.	O
1	Following	O
2	treatment	O
3	,	O
4	serum	O
5	estradiol	O
6	levels	O
7	were	O
8	higher	O
9	in	O
10	groups	O
11	E	O
12	+	O
13	T	O
14	and	O
15	E	O
16	than	O
17	in	O
18	group	O
19	C	O
20	.	O
1	Here	O
2	we	O
3	show	O
4	that	O
5	these	O
6	synthetic	O
7	binding	O
8	sites	O
9	have	O
10	a	O
11	more	O
12	restricted	O
13	and	O
14	specific	O
15	ability	O
16	to	O
17	enhance	O
18	transcription	O
19	when	O
20	assayed	O
21	in	O
22	transformed	O
23	embryos	O
24	.	O
1	A	O
2	high	O
3	-	O
4	frequency	O
5	restriction	O
6	fragment	O
7	length	O
8	polymorphism	O
9	was	O
10	evident	O
11	in	O
12	the	O
13	DNA	O
14	from	O
15	29	O
16	unrelated	O
17	individuals	O
18	using	O
19	the	O
20	enzyme	O
21	BglII	B
22	.	O
1	The	O
2	antilog	O
3	transformation	O
4	of	O
5	pH	O
6	did	O
7	not	O
8	improve	O
9	the	O
10	results	O
11	.	O
1	One	O
2	of	O
3	these	O
4	is	O
5	located	O
6	in	O
7	the	O
8	5	O
9	'-	O
10	untranslated	O
11	region	O
12	,	O
13	and	O
14	may	O
15	encode	O
16	regulatory	O
17	sequences	O
18	.	O
1	Induction	O
2	requires	O
3	the	O
4	ACE1	B
5	gene	I
6	product	I
7	,	O
8	which	O
9	binds	O
10	to	O
11	specific	O
12	sites	O
13	in	O
14	the	O
15	promoter	O
16	region	O
17	of	O
18	the	O
19	CUP1	B
20	gene	I
21	.	O
1	Adenylosuccinate	B
2	synthetase	I
3	(	O
4	IMP	O
5	:	O
6	L	B
7	-	I
8	aspartate	I
9	ligase	I
10	(	O
11	GDP	O
12	),	O
13	EC	B
14	6	I
15	.	I
16	3	I
17	.	I
18	4	I
19	.	I
20	4	I
21	)	O
22	plays	O
23	an	O
24	important	O
25	role	O
26	in	O
27	purine	O
28	biosynthesis	O
29	catalyzing	O
30	the	O
31	GTP	O
32	-	O
33	dependent	O
34	conversion	O
35	of	O
36	IMP	O
37	to	O
38	AMP	O
39	.	O
1	The	O
2	results	O
3	strengthen	O
4	the	O
5	conclusion	O
6	that	O
7	predominantly	O
8	dynamic	O
9	activity	O
10	increases	O
11	the	O
12	G4	B
13	content	O
14	of	O
15	mature	O
16	innervated	O
17	fast	O
18	muscles	O
19	.	O
1	The	O
2	specific	O
3	interaction	O
4	between	O
5	a	O
6	defined	O
7	structural	O
8	element	O
9	of	O
10	the	O
11	human	O
12	immunodeficiency	O
13	virus	O
14	mRNA	O
15	(	O
16	RRE	B
17	,	O
18	the	O
19	Rev	B
20	response	I
21	element	I
22	)	O
23	and	O
24	the	O
25	virus	B
26	-	I
27	encoded	I
28	protein	I
29	Rev	I
30	has	O
31	been	O
32	implicated	O
33	in	O
34	the	O
35	regulation	O
36	of	O
37	the	O
38	export	O
39	of	O
40	unspliced	O
41	or	O
42	singly	O
43	spliced	O
44	mRNA	O
45	from	O
46	the	O
47	nucleus	O
48	to	O
49	the	O
50	cytoplasm	O
51	.	O
1	Alanine	B
2	aminotransferase	I
3	in	O
4	clinical	O
5	practice	O
6	.	O
1	The	O
2	long	O
3	terminal	O
4	repeat	O
5	(	O
6	LTR	O
7	)	O
8	of	O
9	the	O
10	human	O
11	immunodeficiency	O
12	virus	O
13	(	O
14	HIV	O
15	)	O
16	contains	O
17	three	O
18	binding	O
19	sites	O
20	for	O
21	the	O
22	transcriptional	O
23	factor	O
24	Sp1	B
25	.	O
1	The	O
2	first	O
3	follow	O
4	-	O
5	up	O
6	was	O
7	at	O
8	a	O
9	nearly	O
10	constant	O
11	interval	O
12	of	O
13	5	O
14	.	O
15	1	O
16	years	O
17	in	O
18	Caerphilly	O
19	and	O
20	3	O
21	.	O
22	2	O
23	years	O
24	in	O
25	Speedwell	O
26	;	O
27	251	O
28	major	O
29	IHD	O
30	events	O
31	had	O
32	occurred	O
33	.	O
1	Isoform	B
2	C	I
3	beta	I
4	2	I
5	,	O
6	an	O
7	unusual	O
8	form	O
9	of	O
10	the	O
11	bovine	O
12	catalytic	O
13	subunit	O
14	of	O
15	cAMP	B
16	-	I
17	dependent	I
18	protein	I
19	kinase	I
20	.	O
1	ELISA	O
2	was	O
3	found	O
4	to	O
5	make	O
6	a	O
7	contribution	O
8	to	O
9	the	O
10	diagnosis	O
11	of	O
12	tuberculosis	O
13	similar	O
14	to	O
15	that	O
16	of	O
17	sputum	O
18	smear	O
19	.	O
1	No	O
2	positive	O
3	family	O
4	history	O
5	was	O
6	obtained	O
7	.	O
1	The	O
2	disturbance	O
3	of	O
4	pulmonary	O
5	gas	O
6	exchange	O
7	,	O
8	as	O
9	revealed	O
10	by	O
11	the	O
12	high	O
13	value	O
14	of	O
15	AaDO2	O
16	,	O
17	existed	O
18	without	O
19	left	O
20	ventricular	O
21	dysfunction	O
22	,	O
23	and	O
24	AaDO2	O
25	had	O
26	no	O
27	significant	O
28	relationship	O
29	with	O
30	any	O
31	of	O
32	the	O
33	hemodynamic	O
34	parameters	O
35	including	O
36	the	O
37	difference	O
38	between	O
39	plasma	O
40	colloid	O
41	osmotic	O
42	pressure	O
43	and	O
44	PCW	O
45	.	O
1	The	O
2	CDC7	B
3	gene	I
4	has	O
5	two	O
6	in	O
7	-	O
8	frame	O
9	AUG	O
10	codons	O
11	as	O
12	possible	O
13	translation	O
14	start	O
15	sites	O
16	,	O
17	which	O
18	would	O
19	produce	O
20	58	O
21	-	O
22	and	O
23	56	O
24	-	O
25	kDa	O
26	proteins	O
27	,	O
28	respectively	O
29	.	O
1	HeLa	O
2	and	O
3	Jurkat	O
4	cell	O
5	lines	O
6	carrying	O
7	the	O
8	nef	B
9	gene	I
10	linked	O
11	to	O
12	the	O
13	CMV	O
14	promoter	O
15	or	O
16	the	O
17	HIV	B
18	-	I
19	1	I
20	LTR	I
21	were	O
22	isolated	O
23	by	O
24	coselection	O
25	for	O
26	neomycin	O
27	resistance	O
28	.	O
1	Differences	O
2	in	O
3	the	O
4	clinical	O
5	presentation	O
6	and	O
7	the	O
8	gross	O
9	appearance	O
10	of	O
11	the	O
12	two	O
13	cases	O
14	are	O
15	described	O
16	,	O
17	and	O
18	similarities	O
19	in	O
20	the	O
21	microscopic	O
22	features	O
23	are	O
24	discussed	O
25	.	O
1	Polymerase	O
2	chain	O
3	reaction	O
4	analysis	O
5	of	O
6	ETS1	B
7	cDNA	I
8	identified	O
9	several	O
10	amplified	O
11	products	O
12	,	O
13	indicating	O
14	alternative	O
15	splicing	O
16	.	O
1	To	O
2	measure	O
3	the	O
4	enhancer	O
5	activity	O
6	of	O
7	DR60	B
8	,	O
9	a	O
10	reporter	O
11	plasmid	O
12	was	O
13	constructed	O
14	that	O
15	contained	O
16	DR60	B
17	cloned	O
18	upstream	O
19	of	O
20	the	O
21	reporter	O
22	chloramphenicol	B
23	acetyltransferase	I
24	gene	I
25	under	O
26	the	O
27	control	O
28	of	O
29	the	O
30	delayed	O
31	-	O
32	early	O
33	39K	O
34	promoter	O
35	.	O
1	A	O
2	single	O
3	case	O
4	of	O
5	an	O
6	adenocarcinoma	O
7	,	O
8	arising	O
9	in	O
10	a	O
11	retroperitoneal	O
12	enterogenous	O
13	cyst	O
14	and	O
15	which	O
16	presented	O
17	as	O
18	a	O
19	left	O
20	renal	O
21	cyst	O
22	,	O
23	is	O
24	reported	O
25	.	O
1	Hydrophobicity	O
2	analysis	O
3	indicated	O
4	that	O
5	the	O
6	KlaA	B
7	and	O
8	KlaB	B
9	polypeptides	I
10	are	O
11	likely	O
12	to	O
13	be	O
14	soluble	O
15	,	O
16	whereas	O
17	the	O
18	KlaC	B
19	polypeptide	I
20	was	O
21	predicted	O
22	to	O
23	have	O
24	four	O
25	potential	O
26	membrane	O
27	-	O
28	spanning	O
29	domains	O
30	.	O
1	The	O
2	stimulus	O
3	threshold	O
4	for	O
5	EER	O
6	showed	O
7	a	O
8	less	O
9	individual	O
10	variation	O
11	than	O
12	amplitude	O
13	.	O
1	In	O
2	all	O
3	cases	O
4	,	O
5	high	O
6	-	O
7	level	O
8	expression	O
9	of	O
10	the	O
11	truncated	B
12	avian	I
13	integrins	I
14	was	O
15	obtained	O
16	.	O
1	To	O
2	investigate	O
3	the	O
4	regulation	O
5	of	O
6	Spec	B
7	gene	I
8	activity	O
9	,	O
10	the	O
11	region	O
12	around	O
13	the	O
14	Spec1	B
15	transcriptional	I
16	initiation	I
17	site	I
18	was	O
19	analyzed	O
20	for	O
21	sites	O
22	of	O
23	protein	O
24	-	O
25	DNA	O
26	interaction	O
27	.	O
1	Phosphopeptide	O
2	mapping	O
3	revealed	O
4	the	O
5	same	O
6	autophosphorylation	O
7	sites	O
8	utilized	O
9	by	O
10	EGFR	B
11	-	I
12	IC	I
13	as	O
14	those	O
15	identified	O
16	in	O
17	wild	B
18	-	I
19	type	I
20	EGFR	I
21	.	O
1	The	O
2	encoded	O
3	sequence	O
4	revealed	O
5	a	O
6	typical	O
7	signal	O
8	peptide	O
9	,	O
10	a	O
11	predominantly	O
12	hydrophilic	O
13	707	O
14	amino	O
15	acid	O
16	residue	O
17	domain	O
18	with	O
19	8	O
20	N	O
21	-	O
22	glycosylation	O
23	sites	O
24	,	O
25	a	O
26	transmembrane	O
27	domain	O
28	,	O
29	and	O
30	a	O
31	C	O
32	-	O
33	terminal	O
34	domain	O
35	of	O
36	52	O
37	amino	O
38	acids	O
39	.	O
1	IdB	O
2	1031	O
3	was	O
4	first	O
5	extracted	O
6	by	O
7	liquid	O
8	-	O
9	solid	O
10	partition	O
11	and	O
12	the	O
13	extracts	O
14	were	O
15	evaporated	O
16	and	O
17	analysed	O
18	on	O
19	a	O
20	reversed	O
21	-	O
22	phase	O
23	column	O
24	under	O
25	isocratic	O
26	conditions	O
27	,	O
28	using	O
29	either	O
30	an	O
31	electrochemical	O
32	or	O
33	a	O
34	UV	O
35	detector	O
36	.	O
1	A	O
2	new	O
3	method	O
4	for	O
5	the	O
6	in	O
7	vitro	O
8	transfer	O
9	of	O
10	delayed	O
11	hypersensitivity	O
12	by	O
13	dialysed	O
14	transfer	B
15	factor	I
16	.	O
1	However	O
2	,	O
3	overexpression	O
4	of	O
5	both	O
6	the	O
7	STE4	B
8	and	O
9	STE18	B
10	proteins	I
11	did	O
12	not	O
13	generate	O
14	a	O
15	stronger	O
16	pheromone	O
17	response	O
18	than	O
19	overexpression	O
20	of	O
21	STE4	B
22	in	O
23	the	O
24	presence	O
25	of	O
26	wild	O
27	-	O
28	type	O
29	levels	O
30	of	O
31	STE18	B
32	.	O
1	It	O
2	encodes	O
3	a	O
4	protein	O
5	with	O
6	three	O
7	zinc	O
8	fingers	O
9	similar	O
10	to	O
11	those	O
12	of	O
13	the	O
14	transcription	B
15	factor	I
16	Sp1	I
17	.	O
1	Krox	B
2	-	I
3	24	I
4	is	O
5	therefore	O
6	a	O
7	sequence	O
8	-	O
9	specific	O
10	transcriptional	O
11	activator	O
12	.	O
1	Our	O
2	results	O
3	suggest	O
4	that	O
5	a	O
6	sequence	O
7	match	O
8	between	O
9	enhancers	O
10	and	O
11	certain	O
12	promoter	O
13	elements	O
14	is	O
15	critical	O
16	.	O
1	Uses	O
2	of	O
3	orthoclone	O
4	OKT3	O
5	for	O
6	prophylaxis	O
7	of	O
8	rejection	O
9	and	O
10	induction	O
11	in	O
12	initial	O
13	nonfunction	O
14	in	O
15	kidney	O
16	transplantation	O
17	.	O
1	Five	O
2	of	O
3	10	O
4	scars	O
5	studied	O
6	decreased	O
7	at	O
8	least	O
9	50	O
10	%	O
11	in	O
12	linear	O
13	dimensions	O
14	.	O
1	Gel	O
2	-	O
3	mobility	O
4	-	O
5	shift	O
6	assays	O
7	confirmed	O
8	that	O
9	the	O
10	Raji	O
11	nuclear	O
12	proteins	O
13	that	O
14	bound	O
15	to	O
16	W	O
17	and	O
18	V	O
19	elements	O
20	were	O
21	competed	O
22	with	O
23	by	O
24	an	O
25	HLA	B
26	-	I
27	DRA	I
28	X	I
29	-	I
30	box	I
31	oligonucleotide	I
32	.	O
1	The	O
2	NF1	B
3	locus	I
4	encodes	O
5	a	O
6	protein	O
7	functionally	O
8	related	O
9	to	O
10	mammalian	B
11	GAP	I
12	and	O
13	yeast	B
14	IRA	I
15	proteins	I
16	.	O
1	Human	O
2	recombinant	O
3	DNA	O
4	-	O
5	derived	O
6	antihemophilic	B
7	factor	I
8	(	O
9	factor	B
10	VIII	I
11	)	O
12	in	O
13	the	O
14	treatment	O
15	of	O
16	hemophilia	O
17	A	O
18	.	O
19	recombinant	O
20	Factor	B
21	VIII	I
22	Study	O
23	Group	O
24	.	O
1	Effects	O
2	of	O
3	a	O
4	selective	O
5	monoamine	B
6	oxidase	I
7	(	I
8	MAO	I
9	)--	I
10	A	I
11	inhibitor	O
12	,	O
13	clorgyline	O
14	,	O
15	a	O
16	selective	O
17	MAO	B
18	-	I
19	B	I
20	inhibitor	O
21	,	O
22	deprenyl	O
23	,	O
24	and	O
25	a	O
26	non	O
27	-	O
28	selective	O
29	MAO	B
30	inhibitor	O
31	,	O
32	nialamide	O
33	,	O
34	were	O
35	investigated	O
36	on	O
37	footshock	O
38	-	O
39	induced	O
40	aggression	O
41	(	O
42	FIA	O
43	)	O
44	in	O
45	paired	O
46	rats	O
47	.	O
1	Although	O
2	no	O
3	Rh	B
4	-	I
5	antibodies	I
6	were	O
7	demonstrable	O
8	,	O
9	a	O
10	similar	O
11	mechanism	O
12	can	O
13	be	O
14	postulated	O
15	for	O
16	the	O
17	Rh	O
18	-	O
19	system	O
20	.	O
1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	has	O
7	the	O
8	greatest	O
9	homology	O
10	(	O
11	61	O
12	%)	O
13	to	O
14	the	O
15	green	B
16	alga	I
17	Scenedemus	I
18	obliquus	I
19	plastocyanin	I
20	.	O
1	In	O
2	a	O
3	highly	O
4	select	O
5	group	O
6	of	O
7	stable	O
8	hypertensive	O
9	patients	O
10	,	O
11	we	O
12	have	O
13	assessed	O
14	the	O
15	strength	O
16	of	O
17	association	O
18	between	O
19	various	O
20	blood	O
21	pressure	O
22	measurements	O
23	(	O
24	24	O
25	h	O
26	average	O
27	automated	O
28	ambulatory	O
29	blood	O
30	pressure	O
31	,	O
32	4	O
33	h	O
34	automated	O
35	ambulatory	O
36	morning	O
37	average	O
38	blood	O
39	pressure	O
40	,	O
41	multiple	O
42	office	O
43	visit	O
44	average	O
45	blood	O
46	pressure	O
47	,	O
48	and	O
49	a	O
50	single	O
51	office	O
52	visit	O
53	average	O
54	blood	O
55	pressure	O
56	)	O
57	and	O
58	various	O
59	echocardiographic	O
60	indices	O
61	of	O
62	hypertensive	O
63	cardiac	O
64	target	O
65	organ	O
66	damage	O
67	(	O
68	left	O
69	atrial	O
70	diameter	O
71	,	O
72	left	O
73	ventricular	O
74	end	O
75	diastolic	O
76	diameter	O
77	,	O
78	posterior	O
79	wall	O
80	thickness	O
81	,	O
82	combined	O
83	wall	O
84	thickness	O
85	,	O
86	relative	O
87	wall	O
88	thickness	O
89	,	O
90	left	O
91	ventricular	O
92	mass	O
93	and	O
94	mass	O
95	index	O
96	,	O
97	and	O
98	combined	O
99	wall	O
100	thickness	O
101	/	O
102	left	O
103	ventricular	O
104	diastolic	O
105	diameter	O
106	ratio	O
107	).	O
1	The	O
2	major	O
3	promoter	O
4	responds	O
5	strongly	O
6	to	O
7	virus	O
8	-	O
9	encoded	O
10	trans	O
11	activators	O
12	EIA	B
13	and	O
14	EIV	B
15	and	O
16	contains	O
17	four	O
18	elements	O
19	:	O
20	a	O
21	TAGA	O
22	motif	O
23	analogous	O
24	to	O
25	the	O
26	TATA	O
27	box	O
28	,	O
29	two	O
30	EIIF	B
31	sites	I
32	present	O
33	in	O
34	an	O
35	inverted	O
36	orientation	O
37	,	O
38	and	O
39	an	O
40	ATF	B
41	/	O
42	CREB	B
43	site	O
44	.	O
1	With	O
2	the	O
3	modified	O
4	fingertip	O
5	-	O
6	to	O
7	-	O
8	floor	O
9	(	O
10	MFTF	O
11	)	O
12	method	O
13	,	O
14	patients	O
15	stand	O
16	on	O
17	a	O
18	stool	O
19	and	O
20	forward	O
21	bend	O
22	so	O
23	that	O
24	measurements	O
25	can	O
26	be	O
27	taken	O
28	on	O
29	patients	O
30	who	O
31	are	O
32	able	O
33	to	O
34	touch	O
35	the	O
36	floor	O
37	or	O
38	reach	O
39	beyond	O
40	the	O
41	level	O
42	of	O
43	the	O
44	floor	O
45	.	O
1	The	O
2	clinical	O
3	picture	O
4	of	O
5	the	O
6	disease	O
7	was	O
8	significantly	O
9	different	O
10	from	O
11	anthropogenic	O
12	cutaneous	O
13	leishmaniasis	O
14	caused	O
15	by	O
16	L	O
17	.	O
18	tropica	O
19	but	O
20	similar	O
21	to	O
22	cutaneous	O
23	patterns	O
24	caused	O
25	by	O
26	L	O
27	.	O
28	infantum	O
29	which	O
30	was	O
31	a	O
32	prevalent	O
33	pattern	O
34	in	O
35	the	O
36	southern	O
37	France	O
38	.	O
1	Northern	O
2	blot	O
3	analysis	O
4	indicates	O
5	that	O
6	AHA2	B
7	mRNA	I
8	relative	O
9	to	O
10	total	O
11	cellular	O
12	RNA	O
13	is	O
14	expressed	O
15	at	O
16	significantly	O
17	higher	O
18	levels	O
19	in	O
20	root	O
21	tissue	O
22	as	O
23	compared	O
24	with	O
25	shoot	O
26	tissue	O
27	.	O
1	We	O
2	have	O
3	isolated	O
4	and	O
5	sequenced	O
6	the	O
7	gene	O
8	encoding	O
9	the	O
10	human	B
11	U1	I
12	-	I
13	70K	I
14	snRNP	I
15	protein	I
16	.	O
1	Mean	O
2	ROI	O
3	-	O
4	A	O
5	/	O
6	B	O
7	ratio	O
8	was	O
9	49	O
10	.	O
11	6	O
12	+/-	O
13	1	O
14	.	O
15	7	O
16	%	O
17	in	O
18	the	O
19	diabetic	O
20	group	O
21	,	O
22	significantly	O
23	lower	O
24	than	O
25	the	O
26	57	O
27	.	O
28	9	O
29	+/-	O
30	1	O
31	.	O
32	6	O
33	%	O
34	at	O
35	the	O
36	nondiabetic	O
37	group	O
38	(	O
39	p	O
40	less	O
41	than	O
42	0	O
43	.	O
44	005	O
45	).	O
1	The	O
2	sites	O
3	targeted	O
4	for	O
5	mutagenesis	O
6	,	O
7	residues	O
8	60	O
9	,	O
10	61	O
11	,	O
12	and	O
13	66	O
14	,	O
15	are	O
16	located	O
17	within	O
18	a	O
19	putative	O
20	helical	O
21	loop	O
22	structure	O
23	which	O
24	may	O
25	be	O
26	involved	O
27	in	O
28	substrate	O
29	recognition	O
30	by	O
31	the	O
32	enzyme	O
33	.	O
1	With	O
2	only	O
3	purified	O
4	T	B
5	antigen	I
6	in	O
7	the	O
8	presence	O
9	of	O
10	topoisomerase	B
11	I	I
12	to	O
13	unwind	O
14	purified	O
15	DNA	O
16	,	O
17	ori	O
18	-	O
19	auxiliary	O
20	sequences	O
21	strongly	O
22	facilitated	O
23	T	B
24	-	I
25	antigen	I
26	-	O
27	dependent	O
28	DNA	O
29	conformational	O
30	changes	O
31	consistent	O
32	with	O
33	melting	O
34	the	O
35	first	O
36	50	O
37	base	O
38	pairs	O
39	.	O
1	Specific	O
2	binding	O
3	of	O
4	the	O
5	protein	O
6	factors	O
7	to	O
8	the	O
9	sites	O
10	,	O
11	possibly	O
12	to	O
13	the	O
14	three	O
15	Mt	O
16	sequences	O
17	,	O
18	may	O
19	play	O
20	an	O
21	important	O
22	role	O
23	in	O
24	the	O
25	coordinate	O
26	regulation	O
27	of	O
28	the	O
29	transcription	O
30	of	O
31	nuclear	O
32	genes	O
33	encoding	O
34	subunits	O
35	responsible	O
36	for	O
37	mitochondrial	O
38	oxidative	O
39	phosphorylation	O
40	.	O
1	We	O
2	show	O
3	that	O
4	cytR	B
5	expression	O
6	is	O
7	negatively	O
8	controlled	O
9	by	O
10	the	O
11	CytR	B
12	protein	I
13	and	O
14	positively	O
15	affected	O
16	by	O
17	the	O
18	cAMP	B
19	/	I
20	CAP	I
21	complex	I
22	.	O
1	A	O
2	DNA	O
3	motif	O
4	related	O
5	to	O
6	the	O
7	cAMP	O
8	-	O
9	responsive	O
10	element	O
11	and	O
12	an	O
13	exon	B
14	-	I
15	located	I
16	activator	I
17	protein	I
18	-	I
19	2	I
20	binding	I
21	site	I
22	in	O
23	the	O
24	human	B
25	tissue	I
26	-	I
27	type	I
28	plasminogen	I
29	activator	I
30	gene	I
31	promoter	I
32	cooperate	O
33	in	O
34	basal	O
35	expression	O
36	and	O
37	convey	O
38	activation	O
39	by	O
40	phorbol	O
41	ester	O
42	and	O
43	cAMP	O
44	.	O
1	The	O
2	E6	B
3	/	O
4	E7	B
5	promoter	O
6	of	O
7	all	O
8	genital	O
9	human	O
10	papillomaviruses	O
11	is	O
12	responsible	O
13	for	O
14	expression	O
15	of	O
16	the	O
17	viral	O
18	transforming	O
19	genes	O
20	.	O
1	Seventy	O
2	-	O
3	two	O
4	of	O
5	73	O
6	negative	O
7	controls	O
8	and	O
9	all	O
10	positive	O
11	blocks	O
12	as	O
13	seen	O
14	on	O
15	soft	O
16	tissue	O
17	radiographs	O
18	(	O
19	STRs	O
20	)	O
21	were	O
22	correctly	O
23	coded	O
24	(	O
25	specificity	O
26	98	O
27	.	O
28	6	O
29	%,	O
30	sensitivity	O
31	100	O
32	%).	O
1	Immunohistochemical	O
2	analysis	O
3	of	O
4	several	O
5	rat	O
6	organs	O
7	also	O
8	showed	O
9	staining	O
10	in	O
11	epithelial	O
12	cells	O
13	.	O
1	The	O
2	recombinant	O
3	contains	O
4	the	O
5	normal	O
6	beta	B
7	A	I
8	-	I
9	globin	I
10	gene	I
11	,	O
12	the	O
13	mutant	O
14	gene	O
15	and	O
16	Ylp	O
17	vector	O
18	sequences	O
19	between	O
20	the	O
21	two	O
22	copies	O
23	.	O
1	Determination	O
2	of	O
3	diquat	O
4	in	O
5	biological	O
6	materials	O
7	by	O
8	electron	O
9	spin	O
10	resonance	O
11	spectroscopy	O
12	.	O
1	Unlike	O
2	p59v	B
3	-	O
4	rel	B
5	,	O
6	which	O
7	is	O
8	a	O
9	nuclear	O
10	protein	O
11	in	O
12	CEF	O
13	,	O
14	indirect	O
15	immunofluorescence	O
16	showed	O
17	that	O
18	p68c	B
19	-	O
20	rel	B
21	in	O
22	JD214c	O
23	-	O
24	rel	O
25	infected	O
26	CEF	O
27	is	O
28	located	O
29	exclusively	O
30	in	O
31	the	O
32	cytoplasm	O
33	of	O
34	these	O
35	cells	O
36	,	O
37	even	O
38	though	O
39	the	O
40	sequence	O
41	of	O
42	p68c	B
43	-	O
44	rel	B
45	showed	O
46	that	O
47	it	O
48	contains	O
49	a	O
50	nuclear	O
51	localizing	O
52	sequence	O
53	identical	O
54	to	O
55	the	O
56	one	O
57	previously	O
58	identified	O
59	in	O
60	p59v	B
61	-	O
62	rel	B
63	.	O
1	The	O
2	promoter	O
3	activity	O
4	was	O
5	measured	O
6	by	O
7	a	O
8	transient	O
9	expression	O
10	of	O
11	a	O
12	chloramphenicol	B
13	acetyltransferase	I
14	(	O
15	CAT	B
16	)	O
17	gene	O
18	connected	O
19	with	O
20	various	O
21	5	O
22	'-	O
23	deletion	O
24	mutants	O
25	of	O
26	the	O
27	5	O
28	'-	O
29	flanking	O
30	region	O
31	.	O
1	The	O
2	Saccharomyces	B
3	cerevisiae	I
4	14DM	I
5	gene	I
6	,	O
7	encoding	O
8	cytochrome	B
9	P450	I
10	lanosterol	I
11	14	I
12	alpha	I
13	-	I
14	demethylase	I
15	(	O
16	14DM	B
17	),	O
18	was	O
19	overexpressed	O
20	in	O
21	various	O
22	S	O
23	.	O
24	cerevisiae	O
25	strains	O
26	under	O
27	the	O
28	control	O
29	of	O
30	three	O
31	strong	O
32	heterologous	O
33	yeast	O
34	transcription	O
35	promoters	O
36	(	O
37	pADC1	B
38	,	O
39	pGPD	B
40	,	O
41	pPHO5	B
42	)	O
43	and	O
44	under	O
45	the	O
46	control	O
47	of	O
48	its	O
49	own	O
50	promoter	O
51	.	O
1	The	O
2	contribution	O
3	that	O
4	alternative	O
5	splicing	O
6	events	O
7	in	O
8	c	B
9	-	I
10	myb	I
11	expression	O
12	may	O
13	make	O
14	on	O
15	c	B
16	-	I
17	myb	I
18	function	O
19	remains	O
20	to	O
21	be	O
22	elucidated	O
23	.	O
1	R	O
2	.	O
1	Regulation	O
2	of	O
3	yeast	B
4	LEU2	I
5	.	O
1	Analysis	O
2	of	O
3	various	O
4	deletion	O
5	mutants	O
6	indicates	O
7	that	O
8	the	O
9	sequence	O
10	requirements	O
11	for	O
12	binding	O
13	by	O
14	QBP	B
15	in	O
16	vitro	O
17	are	O
18	indistinguishable	O
19	from	O
20	those	O
21	necessary	O
22	for	O
23	Q	O
24	activity	O
25	in	O
26	vivo	O
27	,	O
28	strongly	O
29	suggesting	O
30	that	O
31	QBP	B
32	is	O
33	required	O
34	for	O
35	the	O
36	function	O
37	of	O
38	this	O
39	TATA	O
40	-	O
41	independent	O
42	promoter	O
43	.	O
1	The	O
2	two	O
3	larger	O
4	peptides	O
5	,	O
6	one	O
7	containing	O
8	amino	O
9	acids	O
10	1	O
11	-	O
12	228	O
13	and	O
14	the	O
15	other	O
16	containing	O
17	amino	O
18	acids	O
19	85	O
20	-	O
21	228	O
22	,	O
23	formed	O
24	dimers	O
25	in	O
26	solution	O
27	and	O
28	bound	O
29	DNA	O
30	specifically	O
31	as	O
32	a	O
33	dimer	O
34	.	O
1	In	O
2	vitro	O
3	transcription	O
4	extracts	O
5	from	O
6	ret1	B
7	-	I
8	1	I
9	cells	O
10	terminate	O
11	less	O
12	efficiently	O
13	at	O
14	weak	O
15	transcription	O
16	termination	O
17	signals	O
18	than	O
19	those	O
20	from	O
21	RET1	B
22	cells	O
23	,	O
24	using	O
25	a	O
26	variety	O
27	of	O
28	tRNA	O
29	templates	O
30	.	O
1	These	O
2	factors	O
3	belong	O
4	to	O
5	a	O
6	set	O
7	of	O
8	genetically	O
9	distinct	O
10	molecules	O
11	,	O
12	including	O
13	AP	B
14	-	I
15	4	I
16	and	O
17	MLTF	B
18	,	O
19	that	O
20	bind	O
21	to	O
22	the	O
23	CACCTGTC	O
24	motif	O
25	or	O
26	related	O
27	sequences	O
28	.	O
1	RNase	B
2	protection	O
3	assays	O
4	reveal	O
5	that	O
6	this	O
7	gene	O
8	,	O
9	unr	B
10	,	O
11	is	O
12	transcribed	O
13	in	O
14	the	O
15	same	O
16	direction	O
17	as	O
18	N	B
19	-	I
20	ras	I
21	and	O
22	that	O
23	its	O
24	3	O
25	'	O
26	end	O
27	is	O
28	located	O
29	just	O
30	130	O
31	base	O
32	pairs	O
33	away	O
34	from	O
35	the	O
36	point	O
37	at	O
38	which	O
39	N	B
40	-	I
41	ras	I
42	transcription	O
43	begins	O
44	.	O
1	The	O
2	juxtamembrane	O
3	region	O
4	of	O
5	the	O
6	insulin	B
7	receptor	I
8	(	I
9	IR	I
10	)	I
11	beta	I
12	-	I
13	subunit	I
14	contains	O
15	an	O
16	unphosphorylated	O
17	tyrosyl	O
18	residue	O
19	(	O
20	Tyr960	O
21	)	O
22	that	O
23	is	O
24	essential	O
25	for	O
26	insulin	B
27	-	O
28	stimulated	O
29	tyrosyl	O
30	phosphorylation	O
31	of	O
32	some	O
33	endogenous	O
34	substrates	O
35	and	O
36	certain	O
37	biological	O
38	responses	O
39	(	O
40	White	O
41	,	O
42	M	O
43	.	O
44	F	O
45	.,	O
46	Livingston	O
47	,	O
48	J	O
49	.	O
50	N	O
51	.,	O
52	Backer	O
53	,	O
54	J	O
55	.	O
56	M	O
57	.,	O
58	Lauris	O
59	,	O
60	V	O
61	.,	O
62	Dull	O
63	,	O
64	T	O
65	.	O
66	J	O
67	.,	O
68	Ullrich	O
69	,	O
70	A	O
71	.,	O
72	and	O
73	Kahn	O
74	,	O
75	C	O
76	.	O
77	R	O
78	.	O
1	The	O
2	grandfather	O
3	and	O
4	the	O
5	granddaughter	O
6	both	O
7	had	O
8	microtia	O
9	and	O
10	meatal	O
11	atresia	O
12	,	O
13	whereas	O
14	the	O
15	daughter	O
16	had	O
17	a	O
18	normal	O
19	outer	O
20	ear	O
21	except	O
22	for	O
23	a	O
24	narrow	O
25	meatus	O
26	and	O
27	auricular	O
28	appendages	O
29	.	O
1	Horseradish	B
2	peroxidase	I
3	as	O
4	a	O
5	permeability	O
6	marker	O
7	in	O
8	injured	O
9	rat	O
10	caudal	O
11	and	O
12	iliac	O
13	arteries	O
14	.	O
1	Chick	B
2	brain	I
3	actin	I
4	depolymerizing	I
5	factor	I
6	(	O
7	ADF	B
8	)	O
9	is	O
10	a	O
11	19	O
12	-	O
13	kDa	O
14	protein	O
15	that	O
16	severs	O
17	actin	B
18	filaments	I
19	and	O
20	binds	O
21	actin	B
22	monomers	I
23	.	O
1	We	O
2	conclude	O
3	that	O
4	class	O
5	I	O
6	cytologic	O
7	smears	O
8	with	O
9	moderate	O
10	to	O
11	severe	O
12	inflammation	O
13	may	O
14	be	O
15	associated	O
16	with	O
17	findings	O
18	of	O
19	condylomata	O
20	and	O
21	cervical	O
22	dysplasia	O
23	.	O
1	Expression	O
2	of	O
3	the	O
4	human	O
5	T	B
6	cell	I
7	receptor	I
8	(	I
9	TCR	I
10	)	I
11	alpha	I
12	gene	I
13	is	O
14	regulated	O
15	by	O
16	a	O
17	T	O
18	cell	O
19	-	O
20	specific	O
21	transcriptional	O
22	enhancer	O
23	that	O
24	is	O
25	located	O
26	4	O
27	.	O
28	5	O
29	kilobases	O
30	(	O
31	kb	O
32	)	O
33	3	O
34	'	O
35	to	O
36	the	O
37	C	B
38	alpha	I
39	gene	I
40	segment	I
41	.	O
1	Presidential	O
2	address	O
3	1990	O
4	--	O
5	coming	O
6	in	O
7	from	O
8	the	O
9	cold	O
10	.	O
1	There	O
2	was	O
3	evidence	O
4	of	O
5	attenuated	O
6	regression	O
7	slopes	O
8	relating	O
9	recalled	O
10	to	O
11	observed	O
12	portion	O
13	sizes	O
14	for	O
15	4	O
16	of	O
17	the	O
18	10	O
19	food	O
20	groups	O
21	;	O
22	adjusted	O
23	r2	O
24	values	O
25	for	O
26	the	O
27	recalled	O
28	portion	O
29	sizes	O
30	ranged	O
31	from	O
32	0	O
33	.	O
34	02	O
35	to	O
36	0	O
37	.	O
38	94	O
39	.	O
1	The	O
2	SUP44	B
3	suppressor	I
4	mutation	I
5	occurs	O
6	near	O
7	a	O
8	region	O
9	of	O
10	the	O
11	protein	O
12	that	O
13	corresponds	O
14	to	O
15	the	O
16	known	O
17	positions	O
18	of	O
19	alterations	O
20	in	O
21	E	B
22	.	I
23	coli	I
24	S5	I
25	ram	I
26	mutations	I
27	.	O
1	Interestingly	O
2	,	O
3	disruption	O
4	of	O
5	the	O
6	VPS34	B
7	locus	I
8	resulted	O
9	in	O
10	a	O
11	temperature	O
12	-	O
13	sensitive	O
14	growth	O
15	defect	O
16	,	O
17	indicating	O
18	that	O
19	the	O
20	VPS34	B
21	gene	I
22	is	O
23	essential	O
24	for	O
25	vegetative	O
26	growth	O
27	only	O
28	at	O
29	elevated	O
30	growth	O
31	temperatures	O
32	.	O
1	This	O
2	,	O
3	together	O
4	with	O
5	the	O
6	data	O
7	obtained	O
8	with	O
9	haloperidol	O
10	,	O
11	suggests	O
12	that	O
13	a	O
14	minimal	O
15	increase	O
16	in	O
17	the	O
18	firing	O
19	rate	O
20	of	O
21	LC	O
22	cells	O
23	(+	O
24	140	O
25	%)	O
26	is	O
27	required	O
28	before	O
29	it	O
30	could	O
31	influence	O
32	the	O
33	turnover	O
34	of	O
35	NA	O
36	,	O
37	as	O
38	measured	O
39	by	O
40	DOPAC	O
41	changes	O
42	.	O
1	The	O
2	highly	O
3	restrained	O
4	girls	O
5	had	O
6	a	O
7	significantly	O
8	higher	O
9	EAT	O
10	score	O
11	than	O
12	the	O
13	low	O
14	-	O
15	restrained	O
16	girls	O
17	,	O
18	and	O
19	shared	O
20	with	O
21	their	O
22	mothers	O
23	a	O
24	susceptibility	O
25	to	O
26	the	O
27	disinhibitory	O
28	effects	O
29	of	O
30	negative	O
31	mood	O
32	states	O
33	on	O
34	their	O
35	eating	O
36	behaviour	O
37	.	O
1	Sequence	O
2	and	O
3	genetic	O
4	organization	O
5	of	O
6	a	O
7	Zymomonas	O
8	mobilis	O
9	gene	O
10	cluster	O
11	that	O
12	encodes	O
13	several	O
14	enzymes	O
15	of	O
16	glucose	O
17	metabolism	O
18	.	O
1	Most	O
2	strains	O
3	(	O
4	95	O
5	%)	O
6	of	O
7	S	O
8	.	O
9	lugdunensis	O
10	produced	O
11	a	O
12	delta	B
13	hemolysin	I
14	like	O
15	that	O
16	seen	O
17	with	O
18	nine	O
19	other	O
20	species	O
21	of	O
22	CNS	O
23	.	O
1	MCh	O
2	infusion	O
3	caused	O
4	a	O
5	concentration	O
6	-	O
7	dependent	O
8	increase	O
9	in	O
10	airway	O
11	resistance	O
12	at	O
13	constant	O
14	QBA	O
15	.	O
1	Taste	O
2	reactivity	O
3	tests	O
4	were	O
5	used	O
6	to	O
7	examine	O
8	the	O
9	orofacial	O
10	responses	O
11	of	O
12	alcohol	O
13	preferring	O
14	(	O
15	P	O
16	)	O
17	rats	O
18	and	O
19	alcohol	O
20	nonpreferring	O
21	(	O
22	NP	O
23	)	O
24	rats	O
25	to	O
26	the	O
27	taste	O
28	of	O
29	alcohol	O
30	.	O
1	Liver	O
2	dysfunction	O
3	in	O
4	the	O
5	presence	O
6	of	O
7	different	O
8	adverse	O
9	reactions	O
10	presented	O
11	with	O
12	a	O
13	higher	O
14	activity	O
15	in	O
16	the	O
17	blood	O
18	serum	O
19	of	O
20	indicator	O
21	liver	O
22	enzymes	O
23	and	O
24	its	O
25	impaired	O
26	protein	O
27	-	O
28	forming	O
29	function	O
30	.	O
1	Coenzyme	O
2	Q10	O
3	:	O
4	blood	O
5	levels	O
6	and	O
7	metabolic	O
8	demand	O
9	.	O
1	Serum	O
2	Fibrin	B
3	Degradation	I
4	Products	I
5	(	O
6	FDP	B
7	)	O
8	were	O
9	determined	O
10	in	O
11	50	O
12	oral	O
13	cancer	O
14	patients	O
15	and	O
16	50	O
17	normal	O
18	individuals	O
19	prior	O
20	to	O
21	any	O
22	kind	O
23	of	O
24	treatment	O
25	.	O
1	The	O
2	inspiratory	O
3	oxygen	O
4	concentration	O
5	needed	O
6	(	O
7	FiO2	O
8	)	O
9	and	O
10	the	O
11	Horowitz	O
12	quotient	O
13	differed	O
14	in	O
15	a	O
16	highly	O
17	significant	O
18	manner	O
19	beginning	O
20	on	O
21	the	O
22	1st	O
23	day	O
24	after	O
25	trauma	O
26	.	O
1	The	O
2	application	O
3	of	O
4	these	O
5	microelectrodes	O
6	to	O
7	the	O
8	measurement	O
9	of	O
10	rapid	O
11	,	O
12	transient	O
13	changes	O
14	in	O
15	retinal	O
16	[	O
17	K	O
18	+]	O
19	o	O
20	is	O
21	presented	O
22	.	O
1	Combining	O
2	multiple	O
3	laboratory	O
4	studies	O
5	may	O
6	be	O
7	of	O
8	value	O
9	in	O
10	predetermining	O
11	the	O
12	eventual	O
13	outcome	O
14	in	O
15	near	O
16	-	O
17	drowning	O
18	.	O
1	Accumulations	O
2	of	O
3	Tl	O
4	+	O
5	1	O
6	(	O
7	202Tl	O
8	label	O
9	)	O
10	were	O
11	6	O
12	times	O
13	those	O
14	for	O
15	Ga	O
16	or	O
17	In	O
18	in	O
19	the	O
20	brain	O
21	and	O
22	muscles	O
23	,	O
24	and	O
25	.	O
26	1	O
27	times	O
28	in	O
29	plasma	O
30	.	O
1	They	O
2	were	O
3	then	O
4	subjected	O
5	to	O
6	whole	O
7	-	O
8	body	O
9	heat	O
10	stress	O
11	(	O
12	water	O
13	-	O
14	perfused	O
15	suits	O
16	),	O
17	and	O
18	the	O
19	3	O
20	minutes	O
21	of	O
22	LBNP	O
23	was	O
24	repeated	O
25	.	O
1	The	O
2	effects	O
3	of	O
4	mean	O
5	luminance	O
6	were	O
7	also	O
8	measured	O
9	and	O
10	a	O
11	general	O
12	expression	O
13	that	O
14	would	O
15	take	O
16	them	O
17	into	O
18	account	O
19	was	O
20	derived	O
21	.	O
1	We	O
2	have	O
3	synthesized	O
4	[	O
5	7	O
6	,	O
7	7	O
8	-	O
9	2H2	O
10	]-	O
11	19	O
12	-	O
13	OHA	O
14	with	O
15	high	O
16	deuterium	O
17	content	O
18	and	O
19	,	O
20	together	O
21	with	O
22	[	O
23	7	O
24	,	O
25	7	O
26	-	O
27	2H2	O
28	]	O
29	A	O
30	and	O
31	[	O
32	9	O
33	,	O
34	11	O
35	-	O
36	2H2	O
37	]	O
38	estrone	O
39	(	O
40	E1	O
41	),	O
42	have	O
43	developed	O
44	a	O
45	quantitative	O
46	assay	O
47	of	O
48	serum	O
49	level	O
50	19	O
51	-	O
52	OHA	O
53	,	O
54	A	O
55	,	O
56	and	O
57	E1	O
58	using	O
59	the	O
60	gas	O
61	chromatography	O
62	/	O
63	mass	O
64	spectrometry	O
65	-	O
66	mass	O
67	fragmentography	O
68	method	O
69	to	O
70	monitor	O
71	individual	O
72	subjects	O
73	throughout	O
74	pregnancy	O
75	.	O
1	Fifteen	O
2	light	O
3	for	O
4	dates	O
5	infants	O
6	and	O
7	their	O
8	placentae	O
9	were	O
10	compared	O
11	to	O
12	15	O
13	well	O
14	-	O
15	grown	O
16	infants	O
17	and	O
18	their	O
19	placentae	O
20	.	O
1	These	O
2	findings	O
3	indicate	O
4	that	O
5	hypergastrinemia	O
6	induced	O
7	by	O
8	surgical	O
9	removal	O
10	of	O
11	acid	O
12	-	O
13	producing	O
14	mucosa	O
15	in	O
16	the	O
17	rat	O
18	has	O
19	the	O
20	same	O
21	effects	O
22	on	O
23	oxyntical	O
24	mucosal	B
25	HDC	I
26	activity	O
27	,	O
28	histamine	O
29	concentration	O
30	and	O
31	ECL	O
32	cell	O
33	density	O
34	as	O
35	hypergastrinemia	O
36	induced	O
37	by	O
38	continuous	O
39	gastrin	B
40	infusion	O
41	or	O
42	by	O
43	long	O
44	-	O
45	term	O
46	treatment	O
47	with	O
48	effective	O
49	antisecretagogues	O
50	.	O
1	The	O
2	order	O
3	of	O
4	the	O
5	helicase	B
6	motif	I
7	and	O
8	the	O
9	nsP3	B
10	homology	I
11	region	I
12	in	O
13	the	O
14	RUB	O
15	genome	O
16	is	O
17	reversed	O
18	with	O
19	respect	O
20	to	O
21	the	O
22	alphavirus	O
23	genome	O
24	indicating	O
25	that	O
26	a	O
27	genetic	O
28	rearrangement	O
29	has	O
30	occurred	O
31	during	O
32	the	O
33	evolution	O
34	of	O
35	these	O
36	viruses	O
37	.	O
1	There	O
2	were	O
3	5	O
4	treatments	O
5	:	O
6	control	O
7	(	O
8	C	O
9	);	O
10	a	O
11	wooden	O
12	surround	O
13	in	O
14	one	O
15	rear	O
16	corner	O
17	of	O
18	the	O
19	cage	O
20	(	O
21	S	O
22	);	O
23	a	O
24	fiberglass	O
25	rollaway	O
26	hollow	O
27	in	O
28	one	O
29	rear	O
30	corner	O
31	of	O
32	the	O
33	cage	O
34	(	O
35	H	O
36	);	O
37	a	O
38	hollow	O
39	and	O
40	a	O
41	surround	O
42	(	O
43	H	O
44	/	O
45	S	O
46	);	O
47	a	O
48	nest	O
49	box	O
50	attached	O
51	to	O
52	the	O
53	back	O
54	of	O
55	the	O
56	cage	O
57	,	O
58	containing	O
59	a	O
60	hollow	O
61	(	O
62	N	O
63	).	O
1	The	O
2	patient	O
3	was	O
4	treated	O
5	with	O
6	benzathine	O
7	penicillin	O
8	,	O
9	2	O
10	,	O
11	400	O
12	,	O
13	000	O
14	U	O
15	weekly	O
16	for	O
17	three	O
18	weeks	O
19	.	O
1	PCR	O
2	-	O
3	derived	O
4	fragments	O
5	were	O
6	used	O
7	as	O
8	probes	O
9	for	O
10	the	O
11	isolation	O
12	of	O
13	the	O
14	U3	B
15	snRNA	I
16	genes	I
17	from	O
18	a	O
19	genomic	O
20	library	O
21	of	O
22	Arabidopsis	O
23	.	O
1	The	O
2	findings	O
3	suggest	O
4	that	O
5	,	O
6	although	O
7	iodine	O
8	deficiency	O
9	is	O
10	the	O
11	most	O
12	probable	O
13	cause	O
14	of	O
15	goiter	O
16	among	O
17	immigrants	O
18	of	O
19	the	O
20	1928	O
21	cohort	O
22	,	O
23	where	O
24	the	O
25	native	O
26	population	O
27	is	O
28	concerned	O
29	(	O
30	both	O
31	men	O
32	and	O
33	women	O
34	),	O
35	some	O
36	other	O
37	goitrogenic	O
38	factor	O
39	(	O
40	s	O
41	)	O
42	must	O
43	be	O
44	involved	O
45	.	O
1	Co	O
2	-	O
3	administration	O
4	of	O
5	5FU	O
6	,	O
7	angiotensin	B
8	II	I
9	and	O
10	microspheres	O
11	via	O
12	the	O
13	hepatic	O
14	artery	O
15	may	O
16	reduce	O
17	drug	O
18	exposure	O
19	in	O
20	the	O
21	systemic	O
22	compartment	O
23	and	O
24	therefore	O
25	may	O
26	increase	O
27	the	O
28	therapeutic	O
29	ratio	O
30	of	O
31	5FU	O
32	administration	O
33	via	O
34	the	O
35	hepatic	O
36	artery	O
37	.	O
1	The	O
2	Community	O
3	Adjustment	O
4	Scale	O
5	provided	O
6	outcome	O
7	data	O
8	related	O
9	to	O
10	the	O
11	subjects	O
12	'	O
13	degree	O
14	of	O
15	productivity	O
16	,	O
17	ability	O
18	to	O
19	maintain	O
20	close	O
21	relationships	O
22	,	O
23	and	O
24	presence	O
25	/	O
26	absence	O
27	of	O
28	symptomatology	O
29	an	O
30	average	O
31	of	O
32	32	O
33	years	O
34	after	O
35	initial	O
36	admission	O
37	.	O
1	However	O
2	,	O
3	at	O
4	18	O
5	months	O
6	of	O
7	age	O
8	,	O
9	significantly	O
10	higher	O
11	levels	O
12	of	O
13	IgG1	B
14	(	O
15	P	O
16	less	O
17	than	O
18	0	O
19	.	O
20	05	O
21	)	O
22	and	O
23	of	O
24	IgG4	B
25	(	O
26	P	O
27	less	O
28	than	O
29	0	O
30	.	O
31	01	O
32	)	O
33	were	O
34	found	O
35	in	O
36	infants	O
37	with	O
38	an	O
39	elevated	O
40	IgE	B
41	(	O
42	greater	O
43	than	O
44	or	O
45	equal	O
46	to	O
47	8	O
48	.	O
49	0	O
50	kU	O
51	/	O
52	l	O
53	)	O
54	than	O
55	in	O
56	those	O
57	with	O
58	a	O
59	lower	O
60	level	O
61	.	O
1	The	O
2	eluent	O
3	from	O
4	the	O
5	column	O
6	was	O
7	mixed	O
8	with	O
9	the	O
10	chemiluminescent	O
11	solution	O
12	containing	O
13	lucigenin	B
14	and	O
15	Triton	O
16	X	O
17	-	O
18	100	O
19	and	O
20	a	O
21	0	O
22	.	O
23	28	O
24	M	O
25	KOH	O
26	solution	O
27	by	O
28	pumps	O
29	and	O
30	monitored	O
31	by	O
32	a	O
33	chemiluminescence	O
34	detector	O
35	.	O
1	The	O
2	RF	O
3	values	O
4	correlated	O
5	well	O
6	with	O
7	the	O
8	angiographic	O
9	semiquantitative	O
10	scale	O
11	of	O
12	severity	O
13	of	O
14	aortal	O
15	insufficiency	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	805	O
22	;	O
23	p	O
24	less	O
25	than	O
26	0	O
27	.	O
28	001	O
29	),	O
30	although	O
31	they	O
32	enabled	O
33	the	O
34	authors	O
35	only	O
36	to	O
37	make	O
38	a	O
39	partial	O
40	differentiation	O
41	of	O
42	haemodynamically	O
43	severe	O
44	regurgitations	O
45	and	O
46	mild	O
47	or	O
48	insignificant	O
49	ones	O
50	.	O
1	Sprague	O
2	-	O
3	Dawley	O
4	newborn	O
5	rats	O
6	(	O
7	n	O
8	=	O
9	85	O
10	)	O
11	breathed	O
12	100	O
13	%	O
14	oxygen	O
15	(	O
16	O2	O
17	)	O
18	or	O
19	room	O
20	air	O
21	(	O
22	RA	O
23	)	O
24	during	O
25	the	O
26	first	O
27	8	O
28	days	O
29	of	O
30	life	O
31	,	O
32	and	O
33	then	O
34	RA	O
35	.	O
1	Thus	O
2	,	O
3	this	O
4	reading	O
5	frame	O
6	was	O
7	concluded	O
8	to	O
9	encode	O
10	the	O
11	precursor	O
12	of	O
13	mitochondrial	B
14	fumarase	I
15	.	O
1	The	O
2	trk	B
3	-	I
4	2h	I
5	oncogene	I
6	,	O
7	isolated	O
8	from	O
9	the	O
10	human	O
11	breast	O
12	carcinoma	O
13	cell	O
14	line	O
15	MDA	O
16	-	O
17	MB	O
18	231	O
19	by	O
20	genomic	O
21	DNA	O
22	-	O
23	transfection	O
24	into	O
25	NIH3T3	O
26	cells	O
27	,	O
28	consists	O
29	of	O
30	the	O
31	trk	B
32	proto	I
33	-	I
34	oncogene	I
35	receptor	I
36	kinase	I
37	domain	I
38	fused	O
39	to	O
40	a	O
41	N	O
42	-	O
43	terminal	O
44	41	O
45	amino	O
46	acid	O
47	activating	O
48	sequence	O
49	(	O
50	Kozma	O
51	,	O
52	S	O
53	.	O
54	C	O
55	.,	O
56	Redmond	O
57	,	O
58	S	O
59	.	O
60	M	O
61	.	O
62	S	O
63	.,	O
64	Xiao	O
65	-	O
66	Chang	O
67	,	O
68	F	O
69	.,	O
70	Saurer	O
71	,	O
72	S	O
73	.	O
74	M	O
75	.,	O
76	Groner	O
77	,	O
78	B	O
79	.	O
80	and	O
81	Hynes	O
82	,	O
83	N	O
84	.	O
85	E	O
86	.	O
1	Branch	O
2	occlusion	O
3	of	O
4	Heubner	O
5	'	O
6	s	O
7	artery	O
8	,	O
9	or	O
10	perforators	O
11	from	O
12	the	O
13	proximal	O
14	anterior	O
15	or	O
16	middle	O
17	cerebral	O
18	arteries	O
19	were	O
20	the	O
21	posited	O
22	mechanism	O
23	of	O
24	infarction	O
25	.	O
1	Likewise	O
2	,	O
3	whether	O
4	or	O
5	not	O
6	the	O
7	hypotensive	O
8	action	O
9	of	O
10	converting	O
11	enzyme	O
12	inhibitors	O
13	is	O
14	age	O
15	-	O
16	related	O
17	is	O
18	as	O
19	yet	O
20	unknown	O
21	.	O
1	These	O
2	characteristics	O
3	of	O
4	N22	O
5	/	O
6	P22	O
7	indicate	O
8	that	O
9	it	O
10	is	O
11	a	O
12	localized	O
13	synaptically	O
14	dependent	O
15	event	O
16	conforming	O
17	to	O
18	a	O
19	transverse	O
20	dipole	O
21	with	O
22	dorsal	O
23	negativity	O
24	and	O
25	a	O
26	simultaneous	O
27	anterior	O
28	positivity	O
29	.	O
1	The	O
2	priming	O
3	activity	O
4	of	O
5	DNA	O
6	incised	O
7	by	O
8	either	O
9	of	O
10	the	O
11	Drosophila	O
12	enzymes	O
13	can	O
14	be	O
15	enhanced	O
16	,	O
17	however	O
18	,	O
19	by	O
20	an	O
21	additional	O
22	incubation	O
23	with	O
24	E	B
25	.	I
26	coli	I
27	endonuclease	I
28	IV	I
29	,	O
30	which	O
31	is	O
32	known	O
33	to	O
34	cleave	O
35	depurinated	O
36	DNA	O
37	on	O
38	the	O
39	5	O
40	'-	O
41	side	O
42	of	O
43	an	O
44	apurinic	O
45	site	O
46	.	O
1	The	O
2	levels	O
3	of	O
4	both	O
5	MAP1	B
6	-	I
7	specific	I
8	and	I
9	MAP2	I
10	-	I
11	specific	I
12	mRNAs	I
13	decline	O
14	in	O
15	the	O
16	postnatal	O
17	developing	O
18	brain	O
19	;	O
20	the	O
21	level	O
22	of	O
23	MAP1	B
24	-	I
25	specific	I
26	mRNA	I
27	also	O
28	increases	O
29	slightly	O
30	in	O
31	rat	O
32	PC12	O
33	cells	O
34	upon	O
35	exposure	O
36	to	O
37	nerve	B
38	growth	I
39	factor	I
40	.	O
1	Colorimetric	O
2	method	O
3	of	O
4	determining	O
5	glycerin	O
6	in	O
7	the	O
8	blood	O
1	Tolerance	O
2	to	O
3	fenfluramine	O
4	anorexia	O
5	:	O
6	fact	O
7	or	O
8	fiction	O
9	?	O
10	Recent	O
11	findings	O
12	in	O
13	this	O
14	laboratory	O
15	with	O
16	regard	O
17	to	O
18	tolerance	O
19	to	O
20	fenfluramine	O
21	anorexia	O
22	are	O
23	reviewed	O
24	with	O
25	respect	O
26	to	O
27	generality	O
28	of	O
29	the	O
30	behavioural	O
31	phenomenon	O
32	.	O
1	Comparison	O
2	of	O
3	elastase	B
4	-	I
5	1	I
6	with	O
7	amylase	B
8	,	O
9	lipase	B
10	,	O
11	and	O
12	trypsin	B
13	-	O
14	like	O
15	immunoreactivity	O
16	in	O
17	the	O
18	diagnosis	O
19	of	O
20	acute	O
21	pancreatitis	O
22	.	O
1	No	O
2	reflow	O
3	occurred	O
4	in	O
5	approximately	O
6	30	O
7	percent	O
8	of	O
9	the	O
10	muscle	O
11	microvasculature	O
12	upon	O
13	reperfusion	O
14	.	O
1	The	O
2	first	O
3	involved	O
4	measurements	O
5	of	O
6	the	O
7	steady	O
8	state	O
9	levels	O
10	of	O
11	mRNAs	O
12	for	O
13	subunit	O
14	5	O
15	of	O
16	cytochrome	B
17	oxidase	I
18	and	O
19	the	O
20	beta	O
21	subunit	O
22	of	O
23	F1	B
24	ATPase	I
25	in	O
26	wild	O
27	type	O
28	and	O
29	in	O
30	a	O
31	hem2	B
32	mutant	I
33	.	O
1	We	O
2	discuss	O
3	the	O
4	results	O
5	in	O
6	relation	O
7	to	O
8	previous	O
9	systems	O
10	for	O
11	parcellating	O
12	the	O
13	posterior	O
14	ectosylvian	O
15	gyrus	O
16	of	O
17	the	O
18	cat	O
19	and	O
20	consider	O
21	the	O
22	possibility	O
23	that	O
24	divisions	O
25	of	O
26	the	O
27	feline	O
28	posterior	O
29	ectosylvian	O
30	gyrus	O
31	correspond	O
32	directly	O
33	to	O
34	areas	O
35	making	O
36	up	O
37	the	O
38	superior	O
39	temporal	O
40	gyrus	O
41	in	O
42	primates	O
43	.	O
1	The	O
2	gene	O
3	is	O
4	contained	O
5	within	O
6	a	O
7	1	O
8	.	O
9	8	O
10	-	O
11	kilobase	O
12	AccI	B
13	-	O
14	EcoRI	B
15	restriction	O
16	fragment	O
17	mapping	O
18	at	O
19	map	O
20	coordinates	O
21	0	O
22	.	O
23	136	O
24	to	O
25	0	O
26	.	O
27	148	O
28	in	O
29	the	O
30	UL	O
31	region	O
32	of	O
33	the	O
34	EHV	O
35	-	O
36	1	O
37	genome	O
38	and	O
39	is	O
40	transcribed	O
41	from	O
42	right	O
43	to	O
44	left	O
45	.	O
1	Prognosis	O
2	of	O
3	asymptomatic	O
4	multiple	O
5	myeloma	O
6	.	O
1	The	O
2	size	O
3	discrepancy	O
4	is	O
5	not	O
6	due	O
7	to	O
8	glycosylation	O
9	or	O
10	phosphorylation	O
11	of	O
12	Ag35	B
13	but	O
14	may	O
15	result	O
16	from	O
17	a	O
18	proline	O
19	-	O
20	rich	O
21	sequence	O
22	which	O
23	occurs	O
24	in	O
25	this	O
26	polypeptide	O
27	.	O
1	The	O
2	investigation	O
3	was	O
4	thereafter	O
5	continued	O
6	in	O
7	an	O
8	open	O
9	fashion	O
10	by	O
11	administering	O
12	a	O
13	single	O
14	10	O
15	mg	O
16	dose	O
17	of	O
18	the	O
19	MAO	B
20	-	I
21	B	I
22	inhibitor	O
23	deprenyl	O
24	to	O
25	the	O
26	same	O
27	subjects	O
28	.	O
1	Spontaneous	O
2	sensitization	O
3	to	O
4	cross	O
5	-	O
6	reacting	O
7	chemicals	O
8	in	O
9	a	O
10	proportion	O
11	of	O
12	control	O
13	animals	O
14	is	O
15	strongly	O
16	suggested	O
17	,	O
18	somewhat	O
19	akin	O
20	to	O
21	spontaneous	O
22	sensitization	O
23	in	O
24	patients	O
25	with	O
26	anaphylactoid	O
27	reactions	O
28	to	O
29	neuromuscular	O
30	blockers	O
31	on	O
32	first	O
33	exposure	O
34	,	O
35	and	O
36	in	O
37	whom	O
38	IgE	B
39	antibodies	I
40	are	O
41	detected	O
42	.	O
1	Their	O
2	hydropathic	O
3	plots	O
4	are	O
5	very	O
6	similar	O
7	and	O
8	both	O
9	possess	O
10	three	O
11	hydrophobic	O
12	segments	O
13	that	O
14	are	O
15	likely	O
16	alpha	O
17	-	O
18	helical	O
19	transmembrane	O
20	segments	O
21	.	O
1	NIK	O
2	-	O
3	244	O
4	suppressed	O
5	coronary	O
6	ligation	O
7	-	O
8	and	O
9	digitalis	O
10	-	O
11	induced	O
12	arrhythmias	O
13	,	O
14	and	O
15	the	O
16	minimum	O
17	effective	O
18	plasma	O
19	concentrations	O
20	for	O
21	arrhythmias	O
22	induced	O
23	by	O
24	24	O
25	-	O
26	h	O
27	and	O
28	48	O
29	-	O
30	h	O
31	coronary	O
32	ligation	O
33	and	O
34	digitalis	O
35	were	O
36	0	O
37	.	O
38	41	O
39	+/-	O
40	0	O
41	.	O
42	10	O
43	(	O
44	by	O
45	1	O
46	mg	O
47	/	O
48	kg	O
49	i	O
50	.	O
51	v	O
52	.),	O
53	0	O
54	.	O
55	70	O
56	+/-	O
57	0	O
58	.	O
59	13	O
60	(	O
61	by	O
62	1	O
63	mg	O
64	/	O
65	kg	O
66	i	O
67	.	O
68	v	O
69	.),	O
70	and	O
71	0	O
72	.	O
73	21	O
74	+/-	O
75	0	O
76	.	O
77	08	O
78	(	O
79	by	O
80	0	O
81	.	O
82	5	O
83	mg	O
84	/	O
85	kg	O
86	i	O
87	.	O
88	v	O
89	.)	O
90	microgram	O
91	/	O
92	ml	O
93	,	O
94	respectively	O
95	(	O
96	mean	O
97	+/-	O
98	SD	O
99	of	O
100	the	O
101	mean	O
102	,	O
103	n	O
104	=	O
105	6	O
106	).	O
1	Following	O
2	chondroitinase	B
3	AC	I
4	and	I
5	ABC	I
6	digestion	O
7	,	O
8	staining	O
9	reactions	O
10	suggested	O
11	that	O
12	the	O
13	highest	O
14	levels	O
15	of	O
16	dermatan	O
17	sulfate	O
18	were	O
19	in	O
20	the	O
21	diabetes	O
22	resistant	O
23	group	O
24	(	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	001	O
31	compared	O
32	to	O
33	diabetic	O
34	,	O
35	p	O
36	less	O
37	than	O
38	0	O
39	.	O
40	001	O
41	compared	O
42	to	O
43	diabetes	O
44	prone	O
45	)	O
46	and	O
47	the	O
48	highest	O
49	levels	O
50	of	O
51	chondroitin	O
52	sulfates	O
53	were	O
54	in	O
55	the	O
56	diabetes	O
57	prone	O
58	group	O
59	(	O
60	p	O
61	less	O
62	than	O
63	0	O
64	.	O
65	001	O
66	).	O
1	During	O
2	the	O
3	program	O
4	'	O
5	s	O
6	use	O
7	at	O
8	the	O
9	RSNA	O
10	meeting	O
11	,	O
12	the	O
13	program	O
14	selected	O
15	the	O
16	correct	O
17	diagnosis	O
18	in	O
19	the	O
20	top	O
21	five	O
22	22	O
23	%	O
24	of	O
25	the	O
26	time	O
27	.	O
1	The	O
2	results	O
3	were	O
4	as	O
5	follows	O
6	:	O
7	1	O
8	)	O
9	Total	O
10	integrated	O
11	EMG	O
12	activity	O
13	of	O
14	FB	O
15	group	O
16	was	O
17	approximately	O
18	equal	O
19	in	O
20	any	O
21	occluded	O
22	position	O
23	,	O
24	whereas	O
25	that	O
26	of	O
27	CG	O
28	and	O
29	GF	O
30	group	O
31	varied	O
32	from	O
33	position	O
34	to	O
35	position	O
36	.	O
1	In	O
2	resting	O
3	3T3	O
4	cells	O
5	,	O
6	jun	B
7	-	I
8	D	I
9	is	O
10	expressed	O
11	at	O
12	a	O
13	higher	O
14	level	O
15	compared	O
16	to	O
17	c	B
18	-	I
19	jun	I
20	and	O
21	jun	B
22	-	I
23	B	I
24	,	O
25	and	O
26	its	O
27	transcription	O
28	is	O
29	stimulated	O
30	only	O
31	slightly	O
32	by	O
33	serum	O
34	growth	O
35	factors	O
36	.	O
1	The	O
2	thrombolytic	O
3	effects	O
4	of	O
5	native	O
6	tissue	B
7	-	I
8	type	I
9	plasminogen	I
10	activator	I
11	(	O
12	AK	B
13	-	I
14	124	I
15	)	O
16	on	O
17	experimental	O
18	canine	O
19	coronary	O
20	thrombosis	O
21	.	O
1	O2	O
2	and	O
3	CO2	O
4	in	O
5	the	O
6	tracheostomy	O
7	tube	O
8	were	O
9	continuously	O
10	monitored	O
11	by	O
12	mass	O
13	spectrometry	O
14	using	O
15	a	O
16	special	O
17	sample	O
18	-	O
19	hold	O
20	phase	O
21	-	O
22	locked	O
23	sampling	O
24	technique	O
25	.	O
1	In	O
2	transformed	O
3	E	O
4	.	O
5	coli	O
6	,	O
7	constitutive	B
8	CAT	I
9	expression	O
10	is	O
11	maintained	O
12	when	O
13	as	O
14	little	O
15	as	O
16	0	O
17	.	O
18	3	O
19	kilobase	O
20	of	O
21	DNA	O
22	from	O
23	the	O
24	3	O
25	'	O
26	end	O
27	of	O
28	the	O
29	1	O
30	.	O
31	6	O
32	-	O
33	kilobase	O
34	segment	O
35	is	O
36	inserted	O
37	in	O
38	the	O
39	correct	O
40	orientation	O
41	in	O
42	front	O
43	of	O
44	the	O
45	CAT	B
46	gene	I
47	.	O
1	Tonometry	O
2	of	O
3	blood	O
4	samples	O
5	from	O
6	patients	O
7	may	O
8	also	O
9	be	O
10	used	O
11	in	O
12	the	O
13	determination	O
14	of	O
15	acid	O
16	-	O
17	base	O
18	quantities	O
19	and	O
20	hemoglobin	B
21	-	O
22	oxygen	O
23	affinity	O
24	e	O
25	.	O
26	g	O
27	.	O
28	p50	O
29	.	O
1	Isolation	O
2	of	O
3	Weeksella	O
4	virosa	O
5	(	O
6	formerly	O
7	CDC	O
8	group	O
9	IIf	O
10	)	O
11	from	O
12	a	O
13	vaginal	O
14	sample	O
15	.	O
1	Abundant	O
2	infiltration	O
3	of	O
4	lymphocytes	O
5	and	O
6	plasma	O
7	cells	O
8	was	O
9	also	O
10	wide	O
11	-	O
12	spread	O
13	beneath	O
14	the	O
15	carcinoma	O
16	in	O
17	situ	O
18	,	O
19	together	O
20	with	O
21	the	O
22	lymphoid	O
23	follicles	O
24	.	O
1	These	O
2	case	O
3	reports	O
4	provide	O
5	further	O
6	evidence	O
7	that	O
8	LiCO3	O
9	can	O
10	be	O
11	a	O
12	useful	O
13	medication	O
14	in	O
15	the	O
16	treatment	O
17	of	O
18	aggressive	O
19	behavior	O
20	and	O
21	affective	O
22	instability	O
23	after	O
24	brain	O
25	injury	O
26	,	O
27	but	O
28	that	O
29	it	O
30	has	O
31	significant	O
32	potential	O
33	for	O
34	neurotoxicity	O
35	in	O
36	this	O
37	population	O
38	,	O
39	particularly	O
40	when	O
41	used	O
42	in	O
43	conjunction	O
44	with	O
45	neuroleptic	O
46	agents	O
47	.	O
1	Among	O
2	100	O
3	cases	O
4	of	O
5	post	O
6	-	O
7	transfusion	O
8	hepatitis	O
9	,	O
10	10	O
11	are	O
12	due	O
13	to	O
14	the	O
15	hepatitis	O
16	B	O
17	virus	O
18	(	O
19	despite	O
20	systematic	O
21	search	O
22	for	O
23	HBs	B
24	Ag	I
25	),	O
26	89	O
27	are	O
28	due	O
29	to	O
30	one	O
31	of	O
32	the	O
33	non	O
34	-	O
35	A	O
36	non	O
37	-	O
38	B	O
39	viruses	O
40	(	O
41	not	O
42	detectable	O
43	by	O
44	specific	O
45	serological	O
46	tests	O
47	)	O
48	and	O
49	1	O
50	to	O
51	several	O
52	viruses	O
53	,	O
54	specially	O
55	CMV	O
56	.	O
1	A	O
2	215	O
3	-	O
4	base	O
5	-	O
6	pair	O
7	(	O
8	bp	O
9	)	O
10	region	O
11	of	O
12	the	O
13	mouse	B
14	MOPC	I
15	41	I
16	kappa	I
17	light	I
18	-	I
19	chain	I
20	immunoglobulin	I
21	gene	I
22	enhancer	I
23	has	O
24	been	O
25	analyzed	O
26	for	O
27	specific	O
28	binding	O
29	of	O
30	lymphoid	O
31	and	O
32	nonlymphoid	O
33	nuclear	O
34	factors	O
35	.	O
1	Follow	O
2	-	O
3	up	O
4	study	O
5	showed	O
6	85	O
7	%	O
8	of	O
9	these	O
10	patients	O
11	with	O
12	effectiveness	O
13	.	O
1	The	O
2	other	O
3	patients	O
4	continued	O
5	the	O
6	trial	O
7	with	O
8	single	O
9	daily	O
10	doses	O
11	of	O
12	monotherapy	O
13	.	O
1	Neonatal	O
2	Chagas	O
3	disease	O
4	:	O
5	laboratory	O
6	diagnosis	O
7	during	O
8	the	O
9	first	O
10	year	O
11	of	O
12	life	O
1	Inefficacy	O
2	of	O
3	phosphine	O
4	fumigation	O
5	against	O
6	ticks	O
7	.	O
1	The	O
2	recovery	O
3	index	O
4	(	O
5	T25	O
6	-	O
7	T75	O
8	)	O
9	after	O
10	the	O
11	infusion	O
12	stopped	O
13	was	O
14	similar	O
15	in	O
16	patients	O
17	who	O
18	received	O
19	mivacurium	O
20	and	O
21	those	O
22	who	O
23	received	O
24	suxamethonium	O
25	.	O
1	The	O
2	sign	O
3	of	O
4	Leser	O
5	-	O
6	Trelat	O
7	:	O
8	does	O
9	it	O
10	exist	O
11	?	O
12	The	O
13	sign	O
14	of	O
15	Leser	O
16	-	O
17	Trelat	O
18	is	O
19	usually	O
20	regarded	O
21	as	O
22	a	O
23	reliable	O
24	cutaneous	O
25	marker	O
26	of	O
27	internal	O
28	malignancy	O
29	.	O
1	Southern	O
2	blot	O
3	analyses	O
4	demonstrated	O
5	a	O
6	low	O
7	,	O
8	if	O
9	not	O
10	single	O
11	,	O
12	copy	O
13	number	O
14	for	O
15	this	O
16	gene	O
17	and	O
18	conservation	O
19	of	O
20	this	O
21	domain	O
22	in	O
23	other	O
24	vertebrates	O
25	.	O
1	Three	O
2	missense	O
3	mutants	O
4	in	O
5	subunit	O
6	a	O
7	of	O
8	the	O
9	Escherichia	B
10	coli	I
11	F1F0	I
12	-	I
13	ATPase	I
14	were	O
15	isolated	O
16	and	O
17	characterized	O
18	after	O
19	hydroxylamine	O
20	mutagenesis	O
21	of	O
22	a	O
23	plasmid	O
24	carrying	O
25	the	O
26	uncB	B
27	(	I
28	subunit	I
29	a	I
30	)	I
31	gene	I
32	.	O
1	The	O
2	adenovirus	B
3	E1A	I
4	gene	I
5	encodes	O
6	a	O
7	protein	O
8	that	O
9	transcriptionally	O
10	activates	O
11	viral	B
12	early	I
13	genes	I
14	.	O
1	In	O
2	the	O
3	formalin	O
4	test	O
5	,	O
6	however	O
7	,	O
8	naloxone	O
9	attenuated	O
10	morphine	O
11	analgesia	O
12	at	O
13	the	O
14	lower	O
15	doses	O
16	(	O
17	0	O
18	.	O
19	1	O
20	and	O
21	0	O
22	.	O
23	3	O
24	mg	O
25	/	O
26	kg	O
27	)	O
28	and	O
29	potentiated	O
30	morphine	O
31	analgesia	O
32	at	O
33	the	O
34	highest	O
35	dose	O
36	(	O
37	10	O
38	mg	O
39	/	O
40	kg	O
41	).	O
1	UbiA	B
2	is	O
3	also	O
4	unique	O
5	among	O
6	known	O
7	polyubiquitin	B
8	genes	I
9	in	O
10	containing	O
11	four	O
12	cis	O
13	-	O
14	spliced	O
15	introns	O
16	within	O
17	its	O
18	coding	O
19	sequence	O
20	.	O
1	That	O
2	of	O
3	the	O
4	T2	B
5	gene	I
6	contains	O
7	numerous	O
8	potential	O
9	sites	O
10	for	O
11	binding	O
12	the	O
13	mammalian	B
14	transcription	I
15	factor	I
16	SP1	I
17	,	O
18	but	O
19	no	O
20	TATA	O
21	or	O
22	CCAAT	O
23	sequences	O
24	are	O
25	evident	O
26	near	O
27	to	O
28	its	O
29	5	O
30	'	O
31	end	O
32	,	O
33	although	O
34	these	O
35	latter	O
36	features	O
37	are	O
38	associated	O
39	with	O
40	the	O
41	human	B
42	T1	I
43	gene	I
44	.	O
1	The	O
2	methylation	O
3	of	O
4	nuclear	O
5	and	O
6	chloroplast	O
7	DNAs	O
8	has	O
9	been	O
10	examined	O
11	in	O
12	relation	O
13	to	O
14	the	O
15	known	O
16	differential	O
17	expression	O
18	of	O
19	C4	B
20	photosynthesis	I
21	genes	I
22	in	O
23	the	O
24	bundle	O
25	sheath	O
26	and	O
27	mesophyll	O
28	cells	O
29	of	O
30	etiolated	O
31	,	O
32	greening	O
33	,	O
34	and	O
35	fully	O
36	green	O
37	maize	O
38	leaves	O
39	.	O
1	Synthetic	O
2	oligonucleotides	O
3	representing	O
4	the	O
5	19	O
6	bp	O
7	repeat	O
8	unit	O
9	strongly	O
10	reduced	O
11	the	O
12	activity	O
13	of	O
14	the	O
15	IE1	B
16	/	I
17	2	I
18	enhancer	I
19	/	I
20	promoter	I
21	in	O
22	cotransfection	O
23	assays	O
24	after	O
25	transient	O
26	expression	O
27	.	O
1	Effects	O
2	of	O
3	nitrogen	O
4	(	O
5	PN2	O
6	:	O
7	5	O
8	and	O
9	14	O
10	MPa	O
11	)	O
12	and	O
13	helium	O
14	(	O
15	PHe	O
16	:	O
17	13	O
18	and	O
19	14	O
20	MPa	O
21	)	O
22	were	O
23	also	O
24	tested	O
25	.	O
1	Similarly	O
2	,	O
3	supraventricular	O
4	tachycaydia	O
5	following	O
6	resuscitative	O
7	efforts	O
8	appeared	O
9	to	O
10	be	O
11	associated	O
12	with	O
13	a	O
14	negative	O
15	outcome	O
16	.	O
1	In	O
2	consequence	O
3	,	O
4	the	O
5	gpI	B
6	derived	O
7	from	O
8	cells	O
9	infected	O
10	with	O
11	mO74	O
12	showed	O
13	antigenic	O
14	characteristics	O
15	similar	O
16	to	O
17	those	O
18	of	O
19	gpI	B
20	from	O
21	VZV	O
22	-	O
23	infected	O
24	cells	O
25	as	O
26	determined	O
27	from	O
28	the	O
29	immunoprecipitation	O
30	pattern	O
31	,	O
32	although	O
33	the	O
34	molecular	O
35	weight	O
36	of	O
37	each	O
38	polypeptide	O
39	was	O
40	different	O
41	,	O
42	and	O
43	antibody	O
44	produced	O
45	in	O
46	rabbits	O
47	infected	O
48	with	O
49	recombinant	O
50	virus	O
51	had	O
52	a	O
53	high	O
54	neutralizing	O
55	activity	O
56	,	O
57	when	O
58	the	O
59	reaction	O
60	was	O
61	performed	O
62	with	O
63	complement	O
64	.	O
1	Of	O
2	202	O
3	initially	O
4	seronegative	O
5	caretakers	O
6	(	O
7	observed	O
8	for	O
9	an	O
10	average	O
11	of	O
12	305	O
13	days	O
14	per	O
15	woman	O
16	),	O
17	19	O
18	seroconverted	O
19	,	O
20	for	O
21	an	O
22	annual	O
23	seroconversion	O
24	rate	O
25	of	O
26	11	O
27	percent	O
28	.	O
1	First	O
2	,	O
3	a	O
4	pet54	B
5	::	O
6	LEU2	B
7	cytoductant	O
8	bearing	O
9	the	O
10	'	O
11	short	O
12	'	O
13	mitochondrial	O
14	genome	O
15	that	O
16	lacks	O
17	both	O
18	COX1	B
19	introns	I
20	aI5	I
21	alpha	I
22	and	O
23	aI5	B
24	beta	I
25	is	O
26	defective	O
27	only	O
28	in	O
29	COX3	B
30	gene	I
31	expression	O
32	and	O
33	not	O
34	in	O
35	COX1	B
36	mRNA	I
37	splicing	O
38	or	O
39	mRNA	O
40	translation	O
41	.	O
1	Beta	B
2	-	I
3	endorphin	I
4	,	O
5	ACTH	B
6	and	O
7	cortisol	O
8	secretion	O
9	were	O
10	measured	O
11	in	O
12	twelve	O
13	healthy	O
14	adult	O
15	males	O
16	after	O
17	nasal	O
18	spray	O
19	administration	O
20	200	O
21	IU	O
22	salmon	B
23	calcitonin	I
24	.	O
1	In	O
2	contrast	O
3	,	O
4	the	O
5	neu	B
6	proto	I
7	-	I
8	oncogene	I
9	did	O
10	not	O
11	show	O
12	kinase	O
13	activity	O
14	or	O
15	transforming	O
16	properties	O
17	when	O
18	expressed	O
19	at	O
20	similar	O
21	levels	O
22	in	O
23	NIH	O
24	3T3	O
25	cells	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	250	O
31	WORDS	O
32	)	O
1	In	O
2	contrast	O
3	,	O
4	the	O
5	full	O
6	mu	O
7	-	O
8	opioid	O
9	agonists	O
10	fentanyl	O
11	,	O
12	morphine	O
13	,	O
14	I	O
15	-	O
16	methadone	O
17	and	O
18	levorphanol	O
19	produced	O
20	50	O
21	%	O
22	fentanyl	O
23	-	O
24	appropriate	O
25	responding	O
26	at	O
27	doses	O
28	only	O
29	1	O
30	.	O
31	3	O
32	to	O
33	10	O
34	.	O
35	9	O
36	times	O
37	smaller	O
38	than	O
39	those	O
40	required	O
41	to	O
42	decrease	O
43	response	O
44	rates	O
45	by	O
46	50	O
47	%.	O
1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	a	O
6	cDNA	O
7	encoding	O
8	a	O
9	putative	O
10	cytokine	O
11	which	O
12	is	O
13	induced	O
14	by	O
15	stimulation	O
16	via	O
17	the	O
18	CD2	B
19	structure	I
20	on	O
21	human	O
22	T	O
23	lymphocytes	O
24	.	O
1	An	O
2	experiment	O
3	on	O
4	the	O
5	return	O
6	-	O
7	of	O
8	-	O
9	fear	O
10	(	O
11	ROF	O
12	)	O
13	was	O
14	carried	O
15	out	O
16	on	O
17	40	O
18	snake	O
19	-	O
20	or	O
21	spider	O
22	-	O
23	phobic	O
24	subjects	O
25	in	O
26	order	O
27	to	O
28	determine	O
29	whether	O
30	an	O
31	arousing	O
32	event	O
33	that	O
34	occurs	O
35	shortly	O
36	before	O
37	retest	O
38	influences	O
39	the	O
40	magnitude	O
41	of	O
42	the	O
43	ROF	O
44	.	O
1	Selection	O
2	of	O
3	the	O
4	22	O
5	items	O
6	of	O
7	the	O
8	Clinical	O
9	Institute	O
10	Withdrawal	O
11	Assessment	O
12	-	O
13	Benzodiazepines	O
14	(	O
15	CIWA	O
16	-	O
17	B	O
18	)	O
19	was	O
20	based	O
21	on	O
22	statistically	O
23	significant	O
24	differences	O
25	between	O
26	baseline	O
27	and	O
28	critical	O
29	withdrawal	O
30	periods	O
31	in	O
32	high	O
33	-	O
34	dose	O
35	subjects	O
36	and	O
37	between	O
38	symptoms	O
39	associated	O
40	with	O
41	placebo	O
42	and	O
43	diazepam	O
44	in	O
45	low	O
46	-	O
47	dose	O
48	subjects	O
49	,	O
50	using	O
51	contingency	O
52	tables	O
53	and	O
54	logistic	O
55	regression	O
56	analysis	O
57	.	O
1	Northern	O
2	blot	O
3	analysis	O
4	revealed	O
5	multiple	O
6	oIGF	B
7	-	I
8	I	I
9	transcripts	I
10	in	O
11	a	O
12	broad	O
13	band	O
14	at	O
15	800	O
16	-	O
17	1	O
18	,	O
19	100	O
20	nucleotides	O
21	and	O
22	other	O
23	transcripts	O
24	of	O
25	higher	O
26	molecular	O
27	weight	O
28	in	O
29	liver	O
30	.	O
1	GN101	O
2	,	O
3	YC819	O
4	-	O
5	9	O
6	,	O
7	and	O
8	SB3	O
9	.	O
1	Nodular	O
2	involvement	O
3	of	O
4	the	O
5	left	O
6	lung	O
7	and	O
8	infiltration	O
9	of	O
10	the	O
11	mucosa	O
12	of	O
13	the	O
14	left	O
15	lower	O
16	lobe	O
17	bronchus	O
18	followed	O
19	very	O
20	gradually	O
21	and	O
22	a	O
23	monoclonal	O
24	gammopathy	O
25	(	O
26	IgA	B
27	--	I
28	Type	I
29	Kappa	I
30	)	O
31	was	O
32	demonstrated	O
33	.	O
1	5	O
2	.	O
1	Of	O
2	165	O
3	women	O
4	with	O
5	non	O
6	-	O
7	malignant	O
8	diagnoses	O
9	26	O
10	(	O
11	16	O
12	%)	O
13	had	O
14	CA	B
15	125	I
16	levels	O
17	in	O
18	excess	O
19	of	O
20	35	O
21	U	O
22	/	O
23	ml	O
24	and	O
25	8	O
26	(	O
27	5	O
28	%)	O
29	greater	O
30	than	O
31	65	O
32	U	O
33	/	O
34	ml	O
35	.	O
1	1	O
2	.	O
1	Middle	O
2	-	O
3	latency	O
4	auditory	O
5	evoked	O
6	potentials	O
7	(	O
8	MAEPs	O
9	)	O
10	were	O
11	recorded	O
12	in	O
13	controls	O
14	and	O
15	patients	O
16	with	O
17	focal	O
18	lesions	O
19	in	O
20	dorsolateral	O
21	prefrontal	O
22	cortex	O
23	.	O
1	Specifically	O
2	,	O
3	they	O
4	were	O
5	performed	O
6	to	O
7	determine	O
8	whether	O
9	detection	O
10	of	O
11	envelope	O
12	phase	O
13	disparity	O
14	was	O
15	consistent	O
16	with	O
17	processing	O
18	within	O
19	a	O
20	single	O
21	channel	O
22	in	O
23	which	O
24	the	O
25	AM	O
26	tones	O
27	were	O
28	simply	O
29	added	O
30	.	O
1	A	O
2	protocol	O
3	is	O
4	elaborated	O
5	for	O
6	the	O
7	preparation	O
8	and	O
9	characterization	O
10	of	O
11	a	O
12	quality	O
13	control	O
14	material	O
15	(	O
16	QCM	O
17	)	O
18	containing	O
19	intrinsic	O
20	concentration	O
21	of	O
22	cadmium	O
23	(	O
24	Cd	O
25	)	O
26	(	O
27	0	O
28	.	O
29	8	O
30	microgram	O
31	/	O
32	L	O
33	)	O
34	and	O
35	lead	O
36	(	O
37	Pb	O
38	)	O
39	(	O
40	13	O
41	.	O
42	4	O
43	micrograms	O
44	/	O
45	dL	O
46	)	O
47	from	O
48	bovine	O
49	blood	O
50	and	O
51	an	O
52	elevated	O
53	QCM	O
54	containing	O
55	Cd	O
56	(	O
57	5	O
58	.	O
59	0	O
60	micrograms	O
61	/	O
62	L	O
63	),	O
64	mercury	O
65	(	O
66	Hg	O
67	)	O
68	(	O
69	11	O
70	.	O
71	2	O
72	micrograms	O
73	/	O
74	L	O
75	),	O
76	and	O
77	Pb	O
78	(	O
79	34	O
80	.	O
81	5	O
82	micrograms	O
83	/	O
84	dL	O
85	)	O
86	from	O
87	bovine	O
88	blood	O
89	spiked	O
90	with	O
91	aqueous	O
92	spiking	O
93	-	O
94	solutions	O
95	prepared	O
96	with	O
97	salts	O
98	of	O
99	Cd	O
100	,	O
101	Hg	O
102	,	O
103	and	O
104	Pb	O
105	.	O
1	LON	O
2	-	O
3	72	O
4	(	O
5	34	O
6	isolates	O
7	),	O
8	LON	O
9	-	O
10	73	O
11	(	O
12	1	O
13	),	O
14	LON	O
15	-	O
16	71	O
17	(	O
18	2	O
19	)	O
20	and	O
21	LON	O
22	-	O
23	10	O
24	(	O
25	2	O
26	)	O
27	were	O
28	found	O
29	at	O
30	altitudes	O
31	around	O
32	2000	O
33	m	O
34	,	O
35	3	O
36	of	O
37	them	O
38	in	O
39	a	O
40	single	O
41	village	O
42	.	O
1	Animal	O
2	experimental	O
3	and	O
4	clinical	O
5	applications	O
6	of	O
7	plates	O
8	,	O
9	screws	O
10	and	O
11	spinal	O
12	segmental	O
13	replacement	O
14	implants	O
15	made	O
16	of	O
17	this	O
18	composite	O
19	material	O
20	have	O
21	shown	O
22	good	O
23	results	O
24	so	O
25	far	O
26	.	O
1	The	O
2	antigen	B
3	-	I
4	specific	I
5	IgG4	I
6	antibody	I
7	seems	O
8	to	O
9	be	O
10	an	O
11	index	O
12	in	O
13	evaluating	O
14	immunotherapy	O
15	objectively	O
16	.	O
1	The	O
2	differential	O
3	diagnosis	O
4	of	O
5	both	O
6	affections	O
7	is	O
8	based	O
9	on	O
10	the	O
11	clinical	O
12	course	O
13	,	O
14	sialography	O
15	and	O
16	CT	O
17	examination	O
18	which	O
19	along	O
20	with	O
21	modern	O
22	ATB	O
23	treatment	O
24	significantly	O
25	modify	O
26	hitherto	O
27	used	O
28	surgical	O
29	therapy	O
30	.	O
1	Serological	O
2	studies	O
3	at	O
4	the	O
5	early	O
6	relapse	O
7	stage	O
8	of	O
9	this	O
10	disease	O
11	showed	O
12	increased	O
13	serum	B
14	ANA	I
15	,	O
16	IgA	B
17	and	O
18	IgM	B
19	level	O
20	with	O
21	normal	O
22	IgG	B
23	and	O
24	decrease	O
25	of	O
26	C3	B
27	and	O
28	C4	B
29	.	O
1	Ischemic	O
2	heart	O
3	disease	O
4	evaluated	O
5	by	O
6	exercise	O
7	stress	O
8	thallium	O
9	-	O
10	201	O
11	myocardial	O
12	scintigraphy	O
13	:	O
14	a	O
15	comparison	O
16	of	O
17	SPECT	O
18	and	O
19	bull	O
20	'	O
21	s	O
22	eye	O
23	display	O
1	Concomitant	O
2	chronic	O
3	lymphocytic	O
4	leukemia	O
5	,	O
6	acute	O
7	myeloid	O
8	leukemia	O
9	,	O
10	and	O
11	thrombosis	O
12	with	O
13	protein	B
14	C	I
15	deficiency	O
16	.	O
1	There	O
2	was	O
3	no	O
4	significant	O
5	correlation	O
6	between	O
7	baseline	O
8	PC40	O
9	methacholine	O
10	and	O
11	the	O
12	maximal	O
13	fall	O
14	in	O
15	Vp30	O
16	after	O
17	either	O
18	the	O
19	first	O
20	(	O
21	12	O
22	micrograms	O
23	)	O
24	or	O
25	the	O
26	second	O
27	dose	O
28	(	O
29	24	O
30	micrograms	O
31	)	O
32	of	O
33	platelet	B
34	activating	I
35	factor	I
36	.	O
1	A	O
2	0	O
3	.	O
4	5	O
5	rating	O
6	was	O
7	intended	O
8	to	O
9	characterize	O
10	subjects	O
11	in	O
12	whom	O
13	mild	O
14	cognitive	O
15	impairment	O
16	due	O
17	to	O
18	senile	O
19	dementia	O
20	of	O
21	the	O
22	Alzheimer	O
23	type	O
24	was	O
25	suspected	O
26	but	O
27	was	O
28	insufficient	O
29	in	O
30	degree	O
31	to	O
32	warrant	O
33	a	O
34	diagnosis	O
35	of	O
36	definite	O
37	dementia	O
38	.	O
1	The	O
2	site	O
3	-	O
4	specific	O
5	DNA	O
6	inversion	O
7	system	O
8	Cin	B
9	encoded	O
10	by	O
11	the	O
12	bacteriophage	O
13	P1	O
14	consists	O
15	of	O
16	a	O
17	recombinase	B
18	,	O
19	two	O
20	inverted	O
21	crossing	O
22	-	O
23	over	O
24	sites	O
25	and	O
26	a	O
27	recombinational	O
28	enhancer	O
29	.	O
1	The	O
2	terminator	O
3	region	O
4	supported	O
5	termination	O
6	of	O
7	transcripts	O
8	initiated	O
9	by	O
10	RNA	B
11	polymerase	I
12	I	I
13	in	O
14	vivo	O
15	.	O
1	Doppler	O
2	echo	O
3	in	O
4	evaluating	O
5	arteriovenous	O
6	fistulae	O
7	for	O
8	dialysis	O
1	The	O
2	galactose	B
3	transporter	I
4	shows	O
5	both	O
6	sequence	O
7	and	O
8	structural	O
9	homology	O
10	with	O
11	a	O
12	superfamily	O
13	of	O
14	sugar	B
15	transporters	I
16	which	O
17	includes	O
18	the	O
19	human	B
20	HepG2	I
21	-	I
22	erythrocyte	I
23	and	I
24	fetal	I
25	muscle	I
26	glucose	I
27	transporters	I
28	,	O
29	the	O
30	rat	B
31	brain	I
32	and	I
33	liver	I
34	glucose	I
35	transporters	I
36	,	O
37	the	O
38	Escherichia	B
39	coli	I
40	xylose	I
41	and	I
42	arabinose	I
43	permeases	I
44	,	O
45	and	O
46	the	O
47	S	B
48	.	I
49	cerevisiae	I
50	glucose	I
51	,	I
52	maltose	I
53	,	I
54	and	I
55	galactose	I
56	transporters	I
57	.	O
1	Of	O
2	the	O
3	single	O
4	-	O
5	stranded	O
6	DNA	O
7	transformants	O
8	,	O
9	65	O
10	%	O
11	resulted	O
12	from	O
13	replacement	O
14	of	O
15	the	O
16	resident	O
17	met2	B
18	mutation	I
19	by	O
20	the	O
21	exogenous	O
22	wild	O
23	-	O
24	type	O
25	allele	O
26	.	O
1	Survival	O
2	rates	O
3	for	O
4	the	O
5	original	O
6	treatment	O
7	group	O
8	were	O
9	84	O
10	.	O
11	5	O
12	%	O
13	and	O
14	57	O
15	.	O
16	6	O
17	%	O
18	at	O
19	12	O
20	and	O
21	21	O
22	months	O
23	,	O
24	respectively	O
25	;	O
26	for	O
27	the	O
28	delayed	O
29	treatment	O
30	group	O
31	,	O
32	78	O
33	.	O
34	8	O
35	%	O
36	and	O
37	64	O
38	.	O
39	6	O
40	%	O
41	at	O
42	12	O
43	and	O
44	21	O
45	months	O
46	,	O
47	respectively	O
48	,	O
49	and	O
50	78	O
51	.	O
52	8	O
53	%	O
54	and	O
55	47	O
56	.	O
57	5	O
58	%	O
59	at	O
60	12	O
61	and	O
62	21	O
63	months	O
64	,	O
65	respectively	O
66	,	O
67	for	O
68	77	O
69	subjects	O
70	with	O
71	AIDS	O
72	and	O
73	93	O
74	.	O
75	0	O
76	%	O
77	and	O
78	71	O
79	.	O
80	8	O
81	%,	O
82	respectively	O
83	,	O
84	for	O
85	50	O
86	subjects	O
87	with	O
88	AIDS	O
89	-	O
90	related	O
91	complex	O
92	in	O
93	the	O
94	original	O
95	treatment	O
96	group	O
97	.	O
1	Hybridization	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	size	O
7	of	O
8	the	O
9	mRNA	O
10	is	O
11	about	O
12	1	O
13	.	O
14	4	O
15	kilobases	O
16	.	O
1	Recently	O
2	,	O
3	an	O
4	alternatively	O
5	spliced	O
6	form	O
7	of	O
8	c	B
9	-	I
10	myb	I
11	-	I
12	encoded	I
13	mRNA	I
14	has	O
15	been	O
16	identified	O
17	in	O
18	murine	O
19	cells	O
20	containing	O
21	either	O
22	normal	O
23	or	O
24	rearranged	O
25	c	B
26	-	I
27	myb	I
28	genes	I
29	.	O
1	Routine	O
2	clinical	O
3	analysis	O
4	revealed	O
5	lower	O
6	hematocrit	O
7	and	O
8	hemoglobin	B
9	,	O
10	and	O
11	elevated	O
12	BUN	O
13	and	O
14	alkaline	B
15	phosphatase	I
16	in	O
17	the	O
18	treated	O
19	group	O
20	.	O
1	In	O
2	order	O
3	to	O
4	study	O
5	the	O
6	structural	O
7	and	O
8	functional	O
9	organization	O
10	of	O
11	the	O
12	eukaryotic	O
13	nucleolus	O
14	,	O
15	we	O
16	have	O
17	started	O
18	to	O
19	isolate	O
20	and	O
21	characterize	O
22	nucleolar	O
23	components	O
24	of	O
25	the	O
26	yeast	O
27	Saccharomyces	O
28	cerevisiae	O
29	.	O
1	Psychiatry	O
2	and	O
3	the	O
4	skin	O
5	.	O
1	The	O
2	predicted	O
3	molecular	O
4	weight	O
5	of	O
6	the	O
7	polyprotein	O
8	encoded	O
9	by	O
10	ORF1	O
11	is	O
12	33	O
13	kilodaltons	O
14	(	O
15	kDa	O
16	).	O
1	Primer	O
2	extension	O
3	experiments	O
4	indicated	O
5	that	O
6	the	O
7	transcription	O
8	initiation	O
9	site	O
10	mapped	O
11	to	O
12	a	O
13	position	O
14	on	O
15	gene	B
16	IV	I
17	that	O
18	was	O
19	analogous	O
20	to	O
21	that	O
22	reported	O
23	for	O
24	the	O
25	structurally	O
26	similar	O
27	P	B
28	-	I
29	450e	I
30	gene	I
31	.	O
1	HIV	O
2	infectiousness	O
3	and	O
4	the	O
5	AIDS	O
6	epidemic	O
7	.	O
1	The	O
2	titer	O
3	of	O
4	anti	B
5	HSV	I
6	type	I
7	1	I
8	and	O
9	anti	B
10	HSV	I
11	type	I
12	2	I
13	antibodies	I
14	in	O
15	the	O
16	mothers	O
17	'	O
18	and	O
19	cord	O
20	blood	O
21	was	O
22	determined	O
23	and	O
24	compared	O
25	.	O
1	Allelic	O
2	variation	O
3	in	O
4	HLA	B
5	-	I
6	B	I
7	and	O
8	HLA	B
9	-	I
10	C	I
11	sequences	I
12	and	O
13	the	O
14	evolution	O
15	of	O
16	the	O
17	HLA	B
18	-	I
19	B	I
20	alleles	I
21	.	O
1	NERVTRACK	O
2	contains	O
3	4000	O
4	anatomical	O
5	data	O
6	items	O
7	arranged	O
8	in	O
9	a	O
10	tree	O
11	-	O
12	like	O
13	manner	O
14	reflecting	O
15	structural	O
16	and	O
17	functional	O
18	relationships	O
19	.	O
1	It	O
2	is	O
3	striking	O
4	that	O
5	the	O
6	active	O
7	CHO	O
8	spacer	O
9	promoter	O
10	violated	O
11	the	O
12	otherwise	O
13	universal	O
14	rule	O
15	that	O
16	metazoan	B
17	RNA	I
18	polymerase	I
19	I	I
20	promoters	I
21	all	O
22	have	O
23	a	O
24	G	O
25	residue	O
26	at	O
27	position	O
28	-	O
29	16	O
30	.	O
1	From	O
2	the	O
3	National	O
4	Institutes	O
5	of	O
6	Health	O
7	.	O
1	COUP	B
2	transcription	I
3	factor	I
4	is	O
5	a	O
6	member	O
7	of	O
8	the	O
9	steroid	B
10	receptor	I
11	superfamily	I
12	.	O
1	Behaviorally	O
2	,	O
3	a	O
4	pain	O
5	-	O
6	tolerant	O
7	group	O
8	(	O
9	PT	O
10	=	O
11	29	O
12	Ss	O
13	)	O
14	tolerated	O
15	the	O
16	entire	O
17	3	O
18	-	O
19	min	O
20	test	O
21	(	O
22	means	O
23	=	O
24	180	O
25	+/-	O
26	0	O
27	sec	O
28	),	O
29	while	O
30	a	O
31	pain	O
32	-	O
33	sensitive	O
34	group	O
35	(	O
36	PS	O
37	=	O
38	13	O
39	Ss	O
40	)	O
41	averaged	O
42	only	O
43	50	O
44	.	O
45	31	O
46	+/-	O
47	20	O
48	.	O
49	81	O
50	sec	O
51	of	O
52	the	O
53	cold	O
54	-	O
55	pressor	O
56	test	O
57	(	O
58	t	O
59	=	O
60	16	O
61	.	O
62	75	O
63	,	O
64	P	O
65	less	O
66	than	O
67	0	O
68	.	O
69	0001	O
70	),	O
71	replicating	O
72	our	O
73	earlier	O
74	studies	O
75	.	O
1	On	O
2	admission	O
3	to	O
4	our	O
5	department	O
6	in	O
7	September	O
8	,	O
9	1987	O
10	,	O
11	the	O
12	patient	O
13	was	O
14	alert	O
15	and	O
16	had	O
17	spastic	O
18	paraparesis	O
19	,	O
20	the	O
21	impairment	O
22	of	O
23	all	O
24	sensory	O
25	modalities	O
26	below	O
27	the	O
28	level	O
29	of	O
30	Th	O
31	10	O
32	and	O
33	urinary	O
34	disturbance	O
35	.	O
1	Hence	O
2	follows	O
3	Kurti	O
4	'	O
5	s	O
6	demand	O
7	to	O
8	mete	O
9	out	O
10	appropriate	O
11	importance	O
12	to	O
13	the	O
14	arguments	O
15	.	O
1	A	O
2	correlation	O
3	coefficient	O
4	was	O
5	used	O
6	for	O
7	assessing	O
8	the	O
9	similarity	O
10	of	O
11	each	O
12	map	O
13	pattern	O
14	with	O
15	the	O
16	normal	O
17	mean	O
18	IQRST	O
19	map	O
20	.	O
1	Asthma	O
2	was	O
3	significantly	O
4	more	O
5	often	O
6	associated	O
7	with	O
8	ASA	O
9	group	O
10	(	O
11	91	O
12	%)	O
13	vs	O
14	46	O
15	%	O
16	at	O
17	AT	O
18	and	O
19	in	O
20	only	O
21	16	O
22	%	O
23	at	O
24	INTR	O
25	group	O
26	.	O
1	The	O
2	values	O
3	were	O
4	consistently	O
5	lower	O
6	(	O
7	P	O
8	less	O
9	than	O
10	0	O
11	.	O
12	01	O
13	)	O
14	during	O
15	summer	O
16	(	O
17	3	O
18	.	O
19	79	O
20	+/-	O
21	0	O
22	.	O
23	13	O
24	micrograms	O
25	/	O
26	100	O
27	ml	O
28	),	O
29	as	O
30	compared	O
31	to	O
32	winter	O
33	(	O
34	5	O
35	.	O
36	06	O
37	+/-	O
38	0	O
39	.	O
40	27	O
41	).	O
1	It	O
2	was	O
3	possible	O
4	to	O
5	classify	O
6	the	O
7	animals	O
8	into	O
9	high	O
10	and	O
11	low	O
12	responders	O
13	according	O
14	to	O
15	the	O
16	pattern	O
17	of	O
18	humoral	O
19	immune	O
20	response	O
21	.	O
1	The	O
2	clinical	O
3	tolerance	O
4	and	O
5	pharmacokinetics	O
6	of	O
7	FCE	O
8	22101	O
9	(	O
10	sodium	O
11	(	O
12	5R	O
13	,	O
14	6S	O
15	)-	O
16	6	O
17	-[(	O
18	1R	O
19	)-	O
20	hydroxyethyl	O
21	]-	O
22	2	O
23	-	O
24	carbamoyloxymethyl	O
25	-	O
26	2	O
27	-	O
28	penem	O
29	-	O
30	3	O
31	-	O
32	carboxylate	O
33	),	O
34	a	O
35	new	O
36	penem	O
37	antibiotic	O
38	,	O
39	have	O
40	been	O
41	studied	O
42	after	O
43	giving	O
44	a	O
45	single	O
46	i	O
47	.	O
48	v	O
49	.	O
50	dose	O
51	of	O
52	4	O
53	mg	O
54	.	O
55	kg	O
56	-	O
57	1	O
58	to	O
59	ten	O
60	healthy	O
61	male	O
62	volunteers	O
63	.	O
1	We	O
2	use	O
3	the	O
4	term	O
5	corticosteroid	O
6	-	O
7	dependent	O
8	IA	O
9	to	O
10	refer	O
11	to	O
12	the	O
13	serious	O
14	problem	O
15	of	O
16	chronic	O
17	IA	O
18	requiring	O
19	maintenance	O
20	prednisone	O
21	therapy	O
22	.	O
1	The	O
2	cytoprotective	O
3	and	O
4	antiulcer	O
5	activities	O
6	of	O
7	the	O
8	antacid	O
9	magaldrate	O
10	(	O
11	ES	O
12	Riopan	O
13	)	O
14	as	O
15	well	O
16	as	O
17	its	O
18	effects	O
19	on	O
20	gastric	O
21	mucosal	O
22	blood	O
23	flow	O
24	and	O
25	mucus	O
26	secretions	O
27	,	O
28	were	O
29	determined	O
30	in	O
31	the	O
32	rat	O
33	.	O
1	Electrocardiographic	O
2	right	O
3	ventricular	O
4	hypertrophy	O
5	was	O
6	seen	O
7	in	O
8	4	O
9	,	O
10	and	O
11	biventricular	O
12	hypertrophy	O
13	in	O
14	5	O
15	patients	O
16	.	O
1	The	O
2	disease	O
3	ran	O
4	an	O
5	atypical	O
6	course	O
7	;	O
8	with	O
9	early	O
10	jaundice	O
11	syndrome	O
12	,	O
13	severe	O
14	enterorrhagia	O
15	and	O
16	late	O
17	appearance	O
18	of	O
19	roseola	O
20	.	O
1	In	O
2	the	O
3	group	O
4	of	O
5	asthmatics	O
6	statistically	O
7	significant	O
8	correlation	O
9	was	O
10	found	O
11	between	O
12	PC20	O
13	PGF2	O
14	alpha	O
15	and	O
16	histamine	O
17	values	O
18	(	O
19	r	O
20	=	O
21	0	O
22	.	O
23	538	O
24	,	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	05	O
31	).	O
1	This	O
2	in	O
3	turn	O
4	will	O
5	further	O
6	enhance	O
7	the	O
8	role	O
9	of	O
10	meta	O
11	-	O
12	analysis	O
13	in	O
14	helping	O
15	clinicians	O
16	and	O
17	policy	O
18	makers	O
19	answer	O
20	clinical	O
21	questions	O
22	.	O
1	A	O
2	great	O
3	deal	O
4	of	O
5	information	O
6	is	O
7	available	O
8	on	O
9	the	O
10	morphology	O
11	of	O
12	the	O
13	claustrum	O
14	in	O
15	various	O
16	animal	O
17	species	O
18	,	O
19	as	O
20	well	O
21	as	O
22	on	O
23	its	O
24	neuronal	O
25	distribution	O
26	and	O
27	relationships	O
28	with	O
29	the	O
30	cerebral	O
31	cortex	O
32	and	O
33	other	O
34	nuclei	O
35	.	O
1	Low	O
2	-	O
3	grade	O
4	glioma	O
5	.	O
1	The	O
2	effect	O
3	of	O
4	acetazolamide	O
5	(	O
6	ACZ	O
7	)	O
8	on	O
9	HCO3	O
10	-	O
11	and	O
12	Cl	O
13	-	O
14	activities	O
15	in	O
16	inner	O
17	ear	O
18	fluid	O
19	was	O
20	investigated	O
21	by	O
22	ion	O
23	-	O
24	selective	O
25	microelectrode	O
26	methods	O
27	.	O
1	Simian	O
2	immunodeficiency	O
3	virus	O
4	(	O
5	SIV	O
6	)	O
7	is	O
8	a	O
9	lentivirus	O
10	with	O
11	morphological	O
12	and	O
13	antigenic	O
14	similarities	O
15	to	O
16	human	O
17	immunodeficiency	O
18	virus	O
19	,	O
20	the	O
21	causative	O
22	agent	O
23	of	O
24	acquired	O
25	immunodeficiency	O
26	syndrome	O
27	(	O
28	AIDS	O
29	)	O
30	of	O
31	humans	O
32	.	O
1	The	O
2	use	O
3	of	O
4	CRF	B
5	-	I
6	41	I
7	in	O
8	the	O
9	differential	O
10	diagnosis	O
11	of	O
12	Cushing	O
13	'	O
14	s	O
15	syndrome	O
16	and	O
17	obesity	O
18	.	O
1	The	O
2	bactericidal	O
3	activity	O
4	of	O
5	six	O
6	new	O
7	rifamycin	O
8	derivatives	O
9	--	O
10	rifabutin	O
11	(	O
12	RBU	O
13	),	O
14	FCE	O
15	22250	O
16	(	O
17	F22	O
18	),	O
19	rifapentine	O
20	(	O
21	RPE	O
22	),	O
23	CGP	O
24	29861	O
25	(	O
26	C29	O
27	),	O
28	CGP	O
29	7040	O
30	(	O
31	C70	O
32	)	O
33	and	O
34	CGP	O
35	27557	O
36	(	O
37	C27	O
38	)	O
39	and	O
40	rifampicin	O
41	(	O
42	RMP	O
43	)--	O
44	have	O
45	been	O
46	measured	O
47	against	O
48	log	O
49	phase	O
50	and	O
51	,	O
52	as	O
53	a	O
54	better	O
55	test	O
56	of	O
57	sterilising	O
58	activity	O
59	,	O
60	against	O
61	stationary	O
62	phase	O
63	cultures	O
64	of	O
65	Mycobacterium	O
66	tuberculosis	O
67	,	O
68	H37Rv	O
69	.	O
1	Introduction	O
2	of	O
3	v	B
4	-	I
5	fms	I
6	into	O
7	a	O
8	CSF	B
9	-	I
10	1	I
11	dependent	O
12	murine	O
13	macrophage	O
14	cell	O
15	line	O
16	induced	O
17	factor	O
18	independence	O
19	and	O
20	tumorigenicity	O
21	by	O
22	a	O
23	nonautocrine	O
24	mechanism	O
25	.	O
1	Chronic	O
2	E	O
3	-	O
4	B	O
5	virus	O
6	infection	O
7	terminated	O
8	in	O
9	malignant	O
10	lymphoma	O
11	:	O
12	a	O
13	case	O
14	report	O
1	Whereas	O
2	the	O
3	muscle	O
4	isoform	O
5	consists	O
6	of	O
7	997	O
8	amino	O
9	acids	O
10	and	O
11	terminates	O
12	with	O
13	the	O
14	sequence	O
15	Ala	O
16	-	O
17	Ile	O
18	-	O
19	Leu	O
20	-	O
21	Glu	O
22	,	O
23	the	O
24	second	O
25	isoform	O
26	is	O
27	1043	O
28	amino	O
29	acids	O
30	in	O
31	length	O
32	due	O
33	to	O
34	the	O
35	replacement	O
36	of	O
37	these	O
38	last	O
39	4	O
40	amino	O
41	acids	O
42	with	O
43	a	O
44	50	O
45	-	O
46	amino	O
47	acid	O
48	sequence	O
49	that	O
50	contains	O
51	a	O
52	potential	O
53	transmembrane	O
54	domain	O
55	followed	O
56	by	O
57	a	O
58	consensus	O
59	sequence	O
60	for	O
61	an	O
62	N	O
63	-	O
64	linked	O
65	glycosylation	O
66	site	O
67	.	O
1	A	O
2	family	O
3	of	O
4	RNA	O
5	molecules	O
6	in	O
7	the	O
8	2	O
9	.	O
10	0	O
11	-	O
12	2	O
13	.	O
14	2	O
15	-	O
16	kilobase	O
17	range	O
18	identified	O
19	with	O
20	a	O
21	probe	O
22	from	O
23	this	O
24	gene	O
25	was	O
26	overexpressed	O
27	in	O
28	the	O
29	resistant	O
30	cells	O
31	.	O
1	One	O
2	of	O
3	these	O
4	,	O
5	the	O
6	origin	O
7	core	O
8	,	O
9	is	O
10	required	O
11	only	O
12	for	O
13	DNA	O
14	replication	O
15	.	O
1	The	O
2	progression	O
3	of	O
4	non	O
5	-	O
6	A	O
7	,	O
8	non	O
9	-	O
10	B	O
11	hepatitis	O
12	to	O
13	chronic	O
14	diseases	O
15	,	O
16	and	O
17	the	O
18	transformation	O
19	to	O
20	hepatocellular	O
21	carcinoma	O
1	Poor	O
2	response	O
3	when	O
4	laboratory	O
5	recommended	O
6	range	O
7	for	O
8	serum	O
9	lithium	O
10	is	O
11	changed	O
12	.	O
1	Fentanyl	O
2	,	O
3	a	O
4	prototypic	O
5	mu	B
6	-	I
7	opiate	I
8	receptor	I
9	agonist	O
10	,	O
11	has	O
12	been	O
13	previously	O
14	shown	O
15	to	O
16	produce	O
17	a	O
18	syndrome	O
19	characterized	O
20	by	O
21	marked	O
22	analgesia	O
23	and	O
24	locomotor	O
25	stimulation	O
26	as	O
27	well	O
28	as	O
29	tachycardia	O
30	,	O
31	tachypnoea	O
32	and	O
33	behavioural	O
34	arousal	O
35	.	O
1	Reperfusion	O
2	with	O
3	normal	O
4	blood	O
5	in	O
6	the	O
7	beating	O
8	,	O
9	working	O
10	hearts	O
11	caused	O
12	extensive	O
13	structural	O
14	damage	O
15	,	O
16	reduced	O
17	reflow	O
18	,	O
19	and	O
20	failed	O
21	to	O
22	restore	O
23	contractility	O
24	in	O
25	any	O
26	instance	O
27	(-	O
28	27	O
29	%	O
30	systolic	O
31	shortening	O
32	,	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O
1	In	O
2	metabolic	O
3	acidosis	O
4	there	O
5	was	O
6	a	O
7	marked	O
8	stimulation	O
9	when	O
10	clamped	O
11	at	O
12	-	O
13	10	O
14	to	O
15	-	O
16	100	O
17	mV	O
18	.	O
1	Testing	O
2	blood	O
3	donors	O
4	for	O
5	non	O
6	-	O
7	A	O
8	,	O
9	non	O
10	-	O
11	B	O
12	hepatitis	O
13	:	O
14	irrational	O
15	,	O
16	perhaps	O
17	,	O
18	but	O
19	inescapable	O
20	.	O
1	We	O
2	have	O
3	been	O
4	able	O
5	to	O
6	map	O
7	specific	O
8	DNA	O
9	fragments	O
10	at	O
11	the	O
12	bases	O
13	of	O
14	chromatin	O
15	loops	O
16	with	O
17	the	O
18	help	O
19	of	O
20	a	O
21	novel	O
22	extraction	O
23	procedure	O
24	by	O
25	using	O
26	lithium	O
27	-	O
28	3	O
29	',	O
30	5	O
31	'-	O
32	diiodosalicylate	O
33	.	O
1	Seventy	O
2	-	O
3	one	O
4	supplementary	O
5	doses	O
6	of	O
7	vecuronium	O
8	were	O
9	used	O
10	for	O
11	muscle	O
12	relaxation	O
13	during	O
14	a	O
15	22	O
16	-	O
17	h	O
18	-	O
19	long	O
20	NLA	O
21	II	O
22	anaesthesia	O
23	.	O
1	Finally	O
2	,	O
3	the	O
4	recovery	O
5	indexes	O
6	represented	O
7	by	O
8	the	O
9	times	O
10	required	O
11	for	O
12	T1	O
13	/	O
14	T0	O
15	and	O
16	T4	O
17	/	O
18	T1	O
19	to	O
20	rise	O
21	from	O
22	25	O
23	%	O
24	to	O
25	75	O
26	%	O
27	respectively	O
28	were	O
29	studied	O
30	.	O
1	DPA	O
2	attenuated	O
3	the	O
4	increase	O
5	of	O
6	the	O
7	intensity	O
8	of	O
9	the	O
10	ischemic	O
11	and	O
12	pressure	O
13	pain	O
14	components	O
15	with	O
16	increasing	O
17	ischemia	O
18	duration	O
19	,	O
20	but	O
21	only	O
22	the	O
23	effect	O
24	on	O
25	the	O
26	pressure	O
27	pain	O
28	component	O
29	was	O
30	significant	O
31	.	O
1	Topical	O
2	1	O
3	percent	O
4	isoproterenol	O
5	in	O
6	the	O
7	presence	O
8	of	O
9	the	O
10	phosphodiesterase	O
11	inhibitor	O
12	theophylline	O
13	was	O
14	tested	O
15	for	O
16	its	O
17	ability	O
18	to	O
19	stimulate	O
20	the	O
21	rate	O
22	of	O
23	aqueous	O
24	humor	O
25	flow	O
26	through	O
27	the	O
28	anterior	O
29	chamber	O
30	of	O
31	the	O
32	normal	O
33	and	O
34	the	O
35	partially	O
36	adrenergically	O
37	denervated	O
38	human	O
39	eye	O
40	(	O
41	Horner	O
42	'	O
43	s	O
44	syndrome	O
45	).	O
1	Hyperthyroidism	O
2	is	O
3	one	O
4	of	O
5	the	O
6	numerous	O
7	causes	O
8	of	O
9	infertility	O
10	and	O
11	recurrent	O
12	abortion	O
13	.	O
1	We	O
2	propose	O
3	that	O
4	the	O
5	technique	O
6	of	O
7	low	O
8	-	O
9	frequency	O
10	kindling	O
11	is	O
12	a	O
13	useful	O
14	experimental	O
15	model	O
16	in	O
17	assessing	O
18	the	O
19	effects	O
20	of	O
21	antipsychotic	O
22	or	O
23	antiepileptic	O
24	drugs	O
25	on	O
26	the	O
27	excitability	O
28	of	O
29	the	O
30	limbic	O
31	regions	O
32	.	O
1	The	O
2	biosynthesis	O
3	and	O
4	stability	O
5	of	O
6	the	O
7	three	O
8	mutant	O
9	proteins	O
10	were	O
11	similar	O
12	to	O
13	those	O
14	of	O
15	the	O
16	wild	B
17	-	I
18	type	I
19	erbB	I
20	protein	I
21	,	O
22	and	O
23	all	O
24	three	O
25	retained	O
26	the	O
27	ability	O
28	to	O
29	transform	O
30	chicken	O
31	embryo	O
32	fibroblasts	O
33	.	O
1	In	O
2	the	O
3	first	O
4	group	O
5	,	O
6	0	O
7	.	O
8	02	O
9	%	O
10	Prazosin	O
11	(	O
12	0	O
13	.	O
14	5	O
15	mg	O
16	/	O
17	kg	O
18	)	O
19	was	O
20	administered	O
21	intravenously	O
22	for	O
23	1	O
24	.	O
25	5	O
26	hours	O
27	before	O
28	the	O
29	application	O
30	of	O
31	Oxy	O
32	-	O
33	Hb	O
34	or	O
35	PGF2	O
36	alpha	O
37	.	O
1	A	O
2	decamer	O
3	sequence	O
4	,	O
5	5	O
6	'-	O
7	CGA	O
8	-	O
9	CCCCUCC	O
10	-	O
11	3	O
12	',	O
13	complementary	O
14	to	O
15	a	O
16	conserved	O
17	sequence	O
18	adjacent	O
19	to	O
20	the	O
21	enzymatic	O
22	cleavage	O
23	site	O
24	on	O
25	the	O
26	mitochondrial	O
27	RNA	O
28	substrate	O
29	,	O
30	is	O
31	present	O
32	in	O
33	the	O
34	RNAase	B
35	MRP	I
36	RNA	I
37	.	O
1	Neither	O
2	verapamil	O
3	nor	O
4	nifedipine	O
5	changed	O
6	collateral	O
7	myocardial	O
8	blood	O
9	flow	O
10	from	O
11	0	O
12	.	O
13	10	O
14	+/-	O
15	0	O
16	.	O
17	02	O
18	in	O
19	the	O
20	subendocardium	O
21	and	O
22	0	O
23	.	O
24	17	O
25	+/-	O
26	0	O
27	.	O
28	03	O
29	ml	O
30	/	O
31	min	O
32	/	O
33	g	O
34	in	O
35	the	O
36	subepicardium	O
37	.	O
1	Hemodynamic	O
2	assessment	O
3	was	O
4	obtained	O
5	before	O
6	and	O
7	following	O
8	administration	O
9	of	O
10	digoxin	O
11	10	O
12	micrograms	O
13	/	O
14	kg	O
15	IV	O
16	or	O
17	dopamine	O
18	,	O
19	5	O
20	to	O
21	12	O
22	micrograms	O
23	/	O
24	kg	O
25	/	O
26	min	O
27	IV	O
28	.	O
1	All	O
2	of	O
3	the	O
4	newly	O
5	acquired	O
6	proviruses	O
7	identified	O
8	in	O
9	mosaic	O
10	founder	O
11	SWR	O
12	/	O
13	J	O
14	-	O
15	RF	O
16	/	O
17	J	O
18	mice	O
19	that	O
20	could	O
21	be	O
22	transmitted	O
23	through	O
24	the	O
25	germ	O
26	line	O
27	were	O
28	also	O
29	present	O
30	in	O
31	somatic	O
32	tissues	O
33	,	O
34	demonstrating	O
35	that	O
36	viral	O
37	integration	O
38	occurred	O
39	before	O
40	the	O
41	germ	O
42	line	O
43	was	O
44	set	O
45	aside	O
46	from	O
47	the	O
48	somatic	O
49	lineages	O
50	.	O
1	Platelet	O
2	function	O
3	and	O
4	platelet	O
5	-	O
6	polymorphonuclear	O
7	-	O
8	neutrophil	O
9	interaction	O
10	in	O
11	patients	O
12	with	O
13	deficient	O
14	platelet	B
15	lipoxygenase	I
16	activity	O
17	.	O
1	Transformed	O
2	cell	O
3	lines	O
4	expressing	O
5	solely	O
6	E1a	B
7	or	O
8	E1a	B
9	and	O
10	E1b	B
11	gene	I
12	products	I
13	derived	O
14	from	O
15	these	O
16	viruses	O
17	display	O
18	enhanced	O
19	anchorage	O
20	-	O
21	independent	O
22	growth	O
23	at	O
24	37	O
25	degrees	O
26	C	O
27	versus	O
28	32	O
29	degrees	O
30	C	O
31	and	O
32	display	O
33	a	O
34	cytoskeletal	O
35	architecture	O
36	resembling	O
37	untransformed	O
38	fibroblastic	O
39	CREF	O
40	cells	O
41	.	O
1	This	O
2	study	O
3	reports	O
4	the	O
5	effects	O
6	of	O
7	a	O
8	preparation	O
9	with	O
10	50	O
11	micrograms	O
12	ethinyl	O
13	estradiol	O
14	and	O
15	2	O
16	mg	O
17	cyproterone	O
18	acetate	O
19	on	O
20	gonadotropins	B
21	,	O
22	prolactin	B
23	,	O
24	testosterone	O
25	,	O
26	sex	B
27	hormone	I
28	binding	I
29	globulin	I
30	(	O
31	SHBG	B
32	),	O
33	androstenedione	O
34	,	O
35	and	O
36	calculated	O
37	free	O
38	testosterone	O
39	index	O
40	before	O
41	and	O
42	after	O
43	six	O
44	months	O
45	of	O
46	treatment	O
47	.	O
1	In	O
2	nine	O
3	patients	O
4	with	O
5	renal	O
6	failure	O
7	routine	O
8	haemodialysis	O
9	was	O
10	accompanied	O
11	by	O
12	a	O
13	30	O
14	per	O
15	cent	O
16	reduction	O
17	in	O
18	plasma	O
19	ANP	B
20	concentration	O
21	.	O
1	Our	O
2	data	O
3	,	O
4	however	O
5	,	O
6	did	O
7	not	O
8	suggest	O
9	the	O
10	existence	O
11	of	O
12	a	O
13	conversion	O
14	factor	O
15	for	O
16	LDF	O
17	signal	O
18	to	O
19	absolute	O
20	flow	O
21	values	O
22	from	O
23	experiment	O
24	to	O
25	experiment	O
26	.	O
1	Schedule	O
2	2	O
3	,	O
4	in	O
5	which	O
6	2	O
7	.	O
8	4	O
9	mg	O
10	/	O
11	kg	O
12	c	O
13	-	O
14	DDP	O
15	was	O
16	administered	O
17	immediately	O
18	before	O
19	X	O
20	-	O
21	ray	O
22	on	O
23	5	O
24	consecutive	O
25	days	O
26	produced	O
27	the	O
28	highest	O
29	degree	O
30	of	O
31	enhancement	O
32	of	O
33	radiation	O
34	effect	O
35	(	O
36	expressed	O
37	as	O
38	dose	O
39	-	O
40	effect	O
41	factor	O
42	);	O
43	and	O
44	the	O
45	next	O
46	greatest	O
47	enhancement	O
48	was	O
49	produced	O
50	by	O
51	12	O
52	mg	O
53	/	O
54	kg	O
55	c	O
56	-	O
57	DDP	O
58	administered	O
59	24	O
60	h	O
61	before	O
62	the	O
63	start	O
64	of	O
65	fractionated	O
66	daily	O
67	radiotherapy	O
68	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	calbindin	B
6	-	I
7	D28K	I
8	promoter	I
9	is	O
10	composed	O
11	of	O
12	a	O
13	variety	O
14	of	O
15	simple	O
16	repeated	O
17	sequences	O
18	,	O
19	some	O
20	of	O
21	which	O
22	are	O
23	components	O
24	of	O
25	putative	O
26	regulatory	O
27	signals	O
28	.	O
1	A	O
2	rare	O
3	chronic	O
4	course	O
5	of	O
6	Budd	O
7	-	O
8	Chiari	O
9	syndrome	O
10	associated	O
11	with	O
12	thrombosis	O
13	of	O
14	the	O
15	portal	O
16	vein	O
17	was	O
18	observed	O
19	in	O
20	a	O
21	30	O
22	-	O
23	year	O
24	-	O
25	old	O
26	male	O
27	patient	O
28	suffering	O
29	from	O
30	postmyocarditic	O
31	cardiosclerosis	O
32	.	O
1	Effects	O
2	of	O
3	single	O
4	and	O
5	combined	O
6	maltose	O
7	tetrapalmitate	O
8	immunotherapy	O
9	,	O
10	cyclophosphamide	O
11	chemotherapy	O
12	and	O
13	radiotherapy	O
14	on	O
15	ethyl	O
16	carbamate	O
17	accelerated	O
18	primary	O
19	lung	O
20	cancer	O
21	in	O
22	A	O
23	/	O
24	J	O
25	mice	O
26	.	O
1	An	O
2	unusual	O
3	feature	O
4	of	O
5	these	O
6	replicative	O
7	genes	O
8	is	O
9	that	O
10	the	O
11	smaller	O
12	mRNA	O
13	begins	O
14	within	O
15	a	O
16	long	O
17	open	O
18	reading	O
19	frame	O
20	of	O
21	the	O
22	larger	O
23	mRNA	O
24	.	O
1	These	O
2	IgG	B
3	antibodies	I
4	in	O
5	the	O
6	babies	O
7	diminished	O
8	rapidly	O
9	after	O
10	delivery	O
11	,	O
12	and	O
13	were	O
14	detectable	O
15	only	O
16	in	O
17	3	O
18	cases	O
19	at	O
20	2	O
21	,	O
22	3	O
23	,	O
24	and	O
25	5	O
26	months	O
27	of	O
28	ages	O
29	out	O
30	of	O
31	38	O
32	babies	O
33	up	O
34	to	O
35	21	O
36	months	O
37	.	O
1	Fine	O
2	analysis	O
3	at	O
4	the	O
5	nucleotide	O
6	level	O
7	of	O
8	the	O
9	early	O
10	events	O
11	in	O
12	the	O
13	digestion	O
14	with	O
15	nuclease	B
16	S1	I
17	shows	O
18	that	O
19	the	O
20	enzyme	O
21	attacks	O
22	preferentially	O
23	the	O
24	sequence	O
25	(	O
26	G	O
27	-	O
28	A	O
29	)	O
30	12	O
31	on	O
32	the	O
33	message	O
34	complementary	O
35	strand	O
36	.	O
1	The	O
2	sequence	O
3	analysis	O
4	of	O
5	both	O
6	products	O
7	of	O
8	individual	O
9	phi	O
10	80	O
11	site	O
12	-	O
13	specific	O
14	recombination	O
15	events	O
16	in	O
17	vivo	O
18	shows	O
19	that	O
20	recombination	O
21	with	O
22	a	O
23	secondary	O
24	attachment	O
25	(	O
26	att	O
27	)	O
28	site	O
29	generates	O
30	several	O
31	different	O
32	novel	O
33	joints	O
34	at	O
35	the	O
36	mismatched	O
37	position	O
38	:	O
39	one	O
40	recombination	O
41	event	O
42	resulted	O
43	in	O
44	a	O
45	single	O
46	base	O
47	-	O
48	pair	O
49	deletion	O
50	and	O
51	two	O
52	other	O
53	recombination	O
54	events	O
55	resulted	O
56	in	O
57	two	O
58	different	O
59	single	O
60	base	O
61	-	O
62	pair	O
63	substitutions	O
64	.	O
1	This	O
2	L	B
3	-	I
4	myc	I
5	sequence	I
6	is	O
7	amplified	O
8	10	O
9	-	O
10	20	O
11	-	O
12	fold	O
13	in	O
14	four	O
15	SCLC	O
16	cell	O
17	line	O
18	DNAs	O
19	and	O
20	in	O
21	one	O
22	SCLC	O
23	tumour	O
24	specimen	O
25	taken	O
26	directly	O
27	from	O
28	a	O
29	patient	O
30	.	O
1	Temperature	O
2	-	O
3	shift	O
4	experiments	O
5	using	O
6	synchronously	O
7	grown	O
8	cells	O
9	of	O
10	a	O
11	delta	B
12	top1	I
13	top2	I
14	temperature	I
15	-	I
16	sensitive	I
17	(	I
18	ts	I
19	)	I
20	double	I
21	mutant	I
22	and	O
23	its	O
24	isogenic	O
25	top2	B
26	ts	O
27	strain	O
28	show	O
29	that	O
30	,	O
31	whereas	O
32	mitotic	O
33	blocks	O
34	can	O
35	prevent	O
36	killing	O
37	of	O
38	the	O
39	top2	B
40	ts	I
41	mutant	I
42	at	O
43	a	O
44	nonpermissive	O
45	temperature	O
46	,	O
47	the	O
48	same	O
49	treatments	O
50	are	O
51	ineffective	O
52	in	O
53	preventing	O
54	cell	O
55	death	O
56	of	O
57	the	O
58	delta	B
59	top1	I
60	top2	I
61	ts	I
62	double	I
63	mutant	I
64	.	O
1	The	O
2	sequence	O
3	was	O
4	determined	O
5	for	O
6	a	O
7	4024	O
8	-	O
9	base	O
10	pair	O
11	(	O
12	bp	O
13	)	O
14	segment	O
15	that	O
16	extends	O
17	from	O
18	149	O
19	bp	O
20	5	O
21	'	O
22	to	O
23	the	O
24	cap	O
25	site	O
26	of	O
27	alpha	B
28	1	I
29	to	O
30	207	O
31	bp	O
32	3	O
33	'	O
34	to	O
35	psi	B
36	alpha	I
37	.	O
1	The	O
2	pet56	B
3	and	O
4	his3	B
5	genes	I
6	are	O
7	transcribed	O
8	divergently	O
9	from	O
10	initiation	O
11	sites	O
12	that	O
13	are	O
14	separated	O
15	by	O
16	only	O
17	192	O
18	bp	O
19	.	O
1	Analysis	O
2	of	O
3	glucocorticoid	O
4	unresponsive	O
5	cell	O
6	variants	O
7	using	O
8	a	O
9	mouse	B
10	glucocorticoid	I
11	receptor	I
12	complementary	O
13	DNA	O
14	clone	O
15	.	O
1	13	O
2	men	O
3	with	O
4	a	O
5	history	O
6	of	O
7	recurrent	O
8	genital	O
9	herpes	O
10	simplex	O
11	virus	O
12	type	O
13	2	O
14	(	O
15	HSV	O
16	-	O
17	2	O
18	)	O
19	infection	O
20	were	O
21	followed	O
22	daily	O
23	for	O
24	4	O
25	weeks	O
26	with	O
27	samples	O
28	taken	O
29	from	O
30	the	O
31	urethra	O
32	for	O
33	virus	O
34	isolation	O
35	.	O
1	A	O
2	single	O
3	exon	O
4	encodes	O
5	the	O
6	carboxyl	O
7	-	O
8	terminal	O
9	26	O
10	amino	O
11	acids	O
12	of	O
13	the	O
14	ssd	B
15	chain	I
16	and	O
17	the	O
18	3	O
19	'	O
20	untranslated	O
21	region	O
22	of	O
23	its	O
24	mRNA	O
25	,	O
26	ending	O
27	with	O
28	a	O
29	poly	O
30	(	O
31	A	O
32	)-	O
33	addition	O
34	site	O
35	.	O
1	SPECT	O
2	examination	O
3	of	O
4	the	O
5	TMJ	O
6	using	O
7	99m	O
8	Tc	O
9	-	O
10	MDP	O
11	was	O
12	performed	O
13	in	O
14	43	O
15	patients	O
16	with	O
17	arthrographically	O
18	proven	O
19	anterior	O
20	dislocation	O
21	of	O
22	the	O
23	disc	O
24	and	O
25	in	O
26	30	O
27	normals	O
28	.	O
1	Two	O
2	mutants	O
3	,	O
4	each	O
5	representative	O
6	of	O
7	a	O
8	separate	O
9	pet	B
10	complementation	O
11	group	O
12	,	O
13	have	O
14	been	O
15	analyzed	O
16	.	O
1	We	O
2	inserted	O
3	genes	O
4	or	O
5	gene	O
6	segments	O
7	,	O
8	that	O
9	code	O
10	for	O
11	the	O
12	bacterial	B
13	chloramphenicol	I
14	acetyltransferase	I
15	,	O
16	the	O
17	bacterial	O
18	gene	O
19	conferring	O
20	resistance	O
21	against	O
22	hygromycin	O
23	,	O
24	and	O
25	the	O
26	ORF	O
27	E7	B
28	of	O
29	the	O
30	human	O
31	papillomavirus	O
32	type	O
33	18	O
34	into	O
35	these	O
36	vectors	O
37	.	O
1	Combined	O
2	immunochemotherapy	O
3	with	O
4	cyclophosphamide	O
5	plus	O
6	BCG	O
7	gave	O
8	a	O
9	better	O
10	enhancement	O
11	of	O
12	the	O
13	antitumor	O
14	effect	O
15	of	O
16	the	O
17	cytostatic	O
18	than	O
19	that	O
20	of	O
21	the	O
22	combination	O
23	of	O
24	methotrexate	O
25	plus	O
26	BCG	O
27	and	O
28	cyclophosphamide	O
29	plus	O
30	levamisole	O
31	.	O
1	The	O
2	PSS	B
3	gene	I
4	was	O
5	subcloned	O
6	into	O
7	a	O
8	1	O
9	.	O
10	1	O
11	-	O
12	kb	O
13	fragment	O
14	of	O
15	the	O
16	yeast	O
17	DNA	O
18	on	O
19	the	O
20	YEp13	O
21	vector	O
22	.	O
1	4	O
2	.	O
1	It	O
2	is	O
3	concluded	O
4	that	O
5	suppression	O
6	of	O
7	elevated	O
8	prolactin	B
9	levels	O
10	in	O
11	progressive	O
12	metastatic	O
13	breast	O
14	cancer	O
15	patients	O
16	is	O
17	not	O
18	effective	O
19	in	O
20	restoring	O
21	tumor	O
22	sensitivity	O
23	to	O
24	chemotherapy	O
25	.	O
1	After	O
2	infection	O
3	of	O
4	293	O
5	cells	O
6	(	O
7	which	O
8	provide	O
9	complementary	O
10	E1a	B
11	-	O
12	E1b	B
13	functions	O
14	),	O
15	both	O
16	viruses	O
17	directed	O
18	equal	O
19	amounts	O
20	of	O
21	P	B
22	/	I
23	C	I
24	-	I
25	specific	I
26	mRNA	I
27	transcription	O
28	.	O
1	This	O
2	observation	O
3	cannot	O
4	be	O
5	explained	O
6	by	O
7	the	O
8	scanning	O
9	model	O
10	for	O
11	ribosomal	O
12	initiation	O
13	and	O
14	suggests	O
15	that	O
16	ribosomes	O
17	may	O
18	be	O
19	binding	O
20	directly	O
21	at	O
22	an	O
23	internal	O
24	mRNA	O
25	site	O
26	at	O
27	or	O
28	near	O
29	the	O
30	initiator	O
31	AUG	O
32	codon	O
33	for	O
34	the	O
35	C	B
36	protein	I
37	.	O
1	This	O
2	makes	O
3	these	O
4	compounds	O
5	attractive	O
6	as	O
7	vehicles	O
8	for	O
9	these	O
10	and	O
11	other	O
12	gases	O
13	in	O
14	-	O
15	vivo	O
16	and	O
17	in	O
18	-	O
19	vitro	O
20	.	O
1	The	O
2	relationship	O
3	between	O
4	primary	O
5	malignant	O
6	lymphoma	O
7	of	O
8	the	O
9	thyroid	O
10	and	O
11	chronic	O
12	thyroiditis	O
13	is	O
14	discussed	O
15	.	O
1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	L1	B
6	binding	I
7	site	I
8	of	O
9	23S	B
10	rRNA	I
11	in	I
12	Escherichia	I
13	coli	I
14	.	O
1	These	O
2	results	O
3	imply	O
4	that	O
5	the	O
6	GCN3	B
7	product	I
8	can	O
9	promote	O
10	either	O
11	repression	O
12	or	O
13	activation	O
14	of	O
15	GCN4	B
16	expression	O
17	depending	O
18	on	O
19	amino	O
20	acid	O
21	availability	O
22	.	O
1	Thus	O
2	,	O
3	prostacyclin	O
4	enhanced	O
5	the	O
6	autoregulative	O
7	property	O
8	of	O
9	the	O
10	inner	O
11	ear	O
12	vessels	O
13	.	O
1	Amounts	O
2	of	O
3	glucose	O
4	infused	O
5	during	O
6	the	O
7	last	O
8	20	O
9	min	O
10	of	O
11	each	O
12	2	O
13	hour	O
14	insulin	B
15	infusion	O
16	were	O
17	(	O
18	at	O
19	1	O
20	and	O
21	10	O
22	m	O
23	/	O
24	kg	O
25	/	O
26	min	O
27	respectively	O
28	):	O
29	before	O
30	treatment	O
31	(	O
32	K	O
33	+	O
34	=	O
35	2	O
36	.	O
37	7	O
38	mmol	O
39	/	O
40	l	O
41	):	O
42	2	O
43	.	O
44	4	O
45	and	O
46	8	O
47	.	O
48	4	O
49	mg	O
50	/	O
51	kg	O
52	/	O
53	min	O
54	;	O
55	after	O
56	spironolactone	O
57	(	O
58	K	O
59	+	O
60	=	O
61	3	O
62	.	O
63	9	O
64	mmol	O
65	/	O
66	l	O
67	):	O
68	3	O
69	.	O
70	3	O
71	and	O
72	15	O
73	.	O
74	4	O
75	mg	O
76	/	O
77	kg	O
78	/	O
79	min	O
80	;	O
81	after	O
82	indomethacine	O
83	(	O
84	K	O
85	+	O
86	=	O
87	3	O
88	.	O
89	7	O
90	mmol	O
91	/	O
92	l	O
93	):	O
94	5	O
95	and	O
96	19	O
97	mg	O
98	/	O
99	kg	O
100	/	O
101	min	O
102	after	O
103	stopping	O
104	drugs	O
105	(	O
106	K	O
107	+	O
108	=	O
109	2	O
110	.	O
111	9	O
112	mmol	O
113	/	O
114	l	O
115	):	O
116	2	O
117	.	O
118	5	O
119	and	O
120	5	O
121	.	O
122	3	O
123	mg	O
124	/	O
125	kg	O
126	/	O
127	min	O
128	.	O
1	Intravenous	O
2	glucose	O
3	tolerance	O
4	tests	O
5	were	O
6	performed	O
7	before	O
8	operation	O
9	,	O
10	before	O
11	starting	O
12	CyA	O
13	and	O
14	after	O
15	3	O
16	weeks	O
17	.	O
1	This	O
2	gave	O
3	rise	O
4	to	O
5	RNA	O
6	molecules	O
7	with	O
8	3	O
9	'-	O
10	untranslated	O
11	regions	O
12	of	O
13	roughly	O
14	375	O
15	,	O
16	655	O
17	,	O
18	and	O
19	945	O
20	base	O
21	pairs	O
22	.	O
1	The	O
2	8	O
3	patients	O
4	receiving	O
5	Ir192	O
6	implant	O
7	in	O
8	addition	O
9	to	O
10	external	O
11	radiation	O
12	showed	O
13	improved	O
14	(	O
15	p	O
16	=	O
17	0	O
18	.	O
19	06	O
20	)	O
21	survival	O
22	compared	O
23	to	O
24	the	O
25	9	O
26	receiving	O
27	external	O
28	only	O
29	:	O
30	median	O
31	15	O
32	months	O
33	(	O
34	range	O
35	1	O
36	.	O
37	5	O
38	-	O
39	34	O
40	+	O
41	months	O
42	)	O
43	versus	O
44	7	O
45	months	O
46	(	O
47	range	O
48	2	O
49	.	O
50	5	O
51	-	O
52	21	O
53	months	O
54	).	O
1	Ethylene	O
2	glycol	O
3	and	O
4	diethylene	O
5	glycol	O
6	were	O
7	each	O
8	administered	O
9	once	O
10	weekly	O
11	subcutaneously	O
12	to	O
13	groups	O
14	of	O
15	100	O
16	female	O
17	NMRI	O
18	mice	O
19	at	O
20	3	O
21	dosages	O
22	(	O
23	30	O
24	;	O
25	10	O
26	und	O
27	3	O
28	mg	O
29	single	O
30	dose	O
31	per	O
32	mouse	O
33	).	O
1	The	O
2	remaining	O
3	six	O
4	patients	O
5	had	O
6	slightly	O
7	decreased	O
8	(	O
9	n	O
10	=	O
11	3	O
12	)	O
13	or	O
14	normal	O
15	(	O
16	n	O
17	=	O
18	3	O
19	)	O
20	seminal	O
21	parameters	O
22	.	O
1	Significant	O
2	treatment	O
3	-	O
4	related	O
5	problems	O
6	appeared	O
7	during	O
8	the	O
9	second	O
10	decade	O
11	in	O
12	5	O
13	patients	O
14	,	O
15	including	O
16	one	O
17	chest	O
18	wall	O
19	sarcoma	O
20	;	O
21	all	O
22	of	O
23	these	O
24	patients	O
25	had	O
26	received	O
27	at	O
28	least	O
29	60	O
30	Gy	O
31	to	O
32	breast	O
33	and	O
34	regional	O
35	nodal	O
36	areas	O
37	.	O
1	The	O
2	role	O
3	of	O
4	neuroplasticity	O
5	in	O
6	the	O
7	response	O
8	to	O
9	drugs	O
10	.	O
1	In	O
2	14	O
3	patients	O
4	whose	O
5	PaCO2	O
6	was	O
7	greater	O
8	than	O
9	or	O
10	equal	O
11	to	O
12	39	O
13	torr	O
14	(	O
15	range	O
16	39	O
17	to	O
18	58	O
19	torr	O
20	)	O
21	and	O
22	clinical	O
23	asthma	O
24	score	O
25	was	O
26	6	O
27	or	O
28	greater	O
29	,	O
30	PaCO2	O
31	decreased	O
32	a	O
33	mean	O
34	of	O
35	11	O
36	.	O
37	7	O
38	torr	O
39	during	O
40	a	O
41	mean	O
42	of	O
43	8	O
44	.	O
45	1	O
46	hours	O
47	.	O
1	A	O
2	randomized	O
3	,	O
4	prospective	O
5	study	O
6	was	O
7	conducted	O
8	to	O
9	compare	O
10	ovarian	O
11	stimulation	O
12	with	O
13	human	B
14	menopausal	I
15	gonadotropin	I
16	(	O
17	hMG	B
18	)	O
19	and	O
20	human	B
21	follicle	I
22	-	I
23	stimulating	I
24	hormone	I
25	(	O
26	hFSH	B
27	)	O
28	in	O
29	an	O
30	in	O
31	vitro	O
32	fertilization	O
33	and	O
34	embryo	O
35	transfer	O
36	(	O
37	IVF	O
38	-	O
39	ET	O
40	)	O
41	program	O
42	.	O
1	Here	O
2	we	O
3	report	O
4	the	O
5	complete	O
6	6	O
7	-	O
8	kilobase	O
9	cDNA	O
10	sequence	O
11	coding	O
12	for	O
13	a	O
14	chain	O
15	of	O
16	1775	O
17	amino	O
18	acids	O
19	,	O
20	as	O
21	well	O
22	as	O
23	the	O
24	genomic	O
25	structure	O
26	.	O
1	This	O
2	effect	O
3	and	O
4	the	O
5	fact	O
6	that	O
7	all	O
8	three	O
9	doses	O
10	were	O
11	toxic	O
12	to	O
13	the	O
14	dams	O
15	dictated	O
16	that	O
17	a	O
18	second	O
19	experiment	O
20	be	O
21	carried	O
22	out	O
23	at	O
24	lower	O
25	doses	O
26	.	O
1	The	O
2	CHARGE	O
3	association	O
4	is	O
5	a	O
6	collection	O
7	of	O
8	multisystem	O
9	congenital	O
10	anomalies	O
11	including	O
12	choanal	O
13	atresia	O
14	.	O
1	Aviators	O
2	from	O
3	the	O
4	Light	O
5	Attack	O
6	Wing	O
7	,	O
8	Pacific	O
9	were	O
10	surveyed	O
11	and	O
12	the	O
13	results	O
14	were	O
15	categorized	O
16	by	O
17	aircraft	O
18	type	O
19	.	O
1	Evaluation	O
2	of	O
3	human	O
4	and	O
5	bovine	O
6	modified	O
7	-	O
8	hemoglobin	B
9	solution	O
10	as	O
11	oxygen	O
12	-	O
13	carrying	O
14	fluid	O
15	for	O
16	blood	O
17	volume	O
18	replacement	O
19	.	O
1	Chem	O
2	.	O
1	The	O
2	test	O
3	for	O
4	alpha	B
5	-	I
6	naphthyl	I
7	esterase	I
8	and	O
9	quantitation	O
10	of	O
11	macrophages	O
12	(	O
13	absolute	O
14	number	O
15	)	O
16	per	O
17	infiltration	O
18	area	O
19	unit	O
20	adjacent	O
21	to	O
22	the	O
23	abscess	O
24	suggest	O
25	a	O
26	direct	O
27	correlation	O
28	between	O
29	the	O
30	absolute	O
31	number	O
32	of	O
33	macrophages	O
34	and	O
35	the	O
36	width	O
37	of	O
38	the	O
39	capsule	O
40	.	O
1	No	O
2	UOxase	B
3	mRNA	I
4	was	O
5	detected	O
6	in	O
7	11	O
8	nonhepatic	O
9	tissues	O
10	of	O
11	rat	O
12	,	O
13	suggesting	O
14	tissue	O
15	specificity	O
16	of	O
17	expression	O
18	of	O
19	this	O
20	UOxase	B
21	gene	I
22	.	O
1	The	O
2	platelet	O
3	adhesion	O
4	rate	O
5	on	O
6	these	O
7	layers	O
8	were	O
9	tested	O
10	concerning	O
11	the	O
12	valuation	O
13	of	O
14	the	O
15	haemocompatibility	O
16	of	O
17	the	O
18	basic	O
19	-	O
20	polymers	O
21	polyurethane	O
22	(	O
23	PUR	O
24	),	O
25	polyvinylchloride	O
26	(	O
27	PVC	O
28	),	O
29	and	O
30	polystyrene	O
31	(	O
32	PS	O
33	)	O
34	in	O
35	two	O
36	different	O
37	worked	O
38	test	O
39	chambers	O
40	.	O
1	Existence	O
2	and	O
3	uniqueness	O
4	of	O
5	solutions	O
6	of	O
7	the	O
8	appropriate	O
9	boundary	O
10	value	O
11	problems	O
12	are	O
13	established	O
14	,	O
15	in	O
16	the	O
17	case	O
18	of	O
19	small	O
20	permeability	O
21	coefficients	O
22	and	O
23	transport	O
24	rates	O
25	,	O
26	or	O
27	large	O
28	diffusion	O
29	coefficients	O
30	and	O
31	small	O
32	resistance	O
33	to	O
34	flow	O
35	constants	O
36	.	O
1	An	O
2	ELISA	O
3	procedure	O
4	was	O
5	developed	O
6	for	O
7	monitoring	O
8	the	O
9	specific	O
10	IgE	B
11	response	O
12	in	O
13	dogs	O
14	to	O
15	Dirofilaria	O
16	immitis	O
17	infection	O
18	.	O
1	An	O
2	11	O
3	-	O
4	month	O
5	-	O
6	old	O
7	girl	O
8	suffering	O
9	from	O
10	Dandy	O
11	-	O
12	Walker	O
13	malformation	O
14	(	O
15	DWM	O
16	)	O
17	associated	O
18	with	O
19	tetralogy	O
20	of	O
21	Fallot	O
22	(	O
23	TOF	O
24	)	O
25	is	O
26	presented	O
27	.	O
1	Variety	O
2	of	O
3	cows	O
4	and	O
5	sires	O
6	according	O
7	to	O
8	types	O
9	of	O
10	dermatoglyphics	O
11	(	O
12	patterns	O
13	)	O
14	of	O
15	the	O
16	nose	O
17	-	O
18	labial	O
19	mirror	O
20	of	O
21	cattle	O
1	Incorporation	O
2	of	O
3	0	O
4	.	O
5	1	O
6	or	O
7	0	O
8	.	O
9	2	O
10	M	O
11	sodium	O
12	dihydrogen	O
13	phosphate	O
14	in	O
15	the	O
16	sugar	O
17	solutions	O
18	resulted	O
19	in	O
20	a	O
21	decrease	O
22	in	O
23	the	O
24	shelf	O
25	-	O
26	life	O
27	of	O
28	diltiazem	O
29	.	O
1	None	O
2	had	O
3	a	O
4	past	O
5	history	O
6	of	O
7	opportunistic	O
8	infections	O
9	;	O
10	neither	O
11	did	O
12	any	O
13	have	O
14	lymphopenia	O
15	.	O
1	Increasing	O
2	the	O
3	phosphorus	O
4	content	O
5	of	O
6	the	O
7	diet	O
8	improved	O
9	the	O
10	reabsorption	O
11	of	O
12	calcium	O
13	and	O
14	magnesium	O
15	.	O
1	Baseline	O
2	measurements	O
3	of	O
4	forced	O
5	expiratory	O
6	volume	O
7	in	O
8	1	O
9	s	O
10	(	O
11	FEV1	O
12	),	O
13	specific	O
14	airway	O
15	conductance	O
16	(	O
17	SGaw	O
18	)	O
19	and	O
20	the	O
21	provocative	O
22	dose	O
23	of	O
24	carbachol	O
25	causing	O
26	a	O
27	35	O
28	%	O
29	reduction	O
30	in	O
31	SGaw	O
32	(	O
33	PD35	O
34	),	O
35	and	O
36	a	O
37	20	O
38	%	O
39	reduction	O
40	in	O
41	FEV1	O
42	(	O
43	PD20	O
44	)	O
45	were	O
46	established	O
47	on	O
48	entry	O
49	while	O
50	each	O
51	subject	O
52	was	O
53	still	O
54	smoking	O
55	.	O
1	R	O
2	-	O
3	wave	O
4	voltage	O
5	in	O
6	the	O
7	right	O
8	precordial	O
9	leads	O
10	in	O
11	anthracycline	O
12	cardiomyopathy	O
13	:	O
14	a	O
15	clinical	O
16	study	O
17	.	O
1	Records	O
2	of	O
3	31	O
4	children	O
5	with	O
6	AIDS	O
7	or	O
8	AIDS	O
9	-	O
10	related	O
11	complex	O
12	admitted	O
13	to	O
14	the	O
15	pediatric	O
16	intensive	O
17	care	O
18	unit	O
19	for	O
20	acute	O
21	respiratory	O
22	failure	O
23	throughout	O
24	a	O
25	46	O
26	-	O
27	month	O
28	period	O
29	were	O
30	reviewed	O
31	.	O
1	Fourteen	O
2	patients	O
3	were	O
4	in	O
5	the	O
6	multifocal	O
7	disease	O
8	group	O
9	;	O
10	13	O
11	were	O
12	detected	O
13	by	O
14	SPECT	O
15	and	O
16	10	O
17	by	O
18	TCT	O
19	.	O
1	GRFI	B
2	bound	O
3	to	O
4	sequences	O
5	at	O
6	the	O
7	negative	O
8	regulatory	O
9	elements	O
10	(	O
11	silencers	O
12	)	O
13	of	O
14	the	O
15	silent	B
16	mating	I
17	type	I
18	loci	I
19	HML	I
20	E	I
21	and	O
22	HMR	B
23	E	I
24	and	O
25	to	O
26	the	O
27	upstream	O
28	activating	O
29	sequence	O
30	(	O
31	UAS	O
32	)	O
33	required	O
34	for	O
35	transcription	O
36	of	O
37	the	O
38	MAT	B
39	alpha	I
40	genes	I
41	.	O
1	The	O
2	effects	O
3	of	O
4	these	O
5	mutations	O
6	on	O
7	RNA	B
8	polymerase	I
9	II	I
10	activity	O
11	were	O
12	assayed	O
13	by	O
14	measuring	O
15	the	O
16	ability	O
17	of	O
18	mutant	O
19	genes	O
20	to	O
21	confer	O
22	alpha	B
23	-	I
24	amanitin	I
25	resistance	O
26	after	O
27	transfection	O
28	of	O
29	susceptible	O
30	rodent	O
31	cells	O
32	.	O
1	The	O
2	indications	O
3	for	O
4	its	O
5	use	O
6	include	O
7	every	O
8	primary	O
9	and	O
10	secondary	O
11	rhinoplasty	O
12	candidate	O
13	unless	O
14	tip	O
15	grafts	O
16	are	O
17	going	O
18	to	O
19	be	O
20	under	O
21	tension	O
22	or	O
23	if	O
24	the	O
25	deformity	O
26	is	O
27	minor	O
28	.	O
1	Mutations	O
2	at	O
3	the	O
4	suf12	B
5	locus	I
6	were	O
7	isolated	O
8	in	O
9	Saccharomyces	O
10	cerevisiae	O
11	as	O
12	extragenic	O
13	suppressors	O
14	of	O
15	+	O
16	1	O
17	frameshift	O
18	mutations	O
19	in	O
20	glycine	O
21	(	O
22	GGX	O
23	)	O
24	and	O
25	proline	O
26	(	O
27	CCX	O
28	)	O
29	codons	O
30	,	O
31	as	O
32	well	O
33	as	O
34	UGA	O
35	and	O
36	UAG	O
37	nonsense	O
38	mutations	O
39	.	O
1	Antibodies	O
2	made	O
3	against	O
4	fusion	O
5	protein	O
6	produced	O
7	by	O
8	the	O
9	DP1A	B
10	clone	O
11	reacted	O
12	specifically	O
13	with	O
14	DP	B
15	-	I
16	I	I
17	and	I
18	-	I
19	II	I
20	on	O
21	immunoblots	O
22	.	O
1	Yang	O
2	and	O
3	H	O
4	.	O
1	Time	O
2	delay	O
3	effects	O
4	on	O
5	the	O
6	tensile	O
7	bond	O
8	strength	O
9	developed	O
10	by	O
11	the	O
12	Silicoater	O
13	.	O
1	This	O
2	report	O
3	expands	O
4	on	O
5	previous	O
6	work	O
7	with	O
8	interferon	B
9	alfa	I
10	-	I
11	2b	I
12	(	I
13	Intron	I
14	A	I
15	;	I
16	Schering	I
17	-	I
18	Plough	I
19	)	I
20	in	O
21	the	O
22	treatment	O
23	of	O
24	hairy	O
25	cell	O
26	leukemia	O
27	(	O
28	HCL	O
29	).	O
1	Lysosomal	O
2	enzymes	O
3	that	O
4	degrade	O
5	cartilage	O
6	are	O
7	released	O
8	.	O
1	If	O
2	this	O
3	is	O
4	unavailable	O
5	,	O
6	then	O
7	Supramid	O
8	has	O
9	a	O
10	proven	O
11	record	O
12	for	O
13	good	O
14	tissue	O
15	compatibility	O
16	and	O
17	resistance	O
18	to	O
19	infection	O
20	.	O
1	""""	O
2	In	O
3	vitro	O
4	""""	O
5	study	O
6	of	O
7	dentin	O
8	adhesion	O
9	to	O
10	adhesives	O
11	made	O
12	from	O
13	urethane	O
14	molecules	O
15	with	O
16	free	O
17	groups	O
18	of	O
19	isocyanate	O
1	The	O
2	German	O
3	Society	O
4	of	O
5	Pediatric	O
6	Oncology	O
7	in	O
8	1981	O
9	initiated	O
10	the	O
11	Cooperative	O
12	Ewing	O
13	'	O
14	s	O
15	Sarcoma	O
16	Study	O
17	(	O
18	CESS	O
19	81	O
20	)	O
21	using	O
22	a	O
23	four	O
24	-	O
25	drug	O
26	combination	O
27	of	O
28	chemotherapy	O
29	prior	O
30	to	O
31	definitive	O
32	local	O
33	control	O
34	with	O
35	surgery	O
36	and	O
37	/	O
38	or	O
39	radiation	O
40	.	O
1	A	O
2	significant	O
3	association	O
4	between	O
5	a	O
6	family	O
7	history	O
8	and	O
9	a	O
10	higher	O
11	urinary	O
12	pH	O
13	was	O
14	observed	O
15	among	O
16	the	O
17	female	O
18	calcium	O
19	stone	O
20	patients	O
21	.	O
1	The	O
2	epidermal	B
3	growth	I
4	factor	I
5	(	I
6	EGF	I
7	)	I
8	receptor	I
9	,	O
10	which	O
11	exhibits	O
12	intrinsic	O
13	protein	B
14	tyrosine	I
15	kinase	I
16	activity	O
17	,	O
18	undergoes	O
19	a	O
20	rapid	O
21	,	O
22	intramolecular	O
23	self	O
24	-	O
25	phosphorylation	O
26	reaction	O
27	following	O
28	EGF	B
29	activation	O
30	.	O
1	There	O
2	are	O
3	regions	O
4	with	O
5	long	O
6	runs	O
7	of	O
8	up	O
9	to	O
10	45	O
11	%	O
12	C	O
13	or	O
14	35	O
15	%	O
16	G	O
17	residues	O
18	.	O
1	A	O
2	case	O
3	of	O
4	AIDS	O
5	-	O
6	related	O
7	complex	O
8	(	O
9	ARC	O
10	/	O
11	LAS	O
12	)	O
13	in	O
14	a	O
15	health	O
16	worker	O
1	The	O
2	relations	O
3	among	O
4	various	O
5	negative	O
6	emotional	O
7	and	O
8	behavioral	O
9	characteristics	O
10	(	O
11	e	O
12	.	O
13	g	O
14	.,	O
15	aggression	O
16	,	O
17	anxiety	O
18	,	O
19	undercompliance	O
20	,	O
21	depressive	O
22	mood	O
23	)	O
24	and	O
25	adjustment	O
26	were	O
27	examined	O
28	through	O
29	use	O
30	of	O
31	data	O
32	from	O
33	the	O
34	31	O
35	-	O
36	year	O
37	-	O
38	old	O
39	New	O
40	York	O
41	Longitudinal	O
42	Study	O
43	.	O
1	To	O
2	evaluate	O
3	the	O
4	effect	O
5	of	O
6	altitude	O
7	on	O
8	adolescent	O
9	growth	O
10	and	O
11	development	O
12	,	O
13	three	O
14	groups	O
15	of	O
16	healthy	O
17	,	O
18	well	O
19	-	O
20	nourished	O
21	youth	O
22	of	O
23	similar	O
24	socioeconomic	O
25	status	O
26	and	O
27	ethnic	O
28	grouping	O
29	who	O
30	resided	O
31	at	O
32	sea	O
33	level	O
34	(	O
35	n	O
36	=	O
37	1262	O
38	subjects	O
39	),	O
40	mid	O
41	-	O
42	altitude	O
43	(	O
44	n	O
45	=	O
46	1743	O
47	subjects	O
48	),	O
49	and	O
50	high	O
51	altitude	O
52	(	O
53	n	O
54	=	O
55	1137	O
56	subjects	O
57	)	O
58	were	O
59	studied	O
60	.	O
1	Static	O
2	magnetic	O
3	fields	O
4	affect	O
5	the	O
6	diffusion	O
7	of	O
8	biological	O
9	particles	O
10	in	O
11	solutions	O
12	through	O
13	the	O
14	Lorentz	O
15	force	O
16	and	O
17	Maxwell	O
18	stress	O
19	.	O
1	Chronic	O
2	administration	O
3	of	O
4	sodium	O
5	cyanate	O
6	decreases	O
7	O2	O
8	extraction	O
9	ratio	O
10	in	O
11	dogs	O
12	.	O
1	SPA	O
2	from	O
3	PAG	O
4	sites	O
5	was	O
6	associated	O
7	with	O
8	aversion	O
9	.	O
1	Abnormal	O
2	technetium	O
3	Tc	O
4	99m	O
5	medronate	O
6	scans	O
7	in	O
8	patients	O
9	with	O
10	previously	O
11	undiagnosed	O
12	polyarthralgias	O
13	suggested	O
14	inflammatory	O
15	arthropathy	O
16	and	O
17	influenced	O
18	management	O
19	decisions	O
20	with	O
21	favorable	O
22	therapeutic	O
23	outcomes	O
24	.	O
1	Depending	O
2	on	O
3	the	O
4	location	O
5	and	O
6	size	O
7	of	O
8	the	O
9	mass	O
10	,	O
11	a	O
12	wide	O
13	range	O
14	of	O
15	clinical	O
16	presentations	O
17	is	O
18	associated	O
19	with	O
20	the	O
21	lesion	O
22	.	O
1	Statistical	O
2	analysis	O
3	of	O
4	the	O
5	degrees	O
6	of	O
7	secondary	O
8	spinal	O
9	cord	O
10	compression	O
11	was	O
12	performed	O
13	in	O
14	group	O
15	-	O
16	1	O
17	dogs	O
18	by	O
19	measuring	O
20	and	O
21	comparing	O
22	ratios	O
23	of	O
24	the	O
25	vertical	O
26	to	O
27	the	O
28	horizontal	O
29	diameters	O
30	of	O
31	the	O
32	transverse	O
33	spinal	O
34	cord	O
35	sections	O
36	from	O
37	locations	O
38	within	O
39	(	O
40	T12	O
41	to	O
42	L1	O
43	)	O
44	and	O
45	out	O
46	of	O
47	(	O
48	T11	O
49	,	O
50	T11	O
51	-	O
52	12	O
53	,	O
54	L1	O
55	-	O
56	2	O
57	,	O
58	and	O
59	L2	O
60	)	O
61	the	O
62	region	O
63	of	O
64	surgical	O
65	intervention	O
66	.	O
1	The	O
2	state	O
3	of	O
4	the	O
5	liver	O
6	in	O
7	generalized	O
8	forms	O
9	of	O
10	meningococcal	O
11	infection	O
1	The	O
2	effects	O
3	produced	O
4	by	O
5	oral	O
6	administration	O
7	of	O
8	500	O
9	mg	O
10	/	O
11	kg	O
12	p	O
13	-	O
14	xylene	O
15	or	O
16	toluene	O
17	lasted	O
18	at	O
19	least	O
20	8	O
21	hr	O
22	,	O
23	while	O
24	the	O
25	effect	O
26	of	O
27	inhaled	O
28	p	O
29	-	O
30	xylene	O
31	dissipated	O
32	within	O
33	75	O
34	min	O
35	of	O
36	removal	O
37	from	O
38	the	O
39	exposure	O
40	.	O
1	Papers	O
2	of	O
3	the	O
4	Society	O
5	for	O
6	Clinical	O
7	Vascular	O
8	Surgery	O
9	.	O
1	The	O
2	incidence	O
3	of	O
4	cryptosporidiosis	O
5	in	O
6	young	O
7	children	O
8	was	O
9	determined	O
10	by	O
11	staining	O
12	of	O
13	faecal	O
14	specimens	O
15	with	O
16	a	O
17	modified	O
18	Kinyoun	O
19	stain	O
20	.	O
1	Moreover	O
2	,	O
3	unlike	O
4	control	O
5	rats	O
6	operated	O
7	animals	O
8	did	O
9	not	O
10	show	O
11	aversion	O
12	to	O
13	the	O
14	highest	O
15	concentrations	O
16	of	O
17	saccharin	O
18	solutions	O
19	.	O
1	Overall	O
2	least	O
3	-	O
4	squares	O
5	means	O
6	for	O
7	uncooked	O
8	and	O
9	cooked	O
10	longissimus	O
11	muscle	O
12	and	O
13	subcutaneous	O
14	fat	O
15	were	O
16	63	O
17	.	O
18	32	O
19	,	O
20	80	O
21	.	O
22	27	O
23	and	O
24	98	O
25	.	O
26	90	O
27	mg	O
28	of	O
29	cholesterol	O
30	/	O
31	100	O
32	g	O
33	of	O
34	tissue	O
35	,	O
36	respectively	O
37	.	O
1	The	O
2	role	O
3	of	O
4	supercritical	O
5	fluid	O
6	chromatography	O
7	(	O
8	SFC	O
9	)	O
10	as	O
11	a	O
12	viable	O
13	technique	O
14	for	O
15	analyzing	O
16	agricultural	O
17	products	O
18	has	O
19	been	O
20	investigated	O
21	using	O
22	packed	O
23	and	O
24	capillary	O
25	column	O
26	methodology	O
27	.	O
1	The	O
2	criterion	O
3	was	O
4	reached	O
5	after	O
6	two	O
7	sessions	O
8	and	O
9	generalization	O
10	to	O
11	a	O
12	variety	O
13	of	O
14	pills	O
15	and	O
16	capsules	O
17	occurred	O
18	.	O
1	An	O
2	industry	O
3	-	O
4	wide	O
5	retrospective	O
6	cohort	O
7	mortality	O
8	study	O
9	was	O
10	conducted	O
11	on	O
12	6	O
13	,	O
14	152	O
15	chemical	O
16	workers	O
17	(	O
18	2	O
19	,	O
20	460	O
21	exposed	O
22	and	O
23	3	O
24	,	O
25	692	O
26	nonexposed	O
27	)	O
28	engaged	O
29	in	O
30	chloromethyl	O
31	ether	O
32	manufacture	O
33	at	O
34	7	O
35	major	O
36	U	O
37	.	O
38	S	O
39	.	O
40	companies	O
41	between	O
42	1948	O
43	and	O
44	1980	O
45	.	O
1	A	O
2	total	O
3	of	O
4	117	O
5	EVS	O
6	treatments	O
7	were	O
8	performed	O
9	on	O
10	34	O
11	patients	O
12	.	O
1	Most	O
2	of	O
3	the	O
4	prepeptide	O
5	portion	O
6	of	O
7	the	O
8	precursor	O
9	polypeptide	O
10	is	O
11	encoded	O
12	by	O
13	the	O
14	next	O
15	three	O
16	exons	O
17	,	O
18	and	O
19	the	O
20	mature	O
21	form	O
22	of	O
23	IL	B
24	-	I
25	1	I
26	alpha	I
27	is	O
28	encoded	O
29	by	O
30	the	O
31	remaining	O
32	three	O
33	exons	O
34	.	O
1	The	O
2	detectability	O
3	of	O
4	the	O
5	defects	O
6	in	O
7	RCA	O
8	or	O
9	LAD	O
10	region	O
11	was	O
12	80	O
13	%	O
14	in	O
15	single	O
16	-	O
17	position	O
18	scans	O
19	in	O
20	stress	O
21	studies	O
22	.	O
1	The	O
2	small	O
3	size	O
4	and	O
5	placement	O
6	of	O
7	the	O
8	mutagenesis	O
9	marker	O
10	(	O
11	the	O
12	supF	B
13	suppressor	I
14	tRNA	I
15	gene	I
16	from	I
17	Escherichia	I
18	coli	I
19	)	O
20	within	O
21	the	O
22	vector	O
23	substantially	O
24	reduced	O
25	the	O
26	frequency	O
27	of	O
28	spontaneous	O
29	mutations	O
30	normally	O
31	observed	O
32	after	O
33	transfection	O
34	of	O
35	mammalian	O
36	cells	O
37	with	O
38	plasmid	O
39	DNA	O
40	;	O
41	hence	O
42	,	O
43	UV	O
44	-	O
45	induced	O
46	mutations	O
47	were	O
48	easily	O
49	identified	O
50	above	O
51	the	O
52	spontaneous	O
53	background	O
54	.	O
1	Based	O
2	on	O
3	our	O
4	observations	O
5	,	O
6	we	O
7	propose	O
8	a	O
9	model	O
10	whereby	O
11	inactive	O
12	precursor	O
13	molecules	O
14	produced	O
15	from	O
16	the	O
17	PEP4	B
18	gene	I
19	self	O
20	-	O
21	activate	O
22	within	O
23	the	O
24	yeast	O
25	vacuole	O
26	and	O
27	subsequently	O
28	activate	O
29	other	O
30	vacuolar	B
31	hydrolases	I
32	.	O
1	The	O
2	poly	O
3	(	O
4	A	O
5	)	O
6	segment	O
7	of	O
8	the	O
9	RNA	O
10	was	O
11	selectively	O
12	cross	O
13	-	O
14	linked	O
15	to	O
16	the	O
17	72	O
18	,	O
19	000	O
20	-	O
21	molecular	O
22	-	O
23	weight	O
24	protein	O
25	(	O
26	72K	O
27	protein	O
28	).	O
1	Several	O
2	new	O
3	techniques	O
4	are	O
5	available	O
6	for	O
7	monitoring	O
8	control	O
9	of	O
10	diabetes	O
11	.	O
1	Also	O
2	,	O
3	component	O
4	I	O
5	significantly	O
6	correlated	O
7	with	O
8	fasting	O
9	insulin	B
10	and	O
11	VO2	O
12	max	O
13	for	O
14	both	O
15	sexes	O
16	and	O
17	with	O
18	basal	O
19	metabolism	O
20	and	O
21	HDL	B
22	-	I
23	cholesterol	I
24	for	O
25	females	O
26	and	O
27	males	O
28	,	O
29	respectively	O
30	.	O
1	Development	O
2	of	O
3	a	O
4	yeast	O
5	system	O
6	to	O
7	assay	O
8	mutational	O
9	specificity	O
10	.	O
1	In	O
2	10	O
3	patients	O
4	with	O
5	subacute	O
6	cardiac	O
7	tamponade	O
8	,	O
9	pulmonary	O
10	wedge	O
11	pressure	O
12	(	O
13	PWP	O
14	),	O
15	RAP	O
16	,	O
17	and	O
18	IPP	O
19	were	O
20	measured	O
21	along	O
22	with	O
23	indexes	O
24	of	O
25	systolic	O
26	function	O
27	.	O
1	Due	O
2	to	O
3	its	O
4	relatively	O
5	soluble	O
6	chemical	O
7	form	O
8	,	O
9	90Sr	O
10	was	O
11	rapidly	O
12	translocated	O
13	from	O
14	lung	O
15	to	O
16	bone	O
17	where	O
18	a	O
19	substantial	O
20	portion	O
21	was	O
22	retained	O
23	for	O
24	a	O
25	long	O
26	period	O
27	of	O
28	time	O
29	.	O
1	An	O
2	epidemiological	O
3	survey	O
4	of	O
5	rheumatic	O
6	valve	O
7	disease	O
8	and	O
9	rheumatic	O
10	fever	O
11	in	O
12	primary	O
13	and	O
14	secondary	O
15	school	O
16	students	O
17	in	O
18	Jiangxi	O
19	Province	O
1	Drugs	O
2	that	O
3	are	O
4	transformed	O
5	via	O
6	phase	O
7	II	O
8	reactions	O
9	usually	O
10	do	O
11	not	O
12	require	O
13	dosage	O
14	adjustment	O
15	.	O
1	Thus	O
2	,	O
3	a	O
4	negative	O
5	test	O
6	is	O
7	compatible	O
8	with	O
9	low	O
10	disease	O
11	activity	O
12	and	O
13	/	O
14	or	O
15	efficacy	O
16	of	O
17	calcium	O
18	antagonist	O
19	treatment	O
20	.	O
1	In	O
2	the	O
3	normal	O
4	,	O
5	basal	O
6	(	O
7	unstimulated	O
8	)	O
9	condition	O
10	there	O
11	were	O
12	no	O
13	significant	O
14	correlations	O
15	(	O
16	p	O
17	greater	O
18	than	O
19	0	O
20	.	O
21	05	O
22	)	O
23	between	O
24	the	O
25	systolic	O
26	blood	O
27	pressure	O
28	and	O
29	dopamine	O
30	(	O
31	r	O
32	=	O
33	0	O
34	.	O
35	09	O
36	),	O
37	norepinephrine	O
38	(	O
39	r	O
40	=	O
41	0	O
42	.	O
43	26	O
44	),	O
45	or	O
46	epinephrine	O
47	(	O
48	r	O
49	=	O
50	0	O
51	.	O
52	27	O
53	),	O
54	nor	O
55	were	O
56	there	O
57	significant	O
58	correlations	O
59	between	O
60	melatonin	O
61	and	O
62	dopamine	O
63	(	O
64	r	O
65	=	O
66	-	O
67	0	O
68	.	O
69	01	O
70	),	O
71	norepinephrine	O
72	(	O
73	r	O
74	=	O
75	-	O
76	0	O
77	.	O
78	26	O
79	),	O
80	or	O
81	growth	B
82	hormone	I
83	(	O
84	r	O
85	=	O
86	0	O
87	.	O
88	17	O
89	).	O
1	All	O
2	these	O
3	processes	O
4	were	O
5	fully	O
6	developed	O
7	during	O
8	the	O
9	last	O
10	month	O
11	of	O
12	pregnancy	O
13	,	O
14	offering	O
15	the	O
16	same	O
17	picture	O
18	as	O
19	the	O
20	controls	O
21	.	O
1	In	O
2	cases	O
3	of	O
4	1	O
5	degrees	O
6	HPT	O
7	,	O
8	the	O
9	plasma	O
10	1	O
11	,	O
12	25	O
13	-(	O
14	OH	O
15	)	O
16	2D	O
17	level	O
18	rose	O
19	significantly	O
20	in	O
21	all	O
22	cases	O
23	(	O
24	P	O
25	less	O
26	than	O
27	0	O
28	.	O
29	05	O
30	),	O
31	although	O
32	the	O
33	pattern	O
34	of	O
35	the	O
36	increase	O
37	was	O
38	not	O
39	uniform	O
40	.	O
1	This	O
2	approach	O
3	enables	O
4	the	O
5	sources	O
6	of	O
7	error	O
8	in	O
9	the	O
10	calculation	O
11	of	O
12	nutrient	O
13	utilization	O
14	to	O
15	be	O
16	readily	O
17	identified	O
18	,	O
19	and	O
20	their	O
21	effect	O
22	on	O
23	precision	O
24	to	O
25	be	O
26	assessed	O
27	in	O
28	different	O
29	nutritional	O
30	and	O
31	metabolic	O
32	states	O
33	.	O
1	Weaned	O
2	rats	O
3	were	O
4	fed	O
5	a	O
6	normal	O
7	diet	O
8	or	O
9	a	O
10	low	O
11	-	O
12	protein	O
13	,	O
14	low	O
15	-	O
16	energy	O
17	diet	O
18	,	O
19	and	O
20	injected	O
21	with	O
22	saline	O
23	or	O
24	thyroxine	O
25	(	O
26	5	O
27	micrograms	O
28	/	O
29	100	O
30	g	O
31	BW	O
32	)	O
33	for	O
34	22	O
35	days	O
36	.	O
1	The	O
2	rate	O
3	-	O
4	decreasing	O
5	effects	O
6	of	O
7	morphine	O
8	and	O
9	U50488	O
10	were	O
11	reversed	O
12	completely	O
13	by	O
14	a	O
15	0	O
16	.	O
17	01	O
18	and	O
19	1	O
20	.	O
21	0	O
22	mg	O
23	/	O
24	kg	O
25	dose	O
26	of	O
27	naloxone	O
28	,	O
29	respectively	O
30	.	O
1	Data	O
2	from	O
3	119	O
4	men	O
5	and	O
6	40	O
7	women	O
8	undergoing	O
9	coronary	O
10	angiography	O
11	provide	O
12	an	O
13	opportunity	O
14	to	O
15	compare	O
16	these	O
17	associations	O
18	in	O
19	relation	O
20	to	O
21	a	O
22	direct	O
23	and	O
24	continuous	O
25	measure	O
26	of	O
27	atherosclerosis	O
28	while	O
29	controlling	O
30	for	O
31	age	O
32	,	O
33	sex	O
34	,	O
35	income	O
36	,	O
37	hypertension	O
38	,	O
39	serum	O
40	cholesterol	O
41	,	O
42	smoking	O
43	,	O
44	angina	O
45	,	O
46	diabetes	O
47	,	O
48	family	O
49	history	O
50	of	O
51	heart	O
52	disease	O
53	,	O
54	Type	O
55	A	O
56	behavior	O
57	pattern	O
58	,	O
59	and	O
60	hostility	O
61	.	O
1	Effects	O
2	of	O
3	a	O
4	low	O
5	-	O
6	energy	O
7	laser	O
8	beam	O
9	on	O
10	the	O
11	cells	O
12	of	O
13	the	O
14	newt	O
15	embryo	O
1	The	O
2	role	O
3	of	O
4	saliva	O
5	in	O
6	sour	O
7	taste	O
8	perception	O
9	was	O
10	investigated	O
11	in	O
12	a	O
13	series	O
14	of	O
15	4	O
16	experiments	O
17	.	O
1	Separate	O
2	experiments	O
3	measured	O
4	AIB	O
5	and	O
6	86RbCl	O
7	uptake	O
8	in	O
9	36B	O
10	-	O
11	10	O
12	cells	O
13	in	O
14	vitro	O
15	1	O
16	and	O
17	2	O
18	days	O
19	following	O
20	20	O
21	Gy	O
22	irradiation	O
23	to	O
24	assess	O
25	whether	O
26	this	O
27	radiation	O
28	dose	O
29	reduced	O
30	the	O
31	capacity	O
32	of	O
33	tumor	O
34	cells	O
35	to	O
36	trap	O
37	AIB	O
38	or	O
39	Rb	O
40	+.	O
1	W	O
2	.	O
1	UVA	O
2	-	O
3	induced	O
4	melanocytic	O
5	lesions	O
6	.	O
1	A	O
2	careful	O
3	,	O
4	radiolabelled	O
5	tissue	O
6	-	O
7	distribution	O
8	study	O
9	is	O
10	warranted	O
11	to	O
12	elucidate	O
13	the	O
14	complicated	O
15	metabolic	O
16	fate	O
17	of	O
18	perhexiline	O
19	.	O
1	These	O
2	equilibrium	O
3	solutions	O
4	are	O
5	then	O
6	shown	O
7	to	O
8	arise	O
9	from	O
10	the	O
11	vertices	O
12	of	O
13	a	O
14	particular	O
15	convex	O
16	polyhedron	O
17	.	O
1	Low	O
2	MAO	B
3	subjects	O
4	showed	O
5	a	O
6	pattern	O
7	of	O
8	higher	O
9	scores	O
10	in	O
11	KSP	O
12	Impulsiveness	O
13	,	O
14	EPQ	O
15	Neuroticism	O
16	,	O
17	and	O
18	KSP	O
19	Somatic	O
20	Anxiety	O
21	and	O
22	Irritability	O
23	and	O
24	lower	O
25	scores	O
26	in	O
27	KSP	O
28	Socialization	O
29	,	O
30	in	O
31	line	O
32	with	O
33	personality	O
34	profiles	O
35	found	O
36	in	O
37	alcoholics	O
38	,	O
39	psychopaths	O
40	,	O
41	and	O
42	suicide	O
43	attempters	O
44	who	O
45	also	O
46	tend	O
47	to	O
48	have	O
49	low	O
50	platelet	O
51	MAO	B
52	activity	O
53	.	O
1	In	O
2	group	O
3	I	O
4	,	O
5	Paw	O
6	,	O
7	delta	O
8	V	O
9	,	O
10	PaO2	O
11	,	O
12	Vinj	O
13	and	O
14	VT	O
15	significantly	O
16	decreased	O
17	whereas	O
18	operating	O
19	pressure	O
20	and	O
21	E	O
22	significantly	O
23	increased	O
24	when	O
25	the	O
26	internal	O
27	diameter	O
28	of	O
29	the	O
30	injector	O
31	cannula	O
32	was	O
33	reduced	O
34	.	O
1	The	O
2	histologic	O
3	grade	O
4	for	O
5	the	O
6	same	O
7	anatomic	O
8	site	O
9	varied	O
10	among	O
11	hearts	O
12	and	O
13	among	O
14	different	O
15	anatomic	O
16	sites	O
17	in	O
18	the	O
19	same	O
20	heart	O
21	.	O
1	Endurance	O
2	training	O
3	resulted	O
4	in	O
5	an	O
6	increase	O
7	of	O
8	stiffness	O
9	associated	O
10	with	O
11	a	O
12	decrease	O
13	of	O
14	type	O
15	II	O
16	fibers	O
17	.	O
1	The	O
2	models	O
3	accurately	O
4	localized	O
5	the	O
6	common	O
7	boundaries	O
8	between	O
9	the	O
10	PBB	O
11	and	O
12	CN	O
13	.	O
1	It	O
2	is	O
3	concluded	O
4	that	O
5	contact	O
6	allergy	O
7	to	O
8	K	O
9	-	O
10	CG	O
11	is	O
12	common	O
13	.	O
1	The	O
2	effect	O
3	of	O
4	a	O
5	beta	B
6	-	I
7	adrenoceptor	I
8	antagonist	O
9	,	O
10	pindolol	O
11	,	O
12	on	O
13	uterine	O
14	smooth	O
15	muscle	O
16	in	O
17	term	O
18	pregnant	O
19	women	O
20	was	O
21	studied	O
22	in	O
23	vitro	O
24	and	O
25	in	O
26	vivo	O
27	(	O
28	in	O
29	hypertensive	O
30	women	O
31	).	O
1	The	O
2	development	O
3	of	O
4	a	O
5	data	O
6	base	O
7	is	O
8	described	O
9	which	O
10	can	O
11	be	O
12	used	O
13	as	O
14	common	O
15	reference	O
16	for	O
17	ECG	O
18	computer	O
19	programs	O
20	analyzing	O
21	12	O
22	or	O
23	15	O
24	simultaneously	O
25	recorded	O
26	leads	O
27	.	O
1	The	O
2	number	O
3	of	O
4	crystalline	O
5	deposits	O
6	is	O
7	less	O
8	in	O
9	the	O
10	advanced	O
11	atrophic	O
12	areas	O
13	of	O
14	the	O
15	RPE	O
16	-	O
17	choriocapillaris	O
18	complex	O
19	.	O
1	The	O
2	subjects	O
3	received	O
4	a	O
5	single	O
6	500	O
7	mg	O
8	dose	O
9	of	O
10	acetaminophen	O
11	i	O
12	.	O
13	v	O
14	.	O
15	and	O
16	concentrations	O
17	in	O
18	plasma	O
19	were	O
20	measured	O
21	for	O
22	360	O
23	minutes	O
24	and	O
25	in	O
26	urine	O
27	for	O
28	24	O
29	h	O
30	in	O
31	order	O
32	to	O
33	estimate	O
34	the	O
35	production	O
36	of	O
37	metabolites	O
38	.	O
1	Indium	O
2	-	O
3	111	O
4	leukocyte	O
5	imaging	O
6	in	O
7	patients	O
8	with	O
9	rheumatoid	O
10	arthritis	O
11	.	O
1	Induction	O
2	of	O
3	both	O
4	potential	O
5	transcripts	O
6	follows	O
7	heat	O
8	shock	O
9	in	O
10	vivo	O
11	.	O
1	Liver	O
2	TG	O
3	and	O
4	serum	O
5	NEFA	O
6	concentrations	O
7	were	O
8	positively	O
9	correlated	O
10	.	O
1	When	O
2	the	O
3	coronary	O
4	sinus	O
5	pressure	O
6	reached	O
7	15	O
8	torr	O
9	,	O
10	there	O
11	was	O
12	a	O
13	significant	O
14	decrease	O
15	in	O
16	cardiac	O
17	index	O
18	(	O
19	3	O
20	.	O
21	60	O
22	+/-	O
23	0	O
24	.	O
25	5	O
26	to	O
27	2	O
28	.	O
29	70	O
30	+/-	O
31	0	O
32	.	O
33	6	O
34	L	O
35	/	O
36	min	O
37	/	O
38	m2	O
39	,	O
40	p	O
41	less	O
42	than	O
43	0	O
44	.	O
45	001	O
46	),	O
47	coronary	O
48	blood	O
49	flow	O
50	(	O
51	13	O
52	.	O
53	7	O
54	+/-	O
55	3	O
56	.	O
57	1	O
58	to	O
59	7	O
60	.	O
61	0	O
62	+/-	O
63	2	O
64	.	O
65	1	O
66	ml	O
67	/	O
68	min	O
69	,	O
70	p	O
71	less	O
72	than	O
73	0	O
74	.	O
75	001	O
76	),	O
77	rate	O
78	of	O
79	rise	O
80	of	O
81	left	O
82	ventricular	O
83	pressure	O
84	(	O
85	1	O
86	,	O
87	567	O
88	+/-	O
89	275	O
90	to	O
91	1	O
92	,	O
93	331	O
94	+/-	O
95	314	O
96	,	O
97	p	O
98	less	O
99	than	O
100	0	O
101	.	O
102	05	O
103	),	O
104	and	O
105	an	O
106	increase	O
107	in	O
108	coronary	O
109	arteriovenous	O
110	difference	O
111	(	O
112	62	O
113	.	O
114	8	O
115	%	O
116	+/-	O
117	9	O
118	.	O
119	3	O
120	%	O
121	to	O
122	70	O
123	.	O
124	5	O
125	%	O
126	+/-	O
127	5	O
128	.	O
129	4	O
130	%	O
131	saturation	O
132	,	O
133	p	O
134	less	O
135	than	O
136	0	O
137	.	O
138	03	O
139	).	O
1	On	O
2	transition	O
3	from	O
4	high	O
5	to	O
6	low	O
7	voltage	O
8	there	O
9	was	O
10	a	O
11	significant	O
12	fall	O
13	in	O
14	arterial	O
15	pressure	O
16	(	O
17	7	O
18	%)	O
19	and	O
20	an	O
21	increase	O
22	in	O
23	flow	O
24	(	O
25	19	O
26	-	O
27	38	O
28	%)	O
29	to	O
30	areas	O
31	of	O
32	the	O
33	brain	O
34	corresponding	O
35	to	O
36	the	O
37	arborization	O
38	of	O
39	the	O
40	reticular	O
41	formation	O
42	,	O
43	i	O
44	.	O
45	e	O
46	.	O
47	excluding	O
48	the	O
49	cerebrum	O
50	and	O
51	cerebellum	O
52	.	O
1	One	O
2	hundred	O
3	and	O
4	four	O
5	(	O
6	14	O
7	per	O
8	cent	O
9	)	O
10	second	O
11	primary	O
12	tumours	O
13	were	O
14	reported	O
15	.	O
1	It	O
2	is	O
3	suggested	O
4	that	O
5	these	O
6	results	O
7	may	O
8	raise	O
9	the	O
10	interesting	O
11	possibility	O
12	of	O
13	providing	O
14	a	O
15	means	O
16	of	O
17	identifying	O
18	greater	O
19	or	O
20	lesser	O
21	susceptibility	O
22	to	O
23	the	O
24	coronary	O
25	effects	O
26	of	O
27	Type	O
28	A	O
29	behavior	O
30	.	O
1	Two	O
2	studies	O
3	assessed	O
4	two	O
5	types	O
6	of	O
7	reliability	O
8	of	O
9	the	O
10	student	O
11	Jenkins	O
12	Activity	O
13	Survey	O
14	(	O
15	JAS	O
16	;	O
17	a	O
18	questionnaire	O
19	measure	O
20	of	O
21	Type	O
22	A	O
23	behavior	O
24	).	O
1	Splenectomized	O
2	patients	O
3	are	O
4	predisposed	O
5	toward	O
6	developing	O
7	overwhelming	O
8	bacterial	O
9	infections	O
10	.	O
1	High	O
2	radial	O
3	r	O
4	values	O
5	with	O
6	small	O
7	standard	O
8	deviations	O
9	were	O
10	observed	O
11	in	O
12	normal	O
13	LV	O
14	(	O
15	0	O
16	.	O
17	972	O
18	+/-	O
19	0	O
20	.	O
21	016	O
22	)	O
23	and	O
24	in	O
25	non	O
26	-	O
27	MI	O
28	regions	O
29	(	O
30	0	O
31	.	O
32	964	O
33	+/-	O
34	0	O
35	.	O
36	018	O
37	),	O
38	indicating	O
39	temporally	O
40	homogeneous	O
41	radial	O
42	shortening	O
43	.	O
1	N	O
2	-	O
3	Substituted	O
4	trimethylsilylcarbamates	O
5	were	O
6	tested	O
7	as	O
8	derivatizing	O
9	reagents	O
10	for	O
11	gas	O
12	chromatographic	O
13	analysis	O
14	.	O
1	Parasitological	O
2	post	O
3	-	O
4	mortem	O
5	examination	O
6	of	O
7	all	O
8	seropositive	O
9	animals	O
10	showed	O
11	five	O
12	and	O
13	seven	O
14	false	O
15	-	O
16	positive	O
17	animals	O
18	when	O
19	E	B
20	/	I
21	S	I
22	and	I
23	CWE	I
24	antigens	I
25	were	O
26	used	O
27	,	O
28	respectively	O
29	.	O
1	Examples	O
2	of	O
3	its	O
4	use	O
5	in	O
6	the	O
7	intensive	O
8	therapy	O
9	unit	O
10	are	O
11	described	O
12	.	O
1	The	O
2	growing	O
3	drug	O
4	problem	O
5	is	O
6	also	O
7	reflected	O
8	in	O
9	the	O
10	increasing	O
11	number	O
12	of	O
13	cases	O
14	of	O
15	hepatitis	O
16	B	O
17	and	O
18	of	O
19	drug	O
20	-	O
21	related	O
22	deaths	O
23	.	O
1	Although	O
2	differences	O
3	were	O
4	not	O
5	significant	O
6	,	O
7	infants	O
8	in	O
9	the	O
10	experimental	O
11	group	O
12	had	O
13	more	O
14	changes	O
15	in	O
16	the	O
17	intermittent	O
18	mandatory	O
19	ventilation	O
20	(	O
21	IMV	O
22	)	O
23	settings	O
24	during	O
25	transport	O
26	,	O
27	and	O
28	more	O
29	such	O
30	infants	O
31	arrived	O
32	at	O
33	the	O
34	receiving	O
35	hospital	O
36	with	O
37	acceptable	O
38	pH	O
39	and	O
40	PCO2	O
41	values	O
42	.	O
1	The	O
2	risk	O
3	for	O
4	these	O
5	complications	O
6	is	O
7	increased	O
8	by	O
9	the	O
10	following	O
11	factors	O
12	:	O
13	multiple	O
14	gestation	O
15	,	O
16	the	O
17	combination	O
18	of	O
19	magnesium	O
20	sulfate	O
21	and	O
22	beta	O
23	-	O
24	adrenergic	O
25	agonist	O
26	,	O
27	and	O
28	the	O
29	use	O
30	of	O
31	adrenocortico	O
32	-	O
33	steroids	O
34	to	O
35	hasten	O
36	fetal	O
37	pulmonary	O
38	maturity	O
39	.	O
1	Autotransplantation	O
2	of	O
3	a	O
4	vein	O
5	segment	O
6	with	O
7	valve	O
8	in	O
9	the	O
10	treatment	O
11	of	O
12	deep	O
13	vein	O
14	valvular	O
15	insufficiency	O
16	of	O
17	the	O
18	lower	O
19	extremity	O
1	This	O
2	is	O
3	based	O
4	on	O
5	partitioning	O
6	an	O
7	underlying	O
8	multivariate	O
9	normal	O
10	distribution	O
11	.	O
1	The	O
2	observation	O
3	of	O
4	late	O
5	effects	O
6	after	O
7	irradiations	O
8	or	O
9	after	O
10	space	O
11	flights	O
12	show	O
13	the	O
14	difficulties	O
15	encountered	O
16	in	O
17	assessing	O
18	radiative	O
19	risks	O
20	during	O
21	long	O
22	duration	O
23	space	O
24	flights	O
25	.	O
1	The	O
2	1	O
3	,	O
4	2	O
5	,	O
6	3	O
7	and	O
8	4	O
9	year	O
10	survival	O
11	rates	O
12	were	O
13	94	O
14	%,	O
15	84	O
16	%,	O
17	76	O
18	%	O
19	and	O
20	63	O
21	%,	O
22	respectively	O
23	.	O
1	Northern	O
2	blotting	O
3	with	O
4	a	O
5	unique	O
6	17	O
7	-	O
8	mer	O
9	oligonucleotide	O
10	demonstrated	O
11	the	O
12	absence	O
13	of	O
14	the	O
15	mutant	O
16	sequence	O
17	in	O
18	the	O
19	mRNA	O
20	from	O
21	which	O
22	the	O
23	cDNA	O
24	library	O
25	giving	O
26	rise	O
27	to	O
28	the	O
29	mutant	O
30	cDNA	O
31	was	O
32	constructed	O
33	.	O
1	Deletion	O
2	mapping	O
3	studies	O
4	revealed	O
5	that	O
6	the	O
7	upstream	O
8	DNA	O
9	sequences	O
10	up	O
11	to	O
12	-	O
13	86	O
14	were	O
15	sufficient	O
16	for	O
17	the	O
18	optimal	O
19	basal	O
20	level	O
21	transcription	O
22	in	O
23	HeLa	O
24	cells	O
25	and	O
26	also	O
27	for	O
28	the	O
29	EIA	B
30	-	O
31	induced	O
32	transcription	O
33	.	O
1	Eleven	O
2	healthy	O
3	,	O
4	normotensive	O
5	males	O
6	undergoing	O
7	routine	O
8	restorative	O
9	dental	O
10	care	O
11	were	O
12	evaluated	O
13	during	O
14	treatment	O
15	for	O
16	possible	O
17	hemodynamic	O
18	alterations	O
19	in	O
20	response	O
21	to	O
22	potential	O
23	sympathetic	O
24	nervous	O
25	system	O
26	stimulation	O
27	.	O
1	The	O
2	M	O
3	-	O
4	3	O
5	subtype	O
6	was	O
7	an	O
8	adverse	O
9	prognostic	O
10	factor	O
11	.	O
1	Computer	O
2	assisted	O
3	mapping	O
4	in	O
5	quantitative	O
6	analysis	O
7	of	O
8	cerebral	O
9	positron	O
10	emission	O
11	tomograms	O
12	.	O
1	In	O
2	the	O
3	region	O
4	Walgau	O
5	with	O
6	mixed	O
7	industrial	O
8	-	O
9	rural	O
10	population	O
11	an	O
12	iodine	O
13	deficiency	O
14	I	O
15	was	O
16	found	O
17	in	O
18	81	O
19	%	O
20	and	O
21	an	O
22	iodine	O
23	deficiency	O
24	II	O
25	in	O
26	45	O
27	%.	O
1	Such	O
2	studied	O
3	acquired	O
4	with	O
5	low	O
6	energy	O
7	or	O
8	medium	O
9	energy	O
10	collimation	O
11	and	O
12	a	O
13	window	O
14	centered	O
15	on	O
16	the	O
17	159	O
18	keV	O
19	123I	O
20	photopeak	O
21	contain	O
22	appreciable	O
23	septal	O
24	breakthrough	O
25	signals	O
26	originating	O
27	from	O
28	Compton	O
29	scatter	O
30	of	O
31	high	O
32	energy	O
33	photons	O
34	primarily	O
35	from	O
36	124I	O
37	.	O
1	With	O
2	aging	O
3	,	O
4	many	O
5	aspects	O
6	of	O
7	immune	O
8	function	O
9	change	O
10	.	O
1	Oral	O
2	candidiasis	O
1	This	O
2	suggests	O
3	that	O
4	alaproclate	O
5	acutely	O
6	increases	O
7	the	O
8	responsiveness	O
9	of	O
10	postsynaptic	O
11	muscarinic	B
12	and	I
13	alpha	I
14	1	I
15	adrenoceptors	I
16	.	O
1	The	O
2	concentrations	O
3	of	O
4	apo	B
5	A	I
6	-	I
7	I	I
8	and	O
9	apo	B
10	A	I
11	-	I
12	II	I
13	of	O
14	abstainers	O
15	decreased	O
16	significantly	O
17	compared	O
18	with	O
19	the	O
20	corresponding	O
21	changes	O
22	in	O
23	controls	O
24	.	O
1	The	O
2	distribution	O
3	of	O
4	patients	O
5	was	O
6	as	O
7	follows	O
8	:	O
9	group	O
10	1	O
11	--	O
12	complex	O
13	gamma	O
14	-	O
15	therapy	O
16	(	O
17	55	O
18	cases	O
19	),	O
20	group	O
21	2	O
22	--	O
23	complex	O
24	gamma	O
25	-	O
26	therapy	O
27	plus	O
28	iliac	O
29	lymphadenectomy	O
30	(	O
31	50	O
32	cases	O
33	)	O
34	and	O
35	group	O
36	3	O
37	--	O
38	complex	O
39	radiation	O
40	treatment	O
41	with	O
42	megavolt	O
43	bremsstrahlung	O
44	beam	O
45	from	O
46	the	O
47	luc	O
48	type	O
49	installation	O
50	and	O
51	iliac	O
52	lymphadenectomy	O
53	(	O
54	50	O
55	cases	O
56	).	O
1	In	O
2	a	O
3	blind	O
4	controlled	O
5	trial	O
6	,	O
7	15	O
8	patients	O
9	with	O
10	COCM	O
11	(	O
12	NYHA	O
13	II	O
14	-	O
15	III	O
16	)	O
17	with	O
18	sinus	O
19	rhythm	O
20	and	O
21	a	O
22	left	O
23	ventricular	O
24	ejection	O
25	fraction	O
26	(	O
27	LV	O
28	-	O
29	EF	O
30	)	O
31	of	O
32	34	O
33	.	O
34	5	O
35	+/-	O
36	2	O
37	.	O
38	6	O
39	%	O
40	received	O
41	consecutively	O
42	D	O
43	(	O
44	0	O
45	.	O
46	25	O
47	-	O
48	0	O
49	.	O
50	5	O
51	mg	O
52	/	O
53	d	O
54	),	O
55	placebo	O
56	(	O
57	PLAC	O
58	),	O
59	P	O
60	(	O
61	slow	O
62	releases	O
63	=	O
64	SR	O
65	)	O
66	(	O
67	80	O
68	mg	O
69	/	O
70	d	O
71	SR	O
72	)	O
73	and	O
74	both	O
75	drugs	O
76	combined	O
77	in	O
78	respective	O
79	doses	O
80	.	O
1	Three	O
2	chromosomal	B
3	crsA	I
4	mutations	I
5	,	O
6	crsA1	B
7	,	O
8	crsA4	B
9	,	O
10	and	O
11	crsA47	B
12	,	O
13	were	O
14	transferred	O
15	by	O
16	the	O
17	""""	O
18	gene	O
19	conversion	O
20	""""	O
21	process	O
22	to	O
23	B	O
24	.	O
25	subtilis	O
26	plasmid	O
27	pRPD11	O
28	,	O
29	which	O
30	consists	O
31	of	O
32	the	O
33	entire	O
34	wild	B
35	-	I
36	type	I
37	rpoD	I
38	coding	I
39	sequence	I
40	,	O
41	encoding	O
42	the	O
43	major	B
44	sigma	I
45	43	I
46	factor	I
47	of	I
48	B	I
49	.	I
50	subtilis	I
51	RNA	I
52	polymerase	I
53	,	O
54	and	O
55	pUB110	O
56	.	O
1	Selective	O
2	effect	O
3	of	O
4	pulmonary	O
5	oedema	O
6	on	O
7	prostaglandin	O
8	E2	O
9	pharmacokinetics	O
10	in	O
11	rat	O
12	lung	O
13	.	O
1	The	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	five	O
7	different	O
8	(	O
9	and	O
10	partially	O
11	overlapping	O
12	)	O
13	sry	B
14	messenger	I
15	RNAs	I
16	detectable	O
17	in	O
18	early	O
19	embryos	O
20	are	O
21	initiated	O
22	at	O
23	three	O
24	separate	O
25	sites	O
26	,	O
27	each	O
28	directly	O
29	upstream	O
30	from	O
31	one	O
32	of	O
33	the	O
34	three	O
35	protein	O
36	-	O
37	coding	O
38	regions	O
39	,	O
40	designated	O
41	(	O
42	in	O
43	5	O
44	'	O
45	to	O
46	3	O
47	'	O
48	order	O
49	)	O
50	beta	O
51	,	O
52	alpha	O
53	and	O
54	delta	O
55	.	O
1	Tissue	O
2	pressure	O
3	,	O
4	rCBF	O
5	,	O
6	and	O
7	water	O
8	content	O
9	were	O
10	measured	O
11	from	O
12	gray	O
13	matter	O
14	in	O
15	the	O
16	central	O
17	core	O
18	and	O
19	the	O
20	peripheral	O
21	margin	O
22	of	O
23	the	O
24	MCA	O
25	territory	O
26	over	O
27	6	O
28	h	O
29	after	O
30	MCAO	O
31	.	O
1	To	O
2	evaluate	O
3	the	O
4	effects	O
5	of	O
6	propranolol	O
7	on	O
8	myocardial	O
9	metabolism	O
10	after	O
11	coronary	O
12	reperfusion	O
13	,	O
14	serial	O
15	measurements	O
16	of	O
17	myocardial	B
18	creatine	I
19	kinase	I
20	(	O
21	CK	B
22	)	O
23	and	O
24	calcium	O
25	(	O
26	Ca	O
27	)	O
28	contents	O
29	and	O
30	CK	B
31	and	O
32	lactic	O
33	acid	O
34	(	O
35	LA	O
36	)	O
37	concentrations	O
38	in	O
39	coronary	O
40	sinus	O
41	blood	O
42	were	O
43	carried	O
44	out	O
45	in	O
46	33	O
47	open	O
48	-	O
49	chest	O
50	dogs	O
51	.	O
1	Electrical	O
2	activity	O
3	was	O
4	evaluated	O
5	by	O
6	monitoring	O
7	the	O
8	general	O
9	electrocorticogram	O
10	(	O
11	ECoG	O
12	)	O
13	as	O
14	well	O
15	as	O
16	local	O
17	DC	O
18	steady	O
19	potential	O
20	(	O
21	two	O
22	sites	O
23	).	O
1	A	O
2	flow	O
3	rate	O
4	of	O
5	at	O
6	least	O
7	5	O
8	mL	O
9	/	O
10	h	O
11	is	O
12	required	O
13	through	O
14	the	O
15	receptor	O
16	(	O
17	volume	O
18	,	O
19	0	O
20	.	O
21	4	O
22	mL	O
23	)	O
24	for	O
25	accurate	O
26	results	O
27	.	O
1	The	O
2	effect	O
3	of	O
4	the	O
5	opiate	O
6	antagonist	O
7	naloxone	O
8	was	O
9	evaluated	O
10	in	O
11	11	O
12	unselected	O
13	patients	O
14	with	O
15	cerebral	O
16	ischemia	O
17	.	O
1	The	O
2	generally	O
3	adopted	O
4	criteria	O
5	enabling	O
6	to	O
7	classify	O
8	the	O
9	examined	O
10	persons	O
11	into	O
12	the	O
13	following	O
14	3	O
15	groups	O
16	have	O
17	been	O
18	used	O
19	:	O
20	(	O
21	a	O
22	)	O
23	diseased	O
24	of	O
25	BEN	O
26	;	O
27	(	O
28	b	O
29	)	O
30	suspect	O
31	to	O
32	be	O
33	diseased	O
34	of	O
35	BEN	O
36	,	O
37	and	O
38	(	O
39	c	O
40	)	O
41	individuals	O
42	without	O
43	signs	O
44	of	O
45	a	O
46	renal	O
47	disease	O
48	.	O
1	In	O
2	group	O
3	I	O
4	adults	O
5	both	O
6	of	O
7	these	O
8	variables	O
9	increased	O
10	.	O
1	Either	O
2	a	O
3	UV	O
4	detector	O
5	set	O
6	at	O
7	268	O
8	nm	O
9	or	O
10	an	O
11	electrochemical	O
12	(	O
13	EC	O
14	)	O
15	detector	O
16	set	O
17	at	O
18	a	O
19	potential	O
20	of	O
21	+	O
22	0	O
23	.	O
24	9	O
25	V	O
26	(	O
27	versus	O
28	Ag	O
29	/	O
30	AgCl	O
31	/	O
32	3	O
33	M	O
34	NaCl	O
35	)	O
36	was	O
37	used	O
38	to	O
39	monitor	O
40	the	O
41	drug	O
42	.	O
1	Lower	O
2	extremity	O
3	weight	O
4	bearing	O
5	under	O
6	various	O
7	standing	O
8	conditions	O
9	in	O
10	independently	O
11	ambulatory	O
12	patients	O
13	with	O
14	hemiparesis	O
15	.	O
1	Shape	O
2	factor	O
3	correlated	O
4	well	O
5	with	O
6	hemodynamic	O
7	data	O
8	for	O
9	RV	O
10	/	O
11	LV	O
12	systolic	O
13	pressure	O
14	ratios	O
15	(	O
16	r	O
17	=	O
18	0	O
19	.	O
20	93	O
21	,	O
22	p	O
23	less	O
24	than	O
25	0	O
26	.	O
27	001	O
28	)	O
29	for	O
30	normalized	O
31	interventricular	O
32	pressure	O
33	differences	O
34	(	O
35	r	O
36	=	O
37	-	O
38	0	O
39	.	O
40	95	O
41	,	O
42	p	O
43	less	O
44	than	O
45	0	O
46	.	O
47	001	O
48	).	O
1	On	O
2	d	O
3	112	O
4	,	O
5	progesterone	O
6	was	O
7	higher	O
8	(	O
9	P	O
10	less	O
11	than	O
12	.	O
13	05	O
14	)	O
15	in	O
16	hysterectomized	O
17	heifers	O
18	than	O
19	in	O
20	other	O
21	treatment	O
22	groups	O
23	.	O
1	Rabbit	O
2	eyes	O
3	were	O
4	removed	O
5	and	O
6	held	O
7	in	O
8	temperature	O
9	-	O
10	regulated	O
11	chambers	O
12	and	O
13	irrigated	O
14	with	O
15	saline	O
16	.	O
1	The	O
2	Cox	O
3	proportional	O
4	hazards	O
5	model	O
6	was	O
7	applied	O
8	to	O
9	the	O
10	data	O
11	in	O
12	order	O
13	to	O
14	determine	O
15	the	O
16	prognostic	O
17	factors	O
18	for	O
19	long	O
20	-	O
21	term	O
22	survival	O
23	.	O
1	The	O
2	fast	O
3	real	O
4	-	O
5	time	O
6	digital	O
7	processing	O
8	of	O
9	the	O
10	N2	O
11	and	O
12	flow	O
13	signals	O
14	incorporated	O
15	filtering	O
16	,	O
17	delay	O
18	compensation	O
19	,	O
20	and	O
21	corrections	O
22	for	O
23	the	O
24	effects	O
25	of	O
26	changes	O
27	in	O
28	gas	O
29	composition	O
30	and	O
31	temperature	O
32	.	O
1	The	O
2	weak	O
3	relationships	O
4	between	O
5	F	O
6	and	O
7	Zn	O
8	to	O
9	Mg	O
10	clearly	O
11	have	O
12	no	O
13	significant	O
14	effect	O
15	on	O
16	the	O
17	contents	O
18	of	O
19	these	O
20	elements	O
21	in	O
22	bone	O
23	.	O
1	Diagnosis	O
2	:	O
3	progressive	O
4	multifocal	O
5	leukoencephalopathy	O
6	.	O
1	Component	O
2	P100	O
3	was	O
4	associated	O
5	with	O
6	a	O
7	frontal	O
8	negativity	O
9	of	O
10	similar	O
11	latency	O
12	favoring	O
13	the	O
14	hypothesis	O
15	of	O
16	a	O
17	dipolar	O
18	occipital	O
19	generator	O
20	.	O
1	Factors	O
2	influencing	O
3	semen	O
4	characteristics	O
5	in	O
6	young	O
7	boars	O
8	reared	O
9	in	O
10	a	O
11	subtropical	O
12	environment	O
13	were	O
14	studied	O
15	.	O
1	The	O
2	rates	O
3	of	O
4	total	O
5	energy	O
6	use	O
7	(	O
8	mean	O
9	+/-	O
10	SD	O
11	=	O
12	39	O
13	.	O
14	3	O
15	+/-	O
16	1	O
17	.	O
18	2	O
19	vs	O
20	35	O
21	.	O
22	7	O
23	+/-	O
24	1	O
25	.	O
26	3	O
27	kJ	O
28	X	O
29	min	O
30	-	O
31	1	O
32	;	O
33	P	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	)	O
40	were	O
41	significantly	O
42	higher	O
43	at	O
44	-	O
45	10	O
46	degrees	O
47	C	O
48	than	O
49	at	O
50	22	O
51	degrees	O
52	C	O
53	.	O
1	The	O
2	recommendation	O
3	is	O
4	made	O
5	that	O
6	specific	O
7	sub	O
8	-	O
9	groups	O
10	of	O
11	attempters	O
12	need	O
13	to	O
14	be	O
15	identified	O
16	and	O
17	may	O
18	warrant	O
19	specialized	O
20	intervention	O
21	strategies	O
22	.	O
1	The	O
2	transit	O
3	time	O
4	was	O
5	significantly	O
6	shortened	O
7	.	O
1	Activity	O
2	of	O
3	acid	B
4	hydrolases	I
5	of	O
6	peripheral	O
7	blood	O
8	leukocytes	O
9	in	O
10	focal	O
11	and	O
12	segmental	O
13	pneumonia	O
14	in	O
15	children	O
1	Relations	O
2	between	O
3	cellular	O
4	electrical	O
5	activity	O
6	and	O
7	cardiac	O
8	mechanical	O
9	activity	O
10	in	O
11	man	O
12	,	O
13	the	O
14	dog	O
15	and	O
16	the	O
17	rabbit	O
1	They	O
2	also	O
3	discuss	O
4	the	O
5	existing	O
6	nomenclature	O
7	.	O
1	Poliomyelitis	O
2	from	O
3	a	O
4	vaccine	O
5	.	O
1	Estral	O
2	cycle	O
3	in	O
4	white	O
5	rats	O
6	in	O
7	the	O
8	low	O
9	and	O
10	high	O
11	mountains	O
12	of	O
13	Kirghizia	O
1	Age	O
2	and	O
3	sex	O
4	structure	O
5	of	O
6	the	O
7	natural	O
8	population	O
9	of	O
10	Ornithodoros	O
11	tatarovski	O
12	Ol	O
13	.	O
1	The	O
2	incidence	O
3	of	O
4	tumours	O
5	in	O
6	young	O
7	chickens	O
8	.	O
1	Effect	O
2	of	O
3	variations	O
4	in	O
5	time	O
6	interval	O
7	between	O
8	treatment	O
9	with	O
10	BCG	O
11	and	O
12	quartz	O
13	dust	O
14	on	O
15	translocation	O
16	of	O
17	quartz	O
18	dust	O
19	from	O
20	the	O
21	lungs	O
22	to	O
23	their	O
24	regional	O
25	lymph	O
26	nodes	O
27	.	O
1	Enzyme	O
2	histochemical	O
3	findings	O
4	in	O
5	the	O
6	ultimobranchial	O
7	body	O
8	of	O
9	the	O
10	horse	O
1	Studies	O
2	on	O
3	swine	O
4	enteroviruses	O
5	.	O
1	Genesis	O
2	of	O
3	foam	O
4	cells	O
5	:	O
6	study	O
7	in	O
8	rats	O
9	after	O
10	administration	O
11	of	O
12	Cloforex	O
13	.	O
1	Pre	B
2	-	I
3	beta	I
4	-	I
5	1	I
6	lipoprotein	I
7	and	O
8	early	O
9	detection	O
10	of	O
11	risk	O
12	factors	O
13	for	O
14	coronary	O
15	heart	O
16	disease	O
17	.	O
1	An	O
2	automated	O
3	method	O
4	for	O
5	the	O
6	quantitative	O
7	analysis	O
8	of	O
9	the	O
10	polyamines	O
11	putrescine	O
12	,	O
13	spermidine	O
14	and	O
15	spermine	O
16	in	O
17	cerebrospinal	O
18	fluid	O
19	(	O
20	CSF	O
21	)	O
22	was	O
23	used	O
24	to	O
25	analyze	O
26	CSF	O
27	samples	O
28	from	O
29	37	O
30	patients	O
31	with	O
32	central	O
33	nervous	O
34	system	O
35	(	O
36	CNS	O
37	)	O
38	tumors	O
39	and	O
40	from	O
41	13	O
42	patients	O
43	without	O
44	tumors	O
45	.	O
1	Composites	O
2	as	O
3	restoration	O
4	materials	O
1	Method	O
2	of	O
3	synthesis	O
4	of	O
5	the	O
6	rheumatoid	B
7	factor	I
8	in	O
9	clinico	O
10	-	O
11	immunological	O
12	studies	O
1	Variations	O
2	of	O
3	the	O
4	timing	O
5	of	O
6	deflections	O
7	in	O
8	the	O
9	His	O
10	bundle	O
11	recordings	O
12	.	O
1	Further	O
2	investigation	O
3	on	O
4	the	O
5	chemotactic	O
6	influence	O
7	of	O
8	thymic	B
9	hormone	I
10	on	O
11	lymphocytes	O
1	Temporal	O
2	relationships	O
3	and	O
4	the	O
5	development	O
6	phase	O
7	affected	O
8	.	O
1	Mechanism	O
2	of	O
3	immunogenesis	O
4	in	O
5	vaccination	O
6	with	O
7	streptomycin	O
8	-	O
9	dependent	O
10	mutants	O
11	of	O
12	salmonellae	O
13	and	O
14	shigellae	O
15	.	O
1	Effect	O
2	of	O
3	triftazin	O
4	and	O
5	aminazin	O
6	on	O
7	hippocampal	O
8	bioelectric	O
9	activity	O
1	General	O
2	formulae	O
3	for	O
4	estimating	O
5	heritability	O
6	in	O
7	a	O
8	population	O
9	with	O
10	related	O
11	parents	O
12	.	O
1	Antibiotic	O
2	effect	O
3	of	O
4	the	O
5	mud	O
6	from	O
7	heviz	O
1	Role	O
2	of	O
3	histoclinical	O
4	studies	O
5	in	O
6	the	O
7	prophylaxis	O
8	of	O
9	spontaneous	O
10	abortions	O
1	Chemical	O
2	constituents	O
3	of	O
4	the	O
5	gentianaceae	O
6	V	O
7	:	O
8	tetraoxygenated	O
9	xanthones	O
10	of	O
11	Swertia	O
12	chirata	O
13	Buch	O
14	.-	O
15	Ham	O
16	.	O
1	Disability	O
2	insurance	O
3	under	O
4	social	O
5	security	O
6	.	O
1	Manifest	O
2	anxiety	O
3	of	O
4	Vietnam	O
5	returnees	O
6	and	O
7	undergraduates	O
8	.	O
1	Familial	O
2	juvenile	O
3	nephronophthisis	O
1	9	O
2	,	O
3	11	O
4	-	O
5	Seco	O
6	steroids	O
7	derived	O
8	from	O
9	estradiol	O
10	3	O
11	-	O
12	methyl	O
13	ether	O
14	.	O
1	Psychological	O
2	examinations	O
3	in	O
4	patients	O
5	with	O
6	chronic	O
7	kidney	O
8	insufficiency	O
1	Possibilities	O
2	of	O
3	needleless	O
4	administration	O
5	of	O
6	various	O
7	substances	O
8	to	O
9	animals	O
1	Observations	O
2	on	O
3	the	O
4	flight	O
5	activities	O
6	of	O
7	Chrysops	O
8	caecutiens	O
9	L	O
10	.	O
1	Analysis	O
2	of	O
3	clearance	O
4	curve	O
5	of	O
6	rose	O
7	bengal	O
8	-	O
9	I	O
10	-	O
11	131	O
1	Canine	O
2	reproduction	O
3	:	O
4	effects	O
5	of	O
6	a	O
7	single	O
8	injection	O
9	of	O
10	medroxyprogesterone	O
11	acetate	O
12	on	O
13	the	O
14	reproductive	O
15	organs	O
16	of	O
17	the	O
18	bitch	O
19	.	O
1	3	O
2	.	O
1	VII	O
2	.	O
1	Lack	O
2	of	O
3	effect	O
4	of	O
5	the	O
6	appetite	O
7	stimulant	O
8	pizotifen	O
9	(	O
10	BC	O
11	105	O
12	)	O
13	on	O
14	the	O
15	absorption	O
16	of	O
17	isonicotinylhydrazine	O
18	.	O
1	Human	O
2	synovial	O
3	fluid	O
4	:	O
5	detection	O
6	of	O
7	a	O
8	new	O
9	component	O
10	.	O
1	Immunochemical	O
2	studies	O
3	with	O
4	filarial	O
5	antigens	O
6	.	O
1	Plasma	B
2	histaminase	I
3	in	O
4	patients	O
5	of	O
6	bronchial	O
7	asthma	O
8	and	O
9	the	O
10	effect	O
11	of	O
12	prednisolone	O
13	administration	O
14	on	O
15	it	O
16	.	O
1	Immunogenicity	O
2	of	O
3	various	O
4	mycobacteria	O
5	and	O
6	the	O
7	corresponding	O
8	levels	O
9	of	O
10	cross	O
11	-	O
12	protection	O
13	developed	O
14	between	O
15	species	O
16	.	O
1	Clinicopathologic	O
2	studies	O
3	in	O
4	feminizing	O
5	tumors	O
6	of	O
7	the	O
8	ovary	O
9	.	O
1	Derivatives	O
2	of	O
3	boswellic	O
4	acids	O
5	.	O
1	Separation	O
2	of	O
3	ninhydrin	O
4	-	O
5	positive	O
6	compounds	O
7	in	O
8	urine	O
9	by	O
10	the	O
11	combined	O
12	methods	O
13	of	O
14	medium	O
15	-	O
16	tension	O
17	intophoresis	O
18	and	O
19	partition	O
20	chromatography	O
1	Spasmus	O
2	nutans	O
3	:	O
4	a	O
5	syndrome	O
6	of	O
7	auto	O
8	-	O
9	arousal	O
10	.	O
1	Treatment	O
2	of	O
3	ovarian	O
4	neoplasms	O
1	The	O
2	value	O
3	of	O
4	different	O
5	sources	O
6	of	O
7	nitrogen	O
8	in	O
9	diets	O
10	for	O
11	the	O
12	early	O
13	-	O
14	weaned	O
15	calf	O
16	.	O
1	The	O
2	problem	O
3	of	O
4	disablement	O
5	due	O
6	to	O
7	pulmonary	O
8	tuberculosis	O
9	,	O
10	on	O
11	the	O
12	basis	O
13	of	O
14	an	O
15	analysis	O
16	of	O
17	the	O
18	history	O
19	of	O
20	395	O
21	cases	O
22	as	O
23	observed	O
24	in	O
25	Gdansk	O
26	in	O
27	the	O
28	years	O
29	1946	O
30	-	O
31	1965	O
1	Osteosarcoma	O
2	caused	O
3	by	O
4	3	O
5	,	O
6	4	O
7	-	O
8	benzopyrene	O
1	Relapse	O
2	of	O
3	leukemia	O
4	after	O
5	prolonged	O
6	remission	O
7	.	O
1	The	O
2	non	O
3	-	O
4	role	O
5	of	O
6	fluoride	O
7	in	O
8	the	O
9	control	O
10	of	O
11	plasma	O
12	calcium	O
13	in	O
14	the	O
15	parathyroidectomized	O
16	rat	O
17	.	O
1	BIM	O
2	130	O
3	.	O
1	Homograft	O
2	response	O
3	and	O
4	hemagglutinin	B
5	production	O
6	by	O
7	sensitized	O
8	thymectomized	O
9	irradiated	O
10	adult	O
11	mice	O
12	.	O
1	Histopathology	O
2	and	O
3	pathogenesis	O
4	of	O
5	exanthematous	O
6	viroses	O
1	Genitography	O
2	in	O
3	intersexual	O
4	states	O
5	.	O
1	3	O
2	'-	O
3	Methyl	O
4	,	O
5	8	O
6	-	O
7	methyl	O
8	,	O
9	and	O
10	8	O
11	-	O
12	phenyl	O
13	derivatives	O
14	of	O
15	5	O
16	,	O
17	9	O
18	-	O
19	dimethyl	O
20	-	O
21	6	O
22	,	O
23	7	O
24	-	O
25	benzomorphans	O
26	.	O
1	The	O
2	distribution	O
3	of	O
4	body	O
5	fluids	O
6	following	O
7	hemorrhage	O
8	and	O
9	resuscitation	O
10	in	O
11	combat	O
12	casualties	O
13	.	O
1	Diminished	O
2	forearm	O
3	arteriolar	O
4	dilator	O
5	capacity	O
6	produced	O
7	by	O
8	mineralocorticoid	O
9	-	O
10	induced	O
11	salt	O
12	retention	O
13	in	O
14	man	O
15	.	O
1	A	O
2	new	O
3	hemagglutination	O
4	test	O
5	for	O
6	the	O
7	on	O
8	-	O
9	slide	O
10	assay	O
11	of	O
12	rheumatoid	B
13	factor	I
1	Leukemia	O
2	in	O
3	twins	O
4	:	O
5	world	O
6	-	O
7	wide	O
8	review	O
9	of	O
10	clinical	O
11	cases	O
12	.	O
1	Preliminary	O
2	report	O
3	.	O
1	Total	O
2	body	O
3	water	O
4	,	O
5	rhodanide	O
6	space	O
7	and	O
8	I	B
9	-	I
10	131	I
11	-	I
12	albumin	I
13	space	O
14	under	O
15	the	O
16	acute	O
17	effect	O
18	of	O
19	furosemide	O
1	Propagation	O
2	and	O
3	hormone	O
4	production	O
5	by	O
6	human	O
7	normal	O
8	and	O
9	malignant	O
10	trophoblast	O
11	in	O
12	rats	O
13	.	O
1	Sensitivities	O
2	of	O
3	thromboplastins	B
4	to	O
5	factor	B
6	VII	I
7	deficiency	O
8	.	O
1	Central	O
2	venous	O
3	catheter	O
4	used	O
5	for	O
6	recording	O
7	intracardiac	O
8	electrocardiogram	O
9	.	O
1	Students	O
2	,	O
3	parents	O
4	,	O
5	teachers	O
6	and	O
7	hearing	O
8	disorders	O
1	Evaluation	O
2	of	O
3	automatic	O
4	blood	O
5	cell	O
6	counters	O
7	.	O
1	Determination	O
2	of	O
3	transaminases	O
4	with	O
5	an	O
6	autoanalyzer	O
1	Histological	O
2	observations	O
3	on	O
4	the	O
5	decidua	O
6	in	O
7	the	O
8	second	O
9	half	O
10	of	O
11	pregnancy	O
1	Studies	O
2	carried	O
3	out	O
4	with	O
5	the	O
6	Glossina	O
7	morsitans	O
8	colony	O
9	of	O
10	Lisbon	O
11	.	O
1	Transformations	O
2	in	O
3	the	O
4	morphine	O
5	series	O
6	.	O
1	Dissociative	O
2	anesthetics	O
3	2	O
4	-(	O
5	o	O
6	-	O
7	chlorophenyl	O
8	)-	O
9	2	O
10	-	O
11	methyl	O
12	-	O
13	amino	O
14	cyclohexane	O
15	HCL	O
16	(	O
17	CI	O
18	-	O
19	581	O
20	)	O
1	Measurement	O
2	of	O
3	gastric	O
4	acid	O
5	secretion	O
6	by	O
7	conductivity	O
8	.	O
1	Effect	O
2	of	O
3	castration	O
4	on	O
5	pituitary	B
6	and	I
7	serum	I
8	LH	I
9	and	O
10	FSH	B
11	in	O
12	testosterone	O
13	-	O
14	sterilized	O
15	rats	O
16	.	O
1	Polyvinyl	O
2	alcohol	O
3	as	O
4	a	O
5	solution	O
6	mediator	O
1	Mining	O
2	the	O
3	diagnostic	O
4	iron	O
5	ore	O
6	.	O
1	Hydroxypropyl	O
2	methacrylate	O
3	,	O
4	a	O
5	new	O
6	water	O
7	-	O
8	miscible	O
9	embedding	O
10	medium	O
11	for	O
12	electron	O
13	microscopy	O
14	.	O
1	Statistics	O
2	of	O
3	the	O
4	past	O
5	5	O
6	years	O
1	Naphthalene	O
2	and	O
3	paradichlorobenzene	O
4	in	O
5	clinical	O
6	toxicology	O
1	Interactions	O
2	between	O
3	adrenergics	O
4	,	O
5	adrenolytics	O
6	and	O
7	monoamine	B
8	oxidase	I
9	inhibitors	O
1	I	O
2	.	O
1	Persistence	O
2	of	O
3	toxaphene	O
4	in	O
5	treated	O
6	lakes	O
7	.	O
1	Derivatives	O
2	of	O
3	fluorene	O
4	.	O
1	(	O
2	3	O
3	).	O
1	XXI	O
2	.	O
1	Iron	O
2	and	O
3	folate	O
4	deficiency	O
5	in	O
6	pregnancy	O
1	Upstream	O
2	activation	O
3	sites	O
4	of	O
5	the	O
6	CYC1	B
7	gene	I
8	of	O
9	Saccharomyces	O
10	cerevisiae	O
11	are	O
12	active	O
13	when	O
14	inverted	O
15	but	O
16	not	O
17	when	O
18	placed	O
19	downstream	O
20	of	O
21	the	O
22	""""	O
23	TATA	O
24	box	O
25	"""."	O
1	Neither	O
2	side	O
3	effect	O
4	nor	O
5	abnormal	O
6	laboratory	O
7	findings	O
8	due	O
9	to	O
10	this	O
11	drug	O
12	were	O
13	observed	O
14	.	O
1	Separation	O
2	of	O
3	malaria	O
4	-	O
5	infected	O
6	erythrocytes	O
7	from	O
8	whole	O
9	blood	O
10	:	O
11	use	O
12	of	O
13	a	O
14	selective	O
15	high	O
16	-	O
17	gradient	O
18	magnetic	O
19	separation	O
20	technique	O
21	.	O
1	At	O
2	both	O
3	water	O
4	temperatures	O
5	,	O
6	VO2	O
7	increased	O
8	linearly	O
9	with	O
10	increasing	O
11	swimming	O
12	velocity	O
13	.	O
1	Propranolol	O
2	also	O
3	effectively	O
4	controlled	O
5	her	O
6	familial	O
7	tremor	O
8	.	O
1	Two	O
2	patients	O
3	withdrew	O
4	from	O
5	therapy	O
6	,	O
7	one	O
8	for	O
9	personal	O
10	reasons	O
11	and	O
12	one	O
13	because	O
14	a	O
15	paraspinal	O
16	mass	O
17	developed	O
18	.	O
1	In	O
2	several	O
3	cases	O
4	of	O
5	definite	O
6	SjS	O
7	,	O
8	labial	O
9	salivary	O
10	gland	O
11	examinations	O
12	after	O
13	more	O
14	than	O
15	a	O
16	one	O
17	year	O
18	interval	O
19	were	O
20	performed	O
21	on	O
22	two	O
23	occasions	O
24	,	O
25	and	O
26	the	O
27	clinical	O
28	and	O
29	histopathological	O
30	changes	O
31	were	O
32	investigated	O
33	.	O
1	When	O
2	used	O
3	subcutaneously	O
4	or	O
5	intravenously	O
6	in	O
7	maximum	O
8	tolerated	O
9	doses	O
10	the	O
11	antibiotic	O
12	inhibited	O
13	the	O
14	development	O
15	of	O
16	lymphadenosis	O
17	NK	O
18	/	O
19	Li	O
20	by	O
21	90	O
22	and	O
23	70	O
24	per	O
25	cent	O
26	respectively	O
27	.	O
1	The	O
2	effect	O
3	of	O
4	echothiophate	O
5	on	O
6	the	O
7	biphasic	O
8	response	O
9	of	O
10	rabbit	O
11	ocular	O
12	pressure	O
13	to	O
14	dipivefrin	O
15	.	O
1	We	O
2	have	O
3	followed	O
4	37	O
5	phenytoin	O
6	-	O
7	treated	O
8	patients	O
9	with	O
10	reduced	O
11	serum	B
12	IgA	I
13	concentrations	O
14	for	O
15	2	O
16	-	O
17	7	O
18	years	O
19	.	O
1	Use	O
2	of	O
3	the	O
4	immunofluorescence	O
5	method	O
6	for	O
7	identification	O
8	of	O
9	enteroviruses	O
10	in	O
11	cell	O
12	cultures	O
1	No	O
2	direct	O
3	repeats	O
4	flank	O
5	the	O
6	pseudogene	O
7	in	O
8	the	O
9	U2	B
10	/	I
11	4	I
12	locus	I
13	.	O
1	The	O
2	direct	O
3	effects	O
4	of	O
5	transmitter	O
6	release	O
7	were	O
8	(	O
9	a	O
10	)	O
11	an	O
12	early	O
13	fall	O
14	in	O
15	MAP	O
16	followed	O
17	by	O
18	a	O
19	late	O
20	pressor	O
21	effect	O
22	;	O
23	and	O
24	(	O
25	b	O
26	)	O
27	an	O
28	early	O
29	bradycardia	O
30	followed	O
31	by	O
32	a	O
33	late	O
34	tachycardia	O
35	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	overall	O
6	chance	O
7	that	O
8	a	O
9	patient	O
10	would	O
11	undergo	O
12	ET	O
13	was	O
14	greater	O
15	in	O
16	a	O
17	cycle	O
18	in	O
19	which	O
20	more	O
21	than	O
22	one	O
23	follicle	O
24	20	O
25	mm	O
26	or	O
27	larger	O
28	was	O
29	developing	O
30	than	O
31	in	O
32	a	O
33	cycle	O
34	in	O
35	which	O
36	a	O
37	single	O
38	large	O
39	follicle	O
40	was	O
41	developing	O
42	.	O
1	Weight	O
2	loss	O
3	reduces	O
4	arterial	O
5	pressure	O
6	by	O
7	a	O
8	decrease	O
9	in	O
10	intravascular	O
11	volume	O
12	and	O
13	cardiac	O
14	output	O
15	associated	O
16	with	O
17	a	O
18	fall	O
19	in	O
20	sympathetic	O
21	activity	O
22	.	O
1	Cultivation	O
2	technics	O
3	for	O
4	Codonopsis	O
5	pilosula	O
1	Catecholamines	O
2	and	O
3	aversive	O
4	learning	O
5	:	O
6	a	O
7	review	O
8	.	O
1	Five	O
2	experiments	O
3	examined	O
4	the	O
5	influence	O
6	of	O
7	opiate	O
8	antagonists	O
9	on	O
10	both	O
11	the	O
12	short	O
13	-	O
14	term	O
15	analgesic	O
16	reaction	O
17	resulting	O
18	30	O
19	min	O
20	after	O
21	exposure	O
22	to	O
23	inescapable	O
24	shock	O
25	and	O
26	the	O
27	long	O
28	-	O
29	term	O
30	analgesic	O
31	reaction	O
32	resulting	O
33	after	O
34	reexposure	O
35	to	O
36	shock	O
37	24	O
38	hr	O
39	after	O
40	inescapable	O
41	shock	O
42	exposure	O
43	.	O
1	Both	O
2	neural	O
3	and	O
4	hormonal	O
5	pathways	O
6	and	O
7	both	O
8	opiate	O
9	and	O
10	nonopiate	O
11	substances	O
12	play	O
13	roles	O
14	in	O
15	the	O
16	complex	O
17	modulation	O
18	of	O
19	pain	O
20	transmission	O
21	.	O
1	Survey	O
2	on	O
3	antibody	O
4	against	O
5	egg	O
6	drop	O
7	syndrome	O
8	-	O
9	1976	O
10	virus	O
11	among	O
12	chicken	O
13	flocks	O
14	in	O
15	Japan	O
16	.	O
1	Two	O
2	mutations	O
3	that	O
4	affect	O
5	larval	B
6	cuticle	I
7	protein	I
8	gene	I
9	expression	O
10	in	O
11	the	O
12	2	O
13	/	O
14	3	O
15	variant	O
16	Drosophila	O
17	melanogaster	O
18	strain	O
19	were	O
20	investigated	O
21	.	O
1	Hybridization	O
2	of	O
3	plasmid	O
4	-	O
5	transformed	O
6	Escherichia	O
7	coli	O
8	RR1	O
9	colonies	O
10	with	O
11	32P	O
12	-	O
13	labeled	O
14	viral	O
15	genome	O
16	RNAs	O
17	demonstrated	O
18	the	O
19	presence	O
20	of	O
21	DNA	O
22	clones	O
23	representative	O
24	of	O
25	each	O
26	of	O
27	the	O
28	10	O
29	reovirus	O
30	RNAs	O
31	and	O
32	10	O
33	of	O
34	the	O
35	11	O
36	constituent	O
37	segments	O
38	of	O
39	the	O
40	rotavirus	O
41	genome	O
42	.	O
1	Naloxone	O
2	(	O
3	2	O
4	mg	O
5	/	O
6	kg	O
7	bolus	O
8	+	O
9	2	O
10	mg	O
11	X	O
12	kg	O
13	-	O
14	1	O
15	X	O
16	h	O
17	-	O
18	1	O
19	)	O
20	was	O
21	given	O
22	with	O
23	one	O
24	of	O
25	the	O
26	two	O
27	doses	O
28	of	O
29	the	O
30	lipopolysaccharide	O
31	.	O
1	Viral	O
2	RNA	O
3	,	O
4	molecularly	O
5	cloned	O
6	proviral	O
7	DNA	O
8	,	O
9	and	O
10	virus	O
11	-	O
12	specific	O
13	protein	O
14	of	O
15	avian	O
16	retrovirus	O
17	MH2	O
18	were	O
19	analyzed	O
20	.	O
1	Plasmids	O
2	for	O
3	the	O
4	cloning	O
5	and	O
6	expression	O
7	of	O
8	full	O
9	-	O
10	length	O
11	double	O
12	-	O
13	stranded	O
14	cDNAs	O
15	under	O
16	control	O
17	of	O
18	the	O
19	SV40	B
20	early	I
21	or	O
22	late	B
23	gene	I
24	promoter	O
25	.	O
1	The	O
2	dnaQ	B
3	-	O
4	lacZ	B
5	and	O
6	the	O
7	rnh	B
8	-	O
9	lacZ	B
10	fused	O
11	genes	O
12	were	O
13	constructed	O
14	and	O
15	hybrid	O
16	proteins	O
17	with	O
18	beta	B
19	-	I
20	galactosidase	I
21	activity	O
22	were	O
23	produced	O
24	.	O
1	The	O
2	splice	O
3	acceptor	O
4	site	O
5	is	O
6	ca	O
7	.	O
1	The	O
2	gene	B
3	cat	I
4	-	I
5	86	I
6	,	O
7	specifying	O
8	chloramphenicol	B
9	-	I
10	inducible	I
11	chloramphenicol	I
12	acetyltransferase	I
13	,	O
14	is	O
15	located	O
16	on	O
17	the	O
18	1	O
19	.	O
20	1	O
21	-	O
22	kilobase	O
23	cloned	O
24	DNA	O
25	.	O
1	Here	O
2	we	O
3	have	O
4	determined	O
5	the	O
6	nucleotide	O
7	sequence	O
8	of	O
9	3	O
10	.	O
11	5	O
12	kb	O
13	from	O
14	the	O
15	3	O
16	'	O
17	end	O
18	of	O
19	delta	B
20	gag	I
21	to	O
22	the	O
23	3	O
24	'	O
25	end	O
26	of	O
27	molecularly	O
28	cloned	O
29	proviral	O
30	MH2	O
31	DNA	O
32	,	O
33	in	O
34	order	O
35	to	O
36	elucidate	O
37	the	O
38	genetic	O
39	structure	O
40	of	O
41	the	O
42	virus	O
43	and	O
44	to	O
45	compare	O
46	it	O
47	with	O
48	other	O
49	mht	B
50	-	O
51	and	O
52	myc	B
53	-	O
54	containing	O
55	oncogenic	O
56	viruses	O
57	as	O
58	well	O
59	as	O
60	with	O
61	the	O
62	chicken	B
63	proto	I
64	-	I
65	myc	I
66	gene	I
67	.	O
1	The	O
2	clinical	O
3	efficacy	O
4	rates	O
5	evaluated	O
6	in	O
7	151	O
8	cases	O
9	(	O
10	KS	O
11	-	O
12	R1	O
13	group	O
14	in	O
15	77	O
16	cases	O
17	,	O
18	oral	O
19	group	O
20	in	O
21	74	O
22	cases	O
23	)	O
24	on	O
25	standard	O
26	criteria	O
27	of	O
28	committee	O
29	members	O
30	were	O
31	88	O
32	.	O
33	3	O
34	%	O
35	for	O
36	the	O
37	KS	O
38	-	O
39	R1	O
40	group	O
41	and	O
42	86	O
43	.	O
44	5	O
45	%	O
46	for	O
47	the	O
48	oral	O
49	group	O
50	,	O
51	respectively	O
52	.	O
1	Effects	O
2	of	O
3	negative	O
4	pleural	O
5	pressure	O
6	on	O
7	left	O
8	ventricular	O
9	hemodynamics	O
10	.	O
1	EGV	O
2	had	O
3	no	O
4	detectable	O
5	effect	O
6	on	O
7	PP	B
8	secretion	O
9	under	O
10	basal	O
11	or	O
12	stimulated	O
13	conditions	O
14	.	O
1	Lung	O
2	prostacyclin	O
3	production	O
4	may	O
5	be	O
6	related	O
7	to	O
8	flow	O
9	.	O
1	Management	O
2	of	O
3	hypertension	O
4	in	O
5	the	O
6	elderly	O
7	.	O
1	Climatic	O
2	treatment	O
3	of	O
4	children	O
5	with	O
6	respiratory	O
7	allergy	O
1	Ten	O
2	patients	O
3	with	O
4	advanced	O
5	,	O
6	diffuse	O
7	Hodgkin	O
8	'	O
9	s	O
10	and	O
11	non	O
12	-	O
13	Hodgkin	O
14	'	O
15	s	O
16	lymphomas	O
17	responding	O
18	poorly	O
19	to	O
20	the	O
21	most	O
22	widely	O
23	employed	O
24	primary	O
25	chemotherapy	O
26	regimens	O
27	were	O
28	treated	O
29	with	O
30	a	O
31	high	O
32	-	O
33	dose	O
34	chemotherapy	O
35	(	O
36	HDC	O
37	)	O
38	followed	O
39	by	O
40	rescue	O
41	with	O
42	non	O
43	-	O
44	frozen	O
45	autologous	O
46	bone	O
47	marrow	O
48	infusion	O
49	(	O
50	ABMT	O
51	).	O
1	Effect	O
2	of	O
3	proteolytic	O
4	enzymes	O
5	and	O
6	polypeptides	O
7	on	O
8	the	O
9	antacid	O
10	activity	O
11	of	O
12	almagate	O
13	and	O
14	other	O
15	antacids	O
16	.	O
1	Urease	B
2	activity	O
3	of	O
4	97	O
5	%	O
6	of	O
7	these	O
8	organisms	O
9	became	O
10	evident	O
11	within	O
12	30	O
13	min	O
14	.	O
1	In	O
2	the	O
3	37	O
4	patients	O
5	without	O
6	lung	O
7	disease	O
8	respiratory	O
9	muscle	O
10	weakness	O
11	was	O
12	accompanied	O
13	by	O
14	significant	O
15	decreases	O
16	in	O
17	vital	O
18	capacity	O
19	,	O
20	total	O
21	lung	O
22	capacity	O
23	,	O
24	and	O
25	maximum	O
26	voluntary	O
27	ventilation	O
28	;	O
29	by	O
30	significant	O
31	increases	O
32	in	O
33	residual	O
34	volume	O
35	and	O
36	arterial	O
37	carbon	O
38	dioxide	O
39	tension	O
40	(	O
41	PaCO2	O
42	);	O
43	and	O
44	greater	O
45	likelihood	O
46	of	O
47	dependence	O
48	on	O
49	ventilators	O
50	,	O
51	atelectasis	O
52	,	O
53	and	O
54	pneumonia	O
55	.	O
1	Total	O
2	cumulative	O
3	doses	O
4	of	O
5	doxorubicin	O
6	ranged	O
7	from	O
8	145	O
9	to	O
10	625	O
11	mg	O
12	./	O
13	m	O
14	.	O
15	2	O
16	.	O
1	Following	O
2	20	O
3	min	O
4	of	O
5	steady	O
6	state	O
7	anaesthesia	O
8	during	O
9	which	O
10	measurements	O
11	of	O
12	IOP	O
13	,	O
14	arterial	O
15	pressure	O
16	,	O
17	heart	O
18	rate	O
19	,	O
20	FIO2	O
21	,	O
22	FE	O
23	'	O
24	CO2	O
25	and	O
26	CVP	O
27	were	O
28	recorded	O
29	,	O
30	one	O
31	group	O
32	of	O
33	patients	O
34	received	O
35	atracurium	O
36	0	O
37	.	O
38	45	O
39	mg	O
40	kg	O
41	-	O
42	1	O
43	and	O
44	the	O
45	other	O
46	pancuronium	O
47	0	O
48	.	O
49	1	O
50	mg	O
51	kg	O
52	-	O
53	1	O
54	.	O
1	These	O
2	children	O
3	were	O
4	grouped	O
5	into	O
6	four	O
7	diagnostic	O
8	categories	O
9	:	O
10	1	O
11	)	O
12	idiopathic	O
13	GH	B
14	deficiency	O
15	(	O
16	n	O
17	=	O
18	10	O
19	);	O
20	2	O
21	)	O
22	organic	O
23	hypopituitarism	O
24	(	O
25	n	O
26	=	O
27	7	O
28	);	O
29	3	O
30	)	O
31	intrauterine	O
32	growth	O
33	retardation	O
34	(	O
35	n	O
36	=	O
37	5	O
38	);	O
39	and	O
40	4	O
41	)	O
42	constitutional	O
43	delay	O
44	of	O
45	growth	O
46	and	O
47	/	O
48	or	O
49	familial	O
50	short	O
51	stature	O
52	(	O
53	n	O
54	=	O
55	18	O
56	),	O
57	by	O
58	standard	O
59	clinical	O
60	criteria	O
61	and	O
62	physiological	O
63	and	O
64	pharmacological	O
65	tests	O
66	of	O
67	GH	B
68	reserve	O
69	.	O
1	Cimetidine	O
2	800	O
3	mg	O
4	given	O
5	at	O
6	night	O
7	is	O
8	as	O
9	effective	O
10	as	O
11	400	O
12	mg	O
13	twice	O
14	daily	O
15	;	O
16	the	O
17	single	O
18	dose	O
19	regimen	O
20	may	O
21	improve	O
22	patient	O
23	compliance	O
24	,	O
25	thus	O
26	facilitating	O
27	treatment	O
28	.	O
1	The	O
2	management	O
3	of	O
4	the	O
5	""""	O
6	chronic	O
7	""""	O
8	patient	O
9	.	O
1	Cardiovascular	O
2	and	O
3	adrenal	O
4	medullo	O
5	-	O
6	sympathetic	O
7	reactions	O
8	to	O
9	acute	O
10	tobacco	O
11	poisoning	O
1	A	O
2	pharmacokinetic	O
3	study	O
4	of	O
5	apalcillin	O
6	was	O
7	performed	O
8	in	O
9	12	O
10	patients	O
11	in	O
12	an	O
13	intensive	O
14	-	O
15	care	O
16	unit	O
17	.	O
1	Catch	O
2	-	O
3	up	O
4	growth	O
5	was	O
6	observed	O
7	only	O
8	for	O
9	a	O
10	12	O
11	-	O
12	month	O
13	period	O
14	in	O
15	4	O
16	children	O
17	with	O
18	a	O
19	bone	O
20	age	O
21	of	O
22	7	O
23	to	O
24	8	O
25	years	O
26	.	O
1	Other	O
2	than	O
3	d	O
4	7	O
5	,	O
6	there	O
7	was	O
8	no	O
9	significant	O
10	effect	O
11	on	O
12	the	O
13	number	O
14	of	O
15	implants	O
16	.	O
1	According	O
2	to	O
3	the	O
4	biochemical	O
5	tests	O
6	,	O
7	high	O
8	activity	O
9	(	O
10	over	O
11	200	O
12	U	O
13	/	O
14	l	O
15	)	O
16	of	O
17	alkaline	B
18	phosphatase	I
19	was	O
20	recorded	O
21	exclusively	O
22	in	O
23	patients	O
24	with	O
25	the	O
26	lymphogranulomatosis	O
27	-	O
28	induced	O
29	liver	O
30	damage	O
31	.	O
1	Changes	O
2	of	O
3	plasma	O
4	cortisol	O
5	level	O
6	in	O
7	late	O
8	asthmatic	O
9	responses	O
1	This	O
2	machine	O
3	drift	O
4	,	O
5	which	O
6	was	O
7	not	O
8	associated	O
9	with	O
10	a	O
11	rise	O
12	in	O
13	water	O
14	phantom	O
15	temperature	O
16	and	O
17	did	O
18	not	O
19	consistently	O
20	correlate	O
21	with	O
22	estimated	O
23	x	O
24	-	O
25	ray	O
26	tube	O
27	heat	O
28	,	O
29	could	O
30	result	O
31	in	O
32	a	O
33	significant	O
34	overestimation	O
35	of	O
36	regional	O
37	cerebral	O
38	blood	O
39	flow	O
40	(	O
41	rCBF	O
42	)	O
43	for	O
44	a	O
45	xenon	O
46	/	O
47	CT	O
48	rCBF	O
49	protocol	O
50	involving	O
51	5	O
52	-	O
53	7	O
54	sequential	O
55	scans	O
56	obtained	O
57	at	O
58	1	O
59	-	O
60	min	O
61	interscan	O
62	intervals	O
63	.	O
1	Adenyl	B
2	cyclase	I
3	activity	O
4	of	O
5	gastric	O
6	mucosa	O
7	in	O
8	patients	O
9	with	O
10	duodenal	O
11	ulcer	O
12	before	O
13	and	O
14	after	O
15	treatment	O
1	Proteinuria	O
2	--	O
3	selected	O
4	physiopathological	O
5	and	O
6	clinical	O
7	problems	O
1	The	O
2	results	O
3	obtained	O
4	were	O
5	as	O
6	follows	O
7	:	O
8	The	O
9	mitral	O
10	valve	O
11	orifice	O
12	area	O
13	(	O
14	MVA	O
15	)	O
16	was	O
17	significantly	O
18	smaller	O
19	in	O
20	patients	O
21	with	O
22	type	O
23	III	O
24	of	O
25	the	O
26	LVIT	O
27	flow	O
28	velocity	O
29	pattern	O
30	than	O
31	in	O
32	patients	O
33	with	O
34	type	O
35	I	O
36	(	O
37	p	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O
1	This	O
2	compares	O
3	favorably	O
4	to	O
5	results	O
6	of	O
7	similarly	O
8	sized	O
9	melanomas	O
10	treated	O
11	by	O
12	enucleation	O
13	.	O
1	However	O
2	,	O
3	there	O
4	was	O
5	a	O
6	difference	O
7	in	O
8	the	O
9	quality	O
10	of	O
11	immunity	O
12	:	O
13	fever	O
14	and	O
15	body	O
16	weight	O
17	loss	O
18	were	O
19	seen	O
20	in	O
21	hamsters	O
22	vaccinated	O
23	with	O
24	the	O
25	killed	O
26	-	O
27	toxoplasma	O
28	vaccine	O
29	after	O
30	they	O
31	were	O
32	challenge	O
33	exposed	O
34	with	O
35	T	O
36	-	O
37	1	O
38	strain	O
39	,	O
40	whereas	O
41	these	O
42	changes	O
43	were	O
44	rarely	O
45	seen	O
46	in	O
47	hamsters	O
48	given	O
49	the	O
50	live	O
51	-	O
52	toxoplasma	O
53	vaccine	O
54	and	O
55	then	O
56	challenge	O
57	exposed	O
58	with	O
59	RH	O
60	strain	O
61	.	O
1	To	O
2	evaluate	O
3	the	O
4	comparative	O
5	safety	O
6	of	O
7	U	O
8	-	O
9	P	O
10	and	O
11	D	O
12	&	O
13	E	O
14	,	O
15	we	O
16	analyzed	O
17	2	O
18	,	O
19	805	O
20	U	O
21	-	O
22	P	O
23	and	O
24	9	O
25	,	O
26	572	O
27	D	O
28	&	O
29	E	O
30	abortions	O
31	at	O
32	13	O
33	to	O
34	24	O
35	menstrual	O
36	weeks	O
37	'	O
38	gestation	O
39	.	O
1	Limb	O
2	allografts	O
3	in	O
4	rats	O
5	immunosuppressed	O
6	with	O
7	cyclosporin	O
8	A	O
9	.	O
1	Four	O
2	patients	O
3	(	O
4	group	O
5	1	O
6	)	O
7	had	O
8	type	O
9	I	O
10	basement	O
11	membrane	O
12	nephropathy	O
13	,	O
14	characterized	O
15	by	O
16	marked	O
17	thickening	O
18	and	O
19	lamellation	O
20	of	O
21	the	O
22	basement	O
23	membrane	O
24	in	O
25	a	O
26	pattern	O
27	resembling	O
28	that	O
29	of	O
30	Alport	O
31	'	O
32	s	O
33	syndrome	O
34	.	O
1	Thin	O
2	-	O
3	layer	O
4	chromatographic	O
5	methods	O
6	were	O
7	up	O
8	-	O
9	dated	O
10	for	O
11	pharmacokinetic	O
12	studies	O
13	of	O
14	imipramine	O
15	in	O
16	plasma	O
17	and	O
18	urine	O
19	.	O
1	Increasing	O
2	the	O
3	cut	O
4	-	O
5	off	O
6	point	O
7	to	O
8	3	O
9	positive	O
10	responses	O
11	decreased	O
12	the	O
13	sensitivity	O
14	to	O
15	81	O
16	%	O
17	and	O
18	increased	O
19	the	O
20	specificity	O
21	to	O
22	94	O
23	%.	O
1	After	O
2	clofelin	O
3	administration	O
4	the	O
5	autoregulation	O
6	borders	O
7	shifted	O
8	to	O
9	the	O
10	right	O
11	i	O
12	.	O
13	e	O
14	.	O
15	towards	O
16	higher	O
17	AP	O
18	levels	O
19	.	O
1	Combination	O
2	of	O
3	a	O
4	Shwachman	O
5	syndrome	O
6	and	O
7	a	O
8	complex	O
9	granulocyte	O
10	function	O
11	disorder	O
12	in	O
13	a	O
14	girl	O
1	Trial	O
2	3	O
3	broiler	O
4	chickens	O
5	were	O
6	maintained	O
7	on	O
8	control	O
9	feed	O
10	until	O
11	they	O
12	reached	O
13	3	O
14	weeks	O
15	of	O
16	age	O
17	at	O
18	which	O
19	time	O
20	they	O
21	were	O
22	taken	O
23	off	O
24	of	O
25	feed	O
26	for	O
27	2	O
28	.	O
29	5	O
30	hr	O
31	and	O
32	then	O
33	placed	O
34	on	O
35	either	O
36	control	O
37	feed	O
38	or	O
39	feed	O
40	containing	O
41	4	O
42	.	O
43	0	O
44	ppm	O
45	ochratoxin	O
46	A	O
47	,	O
48	and	O
49	heart	O
50	rate	O
51	and	O
52	blood	O
53	pressure	O
54	were	O
55	measured	O
56	every	O
57	half	O
58	hour	O
59	through	O
60	7	O
61	hr	O
62	.	O
1	Harmful	O
2	effects	O
3	in	O
4	animals	O
5	and	O
6	man	O
7	may	O
8	result	O
9	from	O
10	both	O
11	deficient	O
12	or	O
13	excessive	O
14	amounts	O
15	of	O
16	intake	O
17	.	O
1	Morphofunctional	O
2	status	O
3	of	O
4	the	O
5	formed	O
6	elements	O
7	of	O
8	the	O
9	blood	O
10	in	O
11	rats	O
12	subjected	O
13	to	O
14	different	O
15	variants	O
16	of	O
17	combined	O
18	and	O
19	isolated	O
20	exposure	O
21	to	O
22	BR	O
23	-	O
24	1	O
25	benzene	O
1	These	O
2	results	O
3	confirming	O
4	the	O
5	high	O
6	validity	O
7	of	O
8	NOM	O
9	inhibiting	O
10	test	O
11	in	O
12	the	O
13	diagnosis	O
14	of	O
15	tumoural	O
16	hyperprolactinemic	O
17	states	O
18	,	O
19	reveal	O
20	contradictory	O
21	responses	O
22	to	O
23	CD	O
24	/	O
25	LD	O
26	,	O
27	LD	O
28	and	O
29	DOM	O
30	,	O
31	with	O
32	sustain	O
33	the	O
34	existence	O
35	of	O
36	2	O
37	sub	O
38	-	O
39	group	O
40	of	O
41	Prolactinomas	O
42	:	O
43	with	O
44	or	O
45	without	O
46	a	O
47	maintained	O
48	DA	O
49	central	O
50	tonus	O
51	supporting	O
52	the	O
53	possibility	O
54	of	O
55	different	O
56	etiopathogenetical	O
57	factors	O
58	in	O
59	inducing	O
60	a	O
61	tumoural	O
62	hyperprolactinemic	O
63	states	O
64	.	O
1	Female	O
2	but	O
3	not	O
4	male	O
5	mortalities	O
6	were	O
7	significantly	O
8	higher	O
9	for	O
10	cake	O
11	-	O
12	fed	O
13	rats	O
14	than	O
15	for	O
16	those	O
17	fed	O
18	diet	O
19	41B	O
20	.	O
1	Urinary	B
2	N	I
3	-	I
4	acetylglucosaminidase	I
5	activity	O
6	per	O
7	mg	O
8	creatinine	O
9	did	O
10	not	O
11	differ	O
12	significantly	O
13	between	O
14	groups	O
15	.	O
1	The	O
2	range	O
3	of	O
4	serum	O
5	concentrations	O
6	,	O
7	mean	O
8	values	O
9	,	O
10	median	O
11	values	O
12	,	O
13	and	O
14	standard	O
15	deviations	O
16	for	O
17	each	O
18	analyte	O
19	are	O
20	reported	O
21	for	O
22	males	O
23	and	O
24	females	O
25	and	O
26	for	O
27	three	O
28	age	O
29	groups	O
30	(	O
31	25	O
32	-	O
33	44	O
34	,	O
35	45	O
36	-	O
37	59	O
38	,	O
39	60	O
40	-	O
41	70	O
42	).	O
1	Private	O
2	hospital	O
3	accreditation	O
4	.	O
1	Epileptiform	O
2	activity	O
3	recorded	O
4	from	O
5	superficial	O
6	laminae	O
7	bordering	O
8	layer	O
9	4	O
10	,	O
11	and	O
12	into	O
13	which	O
14	layer	O
15	4	O
16	'	O
17	s	O
18	primary	O
19	projections	O
20	terminate	O
21	,	O
22	is	O
23	suppressed	O
24	preferentially	O
25	by	O
26	phenytoin	O
27	.	O
1	The	O
2	AD	O
3	components	O
4	were	O
5	markedly	O
6	more	O
7	dependent	O
8	on	O
9	the	O
10	affective	O
11	state	O
12	of	O
13	the	O
14	rat	O
15	then	O
16	was	O
17	the	O
18	V1	O
19	component	O
20	.	O
1	Plasma	B
2	lactoferrin	I
3	and	O
4	the	O
5	blood	O
6	count	O
7	of	O
8	polynuclear	O
9	neutrophils	O
1	The	O
2	importance	O
3	of	O
4	selective	O
5	renal	O
6	vein	O
7	phlebography	O
8	in	O
9	the	O
10	evaluation	O
11	of	O
12	unexplained	O
13	hematuria	O
14	and	O
15	filing	O
16	defects	O
17	in	O
18	the	O
19	excretory	O
20	urogram	O
21	is	O
22	illustrated	O
23	.	O
1	In	O
2	this	O
3	study	O
4	the	O
5	splenectomized	O
6	captive	O
7	born	O
8	cynomolgus	O
9	appeared	O
10	to	O
11	be	O
12	capable	O
13	of	O
14	supplementing	O
15	rhesus	O
16	as	O
17	an	O
18	antimalarial	O
19	drug	O
20	testing	O
21	model	O
22	.	O
1	Morphine	O
2	injected	O
3	into	O
4	the	O
5	lateral	O
6	ventricle	O
7	of	O
8	the	O
9	rat	O
10	produced	O
11	unilateral	O
12	analgesia	O
13	in	O
14	the	O
15	formalin	O
16	test	O
17	,	O
18	which	O
19	involves	O
20	continuous	O
21	,	O
22	moderate	O
23	pain	O
24	.	O
1	Mutations	O
2	in	O
3	seven	O
4	other	O
5	lts	B
6	genes	I
7	do	O
8	not	O
9	result	O
10	in	O
11	the	O
12	mak	B
13	-	I
14	phenotype	I
15	.	O
1	4	O
2	Five	O
3	patients	O
4	died	O
5	within	O
6	one	O
7	month	O
8	of	O
9	captopril	O
10	and	O
11	five	O
12	between	O
13	four	O
14	and	O
15	seven	O
16	months	O
17	,	O
18	three	O
19	of	O
20	whom	O
21	had	O
22	improved	O
23	to	O
24	class	O
25	IIM	O
26	and	O
27	one	O
28	to	O
29	IIS	O
30	before	O
31	death	O
32	.	O
1	Regions	O
2	of	O
3	the	O
4	translated	O
5	open	O
6	reading	O
7	frames	O
8	of	O
9	cobA	B
10	and	O
11	the	O
12	third	O
13	intron	O
14	of	O
15	the	O
16	cob	B
17	gene	I
18	in	I
19	yeast	I
20	show	O
21	high	O
22	amino	O
23	acid	O
24	homology	O
25	.	O
1	Multiresistant	O
2	strains	O
3	isolated	O
4	from	O
5	humans	O
6	in	O
7	enteral	O
8	toxico	O
9	-	O
10	infections	O
11	kill	O
12	orally	O
13	infected	O
14	mice	O
15	more	O
16	frequently	O
17	than	O
18	strains	O
19	isolated	O
20	in	O
21	hospital	O
22	infections	O
23	.	O
1	Volume	O
2	of	O
3	distribution	O
4	of	O
5	total	O
6	DMDZ	O
7	(	O
8	range	O
9	,	O
10	1	O
11	.	O
12	33	O
13	to	O
14	6	O
15	.	O
16	30	O
17	l	O
18	/	O
19	kg	O
20	)	O
21	and	O
22	of	O
23	unbound	O
24	DMDZ	O
25	after	O
26	correction	O
27	for	O
28	protein	O
29	binding	O
30	(	O
31	range	O
32	,	O
33	43	O
34	to	O
35	243	O
36	l	O
37	/	O
38	kg	O
39	)	O
40	was	O
41	larger	O
42	in	O
43	women	O
44	than	O
45	in	O
46	men	O
47	of	O
48	all	O
49	ages	O
50	,	O
51	and	O
52	in	O
53	the	O
54	elderly	O
55	as	O
56	opposed	O
57	to	O
58	the	O
59	young	O
60	.	O
1	Factor	B
2	VIII	I
3	procoagulant	O
4	activity	O
5	,	O
6	antigen	O
7	concentration	O
8	and	O
9	von	B
10	Willebrand	I
11	activity	O
12	as	O
13	ristocetin	B
14	cofactor	I
15	were	O
16	determined	O
17	several	O
18	times	O
19	in	O
20	10	O
21	patients	O
22	with	O
23	DIC	O
24	.	O
1	Comparison	O
2	of	O
3	three	O
4	different	O
5	preparations	O
6	of	O
7	disodium	O
8	cromoglycate	O
9	in	O
10	the	O
11	prevention	O
12	of	O
13	exercise	O
14	-	O
15	induced	O
16	bronchospasm	O
17	:	O
18	a	O
19	double	O
20	-	O
21	blind	O
22	study	O
23	.	O
1	LCBF	O
2	in	O
3	normal	O
4	and	O
5	hypoxic	O
6	puppies	O
7	was	O
8	correlated	O
9	with	O
10	local	O
11	cerebral	O
12	glucose	O
13	utilization	O
14	(	O
15	LCGU	O
16	)	O
17	obtained	O
18	under	O
19	the	O
20	same	O
21	experimental	O
22	conditions	O
23	(	O
24	Duffy	O
25	et	O
26	al	O
27	,	O
28	1982	O
29	).	O
1	Detection	O
2	of	O
3	hemophilia	O
4	A	O
5	carriers	O
6	.	O
1	The	O
2	osmotic	O
3	diuretic	O
4	mannitol	O
5	was	O
6	administered	O
7	to	O
8	21	O
9	patients	O
10	.	O
1	At	O
2	43	O
3	%	O
4	blood	O
5	pressure	O
6	reduction	O
7	,	O
8	PCO2	O
9	fell	O
10	by	O
11	0	O
12	.	O
13	53	O
14	kPa	O
15	,	O
16	a	O
17	decrease	O
18	which	O
19	could	O
20	not	O
21	explain	O
22	the	O
23	observed	O
24	CBF	O
25	fall	O
26	of	O
27	27	O
28	%.	O
1	Many	O
2	of	O
3	these	O
4	landfill	O
5	operations	O
6	were	O
7	undertaken	O
8	in	O
9	the	O
10	early	O
11	1950s	O
12	and	O
13	1960s	O
14	,	O
15	when	O
16	knowledge	O
17	regarding	O
18	the	O
19	safe	O
20	and	O
21	prolonged	O
22	containment	O
23	of	O
24	the	O
25	waste	O
26	buried	O
27	was	O
28	nonexistent	O
29	or	O
30	minimal	O
31	at	O
32	best	O
33	.	O
1	Self	O
2	-	O
3	heating	O
4	after	O
5	deep	O
6	hypothermia	O
7	(	O
8	20	O
9	degrees	O
10	C	O
11	)	O
12	causes	O
13	a	O
14	considerable	O
15	increase	O
16	in	O
17	the	O
18	brain	O
19	tissues	O
20	glutaminase	B
21	activity	O
22	at	O
23	all	O
24	studied	O
25	incubation	O
26	temperatures	O
27	(	O
28	37	O
29	,	O
30	30	O
31	,	O
32	20	O
33	and	O
34	10	O
35	degrees	O
36	C	O
37	)	O
38	as	O
39	compared	O
40	to	O
41	control	O
42	rats	O
43	and	O
44	rats	O
45	under	O
46	hypothermia	O
47	.	O
1	A	O
2	case	O
3	of	O
4	a	O
5	dense	O
6	epidermoid	O
7	cyst	O
8	of	O
9	the	O
10	suprasellar	O
11	cistern	O
12	is	O
13	presented	O
14	.	O
1	Because	O
2	of	O
3	a	O
4	rapid	O
5	development	O
6	of	O
7	the	O
8	connective	O
9	tissue	O
10	scars	O
11	,	O
12	however	O
13	,	O
14	at	O
15	the	O
16	place	O
17	of	O
18	the	O
19	destroyed	O
20	glandular	O
21	parenchyma	O
22	areas	O
23	,	O
24	there	O
25	is	O
26	no	O
27	normalization	O
28	of	O
29	the	O
30	organ	O
31	'	O
32	s	O
33	structure	O
34	and	O
35	function	O
36	by	O
37	the	O
38	42d	O
39	day	O
40	.	O
1	Penicillin	O
2	-	O
3	G	O
4	degradation	O
5	products	O
6	inhibit	O
7	in	O
8	vitro	O
9	granulopoiesis	O
10	.	O
1	The	O
2	Tullio	O
3	phenomenon	O
4	,	O
5	fistula	O
6	test	O
7	,	O
8	and	O
9	Hennebert	O
10	'	O
11	s	O
12	sign	O
13	:	O
14	clinical	O
15	significance	O
16	.	O
1	Both	O
2	groups	O
3	were	O
4	subjected	O
5	to	O
6	tests	O
7	of	O
8	delayed	O
9	hypersensitivity	O
10	with	O
11	Candidin	B
12	,	O
13	Trycophytin	B
14	and	O
15	Tuberculin	B
16	.	O
1	High	O
2	levels	O
3	of	O
4	IC	O
5	coincided	O
6	with	O
7	relative	O
8	hypocomplementemia	O
9	.	O
1	Echosismography	O
2	enables	O
3	to	O
4	improve	O
5	the	O
6	diagnosis	O
7	when	O
8	compared	O
9	with	O
10	classical	O
11	sonography	O
12	in	O
13	about	O
14	20	O
15	%	O
16	of	O
17	cases	O
18	.	O
1	Relationships	O
2	with	O
3	the	O
4	acquired	O
5	immune	O
6	deficiency	O
7	syndrome	O
8	.	O
1	In	O
2	the	O
3	ultramarathon	O
4	runner	O
5	the	O
6	testosterone	O
7	levels	O
8	sharply	O
9	rose	O
10	at	O
11	the	O
12	beginning	O
13	of	O
14	the	O
15	training	O
16	session	O
17	(	O
18	from	O
19	the	O
20	7	O
21	,	O
22	20	O
23	ng	O
24	/	O
25	ml	O
26	to	O
27	11	O
28	,	O
29	50	O
30	ng	O
31	/	O
32	ml	O
33	after	O
34	20	O
35	'	O
36	training	O
37	),	O
38	and	O
39	subsequently	O
40	decrease	O
41	after	O
42	3	O
43	hours	O
44	(	O
45	9	O
46	,	O
47	20	O
48	ng	O
49	/	O
50	ml	O
51	)	O
52	and	O
53	at	O
54	the	O
55	end	O
56	of	O
57	the	O
58	6	O
59	hours	O
60	training	O
61	(	O
62	4	O
63	,	O
64	60	O
65	ng	O
66	/	O
67	ml	O
68	).	O
1	Normal	O
2	rates	O
3	of	O
4	weight	O
5	gain	O
6	were	O
7	seen	O
8	once	O
9	absorbed	O
10	energy	O
11	intakes	O
12	reached	O
13	100	O
14	-	O
15	110	O
16	%	O
17	of	O
18	requirements	O
19	.	O
1	Its	O
2	vasodilatory	O
3	,	O
4	anti	O
5	-	O
6	vasopressor	O
7	,	O
8	and	O
9	platelet	O
10	stabilizing	O
11	effects	O
12	could	O
13	be	O
14	expected	O
15	to	O
16	counteract	O
17	the	O
18	placental	O
19	ischemia	O
20	,	O
21	hypertension	O
22	and	O
23	excessive	O
24	coagulation	O
25	that	O
26	are	O
27	seen	O
28	in	O
29	pre	O
30	-	O
31	eclampsia	O
32	.	O
1	The	O
2	hyperacute	O
3	phase	O
4	of	O
5	posterolateral	O
6	myocardial	O
7	infarction	O
8	.	O
1	After	O
2	a	O
3	year	O
4	of	O
5	planning	O
6	in	O
7	the	O
8	Laboratory	O
9	Assistants	O
10	'	O
11	School	O
12	in	O
13	Stockholm	O
14	:	O
15	new	O
16	education	O
17	for	O
18	laboratory	O
19	assistants	O
20	is	O
21	now	O
22	arranged	O
1	Utero	O
2	-	O
3	placental	O
4	blood	O
5	flow	O
6	and	O
7	the	O
8	effect	O
9	of	O
10	beta	B
11	2	I
12	-	I
13	adrenoceptor	I
14	stimulating	O
15	drugs	O
16	.	O
1	The	O
2	arginyl	O
3	peptide	O
4	bonds	O
5	that	O
6	are	O
7	cleaved	O
8	in	O
9	the	O
10	conversion	O
11	of	O
12	human	B
13	factor	I
14	IX	I
15	to	O
16	factor	B
17	IXa	I
18	by	O
19	factor	B
20	XIa	I
21	were	O
22	identified	O
23	as	O
24	Arg145	O
25	-	O
26	Ala146	O
27	and	O
28	Arg180	O
29	-	O
30	Val181	O
31	.	O
1	Fifty	O
2	-	O
3	eight	O
4	RMI	O
5	'	O
6	s	O
7	occurred	O
8	in	O
9	the	O
10	placebo	O
11	group	O
12	as	O
13	compared	O
14	to	O
15	only	O
16	twenty	O
17	in	O
18	the	O
19	AC	O
20	group	O
21	(	O
22	p	O
23	less	O
24	than	O
25	0	O
26	.	O
27	01	O
28	).	O
1	The	O
2	""""	O
3	cracked	O
4	-	O
5	tooth	O
6	""""	O
7	syndrome	O
8	.	O
1	2	O
2	.	O
1	Rats	O
2	underwent	O
3	either	O
4	a	O
5	90	O
6	-	O
7	95	O
8	%	O
9	JIB	O
10	or	O
11	a	O
12	sham	O
13	operation	O
14	.	O
1	There	O
2	was	O
3	a	O
4	significant	O
5	correlation	O
6	between	O
7	tubular	O
8	diameter	O
9	and	O
10	spg	O
11	(	O
12	r	O
13	=	O
14	0	O
15	.	O
16	68	O
17	,	O
18	P	O
19	less	O
20	than	O
21	0	O
22	.	O
23	001	O
24	)	O
25	suggesting	O
26	that	O
27	tubular	O
28	diameter	O
29	measurements	O
30	in	O
31	histological	O
32	sections	O
33	could	O
34	be	O
35	used	O
36	to	O
37	predict	O
38	sperm	O
39	production	O
40	.	O
1	Further	O
2	,	O
3	intracerebroventricular	O
4	injections	O
5	of	O
6	KA	O
7	resulted	O
8	in	O
9	the	O
10	substantial	O
11	loss	O
12	of	O
13	pyramidal	O
14	cells	O
15	in	O
16	the	O
17	whole	O
18	CA3	O
19	field	O
20	of	O
21	the	O
22	hippocampus	O
23	.	O
1	In	O
2	this	O
3	way	O
4	it	O
5	is	O
6	possible	O
7	to	O
8	simulate	O
9	the	O
10	growth	O
11	function	O
12	of	O
13	the	O
14	embryofetal	O
15	curve	O
16	of	O
17	the	O
18	length	O
19	'	O
20	increase	O
21	of	O
22	man	O
23	and	O
24	the	O
25	curve	O
26	of	O
27	the	O
28	mass	O
29	'	O
30	increase	O
31	of	O
32	rat	O
33	.	O
1	The	O
2	highest	O
3	doses	O
4	were	O
5	found	O
6	for	O
7	drivers	O
8	who	O
9	transported	O
10	large	O
11	numbers	O
12	of	O
13	99Mo	O
14	generators	O
15	.	O
1	It	O
2	was	O
3	also	O
4	found	O
5	that	O
6	there	O
7	is	O
8	no	O
9	significant	O
10	difference	O
11	between	O
12	the	O
13	prevalence	O
14	of	O
15	nasal	O
16	carriage	O
17	of	O
18	S	O
19	.	O
20	aureus	O
21	amongst	O
22	the	O
23	hospital	O
24	staff	O
25	and	O
26	the	O
27	patients	O
28	.	O
1	After	O
2	MOPP	O
3	therapy	O
4	,	O
5	complete	O
6	remission	O
7	of	O
8	Hodgkin	O
9	'	O
10	s	O
11	disease	O
12	was	O
13	accompanied	O
14	by	O
15	normalization	O
16	of	O
17	the	O
18	glucocerebrosidase	B
19	level	O
20	and	O
21	disappearance	O
22	of	O
23	Gaucher	O
24	'	O
25	s	O
26	cells	O
27	.	O
1	Parasitological	O
2	and	O
3	pathological	O
4	findings	O
5	in	O
6	capuchin	O
7	monkeys	O
8	infected	O
9	with	O
10	Schistosoma	O
11	japonicum	O
12	or	O
13	Schistosoma	O
14	mansoni	O
15	.	O
1	According	O
2	to	O
3	the	O
4	literature	O
5	,	O
6	second	O
7	malignant	O
8	epithelial	O
9	tumours	O
10	are	O
11	,	O
12	in	O
13	contrast	O
14	to	O
15	mesenchymal	O
16	tumours	O
17	such	O
18	as	O
19	osteosarcoma	O
20	,	O
21	very	O
22	rare	O
23	in	O
24	retinoblastoma	O
25	survivors	O
26	.	O
1	Cramps	O
2	in	O
3	extrapyramidal	O
4	disorders	O
5	.	O
1	For	O
2	various	O
3	dog	O
4	vessels	O
5	in	O
6	vivo	O
7	,	O
8	Q	O
9	/	O
10	Dk	O
11	ranged	O
12	from	O
13	0	O
14	.	O
15	15	O
16	to	O
17	47	O
18	X	O
19	10	O
20	(	O
21	5	O
22	)	O
23	Torr	O
24	/	O
25	cm2	O
26	.	O
1	The	O
2	application	O
3	of	O
4	ultrafiltration	O
5	to	O
6	sample	O
7	preparation	O
8	in	O
9	the	O
10	detection	O
11	and	O
12	quantification	O
13	of	O
14	ethylene	O
15	glycol	O
16	in	O
17	plasma	O
18	by	O
19	gas	O
20	chromatography	O
21	is	O
22	described	O
23	.	O
1	A	O
2	new	O
3	Onchocerca	O
4	species	O
5	,	O
6	a	O
7	parasite	O
8	of	O
9	domestic	O
10	cattle	O
11	,	O
12	in	O
13	Senegal	O
1	Both	O
2	groups	O
3	rejected	O
4	pops	O
5	with	O
6	added	O
7	SOA	O
8	,	O
9	decreasing	O
10	mouthing	O
11	times	O
12	as	O
13	SOA	O
14	concentration	O
15	increased	O
16	.	O
1	To	O
2	evaluate	O
3	the	O
4	gas	O
5	chromatographic	O
6	electron	O
7	capture	O
8	detection	O
9	method	O
10	described	O
11	earlier	O
12	,	O
13	23	O
14	plasma	O
15	samples	O
16	have	O
17	been	O
18	analysed	O
19	by	O
20	both	O
21	techniques	O
22	.	O
1	The	O
2	hemodynamics	O
3	of	O
4	isoproterenol	O
5	-	O
6	induced	O
7	cardiac	O
8	failure	O
9	in	O
10	the	O
11	rat	O
12	.	O
1	Cross	O
2	reactivity	O
3	in	O
4	theophylline	O
5	RIA	O
6	kit	O
7	decreased	O
8	.	O
1	Determination	O
2	of	O
3	aortic	O
4	distensibility	O
5	and	O
6	its	O
7	variations	O
8	in	O
9	arterial	O
10	hypertension	O
11	.	O
1	A	O
2	surgical	O
3	technique	O
4	for	O
5	correcting	O
6	this	O
7	problem	O
8	is	O
9	described	O
10	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	the	O
6	general	O
7	clinical	O
8	criteria	O
9	for	O
10	inhalation	O
11	injury	O
12	--	O
13	presence	O
14	of	O
15	facial	O
16	or	O
17	oropharyngeal	O
18	burns	O
19	,	O
20	carboxyhemoglobin	B
21	levels	O
22	,	O
23	carbonaceous	O
24	sputum	O
25	,	O
26	or	O
27	closed	O
28	space	O
29	injury	O
30	--	O
31	did	O
32	not	O
33	differentiate	O
34	patients	O
35	with	O
36	airway	O
37	injury	O
38	only	O
39	from	O
40	those	O
41	with	O
42	parenchymal	O
43	injury	O
44	.	O
1	With	O
2	Sair	O
3	and	O
4	So2	O
5	,	O
6	mean	O
7	vital	O
8	capacity	O
9	was	O
10	reduced	O
11	by	O
12	44	O
13	%	O
14	from	O
15	control	O
16	.	O
1	Of	O
2	the	O
3	117	O
4	patients	O
5	(	O
6	out	O
7	of	O
8	the	O
9	136	O
10	)	O
11	with	O
12	serologic	O
13	evidence	O
14	of	O
15	chronic	O
16	thyroiditis	O
17	who	O
18	could	O
19	be	O
20	studied	O
21	,	O
22	eight	O
23	(	O
24	7	O
25	%)	O
26	had	O
27	hyperthyroidism	O
28	and	O
29	45	O
30	(	O
31	38	O
32	%)	O
33	were	O
34	hypothyroid	O
35	.	O
1	Forty	O
2	-	O
3	five	O
4	cases	O
5	were	O
6	surgically	O
7	by	O
8	direct	O
9	approach	O
10	to	O
11	the	O
12	tumour	O
13	,	O
14	while	O
15	two	O
16	cases	O
17	were	O
18	treated	O
19	only	O
20	with	O
21	a	O
22	shunt	O
23	.	O
1	Responses	O
2	to	O
3	brainstem	O
4	of	O
5	nuclei	O
6	medialis	O
7	dorsalis	O
8	,	O
9	lateralis	O
10	posterior	O
11	were	O
12	of	O
13	considerably	O
14	longer	O
15	latency	O
16	.	O
1	Effect	O
2	of	O
3	indomethacin	O
4	and	O
5	prostaglandin	O
6	F2	O
7	alpha	O
8	on	O
9	parturition	O
10	in	O
11	swine	O
12	.	O
1	Autotransfusion	O
2	was	O
3	performed	O
4	as	O
5	follows	O
6	:	O
7	Heparin	O
8	-	O
9	ACD	O
10	-	O
11	B	O
12	-	O
13	Heparin	O
14	-	O
15	DPD	O
16	-	O
17	Heparin	O
18	-	O
19	ACD	O
20	-	O
21	B	O
22	etc	O
23	.	O
1	A	O
2	simplified	O
3	thin	O
4	-	O
5	layer	O
6	chromatographic	O
7	determination	O
8	of	O
9	hippuric	O
10	acid	O
11	and	O
12	methylhippuric	O
13	acids	O
14	.	O
1	Mucoepidermoid	O
2	and	O
3	acinous	O
4	cell	O
5	carcinomas	O
6	of	O
7	salivary	O
8	tissues	O
9	.	O
1	As	O
2	a	O
3	result	O
4	,	O
5	beta	O
6	-	O
7	apo	O
8	-	O
9	8	O
10	'-	O
11	carotenoic	O
12	acid	O
13	ethyl	O
14	ester	O
15	(	O
16	apo	O
17	-	O
18	EE	O
19	)	O
20	was	O
21	used	O
22	as	O
23	a	O
24	reference	O
25	standard	O
26	in	O
27	Experiments	O
28	4	O
29	to	O
30	6	O
31	.	O
1	Chemotherapy	O
2	was	O
3	administered	O
4	without	O
5	altering	O
6	the	O
7	course	O
8	of	O
9	the	O
10	disorder	O
11	.	O
1	Autoradiographic	O
2	localisation	O
3	of	O
4	its	O
5	cellular	O
6	distribution	O
7	in	O
8	the	O
9	kidney	O
10	.	O
1	Hippocampal	O
2	stimulation	O
3	overlapping	O
4	conditioned	O
5	stimulus	O
6	preexposure	O
7	produced	O
8	attenuation	O
9	of	O
10	latent	O
11	inhibition	O
12	,	O
13	as	O
14	did	O
15	stimulation	O
16	presented	O
17	during	O
18	conditioning	O
19	after	O
20	preexposure	O
21	.	O
1	Implications	O
2	of	O
3	this	O
4	observation	O
5	for	O
6	pediatrics	O
7	are	O
8	discussed	O
9	.	O
1	For	O
2	the	O
3	study	O
4	of	O
5	the	O
6	transition	O
7	of	O
8	long	O
9	to	O
10	short	O
11	waves	O
12	(	O
13	deep	O
14	-	O
15	water	O
16	waves	O
17	)	O
18	a	O
19	closed	O
20	-	O
21	form	O
22	solution	O
23	is	O
24	advantageous	O
25	;	O
26	this	O
27	can	O
28	,	O
29	however	O
30	,	O
31	only	O
32	be	O
33	obtained	O
34	at	O
35	the	O
36	cost	O
37	of	O
38	further	O
39	simplification	O
40	.	O
1	A	O
2	progressive	O
3	growth	O
4	of	O
5	blood	O
6	erythrocyte	O
7	membrane	O
8	injury	O
9	has	O
10	been	O
11	demonstrated	O
12	after	O
13	rats	O
14	were	O
15	exposed	O
16	to	O
17	gamma	O
18	-	O
19	irradiaton	O
20	at	O
21	a	O
22	dose	O
23	of	O
24	100	O
25	to	O
26	500	O
27	Gy	O
28	.	O
1	Serum	O
2	antibody	O
3	titre	O
4	was	O
5	not	O
6	significantly	O
7	associated	O
8	with	O
9	the	O
10	recurrence	O
11	rate	O
12	or	O
13	the	O
14	duration	O
15	of	O
16	infection	O
17	.	O
1	It	O
2	is	O
3	suggested	O
4	that	O
5	a	O
6	raised	O
7	hydroxykynurenine	O
8	/	O
9	hydroxyanthranilic	O
10	acid	O
11	ratio	O
12	does	O
13	not	O
14	necessarily	O
15	indicate	O
16	vitamin	O
17	B6	O
18	deficiency	O
19	but	O
20	may	O
21	represent	O
22	a	O
23	nonspecific	O
24	response	O
25	of	O
26	tryptophan	O
27	metabolism	O
28	to	O
29	stress	O
30	.	O
1	At	O
2	pH	O
3	6	O
4	.	O
5	9	O
6	,	O
7	the	O
8	same	O
9	lidocaine	O
10	concentrations	O
11	significantly	O
12	reduced	O
13	resting	O
14	potential	O
15	(	O
16	3	O
17	-	O
18	10	O
19	%),	O
20	action	O
21	potential	O
22	amplitude	O
23	(	O
24	3	O
25	-	O
26	8	O
27	%)	O
28	and	O
29	Vmax	O
30	(	O
31	14	O
32	-	O
33	22	O
34	%).	O
1	All	O
2	lambs	O
3	with	O
4	B	O
5	breeding	O
6	had	O
7	significantly	O
8	higher	O
9	Hb	B
10	levels	O
11	at	O
12	the	O
13	end	O
14	of	O
15	the	O
16	experiment	O
17	than	O
18	did	O
19	NB	O
20	lambs	O
21	.	O
22	b	O
23	and	O
24	S	O
25	x	O
26	B	O
27	lambs	O
28	had	O
29	higher	O
30	(	O
31	P	O
32	<	O
33	.	O
34	05	O
35	)	O
36	Hb	B
37	levels	O
38	than	O
39	the	O
40	D	O
41	x	O
42	B	O
43	lambs	O
44	,	O
45	and	O
46	B	O
47	lambs	O
48	had	O
49	the	O
50	highest	O
51	(	O
52	P	O
53	<	O
54	.	O
55	05	O
56	)	O
57	mean	O
58	corpuscular	O
59	hemoglobin	B
60	concentrations	O
61	.	O
1	The	O
2	same	O
3	response	O
4	occurs	O
5	whether	O
6	acrylamide	O
7	is	O
8	given	O
9	immediately	O
10	after	O
11	nerve	O
12	ligation	O
13	or	O
14	1	O
15	week	O
16	later	O
17	.	O
1	Fourteen	O
2	different	O
3	species	O
4	(	O
5	eight	O
6	Platyhelmintha	O
7	,	O
8	one	O
9	Nematoda	O
10	and	O
11	five	O
12	Crustacea	O
13	)	O
14	have	O
15	been	O
16	inventorized	O
17	.	O
1	At	O
2	4	O
3	wk	O
4	however	O
5	,	O
6	tumor	O
7	relapse	O
8	was	O
9	noted	O
10	in	O
11	6	O
12	of	O
13	7	O
14	group	O
15	4	O
16	responders	O
17	,	O
18	10	O
19	of	O
20	12	O
21	in	O
22	group	O
23	5	O
24	,	O
25	13	O
26	of	O
27	16	O
28	in	O
29	group	O
30	7	O
31	,	O
32	but	O
33	only	O
34	4	O
35	of	O
36	19	O
37	group	O
38	8	O
39	responders	O
40	(	O
41	p	O
42	less	O
43	than	O
44	.	O
45	001	O
46	group	O
47	8	O
48	versus	O
49	4	O
50	,	O
51	5	O
52	,	O
53	7	O
54	).	O
1	Early	O
2	infection	O
3	was	O
4	detected	O
5	in	O
6	one	O
7	of	O
8	50	O
9	control	O
10	women	O
11	who	O
12	gave	O
13	birth	O
14	to	O
15	a	O
16	healthy	O
17	infant	O
18	.	O
1	The	O
2	protein	B
3	ELT	I
4	-	I
5	1	I
6	,	O
7	encoded	O
8	by	O
9	a	O
10	single	O
11	-	O
12	copy	O
13	gene	O
14	homologous	O
15	to	O
16	the	O
17	GATA	B
18	family	I
19	of	I
20	vertebrate	I
21	transcription	I
22	factors	I
23	,	O
24	is	O
25	potentially	O
26	capable	O
27	of	O
28	interacting	O
29	with	O
30	this	O
31	element	O
32	.	O
1	However	O
2	,	O
3	in	O
4	contrast	O
5	with	O
6	previous	O
7	in	O
8	vitro	O
9	cell	O
10	-	O
11	free	O
12	integration	O
13	studies	O
14	,	O
15	alteration	O
16	of	O
17	the	O
18	highly	O
19	conserved	O
20	CA	O
21	dinucleotide	O
22	resulted	O
23	in	O
24	a	O
25	mutant	O
26	which	O
27	still	O
28	retained	O
29	40	O
30	%	O
31	of	O
32	wild	O
33	-	O
34	type	O
35	integration	O
36	activity	O
37	.	O
1	The	O
2	resulting	O
3	R	B
4	protein	I
5	terminates	O
6	five	O
7	codons	O
8	downstream	O
9	of	O
10	the	O
11	frameshift	O
12	site	O
13	at	O
14	the	O
15	V	B
16	protein	I
17	stop	O
18	codon	O
19	.	O
1	By	O
2	site	O
3	-	O
4	specific	O
5	mutagenesis	O
6	,	O
7	we	O
8	also	O
9	show	O
10	that	O
11	individual	O
12	ICP27	B
13	C	I
14	-	I
15	terminal	I
16	amino	I
17	acid	I
18	residues	I
19	that	O
20	are	O
21	positionally	O
22	conserved	O
23	in	O
24	ICP27	B
25	homologs	I
26	in	O
27	other	O
28	herpesviruses	O
29	(	O
30	D	O
31	-	O
32	357	O
33	,	O
34	E	O
35	-	O
36	358	O
37	,	O
38	H	O
39	-	O
40	479	O
41	,	O
42	C	O
43	-	O
44	400	O
45	,	O
46	C	O
47	-	O
48	483	O
49	,	O
50	and	O
51	C	O
52	-	O
53	488	O
54	)	O
55	are	O
56	critical	O
57	for	O
58	trans	O
59	-	O
60	regulatory	O
61	activity	O
62	.	O
1	BSE	O
2	and	O
3	farmworkers	O
4	.	O
1	Peroxisome	B
2	proliferator	I
3	-	I
4	activated	I
5	receptors	I
6	(	O
7	PPARs	B
8	)	O
9	and	O
10	retinoid	B
11	X	I
12	receptors	I
13	(	O
14	RXRs	B
15	)	O
16	are	O
17	nuclear	B
18	hormone	I
19	receptors	I
20	that	O
21	are	O
22	activated	O
23	by	O
24	fatty	O
25	acids	O
26	and	O
27	9	O
28	-	O
29	cis	O
30	-	O
31	retinoic	O
32	acid	O
33	,	O
34	respectively	O
35	.	O
1	We	O
2	have	O
3	isolated	O
4	a	O
5	new	O
6	,	O
7	larger	O
8	rat	B
9	B	I
10	-	I
11	myc	I
12	genomic	I
13	clone	I
14	.	O
1	The	O
2	influenza	O
3	virus	O
4	NS1	B
5	protein	O
6	is	O
7	a	O
8	unique	O
9	posttranscriptional	O
10	regulator	O
11	that	O
12	has	O
13	two	O
14	activities	O
15	:	O
16	inhibition	O
17	of	O
18	the	O
19	nuclear	O
20	export	O
21	of	O
22	poly	O
23	A	O
24	-	O
25	containing	O
26	mRNAs	O
27	and	O
28	inhibition	O
29	of	O
30	pre	O
31	-	O
32	mRNA	O
33	splicing	O
34	.	O
1	Vitamin	O
2	D3	O
3	plus	O
4	nicotine	O
5	treatment	O
6	produced	O
7	parallel	O
8	increases	O
9	in	O
10	cardiac	O
11	mass	O
12	and	O
13	elastic	O
14	modulus	O
15	,	O
16	with	O
17	a	O
18	significant	O
19	correlation	O
20	between	O
21	the	O
22	two	O
23	.	O
1	Thus	O
2	,	O
3	as	O
4	expected	O
5	,	O
6	trans	O
7	-	O
8	splicing	O
9	depends	O
10	on	O
11	the	O
12	integrity	O
13	of	O
14	U2	B
15	,	O
16	U4	B
17	,	O
18	and	O
19	U6	B
20	snRNAs	I
21	.	O
1	In	O
2	contrast	O
3	with	O
4	the	O
5	previously	O
6	reported	O
7	HMGR1	B
8	mRNA	I
9	(	O
10	HMGR1S	B
11	mRNA	I
12	),	O
13	which	O
14	is	O
15	detected	O
16	at	O
17	high	O
18	levels	O
19	in	O
20	all	O
21	tissues	O
22	of	O
23	the	O
24	plant	O
25	,	O
26	HMGR1L	B
27	mRNA	I
28	is	O
29	present	O
30	at	O
31	relatively	O
32	low	O
33	levels	O
34	and	O
35	its	O
36	expression	O
37	is	O
38	restricted	O
39	mostly	O
40	to	O
41	seedlings	O
42	,	O
43	roots	O
44	and	O
45	inflorescences	O
46	.	O
1	In	O
2	adult	O
3	tissues	O
4	,	O
5	it	O
6	was	O
7	less	O
8	restricted	O
9	,	O
10	indicating	O
11	that	O
12	RAFTK	B
13	expression	O
14	is	O
15	developmentally	O
16	up	O
17	-	O
18	regulated	O
19	.	O
1	To	O
2	confirm	O
3	the	O
4	GapIII	B
5	protein	I
6	activity	O
7	,	O
8	constructs	O
9	containing	O
10	different	O
11	GapIII	B
12	-	O
13	GRD	B
14	domains	O
15	were	O
16	transformed	O
17	into	O
18	iral	B
19	mutant	O
20	yeast	O
21	to	O
22	determine	O
23	their	O
24	relative	O
25	ability	O
26	to	O
27	replace	O
28	IRA1	B
29	functionally	O
30	.	O
1	We	O
2	have	O
3	also	O
4	tested	O
5	Src	B
6	SH2	I
7	mutants	O
8	for	O
9	their	O
10	binding	O
11	properties	O
12	and	O
13	have	O
14	interpreted	O
15	our	O
16	results	O
17	in	O
18	light	O
19	of	O
20	the	O
21	recent	O
22	crystal	O
23	structure	O
24	solution	O
25	for	O
26	the	O
27	Src	B
28	SH2	I
29	domain	O
30	.	O
1	The	O
2	early	O
3	lethality	O
4	of	O
5	the	O
6	left	O
7	-	O
8	sided	O
9	resectio	O
10	was	O
11	0	O
12	%	O
13	and	O
14	the	O
15	postoperative	O
16	survival	O
17	--	O
18	5	O
19	-	O
20	10	O
21	months	O
22	.	O
1	The	O
2	highest	O
3	decrease	O
4	in	O
5	mutagenic	O
6	activity	O
7	was	O
8	observed	O
9	when	O
10	enzymatic	O
11	bleaching	O
12	was	O
13	used	O
14	together	O
15	with	O
16	chlorine	O
17	.	O
1	There	O
2	was	O
3	also	O
4	a	O
5	highly	O
6	significant	O
7	correlation	O
8	between	O
9	total	O
10	selenium	O
11	intake	O
12	and	O
13	liver	O
14	selenium	O
15	concentration	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	99	O
22	,	O
23	p	O
24	<	O
25	0	O
26	.	O
27	01	O
28	)	O
29	after	O
30	1	O
31	mo	O
32	of	O
33	treatment	O
34	,	O
35	but	O
36	this	O
37	time	O
38	liver	O
39	selenium	O
40	did	O
41	not	O
42	change	O
43	with	O
44	time	O
45	,	O
46	and	O
47	the	O
48	correlation	O
49	remained	O
50	highly	O
51	significant	O
52	throughout	O
53	the	O
54	investigation	O
55	.	O
1	Its	O
2	role	O
3	in	O
4	these	O
5	processes	O
6	suggests	O
7	that	O
8	the	O
9	function	O
10	of	O
11	c	B
12	-	I
13	Myb	I
14	may	O
15	be	O
16	important	O
17	early	O
18	in	O
19	the	O
20	establishment	O
21	of	O
22	the	O
23	hematopoietic	O
24	lineage	O
25	.	O
1	CONCLUSION	O
2	:	O
3	This	O
4	study	O
5	documents	O
6	that	O
7	regression	O
8	of	O
9	choroidal	O
10	neovascularization	O
11	that	O
12	occurred	O
13	with	O
14	alpha	B
15	interferon	I
16	treatment	O
17	was	O
18	minimal	O
19	.	O
1	High	O
2	plasma	O
3	concentrations	O
4	of	O
5	soluble	O
6	E	B
7	-	I
8	selectin	I
9	were	O
10	closely	O
11	associated	O
12	with	O
13	multiple	O
14	-	O
15	organ	O
16	dysfunction	O
17	and	O
18	death	O
19	.	O
1	Activation	O
2	of	O
3	the	O
4	SH2	B
5	-	I
6	containing	I
7	protein	I
8	tyrosine	I
9	phosphatase	I
10	,	O
11	SH	B
12	-	I
13	PTP2	I
14	,	O
15	by	O
16	phosphotyrosine	O
17	-	O
18	containing	O
19	peptides	O
20	derived	O
21	from	O
22	insulin	B
23	receptor	I
24	substrate	I
25	-	I
26	1	I
27	.	O
1	Several	O
2	Src	B
3	SH3	I
4	-	I
5	binding	I
6	proteins	I
7	were	O
8	phosphorylated	O
9	in	O
10	Src	B
11	-	O
12	transformed	O
13	cells	O
14	.	O
1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	cells	O
7	containing	O
8	a	O
9	PTP1C	B
10	in	O
11	which	O
12	the	O
13	catalytic	O
14	site	O
15	had	O
16	been	O
17	inactivated	O
18	through	O
19	mutagenesis	O
20	,	O
21	stably	O
22	phosphorylated	O
23	the	O
24	phosphatase	O
25	.	O
1	Hematopoietic	B
2	growth	I
3	factors	I
4	are	O
5	being	O
6	used	O
7	to	O
8	accelerate	O
9	the	O
10	recovery	O
11	of	O
12	myelopoiesis	O
13	following	O
14	high	O
15	-	O
16	dose	O
17	chemotherapy	O
18	in	O
19	cancer	O
20	patients	O
21	.	O
1	A	O
2	particularly	O
3	striking	O
4	HpaII	B
5	tiny	O
6	fragment	O
7	island	O
8	,	O
9	extending	O
10	over	O
11	nearly	O
12	2	O
13	,	O
14	000	O
15	base	O
16	pairs	O
17	,	O
18	surrounds	O
19	the	O
20	USF2	B
21	translation	I
22	initiation	I
23	site	I
24	.	O
1	Diagnosis	O
2	of	O
3	prostatic	O
4	carcinoma	O
5	:	O
6	the	O
7	yield	O
8	of	O
9	serum	B
10	prostate	I
11	specific	I
12	antigen	I
13	,	O
14	digital	O
15	rectal	O
16	examination	O
17	and	O
18	transrectal	O
19	ultrasonography	O
20	.	O
1	Microvessels	O
2	were	O
3	counted	O
4	in	O
5	a	O
6	x200	O
7	field	O
8	(	O
9	0	O
10	.	O
11	754	O
12	mm2	O
13	)	O
14	in	O
15	the	O
16	area	O
17	of	O
18	maximal	O
19	angiogenesis	O
20	.	O
1	In	O
2	viral	O
3	infections	O
4	,	O
5	G	B
6	-	I
7	CSF	I
8	was	O
9	correlated	O
10	with	O
11	mononuclear	O
12	cells	O
13	(	O
14	rs	O
15	=	O
16	0	O
17	.	O
18	41	O
19	,	O
20	P	O
21	<	O
22	0	O
23	.	O
24	05	O
25	),	O
26	white	O
27	blood	O
28	cell	O
29	counts	O
30	(	O
31	rs	O
32	=	O
33	0	O
34	.	O
35	56	O
36	,	O
37	P	O
38	<	O
39	0	O
40	.	O
41	01	O
42	),	O
43	neutrophils	O
44	(	O
45	rs	O
46	=	O
47	0	O
48	.	O
49	41	O
50	,	O
51	P	O
52	<	O
53	0	O
54	.	O
55	05	O
56	)	O
57	and	O
58	CRP	B
59	(	O
60	rs	O
61	=	O
62	0	O
63	.	O
64	47	O
65	,	O
66	P	O
67	<	O
68	0	O
69	.	O
70	05	O
71	).	O
1	However	O
2	,	O
3	multiple	O
4	alanine	O
5	substitutions	O
6	or	O
7	proline	O
8	(	O
9	helix	O
10	-	O
11	destabilizing	O
12	)	O
13	substitutions	O
14	disrupted	O
15	both	O
16	oligomerization	O
17	and	O
18	transport	O
19	of	O
20	GP64	B
21	EFP	I
22	.	O
1	A	O
2	chicken	B
3	paxillin	I
4	cDNA	I
5	was	O
6	also	O
7	cloned	O
8	and	O
9	is	O
10	predicted	O
11	to	O
12	encode	O
13	a	O
14	protein	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	human	B
21	paxil	I
22	-	I
23	lin	I
24	.	O
1	These	O
2	data	O
3	suggest	O
4	that	O
5	these	O
6	sequences	O
7	located	O
8	immediately	O
9	3	O
10	'	O
11	to	O
12	the	O
13	breakpoint	O
14	of	O
15	the	O
16	HPFH	B
17	-	I
18	3	I
19	deletion	I
20	,	O
21	exhibit	O
22	both	O
23	the	O
24	structure	O
25	and	O
26	the	O
27	function	O
28	of	O
29	an	O
30	enhancer	O
31	,	O
32	and	O
33	can	O
34	modify	O
35	the	O
36	developmental	O
37	specificity	O
38	of	O
39	the	O
40	fetal	B
41	gamma	I
42	-	I
43	globin	I
44	genes	I
45	,	O
46	resulting	O
47	in	O
48	their	O
49	continued	O
50	expression	O
51	during	O
52	adult	O
53	life	O
54	.	O
1	Both	O
2	mutations	O
3	completely	O
4	abolished	O
5	binding	O
6	of	O
7	the	O
8	Abl	B
9	SH3	I
10	domain	O
11	to	O
12	proline	O
13	-	O
14	rich	O
15	target	O
16	proteins	O
17	in	O
18	a	O
19	filter	O
20	-	O
21	binding	O
22	assay	O
23	.	O
1	The	O
2	levels	O
3	of	O
4	NSE	B
5	and	O
6	MBP	B
7	in	O
8	the	O
9	IJVB	O
10	were	O
11	compared	O
12	to	O
13	those	O
14	in	O
15	the	O
16	PVB	O
17	.	O
1	As	O
2	expected	O
3	,	O
4	the	O
5	insulin	B
6	effect	O
7	to	O
8	increase	O
9	ras	B
10	GTP	I
11	formation	O
12	and	O
13	MAP	B
14	kinase	I
15	activity	O
16	was	O
17	negligible	O
18	in	O
19	A	O
20	/	O
21	K1018	O
22	cells	O
23	but	O
24	normal	O
25	,	O
26	or	O
27	supernormal	O
28	,	O
29	in	O
30	Y	O
31	/	O
32	F2	O
33	cells	O
34	.	O
1	The	O
2	gene	O
3	product	O
4	of	O
5	cotS	B
6	was	O
7	confirmed	O
8	to	O
9	be	O
10	identical	O
11	to	O
12	Cot40	B
13	-	I
14	2	I
15	by	O
16	SDS	O
17	-	O
18	PAGE	O
19	and	O
20	immunoblotting	O
21	from	O
22	Escherichia	O
23	coli	O
24	transformed	O
25	with	O
26	a	O
27	plasmid	O
28	containing	O
29	the	O
30	cotS	B
31	region	I
32	.	O
1	Two	O
2	such	O
3	genes	O
4	,	O
5	designated	O
6	hsiggll150	B
7	and	O
8	hsiggll295	B
9	,	O
10	were	O
11	cloned	O
12	and	O
13	sequenced	O
14	from	O
15	genomic	O
16	DNA	O
17	.	O
1	We	O
2	have	O
3	demonstrated	O
4	previously	O
5	that	O
6	two	O
7	binding	O
8	sites	O
9	in	O
10	the	O
11	-	B
12	184	I
13	HNF	I
14	-	I
15	3	I
16	beta	I
17	promoter	I
18	are	O
19	recognized	O
20	by	O
21	widely	O
22	distributed	O
23	factors	O
24	and	O
25	that	O
26	there	O
27	is	O
28	also	O
29	a	O
30	critical	O
31	autoregulatory	O
32	site	O
33	,	O
34	we	O
35	identified	O
36	a	O
37	binding	O
38	site	O
39	for	O
40	a	O
41	cell	O
42	-	O
43	specific	O
44	factor	O
45	,	O
46	LF	B
47	-	I
48	H3	I
49	beta	I
50	,	O
51	that	O
52	may	O
53	function	O
54	in	O
55	restricting	O
56	HNF	B
57	-	I
58	3	I
59	beta	I
60	gene	I
61	expression	O
62	to	O
63	hepatocytes	O
64	.	O
1	The	O
2	flow	O
3	rate	O
4	of	O
5	phosphate	O
6	buffered	O
7	saline	O
8	through	O
9	dermis	O
10	was	O
11	measured	O
12	as	O
13	a	O
14	function	O
15	of	O
16	applied	O
17	pressure	O
18	.	O
1	Although	O
2	within	O
3	normal	O
4	limits	O
5	,	O
6	latency	O
7	was	O
8	high	O
9	.	O
1	Closure	O
2	of	O
3	an	O
4	open	O
5	high	O
6	below	O
7	-	O
8	knee	O
9	guillotine	O
10	amputation	O
11	wound	O
12	using	O
13	a	O
14	skin	O
15	-	O
16	stretching	O
17	device	O
18	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	PCNA	B
7	gene	I
8	is	O
9	a	O
10	likely	O
11	target	O
12	gene	O
13	of	O
14	E2F	B
15	.	O
1	Here	O
2	we	O
3	demonstrate	O
4	genetically	O
5	that	O
6	plus	O
7	-	O
8	strand	O
9	DNA	O
10	synthesis	O
11	of	O
12	the	O
13	yeast	B
14	Ty1	I
15	element	I
16	is	O
17	initiated	O
18	at	O
19	two	O
20	sites	O
21	located	O
22	at	O
23	the	O
24	5	O
25	'	O
26	boundary	O
27	of	O
28	the	O
29	3	O
30	'	O
31	long	O
32	terminal	O
33	repeat	O
34	(	O
35	PPT1	B
36	)	O
37	and	O
38	near	O
39	the	O
40	middle	O
41	of	O
42	the	O
43	pol	B
44	gene	I
45	in	O
46	the	O
47	integrase	B
48	coding	I
49	sequence	I
50	(	O
51	PPT2	B
52	).	O
1	The	O
2	kinase	O
3	is	O
4	essential	O
5	in	O
6	vivo	O
7	for	O
8	normal	O
9	phosphorylation	O
10	of	O
11	the	O
12	CTD	O
13	and	O
14	for	O
15	normal	O
16	growth	O
17	and	O
18	differentiation	O
19	.	O
1	Endocytosis	O
2	and	O
3	vacuolar	O
4	degradation	O
5	of	O
6	the	O
7	plasma	O
8	membrane	O
9	-	O
10	localized	O
11	Pdr5	B
12	ATP	I
13	-	I
14	binding	I
15	cassette	I
16	multidrug	I
17	transporter	I
18	in	O
19	Saccharomyces	O
20	cerevisiae	O
21	.	O
1	Repression	O
2	of	O
3	glucocorticoid	B
4	receptor	I
5	-	O
6	mediated	O
7	transcriptional	O
8	activation	O
9	by	O
10	unliganded	O
11	thyroid	B
12	hormone	I
13	receptor	I
14	(	O
15	TR	B
16	)	O
17	is	O
18	TR	B
19	isoform	O
20	-	O
21	specific	O
22	.	O
1	Obstruction	O
2	of	O
3	the	O
4	ERF	B
5	repressor	I
6	function	O
7	by	O
8	the	O
9	transactivating	O
10	members	O
11	of	O
12	the	O
13	ets	B
14	family	I
15	of	O
16	genes	O
17	(	O
18	i	O
19	.	O
20	e	O
21	.	O
22	gag	B
23	-	O
24	myb	B
25	-	O
26	ets	B
27	)	O
28	may	O
29	be	O
30	essential	O
31	for	O
32	the	O
33	control	O
34	of	O
35	genes	O
36	involved	O
37	in	O
38	cell	O
39	proliferation	O
40	and	O
41	may	O
42	also	O
43	underlie	O
44	their	O
45	tumorigenic	O
46	effects	O
47	.	O
1	A	O
2	2	B
3	.	I
4	4	I
5	-	I
6	kb	I
7	MAPKAPK	I
8	-	I
9	2	I
10	message	I
11	is	O
12	expressed	O
13	throughout	O
14	development	O
15	,	O
16	while	O
17	two	O
18	shorter	O
19	transcripts	O
20	of	O
21	2	O
22	.	O
23	3	O
24	and	O
25	1	O
26	.	O
27	8	O
28	kb	O
29	appear	O
30	to	O
31	be	O
32	specifically	O
33	expressed	O
34	in	O
35	the	O
36	germline	O
37	.	O
1	In	O
2	Trial	O
3	1	O
4	,	O
5	eight	O
6	sows	O
7	were	O
8	allowed	O
9	to	O
10	farrow	O
11	naturally	O
12	(	O
13	d	O
14	114	O
15	,	O
16	NF	O
17	sows	O
18	)	O
19	and	O
20	eight	O
21	sows	O
22	were	O
23	induced	O
24	to	O
25	farrow	O
26	(	O
27	IF	O
28	sows	O
29	)	O
30	prematurely	O
31	by	O
32	injection	O
33	of	O
34	prostaglandin	O
35	F2	O
36	alpha	O
37	on	O
38	d	O
39	112	O
40	of	O
41	gestation	O
42	.	O
1	The	O
2	mechanism	O
3	of	O
4	peroxisome	O
5	proliferation	O
6	is	O
7	poorly	O
8	understood	O
9	.	O
1	It	O
2	contains	O
3	three	O
4	putative	O
5	TATA	O
6	boxes	O
7	far	O
8	upstream	O
9	of	O
10	the	O
11	main	O
12	start	O
13	sites	O
14	region	O
15	,	O
16	one	O
17	AP	B
18	-	I
19	1	I
20	box	I
21	,	O
22	one	O
23	AP	B
24	-	I
25	2	I
26	box	I
27	,	O
28	one	O
29	Malt	B
30	box	I
31	,	O
32	one	O
33	GAGA	O
34	box	O
35	,	O
36	one	O
37	half	O
38	serum	O
39	-	O
40	responsive	O
41	element	O
42	,	O
43	and	O
44	putative	O
45	binding	O
46	sites	O
47	for	O
48	Sp1	B
49	(	O
50	five	O
51	),	O
52	GC	B
53	-	I
54	rich	I
55	binding	I
56	factor	I
57	(	O
58	five	O
59	),	O
60	CTF	B
61	-	I
62	NF1	I
63	(	O
64	one	O
65	),	O
66	Myb	B
67	(	O
68	one	O
69	),	O
70	p53	B
71	(	O
72	two	O
73	),	O
74	Ets	B
75	-	I
76	1	I
77	(	O
78	one	O
79	),	O
80	NF	B
81	-	I
82	IL6	I
83	(	O
84	two	O
85	),	O
86	MyoD	B
87	(	O
88	two	O
89	),	O
90	Zeste	B
91	(	O
92	one	O
93	),	O
94	and	O
95	hepatocyte	B
96	nuclear	I
97	factor	I
98	-	I
99	5	I
100	(	O
101	one	O
102	).	O
1	The	O
2	nucleotide	O
3	sequence	O
4	directly	O
5	upstream	O
6	of	O
7	fimA	B
8	contains	O
9	two	O
10	open	O
11	reading	O
12	frames	O
13	,	O
14	ORF5	O
15	and	O
16	ORF1	O
17	,	O
18	whose	O
19	deduced	O
20	protein	O
21	products	O
22	are	O
23	homologous	O
24	to	O
25	members	O
26	of	O
27	a	O
28	superfamily	O
29	of	O
30	ATP	B
31	-	I
32	binding	I
33	cassette	I
34	membrane	I
35	transport	I
36	proteins	I
37	,	O
38	including	O
39	both	O
40	prokaryotic	O
41	and	O
42	eukaryotic	O
43	uptake	O
44	and	O
45	export	O
46	systems	O
47	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	low	O
6	concentrations	O
7	of	O
8	IL	B
9	-	I
10	1	I
11	beta	I
12	may	O
13	be	O
14	useful	O
15	for	O
16	nonsurgical	O
17	treatment	O
18	of	O
19	human	O
20	vitreous	O
21	hemorrhage	O
22	.	O
1	By	O
2	using	O
3	lacZ	B
4	fusions	I
5	,	O
6	it	O
7	was	O
8	possible	O
9	to	O
10	localize	O
11	the	O
12	DNA	O
13	sequences	O
14	required	O
15	to	O
16	mediate	O
17	nitrate	O
18	repression	O
19	to	O
20	the	O
21	pfl	B
22	promoter	I
23	-	I
24	regulatory	I
25	region	I
26	.	O
1	This	O
2	apparently	O
3	anomalous	O
4	structure	O
5	/	O
6	activity	O
7	relationship	O
8	raises	O
9	important	O
10	issues	O
11	for	O
12	understanding	O
13	the	O
14	evolution	O
15	of	O
16	regulatory	O
17	peptides	O
18	and	O
19	the	O
20	mechanisms	O
21	that	O
22	control	O
23	their	O
24	expression	O
25	.	O
1	When	O
2	excluding	O
3	children	O
4	with	O
5	ocular	O
6	and	O
7	cerebral	O
8	pathology	O
9	,	O
10	32	O
11	matched	O
12	pairs	O
13	of	O
14	premature	O
15	and	O
16	control	O
17	children	O
18	remained	O
19	.	O
1	They	O
2	include	O
3	genes	O
4	encoding	O
5	three	O
6	subunits	O
7	of	O
8	the	O
9	cytochrome	B
10	oxidase	I
11	(	O
12	cox1	B
13	to	I
14	3	I
15	),	O
16	apocytochrome	B
17	b	I
18	(	O
19	cob	B
20	),	O
21	seven	O
22	subunits	O
23	of	O
24	the	O
25	NADH	B
26	dehydrogenase	I
27	complex	I
28	(	O
29	nad1	B
30	to	I
31	6	I
32	,	O
33	nad4L	B
34	),	O
35	two	O
36	ATPase	B
37	subunits	O
38	(	O
39	atp6	B
40	and	O
41	atp9	B
42	),	O
43	three	O
44	ribosomal	O
45	RNAs	O
46	(	O
47	rrn5	B
48	,	O
49	srn	B
50	and	O
51	lrn	B
52	),	O
53	23	O
54	tRNAs	O
55	and	O
56	four	O
57	ribosomal	O
58	proteins	O
59	(	O
60	rps3	B
61	,	O
62	rps11	B
63	,	O
64	rps12	B
65	and	O
66	rpl16	B
67	).	O
1	From	O
2	day	O
3	10	O
4	,	O
5	a	O
6	significant	O
7	increase	O
8	in	O
9	platelet	O
10	count	O
11	was	O
12	observed	O
13	in	O
14	eight	O
15	of	O
16	the	O
17	ten	O
18	patients	O
19	treated	O
20	with	O
21	heparin	O
22	(	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	),	O
29	with	O
30	return	O
31	to	O
32	the	O
33	initial	O
34	value	O
35	after	O
36	heparin	O
37	cessation	O
38	in	O
39	six	O
40	of	O
41	the	O
42	responders	O
43	.	O
1	These	O
2	""""	O
3	nucleocapsid	O
4	-	O
5	like	O
6	""""	O
7	structures	O
8	were	O
9	readily	O
10	purified	O
11	by	O
12	density	O
13	gradient	O
14	centrifugation	O
15	.	O
1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	transactivation	O
6	domain	O
7	of	O
8	heat	B
9	shock	I
10	factor	I
11	1	I
12	is	O
13	negatively	O
14	regulated	O
15	and	O
16	stress	O
17	responsive	O
18	.	O
1	However	O
2	,	O
3	unlike	O
4	Bcl	B
5	-	I
6	2	I
7	and	O
8	the	O
9	E1B	B
10	19K	I
11	proteins	I
12	,	O
13	which	O
14	completely	O
15	block	O
16	apoptosis	O
17	but	O
18	not	O
19	p53	B
20	-	O
21	dependent	O
22	growth	O
23	arrest	O
24	,	O
25	H	B
26	-	I
27	ras	I
28	expression	O
29	permitted	O
30	DNA	O
31	synthesis	O
32	and	O
33	cell	O
34	proliferation	O
35	in	O
36	the	O
37	presence	O
38	of	O
39	high	O
40	levels	O
41	of	O
42	wild	B
43	-	I
44	type	I
45	p53	I
46	.	O
1	Hepatitis	O
2	B	O
3	vaccine	O
4	:	O
5	still	O
6	has	O
7	its	O
8	problems	O
9	.	O
1	We	O
2	show	O
3	here	O
4	that	O
5	RA	O
6	and	O
7	E1A	B
8	induce	O
9	phosphorylation	O
10	of	O
11	the	O
12	E1A	B
13	-	I
14	associated	I
15	300	I
16	kDa	I
17	protein	I
18	(	O
19	p300	B
20	)	O
21	during	O
22	the	O
23	differentiation	O
24	of	O
25	F9	O
26	cells	O
27	.	O
1	Mutational	O
2	analysis	O
3	of	O
4	potential	O
5	activating	O
6	phosphorylation	O
7	sites	O
8	found	O
9	in	O
10	NIMA	B
11	,	O
12	NIM	B
13	-	I
14	1	I
15	,	O
16	and	O
17	related	O
18	protein	O
19	kinases	O
20	was	O
21	performed	O
22	on	O
23	NIMA	B
24	.	O
1	Radiotherapy	O
2	and	O
3	early	O
4	orchiectomy	O
5	in	O
6	stage	O
7	D1	O
8	prostatic	O
9	carcinoma	O
1	Structural	O
2	organization	O
3	and	O
4	developmental	O
5	expression	O
6	pattern	O
7	of	O
8	the	O
9	mouse	B
10	WD	I
11	-	I
12	repeat	I
13	gene	I
14	DMR	I
15	-	I
16	N9	I
17	immediately	O
18	upstream	O
19	of	O
20	the	O
21	myotonic	B
22	dystrophy	I
23	locus	I
24	.	O
1	Here	O
2	we	O
3	show	O
4	that	O
5	messenger	O
6	RNAs	O
7	encoding	O
8	trans	O
9	-	O
10	sialidases	O
11	containing	O
12	the	O
13	repeats	O
14	are	O
15	not	O
16	present	O
17	in	O
18	epimastigotes	O
19	but	O
20	are	O
21	abundant	O
22	in	O
23	trypomastigotes	O
24	.	O
1	In	O
2	contrast	O
3	,	O
4	both	O
5	C	O
6	-	O
7	Lys	O
8	and	O
9	C	O
10	-	O
11	Thr	O
12	retained	O
13	high	O
14	levels	O
15	of	O
16	kinase	O
17	activity	O
18	and	O
19	were	O
20	capable	O
21	of	O
22	responding	O
23	to	O
24	stimulation	O
25	.	O
1	Here	O
2	we	O
3	describe	O
4	an	O
5	in	O
6	vitro	O
7	assay	O
8	where	O
9	the	O
10	NS3	B
11	-	I
12	4A	I
13	polyprotein	I
14	,	O
15	NS3	B
16	,	O
17	the	O
18	serine	O
19	proteinase	O
20	domain	O
21	(	O
22	the	O
23	N	O
24	-	O
25	terminal	O
26	181	O
27	residues	O
28	of	O
29	NS3	O
30	),	O
31	and	O
32	the	O
33	NS4A	B
34	cofactor	I
35	were	O
36	produced	O
37	by	O
38	cell	O
39	-	O
40	free	O
41	translation	O
42	and	O
43	tested	O
44	for	O
45	trans	O
46	-	O
47	processing	O
48	of	O
49	radiolabeled	O
50	substrates	O
51	.	O
1	Our	O
2	evidence	O
3	derives	O
4	from	O
5	three	O
6	principal	O
7	observations	O
8	:	O
9	1	O
10	)	O
11	a	O
12	transfection	O
13	construct	O
14	containing	O
15	only	O
16	122	O
17	nucleotides	O
18	(	O
19	nt	O
20	)	O
21	of	O
22	promoter	O
23	1	O
24	and	O
25	328	O
26	nt	O
27	of	O
28	the	O
29	5	O
30	'-	O
31	UTR	O
32	retained	O
33	full	O
34	PGE2	O
35	-	O
36	stimulated	O
37	reporter	O
38	expression	O
39	;	O
40	2	O
41	)	O
42	maximal	O
43	PGE2	O
44	-	O
45	driven	O
46	reporter	O
47	expression	O
48	required	O
49	the	O
50	presence	O
51	of	O
52	nt	O
53	196	O
54	to	O
55	328	O
56	of	O
57	exon	O
58	1	O
59	when	O
60	tested	O
61	within	O
62	the	O
63	context	O
64	of	O
65	IGF	B
66	-	I
67	I	I
68	promoter	I
69	1	I
70	;	O
71	3	O
72	)	O
73	cotransfection	O
74	of	O
75	IGF	B
76	-	I
77	I	I
78	promoter	I
79	-	O
80	luciferase	B
81	-	O
82	reporter	O
83	constructs	O
84	with	O
85	a	O
86	plasmid	O
87	encoding	O
88	the	O
89	alpha	O
90	-	O
91	isoform	O
92	of	O
93	the	O
94	catalytic	O
95	subunit	O
96	of	O
97	murine	B
98	cAMP	I
99	-	I
100	dependent	I
101	protein	I
102	kinase	I
103	(	O
104	PKA	B
105	)	O
106	produced	O
107	results	O
108	comparable	O
109	to	O
110	those	O
111	seen	O
112	with	O
113	PGE2	O
114	treatment	O
115	,	O
116	whereas	O
117	cotransfection	O
118	with	O
119	a	O
120	plasmid	O
121	encoding	O
122	a	O
123	mutant	O
124	regulatory	O
125	subunit	O
126	of	O
127	PKA	B
128	that	O
129	cannot	O
130	bind	O
131	cAMP	O
132	blocked	O
133	PGE2	O
134	-	O
135	induced	O
136	reporter	O
137	expression	O
138	.	O
1	In	O
2	flies	O
3	,	O
4	the	O
5	dShc	B
6	protein	I
7	physically	O
8	associates	O
9	with	O
10	the	O
11	activated	O
12	Drosophila	B
13	epidermal	I
14	growth	I
15	factor	I
16	receptor	I
17	homolog	I
18	(	O
19	DER	B
20	)	O
21	and	O
22	is	O
23	inducibly	O
24	phosphorylated	O
25	on	O
26	tyrosine	O
27	by	O
28	DER	B
29	.	O
1	In	O
2	wild	O
3	-	O
4	type	O
5	cells	O
6	,	O
7	SSM1b	B
8	transcripts	I
9	accumulate	O
10	to	O
11	twice	O
12	the	O
13	level	O
14	of	O
15	SSM1a	B
16	transcripts	I
17	,	O
18	suggesting	O
19	that	O
20	SSM1b	B
21	is	O
22	responsible	O
23	for	O
24	the	O
25	majority	O
26	of	O
27	the	O
28	Ssm1p	B
29	pool	O
30	.	O
1	The	O
2	yeast	O
3	enzyme	O
4	was	O
5	6	O
6	-	O
7	fold	O
8	slower	O
9	than	O
10	the	O
11	mammalian	O
12	enzymes	O
13	,	O
14	which	O
15	made	O
16	it	O
17	amenable	O
18	to	O
19	pre	O
20	-	O
21	steady	O
22	-	O
23	state	O
24	stopped	O
25	-	O
26	flow	O
27	spectroscopic	O
28	kinetic	O
29	analysis	O
30	at	O
31	30	O
32	degrees	O
33	C	O
34	and	O
35	pH	O
36	6	O
37	.	O
38	0	O
39	.	O
1	We	O
2	conclude	O
3	that	O
4	transcription	O
5	activation	O
6	by	O
7	LEF	B
8	-	I
9	1	I
10	in	O
11	vitro	O
12	is	O
13	a	O
14	chromatin	O
15	-	O
16	dependent	O
17	process	O
18	that	O
19	requires	O
20	a	O
21	functional	O
22	trans	O
23	-	O
24	activation	O
25	domain	O
26	in	O
27	addition	O
28	to	O
29	the	O
30	HMG	B
31	domain	I
32	.	O
1	The	O
2	plant	O
3	hormone	O
4	auxin	O
5	transcriptionally	O
6	activates	O
7	early	B
8	genes	I
9	.	O
1	The	O
2	ubiquitous	O
3	transcription	O
4	factor	O
5	Oct	B
6	-	I
7	1	I
8	forms	O
9	complexes	O
10	with	O
11	an	O
12	octamer	O
13	motif	O
14	present	O
15	within	O
16	FPIV	O
17	by	O
18	gel	O
19	shift	O
20	analysis	O
21	with	O
22	liver	O
23	and	O
24	kidney	O
25	extracts	O
26	,	O
27	making	O
28	Oct	B
29	-	I
30	1	I
31	an	O
32	intriguing	O
33	candidate	O
34	for	O
35	partnership	O
36	in	O
37	androgen	O
38	regulation	O
39	.	O
1	The	O
2	character	O
3	of	O
4	specific	O
5	immune	O
6	response	O
7	in	O
8	101	O
9	immunized	O
10	children	O
11	and	O
12	in	O
13	12	O
14	adults	O
15	belonging	O
16	to	O
17	a	O
18	high	O
19	risk	O
20	group	O
21	with	O
22	respect	O
23	to	O
24	VHB	O
25	.	O
1	After	O
2	nadolol	O
3	,	O
4	heart	O
5	rate	O
6	decreased	O
7	(-	O
8	22	O
9	+/-	O
10	8	O
11	%),	O
12	and	O
13	so	O
14	did	O
15	PBV	O
16	and	O
17	PBF	O
18	(	O
19	8	O
20	.	O
21	8	O
22	+/-	O
23	3	O
24	.	O
25	4	O
26	vs	O
27	.	O
1	Transabdominal	O
2	repair	O
3	of	O
4	type	O
5	IV	O
6	thoraco	O
7	-	O
8	abdominal	O
9	aortic	O
10	aneurysms	O
11	.	O
1	A	O
2	.	O
1	Genomic	O
2	structure	O
3	and	O
4	chromosomal	O
5	location	O
6	of	O
7	the	O
8	mouse	B
9	pre	I
10	-	I
11	T	I
12	-	I
13	cell	I
14	receptor	I
15	alpha	I
16	gene	I
17	.	O
1	A	O
2	single	O
3	-	O
4	case	O
5	experimental	O
6	ABAB	O
7	multiple	O
8	baseline	O
9	design	O
10	was	O
11	employed	O
12	to	O
13	test	O
14	for	O
15	treatment	O
16	effectiveness	O
17	.	O
1	We	O
2	conclude	O
3	that	O
4	,	O
5	in	O
6	comparison	O
7	to	O
8	reports	O
9	from	O
10	other	O
11	regions	O
12	,	O
13	Scandinavian	O
14	renal	O
15	transplant	O
16	recipients	O
17	are	O
18	at	O
19	high	O
20	risk	O
21	of	O
22	dying	O
23	of	O
24	IHD	O
25	.	O
1	Little	O
2	or	O
3	no	O
4	protection	O
5	was	O
6	detected	O
7	using	O
8	adrenal	O
9	cortex	O
10	,	O
11	adrenal	O
12	medulla	O
13	,	O
14	liver	O
15	,	O
16	kidney	O
17	cortex	O
18	,	O
19	spleen	O
20	,	O
21	or	O
22	T	O
23	-	O
24	lymphocyte	O
25	total	O
26	RNA	O
27	.	O
1	RT	O
2	-	O
3	PCR	O
4	using	O
5	1	O
6	.	O
7	D	O
8	-	O
9	specific	O
10	primers	O
11	showed	O
12	that	O
13	kidney	O
14	,	O
15	brain	O
16	and	O
17	prostate	O
18	do	O
19	not	O
20	express	O
21	1	O
22	.	O
23	D	O
24	mRNA	O
25	even	O
26	though	O
27	kidney	O
28	and	O
29	brain	O
30	are	O
31	the	O
32	most	O
33	abundant	O
34	source	O
35	for	O
36	aFGF	B
37	protein	I
38	.	O
1	This	O
2	agent	O
3	,	O
4	isolated	O
5	from	O
6	the	O
7	fungus	O
8	Streptomyces	O
9	tsukubaensis	O
10	,	O
11	has	O
12	a	O
13	mechanism	O
14	of	O
15	action	O
16	similar	O
17	to	O
18	that	O
19	of	O
20	cyclosporine	O
21	.	O
1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	-	I
7	binding	I
8	protein	I
9	-	I
10	2	I
11	(	O
12	IGF	B
13	-	I
14	BP	I
15	-	I
16	2	I
17	)	O
18	transcription	O
19	in	O
20	rat	O
21	liver	O
22	varies	O
23	with	O
24	developmental	O
25	age	O
26	and	O
27	fasting	O
28	.	O
1	Reverse	B
2	transcriptase	I
3	and	O
4	protease	O
5	activities	O
6	of	O
7	avian	O
8	leukosis	O
9	virus	O
10	Gag	B
11	-	O
12	Pol	B
13	fusion	O
14	proteins	O
15	expressed	O
16	in	O
17	insect	O
18	cells	O
19	.	O
1	The	O
2	leader	O
3	sequence	O
4	of	O
5	the	O
6	isolated	O
7	cDNA	O
8	clone	O
9	contains	O
10	several	O
11	small	O
12	open	O
13	reading	O
14	frames	O
15	upstream	O
16	of	O
17	the	O
18	initiation	O
19	codon	O
20	of	O
21	the	O
22	largest	O
23	open	O
24	reading	O
25	frame	O
26	coding	O
27	for	O
28	the	O
29	homeodomain	B
30	protein	I
31	.	O
1	Cell	O
2	adhesion	O
3	and	O
4	migration	O
5	assays	O
6	demonstrate	O
7	that	O
8	alpha	B
9	6	I
10	beta	I
11	1	I
12	is	O
13	the	O
14	major	O
15	laminin	B
16	receptor	I
17	in	O
18	undifferentiated	O
19	F9	O
20	cells	O
21	as	O
22	well	O
23	as	O
24	F9	O
25	-	O
26	derived	O
27	PE	O
28	cells	O
29	.	O
1	Inhibition	O
2	assays	O
3	performed	O
4	with	O
5	over	O
6	30	O
7	different	O
8	natural	O
9	and	O
10	synthetic	O
11	sialylated	O
12	and	O
13	/	O
14	or	O
15	sulfated	O
16	compounds	O
17	are	O
18	utilized	O
19	to	O
20	define	O
21	in	O
22	greater	O
23	detail	O
24	specific	O
25	structural	O
26	features	O
27	involved	O
28	in	O
29	oligosaccharide	O
30	-	O
31	protein	O
32	binding	O
33	.	O
1	Atopic	O
2	dermatitis	O
3	is	O
4	an	O
5	""""	O
6	itch	O
7	which	O
8	rashes	O
9	and	O
10	not	O
11	a	O
12	rash	O
13	which	O
14	itches	O
15	""""	O
16	and	O
17	therefore	O
18	,	O
19	any	O
20	patient	O
21	treatment	O
22	program	O
23	should	O
24	address	O
25	the	O
26	multiplicity	O
27	of	O
28	potential	O
29	trigger	O
30	factors	O
31	that	O
32	provoke	O
33	this	O
34	itching	O
35	.	O
1	To	O
2	study	O
3	the	O
4	mechanisms	O
5	as	O
6	well	O
7	as	O
8	magnitude	O
9	of	O
10	the	O
11	transmembrane	O
12	transfer	O
13	of	O
14	bacterial	O
15	products	O
16	from	O
17	the	O
18	dialysate	O
19	,	O
20	we	O
21	developed	O
22	a	O
23	computerized	O
24	in	O
25	vitro	O
26	dialysis	O
27	model	O
28	which	O
29	provides	O
30	continuous	O
31	pressure	O
32	recording	O
33	from	O
34	the	O
35	arterial	O
36	,	O
37	venous	O
38	,	O
39	dialysate	O
40	inflow	O
41	and	O
42	outflow	O
43	ports	O
44	.	O
1	The	O
2	NarX	B
3	and	O
4	NarQ	B
5	proteins	I
6	with	O
7	amino	O
8	acid	O
9	substitutions	O
10	at	O
11	the	O
12	first	O
13	conserved	O
14	histidine	O
15	position	O
16	were	O
17	also	O
18	unable	O
19	to	O
20	dephosphorylate	O
21	NarL	B
22	-	O
23	phosphate	O
24	in	O
25	vitro	O
26	.	O
1	Because	O
2	ATF	B
3	-	I
4	1	I
5	and	O
6	CREM	B
7	are	O
8	known	O
9	to	O
10	bind	O
11	to	O
12	cAMP	O
13	response	O
14	elements	O
15	(	O
16	CRE	O
17	),	O
18	this	O
19	functional	O
20	sequence	O
21	was	O
22	named	O
23	the	O
24	kappa	O
25	E3	O
26	'-	O
27	CRE	O
28	.	O
1	The	O
2	Ng	B
3	/	I
4	RC3	I
5	and	O
6	PKC	B
7	-	I
8	gamma	I
9	genes	I
10	have	O
11	a	O
12	similar	O
13	expression	O
14	pattern	O
15	in	O
16	the	O
17	brain	O
18	during	O
19	development	O
20	.	O
1	As	O
2	in	O
3	Tb	O
4	,	O
5	U6	B
6	is	O
7	a	O
8	single	O
9	-	O
10	copy	O
11	gene	O
12	and	O
13	two	O
14	tRNA	O
15	genes	O
16	,	O
17	tRNAGln	B
18	and	O
19	tRNAIle	B
20	,	O
21	are	O
22	found	O
23	upstream	O
24	to	O
25	the	O
26	gene	O
27	.	O
1	However	O
2	,	O
3	the	O
4	mouse	O
5	has	O
6	previously	O
7	been	O
8	shown	O
9	to	O
10	possess	O
11	only	O
12	three	O
13	forms	O
14	of	O
15	ADH	B
16	.	O
1	During	O
2	IC	O
3	breaths	O
4	and	O
5	following	O
6	EC	O
7	and	O
8	VC	O
9	breaths	O
10	at	O
11	rest	O
12	,	O
13	end	O
14	-	O
15	tidal	O
16	CO2	O
17	pressure	O
18	(	O
19	PET	O
20	,	O
21	CO2	O
22	)	O
23	fell	O
24	by	O
25	7	O
26	.	O
27	5	O
28	,	O
29	8	O
30	.	O
31	5	O
32	and	O
33	9	O
34	.	O
35	5	O
36	mmHg	O
37	,	O
38	respectively	O
39	.	O
1	Icterus	O
2	and	O
3	beta	O
4	-	O
5	thalassemia	O
6	in	O
7	Congolese	O
8	children	O
9	in	O
10	Brazzaville	O
1	Data	O
2	from	O
3	the	O
4	V	O
5	-	O
6	HeFT	O
7	II	O
8	show	O
9	that	O
10	at	O
11	2	O
12	-	O
13	year	O
14	follow	O
15	-	O
16	up	O
17	,	O
18	a	O
19	progressive	O
20	rise	O
21	of	O
22	plasma	O
23	norepinephrine	O
24	was	O
25	observed	O
26	in	O
27	both	O
28	treatment	O
29	arms	O
30	,	O
31	suggesting	O
32	that	O
33	disease	O
34	progresses	O
35	despite	O
36	treatment	O
37	with	O
38	either	O
39	an	O
40	angiotensin	B
41	-	I
42	converting	I
43	enzyme	I
44	inhibitor	O
45	,	O
46	enalapril	O
47	,	O
48	or	O
49	vasodilator	O
50	therapy	O
51	with	O
52	hydralazine	O
53	/	O
54	isosorbide	O
55	dinitrate	O
56	.	O
1	The	O
2	protein	O
3	is	O
4	composed	O
5	of	O
6	a	O
7	central	O
8	alpha	O
9	-	O
10	helical	O
11	portion	O
12	with	O
13	globular	O
14	domains	O
15	at	O
16	both	O
17	NH2	O
18	and	O
19	COOH	O
20	termini	O
21	,	O
22	and	O
23	the	O
24	epitope	O
25	to	O
26	the	O
27	monoclonal	O
28	antibody	O
29	resides	O
30	in	O
31	the	O
32	central	O
33	alpha	O
34	-	O
35	helical	O
36	stalk	O
37	.	O
1	For	O
2	replication	O
3	reporter	O
4	constructs	O
5	where	O
6	E1	B
7	and	O
8	E2	B
9	are	O
10	supplied	O
11	in	O
12	trans	O
13	by	O
14	the	O
15	respective	O
16	expression	O
17	vectors	O
18	,	O
19	distance	O
20	between	O
21	the	O
22	half	O
23	sites	O
24	seems	O
25	to	O
26	play	O
27	a	O
28	major	O
29	role	O
30	,	O
31	yet	O
32	the	O
33	phasing	O
34	relationships	O
35	are	O
36	measurable	O
37	.	O
1	As	O
2	it	O
3	had	O
4	been	O
5	previously	O
6	reported	O
7	that	O
8	the	O
9	18	O
10	-	O
11	bp	O
12	palindrome	O
13	contains	O
14	sufficient	O
15	nucleotide	O
16	sequence	O
17	information	O
18	for	O
19	E1	B
20	binding	O
21	,	O
22	we	O
23	speculate	O
24	that	O
25	a	O
26	minimal	O
27	E1	B
28	recognition	O
29	motif	O
30	is	O
31	presented	O
32	in	O
33	each	O
34	half	O
35	site	O
36	.	O
1	METHODS	O
2	:	O
3	Out	O
4	of	O
5	171	O
6	patients	O
7	receiving	O
8	anticoagulation	O
9	between	O
10	July	O
11	1992	O
12	and	O
13	December	O
14	1993	O
15	,	O
16	83	O
17	patients	O
18	with	O
19	hemispheric	O
20	embolisms	O
21	received	O
22	heparin	O
23	within	O
24	72	O
25	hours	O
26	from	O
27	onset	O
28	(	O
29	activated	O
30	partial	O
31	thromboplastin	B
32	time	O
33	[	O
34	aPTT	O
35	]	O
36	1	O
37	.	O
38	5	O
39	times	O
40	control	O
41	value	O
42	).	O
1	The	O
2	2	O
3	kb	O
4	of	O
5	5	O
6	'-	O
7	flanking	O
8	region	O
9	and	O
10	the	O
11	1	O
12	.	O
13	1	O
14	kb	O
15	of	O
16	the	O
17	entire	O
18	sGTH	B
19	alpha	I
20	subunit	I
21	coding	O
22	region	O
23	were	O
24	sequenced	O
25	from	O
26	the	O
27	genomic	O
28	clone	O
29	,	O
30	sGTH	B
31	alpha	I
32	-	I
33	G1	I
34	.	O
1	The	O
2	smallest	O
3	active	B
4	FecR	I
5	derivative	I
6	contained	O
7	59	O
8	amino	O
9	acid	O
10	residues	O
11	as	O
12	compared	O
13	to	O
14	the	O
15	317	O
16	residues	O
17	of	O
18	wild	B
19	-	I
20	type	I
21	FecR	I
22	.	O
1	Hybridization	O
2	signals	O
3	were	O
4	also	O
5	detected	O
6	with	O
7	total	O
8	DNAs	O
9	of	O
10	Rhizobium	O
11	leguminosarum	O
12	bv	O
13	.	O
14	phaseoli	O
15	,	O
16	Rhodobacter	O
17	capsulatus	O
18	and	O
19	Escherichia	O
20	coli	O
21	,	O
22	but	O
23	not	O
24	those	O
25	of	O
26	Xanthomonas	O
27	campestris	O
28	pv	O
29	.	O
30	campestris	O
31	and	O
32	Pseudomonas	O
33	putida	O
34	.	O
1	When	O
2	RNA	O
3	encoding	O
4	the	O
5	tail	O
6	domain	O
7	of	O
8	desmoglein	B
9	was	O
10	coinjected	O
11	with	O
12	plakoglobin	B
13	RNA	I
14	,	O
15	both	O
16	the	O
17	dorsalizing	O
18	effect	O
19	and	O
20	nuclear	O
21	accumulation	O
22	of	O
23	plakoglobin	B
24	were	O
25	suppressed	O
26	.	O
1	Intrastriatal	O
2	grafts	O
3	of	O
4	nigral	O
5	and	O
6	adrenal	O
7	tissues	O
8	have	O
9	been	O
10	found	O
11	to	O
12	be	O
13	effective	O
14	in	O
15	alleviating	O
16	many	O
17	of	O
18	the	O
19	simple	O
20	motor	O
21	and	O
22	sensorimotor	O
23	deficits	O
24	associated	O
25	with	O
26	lesions	O
27	of	O
28	the	O
29	nigrostriatal	O
30	dopamine	O
31	system	O
32	.	O
1	Thereafter	O
2	,	O
3	the	O
4	aggregation	O
5	rose	O
6	to	O
7	the	O
8	initial	O
9	100	O
10	%	O
11	value	O
12	4	O
13	h	O
14	after	O
15	drug	O
16	application	O
17	and	O
18	remained	O
19	at	O
20	this	O
21	level	O
22	during	O
23	the	O
24	observation	O
25	period	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	250	O
31	WORDS	O
32	)	O
1	The	O
2	protein	O
3	coding	O
4	region	O
5	,	O
6	1	O
7	,	O
8	696	O
9	bps	O
10	long	O
11	,	O
12	is	O
13	divided	O
14	by	O
15	an	O
16	intron	O
17	into	O
18	two	O
19	exons	O
20	.	O
1	The	O
2	proteins	O
3	are	O
4	more	O
5	than	O
6	90	O
7	%	O
8	identical	O
9	to	O
10	each	O
11	other	O
12	within	O
13	the	O
14	protein	O
15	kinase	O
16	domain	O
17	but	O
18	only	O
19	51	O
20	-	O
21	59	O
22	%	O
23	identical	O
24	to	O
25	other	O
26	casein	B
27	kinase	I
28	I	I
29	isoforms	I
30	within	O
31	this	O
32	region	O
33	.	O
1	Repair	O
2	of	O
3	this	O
4	insertion	O
5	by	O
6	homologous	O
7	recombination	O
8	restores	O
9	the	O
10	activity	O
11	of	O
12	the	O
13	hprt	B
14	locus	I
15	,	O
16	thus	O
17	confirming	O
18	the	O
19	site	O
20	of	O
21	mutation	O
22	.	O
1	Primer	O
2	extension	O
3	experiments	O
4	revealed	O
5	a	O
6	strong	O
7	transcription	O
8	initiation	O
9	site	O
10	102	O
11	bp	O
12	upstream	O
13	of	O
14	the	O
15	translational	O
16	start	O
17	site	O
18	.	O
1	The	O
2	other	O
3	two	O
4	clones	O
5	,	O
6	Ash	B
7	-	I
8	m	I
9	and	I
10	-	I
11	s	I
12	,	O
13	had	O
14	nucleotide	O
15	sequences	O
16	identical	O
17	with	O
18	Ash	B
19	-	I
20	l	I
21	cDNA	O
22	in	O
23	the	O
24	amino	O
25	-	O
26	terminal	O
27	region	O
28	.	O
1	We	O
2	found	O
3	that	O
4	PML	B
5	was	O
6	expressed	O
7	at	O
8	a	O
9	lower	O
10	level	O
11	in	O
12	S	O
13	,	O
14	G2	O
15	,	O
16	and	O
17	M	O
18	phases	O
19	and	O
20	at	O
21	a	O
22	significantly	O
23	higher	O
24	level	O
25	in	O
26	G1	O
27	phase	O
28	.	O
1	OBJECTIVE	O
2	:	O
3	To	O
4	investigate	O
5	the	O
6	incidence	O
7	and	O
8	presentation	O
9	of	O
10	acute	O
11	pernicious	O
12	or	O
13	fulminating	O
14	beriberi	O
15	in	O
16	a	O
17	general	O
18	district	O
19	hospital	O
20	.	O
1	We	O
2	report	O
3	here	O
4	that	O
5	in	O
6	cultured	O
7	Jurkat	O
8	T	O
9	cells	O
10	,	O
11	Cbl	B
12	is	O
13	coprecipitated	O
14	with	O
15	antibody	O
16	against	O
17	the	O
18	adapter	B
19	protein	I
20	Grb2	I
21	.	O
1	Characterization	O
2	of	O
3	fus1	B
4	of	O
5	Schizosaccharomyces	O
6	pombe	O
7	:	O
8	a	O
9	developmentally	O
10	controlled	O
11	function	O
12	needed	O
13	for	O
14	conjugation	O
15	.	O
1	SRY	B
2	-	I
3	related	I
4	cDNA	I
5	encoding	O
6	a	O
7	protein	O
8	with	O
9	a	O
10	high	B
11	-	I
12	mobility	I
13	-	I
14	group	I
15	(	O
16	HMG	B
17	)	O
18	box	O
19	and	O
20	a	O
21	leucine	O
22	zipper	O
23	motif	O
24	,	O
25	which	O
26	was	O
27	designated	O
28	SOX	B
29	-	I
30	LZ	I
31	,	O
32	was	O
33	isolated	O
34	from	O
35	a	O
36	rainbow	O
37	trout	O
38	testis	O
39	cDNA	O
40	library	O
41	.	O
1	The	O
2	RAP74	B
3	subunit	I
4	of	O
5	TFIIF	B
6	alone	O
7	contained	O
8	the	O
9	stimulatory	O
10	activity	O
11	and	O
12	the	O
13	minimal	O
14	region	O
15	sufficient	O
16	for	O
17	stimulation	O
18	corresponds	O
19	to	O
20	COOH	O
21	-	O
22	terminal	O
23	residues	O
24	358	O
25	-	O
26	517	O
27	.	O
1	This	O
2	last	O
3	region	O
4	contains	O
5	two	O
6	sites	O
7	that	O
8	bind	O
9	Ets	B
10	-	I
11	related	I
12	proteins	I
13	present	O
14	in	O
15	liver	O
16	nuclear	O
17	extracts	O
18	as	O
19	well	O
20	as	O
21	recombinant	B
22	purified	I
23	Ets	I
24	-	I
25	1	I
26	protein	I
27	.	O
1	By	O
2	contrast	O
3	,	O
4	deletion	O
5	of	O
6	this	O
7	Ras	B
8	-	I
9	binding	I
10	site	I
11	did	O
12	not	O
13	diminish	O
14	activation	O
15	of	O
16	Raf	B
17	-	I
18	1	I
19	kinase	I
20	by	O
21	Src	B
22	,	O
23	implying	O
24	that	O
25	Src	B
26	and	O
27	Ras	B
28	can	O
29	activate	O
30	Raf	B
31	-	I
32	1	I
33	through	O
34	independent	O
35	mechanisms	O
36	.	O
1	Both	O
2	can	O
3	be	O
4	elevated	O
5	on	O
6	a	O
7	single	O
8	vascular	O
9	pedicle	O
10	based	O
11	on	O
12	the	O
13	superficial	O
14	temporal	O
15	artery	O
16	,	O
17	the	O
18	double	O
19	-	O
20	layered	O
21	temporal	O
22	fascia	O
23	flap	O
24	.	O
1	A	O
2	unique	O
3	leucine	O
4	-	O
5	proline	O
6	repeat	O
7	element	O
8	found	O
9	N	O
10	-	O
11	terminal	O
12	to	O
13	the	O
14	DNA	O
15	-	O
16	binding	O
17	domain	O
18	of	O
19	EmBP	B
20	-	I
21	1	I
22	does	O
23	not	O
24	appear	O
25	to	O
26	play	O
27	a	O
28	role	O
29	in	O
30	DNA	O
31	-	O
32	binding	O
33	or	O
34	dimerization	O
35	.	O
1	Another	O
2	full	O
3	ORF	O
4	was	O
5	found	O
6	on	O
7	the	O
8	opposite	O
9	strand	O
10	downstream	O
11	from	O
12	the	O
13	nspC	B
14	gene	I
15	.	O
1	Two	O
2	related	O
3	cDNAs	O
4	were	O
5	isolated	O
6	that	O
7	encode	O
8	proteins	O
9	that	O
10	recognize	O
11	the	O
12	XMyoDa	B
13	TATA	I
14	motif	I
15	.	O
1	Deletion	O
2	of	O
3	both	O
4	prfA	B
5	and	O
6	ponA	B
7	resulted	O
8	in	O
9	extremely	O
10	slow	O
11	growth	O
12	and	O
13	a	O
14	reduction	O
15	in	O
16	sporulation	O
17	efficiency	O
18	.	O
1	For	O
2	the	O
3	first	O
4	time	O
5	we	O
6	describe	O
7	deletion	O
8	and	O
9	point	O
10	mutations	O
11	within	O
12	the	O
13	plasma	B
14	membrane	I
15	family	I
16	of	I
17	guanylyl	I
18	cyclase	I
19	receptors	I
20	that	O
21	result	O
22	in	O
23	the	O
24	formation	O
25	of	O
26	effective	O
27	dominant	O
28	negative	O
29	proteins	O
30	.	O
1	Atcys1	B
2	,	O
3	Athyp1	B
4	,	O
5	AKin10	B
6	and	O
7	the	O
8	ORF	O
9	are	O
10	very	O
11	close	O
12	to	O
13	each	O
14	other	O
15	and	O
16	organized	O
17	in	O
18	the	O
19	same	O
20	polarity	O
21	;	O
22	hence	O
23	,	O
24	the	O
25	intergenic	O
26	regions	O
27	probably	O
28	contain	O
29	,	O
30	within	O
31	less	O
32	than	O
33	0	O
34	.	O
35	5	O
36	kb	O
37	,	O
38	all	O
39	the	O
40	regulatory	O
41	elements	O
42	necessary	O
43	to	O
44	govern	O
45	initiation	O
46	and	O
47	termination	O
48	of	O
49	transcription	O
50	.	O
1	Southern	O
2	blot	O
3	hybridization	O
4	experiments	O
5	suggest	O
6	the	O
7	presence	O
8	of	O
9	one	O
10	copy	O
11	of	O
12	Atcys1	B
13	,	O
14	Athyp1	B
15	and	O
16	AKin10	B
17	per	O
18	haploid	O
19	genome	O
20	,	O
21	and	O
22	Northern	O
23	blot	O
24	analysis	O
25	demonstrates	O
26	that	O
27	the	O
28	three	O
29	genes	O
30	are	O
31	differentially	O
32	expressed	O
33	in	O
34	roots	O
35	,	O
36	shoots	O
37	and	O
38	leaves	O
39	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	HAC1	B
6	may	O
7	also	O
8	be	O
9	one	O
10	of	O
11	the	O
12	meiotic	O
13	genes	O
14	.	O
1	Furthermore	O
2	,	O
3	the	O
4	identification	O
5	of	O
6	a	O
7	Dr1	B
8	-	I
9	like	I
10	protein	I
11	in	O
12	A	O
13	.	O
14	thaliana	O
15	strongly	O
16	argues	O
17	for	O
18	the	O
19	ubiquity	O
20	of	O
21	this	O
22	protein	O
23	among	O
24	eukaryotic	O
25	genera	O
26	and	O
27	for	O
28	a	O
29	conserved	O
30	mechanism	O
31	to	O
32	regulate	O
33	transcription	O
34	initiation	O
35	that	O
36	involves	O
37	Dr1	B
38	.	O
1	Similarly	O
2	approximately	O
3	300	O
4	bp	O
5	of	O
6	sequence	O
7	downstream	O
8	of	O
9	the	O
10	translation	O
11	terminator	O
12	TGA	O
13	of	O
14	the	O
15	beta	B
16	-	I
17	tubulin	I
18	2	I
19	(	O
20	BTU2	B
21	)	O
22	gene	O
23	could	O
24	substitute	O
25	for	O
26	the	O
27	3	O
28	'	O
29	region	O
30	of	O
31	the	O
32	H4	B
33	-	I
34	I	I
35	gene	I
36	.	O
1	The	O
2	negative	O
3	regulatory	O
4	activity	O
5	of	O
6	the	O
7	N	O
8	-	O
9	terminal	O
10	domain	O
11	was	O
12	antagonized	O
13	by	O
14	a	O
15	C	O
16	-	O
17	terminal	O
18	segment	O
19	of	O
20	Pho81p	B
21	supplied	O
22	in	O
23	trans	O
24	.	O
1	Basal	O
2	components	O
3	of	O
4	the	O
5	transcription	O
6	apparatus	O
7	(	O
8	RNA	B
9	polymerase	I
10	II	I
11	,	O
12	TATA	B
13	-	I
14	binding	I
15	protein	I
16	)	O
17	contain	O
18	activation	O
19	domains	O
20	:	O
21	is	O
22	the	O
23	repetitive	O
24	C	O
25	-	O
26	terminal	O
27	domain	O
28	(	O
29	CTD	O
30	)	O
31	of	O
32	RNA	B
33	polymerase	I
34	II	I
35	a	O
36	""""	O
37	portable	O
38	enhancer	O
39	domain	O
40	"""?"	O
41	Regions	O
42	rich	O
43	in	O
44	serine	O
45	,	O
46	threonine	O
47	,	O
48	and	O
49	proline	O
50	residues	O
51	can	O
52	be	O
53	found	O
54	in	O
55	transcriptional	O
56	activation	O
57	domains	O
58	,	O
59	as	O
60	well	O
61	as	O
62	in	O
63	the	O
64	N	O
65	-	O
66	terminal	O
67	parts	O
68	of	O
69	mammalian	B
70	TATA	I
71	-	I
72	binding	I
73	proteins	I
74	,	O
75	where	O
76	they	O
77	are	O
78	interrupted	O
79	by	O
80	polyglutamine	O
81	stretches	O
82	.	O
1	A	O
2	genetic	O
3	complementation	O
4	system	O
5	was	O
6	developed	O
7	in	O
8	which	O
9	tobacco	B
10	etch	I
11	virus	I
12	(	I
13	TEV	I
14	)	I
15	polymerase	I
16	(	O
17	NIb	B
18	)-	O
19	expressing	O
20	transgenic	O
21	plants	O
22	or	O
23	protoplasts	O
24	were	O
25	inoculated	O
26	with	O
27	NIb	B
28	-	O
29	defective	O
30	TEV	B
31	mutants	I
32	.	O
1	The	O
2	HSD3B1	B
3	and	O
4	HSD3B2	B
5	genes	I
6	encoding	O
7	the	O
8	types	B
9	I	I
10	and	I
11	II	I
12	3	I
13	beta	I
14	-	I
15	HSD	I
16	isoenzymes	I
17	,	O
18	respectively	O
19	,	O
20	have	O
21	been	O
22	previously	O
23	assigned	O
24	by	O
25	in	O
26	situ	O
27	hybridization	O
28	to	O
29	the	O
30	chromosome	O
31	1p13	O
32	.	O
33	1	O
34	region	O
35	.	O
1	An	O
2	interatrial	O
3	communication	O
4	mitigates	O
5	the	O
6	impairment	O
7	of	O
8	LV	O
9	function	O
10	after	O
11	an	O
12	acute	O
13	and	O
14	sustained	O
15	drop	O
16	of	O
17	intrathoracic	O
18	pressure	O
19	.	O
1	Superoxide	B
2	dismutase	I
3	(	O
4	SOD	B
5	)	O
6	activity	O
7	decreased	O
8	significantly	O
9	in	O
10	sperm	O
11	subjected	O
12	to	O
13	direct	O
14	electric	O
15	current	O
16	in	O
17	comparison	O
18	to	O
19	the	O
20	control	O
21	or	O
22	the	O
23	sample	O
24	incubated	O
25	with	O
26	electrolyzed	O
27	medium	O
28	.	O
1	Sex	O
2	selection	O
3	via	O
4	albumin	B
5	columns	O
6	:	O
7	20	O
8	years	O
9	of	O
10	results	O
11	.	O
1	Because	O
2	of	O
3	the	O
4	functional	O
5	conservation	O
6	of	O
7	cell	O
8	cycle	O
9	control	O
10	elements	O
11	,	O
12	the	O
13	expression	O
14	of	O
15	a	O
16	vertebrate	B
17	wee1	I
18	or	O
19	mik1	B
20	homolog	I
21	would	O
22	be	O
23	expected	O
24	to	O
25	rescue	O
26	such	O
27	lethal	O
28	mutations	O
29	in	O
30	yeast	O
31	.	O
1	The	O
2	activity	O
3	of	O
4	6	O
5	-	O
6	fluoroquinolones	O
7	and	O
8	their	O
9	nonfluorinated	O
10	derivatives	O
11	is	O
12	compared	O
13	in	O
14	general	O
15	.	O
1	Lack	O
2	of	O
3	cyclin	B
4	D	I
5	-	O
6	Cdk	B
7	complexes	O
8	in	O
9	Rb	B
10	-	O
11	negative	O
12	cells	O
13	correlates	O
14	with	O
15	high	O
16	levels	O
17	of	O
18	p16INK4	B
19	/	O
20	MTS1	B
21	tumour	O
22	suppressor	O
23	gene	O
24	product	O
25	.	O
1	Cloning	O
2	by	O
3	complementation	O
4	and	O
5	subsequent	O
6	physical	O
7	and	O
8	genetic	O
9	analysis	O
10	revealed	O
11	that	O
12	it	O
13	maps	O
14	to	O
15	RAF1	B
16	.	O
1	The	O
2	interleukin	B
3	2	I
4	receptor	I
5	alpha	I
6	-	I
7	chain	I
8	(	O
9	IL	B
10	-	I
11	2R	I
12	alpha	I
13	)	O
14	gene	O
15	is	O
16	rapidly	O
17	and	O
18	potently	O
19	induced	O
20	in	O
21	T	O
22	cells	O
23	in	O
24	response	O
25	to	O
26	mitogenic	O
27	stimuli	O
28	.	O
1	OBJECTIVES	O
2	:	O
3	1	O
4	)	O
5	to	O
6	determine	O
7	serum	B
8	ACE	I
9	activity	O
10	in	O
11	patients	O
12	with	O
13	COPD	O
14	treated	O
15	with	O
16	and	O
17	without	O
18	continuous	O
19	ambulatory	O
20	oxygen	O
21	therapy	O
22	(	O
23	CAOT	O
24	);	O
25	2	O
26	)	O
27	to	O
28	verify	O
29	whether	O
30	there	O
31	is	O
32	a	O
33	correlation	O
34	between	O
35	ACE	B
36	and	O
37	any	O
38	hematological	O
39	,	O
40	spirometric	O
41	or	O
42	gasometric	O
43	parameter	O
44	.	O
1	In	O
2	order	O
3	to	O
4	infer	O
5	shape	O
6	from	O
7	contour	O
8	,	O
9	the	O
10	human	O
11	visual	O
12	system	O
13	must	O
14	selectively	O
15	integrate	O
16	fragments	O
17	projecting	O
18	from	O
19	a	O
20	common	O
21	object	O
22	while	O
23	keeping	O
24	fragments	O
25	from	O
26	different	O
27	objects	O
28	separate	O
29	.	O
1	The	O
2	tissue	O
3	-	O
4	specific	O
5	expression	O
6	of	O
7	DP	B
8	family	I
9	members	I
10	suggests	O
11	that	O
12	the	O
13	combination	O
14	of	O
15	DP	B
16	/	O
17	E2F	B
18	heterodimers	O
19	that	O
20	constitute	O
21	DRTF1	B
22	/	O
23	E2F	B
24	is	O
25	influenced	O
26	by	O
27	the	O
28	phenotype	O
29	of	O
30	the	O
31	cell	O
32	.	O
1	Analysis	O
2	of	O
3	the	O
4	sequence	O
5	upstream	O
6	of	O
7	this	O
8	initiation	O
9	codon	O
10	reveals	O
11	the	O
12	presence	O
13	of	O
14	a	O
15	promotor	O
16	sequence	O
17	.	O
1	The	O
2	regions	O
3	of	O
4	the	O
5	tooth	O
6	fracture	O
7	are	O
8	determined	O
9	.	O
1	The	O
2	NR2	O
3	hybrid	O
4	is	O
5	a	O
6	powerful	O
7	tool	O
8	for	O
9	the	O
10	mapping	O
11	of	O
12	new	O
13	probes	O
14	of	O
15	this	O
16	region	O
17	,	O
18	as	O
19	well	O
20	as	O
21	for	O
22	obtaining	O
23	new	O
24	informative	O
25	probes	O
26	specific	O
27	for	O
28	the	O
29	deletion	O
30	by	O
31	subtractive	O
32	cloning	O
33	of	O
34	the	O
35	region	O
36	.	O
1	Here	O
2	,	O
3	we	O
4	report	O
5	the	O
6	characterization	O
7	of	O
8	an	O
9	alternatively	O
10	processed	O
11	form	O
12	of	O
13	AFAP	B
14	-	I
15	110	I
16	that	O
17	encodes	O
18	an	O
19	additional	O
20	258	O
21	base	O
22	pair	O
23	(	O
24	bp	O
25	)	O
26	of	O
27	open	O
28	reading	O
29	frame	O
30	.	O
1	Endocytosis	O
2	and	O
3	lysosomal	O
4	targeting	O
5	of	O
6	epidermal	B
7	growth	I
8	factor	I
9	receptors	I
10	are	O
11	mediated	O
12	by	O
13	distinct	O
14	sequences	O
15	independent	O
16	of	O
17	the	O
18	tyrosine	B
19	kinase	I
20	domain	I
21	.	O
1	In	O
2	the	O
3	first	O
4	,	O
5	homologous	O
6	sequences	O
7	were	O
8	deleted	O
9	from	O
10	a	O
11	mouse	O
12	enhancer	O
13	,	O
14	resulting	O
15	in	O
16	a	O
17	tissue	O
18	-	O
19	specific	O
20	loss	O
21	of	O
22	activity	O
23	when	O
24	assayed	O
25	in	O
26	transgenic	O
27	mice	O
28	.	O
1	In	O
2	yeast	O
3	,	O
4	the	O
5	products	O
6	of	O
7	the	O
8	UPF1	B
9	and	O
10	UPF3	B
11	genes	I
12	are	O
13	required	O
14	for	O
15	this	O
16	decay	O
17	pathway	O
18	,	O
19	and	O
20	in	O
21	this	O
22	report	O
23	we	O
24	focus	O
25	on	O
26	the	O
27	identification	O
28	and	O
29	characterization	O
30	of	O
31	additional	O
32	factors	O
33	required	O
34	for	O
35	rapid	O
36	decay	O
37	of	O
38	nonsense	O
39	-	O
40	containing	O
41	mRNAs	O
42	.	O
1	With	O
2	a	O
3	population	O
4	of	O
5	853	O
6	million	O
7	there	O
8	should	O
9	be	O
10	51	O
11	,	O
12	204	O
13	patients	O
14	with	O
15	hemophilia	O
16	A	O
17	in	O
18	India	O
19	assuming	O
20	a	O
21	prevalence	O
22	of	O
23	6	O
24	/	O
25	100	O
26	,	O
27	000	O
28	population	O
29	.	O
1	TcPO2	O
2	measurement	O
3	appears	O
4	to	O
5	be	O
6	a	O
7	reliable	O
8	technique	O
9	that	O
10	can	O
11	influence	O
12	ischaemic	O
13	ulcer	O
14	management	O
15	.	O
1	Expression	O
2	of	O
3	h6	O
4	.	O
5	1	O
6	in	O
7	COS	O
8	-	O
9	1	O
10	cells	O
11	led	O
12	to	O
13	the	O
14	production	O
15	of	O
16	a	O
17	typical	O
18	type	B
19	IV	I
20	PDE	I
21	activity	O
22	in	O
23	that	O
24	cAMP	O
25	,	O
26	but	O
27	not	O
28	cGMP	O
29	,	O
30	served	O
31	as	O
32	substrate	O
33	and	O
34	its	O
35	activity	O
36	was	O
37	insensitive	O
38	to	O
39	either	O
40	Ca2	O
41	+/	O
42	CaM	B
43	or	O
44	cGMP	O
45	but	O
46	was	O
47	inhibited	O
48	by	O
49	low	O
50	concentrations	O
51	of	O
52	rolipram	O
53	.(	O
54	ABSTRACT	O
55	TRUNCATED	O
56	AT	O
57	400	O
58	WORDS	O
59	)	O
1	With	O
2	steady	O
3	illumination	O
4	,	O
5	outer	O
6	retinal	O
7	(	O
8	photoreceptor	O
9	)	O
10	QO2	O
11	decreased	O
12	to	O
13	1	O
14	.	O
15	4	O
16	+/-	O
17	0	O
18	.	O
19	9	O
20	ml	O
21	O2	O
22	/(	O
23	100	O
24	g	O
25	.	O
26	min	O
27	),	O
28	but	O
29	inner	O
30	retinal	O
31	QO2	O
32	remained	O
33	unchanged	O
34	at	O
35	3	O
36	.	O
37	7	O
38	+/-	O
39	1	O
40	.	O
41	5	O
42	ml	O
43	O2	O
44	/(	O
45	100	O
46	g	O
47	.	O
48	min	O
49	)	O
50	(	O
51	5	O
52	cats	O
53	).	O
1	These	O
2	observations	O
3	indicate	O
4	that	O
5	there	O
6	are	O
7	multiple	O
8	mechanisms	O
9	by	O
10	which	O
11	an	O
12	individual	O
13	transcript	O
14	can	O
15	be	O
16	degraded	O
17	following	O
18	deadenylation	O
19	.	O
1	Glomerular	O
2	hemodynamics	O
3	during	O
4	abortion	O
5	induced	O
6	by	O
7	RU	O
8	486	O
9	and	O
10	sepsis	O
11	in	O
12	rats	O
13	.	O
1	The	O
2	contribution	O
3	of	O
4	skin	O
5	flow	O
6	to	O
7	the	O
8	changes	O
9	in	O
10	760	O
11	-	O
12	800	O
13	nm	O
14	absorption	O
15	was	O
16	investigated	O
17	by	O
18	simultaneous	O
19	measurement	O
20	of	O
21	skin	O
22	flow	O
23	by	O
24	laser	O
25	flow	O
26	Doppler	O
27	and	O
28	NIR	O
29	recordings	O
30	during	O
31	hot	O
32	water	O
33	immersion	O
34	.	O
1	The	O
2	wild	O
3	-	O
4	type	O
5	and	O
6	altered	O
7	forms	O
8	of	O
9	the	O
10	F	B
11	protein	I
12	were	O
13	expressed	O
14	in	O
15	BHK	O
16	-	O
17	21	O
18	and	O
19	HeLa	O
20	T4	O
21	cells	O
22	by	O
23	use	O
24	of	O
25	the	O
26	recombinant	B
27	vaccinia	I
28	virus	I
29	-	I
30	encoding	I
31	T7	I
32	polymerase	I
33	system	O
34	.	O
1	Cooperative	O
2	dimerization	O
3	of	O
4	paired	B
5	class	O
6	homeo	O
7	domains	O
8	on	O
9	DNA	O
10	.	O
1	The	O
2	mutant	O
3	allele	O
4	of	O
5	the	O
6	alpha	B
7	1	I
8	-	I
9	tubulin	I
10	gene	I
11	was	O
12	designated	O
13	tua1	B
14	-	I
15	1	I
16	.	O
1	At	O
2	the	O
3	MTD	O
4	(	O
5	8	O
6	mg	O
7	/	O
8	m2	O
9	/	O
10	day	O
11	),	O
12	the	O
13	dose	O
14	-	O
15	limiting	O
16	toxicity	O
17	of	O
18	this	O
19	agent	O
20	is	O
21	myelosuppression	O
22	.	O
1	Some	O
2	of	O
3	these	O
4	targets	O
5	were	O
6	reported	O
7	to	O
8	code	O
9	for	O
10	molecules	O
11	involved	O
12	in	O
13	cell	O
14	-	O
15	cell	O
16	interactions	O
17	,	O
18	whereas	O
19	no	O
20	relationship	O
21	has	O
22	yet	O
23	been	O
24	demonstrated	O
25	between	O
26	Hox	B
27	genes	I
28	and	O
29	other	O
30	transcription	O
31	factors	O
32	involved	O
33	in	O
34	determining	O
35	and	O
36	/	O
37	or	O
38	maintaining	O
39	tissue	O
40	specificity	O
41	.	O
1	High	O
2	-	O
3	frequency	O
4	electrical	O
5	stimulation	O
6	in	O
7	the	O
8	hippocampus	O
9	leads	O
10	to	O
11	an	O
12	increase	O
13	in	O
14	synaptic	O
15	efficacy	O
16	that	O
17	lasts	O
18	for	O
19	many	O
20	hours	O
21	.	O
1	The	O
2	ratio	O
3	of	O
4	the	O
5	activity	O
6	of	O
7	arogenate	B
8	dehydrogenase	I
9	to	O
10	that	O
11	of	O
12	prephenate	B
13	dehydrogenase	I
14	(	O
15	approximately	O
16	3	O
17	:	O
18	1	O
19	)	O
20	remained	O
21	constant	O
22	throughout	O
23	purification	O
24	,	O
25	and	O
26	the	O
27	two	O
28	activities	O
29	were	O
30	therefore	O
31	inseparable	O
32	.	O
1	In	O
2	the	O
3	presence	O
4	of	O
5	the	O
6	in	O
7	vivo	O
8	reducing	O
9	system	O
10	(	O
11	thioredoxin	B
12	,	O
13	thioredoxin	B
14	reductase	I
15	,	O
16	and	O
17	NADPH	O
18	),	O
19	however	O
20	,	O
21	each	O
22	of	O
23	these	O
24	mutants	O
25	catalyzed	O
26	the	O
27	formation	O
28	of	O
29	only	O
30	0	O
31	.	O
32	6	O
33	-	O
34	0	O
35	.	O
36	8	O
37	dCTPs	O
38	per	O
39	mole	O
40	of	O
41	enzyme	O
42	.	O
1	Immunoreactive	O
2	AR	B
3	content	O
4	in	O
5	transfected	O
6	COS	O
7	-	O
8	1	O
9	cells	O
10	was	O
11	not	O
12	influenced	O
13	by	O
14	exposure	O
15	to	O
16	8	O
17	-	O
18	Br	O
19	-	O
20	cAMP	O
21	.	O
1	Genetic	O
2	alterations	O
3	in	O
4	elements	O
5	of	O
6	normal	O
7	signal	O
8	transduction	O
9	mechanisms	O
10	are	O
11	known	O
12	to	O
13	be	O
14	oncogenic	O
15	events	O
16	often	O
17	resulting	O
18	in	O
19	aberrant	O
20	activation	O
21	of	O
22	programs	O
23	of	O
24	gene	O
25	transcription	O
26	.	O
1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	One	O
6	hundred	O
7	eighty	O
8	-	O
9	four	O
10	chemotherapy	O
11	-	O
12	naive	O
13	patients	O
14	receiving	O
15	high	O
16	-	O
17	dose	O
18	cisplatin	O
19	(	O
20	81	O
21	to	O
22	120	O
23	mg	O
24	/	O
25	m2	O
26	)	O
27	were	O
28	randomized	O
29	to	O
30	receive	O
31	one	O
32	of	O
33	four	O
34	granisetron	O
35	doses	O
36	(	O
37	5	O
38	,	O
39	10	O
40	,	O
41	20	O
42	,	O
43	or	O
44	40	O
45	micrograms	O
46	/	O
47	kg	O
48	)	O
49	administered	O
50	before	O
51	chemotherapy	O
52	.	O
1	Specifically	O
2	,	O
3	this	O
4	study	O
5	determined	O
6	the	O
7	influence	O
8	of	O
9	:	O
10	(	O
11	1	O
12	)	O
13	an	O
14	awareness	O
15	strategy	O
16	,	O
17	(	O
18	2	O
19	)	O
20	a	O
21	non	O
22	-	O
23	awareness	O
24	strategy	O
25	,	O
26	(	O
27	3	O
28	)	O
29	a	O
30	Five	O
31	-	O
32	Step	O
33	Approach	O
34	strategy	O
35	and	O
36	(	O
37	4	O
38	)	O
39	a	O
40	control	O
41	condition	O
42	.	O
1	A	O
2	simple	O
3	registration	O
4	as	O
5	an	O
6	incentive	O
7	for	O
8	improvement	O
1	RESULTS	O
2	:	O
3	The	O
4	diagnostic	O
5	quality	O
6	of	O
7	FDG	O
8	images	O
9	was	O
10	at	O
11	least	O
12	as	O
13	good	O
14	as	O
15	that	O
16	of	O
17	their	O
18	Tl	O
19	-	O
20	201	O
21	counterparts	O
22	,	O
23	with	O
24	less	O
25	liver	O
26	background	O
27	in	O
28	all	O
29	but	O
30	one	O
31	FDG	O
32	study	O
33	.	O
1	Only	O
2	two	O
3	of	O
4	the	O
5	isoforms	O
6	possess	O
7	the	O
8	N	O
9	-	O
10	terminal	O
11	zinc	O
12	finger	O
13	domain	O
14	that	O
15	is	O
16	necessary	O
17	and	O
18	sufficient	O
19	for	O
20	TdT	B
21	promoter	I
22	binding	O
23	.	O
1	Because	O
2	endogenous	O
3	HSF	B
4	DNA	O
5	-	O
6	binding	O
7	activity	O
8	is	O
9	low	O
10	and	O
11	anti	B
12	-	I
13	hHSF1	I
14	antibody	I
15	does	O
16	not	O
17	recognize	O
18	Xenopus	B
19	HSF	I
20	,	O
21	we	O
22	employed	O
23	this	O
24	system	O
25	for	O
26	mapping	O
27	regions	O
28	in	O
29	hHSF1	B
30	that	O
31	are	O
32	required	O
33	for	O
34	the	O
35	maintenance	O
36	of	O
37	the	O
38	monomeric	O
39	state	O
40	.	O
1	The	O
2	predominant	O
3	binding	O
4	activity	O
5	was	O
6	not	O
7	Ets	B
8	-	I
9	1	I
10	but	O
11	rather	O
12	two	O
13	independent	O
14	DNA	O
15	-	O
16	protein	O
17	complexes	O
18	that	O
19	comigrated	O
20	in	O
21	mobility	O
22	shift	O
23	assays	O
24	.	O
1	Using	O
2	this	O
3	method	O
4	,	O
5	we	O
6	were	O
7	able	O
8	to	O
9	select	O
10	strong	O
11	enhancer	O
12	-	O
13	type	O
14	activation	O
15	domains	O
16	from	O
17	the	O
18	immediate	B
19	early	I
20	regions	I
21	of	O
22	two	O
23	herpesviruses	O
24	,	O
25	namely	O
26	pseudorabies	O
27	virus	O
28	and	O
29	bovine	O
30	herpesvirus	O
31	1	O
32	.	O
1	In	O
2	these	O
3	vectors	O
4	the	O
5	chimeric	B
6	long	I
7	terminal	I
8	repeat	I
9	(	O
10	chLTR	B
11	)	O
12	drives	O
13	the	O
14	expression	O
15	of	O
16	the	O
17	chloramphenicol	B
18	acetyl	I
19	transferase	I
20	(	O
21	CAT	B
22	)	O
23	reporter	O
24	gene	O
25	that	O
26	is	O
27	followed	O
28	by	O
29	an	O
30	internal	O
31	SV40	B
32	virus	I
33	early	I
34	region	I
35	promoter	I
36	linked	O
37	to	O
38	the	O
39	neomycin	B
40	phosphotransferase	I
41	II	I
42	(	O
43	NEO	B
44	)	O
45	gene	O
46	.	O
1	The	O
2	pretransplant	O
3	regimen	O
4	consisted	O
5	of	O
6	cyclophosphamide	O
7	(	O
8	120	O
9	mg	O
10	/	O
11	kg	O
12	)	O
13	and	O
14	total	O
15	body	O
16	irradiation	O
17	.	O
1	The	O
2	site	O
3	-	O
4	directed	O
5	mutation	O
6	of	O
7	the	O
8	kappa	B
9	B	I
10	motif	I
11	in	O
12	IL	B
13	-	I
14	6	I
15	/	O
16	CAT	B
17	plasmid	O
18	resulted	O
19	in	O
20	the	O
21	complete	O
22	abrogation	O
23	of	O
24	IL	B
25	-	I
26	6	I
27	promoter	I
28	activity	O
29	in	O
30	these	O
31	cells	O
32	.	O
1	Curiously	O
2	,	O
3	testololactone	O
4	was	O
5	earlier	O
6	and	O
7	more	O
8	widely	O
9	used	O
10	than	O
11	aminoglutethimide	O
12	in	O
13	treating	O
14	advanced	O
15	breast	O
16	carcinoma	O
17	.	O
1	However	O
2	,	O
3	rapamycin	O
4	inhibited	O
5	proliferation	O
6	of	O
7	Ba	O
8	/	O
9	F3	O
10	-	O
11	EpoRgp55	O
12	but	O
13	not	O
14	of	O
15	MEL	O
16	cells	O
17	despite	O
18	inhibition	O
19	of	O
20	p70	B
21	S6	I
22	kinase	I
23	activity	O
24	in	O
25	both	O
26	cells	O
27	.	O
1	The	O
2	hepatocyte	B
3	nuclear	I
4	factor	I
5	-	I
6	3	I
7	(	O
8	HNF	B
9	-	I
10	3	I
11	)/	O
12	forkhead	B
13	(	O
14	fkh	B
15	)	O
16	proteins	O
17	consist	O
18	of	O
19	an	O
20	extensive	O
21	family	O
22	of	O
23	tissue	O
24	-	O
25	specific	O
26	and	O
27	developmental	O
28	gene	O
29	regulators	O
30	which	O
31	share	O
32	homology	O
33	within	O
34	the	O
35	winged	O
36	helix	O
37	DNA	O
38	binding	O
39	motif	O
40	.	O
1	IFI16	B
2	consists	O
3	of	O
4	ten	O
5	exons	O
6	and	O
7	nine	O
8	intervening	O
9	introns	O
10	spanning	O
11	at	O
12	least	O
13	28	O
14	kilobases	O
15	(	O
16	kb	O
17	)	O
18	of	O
19	DNA	O
20	.	O
1	A	O
2	candidate	O
3	gene	O
4	for	O
5	Bcg	B
6	,	O
7	designated	O
8	natural	B
9	resistance	I
10	-	I
11	associated	I
12	macrophage	I
13	protein	I
14	(	O
15	Nramp	B
16	),	O
17	has	O
18	been	O
19	isolated	O
20	and	O
21	shown	O
22	to	O
23	encode	O
24	a	O
25	novel	O
26	macrophage	O
27	-	O
28	specific	O
29	membrane	O
30	protein	O
31	,	O
32	which	O
33	is	O
34	altered	O
35	in	O
36	susceptible	O
37	animals	O
38	.	O
1	Elementary	O
2	visual	O
3	hallucinations	O
4	in	O
5	migraine	O
6	and	O
7	epilepsy	O
8	.	O
1	All	O
2	nuclear	O
3	receptors	O
4	have	O
5	several	O
6	well	O
7	-	O
8	characterized	O
9	structural	O
10	domains	O
11	,	O
12	including	O
13	a	O
14	conserved	O
15	DNA	O
16	-	O
17	binding	O
18	domain	O
19	,	O
20	and	O
21	a	O
22	ligand	O
23	binding	O
24	domain	O
25	at	O
26	the	O
27	carboxyl	O
28	terminus	O
29	of	O
30	the	O
31	receptor	O
32	.	O
1	One	O
2	class	O
3	of	O
4	plasmids	O
5	contained	O
6	tRNA	B
7	(	I
8	His	I
9	)	I
10	genes	I
11	and	O
12	conferred	O
13	efficient	O
14	suppression	O
15	only	O
16	when	O
17	cells	O
18	were	O
19	starved	O
20	for	O
21	histidine	O
22	;	O
23	these	O
24	plasmids	O
25	suppressed	O
26	a	O
27	gcn2	B
28	deletion	O
29	much	O
30	less	O
31	efficiently	O
32	than	O
33	they	O
34	suppressed	O
35	gcn2	B
36	-	I
37	507	I
38	.	O
1	Thus	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	the	O
7	Cln2	B
8	PEST	I
9	domain	I
10	was	O
11	sufficient	O
12	to	O
13	destabilize	O
14	a	O
15	heterologous	O
16	protein	O
17	.	O
1	Although	O
2	a	O
3	carboxyl	O
4	-	O
5	terminal	O
6	HSF	B
7	transcriptional	O
8	activation	O
9	domain	O
10	is	O
11	critical	O
12	for	O
13	the	O
14	activation	O
15	of	O
16	CUP1	B
17	transcription	O
18	in	O
19	response	O
20	to	O
21	both	O
22	heat	O
23	shock	O
24	stress	O
25	and	O
26	glucose	O
27	starvation	O
28	,	O
29	this	O
30	region	O
31	is	O
32	dispensable	O
33	for	O
34	transient	O
35	heat	O
36	shock	O
37	activation	O
38	of	O
39	at	O
40	least	O
41	two	O
42	genes	O
43	encoding	O
44	members	O
45	of	O
46	the	O
47	S	O
48	.	O
49	cerevisiae	O
50	hsp70	B
51	family	I
52	.	O
1	PAI	B
2	-	I
3	1	I
4	levels	O
5	increased	O
6	significantly	O
7	in	O
8	patients	O
9	who	O
10	received	O
11	iohexol	O
12	but	O
13	not	O
14	in	O
15	those	O
16	who	O
17	received	O
18	ioxaglate	O
19	.	O
1	The	O
2	recovery	O
3	value	O
4	of	O
5	systolic	O
6	pressure	O
7	was	O
8	higher	O
9	than	O
10	diastolic	O
11	pressure	O
12	and	O
13	pulse	O
14	pressure	O
15	increased	O
16	.	O
1	An	O
2	unusual	O
3	complication	O
4	in	O
5	an	O
6	unsuitable	O
7	patient	O
8	.	O
1	Acta	O
2	572	O
3	,	O
4	113	O
5	-	O
6	120	O
7	].	O
1	Basal	O
2	plasma	O
3	AVP	B
4	levels	O
5	and	O
6	AVP	B
7	release	O
8	after	O
9	postural	O
10	change	O
11	were	O
12	assessed	O
13	,	O
14	and	O
15	plasma	O
16	NPY	B
17	levels	O
18	were	O
19	measured	O
20	in	O
21	the	O
22	same	O
23	samples	O
24	.	O
1	Sequence	O
2	analysis	O
3	revealed	O
4	:	O
5	1	O
6	)	O
7	a	O
8	kinase	O
9	catalytic	O
10	domain	O
11	most	O
12	characteristic	O
13	of	O
14	serine	B
15	/	I
16	threonine	I
17	kinases	I
18	but	O
19	hybrid	O
20	between	O
21	members	O
22	of	O
23	the	O
24	family	O
25	of	O
26	microtubule	B
27	-	I
28	associated	I
29	protein	I
30	kinase	I
31	kinase	I
32	kinases	I
33	and	O
34	the	O
35	fibroblast	B
36	growth	I
37	factor	I
38	receptor	I
39	family	I
40	;	O
41	2	O
42	)	O
43	two	O
44	putative	O
45	alpha	O
46	-	O
47	helical	O
48	leucine	O
49	zipper	O
50	motifs	O
51	separated	O
52	by	O
53	a	O
54	25	O
55	-	O
56	amino	O
57	acid	O
58	charged	O
59	intermediate	O
60	segment	O
61	but	O
62	lacking	O
63	an	O
64	NH2	O
65	-	O
66	terminal	O
67	basic	O
68	domain	O
69	;	O
70	and	O
71	3	O
72	)	O
73	COOH	O
74	-	O
75	terminal	O
76	and	O
77	NH2	O
78	-	O
79	terminal	O
80	proline	O
81	-	O
82	rich	O
83	domains	O
84	suggestive	O
85	of	O
86	src	B
87	homology	I
88	3	I
89	(	O
90	SH3	B
91	)	O
92	domain	O
93	binding	O
94	regions	O
95	.	O
1	The	O
2	other	O
3	element	O
4	bound	O
5	RBP	B
6	-	I
7	J	I
8	kappa	I
9	with	O
10	low	O
11	affinity	O
12	.	O
1	Moreover	O
2	,	O
3	the	O
4	ability	O
5	to	O
6	selectivity	O
7	arrest	O
8	elongation	O
9	by	O
10	polIII	B
11	at	O
12	defined	O
13	positions	O
14	within	O
15	the	O
16	tRNA	O
17	gene	O
18	transcription	O
19	unit	O
20	has	O
21	permitted	O
22	the	O
23	identification	O
24	of	O
25	discrete	O
26	functional	O
27	properties	O
28	of	O
29	paused	O
30	mammalian	B
31	polIII	I
32	ternary	I
33	complexes	I
34	.	O
1	Mutational	O
2	analysis	O
3	of	O
4	yeast	B
5	CEG1	I
6	demonstrated	O
7	that	O
8	four	O
9	of	O
10	the	O
11	five	O
12	conserved	O
13	motifs	O
14	are	O
15	essential	O
16	for	O
17	capping	B
18	enzyme	I
19	function	O
20	in	O
21	vivo	O
22	.	O
1	Splice	O
2	variations	O
3	in	O
4	genes	O
5	coding	O
6	for	O
7	the	O
8	transmembrane	B
9	FGF	I
10	receptor	I
11	(	O
12	FGFR	B
13	)	O
14	result	O
15	in	O
16	isoforms	O
17	that	O
18	vary	O
19	in	O
20	the	O
21	ectodomain	O
22	,	O
23	intracellular	O
24	juxtamembrane	O
25	domain	O
26	,	O
27	and	O
28	the	O
29	intracellular	O
30	kinase	O
31	domain	O
32	.	O
1	These	O
2	same	O
3	regions	O
4	showed	O
5	remarkable	O
6	homology	O
7	to	O
8	two	O
9	invertebrate	O
10	proteins	O
11	,	O
12	CNC	B
13	and	O
14	skin	B
15	-	I
16	1	I
17	,	O
18	postulated	O
19	to	O
20	regulate	O
21	embryonic	O
22	development	O
23	in	O
24	Drosophila	O
25	melanogaster	O
26	and	O
27	Caenorhabditis	O
28	elegans	O
29	,	O
30	respectively	O
31	.	O
1	I	O
2	hypothesize	O
3	that	O
4	white	B
5	gene	I
6	expression	O
7	from	O
8	P	B
9	[	I
10	en	I
11	]	I
12	is	O
13	repressed	O
14	by	O
15	the	O
16	formation	O
17	of	O
18	a	O
19	protein	O
20	complex	O
21	which	O
22	is	O
23	initiated	O
24	at	O
25	the	O
26	engrailed	B
27	PS	I
28	sites	I
29	and	O
30	also	O
31	requires	O
32	interactions	O
33	with	O
34	flanking	O
35	genomic	O
36	DNA	O
37	.	O
1	Sample	O
2	treatment	O
3	was	O
4	optimized	O
5	in	O
6	order	O
7	to	O
8	achieve	O
9	a	O
10	complete	O
11	extraction	O
12	of	O
13	labetalol	O
14	diastereoisomers	O
15	and	O
16	to	O
17	avoid	O
18	racemization	O
19	during	O
20	extraction	O
21	.	O
1	This	O
2	sequenced	O
3	region	O
4	of	O
5	the	O
6	V	O
7	beta	O
8	locus	O
9	contains	O
10	an	O
11	average	O
12	number	O
13	of	O
14	repetitive	O
15	DNA	O
16	elements	O
17	(	O
18	21	O
19	Alu	B
20	,	O
21	three	O
22	L1	B
23	,	O
24	three	O
25	MER	O
26	,	O
27	and	O
28	three	O
29	retrovirus	O
30	-	O
31	related	O
32	elements	O
33	.	O
1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	a	O
6	class	O
7	of	O
8	proline	O
9	-	O
10	rich	O
11	activator	O
12	proteins	O
13	and	O
14	RNA	B
15	polymerase	I
16	II	I
17	possess	O
18	a	O
19	common	O
20	structural	O
21	and	O
22	functional	O
23	component	O
24	which	O
25	can	O
26	interact	O
27	with	O
28	the	O
29	same	O
30	target	O
31	in	O
32	the	O
33	general	O
34	transcription	O
35	machinery	O
36	.	O
1	CONCLUSION	O
2	:	O
3	Human	O
4	preterm	O
5	birth	O
6	is	O
7	associated	O
8	with	O
9	significantly	O
10	lower	O
11	progesterone	O
12	/	O
13	17	O
14	beta	O
15	-	O
16	estradiol	O
17	ratios	O
18	than	O
19	those	O
20	of	O
21	women	O
22	with	O
23	preterm	O
24	labor	O
25	delivered	O
26	at	O
27	term	O
28	.	O
1	The	O
2	molecular	O
3	basis	O
4	for	O
5	commitment	O
6	of	O
7	progenitors	O
8	to	O
9	the	O
10	eosinophil	O
11	lineage	O
12	and	O
13	mechanisms	O
14	by	O
15	which	O
16	eosinophil	O
17	-	O
18	specific	O
19	genes	O
20	are	O
21	expressed	O
22	and	O
23	regulated	O
24	during	O
25	differentiation	O
26	is	O
27	unknown	O
28	.	O
1	At	O
2	least	O
3	some	O
4	of	O
5	the	O
6	difference	O
7	in	O
8	stability	O
9	of	O
10	the	O
11	two	O
12	kinds	O
13	of	O
14	complexes	O
15	was	O
16	due	O
17	to	O
18	the	O
19	fact	O
20	that	O
21	the	O
22	dissociation	O
23	rate	O
24	of	O
25	the	O
26	A	O
27	stem	O
28	substrate	O
29	from	O
30	the	O
31	protein	O
32	-	O
33	DNA	O
34	complexes	O
35	was	O
36	approximately	O
37	fourfold	O
38	faster	O
39	than	O
40	that	O
41	of	O
42	the	O
43	complete	O
44	TR	B
45	.	O
1	However	O
2	,	O
3	each	O
4	promoter	O
5	activated	O
6	by	O
7	IEP86	B
8	was	O
9	synergistically	O
10	affected	O
11	by	O
12	the	O
13	addition	O
14	of	O
15	IEP72	B
16	.	O
1	Furthermore	O
2	,	O
3	an	O
4	upstream	O
5	element	O
6	,	O
7	collagen	O
8	element	O
9	I	O
10	(-	O
11	370	O
12	/-	O
13	344	O
14	),	O
15	which	O
16	shares	O
17	homology	O
18	with	O
19	the	O
20	LAP	B
21	binding	O
22	cis	O
23	-	O
24	element	O
25	of	O
26	the	O
27	albumin	B
28	promoter	I
29	(	O
30	9	O
31	of	O
32	13	O
33	bp	O
34	)	O
35	is	O
36	described	O
37	.	O
1	An	O
2	examination	O
3	was	O
4	performed	O
5	in	O
6	15	O
7	patients	O
8	who	O
9	had	O
10	developed	O
11	pronounced	O
12	osteomalacia	O
13	following	O
14	gastric	O
15	resection	O
16	.	O
1	Alginate	O
2	biosynthesis	O
3	is	O
4	controlled	O
5	by	O
6	a	O
7	complex	O
8	regulatory	O
9	mechanism	O
10	.	O
1	The	O
2	sequence	O
3	upstream	O
4	of	O
5	the	O
6	rhlA	B
7	promoter	I
8	contains	O
9	two	O
10	inverted	O
11	repeats	O
12	which	O
13	define	O
14	putative	O
15	binding	O
16	sites	O
17	for	O
18	the	O
19	RhlR	B
20	regulator	I
21	.	O
1	We	O
2	have	O
3	examined	O
4	by	O
5	in	O
6	vitro	O
7	footprinting	O
8	a	O
9	region	O
10	located	O
11	downstream	O
12	of	O
13	the	O
14	human	O
15	immunodeficiency	O
16	virus	O
17	,	O
18	type	O
19	1	O
20	(	O
21	HIV	O
22	-	O
23	1	O
24	)	O
25	promoter	O
26	found	O
27	to	O
28	be	O
29	hypersensitive	O
30	to	O
31	DNase	B
32	I	I
33	digestion	O
34	in	O
35	vivo	O
36	.	O
1	A	O
2	constitutive	O
3	mutant	O
4	form	O
5	with	O
6	a	O
7	single	O
8	substitution	O
9	(	O
10	V88A	O
11	)	O
12	in	O
13	the	O
14	amino	O
15	-	O
16	terminal	O
17	(	O
18	response	O
19	regulator	O
20	)	O
21	region	O
22	was	O
23	used	O
24	.	O
1	Comparisons	O
2	of	O
3	the	O
4	four	O
5	operon	O
6	control	O
7	regions	O
8	studied	O
9	indicate	O
10	that	O
11	the	O
12	NarL	B
13	heptamers	I
14	are	O
15	arranged	O
16	with	O
17	diverse	O
18	orientations	O
19	and	O
20	spacing	O
21	.	O
1	We	O
2	conclude	O
3	that	O
4	c	B
5	-	I
6	Abl	I
7	activates	O
8	c	B
9	-	I
10	myc	I
11	transcription	O
12	indirectly	O
13	with	O
14	no	O
15	requirement	O
16	for	O
17	DNA	O
18	binding	O
19	by	O
20	c	B
21	-	I
22	Abl	I
23	.	O
1	Here	O
2	we	O
3	show	O
4	that	O
5	for	O
6	expression	O
7	of	O
8	snRNA	O
9	genes	O
10	in	O
11	maize	O
12	,	O
13	a	O
14	monocotyledonous	O
15	plant	O
16	,	O
17	the	O
18	USE	O
19	and	O
20	TATA	O
21	elements	O
22	are	O
23	essential	O
24	,	O
25	but	O
26	not	O
27	sufficient	O
28	,	O
29	for	O
30	transcription	O
31	.	O
1	An	O
2	in	O
3	vitro	O
4	binding	O
5	site	O
6	selection	O
7	procedure	O
8	was	O
9	used	O
10	to	O
11	determine	O
12	DNA	O
13	sequences	O
14	preferentially	O
15	bound	O
16	by	O
17	wild	B
18	-	I
19	type	I
20	HLF	I
21	and	O
22	chimeric	O
23	E2A	B
24	-	O
25	HLF	B
26	proteins	O
27	isolated	O
28	from	O
29	various	O
30	t	O
31	(	O
32	17	O
33	;	O
34	19	O
35	)-	O
36	bearing	O
37	leukemias	O
38	.	O
1	According	O
2	to	O
3	the	O
4	results	O
5	of	O
6	assays	O
7	obtained	O
8	with	O
9	the	O
10	use	O
11	of	O
12	assay	O
13	systems	O
14	ORTHO	O
15	ELISA	O
16	and	O
17	ABBOTT	O
18	HCV	O
19	EIA	O
20	(	O
21	USA	O
22	),	O
23	the	O
24	detection	O
25	rate	O
26	of	O
27	anti	B
28	-	I
29	HCV	I
30	-	I
31	C100	I
32	-	I
33	3	I
34	among	O
35	primary	O
36	blood	O
37	donors	O
38	in	O
39	Moscow	O
40	was	O
41	1	O
42	.	O
43	37	O
44	%	O
45	and	O
46	was	O
47	not	O
48	different	O
49	from	O
50	that	O
51	among	O
52	HBsAg	B
53	carriers	O
54	(	O
55	1	O
56	.	O
57	8	O
58	%)	O
59	and	O
60	among	O
61	donors	O
62	with	O
63	anti	B
64	-	I
65	HCV	I
66	-	I
67	C100	I
68	-	I
69	3	I
70	in	O
71	the	O
72	blood	O
73	(	O
74	1	O
75	.	O
76	6	O
77	%)	O
78	(	O
79	p	O
80	<	O
81	0	O
82	.	O
83	01	O
84	).	O
1	Roux	O
2	-	O
3	en	O
4	-	O
5	Y	O
6	gastroenterostomy	O
7	severely	O
8	disturbs	O
9	emptying	O
10	of	O
11	the	O
12	gallbladder	O
13	.	O
1	Surface	O
2	-	O
3	coil	O
4	experiments	O
5	on	O
6	phantoms	O
7	and	O
8	on	O
9	human	O
10	calf	O
11	muscles	O
12	in	O
13	vivo	O
14	are	O
15	presented	O
16	.	O
1	Ras	B
2	-	I
3	and	I
4	ultra	I
5	-	I
6	violet	I
7	-	I
8	responsive	I
9	protein	I
10	kinases	I
11	that	O
12	phosphorylate	O
13	c	B
14	-	I
15	Jun	I
16	on	O
17	serine	O
18	residues	O
19	at	O
20	positions	O
21	63	O
22	and	O
23	73	O
24	and	O
25	stimulate	O
26	its	O
27	transcriptional	O
28	activity	O
29	have	O
30	been	O
31	identified	O
32	.	O
1	Wild	B
2	type	I
3	and	I
4	mutant	I
5	Epo	I
6	cDNAs	I
7	were	O
8	transiently	O
9	expressed	O
10	at	O
11	high	O
12	levels	O
13	in	O
14	COS1	O
15	and	O
16	COS7	O
17	cells	O
18	.	O
1	OBJECTIVE	O
2	--	O
3	To	O
4	assess	O
5	the	O
6	risk	O
7	of	O
8	hepatitis	O
9	A	O
10	in	O
11	international	O
12	travelers	O
13	and	O
14	to	O
15	recommend	O
16	preventive	O
17	measures	O
18	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	leader	O
6	-	O
7	mRNA	O
8	fusion	O
9	in	O
10	coronavirus	O
11	transcription	O
12	does	O
13	not	O
14	require	O
15	direct	O
16	RNA	O
17	-	O
18	RNA	O
19	interaction	O
20	between	O
21	complementary	O
22	sequences	O
23	.	O
1	This	O
2	alternatively	O
3	spliced	O
4	transcript	O
5	contained	O
6	an	O
7	open	O
8	reading	O
9	frame	O
10	extending	O
11	from	O
12	the	O
13	upstream	O
14	J	O
15	alpha	O
16	11	O
17	-	O
18	2	O
19	region	O
20	to	O
21	82	O
22	nucleotides	O
23	downstream	O
24	of	O
25	the	O
26	beginning	O
27	of	O
28	the	O
29	TCR	B
30	C	I
31	alpha	I
32	region	I
33	,	O
34	and	O
35	potentially	O
36	encoded	O
37	a	O
38	36	O
39	amino	O
40	acid	O
41	polypeptide	O
42	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	megabase	O
6	region	O
7	surrounding	O
8	the	O
9	dagA	B
10	locus	I
11	was	O
12	mapped	O
13	.	O
1	SECONDARY	O
2	OUTCOME	O
3	MEASURE	O
4	--	O
5	Double	O
6	-	O
7	blind	O
8	caffeine	O
9	-	O
10	withdrawal	O
11	evaluation	O
12	.	O
1	In	O
2	addition	O
3	,	O
4	a	O
5	microsatellite	O
6	repeat	O
7	polymorphism	O
8	with	O
9	a	O
10	heterozygosity	O
11	of	O
12	71	O
13	%	O
14	at	O
15	the	O
16	RET	B
17	locus	I
18	and	O
19	a	O
20	restriction	O
21	fragment	O
22	length	O
23	polymorphism	O
24	with	O
25	a	O
26	heterozygosity	O
27	of	O
28	42	O
29	%	O
30	detected	O
31	by	O
32	a	O
33	lambda	O
34	clone	O
35	from	O
36	the	O
37	D10S94	B
38	locus	I
39	have	O
40	been	O
41	developed	O
42	for	O
43	high	O
44	-	O
45	resolution	O
46	genetic	O
47	linkage	O
48	mapping	O
49	and	O
50	predictive	O
51	diagnostic	O
52	testing	O
53	.	O
1	Furthermore	O
2	,	O
3	this	O
4	study	O
5	demonstrates	O
6	that	O
7	reduced	O
8	inotropy	O
9	with	O
10	timolol	O
11	helped	O
12	uniform	O
13	local	O
14	contraction	O
15	as	O
16	estimated	O
17	by	O
18	the	O
19	increased	O
20	LONG	O
21	/	O
22	CIRC	O
23	ratio	O
24	,	O
25	a	O
26	transition	O
27	that	O
28	could	O
29	improve	O
30	contraction	O
31	efficacy	O
32	.	O
1	Effects	O
2	of	O
3	moderate	O
4	hypercapnia	O
5	on	O
6	hypothermia	O
7	induced	O
8	by	O
9	cold	O
10	He	O
11	-	O
12	O2	O
13	in	O
14	rats	O
15	.	O
1	These	O
2	data	O
3	suggest	O
4	that	O
5	:	O
6	(	O
7	a	O
8	)	O
9	proSRIF	B
10	cleavage	O
11	is	O
12	initiated	O
13	in	O
14	the	O
15	TGN	O
16	,	O
17	and	O
18	(	O
19	b	O
20	)	O
21	this	O
22	reaction	O
23	requires	O
24	an	O
25	acidic	O
26	pH	O
27	which	O
28	is	O
29	facilitated	O
30	by	O
31	a	O
32	Golgi	B
33	-	I
34	associated	I
35	vacuolar	I
36	-	I
37	type	I
38	ATPase	I
39	.	O
1	In	O
2	the	O
3	3	O
4	'	O
5	flanking	O
6	region	O
7	of	O
8	the	O
9	27	B
10	kDa	I
11	zein	I
12	gene	I
13	,	O
14	several	O
15	AATAAA	O
16	-	O
17	like	O
18	sequences	O
19	and	O
20	a	O
21	sequence	O
22	resembling	O
23	the	O
24	mammalian	O
25	GT	O
26	-	O
27	rich	O
28	sequence	O
29	are	O
30	present	O
31	around	O
32	the	O
33	polyadenylation	O
34	sites	O
35	.	O
1	When	O
2	the	O
3	promoter	O
4	region	O
5	was	O
6	linked	O
7	with	O
8	a	O
9	heterologous	O
10	reporter	O
11	gene	O
12	,	O
13	we	O
14	found	O
15	that	O
16	the	O
17	promoter	O
18	region	O
19	is	O
20	inducible	O
21	by	O
22	both	O
23	interferons	B
24	(	O
25	interferon	B
26	-	I
27	alpha	I
28	and	I
29	-	I
30	gamma	I
31	)	O
32	and	O
33	interferon	B
34	regulatory	I
35	factor	I
36	1	I
37	.	O
1	Increasing	O
2	the	O
3	extracellular	O
4	calcium	O
5	concentration	O
6	enhanced	O
7	detrusor	O
8	contractility	O
9	in	O
10	a	O
11	dose	O
12	-	O
13	dependent	O
14	manner	O
15	in	O
16	both	O
17	control	O
18	and	O
19	obstructed	O
20	bladders	O
21	.	O
1	Structural	O
2	organization	O
3	of	O
4	the	O
5	gene	O
6	encoding	O
7	the	O
8	human	B
9	lipocalin	I
10	tear	I
11	prealbumin	I
12	and	O
13	synthesis	O
14	of	O
15	the	O
16	recombinant	O
17	protein	O
18	in	O
19	Escherichia	O
20	coli	O
21	.	O
1	Members	O
2	of	O
3	the	O
4	myocyte	B
5	-	I
6	specific	I
7	enhancer	I
8	-	I
9	binding	I
10	factor	I
11	2	I
12	(	O
13	MEF2	B
14	)	O
15	family	O
16	of	O
17	transcription	O
18	factors	O
19	bind	O
20	a	O
21	conserved	O
22	A	O
23	/	O
24	T	O
25	-	O
26	rich	O
27	sequence	O
28	in	O
29	the	O
30	control	O
31	regions	O
32	of	O
33	numerous	O
34	muscle	O
35	-	O
36	specific	O
37	genes	O
38	.	O
1	We	O
2	have	O
3	previously	O
4	shown	O
5	that	O
6	LBP	B
7	-	I
8	1	I
9	represses	O
10	HIV	O
11	-	O
12	1	O
13	transcription	O
14	by	O
15	inhibiting	O
16	the	O
17	binding	O
18	of	O
19	TFIID	B
20	to	O
21	the	O
22	TATA	O
23	box	O
24	.	O
1	Furthermore	O
2	,	O
3	in	O
4	vitro	O
5	decay	O
6	reaction	O
7	mixtures	O
8	supplemented	O
9	with	O
10	the	O
11	20	O
12	-	O
13	nt	O
14	sense	O
15	RNA	O
16	transcript	O
17	resulted	O
18	in	O
19	stabilization	O
20	of	O
21	R2	B
22	message	I
23	.	O
1	The	O
2	previously	O
3	described	O
4	enhanced	O
5	translation	O
6	of	O
7	spinach	O
8	L12	B
9	mRNA	I
10	from	O
11	its	O
12	two	O
13	tandem	O
14	AUG	O
15	codons	O
16	and	O
17	the	O
18	two	O
19	functional	O
20	rpl12	B
21	genes	I
22	in	O
23	Arabidopsis	O
24	probably	O
25	provide	O
26	two	O
27	mechanisms	O
28	for	O
29	generating	O
30	the	O
31	four	O
32	copies	O
33	of	O
34	L12	B
35	/	I
36	chloroplast	I
37	ribosome	I
38	,	O
39	qualitatively	O
40	different	O
41	from	O
42	those	O
43	attempted	O
44	in	O
45	eubacteria	O
46	.	O
1	In	O
2	these	O
3	experiments	O
4	we	O
5	begin	O
6	to	O
7	study	O
8	the	O
9	potential	O
10	functions	O
11	of	O
12	the	O
13	alpha	B
14	7	I
15	cytoplasmic	I
16	domain	I
17	by	O
18	analyzing	O
19	homologies	O
20	between	O
21	the	O
22	rat	O
23	and	O
24	human	O
25	sequences	O
26	,	O
27	by	O
28	immunologic	O
29	studies	O
30	using	O
31	an	O
32	anti	O
33	-	O
34	cytoplasmic	O
35	domain	O
36	antiserum	O
37	,	O
38	and	O
39	by	O
40	identifying	O
41	two	O
42	alternate	O
43	forms	O
44	.	O
1	MSSP	B
2	-	I
3	1	I
4	produced	O
5	in	O
6	E	O
7	.	O
8	coli	O
9	as	O
10	a	O
11	fusion	O
12	protein	O
13	with	O
14	GST	B
15	specifically	O
16	interacted	O
17	with	O
18	single	O
19	-	O
20	stranded	O
21	TCTTAT	O
22	(	O
23	plus	O
24	myc	B
25	(	O
26	H	O
27	-	O
28	P	O
29	)	O
30	21	O
31	)	O
32	and	O
33	ACT	O
34	-	O
35	ATT	O
36	(	O
37	in	O
38	minus	O
39	myc	B
40	(	O
41	H	O
42	-	O
43	P	O
44	)	O
45	21	O
46	),	O
47	the	O
48	consensus	O
49	of	O
50	which	O
51	can	O
52	be	O
53	referred	O
54	to	O
55	as	O
56	A	O
57	/	O
58	TCTA	O
59	/	O
60	TA	O
61	/	O
62	TT	O
63	.	O
1	Within	O
2	12	O
3	hours	O
4	after	O
5	MR	O
6	tomography	O
7	the	O
8	patients	O
9	were	O
10	surgically	O
11	explored	O
12	,	O
13	biopsied	O
14	and	O
15	if	O
16	necessary	O
17	orchiectomised	O
18	.	O
1	The	O
2	results	O
3	show	O
4	that	O
5	both	O
6	the	O
7	amino	O
8	and	O
9	carboxy	O
10	termini	O
11	of	O
12	the	O
13	NS1	B
14	protein	I
15	molecule	I
16	and	O
17	the	O
18	cysteines	O
19	at	O
20	residues	O
21	337	O
22	and	O
23	340	O
24	are	O
25	essential	O
26	for	O
27	tubule	O
28	formation	O
29	.	O
1	In	O
2	Rat	O
3	1a	O
4	cells	O
5	,	O
6	m1R	B
7	stimulation	O
8	of	O
9	phospholipase	B
10	C	I
11	beta	I
12	and	O
13	the	O
14	marked	O
15	rise	O
16	in	O
17	intracellular	O
18	calcium	O
19	stimulated	O
20	cyclic	O
21	AMP	O
22	(	O
23	cAMP	O
24	)	O
25	synthesis	O
26	,	O
27	resulting	O
28	in	O
29	the	O
30	activation	O
31	of	O
32	protein	B
33	kinase	I
34	A	I
35	.	O
1	Genetic	O
2	and	O
3	phenotypic	O
4	analysis	O
5	indicates	O
6	that	O
7	NHP6A	B
8	and	O
9	NHP6B	B
10	function	O
11	downstream	O
12	of	O
13	SLT2	B
14	.	O
1	Neither	O
2	ethanol	O
3	regimen	O
4	impaired	O
5	spontaneous	O
6	alternation	O
7	,	O
8	but	O
9	the	O
10	4	O
11	g	O
12	ethanol	O
13	.	O
14	kg	O
15	-	O
16	1	O
17	x	O
18	day	O
19	-	O
20	1	O
21	regimen	O
22	increased	O
23	the	O
24	percent	O
25	completed	O
26	trials	O
27	.	O
1	Signaling	O
2	by	O
3	tyrosine	B
4	kinases	I
5	involves	O
6	direct	O
7	associations	O
8	between	O
9	proteins	O
10	with	O
11	Src	B
12	homology	I
13	2	I
14	(	O
15	SH2	B
16	)	O
17	domains	O
18	and	O
19	sites	O
20	of	O
21	tyrosine	O
22	phosphorylation	O
23	.	O
1	Thus	O
2	our	O
3	observations	O
4	establish	O
5	a	O
6	functional	O
7	link	O
8	between	O
9	the	O
10	PKC	B
11	and	O
12	retinoid	O
13	pathways	O
14	,	O
15	which	O
16	are	O
17	generally	O
18	considered	O
19	to	O
20	have	O
21	antagonistic	O
22	activities	O
23	on	O
24	differentiation	O
25	processes	O
26	.	O
1	Since	O
2	the	O
3	ETS	B
4	domain	I
5	,	O
6	which	O
7	is	O
8	localized	O
9	in	O
10	the	O
11	carboxy	O
12	terminal	O
13	region	O
14	of	O
15	the	O
16	encoded	O
17	protein	O
18	,	O
19	is	O
20	95	O
21	%	O
22	and	O
23	96	O
24	%	O
25	identical	O
26	to	O
27	that	O
28	of	O
29	PEA3	B
30	and	O
31	ER81	B
32	,	O
33	respectively	O
34	,	O
35	we	O
36	named	O
37	this	O
38	new	O
39	member	O
40	'	B
41	Ets	I
42	Related	I
43	Molecule	I
44	PEA3	I
45	-	I
46	like	I
47	'	I
48	(	O
49	ERM	B
50	).	O
1	Dotarizine	O
2	produced	O
3	arterial	O
4	dilation	O
5	in	O
6	both	O
7	systemic	O
8	and	O
9	pulmonary	O
10	circulation	O
11	:	O
12	the	O
13	total	O
14	peripheral	O
15	resistance	O
16	dropped	O
17	,	O
18	and	O
19	femoral	O
20	artery	O
21	flow	O
22	rose	O
23	;	O
24	aortic	O
25	and	O
26	pulmonary	O
27	artery	O
28	mean	O
29	and	O
30	diastolic	O
31	pressures	O
32	declined	O
33	,	O
34	and	O
35	systolic	O
36	pressures	O
37	remained	O
38	almost	O
39	stable	O
40	.	O
1	Functional	O
2	postnatal	O
3	development	O
4	of	O
5	the	O
6	rat	O
7	primary	O
8	visual	O
9	cortex	O
10	and	O
11	the	O
12	role	O
13	of	O
14	visual	O
15	experience	O
16	:	O
17	dark	O
18	rearing	O
19	and	O
20	monocular	O
21	deprivation	O
22	.	O
1	We	O
2	estimate	O
3	that	O
4	the	O
5	protease	O
6	activity	O
7	is	O
8	at	O
9	least	O
10	35	O
11	-	O
12	fold	O
13	greater	O
14	in	O
15	mature	O
16	B	O
17	cells	O
18	than	O
19	in	O
20	pre	O
21	-	O
22	B	O
23	cells	O
24	.	O
1	Northern	O
2	-	O
3	blot	O
4	analysis	O
5	of	O
6	mRNA	O
7	from	O
8	Avicel	O
9	-	O
10	grown	O
11	N	O
12	.	O
13	patriciarum	O
14	showed	O
15	that	O
16	xynB	B
17	hybridized	O
18	to	O
19	a	O
20	3	O
21	.	O
22	4	O
23	kb	O
24	mRNA	O
25	species	O
26	.	O
1	These	O
2	viruses	O
3	depend	O
4	on	O
5	the	O
6	host	O
7	cell	O
8	machinery	O
9	for	O
10	their	O
11	existence	O
12	,	O
13	and	O
14	interference	O
15	with	O
16	these	O
17	processes	O
18	typically	O
19	interferes	O
20	with	O
21	other	O
22	important	O
23	host	O
24	physiology	O
25	.	O
1	Northern	O
2	analysis	O
3	,	O
4	to	O
5	search	O
6	for	O
7	a	O
8	pcbAB	B
9	transcript	I
10	,	O
11	showed	O
12	no	O
13	distinct	O
14	transcript	O
15	and	O
16	indicated	O
17	severely	O
18	degraded	O
19	mRNA	O
20	.	O
1	The	O
2	efficacy	O
3	of	O
4	a	O
5	Propionibacterium	O
6	acnes	O
7	product	O
8	for	O
9	treatment	O
10	of	O
11	coliform	O
12	mastitis	O
13	was	O
14	evaluated	O
15	following	O
16	intramammary	O
17	infusion	O
18	of	O
19	Escherichia	O
20	coli	O
21	.	O
1	The	O
2	human	B
3	eps15	I
4	gene	I
5	,	O
6	encoding	O
7	a	O
8	tyrosine	B
9	kinase	I
10	substrate	O
11	,	O
12	is	O
13	conserved	O
14	in	O
15	evolution	O
16	and	O
17	maps	O
18	to	O
19	1p31	O
20	-	O
21	p32	O
22	.	O
1	Alternative	O
2	splicing	O
3	of	O
4	RNA	O
5	transcripts	O
6	encoded	O
7	by	O
8	the	O
9	murine	O
10	p105	B
11	NF	I
12	-	I
13	kappa	I
14	B	I
15	gene	O
16	generates	O
17	I	B
18	kappa	I
19	B	I
20	gamma	I
21	isoforms	I
22	with	O
23	different	O
24	inhibitory	O
25	activities	O
26	.	O
1	Glutamyl	B
2	-	I
3	tRNA	I
4	synthetase	I
5	and	O
6	prolyl	B
7	-	I
8	tRNA	I
9	synthetase	I
10	belong	O
11	to	O
12	different	O
13	classes	O
14	of	O
15	aminoacyl	B
16	-	I
17	tRNA	I
18	synthetases	I
19	that	O
20	are	O
21	thought	O
22	to	O
23	have	O
24	evolved	O
25	along	O
26	independent	O
27	evolutionary	O
28	pathways	O
29	.	O
1	DESIGN	O
2	--	O
3	A	O
4	randomised	O
5	study	O
6	was	O
7	conducted	O
8	in	O
9	all	O
10	women	O
11	aged	O
12	50	O
13	-	O
14	70	O
15	years	O
16	who	O
17	were	O
18	eligible	O
19	for	O
20	breast	O
21	cancer	O
22	screening	O
23	and	O
24	living	O
25	in	O
26	the	O
27	city	O
28	of	O
29	Utrecht	O
30	.	O
1	The	O
2	transcription	B
3	factor	I
4	AP	I
5	-	I
6	2	I
7	is	O
8	encoded	O
9	by	O
10	a	O
11	gene	O
12	located	O
13	on	O
14	chromosome	O
15	6	O
16	near	O
17	the	O
18	HLA	B
19	locus	I
20	.	O
1	Women	O
2	'	O
3	s	O
4	opportunities	O
5	for	O
6	paid	O
7	work	O
8	outside	O
9	the	O
10	home	O
11	are	O
12	constrained	O
13	by	O
14	their	O
15	role	O
16	as	O
17	primary	O
18	carer	O
19	within	O
20	the	O
21	family	O
22	,	O
23	writes	O
24	Trudy	O
25	Wynne	O
26	.	O
1	Deletion	O
2	analysis	O
3	of	O
4	the	O
5	ICL1	B
6	promoter	I
7	led	O
8	to	O
9	the	O
10	identification	O
11	of	O
12	an	O
13	upstream	O
14	activating	O
15	sequence	O
16	element	O
17	,	O
18	UASICL1	O
19	(	O
20	5	O
21	'	O
22	CATTCATCCG	O
23	3	O
24	'),	O
25	necessary	O
26	and	O
27	sufficient	O
28	for	O
29	conferring	O
30	carbon	O
31	source	O
32	-	O
33	dependent	O
34	regulation	O
35	on	O
36	a	O
37	heterologous	O
38	reporter	O
39	gene	O
40	.	O
1	The	O
2	effects	O
3	of	O
4	systemic	O
5	glucose	O
6	concentration	O
7	on	O
8	brain	O
9	metabolism	O
10	following	O
11	repeated	O
12	brain	O
13	ischemia	O
14	.	O
1	A	O
2	total	O
3	of	O
4	7	O
5	(	O
6	4	O
7	males	O
8	and	O
9	3	O
10	females	O
11	)	O
12	patients	O
13	were	O
14	included	O
15	in	O
16	this	O
17	retrospective	O
18	study	O
19	to	O
20	determine	O
21	the	O
22	sensitivity	O
23	of	O
24	radioimmunoscintigraphy	O
25	with	O
26	I	O
27	-	O
28	131	O
29	labeled	O
30	anti	B
31	CEA	I
32	/	O
33	CA	B
34	19	I
35	-	I
36	9	I
37	monoclonal	O
38	antibodies	O
39	.	O
1	Simultaneous	O
2	,	O
3	bilateral	O
4	and	O
5	permanent	O
6	ventilation	O
7	with	O
8	a	O
9	diaphragm	O
10	pacing	O
11	in	O
12	childhood	O
13	:	O
14	the	O
15	implantation	O
16	technique	O
17	and	O
18	indications	O
1	A	O
2	genomic	O
3	clone	O
4	for	O
5	the	O
6	cyc07	B
7	gene	I
8	,	O
9	which	O
10	is	O
11	expressed	O
12	specifically	O
13	at	O
14	the	O
15	S	O
16	phase	O
17	during	O
18	the	O
19	cell	O
20	cycle	O
21	in	O
22	synchronous	O
23	cultures	O
24	of	O
25	periwinkle	O
26	(	O
27	Catharanthus	O
28	roseus	O
29	)	O
30	cells	O
31	,	O
32	was	O
33	isolated	O
34	.	O
1	BYV	O
2	,	O
3	citrus	O
4	tristeza	O
5	virus	O
6	(	O
7	CTV	O
8	),	O
9	beet	O
10	yellow	O
11	stunt	O
12	virus	O
13	(	O
14	BYSV	O
15	)	O
16	and	O
17	carnation	O
18	necrotic	O
19	fleck	O
20	virus	O
21	templates	O
22	produced	O
23	1	O
24	kb	O
25	amplification	O
26	products	O
27	,	O
28	which	O
29	were	O
30	shown	O
31	by	O
32	sequencing	O
33	to	O
34	represent	O
35	fragments	O
36	of	O
37	the	O
38	respective	O
39	HSP70	B
40	genes	I
41	.	O
1	The	O
2	p53	B
3	tumor	I
4	suppressor	I
5	gene	I
6	product	I
7	,	O
8	a	O
9	sequence	O
10	-	O
11	specific	O
12	DNA	O
13	-	O
14	binding	O
15	protein	O
16	,	O
17	has	O
18	been	O
19	shown	O
20	to	O
21	act	O
22	as	O
23	a	O
24	transcriptional	O
25	activator	O
26	and	O
27	repressor	O
28	both	O
29	in	O
30	vitro	O
31	and	O
32	in	O
33	vivo	O
34	.	O
1	Also	O
2	,	O
3	HR21ap	B
4	as	O
5	well	O
6	as	O
7	HR21Xap	B
8	are	O
9	specific	O
10	in	O
11	their	O
12	inhibition	O
13	of	O
14	Sp1	B
15	binding	O
16	.	O
1	The	O
2	regulatory	O
3	region	O
4	also	O
5	has	O
6	a	O
7	sequence	O
8	similar	O
9	to	O
10	the	O
11	binding	O
12	site	O
13	for	O
14	a	O
15	liver	O
16	-	O
17	specific	O
18	transcription	O
19	factor	O
20	,	O
21	hepatocyte	B
22	nuclear	I
23	factor	I
24	1	I
25	(	O
26	HNF	B
27	-	I
28	1	I
29	),	O
30	at	O
31	positions	O
32	-	O
33	120	O
34	to	O
35	-	O
36	132	O
37	.	O
1	Thus	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	GRE	O
8	sufficient	O
9	to	O
10	account	O
11	for	O
12	full	O
13	glucocorticoid	O
14	inducibility	O
15	and	O
16	an	O
17	HNF	B
18	-	I
19	1	I
20	site	I
21	close	O
22	to	O
23	the	O
24	promoter	O
25	that	O
26	are	O
27	major	O
28	determinants	O
29	of	O
30	transcriptional	O
31	control	O
32	of	O
33	the	O
34	Xenopus	B
35	fibrinogen	I
36	B	I
37	beta	I
38	subunit	I
39	gene	I
40	in	O
41	cells	O
42	from	O
43	normal	O
44	liver	O
45	tissue	O
46	.	O
1	We	O
2	suggest	O
3	that	O
4	CT	O
5	scan	O
6	be	O
7	preferable	O
8	in	O
9	diagnosis	O
10	of	O
11	tumors	O
12	in	O
13	that	O
14	area	O
15	.	O
1	Two	O
2	BASIC	O
3	computer	O
4	programs	O
5	using	O
6	logit	O
7	transformation	O
8	for	O
9	the	O
10	analysis	O
11	of	O
12	S	O
13	-	O
14	shaped	O
15	curves	O
16	are	O
17	presented	O
18	.	O
1	Our	O
2	results	O
3	indicate	O
4	that	O
5	periseizure	O
6	lipid	O
7	accumulation	O
8	is	O
9	related	O
10	to	O
11	cortical	O
12	oxygenation	O
13	.	O
1	The	O
2	action	O
3	of	O
4	nef	B
5	was	O
6	specific	O
7	to	O
8	the	O
9	LTR	O
10	,	O
11	as	O
12	expression	O
13	of	O
14	nef	B
15	had	O
16	no	O
17	effect	O
18	on	O
19	the	O
20	activity	O
21	of	O
22	the	O
23	simian	O
24	virus	O
25	40	O
26	,	O
27	c	B
28	-	I
29	fms	I
30	,	O
31	urokinase	B
32	plasminogen	I
33	activator	I
34	,	O
35	or	O
36	type	B
37	5	I
38	acid	I
39	phosphatase	I
40	promoter	I
41	.	O
42	trans	O
43	-	O
44	activating	O
45	activity	O
46	was	O
47	also	O
48	manifested	O
49	by	O
50	a	O
51	frameshift	O
52	mutant	O
53	expressing	O
54	only	O
55	the	O
56	first	O
57	35	O
58	amino	O
59	acids	O
60	of	O
61	the	O
62	protein	O
63	.	O
1	By	O
2	using	O
3	total	O
4	-	O
5	protein	O
6	extracts	O
7	from	O
8	mycelia	O
9	grown	O
10	under	O
11	penicillin	O
12	producing	O
13	conditions	O
14	we	O
15	have	O
16	detected	O
17	a	O
18	DNA	O
19	-	O
20	binding	O
21	activity	O
22	that	O
23	specifically	O
24	shifts	O
25	a	O
26	promoter	O
27	fragment	O
28	located	O
29	between	O
30	-	O
31	654	O
32	and	O
33	-	O
34	455	O
35	(	O
36	relative	O
37	to	O
38	IPNS	B
39	tsp	I
40	).	O
1	No	O
2	homology	O
3	was	O
4	found	O
5	between	O
6	the	O
7	36K	O
8	protein	O
9	and	O
10	known	O
11	structures	O
12	of	O
13	proteins	O
14	.	O
1	Hu	B
2	-	I
3	Met	I
4	-	I
5	1	I
6	mRNA	I
7	expression	O
8	in	O
9	a	O
10	small	O
11	number	O
12	of	O
13	human	O
14	T	O
15	cell	O
16	tumor	O
17	lines	O
18	did	O
19	not	O
20	correlate	O
21	with	O
22	any	O
23	particular	O
24	phenotype	O
25	or	O
26	stage	O
27	of	O
28	development	O
29	.	O
1	The	O
2	duration	O
3	of	O
4	diabetes	O
5	mellitus	O
6	in	O
7	these	O
8	patients	O
9	was	O
10	from	O
11	5	O
12	months	O
13	to	O
14	6	O
15	years	O
16	,	O
17	and	O
18	in	O
19	all	O
20	patients	O
21	this	O
22	was	O
23	the	O
24	first	O
25	myocardial	O
26	infarction	O
27	.	O
1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	lesions	O
7	of	O
8	the	O
9	OPT	O
10	complex	O
11	(	O
12	the	O
13	thalamic	O
14	source	O
15	of	O
16	afferents	O
17	to	O
18	IHA	O
19	and	O
20	HD	O
21	)	O
22	were	O
23	found	O
24	to	O
25	have	O
26	no	O
27	effect	O
28	on	O
29	color	O
30	-	O
31	reversal	O
32	learning	O
33	performance	O
34	.	O
1	The	O
2	phi	B
3	AP3	I
4	factor	I
5	is	O
6	a	O
7	nuclear	O
8	phosphoprotein	O
9	;	O
10	the	O
11	extent	O
12	of	O
13	its	O
14	phosphorylation	O
15	is	O
16	regulated	O
17	during	O
18	the	O
19	cell	O
20	cycle	O
21	.	O
1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	P	B
6	-	I
7	type	I
8	ATPase	I
9	gene	I
10	from	O
11	the	O
12	cyanobacterium	O
13	Synechocystis	O
14	sp	O
15	.	O
1	The	O
2	cloning	O
3	of	O
4	PTR2	B
5	represents	O
6	the	O
7	first	O
8	example	O
9	of	O
10	the	O
11	molecular	O
12	genetic	O
13	characterization	O
14	of	O
15	a	O
16	eucaryotic	O
17	peptide	O
18	transport	O
19	gene	O
20	.	O
1	Pentazocine	O
2	analgesia	O
3	:	O
4	is	O
5	there	O
6	a	O
7	niche	O
8	for	O
9	Talwin	O
10	Nx	O
11	?	O
12	Pentazocine	O
13	can	O
14	be	O
15	a	O
16	useful	O
17	analgesic	O
18	agent	O
19	for	O
20	the	O
21	management	O
22	of	O
23	acute	O
24	dental	O
25	pain	O
26	.	O
1	Response	O
2	durations	O
3	were	O
4	short	O
5	.	O
1	In	O
2	addition	O
3	,	O
4	REP21	O
5	plants	O
6	were	O
7	resistant	O
8	to	O
9	an	O
10	unusually	O
11	broad	O
12	range	O
13	of	O
14	tobamoviruses	O
15	including	O
16	tomato	O
17	mosaic	O
18	virus	O
19	,	O
20	tobacco	O
21	mild	O
22	green	O
23	mosaic	O
24	virus	O
25	,	O
26	TMV	O
27	-	O
28	U5	O
29	,	O
30	green	O
31	tomato	O
32	atypical	O
33	mosaic	O
34	virus	O
35	,	O
36	and	O
37	ribgrass	O
38	mosaic	O
39	virus	O
40	.	O
1	The	O
2	rate	O
3	of	O
4	decrement	O
5	in	O
6	DPOAE	O
7	amplitude	O
8	over	O
9	a	O
10	prescribed	O
11	time	O
12	period	O
13	was	O
14	utilized	O
15	as	O
16	a	O
17	measure	O
18	of	O
19	susceptibility	O
20	to	O
21	the	O
22	acoustic	O
23	trauma	O
24	.	O
1	Effect	O
2	of	O
3	single	O
4	base	O
5	substitutions	O
6	at	O
7	glycine	O
8	-	O
9	870	O
10	codon	O
11	of	O
12	gramicidin	B
13	S	I
14	synthetase	I
15	2	I
16	gene	I
17	on	O
18	proline	O
19	activation	O
20	.	O
1	The	O
2	kinase	O
3	inhibitor	O
4	staurosporine	O
5	(	O
6	1	O
7	microM	O
8	)	O
9	blocks	O
10	LPA	O
11	-	O
12	induced	O
13	,	O
14	but	O
15	not	O
16	epidermal	O
17	growth	O
18	factor	O
19	-	O
20	induced	O
21	,	O
22	activation	O
23	of	O
24	p21ras	B
25	and	O
26	MAP	B
27	kinase	I
28	,	O
29	consistent	O
30	with	O
31	an	O
32	intermediate	O
33	protein	O
34	kinase	O
35	linking	O
36	the	O
37	LPA	B
38	receptor	I
39	to	O
40	p21ras	B
41	activation	O
42	.	O
1	G	O
2	.	O
1	These	O
2	data	O
3	are	O
4	consistent	O
5	with	O
6	the	O
7	idea	O
8	that	O
9	the	O
10	neuron	B
11	-	I
12	specific	I
13	SCG10	I
14	gene	I
15	evolved	O
16	by	O
17	duplication	O
18	and	O
19	modification	O
20	of	O
21	the	O
22	more	O
23	broadly	O
24	expressed	O
25	stathmin	B
26	/	O
27	Lap18	B
28	gene	O
29	.	O
1	Therefore	O
2	,	O
3	Mxi1	B
4	and	O
5	Mad	B
6	might	O
7	antagonize	O
8	Myc	B
9	function	O
10	and	O
11	are	O
12	candidate	O
13	tumor	O
14	suppressor	O
15	genes	O
16	.	O
1	To	O
2	our	O
3	knowledge	O
4	,	O
5	type	O
6	IV	O
7	renal	O
8	tubular	O
9	acidosis	O
10	has	O
11	not	O
12	been	O
13	reported	O
14	previously	O
15	in	O
16	association	O
17	with	O
18	Alport	O
19	'	O
20	s	O
21	syndrome	O
22	in	O
23	an	O
24	adult	O
25	patient	O
26	.	O
1	Animal	O
2	age	O
3	and	O
4	sex	O
5	had	O
6	no	O
7	significant	O
8	effects	O
9	on	O
10	CSF	O
11	composition	O
12	,	O
13	but	O
14	serum	O
15	IgG	B
16	concentration	O
17	increased	O
18	with	O
19	age	O
20	.	O
1	Each	O
2	repeat	O
3	consists	O
4	of	O
5	12	O
6	nt	O
7	,	O
8	coding	O
9	for	O
10	the	O
11	reiterated	O
12	sequence	O
13	,	O
14	K	O
15	/	O
16	NPAG	O
17	.	O
1	Several	O
2	features	O
3	of	O
4	10	O
5	.	O
6	24	O
7	.	O
8	6	O
9	cells	O
10	suggest	O
11	that	O
12	the	O
13	mutation	O
14	disrupts	O
15	normal	O
16	intracellular	O
17	formation	O
18	of	O
19	peptide	B
20	/	I
21	DR	I
22	complexes	I
23	.	O
1	Subretinal	O
2	fluid	O
3	was	O
4	punctured	O
5	on	O
6	the	O
7	poorer	O
8	eye	O
9	in	O
10	19	O
11	eyes	O
12	(	O
13	52	O
14	.	O
15	7	O
16	%)	O
17	and	O
18	on	O
19	the	O
20	better	O
21	eye	O
22	in	O
23	7	O
24	eyes	O
25	(	O
26	19	O
27	.	O
28	4	O
29	%).	O
1	The	O
2	inserted	O
3	region	O
4	,	O
5	which	O
6	represents	O
7	an	O
8	intron	O
9	in	O
10	brain	O
11	and	O
12	muscle	O
13	,	O
14	is	O
15	expressed	O
16	in	O
17	the	O
18	tumor	O
19	cell	O
20	lines	O
21	either	O
22	as	O
23	a	O
24	""""	O
25	readthrough	O
26	""""	O
27	form	O
28	or	O
29	with	O
30	78	O
31	residues	O
32	deleted	O
33	from	O
34	its	O
35	5	O
36	'	O
37	end	O
38	.	O
1	Inhibition	O
2	of	O
3	erythromycin	O
4	synthesis	O
5	by	O
6	disruption	O
7	of	O
8	malonyl	B
9	-	I
10	coenzyme	I
11	A	I
12	decarboxylase	I
13	gene	I
14	eryM	I
15	in	O
16	Saccharopolyspora	O
17	erythraea	O
18	.	O
1	IFN	B
2	alpha	I
3	and	O
4	IFN	B
5	gamma	I
6	inducibility	O
7	is	O
8	mediated	O
9	by	O
10	a	O
11	single	O
12	element	O
13	:	O
14	a	O
15	high	O
16	affinity	O
17	,	O
18	nearly	O
19	palindromic	O
20	version	O
21	of	O
22	the	O
23	IFN	B
24	gamma	I
25	activation	I
26	site	I
27	(	O
28	GAS	B
29	).	O
1	Analysis	O
2	of	O
3	the	O
4	upstream	O
5	untranslated	O
6	region	O
7	of	O
8	CHL15	B
9	revealed	O
10	the	O
11	presence	O
12	of	O
13	the	O
14	hexamer	O
15	element	O
16	,	O
17	ACGCGT	O
18	(	O
19	an	O
20	MluI	B
21	restriction	I
22	site	I
23	)	O
24	controlling	O
25	both	O
26	the	O
27	periodic	O
28	expression	O
29	and	O
30	coordinate	O
31	regulation	O
32	of	O
33	the	O
34	DNA	O
35	synthesis	O
36	genes	O
37	in	O
38	budding	O
39	yeast	O
40	.	O
1	Neither	O
2	RD19	B
3	nor	O
4	RD21	B
5	mRNA	I
6	synthesis	O
7	was	O
8	responsive	O
9	to	O
10	cold	O
11	or	O
12	to	O
13	heat	O
14	stress	O
15	.	O
1	TFEC	B
2	,	O
3	a	O
4	basic	B
5	helix	I
6	-	I
7	loop	I
8	-	I
9	helix	I
10	protein	I
11	,	O
12	forms	O
13	heterodimers	O
14	with	O
15	TFE3	B
16	and	O
17	inhibits	O
18	TFE3	B
19	-	O
20	dependent	O
21	transcription	O
22	activation	O
23	.	O
1	In	O
2	infected	O
3	mammalian	O
4	cells	O
5	,	O
6	the	O
7	ARV	B
8	G	I
9	and	O
10	GNS	B
11	genes	I
12	are	O
13	transcribed	O
14	primarily	O
15	as	O
16	a	O
17	polycistronic	O
18	mRNA	O
19	which	O
20	appears	O
21	to	O
22	extend	O
23	from	O
24	the	O
25	consensus	O
26	sequence	O
27	(	O
28	AACAG	O
29	)	O
30	at	O
31	the	O
32	start	O
33	of	O
34	the	O
35	G	B
36	gene	I
37	to	O
38	the	O
39	next	O
40	recognized	O
41	polyadenylation	O
42	signal	O
43	(	O
44	CATG	O
45	[	O
46	A	O
47	]	O
48	7	O
49	)	O
50	located	O
51	697	O
52	nucleotides	O
53	downstream	O
54	of	O
55	the	O
56	GNS	B
57	protein	I
58	termination	O
59	codon	O
60	.	O
1	Surprisingly	O
2	,	O
3	the	O
4	results	O
5	of	O
6	several	O
7	experiments	O
8	suggest	O
9	that	O
10	the	O
11	TSF	B
12	genes	I
13	encode	O
14	global	O
15	regulatory	O
16	factors	O
17	.	O
18	tsf1	B
19	to	O
20	tsf6	B
21	mutations	O
22	derepressed	O
23	expression	O
24	from	O
25	yeast	O
26	CYC	B
27	-	O
28	GAL	B
29	hybrid	O
30	promoters	O
31	(	O
32	fused	O
33	to	O
34	lacZ	B
35	)	O
36	that	O
37	harbor	O
38	a	O
39	variety	O
40	of	O
41	operator	O
42	sequences	O
43	,	O
44	and	O
45	caused	O
46	pleiotropic	O
47	defects	O
48	in	O
49	cell	O
50	growth	O
51	,	O
52	mating	O
53	,	O
54	and	O
55	sporulation	O
56	.	O
1	Sequence	O
2	comparison	O
3	indicates	O
4	that	O
5	exons	O
6	5	O
7	'/	O
8	L	O
9	and	O
10	L	O
11	/	O
12	N	O
13	in	O
14	PSG12	B
15	and	O
16	PSG12	B
17	psi	I
18	are	O
19	99	O
20	%	O
21	identical	O
22	,	O
23	except	O
24	that	O
25	the	O
26	L	O
27	/	O
28	N	O
29	exon	O
30	in	O
31	the	O
32	PSG12	B
33	psi	I
34	gene	I
35	contains	O
36	a	O
37	stop	O
38	codon	O
39	.	O
1	We	O
2	recently	O
3	found	O
4	that	O
5	17	O
6	beta	O
7	-	O
8	estradiol	O
9	(	O
10	E2	O
11	)	O
12	not	O
13	only	O
14	suppresses	O
15	bone	O
16	resorption	O
17	but	O
18	also	O
19	stimulates	O
20	bone	O
21	formation	O
22	in	O
23	the	O
24	cancellous	O
25	bone	O
26	of	O
27	female	O
28	rats	O
29	.	O
1	Recombinant	B
2	human	I
3	erythropoietin	I
4	(	O
5	epoetin	B
6	)	O
7	is	O
8	approved	O
9	to	O
10	be	O
11	administered	O
12	by	O
13	the	O
14	intravenous	O
15	(	O
16	i	O
17	.	O
18	v	O
19	.)	O
20	or	O
21	subcutaneous	O
22	(	O
23	SC	O
24	)	O
25	route	O
26	.	O
1	Single	O
2	-	O
3	photon	O
4	emission	O
5	computed	O
6	tomography	O
7	(	O
8	SPECT	O
9	)	O
10	with	O
11	99mTc	O
12	-	O
13	hexamethylpropyleneamine	O
14	oxime	O
15	(	O
16	HMPAO	O
17	)	O
18	was	O
19	used	O
20	to	O
21	investigate	O
22	changes	O
23	in	O
24	cerebral	O
25	blood	O
26	flow	O
27	in	O
28	seven	O
29	patients	O
30	with	O
31	cortical	O
32	visual	O
33	impairment	O
34	.	O
1	The	O
2	rCBF	O
3	ratio	O
4	was	O
5	mainly	O
6	reduced	O
7	in	O
8	frontal	O
9	lobes	O
10	(	O
11	65	O
12	%).	O
1	METHODS	O
2	:	O
3	Twenty	O
4	-	O
5	two	O
6	patients	O
7	were	O
8	grouped	O
9	according	O
10	to	O
11	their	O
12	etiology	O
13	based	O
14	on	O
15	the	O
16	study	O
17	of	O
18	antiadrenal	O
19	antibodies	O
20	at	O
21	diagnosis	O
22	of	O
23	the	O
24	disease	O
25	:	O
26	7	O
27	were	O
28	positive	O
29	(	O
30	autoimmune	O
31	etiology	O
32	or	O
33	EAA	O
34	),	O
35	11	O
36	were	O
37	negative	O
38	(	O
39	tuberculous	O
40	etiology	O
41	or	O
42	EAT	O
43	)	O
44	and	O
45	in	O
46	four	O
47	serologic	O
48	study	O
49	was	O
50	not	O
51	available	O
52	(	O
53	undetermined	O
54	etiology	O
55	or	O
56	EAI	O
57	).	O
1	HTLV	O
2	-	O
3	1	O
4	gene	O
5	expression	O
6	by	O
7	defective	O
8	proviruses	O
9	in	O
10	an	O
11	infected	O
12	T	O
13	-	O
14	cell	O
15	line	O
16	.	O
1	These	O
2	contain	O
3	a	O
4	single	O
5	1977	O
6	-	O
7	bp	O
8	exon	O
9	that	O
10	encodes	O
11	900	O
12	bp	O
13	of	O
14	the	O
15	5	O
16	'	O
17	and	O
18	3	O
19	'	O
20	untranslated	O
21	sequences	O
22	in	O
23	addition	O
24	to	O
25	a	O
26	1077	O
27	-	O
28	bp	O
29	open	O
30	reading	O
31	frame	O
32	identical	O
33	to	O
34	that	O
35	found	O
36	in	O
37	vascular	B
38	smooth	I
39	muscle	I
40	cell	I
41	AT1a	I
42	receptor	I
43	cDNAs	I
44	.	O
1	Deletion	O
2	of	O
3	a	O
4	53	O
5	-	O
6	bp	O
7	early	O
8	promoter	O
9	region	O
10	containing	O
11	the	O
12	transcription	O
13	start	O
14	site	O
15	and	O
16	a	O
17	putative	O
18	TATA	O
19	box	O
20	completely	O
21	abolishes	O
22	the	O
23	ability	O
24	of	O
25	upstream	O
26	elements	O
27	to	O
28	drive	O
29	transcription	O
30	of	O
31	the	O
32	luciferase	B
33	cDNA	I
34	.	O
1	The	O
2	Functional	O
3	Independence	O
4	Measure	O
5	:	O
6	a	O
7	comparative	O
8	study	O
9	of	O
10	clinician	O
11	and	O
12	self	O
13	ratings	O
14	.	O
1	The	O
2	binding	O
3	specificity	O
4	of	O
5	this	O
6	protein	O
7	was	O
8	compared	O
9	to	O
10	that	O
11	of	O
12	human	B
13	E2F	I
14	using	O
15	a	O
16	number	O
17	of	O
18	mutant	B
19	E2F	I
20	sites	I
21	as	O
22	competitors	O
23	.	O
1	McCann	O
2	III	O
3	,	O
4	F	O
5	.	O
1	These	O
2	cell	O
3	lines	O
4	,	O
5	selected	O
6	for	O
7	the	O
8	ability	O
9	to	O
10	support	O
11	the	O
12	replication	O
13	of	O
14	a	O
15	temperature	O
16	-	O
17	sensitive	O
18	VP5	B
19	mutant	I
20	,	O
21	were	O
22	used	O
23	to	O
24	isolate	O
25	VP5	B
26	and	O
27	VP23	B
28	null	O
29	mutants	O
30	.	O
1	We	O
2	conclude	O
3	that	O
4	the	O
5	conservation	O
6	of	O
7	nucleotides	O
8	154	O
9	to	O
10	156	O
11	is	O
12	likely	O
13	to	O
14	be	O
15	a	O
16	consequence	O
17	of	O
18	their	O
19	role	O
20	as	O
21	a	O
22	sequence	O
23	-	O
24	specific	O
25	recognition	O
26	element	O
27	for	O
28	the	O
29	SRP54	B
30	protein	I
31	.	O
1	Secondary	O
2	cleavage	O
3	of	O
4	RT	B
5	at	O
6	Trp	O
7	-	O
8	595	O
9	-	O
10	Tyr	O
11	-	O
12	596	O
13	of	O
14	Pol	B
15	yields	O
16	a	O
17	truncated	O
18	form	O
19	lacking	O
20	the	O
21	C	B
22	-	I
23	terminal	I
24	RNase	I
25	H	I
26	domain	I
27	.	O
1	All	O
2	four	O
3	of	O
4	the	O
5	genes	O
6	have	O
7	a	O
8	similar	O
9	structure	O
10	,	O
11	with	O
12	the	O
13	receptor	O
14	protein	O
15	encoded	O
16	in	O
17	a	O
18	single	O
19	exon	O
20	.	O
1	We	O
2	show	O
3	that	O
4	IL	B
5	-	I
6	6	I
7	activates	O
8	JRE	B
9	-	I
10	IL6	I
11	through	O
12	an	O
13	H7	O
14	-	O
15	sensitive	O
16	pathway	O
17	that	O
18	does	O
19	not	O
20	involve	O
21	protein	B
22	kinase	I
23	C	I
24	,	O
25	cyclic	B
26	AMP	I
27	-	I
28	dependent	I
29	kinase	I
30	,	O
31	Ca	B
32	(	I
33	2	I
34	+)-	I
35	or	I
36	calmodulin	I
37	-	I
38	dependent	I
39	kinases	I
40	,	O
41	Ras	B
42	,	O
43	Raf	B
44	-	I
45	1	I
46	,	O
47	or	O
48	NF	B
49	-	I
50	IL6	I
51	(	O
52	C	B
53	/	I
54	EBP	I
55	beta	I
56	).	O
1	Mutation	O
2	of	O
3	the	O
4	presumptive	O
5	phosphorylated	O
6	tyrosine	O
7	and	O
8	threonine	O
9	residues	O
10	of	O
11	Mpk1p	B
12	individually	O
13	to	O
14	phenylalanine	O
15	and	O
16	alanine	O
17	,	O
18	respectively	O
19	,	O
20	severely	O
21	impaired	O
22	Mpk1p	B
23	function	O
24	.	O
1	16	O
2	,	O
3	99	O
4	-	O
5	104	O
6	).	O
1	Mutations	O
2	at	O
3	the	O
4	extreme	O
5	C	O
6	-	O
7	terminus	O
8	of	O
9	EIAV	B
10	Tat	I
11	impaired	O
12	both	O
13	RNA	O
14	binding	O
15	and	O
16	activation	O
17	domain	O
18	functions	O
19	,	O
20	suggesting	O
21	effects	O
22	on	O
23	secondary	O
24	or	O
25	tertiary	O
26	structure	O
27	.	O
1	Drugs	O
2	suppressed	O
3	>	O
4	or	O
5	=	O
6	75	O
7	%	O
8	of	O
9	the	O
10	total	O
11	premature	O
12	ventricular	O
13	contractions	O
14	in	O
15	all	O
16	patients	O
17	who	O
18	had	O
19	both	O
20	use	O
21	-	O
22	dependent	O
23	QRS	O
24	prolongation	O
25	and	O
26	reverse	O
27	use	O
28	-	O
29	dependent	O
30	QT	O
31	prolongation	O
32	,	O
33	in	O
34	79	O
35	%	O
36	of	O
37	patients	O
38	with	O
39	use	O
40	-	O
41	dependent	O
42	QRS	O
43	prolongation	O
44	alone	O
45	,	O
46	in	O
47	70	O
48	%	O
49	with	O
50	reverse	O
51	use	O
52	-	O
53	dependent	O
54	QT	O
55	prolongation	O
56	alone	O
57	,	O
58	and	O
59	in	O
60	11	O
61	%	O
62	with	O
63	neither	O
64	use	O
65	-	O
66	dependent	O
67	QRS	O
68	prolongation	O
69	nor	O
70	reverse	O
71	use	O
72	-	O
73	dependent	O
74	QT	O
75	prolongation	O
76	.	O
1	The	O
2	ability	O
3	of	O
4	spt2	B
5	mutations	I
6	to	O
7	suppress	O
8	the	O
9	transcriptional	O
10	interference	O
11	caused	O
12	by	O
13	the	O
14	delta	B
15	promoter	I
16	insertion	I
17	his	I
18	-	I
19	4	I
20	-	I
21	912	I
22	delta	I
23	correlates	O
24	with	O
25	an	O
26	increase	O
27	in	O
28	wild	B
29	-	I
30	type	I
31	HIS4	I
32	mRNA	I
33	levels	O
34	.	O
1	To	O
2	study	O
3	the	O
4	functional	O
5	differences	O
6	between	O
7	cutaneous	O
8	HPV5	O
9	and	O
10	HPV8	O
11	E7s	B
12	and	O
13	genital	B
14	HPV16	I
15	E7	I
16	,	O
17	we	O
18	cloned	O
19	each	O
20	of	O
21	the	O
22	E7	B
23	open	O
24	reading	O
25	frames	O
26	and	O
27	tested	O
28	their	O
29	immortalizing	O
30	and	O
31	transforming	O
32	activities	O
33	,	O
34	the	O
35	binding	O
36	ability	O
37	of	O
38	their	O
39	products	O
40	with	O
41	retinoblastoma	B
42	protein	I
43	(	O
44	RB	B
45	)	O
46	and	O
47	their	O
48	complementation	O
49	activity	O
50	of	O
51	a	O
52	RB	B
53	-	I
54	nonbinding	I
55	adenovirus	I
56	E1A	I
57	mutant	I
58	.	O
1	These	O
2	experiments	O
3	confirm	O
4	that	O
5	the	O
6	6	O
7	-	O
8	S	O
9	liganded	O
10	form	O
11	of	O
12	the	O
13	receptor	O
14	identified	O
15	in	O
16	nuclear	O
17	extracts	O
18	of	O
19	cells	O
20	treated	O
21	with	O
22	2	O
23	,	O
24	3	O
25	,	O
26	7	O
27	,	O
28	8	O
29	-	O
30	tetrachlorodibenzo	O
31	-	O
32	p	O
33	-	O
34	dioxin	O
35	(	O
36	TCDD	O
37	)	O
38	contains	O
39	the	O
40	Ah	B
41	receptor	I
42	protein	I
43	and	O
44	ARNT	B
45	but	O
46	not	O
47	the	O
48	90	B
49	-	I
50	kDa	I
51	heat	I
52	shock	I
53	protein	I
54	.	O
1	We	O
2	linked	O
3	hypersensitivity	O
4	site	O
5	2	O
6	(	O
7	HS2	O
8	)	O
9	from	O
10	the	O
11	locus	O
12	control	O
13	region	O
14	(	O
15	LCR	O
16	)	O
17	to	O
18	a	O
19	A	B
20	gamma	I
21	-	I
22	globin	I
23	gene	O
24	(	O
25	A	O
26	gamma	O
27	*)	O
28	mutationally	O
29	marked	O
30	to	O
31	allow	O
32	its	O
33	transcript	O
34	to	O
35	be	O
36	distinguished	O
37	from	O
38	endogenous	O
39	gamma	B
40	-	I
41	globin	I
42	mRNA	O
43	.	O
1	The	O
2	human	B
3	insulin	I
4	-	I
5	like	I
6	growth	I
7	factor	I
8	II	I
9	(	O
10	IGF	B
11	-	I
12	II	I
13	)	O
14	gene	O
15	contains	O
16	four	O
17	promoters	O
18	(	O
19	P1	O
20	,	O
21	P2	O
22	,	O
23	P3	O
24	and	O
25	P4	O
26	).	O
1	1	O
2	)	O
3	CFDN	O
4	,	O
5	AMPC	O
6	and	O
7	MNZ	O
8	showed	O
9	a	O
10	potent	O
11	antimicrobial	O
12	activity	O
13	against	O
14	H	O
15	.	O
16	pylori	O
17	,	O
18	and	O
19	especially	O
20	,	O
21	AMPC	O
22	showed	O
23	a	O
24	marked	O
25	bactericidal	O
26	activity	O
27	in	O
28	a	O
29	short	O
30	time	O
31	.	O
1	A	O
2	patient	O
3	matches	O
4	a	O
5	PIC	O
6	patient	O
7	if	O
8	both	O
9	have	O
10	the	O
11	same	O
12	mechanism	O
13	of	O
14	injury	O
15	,	O
16	the	O
17	same	O
18	coding	O
19	of	O
20	Revised	O
21	Trauma	O
22	Score	O
23	variables	O
24	(	O
25	Glascow	O
26	Coma	O
27	Scale	O
28	score	O
29	,	O
30	systolic	O
31	blood	O
32	pressure	O
33	,	O
34	respiratory	O
35	rate	O
36	),	O
37	the	O
38	same	O
39	coded	O
40	age	O
41	per	O
42	A	O
43	Severity	O
44	Characterization	O
45	of	O
46	Trauma	O
47	)	O
48	(	O
49	ASCOT	O
50	),	O
51	and	O
52	if	O
53	they	O
54	differ	O
55	by	O
56	no	O
57	more	O
58	than	O
59	0	O
60	.	O
61	5	O
62	for	O
63	A	O
64	,	O
65	B	O
66	,	O
67	and	O
68	C	O
69	(	O
70	the	O
71	ASCOT	O
72	components	O
73	for	O
74	serious	O
75	injuries	O
76	).	O
1	Transient	O
2	transfection	O
3	experiments	O
4	revealed	O
5	that	O
6	Pax	B
7	-	I
8	8	I
9	isoforms	I
10	a	I
11	and	I
12	b	I
13	,	O
14	but	O
15	not	O
16	c	O
17	and	O
18	d	O
19	,	O
20	strongly	O
21	stimulate	O
22	transcription	O
23	from	O
24	a	O
25	promoter	O
26	containing	O
27	six	O
28	copies	O
29	of	O
30	a	O
31	paired	B
32	-	I
33	domain	I
34	recognition	I
35	sequence	I
36	.	O
1	The	O
2	ADP	B
3	-	I
4	ribosylation	I
5	factor	I
6	(	O
7	ARF	B
8	)	O
9	family	O
10	is	O
11	one	O
12	of	O
13	four	O
14	subfamilies	O
15	of	O
16	the	O
17	RAS	B
18	superfamily	I
19	of	O
20	low	B
21	molecular	I
22	weight	I
23	GTP	I
24	-	I
25	binding	I
26	proteins	I
27	(	O
28	G	B
29	proteins	I
30	).	O
1	All	O
2	of	O
3	these	O
4	data	O
5	suggest	O
6	that	O
7	replication	O
8	of	O
9	UV	O
10	-	O
11	damaged	O
12	templates	O
13	occurs	O
14	in	O
15	vitro	O
16	as	O
17	it	O
18	does	O
19	in	O
20	vivo	O
21	and	O
22	that	O
23	this	O
24	replication	O
25	results	O
26	in	O
27	mutation	O
28	fixation	O
29	.	O
1	Biol	O
2	.	O
1	To	O
2	characterize	O
3	the	O
4	expression	O
5	of	O
6	this	O
7	DNA	B
8	repair	I
9	enzyme	I
10	,	O
11	we	O
12	have	O
13	isolated	O
14	the	O
15	corresponding	O
16	genomic	O
17	clone	O
18	.	O
1	L	O
2	.,	O
3	Stange	O
4	,	O
5	G	O
6	.,	O
7	Markovich	O
8	,	O
9	D	O
10	.,	O
11	Biber	O
12	,	O
13	J	O
14	.,	O
15	Testar	O
16	,	O
17	X	O
18	.,	O
19	Zorzano	O
20	,	O
21	A	O
22	.,	O
23	Palacin	O
24	,	O
25	M	O
26	.,	O
27	and	O
28	Murer	O
29	,	O
30	H	O
31	.	O
1	SAECG	O
2	,	O
3	echocardiography	O
4	and	O
5	thallium	O
6	-	O
7	201	O
8	imaging	O
9	were	O
10	performed	O
11	before	O
12	and	O
13	1	O
14	month	O
15	after	O
16	attempted	O
17	angioplasty	O
18	.	O
1	CONCLUSIONS	O
2	:	O
3	Free	O
4	protein	B
5	S	I
6	deficiency	O
7	is	O
8	common	O
9	among	O
10	hospitalized	O
11	patients	O
12	,	O
13	even	O
14	in	O
15	the	O
16	absence	O
17	of	O
18	a	O
19	recognized	O
20	predisposing	O
21	condition	O
22	.	O
1	During	O
2	the	O
3	past	O
4	decade	O
5	,	O
6	different	O
7	types	O
8	of	O
9	endogenous	O
10	retroviral	O
11	sequences	O
12	have	O
13	been	O
14	defined	O
15	in	O
16	the	O
17	human	O
18	genome	O
19	usually	O
20	by	O
21	low	O
22	stringency	O
23	hybridization	O
24	employing	O
25	DNA	O
26	probes	O
27	of	O
28	evolutionary	O
29	conserved	O
30	animal	O
31	retrovirus	O
32	genes	O
33	.	O
1	Localization	O
2	of	O
3	the	O
4	intronless	O
5	gene	O
6	coding	O
7	for	O
8	calmodulin	B
9	-	I
10	like	I
11	protein	I
12	CLP	I
13	to	O
14	human	O
15	chromosome	O
16	10p13	O
17	-	O
18	ter	O
19	.	O
1	One	O
2	such	O
3	mutant	O
4	also	O
5	affects	O
6	the	O
7	overlapping	O
8	-	O
9	10	O
10	hexamer	O
11	of	O
12	PR	O
13	and	O
14	results	O
15	in	O
16	reduced	O
17	occupancy	O
18	by	O
19	both	O
20	MerR	B
21	and	O
22	RNA	B
23	polymerase	I
24	,	O
25	likely	O
26	as	O
27	a	O
28	result	O
29	of	O
30	inefficient	O
31	transcriptional	O
32	initiation	O
33	of	O
34	merR	B
35	mRNA	I
36	.	O
1	CONCLUSIONS	O
2	.	O
1	Naval	O
2	personnel	O
3	who	O
4	exceed	O
5	standards	O
6	for	O
7	%	O
8	BF	O
9	can	O
10	be	O
11	separated	O
12	from	O
13	active	O
14	duty	O
15	.	O
1	Weak	O
2	promoter	O
3	activity	O
4	was	O
5	observed	O
6	for	O
7	the	O
8	promoter	O
9	of	O
10	the	O
11	C1	B
12	and	O
13	C2	B
14	ORFs	O
15	(	O
16	C1	B
17	-	O
18	C2	B
19	gene	O
20	)	O
21	and	O
22	for	O
23	the	O
24	promoter	O
25	of	O
26	the	O
27	V1	B
28	ORF	I
29	.	O
1	A	O
2	region	O
3	in	O
4	the	O
5	C	O
6	-	O
7	terminus	O
8	of	O
9	adenovirus	B
10	2	I
11	/	I
12	5	I
13	E1a	I
14	protein	I
15	is	O
16	required	O
17	for	O
18	association	O
19	with	O
20	a	O
21	cellular	O
22	phosphoprotein	O
23	and	O
24	important	O
25	for	O
26	the	O
27	negative	O
28	modulation	O
29	of	O
30	T24	O
31	-	O
32	ras	B
33	mediated	O
34	transformation	O
35	,	O
36	tumorigenesis	O
37	and	O
38	metastasis	O
39	.	O
1	These	O
2	studies	O
3	demonstrate	O
4	that	O
5	both	O
6	G	B
7	alpha	I
8	i	I
9	genes	I
10	are	O
11	dynamically	O
12	regulated	O
13	in	O
14	LLC	O
15	-	O
16	PK1	O
17	cells	O
18	by	O
19	both	O
20	growth	O
21	,	O
22	differentiation	O
23	,	O
24	and	O
25	hormone	O
26	signals	O
27	.	O
1	While	O
2	the	O
3	latter	O
4	corresponded	O
5	to	O
6	a	O
7	protein	O
8	of	O
9	824	O
10	amino	O
11	acids	O
12	,	O
13	an	O
14	upstream	O
15	open	O
16	reading	O
17	frame	O
18	(	O
19	uORF	O
20	)	O
21	within	O
22	the	O
23	5	O
24	'	O
25	leader	O
26	could	O
27	potentially	O
28	encode	O
29	a	O
30	54	O
31	amino	O
32	acid	O
33	peptide	O
34	.	O
1	The	O
2	SCH9	B
3	protein	I
4	kinase	I
5	mRNA	I
6	contains	O
7	a	O
8	long	O
9	5	O
10	'	O
11	leader	O
12	with	O
13	a	O
14	small	O
15	open	O
16	reading	O
17	frame	O
18	.	O
1	Sudomoina	O
2	,	O
3	A	O
4	.	O
1	Zinc	O
2	fingers	O
3	(	O
4	Zf	O
5	)	O
6	are	O
7	a	O
8	common	O
9	structural	O
10	motif	O
11	found	O
12	in	O
13	many	O
14	nucleic	O
15	acid	O
16	-	O
17	binding	O
18	proteins	O
19	.	O
1	Pathways	O
2	linking	O
3	the	O
4	olfactory	O
5	bulbs	O
6	with	O
7	the	O
8	medial	O
9	preoptic	O
10	anterior	O
11	hypothalamus	O
12	are	O
13	important	O
14	for	O
15	intermale	O
16	aggression	O
17	in	O
18	mice	O
19	.	O
1	Pokeweed	B
2	mitogen	I
3	(	O
4	PWM	B
5	)	O
6	or	O
7	anti	B
8	-	I
9	CD3	I
10	significantly	O
11	increases	O
12	c	B
13	-	I
14	jun	I
15	messenger	I
16	RNA	I
17	(	I
18	mRNA	I
19	)	I
20	levels	O
21	in	O
22	T	O
23	cells	O
24	.	O
1	In	O
2	contrast	O
3	,	O
4	rats	O
5	receiving	O
6	U74500A	O
7	(	O
8	2	O
9	mg	O
10	/	O
11	kg	O
12	i	O
13	.	O
14	v	O
15	.	O
16	infusion	O
17	commencing	O
18	30	O
19	min	O
20	prior	O
21	to	O
22	revascularisation	O
23	)	O
24	exhibited	O
25	enhanced	O
26	GMBF	O
27	throughout	O
28	reperfusion	O
29	[	O
30	PI	O
31	10	O
32	min	O
33	:	O
34	3	O
35	.	O
36	26	O
37	(	O
38	2	O
39	.	O
40	56	O
41	-	O
42	3	O
43	.	O
44	63	O
45	);	O
46	120	O
47	min	O
48	:	O
49	2	O
50	.	O
51	03	O
52	(	O
53	1	O
54	.	O
55	73	O
56	-	O
57	2	O
58	.	O
59	25	O
60	);	O
61	240	O
62	min	O
63	:	O
64	2	O
65	.	O
66	13	O
67	(	O
68	1	O
69	.	O
70	75	O
71	-	O
72	2	O
73	.	O
74	44	O
75	),	O
76	p	O
77	<	O
78	0	O
79	.	O
80	01	O
81	vs	O
82	.	O
83	controls	O
84	and	O
85	normals	O
86	]	O
87	with	O
88	complete	O
89	muscle	O
90	salvage	O
91	[	O
92	GMV	O
93	100	O
94	%	O
95	in	O
96	all	O
97	reperfused	O
98	muscles	O
99	,	O
100	p	O
101	<	O
102	0	O
103	.	O
104	01	O
105	vs	O
106	.	O
107	controls	O
108	,	O
109	not	O
110	significant	O
111	(	O
112	NS	O
113	)	O
114	vs	O
115	.	O
116	normals	O
117	and	O
118	6	O
119	h	O
120	ischaemia	O
121	].(	O
122	ABSTRACT	O
123	TRUNCATED	O
124	AT	O
125	250	O
126	WORDS	O
127	)	O
1	Sterile	O
2	mutants	O
3	of	O
4	Saccharomyces	O
5	cerevisiae	O
6	were	O
7	isolated	O
8	from	O
9	alpha	O
10	*	O
11	cells	O
12	having	O
13	the	O
14	a	B
15	/	I
16	alpha	I
17	aar1	I
18	-	I
19	6	I
20	genotype	O
21	(	O
22	exhibiting	O
23	alpha	O
24	mating	O
25	ability	O
26	and	O
27	weak	O
28	a	O
29	mating	O
30	ability	O
31	as	O
32	a	O
33	result	O
34	of	O
35	a	O
36	defect	O
37	in	O
38	a1	B
39	-	I
40	alpha	I
41	2	I
42	repression	O
43	).	O
1	OBJECTIVE	O
2	:	O
3	Our	O
4	purpose	O
5	was	O
6	to	O
7	determine	O
8	the	O
9	simultaneous	O
10	concentrations	O
11	of	O
12	serum	O
13	cotinine	O
14	in	O
15	both	O
16	fetal	O
17	and	O
18	maternal	O
19	blood	O
20	.	O
1	Estradiol	O
2	is	O
3	known	O
4	to	O
5	induce	O
6	expression	O
7	of	O
8	certain	O
9	proto	O
10	-	O
11	oncogenes	O
12	,	O
13	and	O
14	this	O
15	led	O
16	us	O
17	to	O
18	examine	O
19	potential	O
20	regulatory	O
21	regions	O
22	of	O
23	the	O
24	cellular	B
25	c	I
26	-	I
27	fos	I
28	oncogene	I
29	.	O
1	This	O
2	was	O
3	performed	O
4	in	O
5	a	O
6	double	O
7	blinded	O
8	,	O
9	randomized	O
10	,	O
11	placebo	O
12	-	O
13	controlled	O
14	study	O
15	.	O
1	Based	O
2	on	O
3	these	O
4	results	O
5	,	O
6	a	O
7	new	O
8	model	O
9	for	O
10	the	O
11	regulation	O
12	of	O
13	nif	B
14	/	O
15	fix	B
16	gene	O
17	expression	O
18	in	O
19	A	O
20	.	O
21	caulinodans	O
22	is	O
23	proposed	O
24	.	O
1	Mutations	O
2	at	O
3	three	O
4	sites	O
5	have	O
6	larger	O
7	effects	O
8	in	O
9	muscle	O
10	than	O
11	nonmuscle	O
12	cells	O
13	;	O
14	an	O
15	A	O
16	/	O
17	T	O
18	-	O
19	rich	O
20	site	O
21	mutation	O
22	has	O
23	a	O
24	pronounced	O
25	effect	O
26	in	O
27	both	O
28	striated	O
29	muscle	O
30	types	O
31	,	O
32	mutations	O
33	at	O
34	the	O
35	MEF1	B
36	(	I
37	Right	I
38	E	I
39	-	I
40	box	I
41	)	I
42	site	I
43	are	O
44	relatively	O
45	specific	O
46	to	O
47	expression	O
48	in	O
49	skeletal	O
50	muscle	O
51	,	O
52	and	O
53	mutations	O
54	at	O
55	the	O
56	CArG	O
57	site	O
58	are	O
59	relatively	O
60	specific	O
61	to	O
62	expression	O
63	in	O
64	cardiac	O
65	muscle	O
66	.	O
1	DNase	B
2	I	I
3	footprinting	O
4	with	O
5	rat	O
6	liver	O
7	nuclear	O
8	extracts	O
9	identified	O
10	7	O
11	major	O
12	protein	O
13	-	O
14	binding	O
15	domains	O
16	termed	O
17	P1	O
18	through	O
19	P7	O
20	in	O
21	a	O
22	796	O
23	base	O
24	pair	O
25	DNA	O
26	fragment	O
27	(	O
28	base	O
29	pairs	O
30	-	O
31	763	O
32	to	O
33	+	O
34	33	O
35	).	O
1	Neither	O
2	clone	O
3	encoded	O
4	the	O
5	cognate	O
6	endonuclease	O
7	.	O
1	Northern	O
2	blot	O
3	analysis	O
4	of	O
5	total	O
6	cellular	O
7	RNA	O
8	indicated	O
9	that	O
10	xylP	B
11	encodes	O
12	a	O
13	1	O
14	.	O
15	3	O
16	-	O
17	kb	O
18	transcript	O
19	which	O
20	is	O
21	induced	O
22	by	O
23	xylan	O
24	.	O
1	These	O
2	data	O
3	show	O
4	that	O
5	PTH	B
6	and	O
7	cAMP	O
8	can	O
9	repress	O
10	collagen	B
11	promoter	I
12	activity	O
13	in	O
14	calvariae	O
15	from	O
16	transgenic	O
17	mice	O
18	,	O
19	suggesting	O
20	that	O
21	the	O
22	alpha	B
23	1	I
24	(	I
25	I	I
26	)	I
27	collagen	I
28	promoter	I
29	may	O
30	contain	O
31	cis	O
32	elements	O
33	down	O
34	-	O
35	stream	O
36	of	O
37	-	O
38	2	O
39	.	O
40	3	O
41	kilobases	O
42	that	O
43	mediate	O
44	PTH	B
45	and	O
46	cAMP	O
47	repression	O
48	of	O
49	collagen	B
50	gene	I
51	expression	O
52	in	O
53	bone	O
54	.	O
1	Spontaneous	O
2	burst	O
3	firing	O
4	in	O
5	cat	O
6	primary	O
7	auditory	O
8	cortex	O
9	:	O
10	age	O
11	and	O
12	depth	O
13	dependence	O
14	and	O
15	its	O
16	effect	O
17	on	O
18	neural	O
19	interaction	O
20	measures	O
21	.	O
1	The	O
2	active	O
3	open	O
4	reading	O
5	frame	O
6	in	O
7	the	O
8	clone	O
9	maps	O
10	at	O
11	27	O
12	min	O
13	on	O
14	the	O
15	E	O
16	.	O
17	coli	O
18	chromosome	O
19	and	O
20	is	O
21	identical	O
22	in	O
23	sequence	O
24	to	O
25	a	O
26	wild	O
27	type	O
28	counterpart	O
29	.	O
1	We	O
2	conclude	O
3	that	O
4	grade	O
5	III	O
6	BGCT	O
7	can	O
8	be	O
9	treated	O
10	by	O
11	modified	O
12	intralesional	O
13	excision	O
14	provided	O
15	the	O
16	articular	O
17	surfaces	O
18	and	O
19	part	O
20	of	O
21	the	O
22	metaphysis	O
23	are	O
24	intact	O
25	.	O
1	Analysis	O
2	of	O
3	the	O
4	binding	O
5	of	O
6	Lrp	B
7	to	O
8	a	O
9	set	O
10	of	O
11	circularly	O
12	permuted	O
13	DNA	O
14	fragments	O
15	from	O
16	this	O
17	region	O
18	indicates	O
19	that	O
20	Lrp	B
21	induces	O
22	DNA	O
23	bending	O
24	.	O
1	The	O
2	patients	O
3	were	O
4	divided	O
5	into	O
6	ischaemia	O
7	and	O
8	non	O
9	-	O
10	ischaemia	O
11	groups	O
12	on	O
13	the	O
14	basis	O
15	of	O
16	the	O
17	change	O
18	in	O
19	lactate	O
20	extraction	O
21	ratio	O
22	during	O
23	balloon	O
24	inflation	O
25	.	O
1	A	O
2	36	O
3	-	O
4	kDa	O
5	protein	O
6	that	O
7	was	O
8	localized	O
9	to	O
10	the	O
11	membrane	O
12	fraction	O
13	was	O
14	detected	O
15	in	O
16	minicells	O
17	containing	O
18	plasmids	O
19	with	O
20	the	O
21	ftsN	B
22	gene	I
23	,	O
24	confirming	O
25	that	O
26	FtsN	B
27	was	O
28	a	O
29	membrane	O
30	protein	O
31	.	O
1	This	O
2	gene	O
3	spans	O
4	23	O
5	kb	O
6	and	O
7	is	O
8	composed	O
9	of	O
10	five	O
11	exons	O
12	and	O
13	four	O
14	introns	O
15	.	O
1	The	O
2	remaining	O
3	RAD	B
4	+	I
5	cells	O
6	progressed	O
7	to	O
8	form	O
9	microcolonies	O
10	(<	O
11	30	O
12	cells	O
13	)	O
14	containing	O
15	aberrantly	O
16	shaped	O
17	inviable	O
18	cells	O
19	.	O
1	These	O
2	findings	O
3	suggest	O
4	that	O
5	a	O
6	range	O
7	of	O
8	microenvironmental	O
9	conditions	O
10	exist	O
11	within	O
12	purified	O
13	water	O
14	systems	O
15	,	O
16	leading	O
17	to	O
18	variable	O
19	populations	O
20	of	O
21	bacteria	O
22	.	O
1	Measurement	O
2	of	O
3	anti	B
4	-	I
5	HCV	I
6	IgM	I
7	antibodies	I
8	with	O
9	an	O
10	experimental	O
11	kit	O
1	These	O
2	cell	O
3	lines	O
4	displayed	O
5	methylation	O
6	of	O
7	the	O
8	CpG	O
9	island	O
10	surrounding	O
11	the	O
12	first	O
13	exon	O
14	of	O
15	p16INK4A	B
16	and	O
17	expressed	O
18	abundant	O
19	levels	O
20	of	O
21	a	O
22	nontranslated	O
23	mRNA	O
24	containing	O
25	an	O
26	alternative	O
27	first	O
28	exon	O
29	(	O
30	E1	O
31	beta	O
32	),	O
33	as	O
34	did	O
35	all	O
36	other	O
37	cell	O
38	lines	O
39	in	O
40	which	O
41	the	O
42	p16INK4A	B
43	locus	I
44	was	O
45	not	O
46	deleted	O
47	.	O
1	Egd1p	B
2	is	O
3	homologous	O
4	to	O
5	human	B
6	BTF3b	I
7	,	O
8	recently	O
9	identified	O
10	as	O
11	the	O
12	beta	O
13	subunit	O
14	of	O
15	the	O
16	heterodimeric	B
17	nascent	I
18	-	I
19	polypeptide	I
20	-	I
21	associated	I
22	complex	I
23	(	O
24	NAC	B
25	)	O
26	involved	O
27	in	O
28	ensuring	O
29	signal	O
30	-	O
31	sequence	O
32	-	O
33	specific	O
34	protein	O
35	sorting	O
36	and	O
37	translocation	O
38	[	O
39	Wiedmann	O
40	et	O
41	al	O
42	.,	O
43	Nature	O
44	370	O
45	(	O
46	1994	O
47	)	O
48	434	O
49	-	O
50	440	O
51	].	O
1	We	O
2	failed	O
3	to	O
4	find	O
5	these	O
6	data	O
7	to	O
8	be	O
9	useful	O
10	in	O
11	predicting	O
12	the	O
13	time	O
14	of	O
15	onset	O
16	of	O
17	initial	O
18	seizures	O
19	after	O
20	acute	O
21	ischemic	O
22	stroke	O
23	and	O
24	recurrence	O
25	.	O
1	Degradation	O
2	of	O
3	the	O
4	soybean	B
5	ribulose	I
6	-	I
7	1	I
8	,	I
9	5	I
10	-	I
11	bisphosphate	I
12	carboxylase	I
13	small	I
14	-	I
15	subunit	I
16	mRNA	I
17	,	O
18	SRS4	B
19	,	O
20	initiates	O
21	with	O
22	endonucleolytic	O
23	cleavage	O
24	.	O
1	The	O
2	TEA1	B
3	(	O
4	Ty	B
5	enhancer	I
6	activator	I
7	)	O
8	gene	O
9	sequence	O
10	predicts	O
11	a	O
12	protein	O
13	of	O
14	86	O
15	.	O
16	9	O
17	kDa	O
18	whose	O
19	N	O
20	terminus	O
21	contains	O
22	a	O
23	zinc	O
24	cluster	O
25	and	O
26	dimerization	O
27	motif	O
28	typical	O
29	of	O
30	the	O
31	Gal4	B
32	-	I
33	type	I
34	family	I
35	of	O
36	DNA	O
37	-	O
38	binding	O
39	proteins	O
40	.	O
1	Together	O
2	,	O
3	our	O
4	data	O
5	suggest	O
6	that	O
7	the	O
8	TR2	B
9	orphan	I
10	receptor	I
11	may	O
12	be	O
13	a	O
14	master	O
15	regulator	O
16	in	O
17	modulating	O
18	the	O
19	activation	O
20	of	O
21	two	O
22	key	O
23	HREs	O
24	,	O
25	RARE	O
26	beta	O
27	and	O
28	CRBPIIp	O
29	,	O
30	involved	O
31	in	O
32	the	O
33	retinoic	O
34	acid	O
35	signal	O
36	transduction	O
37	pathway	O
38	.	O
1	All	O
2	three	O
3	NR	B
4	isoforms	O
5	are	O
6	expressed	O
7	in	O
8	cv	O
9	.	O
1	Certain	O
2	transcript	O
3	patterns	O
4	in	O
5	Epifagus	O
6	plastids	O
7	are	O
8	highly	O
9	complex	O
10	and	O
11	similar	O
12	to	O
13	those	O
14	of	O
15	tobacco	O
16	operons	O
17	.	O
1	To	O
2	identify	O
3	some	O
4	of	O
5	the	O
6	genes	O
7	expressed	O
8	in	O
9	LPS	O
10	-	O
11	activated	O
12	coelomocytes	O
13	,	O
14	we	O
15	sequenced	O
16	randomly	O
17	chosen	O
18	clones	O
19	from	O
20	a	O
21	directionally	O
22	constructed	O
23	cDNA	O
24	library	O
25	to	O
26	produce	O
27	a	O
28	set	O
29	of	O
30	expressed	O
31	sequence	O
32	tags	O
33	(	O
34	ESTs	O
35	).	O
1	Characterization	O
2	of	O
3	an	O
4	EcR	B
5	/	O
6	USP	B
7	heterodimer	O
8	target	O
9	site	O
10	that	O
11	mediates	O
12	ecdysone	O
13	responsiveness	O
14	of	O
15	the	O
16	Drosophila	B
17	Lsp	I
18	-	I
19	2	I
20	gene	I
21	.	O
1	An	O
2	epidemic	O
3	of	O
4	hepatitis	O
5	B	O
6	virus	O
7	infection	O
8	among	O
9	intravenous	O
10	drug	O
11	users	O
12	in	O
13	Iceland	O
14	.	O
1	The	O
2	transposon	O
3	-	O
4	inactivated	O
5	gene	O
6	,	O
7	designated	O
8	pilP	B
9	,	O
10	is	O
11	525	O
12	bp	O
13	long	O
14	,	O
15	potentially	O
16	encoding	O
17	a	O
18	19	O
19	.	O
20	1	O
21	-	O
22	kDa	O
23	protein	O
24	precursor	O
25	that	O
26	contains	O
27	a	O
28	typical	O
29	membrane	O
30	lipoprotein	O
31	leader	O
32	sequence	O
33	.	O
1	In	O
2	this	O
3	case	O
4	the	O
5	degree	O
6	of	O
7	promoter	O
8	methylation	O
9	,	O
10	which	O
11	could	O
12	extend	O
13	beyond	O
14	the	O
15	T	O
16	-	O
17	DNA	O
18	borders	O
19	,	O
20	was	O
21	not	O
22	correlated	O
23	with	O
24	the	O
25	reduction	O
26	in	O
27	steady	O
28	-	O
29	state	O
30	poly	O
31	(	O
32	A	O
33	)+	O
34	mRNA	O
35	levels	O
36	,	O
37	the	O
38	silenced	O
39	state	O
40	was	O
41	transmitted	O
42	through	O
43	meiosis	O
44	and	O
45	reactivation	O
46	lasted	O
47	several	O
48	generations	O
49	.	O
1	In	O
2	addition	O
3	to	O
4	protein	O
5	binding	O
6	at	O
7	sequences	O
8	known	O
9	to	O
10	be	O
11	involved	O
12	in	O
13	the	O
14	regulation	O
15	of	O
16	transcription	O
17	,	O
18	genomic	O
19	footprinting	O
20	of	O
21	the	O
22	entire	O
23	promoter	O
24	region	O
25	also	O
26	showed	O
27	that	O
28	a	O
29	protein	O
30	factor	O
31	is	O
32	constitutively	O
33	bound	O
34	to	O
35	the	O
36	first	O
37	intron	O
38	of	O
39	the	O
40	rep3	B
41	gene	I
42	.	O
1	Using	O
2	a	O
3	high	O
4	-	O
5	copy	O
6	suppression	O
7	strategy	O
8	,	O
9	we	O
10	have	O
11	identified	O
12	a	O
13	yeast	O
14	gene	O
15	(	O
16	UBS1	B
17	)	O
18	whose	O
19	elevated	O
20	expression	O
21	suppresses	O
22	the	O
23	conditional	O
24	cell	O
25	cycle	O
26	defects	O
27	associated	O
28	with	O
29	cdc34	B
30	mutations	O
31	.	O
1	Transgenic	O
2	tobacco	O
3	plants	O
4	(	O
5	ppa	B
6	-	I
7	1	I
8	)	O
9	constitutively	O
10	expressing	O
11	Escherichia	B
12	coli	I
13	pyrophosphatase	I
14	behind	O
15	the	O
16	35S	B
17	CaMV	I
18	promoter	I
19	accumulate	O
20	high	O
21	levels	O
22	of	O
23	soluble	O
24	sugars	O
25	in	O
26	their	O
27	leaves	O
28	[	O
29	27	O
30	].	O
1	Mobility	O
2	and	O
3	supershift	O
4	assays	O
5	demonstrated	O
6	that	O
7	upstream	B
8	stimulatory	I
9	factor	I
10	(	O
11	USF	B
12	)	O
13	and	O
14	Sp1	B
15	bind	O
16	to	O
17	the	O
18	former	O
19	elements	O
20	and	O
21	competition	O
22	experiments	O
23	confirmed	O
24	that	O
25	CREB	B
26	/	O
27	ATF	B
28	and	O
29	AP	B
30	-	I
31	1	I
32	bind	O
33	to	O
34	the	O
35	CRE	O
36	/	O
37	TRE	O
38	element	O
39	.	O
1	High	O
2	fibrinogen	B
3	levels	O
4	could	O
5	thus	O
6	be	O
7	a	O
8	risk	O
9	for	O
10	perioperative	O
11	thrombosis	O
12	.	O
1	This	O
2	approach	O
3	places	O
4	gHoxb	B
5	-	I
6	1	I
7	into	O
8	the	O
9	normal	O
10	embryonic	O
11	spatiotemporal	O
12	context	O
13	in	O
14	which	O
15	lab	O
16	acts	O
17	.	O
1	A	O
2	mutant	B
3	areA	I
4	product	I
5	truncated	O
6	immediately	O
7	after	O
8	the	O
9	last	O
10	residue	O
11	of	O
12	the	O
13	highly	O
14	conserved	O
15	GATA	B
16	(	I
17	DNA	I
18	-	I
19	binding	I
20	)	I
21	domain	I
22	retains	O
23	partial	O
24	function	O
25	.	O
1	Disruption	O
2	of	O
3	RB	B
4	/	O
5	E2F	B
6	-	I
7	1	I
8	interaction	O
9	by	O
10	single	O
11	point	O
12	mutations	O
13	in	O
14	E2F	B
15	-	I
16	1	I
17	enhances	O
18	S	O
19	-	O
20	phase	O
21	entry	O
22	and	O
23	apoptosis	O
24	.	O
1	The	O
2	preferential	O
3	heterodimerization	O
4	of	O
5	USF	B
6	subunits	I
7	was	O
8	reproduced	O
9	ex	O
10	vivo	O
11	,	O
12	while	O
13	the	O
14	in	O
15	vitro	O
16	association	O
17	of	O
18	cotranslated	O
19	subunits	O
20	,	O
21	or	O
22	recombinant	B
23	USF	I
24	proteins	I
25	,	O
26	appeared	O
27	to	O
28	be	O
29	random	O
30	.	O
1	We	O
2	conducted	O
3	a	O
4	prospective	O
5	,	O
6	randomized	O
7	controlled	O
8	trial	O
9	of	O
10	metoprolol	O
11	,	O
12	a	O
13	selective	O
14	beta	O
15	-	O
16	blocker	O
17	for	O
18	prevention	O
19	of	O
20	gastrointestinal	O
21	bleeding	O
22	from	O
23	portal	O
24	hypertension	O
25	in	O
26	29	O
27	non	O
28	-	O
29	selected	O
30	patients	O
31	with	O
32	liver	O
33	disease	O
34	and	O
35	previous	O
36	gastrointestinal	O
37	bleeding	O
38	.	O
1	These	O
2	studies	O
3	indicate	O
4	that	O
5	the	O
6	acidimetric	O
7	test	O
8	was	O
9	less	O
10	sensitive	O
11	than	O
12	the	O
13	chromogenic	O
14	cephalosporin	O
15	substrates	O
16	and	O
17	that	O
18	nitrocefin	O
19	and	O
20	S1	O
21	could	O
22	be	O
23	used	O
24	to	O
25	screen	O
26	for	O
27	beta	B
28	-	I
29	lactamase	I
30	production	O
31	in	O
32	these	O
33	tested	O
34	species	O
35	.	O
1	Although	O
2	ANP	B
3	induced	O
4	systemic	O
5	capillary	O
6	filtration	O
7	,	O
8	in	O
9	the	O
10	calf	O
11	,	O
12	filtration	O
13	was	O
14	reduced	O
15	with	O
16	ANP	B
17	.	O
1	Gel	O
2	mobility	O
3	shift	O
4	assays	O
5	indicated	O
6	that	O
7	at	O
8	least	O
9	four	O
10	nuclear	O
11	proteins	O
12	with	O
13	distinct	O
14	biochemical	O
15	and	O
16	binding	O
17	properties	O
18	possess	O
19	the	O
20	ability	O
21	to	O
22	bind	O
23	the	O
24	3	O
25	beta	O
26	I	O
27	-	O
28	A	O
29	element	O
30	to	O
31	produce	O
32	four	O
33	DNA	O
34	-	O
35	protein	O
36	complexes	O
37	(	O
38	R1	O
39	to	O
40	R4	O
41	).	O
1	Sixty	O
2	-	O
3	five	O
4	patients	O
5	(	O
6	aged	O
7	between	O
8	3	O
9	years	O
10	5	O
11	months	O
12	and	O
13	60	O
14	years	O
15	)	O
16	suffering	O
17	from	O
18	medically	O
19	resistant	O
20	temporal	O
21	lobe	O
22	epilepsy	O
23	(	O
24	TLE	O
25	)	O
26	were	O
27	operated	O
28	on	O
29	over	O
30	a	O
31	period	O
32	of	O
33	33	O
34	months	O
35	in	O
36	Bethel	O
37	Epilepsy	O
38	Center	O
39	.	O
1	Occupational	O
2	exposure	O
3	to	O
4	hepatitis	O
5	B	O
6	virus	O
7	and	O
8	human	O
9	immunodeficiency	O
10	virus	O
11	:	O
12	a	O
13	comparative	O
14	risk	O
15	analysis	O
16	.	O
1	Despite	O
2	an	O
3	overall	O
4	survival	O
5	rate	O
6	of	O
7	43	O
8	%,	O
9	survival	O
10	to	O
11	discharge	O
12	varied	O
13	greatly	O
14	(	O
15	0	O
16	to	O
17	100	O
18	%)	O
19	among	O
20	the	O
21	24	O
22	diagnostic	O
23	groups	O
24	:	O
25	tumor	O
26	lysis	O
27	syndrome	O
28	and	O
29	systemic	O
30	lupus	O
31	erythematosus	O
32	(	O
33	3	O
34	/	O
35	3	O
36	patients	O
37	each	O
38	,	O
39	100	O
40	%),	O
41	hemolytic	O
42	uremic	O
43	syndrome	O
44	(	O
45	8	O
46	/	O
47	9	O
48	patients	O
49	,	O
50	89	O
51	%).	O
1	Polysome	O
2	analysis	O
3	further	O
4	indicated	O
5	that	O
6	these	O
7	germ	B
8	cell	I
9	-	I
10	specific	I
11	Sp1	I
12	mRNAs	I
13	are	O
14	translated	O
15	,	O
16	albeit	O
17	with	O
18	a	O
19	lower	O
20	efficiency	O
21	than	O
22	the	O
23	somatic	O
24	transcript	O
25	.	O
1	The	O
2	assembly	O
3	of	O
4	sequence	O
5	ready	O
6	,	O
7	high	O
8	-	O
9	resolution	O
10	physical	O
11	maps	O
12	and	O
13	construction	O
14	of	O
15	minimally	O
16	overlapping	O
17	contigs	O
18	for	O
19	the	O
20	human	O
21	as	O
22	well	O
23	as	O
24	model	O
25	genomes	O
26	requires	O
27	accurate	O
28	determination	O
29	of	O
30	the	O
31	extent	O
32	of	O
33	overlap	O
34	between	O
35	adjacent	O
36	clones	O
37	as	O
38	well	O
39	as	O
40	their	O
41	relative	O
42	orientation	O
43	.	O
1	The	O
2	gene	O
3	encodes	O
4	an	O
5	ATP	B
6	-	I
7	binding	I
8	cassette	I
9	,	O
10	ABC	B
11	transporter	I
12	.	O
1	Our	O
2	data	O
3	suggest	O
4	that	O
5	trans	O
6	-	O
7	activation	O
8	from	O
9	the	O
10	prothymosin	B
11	intron	I
12	enhancer	I
13	is	O
14	a	O
15	faithful	O
16	reflection	O
17	of	O
18	the	O
19	transforming	O
20	properties	O
21	of	O
22	the	O
23	Myc	B
24	protein	I
25	.	O
1	Pseudomembranous	O
2	conjunctivitis	O
3	following	O
4	bone	O
5	marrow	O
6	transplantation	O
7	:	O
8	immunopathological	O
9	and	O
10	ultrastructural	O
11	study	O
12	of	O
13	one	O
14	case	O
15	.	O
1	In	O
2	view	O
3	of	O
4	the	O
5	presence	O
6	of	O
7	SECIS	O
8	elements	O
9	in	O
10	the	O
11	open	O
12	reading	O
13	frames	O
14	(	O
15	ORFs	O
16	)	O
17	of	O
18	bacterial	B
19	selenoproteins	I
20	,	O
21	we	O
22	examine	O
23	the	O
24	effects	O
25	in	O
26	the	O
27	type	B
28	1	I
29	deiodinase	I
30	of	O
31	extending	O
32	the	O
33	ORF	O
34	into	O
35	the	O
36	SECIS	O
37	element	O
38	,	O
39	and	O
40	find	O
41	that	O
42	this	O
43	dramatically	O
44	inhibits	O
45	SECIS	O
46	function	O
47	.	O
1	Carboxy	O
2	-	O
3	terminal	O
4	Spc110p	B
5	truncations	O
6	lacking	O
7	the	O
8	calmodulin	B
9	binding	O
10	site	O
11	can	O
12	support	O
13	growth	O
14	and	O
15	are	O
16	also	O
17	phosphorylated	O
18	in	O
19	a	O
20	cell	O
21	cycle	O
22	-	O
23	specific	O
24	manner	O
25	.	O
1	DNA	O
2	methylation	O
3	,	O
4	especially	O
5	of	O
6	either	O
7	one	O
8	or	O
9	both	O
10	of	O
11	the	O
12	deoxyadenosines	O
13	at	O
14	the	O
15	two	O
16	GATC	O
17	motifs	O
18	(	O
19	one	O
20	in	O
21	the	O
22	first	O
23	exon	O
24	and	O
25	the	O
26	other	O
27	in	O
28	the	O
29	first	O
30	intron	O
31	of	O
32	the	O
33	rice	O
34	CatA	B
35	gene	I
36	),	O
37	appeared	O
38	to	O
39	be	O
40	responsible	O
41	for	O
42	the	O
43	CatA	B
44	promoter	I
45	activity	O
46	identified	O
47	in	O
48	the	O
49	transient	O
50	assay	O
51	.	O
1	The	O
2	viral	B
3	LTR	I
4	was	O
5	used	O
6	as	O
7	the	O
8	promoter	O
9	.	O
1	Variables	O
2	evaluated	O
3	were	O
4	number	O
5	of	O
6	weekly	O
7	anginal	O
8	events	O
9	,	O
10	data	O
11	from	O
12	ergometric	O
13	exercise	O
14	testing	O
15	with	O
16	simultaneous	O
17	electrocardiographic	O
18	registration	O
19	,	O
20	semiquantitative	O
21	evaluation	O
22	of	O
23	Tc	O
24	-	O
25	99m	O
26	2	O
27	-	O
28	methoxy	O
29	isobutyl	O
30	isonitrile	O
31	(	O
32	MIBI	O
33	)	O
34	scans	O
35	and	O
36	rheologic	O
37	variables	O
38	.	O
1	We	O
2	then	O
3	demonstrated	O
4	that	O
5	1	O
6	)	O
7	GAL4	B
8	-	O
9	REV	B
10	-	O
11	erbA	B
12	alpha	I
13	chimeras	O
14	that	O
15	contain	O
16	the	O
17	'	O
18	AB	O
19	'	O
20	region	O
21	and	O
22	lack	O
23	the	O
24	'	O
25	E	O
26	'	O
27	region	O
28	activated	O
29	transcription	O
30	of	O
31	GAL4	B
32	response	I
33	elements	I
34	in	O
35	the	O
36	presence	O
37	of	O
38	8	O
39	-	O
40	Br	O
41	-	O
42	cAMP	O
43	and	O
44	2	O
45	)	O
46	the	O
47	ligand	O
48	-	O
49	binding	O
50	domain	O
51	(	O
52	LBD	O
53	)	O
54	contains	O
55	an	O
56	active	O
57	transcriptional	O
58	silencer	O
59	.	O
1	The	O
2	two	O
3	different	O
4	phosphoforms	O
5	of	O
6	STAT5	B
7	have	O
8	identical	O
9	in	O
10	vitro	O
11	DNA	O
12	binding	O
13	specificity	O
14	and	O
15	reactivity	O
16	with	O
17	tyrosine	O
18	phosphopeptides	O
19	,	O
20	but	O
21	differ	O
22	in	O
23	their	O
24	cellular	O
25	localization	O
26	.	O
1	However	O
2	,	O
3	while	O
4	the	O
5	sequence	O
6	similarity	O
7	between	O
8	the	O
9	membrane	O
10	exons	O
11	of	O
12	avian	B
13	mIgY	I
14	and	O
15	mammalian	B
16	mIgG	I
17	and	I
18	IgE	I
19	is	O
20	striking	O
21	,	O
22	the	O
23	overall	O
24	similarity	O
25	with	O
26	Xenopus	B
27	mIgY	I
28	is	O
29	very	O
30	low	O
31	.	O
1	Analysis	O
2	of	O
3	RAR	B
4	alpha	I
5	mutants	I
6	in	O
7	transfection	O
8	studies	O
9	reveals	O
10	that	O
11	the	O
12	DNA	O
13	binding	O
14	domain	O
15	is	O
16	sufficient	O
17	for	O
18	inhibition	O
19	of	O
20	BZLF1	B
21	activity	O
22	.	O
1	We	O
2	isolated	O
3	a	O
4	complementary	O
5	DNA	O
6	(	O
7	cDNA	O
8	)	O
9	clone	O
10	from	O
11	an	O
12	RL95	O
13	-	O
14	2	O
15	expression	O
16	library	O
17	that	O
18	encodes	O
19	the	O
20	C1	B
21	site	I
22	-	I
23	binding	I
24	protein	I
25	.	O
1	Both	O
2	P5CDh	B
3	cDNA	I
4	clones	O
5	detect	O
6	a	O
7	single	O
8	3	O
9	.	O
10	2	O
11	-	O
12	kb	O
13	transcript	O
14	on	O
15	Northern	O
16	blots	O
17	of	O
18	multiple	O
19	human	O
20	tissues	O
21	,	O
22	indicating	O
23	the	O
24	long	O
25	cDNA	O
26	containing	O
27	the	O
28	3	O
29	'-	O
30	untranslated	O
31	intron	O
32	represents	O
33	the	O
34	predominant	O
35	transcript	O
36	.	O
1	The	O
2	protein	O
3	folds	O
4	correctly	O
5	with	O
6	two	O
7	disulfide	O
8	bonds	O
9	and	O
10	a	O
11	free	O
12	thiol	O
13	group	O
14	at	O
15	Cys25	O
16	.	O
1	The	O
2	large	O
3	subfamily	O
4	of	O
5	receptor	B
6	tyrosine	I
7	kinases	I
8	(	O
9	RTKs	B
10	)	O
11	for	O
12	which	O
13	EPH	B
14	is	O
15	the	O
16	prototype	O
17	have	O
18	likely	O
19	roles	O
20	in	O
21	intercellular	O
22	communication	O
23	during	O
24	normal	O
25	mammalian	O
26	development	O
27	,	O
28	but	O
29	the	O
30	biochemical	O
31	signalling	O
32	pathways	O
33	utilised	O
34	by	O
35	this	O
36	family	O
37	are	O
38	poorly	O
39	characterised	O
40	.	O
1	Binding	O
2	specificity	O
3	and	O
4	modulation	O
5	of	O
6	the	O
7	ApoA	B
8	-	I
9	I	I
10	promoter	I
11	activity	O
12	by	O
13	homo	O
14	-	O
15	and	O
16	heterodimers	O
17	of	O
18	nuclear	O
19	receptors	O
20	.	O
1	Sterol	O
2	-	O
3	mediated	O
4	suppression	O
5	of	O
6	cleavage	O
7	of	O
8	SREBP	B
9	-	I
10	1	I
11	was	O
12	found	O
13	to	O
14	be	O
15	dependent	O
16	on	O
17	the	O
18	extreme	O
19	COOH	O
20	-	O
21	terminal	O
22	region	O
23	(	O
24	residue	O
25	1034	O
26	to	O
27	the	O
28	COOH	O
29	terminus	O
30	),	O
31	which	O
32	exists	O
33	in	O
34	two	O
35	forms	O
36	as	O
37	a	O
38	result	O
39	of	O
40	alternative	O
41	splicing	O
42	.	O
1	Am	O
2	.	O
1	Transcription	O
2	from	O
3	the	O
4	promoter	O
5	containing	O
6	the	O
7	mutated	O
8	direct	O
9	repeats	O
10	was	O
11	increased	O
12	greatly	O
13	,	O
14	consistent	O
15	with	O
16	the	O
17	conclusion	O
18	that	O
19	these	O
20	motifs	O
21	functions	O
22	in	O
23	vivo	O
24	to	O
25	repress	O
26	GPT	B
27	gene	I
28	expression	O
29	.	O
1	Significantly	O
2	,	O
3	pPKR	B
4	is	O
5	capable	O
6	of	O
7	specifically	O
8	phosphorylating	O
9	Ser51	O
10	in	O
11	a	O
12	synthetic	B
13	eIF	I
14	-	I
15	2alpha	I
16	peptide	I
17	,	O
18	a	O
19	key	O
20	characteristic	O
21	of	O
22	the	O
23	eIF	B
24	-	I
25	2alpha	I
26	kinase	I
27	family	I
28	.	O
1	We	O
2	show	O
3	here	O
4	that	O
5	these	O
6	Jun	B
7	/	O
8	eb1	B
9	chimeras	O
10	are	O
11	potent	O
12	transactivators	O
13	of	O
14	AP1	B
15	sites	I
16	and	O
17	that	O
18	they	O
19	can	O
20	cooperate	O
21	with	O
22	c	B
23	-	I
24	Ha	I
25	-	I
26	Ras	I
27	to	O
28	induce	O
29	foci	O
30	.	O
1	Sequence	O
2	conservation	O
3	is	O
4	greatest	O
5	for	O
6	residues	O
7	located	O
8	near	O
9	the	O
10	active	O
11	centers	O
12	of	O
13	the	O
14	exo	B
15	and	O
16	pol	B
17	domains	I
18	of	O
19	the	O
20	E	B
21	.	I
22	coli	I
23	DNA	I
24	polymerase	I
25	I	I
26	structure	O
27	.	O
1	These	O
2	findings	O
3	suggest	O
4	that	O
5	the	O
6	increase	O
7	in	O
8	V	O
9	O2	O
10	may	O
11	have	O
12	been	O
13	a	O
14	consequence	O
15	of	O
16	the	O
17	increase	O
18	in	O
19	Q	O
20	O2	O
21	rather	O
22	than	O
23	a	O
24	response	O
25	to	O
26	the	O
27	procedure	O
28	itself	O
29	.	O
1	No	O
2	difference	O
3	in	O
4	elastin	B
5	peptide	I
6	concentration	O
7	was	O
8	observed	O
9	between	O
10	emphysematous	O
11	patients	O
12	and	O
13	control	O
14	subjects	O
15	(	O
16	mean	O
17	+/-	O
18	SD	O
19	=	O
20	2	O
21	.	O
22	39	O
23	+/-	O
24	1	O
25	.	O
26	18	O
27	micrograms	O
28	/	O
29	ml	O
30	in	O
31	patients	O
32	versus	O
33	2	O
34	.	O
35	55	O
36	+/-	O
37	1	O
38	.	O
39	34	O
40	micrograms	O
41	/	O
42	ml	O
43	in	O
44	policemen	O
45	and	O
46	2	O
47	.	O
48	59	O
49	+/-	O
50	1	O
51	.	O
52	20	O
53	micrograms	O
54	/	O
55	ml	O
56	in	O
57	coal	O
58	miners	O
59	).	O
1	Identification	O
2	of	O
3	a	O
4	consensus	O
5	cyclin	B
6	-	I
7	dependent	I
8	kinase	I
9	phosphorylation	I
10	site	I
11	unique	O
12	to	O
13	the	O
14	nuclear	O
15	form	O
16	of	O
17	human	B
18	deoxyuridine	I
19	triphosphate	I
20	nucleotidohydrolase	I
21	.	O
1	This	O
2	result	O
3	supports	O
4	the	O
5	argument	O
6	that	O
7	the	O
8	beta	O
9	'	O
10	subunit	O
11	plays	O
12	an	O
13	essential	O
14	role	O
15	in	O
16	determining	O
17	the	O
18	progress	O
19	of	O
20	transcription	O
21	elongation	O
22	.	O
1	The	O
2	sequence	O
3	and	O
4	isolated	O
5	cDNAs	O
6	will	O
7	provide	O
8	useful	O
9	reagents	O
10	for	O
11	studying	O
12	the	O
13	expression	O
14	of	O
15	Brca1	B
16	in	O
17	the	O
18	mouse	O
19	,	O
20	and	O
21	for	O
22	testing	O
23	the	O
24	importance	O
25	of	O
26	the	O
27	evolutionarily	O
28	conserved	O
29	domains	O
30	.	O
1	Interaction	O
2	of	O
3	the	O
4	Fur	B
5	repressor	I
6	with	O
7	a	O
8	150	O
9	-	O
10	bp	O
11	fragment	O
12	encompassing	O
13	the	O
14	pvdS	B
15	promoter	I
16	was	O
17	demonstrated	O
18	in	O
19	vivo	O
20	by	O
21	the	O
22	Fur	B
23	titration	O
24	assay	O
25	and	O
26	confirmed	O
27	in	O
28	vitro	O
29	by	O
30	gel	O
31	retardation	O
32	experiments	O
33	with	O
34	a	O
35	partially	O
36	purified	O
37	Fur	B
38	preparation	O
39	.	O
1	This	O
2	fragment	O
3	can	O
4	bind	O
5	several	O
6	trans	O
7	-	O
8	acting	O
9	factors	O
10	in	O
11	vitro	O
12	,	O
13	including	O
14	GATA	B
15	-	I
16	1	I
17	and	O
18	members	O
19	of	O
20	the	O
21	Ets	B
22	family	I
23	.	O
1	T	O
2	cell	O
3	leukemia	O
4	-	O
5	associated	O
6	human	O
7	Notch	B
8	/	O
9	translocation	O
10	-	O
11	associated	O
12	Notch	B
13	homologue	O
14	has	O
15	I	B
16	kappa	I
17	B	I
18	-	O
19	like	O
20	activity	O
21	and	O
22	physically	O
23	interacts	O
24	with	O
25	nuclear	B
26	factor	I
27	-	I
28	kappa	I
29	B	I
30	proteins	O
31	in	O
32	T	O
33	cells	O
34	.	O
1	Deletion	O
2	analysis	O
3	of	O
4	rOC	B
5	promoter	I
6	-	O
7	chloramphenicol	B
8	acetyltransferase	I
9	constructs	O
10	demonstrates	O
11	that	O
12	an	O
13	AML	B
14	-	I
15	1	I
16	-	I
17	binding	I
18	sequence	I
19	within	O
20	the	O
21	proximal	O
22	promoter	O
23	(-	O
24	138	O
25	to	O
26	-	O
27	130	O
28	nt	O
29	)	O
30	contributes	O
31	to	O
32	75	O
33	%	O
34	of	O
35	the	O
36	level	O
37	of	O
38	osteocalcin	B
39	gene	I
40	expression	O
41	.	O
1	Thus	O
2	,	O
3	a	O
4	critical	O
5	question	O
6	is	O
7	how	O
8	HOX	B
9	proteins	I
10	select	O
11	the	O
12	correct	O
13	sets	O
14	of	O
15	target	O
16	genes	O
17	in	O
18	vivo	O
19	.	O
1	Subcellular	O
2	localizations	O
3	of	O
4	the	O
5	wild	B
6	-	I
7	type	I
8	CBFbeta	I
9	and	O
10	the	O
11	CBFbeta	B
12	-	O
13	SMMHC	B
14	fusion	O
15	protein	O
16	were	O
17	determined	O
18	by	O
19	immunofluorescence	O
20	of	O
21	NIH	O
22	3T3	O
23	cells	O
24	that	O
25	overexpress	O
26	wild	O
27	-	O
28	type	O
29	or	O
30	fusion	O
31	protein	O
32	.	O
1	Escherichia	O
2	coli	O
3	BL21	O
4	(	O
5	DE3	O
6	)	O
7	plysS	O
8	,	O
9	harbouring	O
10	a	O
11	recombinant	O
12	plasmid	O
13	containing	O
14	the	O
15	catalase	B
16	-	O
17	peroxidase	B
18	gene	O
19	,	O
20	produced	O
21	a	O
22	large	O
23	amount	O
24	of	O
25	proteins	O
26	that	O
27	co	O
28	-	O
29	migrated	O
30	on	O
31	SDS	O
32	/	O
33	PAGE	O
34	with	O
35	the	O
36	native	O
37	enzyme	O
38	.	O
1	Large	B
2	T	I
3	antigen	I
4	was	O
5	coimmunoprecipitated	O
6	by	O
7	antibodies	O
8	to	O
9	epitope	O
10	-	O
11	tagged	O
12	TBP	B
13	,	O
14	endogenous	O
15	TBP	B
16	,	O
17	hTAF	B
18	(	I
19	II	I
20	)	I
21	100	I
22	,	O
23	hTAF	B
24	(	I
25	II	I
26	)	I
27	130	I
28	,	O
29	and	O
30	hTAF	B
31	(	I
32	II	I
33	)	I
34	250	I
35	,	O
36	under	O
37	conditions	O
38	where	O
39	holo	B
40	-	I
41	TFIID	I
42	would	O
43	be	O
44	precipitated	O
45	.	O
1	A	O
2	human	O
3	cytoplasmic	O
4	signaling	O
5	protein	O
6	has	O
7	been	O
8	cloned	O
9	that	O
10	possesses	O
11	the	O
12	same	O
13	structural	O
14	arrangement	O
15	of	O
16	SH3	B
17	-	O
18	SH2	B
19	-	O
20	SH3	B
21	domains	O
22	as	O
23	Grb2	B
24	.	O
1	When	O
2	the	O
3	PHT	O
4	and	O
5	CSA	O
6	groups	O
7	were	O
8	compared	O
9	,	O
10	Hyp	O
11	levels	O
12	were	O
13	significantly	O
14	higher	O
15	in	O
16	the	O
17	PHT	O
18	-	O
19	GO	O
20	+	O
21	group	O
22	than	O
23	in	O
24	the	O
25	CSA	O
26	-	O
27	GO	O
28	+	O
29	group	O
30	.	O
1	Expression	O
2	of	O
3	the	O
4	phenylalanine	B
5	hydroxylase	I
6	gene	I
7	in	O
8	livers	O
9	and	O
10	kidneys	O
11	of	O
12	rodents	O
13	is	O
14	activated	O
15	at	O
16	birth	O
17	and	O
18	is	O
19	induced	O
20	by	O
21	glucocorticoids	O
22	and	O
23	cyclic	O
24	AMP	O
25	in	O
26	the	O
27	liver	O
28	.	O
1	A	O
2	secondary	O
3	spread	O
4	of	O
5	an	O
6	imported	O
7	methicillin	O
8	-	O
9	resistant	O
10	Staphylococcus	O
11	aureus	O
12	strain	O
13	(	O
14	MRSA	O
15	)	O
16	to	O
17	two	O
18	other	O
19	patients	O
20	occurred	O
21	within	O
22	a	O
23	Danish	O
24	surgical	O
25	ward	O
26	in	O
27	spite	O
28	of	O
29	isolation	O
30	of	O
31	a	O
32	multitraumatized	O
33	index	O
34	-	O
35	patient	O
36	immediately	O
37	after	O
38	arrival	O
39	from	O
40	a	O
41	hospital	O
42	in	O
43	the	O
44	Mediterranean	O
45	area	O
46	.	O
1	Mesial	O
2	temporal	O
3	sclerosis	O
4	.	O
1	More	O
2	specific	O
3	adverse	O
4	events	O
5	,	O
6	also	O
7	frequently	O
8	considered	O
9	as	O
10	dose	O
11	-	O
12	limiting	O
13	toxicities	O
14	,	O
15	include	O
16	hypotension	O
17	with	O
18	IL	B
19	-	I
20	1	I
21	,	O
22	severe	O
23	headache	O
24	or	O
25	skin	O
26	rash	O
27	with	O
28	IL	B
29	-	I
30	3	I
31	,	O
32	and	O
33	nasal	O
34	congestion	O
35	and	O
36	gastroduodenal	O
37	lesions	O
38	with	O
39	IL	B
40	-	I
41	4	I
42	.	O
1	An	O
2	apparent	O
3	ufo	B
4	mRNA	I
5	overexpression	O
6	was	O
7	not	O
8	found	O
9	in	O
10	any	O
11	of	O
12	the	O
13	positive	O
14	leukemia	O
15	cell	O
16	lines	O
17	,	O
18	but	O
19	was	O
20	identified	O
21	in	O
22	the	O
23	drug	O
24	-	O
25	resistant	O
26	subclones	O
27	of	O
28	the	O
29	cervix	O
30	carcinoma	O
31	cell	O
32	line	O
33	HeLa	O
34	.	O
1	We	O
2	found	O
3	strand	O
4	selective	O
5	repair	O
6	in	O
7	DNA	O
8	fragments	O
9	within	O
10	two	O
11	active	O
12	genes	O
13	,	O
14	DHFR	B
15	and	O
16	an	O
17	unknown	O
18	gene	O
19	adjacent	O
20	to	O
21	DHFR	B
22	.	O
1	The	O
2	receptor	B
3	for	I
4	hyaluronan	I
5	mediated	I
6	motility	I
7	(	I
8	RHAMM	I
9	)	I
10	gene	I
11	expression	O
12	is	O
13	markedly	O
14	elevated	O
15	in	O
16	fibrosarcomas	O
17	exposed	O
18	to	O
19	transforming	B
20	growth	I
21	factor	I
22	-	I
23	beta1	I
24	(	O
25	TGF	B
26	-	I
27	beta1	I
28	).	O
1	None	O
2	of	O
3	the	O
4	five	O
5	proprotein	O
6	processing	O
7	proteases	O
8	tested	O
9	were	O
10	capable	O
11	of	O
12	cleaving	O
13	human	B
14	pro	I
15	-	I
16	LPH	I
17	,	O
18	strongly	O
19	suggesting	O
20	that	O
21	they	O
22	are	O
23	not	O
24	involved	O
25	in	O
26	the	O
27	maturation	O
28	of	O
29	this	O
30	enzyme	O
31	.	O
1	Furthermore	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	43	O
8	-	O
9	bp	O
10	region	O
11	of	O
12	the	O
13	24p3	B
14	promoter	I
15	required	O
16	for	O
17	the	O
18	Dex	O
19	responsiveness	O
20	.	O
1	The	O
2	Dox	B
3	-	I
4	A2	I
5	ORF	I
6	driven	O
7	by	O
8	the	O
9	TDH3	B
10	promoter	I
11	complemented	O
12	the	O
13	phenotype	O
14	of	O
15	a	O
16	strain	O
17	deleted	O
18	for	O
19	sun2	B
20	.	O
1	Merlie	O
2	,	O
3	Cold	O
4	Spring	O
5	Harbor	O
6	Symp	O
7	.	O
1	By	O
2	using	O
3	reporter	O
4	gene	O
5	constructs	O
6	,	O
7	it	O
8	is	O
9	shown	O
10	that	O
11	upstream	O
12	sequences	O
13	of	O
14	the	O
15	P1	O
16	promoter	O
17	contain	O
18	several	O
19	regions	O
20	that	O
21	modulate	O
22	the	O
23	expression	O
24	either	O
25	positively	O
26	or	O
27	negatively	O
28	.	O
1	However	O
2	,	O
3	one	O
4	3	O
5	'	O
6	splice	O
7	site	O
8	,	O
9	located	O
10	at	O
11	nucleotide	O
12	(	O
13	nt	O
14	)	O
15	3225	O
16	,	O
17	is	O
18	used	O
19	for	O
20	the	O
21	processing	O
22	of	O
23	most	O
24	BPV	O
25	-	O
26	1	O
27	pre	O
28	-	O
29	mRNAs	O
30	in	O
31	BPV	O
32	-	O
33	1	O
34	-	O
35	transformed	O
36	C127	O
37	cells	O
38	and	O
39	at	O
40	early	O
41	to	O
42	intermediate	O
43	times	O
44	in	O
45	productively	O
46	infected	O
47	warts	O
48	.	O
1	Here	O
2	,	O
3	the	O
4	cloning	O
5	and	O
6	characterization	O
7	of	O
8	S	B
9	-	I
10	RNase	I
11	genes	I
12	from	O
13	two	O
14	species	O
15	of	O
16	Rosaceae	O
17	,	O
18	apple	O
19	(	O
20	Malus	O
21	x	O
22	domestica	O
23	)	O
24	and	O
25	Japanese	O
26	pear	O
27	(	O
28	Pyrus	O
29	serotina	O
30	)	O
31	is	O
32	described	O
33	and	O
34	these	O
35	sequences	O
36	are	O
37	compared	O
38	with	O
39	those	O
40	of	O
41	other	O
42	T2	B
43	-	I
44	type	I
45	RNases	I
46	.	O
1	Although	O
2	IL	B
3	-	I
4	2	I
5	and	O
6	IFN	B
7	-	I
8	alpha	I
9	activated	O
10	STAT1	B
11	alpha	I
12	and	O
13	STAT5	B
14	,	O
15	IL	B
16	-	I
17	2	I
18	predominantly	O
19	activated	O
20	STAT5	B
21	,	O
22	while	O
23	IFN	B
24	-	I
25	alpha	I
26	predominantly	O
27	activated	O
28	STAT1	B
29	alpha	I
30	.	O
1	One	O
2	complex	O
3	containing	O
4	a	O
5	70	O
6	D	O
7	protein	O
8	was	O
9	found	O
10	to	O
11	be	O
12	associated	O
13	specifically	O
14	with	O
15	transcriptionally	O
16	active	O
17	leukemia	O
18	cells	O
19	.	O
1	The	O
2	logistic	O
3	regression	O
4	analysis	O
5	of	O
6	the	O
7	manual	O
8	method	O
9	(	O
10	percentage	O
11	normal	O
12	morphology	O
13	)	O
14	and	O
15	IVOS	O
16	indicated	O
17	that	O
18	both	O
19	were	O
20	predictors	O
21	of	O
22	fertilization	O
23	.	O
1	We	O
2	previously	O
3	described	O
4	the	O
5	purification	O
6	of	O
7	an	O
8	83	B
9	-	I
10	kDa	I
11	phosphatidic	I
12	acid	I
13	phosphatase	I
14	(	O
15	PAP	B
16	)	O
17	from	O
18	the	O
19	porcine	O
20	thymus	O
21	membranes	O
22	(	O
23	Kanoh	O
24	,	O
25	H	O
26	.,	O
27	Imai	O
28	,	O
29	S	O
30	.-	O
31	i	O
32	.,	O
33	Yamada	O
34	,	O
35	K	O
36	.	O
37	and	O
38	Sakane	O
39	,	O
40	F	O
41	.(	O
42	1992	O
43	)	O
44	J	O
45	.	O
1	Therefore	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	cis	O
8	-	O
9	acting	O
10	element	O
11	,	O
12	the	O
13	E1	O
14	E	O
15	-	O
16	box	O
17	,	O
18	located	O
19	in	O
20	the	O
21	GAP	B
22	-	I
23	43	I
24	promoter	O
25	region	O
26	that	O
27	modulates	O
28	either	O
29	positively	O
30	or	O
31	negatively	O
32	the	O
33	expression	O
34	of	O
35	the	O
36	GAP	B
37	-	I
38	43	I
39	gene	I
40	depending	O
41	on	O
42	which	O
43	E	B
44	-	I
45	box	I
46	-	I
47	binding	I
48	proteins	I
49	occupy	O
50	this	O
51	site	O
52	.	O
1	Using	O
2	one	O
3	of	O
4	the	O
5	six	O
6	fragments	O
7	(	O
8	CPK3	B
9	-	I
10	8	I
11	),	O
12	we	O
13	isolated	O
14	a	O
15	2022	B
16	bp	I
17	cDNA	I
18	(	I
19	VrCDPK	I
20	-	I
21	1	I
22	)	I
23	from	O
24	a	O
25	Vigna	O
26	radiata	O
27	lambda	O
28	gt11	O
29	library	O
30	.	O
1	Epstein	B
2	-	I
3	Barr	I
4	virus	I
5	nuclear	I
6	protein	I
7	2	I
8	(	O
9	EBNA2	B
10	)	O
11	binds	O
12	to	O
13	a	O
14	component	O
15	of	O
16	the	O
17	human	O
18	SNF	B
19	-	O
20	SWI	B
21	complex	O
22	,	O
23	hSNF5	B
24	/	O
25	Ini1	B
26	.	O
1	Site	O
2	S	O
3	-	O
4	II	O
5	also	O
6	spans	O
7	a	O
8	23	O
9	bp	O
10	sequence	O
11	containing	O
12	two	O
13	tandem	O
14	consensus	O
15	binding	O
16	sites	O
17	with	O
18	three	O
19	base	O
20	pair	O
21	mismatches	O
22	in	O
23	each	O
24	and	O
25	a	O
26	one	O
27	base	O
28	pair	O
29	deletion	O
30	.	O
1	There	O
2	are	O
3	no	O
4	introns	O
5	within	O
6	the	O
7	gene	O
8	,	O
9	which	O
10	contains	O
11	a	O
12	9360	O
13	-	O
14	bp	O
15	open	O
16	reading	O
17	frame	O
18	and	O
19	encodes	O
20	a	O
21	377	O
22	-	O
23	kDa	O
24	protein	O
25	.	O
1	METHODS	O
2	:	O
3	DSF	O
4	was	O
5	instilled	O
6	in	O
7	one	O
8	eye	O
9	chosen	O
10	at	O
11	random	O
12	and	O
13	CF	O
14	in	O
15	the	O
16	fellow	O
17	eye	O
18	of	O
19	13	O
20	normal	O
21	subjects	O
22	and	O
23	in	O
24	13	O
25	patients	O
26	with	O
27	KCS	O
28	.	O
1	This	O
2	complex	O
3	interacts	O
4	at	O
5	the	O
6	GTPase	B
7	domain	I
8	in	O
9	the	O
10	large	O
11	subunit	O
12	rRNA	O
13	,	O
14	overlapping	O
15	the	O
16	binding	O
17	site	O
18	of	O
19	the	O
20	protein	B
21	L11	I
22	-	I
23	like	I
24	eukaryotic	I
25	counterpart	I
26	(	O
27	Saccharomyces	B
28	cerevisiae	I
29	protein	I
30	L15	I
31	and	O
32	mammalian	B
33	protein	I
34	L12	I
35	).	O
1	Eight	O
2	cats	O
3	infected	O
4	with	O
5	H	O
6	.	O
7	pylori	O
8	were	O
9	used	O
10	in	O
11	the	O
12	study	O
13	.	O
1	To	O
2	derive	O
3	quantitative	O
4	concentration	O
5	changes	O
6	from	O
7	measurements	O
8	of	O
9	light	O
10	attenuation	O
11	,	O
12	the	O
13	optical	O
14	path	O
15	length	O
16	must	O
17	be	O
18	known	O
19	.	O
1	Following	O
2	the	O
3	injection	O
4	of	O
5	PGF2	O
6	alpha	O
7	,	O
8	heifers	O
9	were	O
10	observed	O
11	visually	O
12	for	O
13	signs	O
14	of	O
15	estrus	O
16	at	O
17	0730	O
18	and	O
19	1630	O
20	(	O
21	45	O
22	min	O
23	each	O
24	).	O
1	Differential	O
2	activation	O
3	of	O
4	the	O
5	extracellular	B
6	signal	I
7	-	I
8	regulated	I
9	kinase	I
10	,	O
11	Jun	B
12	kinase	I
13	and	O
14	Janus	B
15	kinase	I
16	-	O
17	Stat	B
18	pathways	O
19	by	O
20	oncostatin	B
21	M	I
22	and	O
23	basic	B
24	fibroblast	I
25	growth	I
26	factor	I
27	in	O
28	AIDS	O
29	-	O
30	derived	O
31	Kaposi	O
32	'	O
33	s	O
34	sarcoma	O
35	cells	O
36	.	O
1	Facioscapulohumeral	O
2	muscular	O
3	dystrophy	O
4	(	O
5	FSHD	O
6	)	O
7	is	O
8	an	O
9	autosomal	O
10	dominant	O
11	,	O
12	neuromuscular	O
13	disorder	O
14	characterized	O
15	by	O
16	progressive	O
17	weakness	O
18	of	O
19	muscles	O
20	in	O
21	the	O
22	face	O
23	,	O
24	shoulder	O
25	and	O
26	upper	O
27	arm	O
28	.	O
1	The	O
2	relative	O
3	tumor	O
4	FDG	O
5	-	O
6	uptake	O
7	(	O
8	Q	O
9	-	O
10	MRGlu	O
11	)	O
12	(	O
13	tumor	O
14	/	O
15	contralateral	O
16	cortex	O
17	)	O
18	of	O
19	all	O
20	meningiomas	O
21	was	O
22	calculated	O
23	with	O
24	0	O
25	.	O
26	73	O
27	+/-	O
28	0	O
29	.	O
30	37	O
31	(	O
32	0	O
33	.	O
34	24	O
35	-	O
36	1	O
37	.	O
38	79	O
39	).	O
1	Large	O
2	ones	O
3	were	O
4	similar	O
5	in	O
6	size	O
7	to	O
8	the	O
9	main	O
10	lobe	O
11	and	O
12	small	O
13	ones	O
14	were	O
15	approximately	O
16	1	O
17	/	O
18	4	O
19	of	O
20	the	O
21	length	O
22	of	O
23	the	O
24	main	O
25	lobe	O
26	.	O
1	The	O
2	most	O
3	frequent	O
4	causes	O
5	of	O
6	the	O
7	meningitis	O
8	was	O
9	the	O
10	external	O
11	ventricular	O
12	drainage	O
13	(	O
14	14	O
15	.	O
16	8	O
17	%),	O
18	post	O
19	-	O
20	neurosurgical	O
21	(	O
22	0	O
23	.	O
24	8	O
25	%)	O
26	and	O
27	head	O
28	injury	O
29	(	O
30	0	O
31	.	O
32	0007	O
33	%).	O
1	AIMS	O
2	/	O
3	METHODS	O
4	:	O
5	Reticuloendothelial	O
6	system	O
7	function	O
8	,	O
9	as	O
10	assessed	O
11	by	O
12	clearance	O
13	of	O
14	radiolabelled	O
15	bacteria	O
16	,	O
17	was	O
18	evaluated	O
19	in	O
20	acute	O
21	liver	O
22	injury	O
23	induced	O
24	by	O
25	D	O
26	-	O
27	galactosamine	O
28	in	O
29	rats	O
30	,	O
31	and	O
32	compared	O
33	with	O
34	that	O
35	after	O
36	70	O
37	%	O
38	liver	O
39	resection	O
40	model	O
41	.	O
1	This	O
2	caused	O
3	severe	O
4	cortical	O
5	damage	O
6	and	O
7	neuronal	O
8	loss	O
9	in	O
10	hippocampus	O
11	subfields	O
12	CA1	O
13	,	O
14	CA3	O
15	,	O
16	and	O
17	hilus	O
18	.	O
1	The	O
2	occurrence	O
3	of	O
4	multiple	O
5	malignancy	O
6	was	O
7	studied	O
8	in	O
9	674	O
10	patients	O
11	with	O
12	hematologic	O
13	malignancies	O
14	who	O
15	were	O
16	admitted	O
17	to	O
18	this	O
19	department	O
20	during	O
21	the	O
22	past	O
23	10	O
24	years	O
25	.	O
1	Two	O
2	classes	O
3	of	O
4	Xanthomonas	O
5	pathogens	O
6	evading	O
7	Bs2	O
8	host	O
9	resistance	O
10	and	O
11	displaying	O
12	reduced	O
13	fitness	O
14	were	O
15	found	O
16	to	O
17	be	O
18	specifically	O
19	mutated	O
20	in	O
21	avrBs2	B
22	.	O
1	The	O
2	cDNA	O
3	encoded	O
4	a	O
5	mature	O
6	protein	O
7	of	O
8	240	O
9	amino	O
10	acids	O
11	,	O
12	including	O
13	a	O
14	29	O
15	-	O
16	amino	O
17	acid	O
18	signal	O
19	sequence	O
20	.	O
1	The	O
2	structural	O
3	similarity	O
4	between	O
5	Vav	B
6	and	O
7	other	O
8	guanine	B
9	nucleotide	I
10	exchange	I
11	factors	I
12	for	O
13	small	B
14	GTP	I
15	-	I
16	binding	I
17	proteins	I
18	,	O
19	together	O
20	with	O
21	the	O
22	recent	O
23	identification	O
24	of	O
25	biochemical	O
26	routes	O
27	specific	O
28	for	O
29	members	O
30	of	O
31	the	O
32	Ras	B
33	and	O
34	Rho	B
35	family	I
36	of	O
37	GTPases	B
38	,	O
39	prompted	O
40	us	O
41	to	O
42	explore	O
43	whether	O
44	MAPK	B
45	or	O
46	JNK	B
47	are	O
48	downstream	O
49	components	O
50	of	O
51	the	O
52	Vav	B
53	signaling	O
54	pathways	O
55	.	O
1	The	O
2	cDNA	O
3	clone	O
4	was	O
5	used	O
6	as	O
7	a	O
8	homologous	O
9	probe	O
10	to	O
11	isolate	O
12	a	O
13	truncated	O
14	genomic	O
15	clone	O
16	encoding	O
17	H2A1	B
18	.	O
1	Interaction	O
2	was	O
3	apparently	O
4	determined	O
5	by	O
6	the	O
7	N	O
8	-	O
9	terminal	O
10	splice	O
11	region	O
12	of	O
13	RPDE	B
14	-	I
15	6	I
16	,	O
17	as	O
18	the	O
19	PDE4A	B
20	splice	O
21	variant	O
22	RPDE	B
23	-	I
24	39	I
25	,	O
26	which	O
27	differs	O
28	from	O
29	RPDE	B
30	-	I
31	6	I
32	at	O
33	the	O
34	extreme	O
35	N	O
36	-	O
37	terminus	O
38	,	O
39	failed	O
40	to	O
41	associate	O
42	with	O
43	v	B
44	-	I
45	Src	I
46	-	O
47	SH3	B
48	;	O
49	met26RD1	B
50	(	O
51	where	O
52	RD1	B
53	is	O
54	rat	B
55	'	I
56	dunc	I
57	-	I
58	like	I
59	'	I
60	PDE	I
61	),	O
62	which	O
63	has	O
64	the	O
65	N	O
66	-	O
67	terminal	O
68	splice	O
69	region	O
70	deleted	O
71	,	O
72	failed	O
73	to	O
74	associate	O
75	with	O
76	v	B
77	-	I
78	Src	I
79	-	O
80	SH3	B
81	,	O
82	and	O
83	the	O
84	association	O
85	of	O
86	RPDE	B
87	-	I
88	6	I
89	and	O
90	v	B
91	-	I
92	Src	I
93	-	O
94	SH3	B
95	was	O
96	blocked	O
97	by	O
98	a	O
99	fusion	O
100	protein	O
101	formed	O
102	from	O
103	the	O
104	N	O
105	-	O
106	terminal	O
107	splice	O
108	region	O
109	.	O
1	Phenylephrine	O
2	is	O
3	a	O
4	pure	O
5	alpha	B
6	-	I
7	1	I
8	adrenoreceptor	I
9	agonist	O
10	known	O
11	to	O
12	produce	O
13	marked	O
14	systemic	O
15	vasoconstriction	O
16	and	O
17	associated	O
18	hypertension	O
19	with	O
20	occasional	O
21	profound	O
22	reflex	O
23	bradycardia	O
24	.	O
1	The	O
2	P	B
3	-	I
4	wr	I
5	and	O
6	P	B
7	-	I
8	rr	I
9	cDNA	I
10	sequences	I
11	are	O
12	very	O
13	similar	O
14	in	O
15	their	O
16	5	O
17	'	O
18	regions	O
19	.	O
1	In	O
2	a	O
3	randomized	O
4	single	O
5	-	O
6	blind	O
7	3	O
8	x	O
9	3	O
10	Latin	O
11	-	O
12	square	O
13	study	O
14	with	O
15	corrections	O
16	for	O
17	any	O
18	carryover	O
19	effects	O
20	,	O
21	27	O
22	males	O
23	and	O
24	30	O
25	females	O
26	consumed	O
27	supplements	O
28	containing	O
29	glucose	O
30	or	O
31	resistant	O
32	starch	O
33	(	O
34	RS	O
35	)	O
36	from	O
37	raw	O
38	high	O
39	-	O
40	amylose	O
41	cornstarch	O
42	(	O
43	RS2	O
44	)	O
45	or	O
46	from	O
47	retrograded	O
48	high	O
49	-	O
50	amylose	O
51	cornstarch	O
52	(	O
53	RS3	O
54	).	O
1	In	O
2	the	O
3	rat	B
4	rnu	I
5	allele	I
6	described	O
7	here	O
8	,	O
9	a	O
10	nonsense	O
11	mutation	O
12	in	O
13	exon	O
14	8	O
15	of	O
16	the	O
17	whn	B
18	gene	I
19	was	O
20	identified	O
21	.	O
1	Biol	O
2	.	O
1	A	O
2	novel	O
3	phosphotyrosine	O
4	-	O
5	binding	O
6	domain	O
7	in	O
8	the	O
9	N	O
10	-	O
11	terminal	O
12	transforming	O
13	region	O
14	of	O
15	Cbl	B
16	interacts	O
17	directly	O
18	and	O
19	selectively	O
20	with	O
21	ZAP	B
22	-	I
23	70	I
24	in	O
25	T	O
26	cells	O
27	.	O
1	Targeted	O
2	disruption	O
3	of	O
4	the	O
5	OGG1	B
6	gene	I
7	in	O
8	yeast	O
9	revealed	O
10	a	O
11	second	O
12	OG	B
13	glycosylase	I
14	/	I
15	lyase	I
16	protein	I
17	,	O
18	tentatively	O
19	named	O
20	Ogg2	B
21	,	O
22	which	O
23	differs	O
24	from	O
25	Ogg1	B
26	in	O
27	that	O
28	it	O
29	preferentially	O
30	acts	O
31	on	O
32	OG	O
33	:	O
34	G	O
35	.	O
1	Sequence	O
2	analysis	O
3	of	O
4	reverse	O
5	transcribed	O
6	,	O
7	amplified	O
8	cDNA	O
9	generated	O
10	from	O
11	total	O
12	RNA	O
13	isolated	O
14	from	O
15	transfected	O
16	cells	O
17	demonstrated	O
18	the	O
19	presence	O
20	of	O
21	abnormally	O
22	spliced	O
23	products	O
24	containing	O
25	13	O
26	and	O
27	78	O
28	additional	O
29	bases	O
30	as	O
31	well	O
32	as	O
33	the	O
34	accumulation	O
35	of	O
36	unspliced	O
37	mRNA	O
38	.	O
1	The	O
2	effects	O
3	of	O
4	procedural	O
5	variations	O
6	on	O
7	lateralized	O
8	Stroop	O
9	effects	O
10	.	O
1	In	O
2	a	O
3	third	O
4	experiment	O
5	,	O
6	a	O
7	Chessmaster	O
8	gradually	O
9	increases	O
10	the	O
11	number	O
12	of	O
13	boards	O
14	he	O
15	can	O
16	reproduce	O
17	with	O
18	higher	O
19	than	O
20	70	O
21	%	O
22	average	O
23	accuracy	O
24	to	O
25	nine	O
26	,	O
27	replacing	O
28	as	O
29	many	O
30	as	O
31	160	O
32	pieces	O
33	correctly	O
34	.	O
1	PCNA	B
2	mRNA	I
3	has	O
4	a	O
5	3	O
6	'	O
7	UTR	O
8	antisense	O
9	to	O
10	yellow	O
11	crescent	O
12	RNA	O
13	and	O
14	is	O
15	localized	O
16	in	O
17	ascidian	O
18	eggs	O
19	and	O
20	embryos	O
21	.	O
1	The	O
2	third	O
3	ORF	O
4	generates	O
5	a	O
6	transcript	O
7	of	O
8	1	O
9	.	O
10	6	O
11	kb	O
12	and	O
13	encodes	O
14	a	O
15	protein	O
16	of	O
17	382	O
18	residues	O
19	including	O
20	a	O
21	perfect	O
22	match	O
23	to	O
24	the	O
25	consensus	O
26	sequence	O
27	of	O
28	a	O
29	C2H2	O
30	zinc	O
31	finger	O
32	domain	O
33	;	O
34	it	O
35	shares	O
36	a	O
37	strong	O
38	homology	O
39	with	O
40	yeast	B
41	Mig1p	I
42	and	O
43	Cre	B
44	-	I
45	A	I
46	from	I
47	Aspergillus	I
48	,	I
49	Emericella	I
50	and	I
51	E	I
52	.	I
53	coli	I
54	.	O
1	Thus	O
2	,	O
3	the	O
4	multidomained	O
5	ROK	B
6	alpha	I
7	appears	O
8	to	O
9	be	O
10	involved	O
11	in	O
12	reorganization	O
13	of	O
14	the	O
15	cytoskeleton	O
16	,	O
17	with	O
18	the	O
19	N	O
20	and	O
21	C	O
22	termini	O
23	acting	O
24	as	O
25	positive	O
26	and	O
27	negative	O
28	regulators	O
29	,	O
30	respectively	O
31	,	O
32	of	O
33	the	O
34	kinase	O
35	domain	O
36	whose	O
37	activity	O
38	is	O
39	crucial	O
40	for	O
41	formation	O
42	of	O
43	stress	O
44	fibers	O
45	and	O
46	focal	O
47	adhesion	O
48	complexes	O
49	.	O
1	The	O
2	serine	B
3	/	I
4	threonine	I
5	kinase	I
6	Raf	I
7	-	I
8	1	I
9	functions	O
10	downstream	O
11	of	O
12	Rats	B
13	in	O
14	a	O
15	signal	O
16	transduction	O
17	cascade	O
18	which	O
19	transmits	O
20	mitogenic	O
21	stimuli	O
22	from	O
23	the	O
24	plasma	O
25	membrane	O
26	to	O
27	the	O
28	nucleus	O
29	.	O
1	The	O
2	retinoid	B
3	Z	I
4	receptor	I
5	beta	I
6	(	O
7	RZR	B
8	beta	I
9	),	O
10	an	O
11	orphan	O
12	receptor	O
13	,	O
14	is	O
15	a	O
16	member	O
17	of	O
18	the	O
19	retinoic	B
20	acid	I
21	receptor	I
22	(	O
23	RAR	B
24	)/	O
25	thyroid	B
26	hormone	I
27	receptor	I
28	(	O
29	TR	B
30	)	O
31	subfamily	O
32	of	O
33	nuclear	O
34	receptors	O
35	.	O
1	Sequencing	O
2	of	O
3	the	O
4	16p	O
5	11	O
6	.	O
7	1	O
8	/	O
9	Xq28	O
10	duplication	O
11	breakpoints	O
12	has	O
13	revealed	O
14	the	O
15	presence	O
16	of	O
17	repetitive	O
18	immunoglobulin	B
19	-	I
20	like	I
21	CAGGG	I
22	pentamer	I
23	sequences	I
24	at	O
25	or	O
26	near	O
27	the	O
28	paralogy	O
29	boundaries	O
30	.	O
1	Chernoff	O
2	,	O
3	submitted	O
4	for	O
5	publication	O
6	).	O
1	We	O
2	have	O
3	cloned	O
4	a	O
5	novel	O
6	protein	O
7	kinase	O
8	,	O
9	termed	O
10	hematopoietic	B
11	progenitor	I
12	kinase	I
13	1	I
14	(	O
15	HPK1	B
16	),	O
17	that	O
18	is	O
19	expressed	O
20	predominantly	O
21	in	O
22	hematopoietic	O
23	cells	O
24	,	O
25	including	O
26	early	O
27	progenitor	O
28	cells	O
29	.	O
1	The	O
2	cytogenetic	O
3	expression	O
4	of	O
5	the	O
6	folate	O
7	sensitive	O
8	fragile	O
9	site	O
10	,	O
11	FRAXE	B
12	,	O
13	is	O
14	due	O
15	to	O
16	the	O
17	expansion	O
18	of	O
19	a	O
20	GCC	O
21	repeat	O
22	in	O
23	proximal	O
24	Xq28	O
25	of	O
26	the	O
27	human	O
28	X	O
29	chromosome	O
30	and	O
31	is	O
32	associated	O
33	with	O
34	a	O
35	mild	O
36	form	O
37	of	O
38	mental	O
39	handicap	O
40	.	O
1	Proximal	O
2	CBD	O
3	was	O
4	inversely	O
5	correlated	O
6	with	O
7	bone	B
8	alkaline	I
9	phosphatase	I
10	(	O
11	r	O
12	=	O
13	-	O
14	0	O
15	.	O
16	71	O
17	,	O
18	p	O
19	<	O
20	0	O
21	.	O
22	01	O
23	)	O
24	and	O
25	intact	O
26	PTH	B
27	(	O
28	r	O
29	=	O
30	-	O
31	0	O
32	.	O
33	59	O
34	,	O
35	p	O
36	<	O
37	0	O
38	.	O
39	05	O
40	).	O
1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	LIM	B
7	domain	I
8	homeobox	I
9	protein	I
10	isl	I
11	-	I
12	1	I
13	activates	O
14	the	O
15	rat	B
16	amylin	I
17	promoter	I
18	in	O
19	both	O
20	fibroblast	O
21	and	O
22	islet	O
23	cell	O
24	lines	O
25	.	O
1	Although	O
2	diagnostic	O
3	laparoscopy	O
4	is	O
5	still	O
6	considered	O
7	the	O
8	standard	O
9	reference	O
10	in	O
11	the	O
12	diagnosis	O
13	of	O
14	ectopic	O
15	pregnancy	O
16	(	O
17	EP	O
18	),	O
19	use	O
20	of	O
21	high	O
22	-	O
23	resolution	O
24	endovaginal	O
25	sonography	O
26	,	O
27	in	O
28	conjunction	O
29	with	O
30	qualitative	O
31	serum	O
32	assays	O
33	of	O
34	the	O
35	beta	O
36	subunit	O
37	of	O
38	human	B
39	chorionic	I
40	gonadotropin	I
41	(	O
42	beta	B
43	-	I
44	hCG	I
45	),	O
46	allows	O
47	detection	O
48	of	O
49	earlier	O
50	and	O
51	smaller	O
52	EPs	O
53	.	O
1	RVR	B
2	'	O
3	loss	O
4	of	O
5	function	O
6	'	O
7	studies	O
8	by	O
9	constitutive	O
10	over	O
11	-	O
12	expression	O
13	of	O
14	a	O
15	dominant	O
16	negative	O
17	RVR	B
18	delta	I
19	E	I
20	resulted	O
21	in	O
22	increased	O
23	levels	O
24	of	O
25	p21Cip1	B
26	/	O
27	Waf1	B
28	and	O
29	myogenin	B
30	mRNAs	I
31	after	O
32	serum	O
33	withdrawal	O
34	.	O
1	We	O
2	report	O
3	here	O
4	the	O
5	discovery	O
6	of	O
7	a	O
8	new	O
9	actin	B
10	-	I
11	related	I
12	gene	I
13	in	O
14	this	O
15	organism	O
16	,	O
17	which	O
18	we	O
19	have	O
20	named	O
21	ACT4	B
22	.	O
1	Here	O
2	we	O
3	localize	O
4	a	O
5	transferable	O
6	40	O
7	-	O
8	amino	O
9	acid	O
10	region	O
11	within	O
12	the	O
13	LBDs	B
14	of	O
15	RXR	B
16	,	O
17	RAR	B
18	,	O
19	TR	B
20	,	O
21	and	O
22	chicken	B
23	ovalbumin	I
24	upstream	I
25	promoter	I
26	transcription	I
27	factor	I
28	that	O
29	is	O
30	critical	O
31	for	O
32	determining	O
33	identity	O
34	in	O
35	the	O
36	heterodimeric	O
37	interaction	O
38	and	O
39	for	O
40	high	O
41	-	O
42	affinity	O
43	DNA	O
44	binding	O
45	.	O
1	An	O
2	open	O
3	-	O
4	label	O
5	,	O
6	placebo	O
7	-	O
8	controlled	O
9	,	O
10	randomized	O
11	,	O
12	two	O
13	-	O
14	way	O
15	crossover	O
16	study	O
17	was	O
18	performed	O
19	in	O
20	12	O
21	healthy	O
22	volunteers	O
23	(	O
24	between	O
25	20	O
26	and	O
27	44	O
28	years	O
29	of	O
30	age	O
31	)	O
32	to	O
33	assess	O
34	the	O
35	effect	O
36	of	O
37	orlistat	O
38	,	O
39	a	O
40	gastrointestinal	B
41	lipase	I
42	inhibitor	O
43	that	O
44	reduces	O
45	dietary	O
46	fat	O
47	absorption	O
48	and	O
49	is	O
50	being	O
51	developed	O
52	for	O
53	weight	O
54	control	O
55	in	O
56	obesity	O
57	,	O
58	on	O
59	the	O
60	absorption	O
61	of	O
62	vitamins	O
63	A	O
64	and	O
65	E	O
66	.	O
1	The	O
2	detection	O
3	ratio	O
4	peaked	O
5	at	O
6	ages	O
7	30	O
8	to	O
9	34	O
10	and	O
11	decreased	O
12	heavily	O
13	during	O
14	the	O
15	next	O
16	15	O
17	years	O
18	of	O
19	age	O
20	.	O
1	The	O
2	enzyme	O
3	activities	O
4	studied	O
5	are	O
6	important	O
7	elements	O
8	in	O
9	the	O
10	pathophysiology	O
11	of	O
12	dental	O
13	caries	O
14	and	O
15	may	O
16	even	O
17	be	O
18	addressed	O
19	as	O
20	virulence	O
21	factors	O
22	.	O
1	Tonsillectomy	O
2	is	O
3	an	O
4	effective	O
5	means	O
6	of	O
7	prophylaxis	O
8	for	O
9	upper	O
10	respiratory	O
11	infection	O
12	in	O
13	habitual	O
14	angina	O
15	patients	O
16	.	O
1	This	O
2	paper	O
3	gives	O
4	an	O
5	overview	O
6	of	O
7	the	O
8	global	O
9	pattern	O
10	of	O
11	casualties	O
12	in	O
13	earthquakes	O
14	which	O
15	occurred	O
16	during	O
17	the	O
18	30	O
19	-	O
20	month	O
21	period	O
22	from	O
23	1	O
24	September	O
25	1993	O
26	to	O
27	29	O
28	February	O
29	1996	O
30	.	O
1	This	O
2	GAP	B
3	activity	O
4	was	O
5	observed	O
6	in	O
7	3T3	O
8	-	O
9	L1	O
10	adipocyte	O
11	lysates	O
12	,	O
13	and	O
14	was	O
15	able	O
16	to	O
17	accelerate	O
18	the	O
19	hydrolysis	O
20	of	O
21	the	O
22	[	O
23	alpha	O
24	-	O
25	32P	O
26	]	O
27	GTP	O
28	bound	O
29	to	O
30	GST	B
31	-	O
32	Rab4	B
33	into	O
34	[	O
35	alpha	O
36	-	O
37	32P	O
38	]	O
39	GDP	O
40	.	O
1	We	O
2	conclude	O
3	that	O
4	,	O
5	in	O
6	AIDS	O
7	patients	O
8	with	O
9	cryptococcosis	O
10	,	O
11	tolerance	O
12	to	O
13	ILd	O
14	-	O
15	AmB	O
16	was	O
17	acceptable	O
18	when	O
19	the	O
20	daily	O
21	dosage	O
22	did	O
23	not	O
24	exceed	O
25	1	O
26	mg	O
27	/	O
28	kg	O
29	,	O
30	but	O
31	the	O
32	higher	O
33	1	O
34	.	O
35	5	O
36	mg	O
37	/	O
38	kg	O
39	daily	O
40	dosage	O
41	was	O
42	associated	O
43	with	O
44	an	O
45	unacceptable	O
46	rate	O
47	of	O
48	nephrotoxicity	O
49	.	O
1	Consistent	O
2	with	O
3	this	O
4	similarity	O
5	,	O
6	the	O
7	cdc28	B
8	-	O
9	P8	O
10	mutant	O
11	accumulates	O
12	unspliced	O
13	precursors	O
14	at	O
15	the	O
16	restrictive	O
17	temperature	O
18	.	O
1	Expression	O
2	of	O
3	thymidine	B
4	kinase	I
5	gene	I
6	in	O
7	normal	O
8	human	O
9	diploid	O
10	cells	O
11	is	O
12	both	O
13	cell	O
14	cycle	O
15	-	O
16	and	O
17	age	O
18	-	O
19	dependent	O
20	and	O
21	appears	O
22	to	O
23	be	O
24	transcriptionally	O
25	regulated	O
26	.	O
1	These	O
2	bacteria	O
3	produce	O
4	and	O
5	export	O
6	proteins	O
7	capable	O
8	of	O
9	specific	O
10	interactions	O
11	with	O
12	key	O
13	mammalian	O
14	cell	O
15	regulatory	O
16	molecules	O
17	in	O
18	order	O
19	to	O
20	derail	O
21	the	O
22	normal	O
23	functions	O
24	of	O
25	the	O
26	cells	O
27	.	O
1	The	O
2	elevations	O
3	achieved	O
4	by	O
5	LDEE	O
6	given	O
7	s	O
8	.	O
9	c	O
10	.	O
11	were	O
12	higher	O
13	than	O
14	those	O
15	achieved	O
16	after	O
17	i	O
18	.	O
19	p	O
20	.	O
21	administration	O
22	and	O
23	lasted	O
24	for	O
25	longer	O
26	periods	O
27	.	O
1	The	O
2	model	O
3	also	O
4	predicts	O
5	that	O
6	blood	O
7	flow	O
8	shunt	O
9	fraction	O
10	(	O
11	Qs	O
12	/	O
13	QT	O
14	)	O
15	is	O
16	directly	O
17	related	O
18	to	O
19	the	O
20	oxygen	O
21	sine	O
22	-	O
23	wave	O
24	amplitude	O
25	perturbations	O
26	transmitted	O
27	to	O
28	end	O
29	-	O
30	expired	O
31	air	O
32	and	O
33	arterial	O
34	and	O
35	mixed	O
36	-	O
37	venous	O
38	blood	O
39	through	O
40	two	O
41	simple	O
42	equations	O
43	.	O
1	Sixty	O
2	days	O
3	after	O
4	the	O
5	intervention	O
6	,	O
7	twitch	O
8	and	O
9	tetanic	O
10	tensions	O
11	remained	O
12	dependent	O
13	upon	O
14	the	O
15	extracellular	O
16	Ca2	O
17	+	O
18	concentration	O
19	([	O
20	Ca	O
21	]	O
22	o	O
23	)	O
24	both	O
25	in	O
26	groups	O
27	A	O
28	and	O
29	B	O
30	.	O
1	Discrimination	O
2	between	O
3	HIV	O
4	-	O
5	1	O
6	and	O
7	HIV	O
8	-	O
9	2	O
10	showed	O
11	evidence	O
12	for	O
13	the	O
14	presence	O
15	of	O
16	HIV	O
17	-	O
18	1	O
19	only	O
20	.	O
1	However	O
2	,	O
3	an	O
4	intrinsic	O
5	DNA	O
6	-	O
7	binding	O
8	subunit	O
9	for	O
10	HiNF	B
11	-	I
12	D	I
13	was	O
14	not	O
15	identified	O
16	.	O
1	The	O
2	HiNF	B
3	-	I
4	D	I
5	(	O
6	CDP	B
7	/	O
8	cut	B
9	)	O
10	complex	O
11	with	O
12	the	O
13	H4	B
14	promoter	I
15	is	O
16	immunoreactive	O
17	with	O
18	antibodies	O
19	against	O
20	CDP	B
21	/	O
22	cut	B
23	and	O
24	pRB	B
25	but	O
26	not	O
27	p107	B
28	,	O
29	whereas	O
30	the	O
31	CDP	B
32	/	O
33	cut	B
34	complex	O
35	with	O
36	a	O
37	nonhistone	O
38	promoter	O
39	(	O
40	gp91	B
41	-	O
42	phox	B
43	)	O
44	reacts	O
45	only	O
46	with	O
47	CDP	B
48	and	O
49	p107	B
50	antibodies	O
51	.	O
1	The	O
2	amplification	O
3	was	O
4	achieved	O
5	using	O
6	two	O
7	primers	O
8	which	O
9	correspond	O
10	to	O
11	TRH	B
12	progenitor	I
13	sequence	I
14	(	O
15	Lys	O
16	/	O
17	Arg	O
18	-	O
19	Arg	O
20	-	O
21	Gln	O
22	-	O
23	His	O
24	-	O
25	Pro	O
26	-	O
27	Gly	O
28	-	O
29	Lys	O
30	/	O
31	Arg	O
32	-	O
33	Arg	O
34	).	O
1	The	O
2	gene	B
3	ccpA	I
4	encoding	O
5	the	O
6	catabolite	B
7	control	I
8	protein	I
9	CcpA	I
10	of	O
11	Staphylococcus	O
12	xylosus	O
13	has	O
14	been	O
15	cloned	O
16	and	O
17	characterized	O
18	.	O
1	Eight	O
2	-	O
3	four	O
4	ACOAs	O
5	were	O
6	tested	O
7	in	O
8	order	O
9	to	O
10	examine	O
11	the	O
12	fit	O
13	of	O
14	the	O
15	model	O
16	to	O
17	the	O
18	data	O
19	by	O
20	path	O
21	analysis	O
22	with	O
23	LISREL	O
24	VII	O
25	.	O
1	Fission	B
2	yeast	I
3	mal2	I
4	+	I
5	is	O
6	required	O
7	for	O
8	chromosome	O
9	segregation	O
10	.	O
1	A	O
2	subset	O
3	of	O
4	these	O
5	DMP1	B
6	recognition	I
7	sequences	I
8	containing	O
9	a	O
10	GGA	O
11	trinucleotide	O
12	core	O
13	can	O
14	also	O
15	function	O
16	as	O
17	Ets	B
18	-	I
19	responsive	I
20	elements	I
21	.	O
1	Transient	O
2	transfection	O
3	assays	O
4	using	O
5	reporter	O
6	gene	O
7	constructs	O
8	containing	O
9	various	O
10	lengths	O
11	of	O
12	the	O
13	5	B
14	'	I
15	mdr1b	I
16	sequences	I
17	revealed	O
18	that	O
19	the	O
20	sequence	O
21	located	O
22	between	O
23	-	O
24	247	O
25	to	O
26	-	O
27	126	O
28	bp	O
29	was	O
30	important	O
31	for	O
32	the	O
33	expression	O
34	of	O
35	the	O
36	reporter	O
37	gene	O
38	in	O
39	many	O
40	different	O
41	cell	O
42	lines	O
43	.	O
1	Forty	O
2	-	O
3	eight	O
4	10	O
5	-	O
6	12	O
7	-	O
8	week	O
9	-	O
10	old	O
11	male	O
12	Sprague	O
13	-	O
14	Dawley	O
15	rats	O
16	were	O
17	randomized	O
18	to	O
19	receive	O
20	,	O
21	daily	O
22	for	O
23	28	O
24	days	O
25	:	O
26	(	O
27	1	O
28	)	O
29	CsA	O
30	vehicle	O
31	p	O
32	.	O
33	o	O
34	.	O
35	plus	O
36	FB	O
37	vehicle	O
38	sc	O
39	;	O
40	(	O
41	2	O
42	)	O
43	CsA	O
44	(	O
45	15	O
46	mg	O
47	/	O
48	kg	O
49	)	O
50	p	O
51	.	O
52	o	O
53	.	O
54	plus	O
55	FB	O
56	vehicle	O
57	sc	O
58	,	O
59	(	O
60	3	O
61	)	O
62	CsA	O
63	vehicle	O
64	p	O
65	.	O
66	o	O
67	.	O
68	plus	O
69	FB	O
70	(	O
71	1	O
72	.	O
73	5	O
74	mg	O
75	/	O
76	kg	O
77	)	O
78	sc	O
79	;	O
80	and	O
81	(	O
82	4	O
83	)	O
84	CsA	O
85	(	O
86	15	O
87	mg	O
88	/	O
89	kg	O
90	)	O
91	p	O
92	.	O
93	o	O
94	.	O
95	plus	O
96	FB	O
97	(	O
98	1	O
99	.	O
100	5	O
101	mg	O
102	/	O
103	kg	O
104	)	O
105	sc	O
106	.	O
1	Natural	O
2	FL	B
3	protein	I
4	has	O
5	been	O
6	purified	O
7	from	O
8	a	O
9	stromal	O
10	cell	O
11	line	O
12	and	O
13	shown	O
14	to	O
15	be	O
16	a	O
17	65	O
18	kD	O
19	nondisulfide	O
20	-	O
21	linked	O
22	homodimeric	O
23	glycoprotein	O
24	comprised	O
25	of	O
26	30	O
27	kD	O
28	subunits	O
29	,	O
30	each	O
31	containing	O
32	12	O
33	kD	O
34	of	O
35	N	O
36	-	O
37	and	O
38	O	O
39	-	O
40	linked	O
41	sugars	O
42	.	O
1	The	O
2	present	O
3	study	O
4	investigated	O
5	dose	O
6	dependence	O
7	and	O
8	time	O
9	course	O
10	effects	O
11	of	O
12	the	O
13	benzodiazepine	O
14	(	O
15	BDZ	O
16	)	O
17	partial	O
18	inverse	O
19	agonist	O
20	,	O
21	RO19	O
22	-	O
23	4603	O
24	(	O
25	0	O
26	.	O
27	005	O
28	-	O
29	0	O
30	.	O
31	30	O
32	mg	O
33	/	O
34	kg	O
35	)	O
36	alone	O
37	,	O
38	and	O
39	in	O
40	combination	O
41	with	O
42	the	O
43	BDZ	B
44	receptor	I
45	antagonists	O
46	flumazenil	O
47	,	O
48	ZK	O
49	93426	O
50	,	O
51	and	O
52	CGS	O
53	8216	O
54	(	O
55	20	O
56	mg	O
57	/	O
58	kg	O
59	)	O
60	in	O
61	selectively	O
62	bred	O
63	alcohol	O
64	-	O
65	preferring	O
66	(	O
67	P	O
68	)	O
69	rats	O
70	provided	O
71	a	O
72	two	O
73	-	O
74	bottle	O
75	choice	O
76	test	O
77	between	O
78	ethanol	O
79	(	O
80	EtOH	O
81	)	O
82	(	O
83	10	O
84	%	O
85	v	O
86	/	O
87	v	O
88	),	O
89	and	O
90	a	O
91	palatable	O
92	saccharin	O
93	(	O
94	0	O
95	.	O
96	0125	O
97	%	O
98	g	O
99	/	O
100	v	O
101	)	O
102	solution	O
103	.	O
1	Beyond	O
2	the	O
3	Tower	O
4	of	O
5	Babel	O
6	:	O
7	a	O
8	nomenclature	O
9	for	O
10	suicidology	O
11	.	O
1	RNase	B
2	protection	O
3	analysis	O
4	of	O
5	two	O
6	rRNA	O
7	fragments	O
8	whose	O
9	genes	O
10	are	O
11	adjacent	O
12	provided	O
13	evidence	O
14	for	O
15	a	O
16	polycistronic	O
17	transcript	O
18	containing	O
19	sequences	O
20	from	O
21	both	O
22	,	O
23	as	O
24	well	O
25	as	O
26	separate	O
27	small	O
28	RNAs	O
29	.	O
1	T	O
2	.,	O
3	Patel	O
4	,	O
5	S	O
6	.	O
1	Factor	O
2	V	O
3	Leiden	O
4	is	O
5	a	O
6	genetic	O
7	disorder	O
8	associated	O
9	with	O
10	an	O
11	increased	O
12	risk	O
13	of	O
14	venous	O
15	thrombosis	O
16	.	O
1	We	O
2	have	O
3	found	O
4	that	O
5	PEA2	B
6	is	O
7	also	O
8	required	O
9	for	O
10	the	O
11	bipolar	O
12	budding	O
13	pattern	O
14	and	O
15	that	O
16	it	O
17	encodes	O
18	a	O
19	novel	O
20	protein	O
21	with	O
22	a	O
23	predicted	O
24	coiled	O
25	-	O
26	coil	O
27	domain	O
28	.	O
1	Signaling	O
2	from	O
3	the	O
4	small	B
5	GTP	I
6	-	I
7	binding	I
8	proteins	I
9	Rac1	I
10	and	O
11	Cdc42	B
12	to	O
13	the	O
14	c	B
15	-	I
16	Jun	I
17	N	I
18	-	I
19	terminal	I
20	kinase	I
21	/	O
22	stress	B
23	-	I
24	activated	I
25	protein	I
26	kinase	I
27	pathway	O
28	.	O
1	Percent	O
2	identities	O
3	of	O
4	the	O
5	mouse	B
6	PP2	I
7	to	O
8	mouse	B
9	Y1	I
10	,	O
11	mouse	O
12	Y4	B
13	/	O
14	PP1	B
15	and	O
16	human	B
17	Y2	I
18	receptors	I
19	are	O
20	53	O
21	,	O
22	42	O
23	,	O
24	and	O
25	31	O
26	,	O
27	respectively	O
28	.	O
1	However	O
2	,	O
3	the	O
4	truncated	O
5	deer	B
6	receptor	I
7	lacks	O
8	the	O
9	most	O
10	C	O
11	-	O
12	terminal	O
13	tyrosine	O
14	residue	O
15	in	O
16	the	O
17	intracellular	O
18	domain	O
19	which	O
20	is	O
21	believed	O
22	to	O
23	be	O
24	essential	O
25	for	O
26	activation	O
27	of	O
28	the	O
29	beta	B
30	-	I
31	casein	I
32	promoter	I
33	.	O
1	Ninety	O
2	-	O
3	four	O
4	percent	O
5	of	O
6	the	O
7	EPs	O
8	were	O
9	tubal	O
10	,	O
11	and	O
12	90	O
13	%	O
14	of	O
15	the	O
16	tubes	O
17	exhibited	O
18	some	O
19	pathologic	O
20	changes	O
21	,	O
22	including	O
23	chronic	O
24	salpingitis	O
25	(	O
26	49	O
27	.	O
28	5	O
29	%)	O
30	and	O
31	follicular	O
32	salpingitis	O
33	(	O
34	10	O
35	%),	O
36	among	O
37	others	O
38	.	O
1	Magnetic	O
2	resonance	O
3	imaging	O
4	in	O
5	coccidioidal	O
6	arthritis	O
7	.	O
1	The	O
2	same	O
3	ligands	O
4	also	O
5	exhibit	O
6	a	O
7	similar	O
8	inhibitory	O
9	effect	O
10	on	O
11	PDGF	B
12	-	I
13	BB	I
14	-	O
15	dependent	O
16	[	O
17	3H	O
18	]	O
19	thymidine	O
20	incorporation	O
21	in	O
22	PAE	O
23	cells	O
24	expressing	O
25	the	O
26	PDGF	B
27	beta	I
28	-	I
29	receptors	I
30	.	O
1	To	O
2	analyze	O
3	the	O
4	mechanism	O
5	of	O
6	fos	B
7	/	O
8	jun	B
9	activation	O
10	by	O
11	TCDD	O
12	we	O
13	have	O
14	used	O
15	electrophoretic	O
16	mobility	O
17	shift	O
18	and	O
19	transient	O
20	expression	O
21	assays	O
22	of	O
23	reporter	O
24	gene	O
25	constructs	O
26	containing	O
27	response	O
28	elements	O
29	for	O
30	12	O
31	-	O
32	O	O
33	-	O
34	tetradecanoyl	O
35	-	O
36	phorbol	O
37	-	O
38	13	O
39	-	O
40	acetate	O
41	(	O
42	TRE	O
43	),	O
44	serum	O
45	(	O
46	SRE	O
47	),	O
48	cAMP	O
49	(	O
50	CRE	O
51	),	O
52	and	O
53	aromatic	O
54	hydrocarbons	O
55	(	O
56	AhRE	O
57	)	O
58	from	O
59	the	O
60	fos	B
61	and	O
62	jun	B
63	genes	I
64	fused	O
65	to	O
66	the	O
67	firefly	B
68	luciferase	I
69	gene	I
70	under	O
71	the	O
72	control	O
73	of	O
74	the	O
75	SV40	B
76	minimal	I
77	promoter	I
78	.	O
1	Kss1	B
2	binds	O
3	specifically	O
4	to	O
5	a	O
6	GST	B
7	-	O
8	Dig1	B
9	fusion	O
10	in	O
11	the	O
12	absence	O
13	of	O
14	any	O
15	other	O
16	yeast	O
17	protein	O
18	.	O
1	It	O
2	can	O
3	be	O
4	concluded	O
5	that	O
6	in	O
7	normotensive	O
8	subjects	O
9	,	O
10	uric	O
11	acid	O
12	and	O
13	xanthine	B
14	oxidase	I
15	have	O
16	significant	O
17	association	O
18	with	O
19	blood	O
20	pressure	O
21	and	O
22	thus	O
23	are	O
24	one	O
25	of	O
26	the	O
27	many	O
28	factors	O
29	which	O
30	are	O
31	involved	O
32	in	O
33	the	O
34	cause	O
35	or	O
36	effect	O
37	of	O
38	hypertension	O
39	.	O
1	These	O
2	data	O
3	demonstrate	O
4	the	O
5	presence	O
6	of	O
7	a	O
8	single	O
9	binding	O
10	site	O
11	for	O
12	vinculin	B
13	,	O
14	and	O
15	at	O
16	least	O
17	two	O
18	binding	O
19	sites	O
20	for	O
21	FAK	B
22	that	O
23	are	O
24	separated	O
25	by	O
26	an	O
27	intervening	O
28	stretch	O
29	of	O
30	100	O
31	amino	O
32	acids	O
33	.	O
1	These	O
2	data	O
3	demonstrate	O
4	that	O
5	paxillin	B
6	localizes	O
7	to	O
8	focal	O
9	adhesions	O
10	independent	O
11	of	O
12	interactions	O
13	with	O
14	vinculin	B
15	and	O
16	/	O
17	or	O
18	FAK	B
19	,	O
20	and	O
21	represents	O
22	the	O
23	first	O
24	definitive	O
25	demonstration	O
26	of	O
27	LIM	B
28	domains	I
29	functioning	O
30	as	O
31	a	O
32	primary	O
33	determinant	O
34	of	O
35	protein	O
36	subcellular	O
37	localization	O
38	to	O
39	focal	O
40	adhesions	O
41	.	O
1	Several	O
2	agents	O
3	have	O
4	been	O
5	tried	O
6	for	O
7	treatment	O
8	,	O
9	often	O
10	limited	O
11	by	O
12	toxic	O
13	side	O
14	effects	O
15	.	O
1	RUSH	B
2	-	I
3	1	I
4	beta	I
5	is	O
6	a	O
7	95	O
8	-	O
9	kDa	O
10	truncated	O
11	version	O
12	of	O
13	RUSH	B
14	-	I
15	1	I
16	alpha	I
17	that	O
18	results	O
19	from	O
20	alternative	O
21	splicing	O
22	of	O
23	a	O
24	57	O
25	-	O
26	bp	O
27	exon	O
28	as	O
29	confirmed	O
30	by	O
31	genomic	O
32	cloning	O
33	.	O
1	These	O
2	results	O
3	are	O
4	consistent	O
5	with	O
6	the	O
7	well	O
8	established	O
9	polarity	O
10	of	O
11	RXR	B
12	heterodimer	O
13	binding	O
14	to	O
15	bipartite	O
16	hormone	O
17	response	O
18	elements	O
19	,	O
20	with	O
21	the	O
22	VDR	B
23	recognizing	O
24	the	O
25	3	O
26	'-	O
27	half	O
28	-	O
29	element	O
30	.	O
1	Small	O
2	Maf	B
3	proteins	I
4	interact	O
5	with	O
6	the	O
7	human	O
8	transcription	O
9	factor	O
10	TCF11	B
11	/	O
12	Nrf1	B
13	/	O
14	LCR	B
15	-	I
16	F1	I
17	.	O
1	DATA	O
2	SOURCES	O
3	:	O
4	Epidemiologic	O
5	studies	O
6	,	O
7	research	O
8	studies	O
9	,	O
10	review	O
11	articles	O
12	,	O
13	and	O
14	government	O
15	reports	O
16	pertaining	O
17	to	O
18	epidemiology	O
19	of	O
20	lung	O
21	cancer	O
22	.	O
1	Histological	O
2	changes	O
3	,	O
4	including	O
5	cortical	O
6	cell	O
7	involution	O
8	and	O
9	hemorrhage	O
10	occurring	O
11	during	O
12	the	O
13	neonatal	O
14	period	O
15	,	O
16	would	O
17	seem	O
18	to	O
19	have	O
20	crucial	O
21	relevance	O
22	to	O
23	the	O
24	remodeling	O
25	of	O
26	the	O
27	adrenal	O
28	vasculature	O
29	.	O
1	In	O
2	3Y1	O
3	and	O
4	3Y1	O
5	v	B
6	-	I
7	crk	I
8	-	O
9	transformed	O
10	fibroblasts	O
11	,	O
12	almost	O
13	all	O
14	of	O
15	the	O
16	total	O
17	PTP1B	B
18	and	O
19	about	O
20	40	O
21	%	O
22	of	O
23	total	O
24	p130	B
25	(	O
26	Cas	B
27	)	O
28	co	O
29	-	O
30	sediment	O
31	with	O
32	membranes	O
33	composed	O
34	primarily	O
35	of	O
36	endoplasmic	O
37	reticulum	O
38	.	O
1	But	O
2	,	O
3	as	O
4	Theriault	O
5	explains	O
6	,	O
7	improvements	O
8	in	O
9	assessing	O
10	exposure	O
11	have	O
12	not	O
13	yet	O
14	translated	O
15	into	O
16	clear	O
17	and	O
18	consistent	O
19	findings	O
20	.	O
1	Our	O
2	results	O
3	demonstrate	O
4	that	O
5	the	O
6	promoter	O
7	and	O
8	enhancer	O
9	regions	O
10	identified	O
11	here	O
12	are	O
13	essential	O
14	for	O
15	maintaining	O
16	the	O
17	efficient	O
18	promoter	O
19	activity	O
20	of	O
21	the	O
22	human	B
23	activin	I
24	betaA	I
25	subunit	I
26	gene	I
27	.	O
1	We	O
2	report	O
3	a	O
4	case	O
5	of	O
6	vasculitis	O
7	(	O
8	cutaneous	O
9	and	O
10	neurologic	O
11	)	O
12	which	O
13	led	O
14	to	O
15	the	O
16	discovery	O
17	of	O
18	a	O
19	selective	O
20	immunodeficit	O
21	towards	O
22	EBV	O
23	,	O
24	similar	O
25	to	O
26	Purtilo	O
27	'	O
28	s	O
29	syndrome	O
30	.	O
1	However	O
2	,	O
3	we	O
4	did	O
5	not	O
6	observe	O
7	a	O
8	correlation	O
9	between	O
10	serum	O
11	and	O
12	seminal	B
13	plasma	I
14	PSA	I
15	levels	O
16	.	O
1	The	O
2	implications	O
3	for	O
4	estimates	O
5	of	O
6	cortical	O
7	magnification	O
8	and	O
9	possible	O
10	differences	O
11	in	O
12	the	O
13	specializations	O
14	of	O
15	foveal	O
16	and	O
17	peripheral	O
18	vision	O
19	are	O
20	discussed	O
21	.	O
1	G	B
2	-	I
3	CSF	I
4	activates	O
5	multiple	O
6	signaling	O
7	molecules	O
8	,	O
9	including	O
10	the	O
11	JAK1	B
12	and	O
13	JAK2	B
14	kinases	I
15	and	O
16	the	O
17	STAT	B
18	transcription	O
19	factors	O
20	.	O
1	The	O
2	RI	B
3	alpha	I
4	gene	I
5	is	O
6	composed	O
7	of	O
8	nine	O
9	coding	O
10	exons	O
11	of	O
12	varying	O
13	lengths	O
14	,	O
15	separated	O
16	by	O
17	introns	O
18	,	O
19	giving	O
20	the	O
21	gene	O
22	a	O
23	total	O
24	length	O
25	of	O
26	at	O
27	least	O
28	21	O
29	kb	O
30	.	O
31	our	O
32	recent	O
33	cloning	O
34	of	O
35	a	O
36	processed	O
37	RI	B
38	alpha	I
39	pseudogene	I
40	with	O
41	a	O
42	5	O
43	'-	O
44	noncoding	O
45	region	O
46	different	O
47	from	O
48	the	O
49	previously	O
50	reported	O
51	RI	B
52	alpha	I
53	complementary	I
54	RNA	I
55	indicated	O
56	that	O
57	the	O
58	RI	B
59	alpha	I
60	gene	I
61	may	O
62	have	O
63	multiple	O
64	leader	O
65	exons	O
66	giving	O
67	rise	O
68	to	O
69	alternately	O
70	spliced	O
71	messenger	O
72	RNAs	O
73	(	O
74	mRNAs	O
75	).	O
1	The	O
2	identification	O
3	of	O
4	the	O
5	hepatitis	O
6	C	O
7	virus	O
8	as	O
9	the	O
10	major	O
11	cause	O
12	of	O
13	liver	O
14	disease	O
15	both	O
16	in	O
17	dialysis	O
18	patients	O
19	and	O
20	in	O
21	transplant	O
22	patients	O
23	has	O
24	focused	O
25	attention	O
26	on	O
27	the	O
28	epidemiology	O
29	and	O
30	the	O
31	impact	O
32	of	O
33	continuing	O
34	infection	O
35	in	O
36	these	O
37	patient	O
38	groups	O
39	.	O
1	The	O
2	first	O
3	identification	O
4	of	O
5	the	O
6	active	O
7	37LRP	B
8	/	O
9	p40	B
10	gene	O
11	presented	O
12	in	O
13	this	O
14	study	O
15	is	O
16	a	O
17	critical	O
18	step	O
19	toward	O
20	the	O
21	isolation	O
22	of	O
23	the	O
24	corresponding	O
25	human	O
26	gene	O
27	and	O
28	the	O
29	understanding	O
30	of	O
31	the	O
32	molecular	O
33	mechanisms	O
34	involved	O
35	in	O
36	the	O
37	up	O
38	-	O
39	regulation	O
40	of	O
41	its	O
42	expression	O
43	during	O
44	tumor	O
45	invasion	O
46	and	O
47	metastasis	O
48	.	O
1	Here	O
2	we	O
3	report	O
4	that	O
5	expression	O
6	of	O
7	the	O
8	I	B
9	-	I
10	POU	I
11	/	O
12	tI	B
13	-	I
14	POU	I
15	message	O
16	is	O
17	maximal	O
18	late	O
19	in	O
20	the	O
21	embryonic	O
22	phase	O
23	of	O
24	Drosophila	O
25	development	O
26	,	O
27	and	O
28	I	B
29	-	I
30	POU	I
31	is	O
32	the	O
33	preferred	O
34	splice	O
35	variant	O
36	.	O
1	The	O
2	patient	O
3	'	O
4	s	O
5	role	O
6	,	O
7	organized	O
8	by	O
9	the	O
10	prerequisites	O
11	of	O
12	expressive	O
13	freedom	O
14	,	O
15	is	O
16	counter	O
17	posed	O
18	with	O
19	the	O
20	psychoanalyst	O
21	'	O
22	s	O
23	,	O
24	which	O
25	is	O
26	structured	O
27	to	O
28	empower	O
29	listening	O
30	and	O
31	understanding	O
32	.	O
1	In	O
2	contrast	O
3	with	O
4	previous	O
5	two	O
6	-	O
7	pool	O
8	models	O
9	,	O
10	provisions	O
11	were	O
12	made	O
13	for	O
14	folate	O
15	turnover	O
16	by	O
17	urinary	O
18	folate	O
19	excretion	O
20	(	O
21	as	O
22	measured	O
23	here	O
24	)	O
25	and	O
26	by	O
27	fecal	O
28	excretion	O
29	and	O
30	catabolic	O
31	processes	O
32	.	O
1	The	O
2	syndrome	O
3	of	O
4	resistance	O
5	to	O
6	thyroid	O
7	hormone	O
8	is	O
9	characterized	O
10	by	O
11	elevated	O
12	serum	O
13	free	O
14	thyroid	O
15	hormones	O
16	,	O
17	failure	O
18	to	O
19	suppress	O
20	pituitary	B
21	thyrotropin	I
22	secretion	O
23	,	O
24	and	O
25	variable	O
26	peripheral	O
27	refractoriness	O
28	to	O
29	hormone	O
30	action	O
31	.	O
1	Expression	O
2	of	O
3	neuronal	O
4	traits	O
5	in	O
6	pancreatic	O
7	beta	O
8	cells	O
9	.	O
1	In	O
2	vitro	O
3	translation	O
4	of	O
5	the	O
6	mTRF1	B
7	cDNA	I
8	resulted	O
9	in	O
10	a	O
11	56	O
12	kDa	O
13	protein	O
14	that	O
15	binds	O
16	to	O
17	TTAGGG	O
18	repeat	O
19	arrays	O
20	.	O
21	mTRF1	B
22	displayed	O
23	the	O
24	same	O
25	sequence	O
26	specificity	O
27	as	O
28	hTRF1	B
29	,	O
30	preferring	O
31	arrays	O
32	of	O
33	TTAGGG	O
34	repeats	O
35	as	O
36	a	O
37	binding	O
38	substrate	O
39	over	O
40	TTAGGC	O
41	and	O
42	TTGGGG	O
43	repeats	O
44	.	O
1	This	O
2	report	O
3	presents	O
4	the	O
5	isolation	O
6	and	O
7	characterization	O
8	of	O
9	the	O
10	5	O
11	'-	O
12	flanking	O
13	region	O
14	(	O
15	1	O
16	.	O
17	2	O
18	kb	O
19	)	O
20	and	O
21	exon	O
22	1	O
23	of	O
24	the	O
25	human	B
26	RII	I
27	alpha	I
28	gene	I
29	.	O
1	The	O
2	results	O
3	demonstrate	O
4	(	O
5	i	O
6	)	O
7	that	O
8	the	O
9	selenocysteine	O
10	-	O
11	specific	O
12	UGA	O
13	codon	O
14	is	O
15	readily	O
16	suppressed	O
17	under	O
18	conditions	O
19	where	O
20	the	O
21	homologous	B
22	SelB	I
23	protein	I
24	is	O
25	absent	O
26	and	O
27	(	O
28	ii	O
29	)	O
30	that	O
31	apart	O
32	from	O
33	the	O
34	specificity	O
35	of	O
36	the	O
37	SelB	B
38	-	I
39	mRNA	I
40	interaction	O
41	,	O
42	a	O
43	structural	O
44	compatibility	O
45	of	O
46	the	O
47	quaternary	O
48	complex	O
49	with	O
50	the	O
51	ribosome	O
52	is	O
53	required	O
54	.	O
1	One	O
2	linker	O
3	-	O
4	peptide	O
5	insertion	O
6	in	O
7	the	O
8	RsaA	B
9	C	I
10	terminus	I
11	(	I
12	amino	I
13	acid	I
14	784	I
15	)	I
16	had	O
17	no	O
18	effect	O
19	on	O
20	S	O
21	-	O
22	layer	O
23	biogenesis	O
24	,	O
25	while	O
26	another	O
27	(	O
28	amino	O
29	acid	O
30	907	O
31	)	O
32	disrupted	O
33	secretion	O
34	of	O
35	the	O
36	protein	O
37	,	O
38	suggesting	O
39	that	O
40	RsaA	B
41	possesses	O
42	a	O
43	secretion	O
44	signal	O
45	lying	O
46	C	O
47	terminal	O
48	to	O
49	amino	O
50	acid	O
51	784	O
52	,	O
53	near	O
54	or	O
55	including	O
56	amino	O
57	acid	O
58	907	O
59	.	O
1	We	O
2	have	O
3	isolated	O
4	a	O
5	cDNA	O
6	encoding	O
7	human	B
8	MEKK3	I
9	.	O
1	To	O
2	investigate	O
3	the	O
4	mechanisms	O
5	involved	O
6	in	O
7	the	O
8	transcriptional	O
9	control	O
10	of	O
11	retinoid	B
12	X	I
13	receptor	I
14	(	O
15	RXR	B
16	)	O
17	gene	O
18	expression	O
19	,	O
20	the	O
21	5	O
22	'-	O
23	flanking	O
24	region	O
25	of	O
26	the	O
27	human	B
28	RXRgamma2	I
29	isoform	I
30	was	O
31	characterized	O
32	.	O
1	CDNA	O
2	cloning	O
3	of	O
4	chick	B
5	brain	I
6	alpha	I
7	-	I
8	amino	I
9	-	I
10	3	I
11	-	I
12	hydroxy	I
13	-	I
14	5	I
15	-	I
16	methyl	I
17	-	I
18	4	I
19	-	I
20	isoxazolepropionic	I
21	acid	I
22	receptors	I
23	reveals	O
24	conservation	O
25	of	O
26	structure	O
27	,	O
28	function	O
29	and	O
30	post	O
31	-	O
32	transcriptional	O
33	processes	O
34	with	O
35	mammalian	O
36	receptors	O
37	.	O
1	Structural	O
2	analysis	O
3	and	O
4	characterization	O
5	of	O
6	tissue	O
7	and	O
8	hormonal	O
9	responsive	O
10	expression	O
11	of	O
12	the	O
13	avian	B
14	bone	I
15	sialoprotein	I
16	(	O
17	BSP	B
18	)	O
19	gene	O
20	.	O
1	Moreover	O
2	,	O
3	the	O
4	effect	O
5	exerted	O
6	by	O
7	TIS1	B
8	appeared	O
9	to	O
10	be	O
11	selective	O
12	for	O
13	the	O
14	MCK	B
15	promoter	I
16	.	O
1	OBJECTIVE	O
2	:	O
3	Our	O
4	goal	O
5	was	O
6	to	O
7	determine	O
8	whether	O
9	chlamydia	O
10	-	O
11	infected	O
12	women	O
13	have	O
14	a	O
15	higher	O
16	rate	O
17	of	O
18	febrile	O
19	complications	O
20	after	O
21	postpartum	O
22	tubal	O
23	ligation	O
24	.	O
1	cDNA	O
2	cloning	O
3	,	O
4	expression	O
5	analysis	O
6	,	O
7	and	O
8	chromosomal	O
9	localization	O
10	of	O
11	a	O
12	gene	O
13	with	O
14	high	O
15	homology	O
16	to	O
17	wheat	B
18	eIF	I
19	-(	I
20	iso	I
21	)	I
22	4F	I
23	and	O
24	mammalian	B
25	eIF	I
26	-	I
27	4G	I
28	.	O
1	The	O
2	14	B
3	.	I
4	1	I
5	(	I
6	IGLL1	I
7	)	I
8	gene	I
9	is	O
10	expressed	O
11	in	O
12	a	O
13	lineage	O
14	-	O
15	and	O
16	stage	O
17	-	O
18	restricted	O
19	manner	O
20	.	O
1	Most	O
2	kinases	O
3	are	O
4	not	O
5	significantly	O
6	inhibited	O
7	by	O
8	roscovitine	O
9	.	O
10	cdc2	B
11	/	O
12	cyclin	B
13	B	I
14	,	O
15	cdk2	B
16	/	O
17	cyclin	B
18	A	I
19	,	O
20	cdk2	B
21	/	O
22	cyclin	B
23	E	I
24	and	O
25	cdk5	B
26	/	O
27	p35	B
28	only	O
29	are	O
30	substantially	O
31	inhibited	O
32	(	O
33	IC50	O
34	values	O
35	of	O
36	0	O
37	.	O
38	65	O
39	,	O
40	0	O
41	.	O
42	7	O
43	,	O
44	0	O
45	.	O
46	7	O
47	and	O
48	0	O
49	.	O
50	2	O
51	microM	O
52	,	O
53	respectively	O
54	).	O
55	cdk4	B
56	/	O
57	cyclin	B
58	D1	I
59	and	O
60	cdk6	B
61	/	O
62	cyclin	B
63	D2	I
64	are	O
65	very	O
66	poorly	O
67	inhibited	O
68	by	O
69	roscovitine	O
70	(	O
71	IC50	O
72	>	O
73	100	O
74	microM	O
75	).	O
1	Interaction	O
2	of	O
3	Ets	B
4	-	I
5	1	I
6	and	O
7	the	O
8	POU	B
9	-	I
10	homeodomain	I
11	protein	I
12	GHF	I
13	-	I
14	1	I
15	/	O
16	Pit	B
17	-	I
18	1	I
19	reconstitutes	O
20	pituitary	O
21	-	O
22	specific	O
23	gene	O
24	expression	O
25	.	O
1	Overexpression	O
2	of	O
3	the	O
4	bZip	O
5	interaction	O
6	domain	O
7	of	O
8	CBP	B
9	specifically	O
10	abolishes	O
11	the	O
12	positive	O
13	cross	O
14	talk	O
15	between	O
16	TR	B
17	and	O
18	p45	B
19	/	O
20	NF	B
21	-	I
22	E2	I
23	.	O
1	We	O
2	report	O
3	herein	O
4	the	O
5	case	O
6	of	O
7	a	O
8	30	O
9	-	O
10	year	O
11	-	O
12	old	O
13	man	O
14	in	O
15	whom	O
16	ectopic	O
17	mediastinal	O
18	parathyroid	O
19	adenoma	O
20	was	O
21	detected	O
22	by	O
23	99mTc	O
24	-	O
25	methoxyisobutylisonitrile	O
26	scintigraphy	O
27	(	O
28	99mTc	O
29	-	O
30	MIBI	O
31	).	O
1	A	O
2	MEK	B
3	-	O
4	specific	O
5	inhibitor	O
6	(	O
7	PD098059	O
8	)	O
9	(	O
10	Dudley	O
11	,	O
12	D	O
13	.	O
1	The	O
2	FBF	O
3	questionnaire	O
4	did	O
5	not	O
6	highlight	O
7	a	O
8	characteristic	O
9	basic	O
10	symptoms	O
11	profile	O
12	of	O
13	schizoaffective	O
14	disorder	O
15	,	O
16	when	O
17	compared	O
18	with	O
19	bipolar	O
20	affective	O
21	disorder	O
22	and	O
23	schizophrenia	O
24	.	O
1	Marinol	O
2	/	O
3	marijuana	O
4	usage	O
5	was	O
6	associated	O
7	with	O
8	depressed	O
9	CD4	B
10	+	I
11	counts	O
12	and	O
13	elevated	O
14	amylase	B
15	levels	O
16	within	O
17	the	O
18	DDI	O
19	subgroup	O
20	.	O
1	Unlike	O
2	class	O
3	II	O
4	-	O
5	and	O
6	III	O
7	-	O
8	specific	O
9	TBP	B
10	-	O
11	TAF	B
12	complexes	O
13	,	O
14	the	O
15	corresponding	O
16	murine	O
17	and	O
18	human	O
19	class	O
20	I	O
21	-	O
22	specific	O
23	transcription	O
24	initiation	O
25	factor	O
26	TIF	B
27	-	I
28	IB	I
29	/	O
30	SL1	B
31	exhibits	O
32	a	O
33	pronounced	O
34	selectivity	O
35	for	O
36	its	O
37	homologous	O
38	promoter	O
39	.	O
1	These	O
2	elements	O
3	comprise	O
4	a	O
5	binding	O
6	site	O
7	for	O
8	Krox	B
9	proteins	I
10	,	O
11	one	O
12	for	O
13	nuclear	B
14	factor	I
15	1	I
16	,	O
17	an	O
18	octamer	O
19	motif	O
20	that	O
21	binds	O
22	POU	B
23	-	I
24	homeodomain	I
25	proteins	I
26	,	O
27	and	O
28	a	O
29	novel	O
30	TN	B
31	control	I
32	element	I
33	.	O
1	Therefore	O
2	,	O
3	the	O
4	impaired	O
5	floor	O
6	plate	O
7	development	O
8	in	O
9	oep	B
10	mutants	I
11	is	O
12	not	O
13	caused	O
14	by	O
15	the	O
16	absence	O
17	of	O
18	the	O
19	floor	B
20	plate	I
21	inducer	I
22	shh	I
23	.	O
1	The	O
2	intensity	O
3	of	O
4	the	O
5	SSTEs	O
6	is	O
7	an	O
8	order	O
9	of	O
10	magnitude	O
11	larger	O
12	than	O
13	that	O
14	of	O
15	the	O
16	MSEs	O
17	and	O
18	determines	O
19	the	O
20	signal	O
21	contrast	O
22	if	O
23	both	O
24	effects	O
25	are	O
26	selected	O
27	simultaneously	O
28	.	O
1	To	O
2	avoid	O
3	complications	O
4	,	O
5	accurate	O
6	quantitative	O
7	analysis	O
8	of	O
9	NO	O
10	and	O
11	NO2	O
12	is	O
13	necessary	O
14	during	O
15	this	O
16	therapy	O
17	.	O
1	Conversely	O
2	,	O
3	activated	O
4	glucocorticoid	B
5	receptors	I
6	suppressed	O
7	the	O
8	transactivation	O
9	function	O
10	of	O
11	p53	B
12	,	O
13	while	O
14	transrepression	O
15	by	O
16	p53	B
17	was	O
18	largely	O
19	unaffected	O
20	.	O
1	This	O
2	brief	O
3	review	O
4	analyses	O
5	these	O
6	interactions	O
7	and	O
8	defines	O
9	clinical	O
10	settings	O
11	where	O
12	antibiotic	O
13	-	O
14	induced	O
15	endotoxin	O
16	release	O
17	may	O
18	prove	O
19	to	O
20	be	O
21	clinically	O
22	relevant	O
23	.	O
1	Relief	O
2	from	O
3	autoinhibition	O
4	and	O
5	a	O
6	subsequent	O
7	10	O
8	-	O
9	60	O
10	-	O
11	fold	O
12	increase	O
13	in	O
14	V	O
15	(	O
16	max	O
17	)	O
18	have	O
19	been	O
20	observed	O
21	upon	O
22	N	B
23	-	I
24	SH2	I
25	domain	I
26	engagement	O
27	by	O
28	a	O
29	specific	O
30	phosphotyrosyl	O
31	ligand	O
32	or	O
33	upon	O
34	deletion	O
35	of	O
36	the	O
37	SH2	B
38	domains	I
39	to	O
40	yield	O
41	the	O
42	catalytic	O
43	PTPase	B
44	domain	I
45	.	O
1	The	O
2	addition	O
3	of	O
4	zidovudine	O
5	did	O
6	not	O
7	influence	O
8	this	O
9	transfer	O
10	.	O
1	DNA	O
2	strand	O
3	exchange	O
4	catalyzed	O
5	by	O
6	Rad51	B
7	protein	I
8	is	O
9	also	O
10	greatly	O
11	stimulated	O
12	by	O
13	RPA	B
14	.	O
1	The	O
2	second	O
3	class	O
4	of	O
5	cDNA	O
6	hybridized	O
7	to	O
8	a	O
9	13	O
10	kb	O
11	transcript	O
12	,	O
13	which	O
14	was	O
15	approximately	O
16	twice	O
17	as	O
18	large	O
19	as	O
20	the	O
21	mammalian	B
22	lactase	I
23	mRNA	I
24	.	O
1	In	O
2	cell	O
3	lines	O
4	transformed	O
5	by	O
6	BCR	B
7	/	O
8	ABL	B
9	,	O
10	CRKL	B
11	was	O
12	tyrosine	O
13	phosphorylated	O
14	,	O
15	while	O
16	CRK	B
17	was	O
18	not	O
19	.	O
1	During	O
2	the	O
3	febrile	O
4	period	O
5	,	O
6	pleocytosis	O
7	was	O
8	associated	O
9	with	O
10	high	O
11	levels	O
12	of	O
13	IgG	B
14	,	O
15	IL	B
16	-	I
17	6	I
18	,	O
19	TNF	B
20	-	I
21	alpha	I
22	,	O
23	and	O
24	PGE2	O
25	in	O
26	the	O
27	cerebrospinal	O
28	fluid	O
29	.	O
1	The	O
2	reduced	O
3	NO	O
4	production	O
5	in	O
6	these	O
7	cells	O
8	was	O
9	associated	O
10	with	O
11	low	O
12	levels	O
13	of	O
14	mRNA	O
15	of	O
16	inducible	B
17	NO	I
18	synthetase	I
19	.	O
1	Therefore	O
2	more	O
3	active	O
4	and	O
5	tolerable	O
6	salvage	O
7	regimens	O
8	are	O
9	needed	O
10	.	O
1	Recombinant	O
2	plasmids	O
3	containing	O
4	the	O
5	entire	O
6	322	O
7	nt	O
8	5	O
9	'	O
10	UTR	O
11	of	O
12	exon	O
13	1	O
14	and	O
15	a	O
16	1630	O
17	nt	O
18	segment	O
19	of	O
20	5	O
21	'	O
22	flanking	O
23	sequence	O
24	stimulated	O
25	luciferase	B
26	activity	O
27	nearly	O
28	70	O
29	times	O
30	higher	O
31	than	O
32	a	O
33	promoterless	O
34	control	O
35	plasmid	O
36	.	O
1	Although	O
2	methods	O
3	to	O
4	align	O
5	the	O
6	control	O
7	and	O
8	activation	O
9	fMR	O
10	images	O
11	may	O
12	correct	O
13	for	O
14	some	O
15	of	O
16	this	O
17	motional	O
18	error	O
19	,	O
20	they	O
21	will	O
22	be	O
23	incomplete	O
24	in	O
25	correcting	O
26	for	O
27	those	O
28	that	O
29	depend	O
30	on	O
31	spatial	O
32	orientation	O
33	.	O
1	Autorosette	O
2	-	O
3	forming	O
4	cells	O
5	are	O
6	characterized	O
7	by	O
8	a	O
9	high	O
10	activity	O
11	of	O
12	alkaline	B
13	and	I
14	acid	I
15	phosphatases	I
16	and	O
17	low	O
18	NBT	O
19	-	O
20	test	O
21	values	O
22	.	O
1	Based	O
2	on	O
3	the	O
4	sequence	O
5	of	O
6	the	O
7	conRTRE	B
8	,	O
9	we	O
10	located	O
11	a	O
12	putative	O
13	RTRE	B
14	,	O
15	referred	O
16	to	O
17	as	O
18	P2	B
19	-	I
20	RE	I
21	,	O
22	in	O
23	the	O
24	5	O
25	'	O
26	promoter	O
27	-	O
28	flanking	O
29	region	O
30	of	O
31	the	O
32	mouse	B
33	protamine	I
34	2	I
35	gene	I
36	,	O
37	which	O
38	is	O
39	induced	O
40	during	O
41	the	O
42	same	O
43	stage	O
44	of	O
45	spermatogenesis	O
46	as	O
47	RTR	B
48	.	O
1	Thirty	O
2	Class	O
3	I	O
4	and	O
5	Class	O
6	II	O
7	recessions	O
8	in	O
9	30	O
10	patients	O
11	were	O
12	treated	O
13	with	O
14	a	O
15	modified	O
16	subepithelial	O
17	connective	O
18	tissue	O
19	graft	O
20	procedure	O
21	.	O
1	The	O
2	new	O
3	FIGO	O
4	definition	O
5	of	O
6	cervical	O
7	cancer	O
8	stage	O
9	IA	O
10	:	O
11	a	O
12	critique	O
13	.	O
1	The	O
2	effect	O
3	of	O
4	Vpu	B
5	on	O
6	class	O
7	I	O
8	biogenesis	O
9	was	O
10	analyzed	O
11	in	O
12	more	O
13	detail	O
14	using	O
15	a	O
16	Vpu	B
17	-	O
18	expressing	O
19	recombinant	O
20	vaccinia	O
21	virus	O
22	(	O
23	VV	O
24	).	O
1	An	O
2	egg	O
3	protein	O
4	,	O
5	lysozyme	B
6	,	O
7	is	O
8	a	O
9	still	O
10	unlabeled	O
11	additive	O
12	currently	O
13	used	O
14	in	O
15	cheese	O
16	preparation	O
17	.	O
1	A	O
2	method	O
3	for	O
4	the	O
5	simultaneous	O
6	determination	O
7	of	O
8	de	O
9	(	O
10	N	O
11	-	O
12	methyl	O
13	)-	O
14	N	O
15	-	O
16	ethyl	O
17	-	O
18	8	O
19	,	O
20	9	O
21	-	O
22	anhydroerythromycin	O
23	A	O
24	6	O
25	,	O
26	9	O
27	-	O
28	hemiacetal	O
29	(	O
30	EM523	O
31	,	O
32	I	O
33	)	O
34	and	O
35	its	O
36	three	O
37	metabolites	O
38	in	O
39	human	O
40	plasma	O
41	and	O
42	urine	O
43	has	O
44	been	O
45	developed	O
46	using	O
47	high	O
48	-	O
49	performance	O
50	liquid	O
51	chromatography	O
52	(	O
53	HPLC	O
54	)	O
55	with	O
56	chemiluminescence	O
57	(	O
58	CL	O
59	)	O
60	detection	O
61	.	O
1	Similarly	O
2	,	O
3	the	O
4	DNA	O
5	-	O
6	binding	O
7	activity	O
8	of	O
9	activator	B
10	protein	I
11	1	I
12	(	O
13	AP	B
14	-	I
15	1	I
16	)	O
17	is	O
18	modified	O
19	by	O
20	a	O
21	DNA	B
22	repair	I
23	enzyme	I
24	,	O
25	redox	B
26	factor	I
27	1	I
28	(	O
29	Ref	B
30	-	I
31	1	I
32	),	O
33	which	O
34	is	O
35	identical	O
36	to	O
37	a	O
38	DNA	B
39	repair	I
40	enzyme	I
41	,	O
42	AP	B
43	endonuclease	I
44	.	O
1	Two	O
2	predominant	O
3	effects	O
4	were	O
5	noted	O
6	:	O
7	(	O
8	i	O
9	)	O
10	the	O
11	Xaa	O
12	residue	O
13	in	O
14	the	O
15	dual	O
16	phosphorylation	O
17	motif	O
18	Thr	O
19	-	O
20	Xaa	O
21	-	O
22	Tyr	O
23	as	O
24	well	O
25	as	O
26	the	O
27	length	O
28	of	O
29	L12	O
30	influence	O
31	p38	B
32	substrate	O
33	specificity	O
34	,	O
35	and	O
36	(	O
37	ii	O
38	)	O
39	the	O
40	length	O
41	of	O
42	L12	O
43	plays	O
44	a	O
45	major	O
46	role	O
47	in	O
48	controlling	O
49	autophosphorylation	O
50	.	O
1	Unlike	O
2	the	O
3	MAR	O
4	-	O
5	binding	O
6	domain	O
7	,	O
8	the	O
9	homeodomain	B
10	when	O
11	isolated	O
12	binds	O
13	poorly	O
14	and	O
15	with	O
16	low	O
17	specificity	O
18	to	O
19	DNA	O
20	.	O
1	To	O
2	identify	O
3	cis	O
4	-	O
5	acting	O
6	elements	O
7	that	O
8	target	O
9	c	B
10	-	I
11	myc	I
12	mRNA	I
13	for	O
14	downregulation	O
15	during	O
16	myogenesis	O
17	,	O
18	we	O
19	stably	O
20	transfected	O
21	C2C12	O
22	cells	O
23	with	O
24	mutant	B
25	myc	I
26	genes	I
27	or	O
28	chimeric	O
29	genes	O
30	in	O
31	which	O
32	various	O
33	myc	B
34	sequences	I
35	were	O
36	fused	O
37	to	O
38	the	O
39	human	B
40	beta	I
41	-	I
42	globin	I
43	gene	I
44	or	O
45	to	O
46	the	O
47	bacterial	B
48	chloramphenicol	I
49	acetyltransferase	I
50	(	O
51	CAT	B
52	)	O
53	gene	O
54	.	O
1	The	O
2	likelihood	O
3	that	O
4	a	O
5	common	O
6	region	O
7	of	O
8	deletions	O
9	would	O
10	contain	O
11	a	O
12	tumor	O
13	suppressor	O
14	is	O
15	strongly	O
16	enhanced	O
17	by	O
18	coincidence	O
19	of	O
20	that	O
21	region	O
22	with	O
23	a	O
24	chromosome	O
25	fragment	O
26	suppressing	O
27	tumorigenicity	O
28	upon	O
29	introduction	O
30	in	O
31	tumor	O
32	cells	O
33	.	O
1	However	O
2	,	O
3	in	O
4	some	O
5	of	O
6	them	O
7	either	O
8	pattern	O
9	may	O
10	predominate	O
11	or	O
12	be	O
13	exclusively	O
14	present	O
15	.	O
1	In	O
2	particular	O
3	,	O
4	Western	O
5	,	O
6	supershift	O
7	,	O
8	and	O
9	promoter	O
10	deletion	O
11	analyses	O
12	suggested	O
13	a	O
14	role	O
15	for	O
16	CCAAT	B
17	/	I
18	enhancer	I
19	-	I
20	binding	I
21	protein	I
22	-	I
23	beta	I
24	(	O
25	C	B
26	/	I
27	EBP	I
28	-	I
29	beta	I
30	)	O
31	binding	O
32	site	O
33	between	O
34	-	O
35	2010	O
36	and	O
37	-	O
38	1954	O
39	in	O
40	regulating	O
41	transcription	O
42	of	O
43	collagenase	B
44	-	I
45	1	I
46	in	O
47	monocytic	O
48	cells	O
49	.	O
1	L	O
2	-	O
3	canavanine	O
4	,	O
5	a	O
6	selective	O
7	inhibitor	O
8	of	O
9	the	O
10	inducible	O
11	nitric	B
12	oxide	I
13	synthase	I
14	,	O
15	increases	O
16	the	O
17	mean	O
18	systemic	O
19	filling	O
20	pressure	O
21	,	O
22	thereby	O
23	improving	O
24	venous	O
25	return	O
26	,	O
27	under	O
28	these	O
29	conditions	O
30	.	O
1	These	O
2	data	O
3	are	O
4	consistent	O
5	with	O
6	a	O
7	model	O
8	in	O
9	which	O
10	GATA	B
11	-	I
12	5	I
13	performs	O
14	a	O
15	unique	O
16	temporally	O
17	and	O
18	spatially	O
19	restricted	O
20	function	O
21	in	O
22	the	O
23	embryonic	O
24	heart	O
25	and	O
26	lung	O
27	.	O
1	Here	O
2	we	O
3	characterize	O
4	an	O
5	S	B
6	.	I
7	cerevisiae	I
8	Swi3	I
9	homolog	I
10	(	O
11	Swh3	B
12	)	O
13	and	O
14	present	O
15	evidence	O
16	that	O
17	it	O
18	associates	O
19	in	O
20	a	O
21	complex	O
22	with	O
23	a	O
24	Snf2	B
25	homolog	I
26	,	O
27	Sthl	B
28	.	O
1	The	O
2	Ras	B
3	guanine	I
4	nucleotide	I
5	-	I
6	binding	I
7	protein	I
8	functions	O
9	as	O
10	a	O
11	molecular	O
12	switch	O
13	in	O
14	signalling	O
15	downstream	O
16	of	O
17	protein	B
18	-	I
19	tyrosine	I
20	kinases	I
21	.	O
1	We	O
2	show	O
3	that	O
4	Rlm1	B
5	and	O
6	Smp1	B
7	have	O
8	MEF2	B
9	-	O
10	related	O
11	DNA	O
12	-	O
13	binding	O
14	specificities	O
15	:	O
16	Rlm1	B
17	binds	O
18	with	O
19	the	O
20	same	O
21	specificity	O
22	as	O
23	MEF2	B
24	,	O
25	CTA	B
26	(	I
27	T	I
28	/	I
29	A	I
30	)	I
31	4TAG	I
32	,	O
33	while	O
34	SMP1	B
35	binds	O
36	a	O
37	more	O
38	extended	O
39	consensus	O
40	sequence	O
41	,	O
42	ACTACTA	O
43	(	O
44	T	O
45	/	O
46	A	O
47	)	O
48	4TAG	O
49	.	O
1	The	O
2	similar	O
3	phenotypes	O
4	of	O
5	bur6	B
6	and	O
7	bur3	B
8	(	O
9	mot1	B
10	)	O
11	mutations	O
12	suggest	O
13	that	O
14	Bur6p	B
15	and	O
16	Mot1p	B
17	have	O
18	related	O
19	,	O
20	but	O
21	not	O
22	identical	O
23	,	O
24	functions	O
25	in	O
26	modulating	O
27	the	O
28	activity	O
29	of	O
30	the	O
31	general	O
32	transcription	O
33	machinery	O
34	in	O
35	vivo	O
36	.	O
1	We	O
2	describe	O
3	a	O
4	novel	O
5	method	O
6	using	O
7	Saccharomyces	O
8	cerevisiae	O
9	for	O
10	detecting	O
11	protein	O
12	-	O
13	truncating	O
14	mutations	O
15	in	O
16	any	O
17	gene	O
18	of	O
19	interest	O
20	.	O
1	(	O
2	1994	O
3	,	O
4	Hum	O
5	.	O
1	Implication	O
2	of	O
3	PAF	B
4	and	O
5	acetylhydrolase	B
6	(	O
7	PAF	B
8	-	I
9	AH	I
10	)	O
11	activity	O
12	in	O
13	periodontal	O
14	disease	O
15	.	O
1	Additional	O
2	information	O
3	including	O
4	echocardiographic	O
5	sequences	O
6	,	O
7	perioperative	O
8	video	O
9	sequences	O
10	,	O
11	x	O
12	-	O
13	ray	O
14	analysis	O
15	,	O
16	angiograms	O
17	,	O
18	etc	O
19	.	O
20	is	O
21	represented	O
22	in	O
23	the	O
24	program	O
25	.	O
1	We	O
2	report	O
3	here	O
4	that	O
5	constitutively	O
6	active	O
7	Mek1	B
8	could	O
9	activate	O
10	p96h2bk	B
11	in	O
12	the	O
13	absence	O
14	of	O
15	oncogenic	B
16	Ras	I
17	.	O
1	(	O
2	3	O
3	)	O
4	This	O
5	effect	O
6	occurs	O
7	without	O
8	removing	O
9	TRs	B
10	from	O
11	the	O
12	TRE	O
13	.	O
1	This	O
2	conformer	O
3	features	O
4	a	O
5	Type	O
6	I	O
7	beta	O
8	-	O
9	turn	O
10	and	O
11	has	O
12	extensive	O
13	hydrophobic	O
14	contacts	O
15	with	O
16	the	O
17	FKBP12	B
18	binding	O
19	surface	O
20	.	O
1	Children	O
2	'	O
3	s	O
4	temperament	O
5	and	O
6	maternal	O
7	socialization	O
8	at	O
9	Time	O
10	1	O
11	(	O
12	n	O
13	=	O
14	103	O
15	,	O
16	aged	O
17	2	O
18	-	O
19	3	O
20	years	O
21	)	O
22	were	O
23	considered	O
24	predictors	O
25	of	O
26	future	O
27	conscience	O
28	,	O
29	assessed	O
30	using	O
31	new	O
32	observational	O
33	and	O
34	narrative	O
35	measures	O
36	.	O
1	FN	B
2	-	O
3	stimulated	O
4	c	B
5	-	I
6	Src	I
7	PTK	I
8	activity	O
9	was	O
10	enhanced	O
11	by	O
12	wild	O
13	type	O
14	FAK	B
15	expression	O
16	,	O
17	whereas	O
18	FN	B
19	-	O
20	stimulated	O
21	activation	O
22	of	O
23	ERK2	B
24	was	O
25	blocked	O
26	by	O
27	expression	O
28	of	O
29	the	O
30	c	B
31	-	I
32	Src	I
33	binding	I
34	site	I
35	Phe	I
36	-	I
37	397	I
38	mutant	I
39	of	O
40	FAK	B
41	.	O
1	Each	O
2	sample	O
3	was	O
4	analysed	O
5	as	O
6	soon	O
7	as	O
8	possible	O
9	,	O
10	and	O
11	repeated	O
12	15	O
13	,	O
14	30	O
15	,	O
16	60	O
17	and	O
18	120	O
19	min	O
20	after	O
21	sampling	O
22	.	O
1	The	O
2	altered	O
3	amino	O
4	acid	O
5	residues	O
6	of	O
7	the	O
8	seven	O
9	mutant	B
10	9ORF1	I
11	polypeptides	I
12	clustered	O
13	within	O
14	three	O
15	separate	O
16	regions	O
17	referred	O
18	to	O
19	as	O
20	region	O
21	I	O
22	(	O
23	residues	O
24	34	O
25	to	O
26	41	O
27	),	O
28	region	O
29	II	O
30	(	O
31	residues	O
32	89	O
33	to	O
34	91	O
35	),	O
36	and	O
37	C	O
38	-	O
39	terminal	O
40	region	O
41	III	O
42	(	O
43	residues	O
44	122	O
45	to	O
46	125	O
47	).	O
1	Thus	O
2	,	O
3	an	O
4	increase	O
5	in	O
6	plasma	B
7	TBG	I
8	and	O
9	a	O
10	shift	O
11	from	O
12	adrenal	O
13	androgen	O
14	and	O
15	mineralocorticoid	O
16	steroid	O
17	secretion	O
18	towards	O
19	cortisol	O
20	secretion	O
21	may	O
22	be	O
23	endocrine	O
24	markers	O
25	for	O
26	progression	O
27	of	O
28	the	O
29	disease	O
30	in	O
31	patients	O
32	with	O
33	HIV	O
34	-	O
35	infection	O
36	.	O
1	An	O
2	alternatively	O
3	spliced	O
4	MAdCAM	B
5	-	I
6	1	I
7	variant	O
8	was	O
9	identified	O
10	that	O
11	lacks	O
12	exon	O
13	4	O
14	encoding	O
15	the	O
16	mucin	B
17	domain	O
18	,	O
19	and	O
20	may	O
21	mediate	O
22	leukocyte	O
23	adhesion	O
24	to	O
25	LPAM	B
26	-	I
27	1	I
28	without	O
29	adhesion	O
30	to	O
31	the	O
32	alternate	O
33	receptor	O
34	,	O
35	L	B
36	-	I
37	selectin	I
38	.	O
1	In	O
2	conclusion	O
3	,	O
4	marmoset	B
5	monkey	I
6	LHR	I
7	seems	O
8	to	O
9	lack	O
10	the	O
11	sequence	O
12	corresponding	O
13	to	O
14	exon	O
15	10	O
16	of	O
17	the	O
18	LHR	B
19	gene	I
20	in	O
21	other	O
22	mammalian	O
23	species	O
24	.	O
1	Sequence	O
2	comparison	O
3	of	O
4	the	O
5	0	O
6	.	O
7	38	O
8	kb	O
9	promoter	O
10	sequence	O
11	with	O
12	the	O
13	promoters	O
14	of	O
15	the	O
16	Sm	B
17	-	I
18	E	I
19	gene	O
20	and	O
21	U1	B
22	snRNA	I
23	genes	I
24	revealed	O
25	several	O
26	homologous	O
27	motifs	O
28	,	O
29	suggesting	O
30	that	O
31	genes	O
32	encoding	O
33	the	O
34	snRNP	O
35	components	O
36	may	O
37	be	O
38	coordinately	O
39	regulated	O
40	.	O
1	Mutation	O
2	of	O
3	nucleotides	O
4	adjacent	O
5	to	O
6	the	O
7	AP	B
8	-	I
9	1	I
10	cis	I
11	-	I
12	response	I
13	elements	I
14	had	O
15	no	O
16	effect	O
17	on	O
18	trans	O
19	-	O
20	activation	O
21	.	O
1	In	O
2	the	O
3	studies	O
4	reported	O
5	here	O
6	,	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	of	O
13	the	O
14	human	B
15	gp130	I
16	gene	I
17	was	O
18	isolated	O
19	and	O
20	the	O
21	transcription	O
22	initiation	O
23	sites	O
24	were	O
25	mapped	O
26	.	O
1	Instead	O
2	,	O
3	they	O
4	contained	O
5	dendritic	O
6	cells	O
7	that	O
8	express	O
9	melanogenic	O
10	marker	O
11	proteins	O
12	such	O
13	as	O
14	tyrosinase	B
15	and	O
16	tyrosinase	B
17	-	I
18	related	I
19	protein	I
20	1	I
21	.	O
1	Here	O
2	,	O
3	a	O
4	case	O
5	of	O
6	Sjogren	O
7	'	O
8	s	O
9	syndrome	O
10	is	O
11	presented	O
12	that	O
13	was	O
14	initially	O
15	diagnosed	O
16	because	O
17	of	O
18	dental	O
19	complaints	O
20	,	O
21	and	O
22	long	O
23	-	O
24	term	O
25	treatment	O
26	of	O
27	Sjogren	O
28	'	O
29	s	O
30	patients	O
31	is	O
32	discussed	O
33	.	O
1	Computer	O
2	software	O
3	assisted	O
4	ordering	O
5	(	O
6	CSAO	O
7	)	O
8	was	O
9	developed	O
10	to	O
11	integrate	O
12	PN	O
13	Ca	O
14	:	O
15	P	O
16	solubility	O
17	with	O
18	clinical	O
19	data	O
20	to	O
21	improve	O
22	parenteral	O
23	Ca	O
24	and	O
25	P	O
26	administration	O
27	.	O
1	Indeed	O
2	the	O
3	predicted	O
4	folding	O
5	of	O
6	the	O
7	5	O
8	'	O
9	and	O
10	3	O
11	'-	O
12	untranslated	O
13	regions	O
14	revealed	O
15	patterns	O
16	of	O
17	stem	O
18	and	O
19	loop	O
20	structures	O
21	conserved	O
22	for	O
23	all	O
24	tick	O
25	-	O
26	borne	O
27	flaviviruses	O
28	suggesting	O
29	a	O
30	purifying	O
31	selection	O
32	for	O
33	preservation	O
34	of	O
35	essential	O
36	RNA	O
37	secondary	O
38	structures	O
39	which	O
40	could	O
41	be	O
42	involved	O
43	in	O
44	translational	O
45	control	O
46	and	O
47	replication	O
48	.	O
1	Consistent	O
2	with	O
3	its	O
4	role	O
5	in	O
6	p53	B
7	ubiquitination	O
8	,	O
9	mE6	B
10	-	I
11	AP	I
12	was	O
13	found	O
14	both	O
15	in	O
16	the	O
17	nucleus	O
18	and	O
19	cytosol	O
20	,	O
21	while	O
22	Nedd	B
23	-	I
24	4	I
25	was	O
26	found	O
27	only	O
28	in	O
29	the	O
30	cytosol	O
31	.	O
1	Comparison	O
2	of	O
3	Tc	O
4	-	O
5	99m	O
6	sestamibi	O
7	perfusion	O
8	imaging	O
9	and	O
10	echocardiography	O
11	using	O
12	an	O
13	arbutamine	O
14	infusion	O
15	for	O
16	the	O
17	detection	O
18	of	O
19	coronary	O
20	artery	O
21	disease	O
22	.	O
1	Five	O
2	of	O
3	these	O
4	have	O
5	ocular	O
6	or	O
7	oculocutaneous	O
8	albinism	O
9	.	O
1	The	O
2	1	O
3	.	O
4	1	O
5	-	O
6	and	O
7	1	O
8	.	O
9	3	O
10	-	O
11	kb	O
12	mRNA	O
13	species	O
14	were	O
15	found	O
16	only	O
17	in	O
18	the	O
19	heart	O
20	,	O
21	and	O
22	the	O
23	2	O
24	.	O
25	6	O
26	-	O
27	kb	O
28	species	O
29	was	O
30	found	O
31	in	O
32	the	O
33	heart	O
34	,	O
35	kidney	O
36	and	O
37	brain	O
38	,	O
39	but	O
40	not	O
41	in	O
42	skeletal	O
43	muscle	O
44	or	O
45	liver	O
46	.	O
1	We	O
2	suggest	O
3	that	O
4	apart	O
5	from	O
6	the	O
7	World	O
8	Summit	O
9	for	O
10	Children	O
11	'	O
12	s	O
13	under	O
14	-	O
15	five	O
16	mortality	O
17	target	O
18	for	O
19	the	O
20	year	O
21	2000	O
22	,	O
23	intraregional	O
24	targets	O
25	to	O
26	reduce	O
27	geographical	O
28	inequalities	O
29	in	O
30	under	O
31	-	O
32	five	O
33	mortality	O
34	should	O
35	be	O
36	specified	O
37	.	O
1	Secretion	O
2	in	O
3	milk	O
4	and	O
5	transplacental	O
6	transfer	O
7	of	O
8	two	O
9	iodized	O
10	oils	O
11	,	O
12	Lipiodol	O
13	UF	O
14	and	O
15	Oriodol	O
16	,	O
17	in	O
18	rabbits	O
19	.	O
1	Strikingly	O
2	,	O
3	stoichiometric	O
4	association	O
5	of	O
6	p107	B
7	or	O
8	p130	B
9	with	O
10	either	O
11	cyclin	B
12	E	I
13	-	O
14	cdk2	B
15	or	O
16	cyclin	B
17	A	I
18	-	O
19	cdk2	B
20	negated	O
21	the	O
22	activities	O
23	of	O
24	these	O
25	kinases	O
26	.	O
1	Interdigitated	O
2	residues	O
3	within	O
4	a	O
5	small	O
6	region	O
7	of	O
8	VP16	B
9	interact	O
10	with	O
11	Oct	B
12	-	I
13	1	I
14	,	O
15	HCF	B
16	,	O
17	and	O
18	DNA	O
19	.	O
1	In	O
2	12	O
3	cases	O
4	(	O
5	3	O
6	.	O
7	1	O
8	%),	O
9	a	O
10	change	O
11	in	O
12	stage	O
13	resulted	O
14	.	O
1	Recombinant	B
2	soluble	I
3	pMCP	I
4	that	O
5	lacked	O
6	transmembrane	O
7	and	O
8	cytoplasmic	O
9	domains	O
10	had	O
11	factor	B
12	I	I
13	cofactor	I
14	activity	O
15	in	O
16	C3b	B
17	cleavage	O
18	,	O
19	indicating	O
20	that	O
21	it	O
22	is	O
23	functionally	O
24	,	O
25	as	O
26	well	O
27	as	O
28	structurally	O
29	homologous	O
30	to	O
31	MCP	B
32	.	O
1	The	O
2	RNA	O
3	-	O
4	binding	O
5	and	O
6	RNA	B
7	-	I
8	DNA	I
9	helicase	I
10	activities	O
11	of	O
12	the	O
13	Escherichia	B
14	coli	I
15	transcription	I
16	termination	I
17	factor	I
18	rho	I
19	have	O
20	been	O
21	investigated	O
22	using	O
23	natural	O
24	RNA	O
25	molecules	O
26	that	O
27	are	O
28	255	O
29	and	O
30	391	O
31	nucleotide	O
32	residues	O
33	in	O
34	length	O
35	and	O
36	that	O
37	contain	O
38	the	O
39	trp	B
40	t	I
41	'	I
42	rho	I
43	-	I
44	dependent	I
45	termination	I
46	sequence	I
47	of	O
48	E	O
49	.	O
50	coli	O
51	.	O
1	The	O
2	data	O
3	suggest	O
4	that	O
5	like	O
6	in	O
7	yeast	O
8	,	O
9	in	O
10	plants	O
11	a	O
12	certain	O
13	subfamily	O
14	of	O
15	UBC	B
16	is	O
17	specifically	O
18	involved	O
19	in	O
20	the	O
21	proteolytic	O
22	degradation	O
23	of	O
24	abnormal	O
25	proteins	O
26	as	O
27	result	O
28	of	O
29	stress	O
30	.	O
1	The	O
2	serum	O
3	levels	O
4	of	O
5	beta	B
6	-	I
7	human	I
8	chorionic	I
9	gonadotropin	I
10	(	O
11	HCG	B
12	)	O
13	and	O
14	placental	B
15	alkaline	I
16	phosphatase	I
17	(	O
18	PLAP	B
19	)	O
20	were	O
21	not	O
22	elevated	O
23	.	O
1	In	O
2	1990	O
3	,	O
4	an	O
5	International	O
6	Commission	O
7	for	O
8	the	O
9	Certification	O
10	of	O
11	Eradication	O
12	of	O
13	Poliomyelitis	O
14	Eradication	O
15	(	O
16	ICCPE	O
17	)	O
18	was	O
19	established	O
20	by	O
21	the	O
22	Pan	O
23	American	O
24	Health	O
25	Organization	O
26	to	O
27	eventually	O
28	determine	O
29	if	O
30	transmission	O
31	was	O
32	interrupted	O
33	.	O
1	Sternocleidomastoid	O
2	,	O
3	neck	O
4	or	O
5	facial	O
6	muscles	O
7	wasting	O
8	were	O
9	also	O
10	found	O
11	in	O
12	three	O
13	cases	O
14	.	O
1	One	O
2	RNA	O
3	construct	O
4	which	O
5	consisted	O
6	of	O
7	112	O
8	nucleotides	O
9	(	O
10	nt	O
11	)	O
12	from	O
13	nt	O
14	639	O
15	to	O
16	nt	O
17	750	O
18	formed	O
19	a	O
20	heterodimeric	O
21	complex	O
22	with	O
23	the	O
24	RNA	O
25	which	O
26	consisted	O
27	of	O
28	200	O
29	nucleotides	O
30	from	O
31	nt	O
32	551	O
33	to	O
34	nt	O
35	750	O
36	.	O
1	Aryl	B
2	hydrocarbon	I
3	receptor	I
4	nuclear	I
5	translocator	I
6	(	O
7	ARNT	B
8	)	O
9	is	O
10	a	O
11	component	O
12	of	O
13	the	O
14	transcription	O
15	factors	O
16	,	O
17	aryl	B
18	hydrocarbon	I
19	receptor	I
20	(	O
21	AhR	B
22	)	O
23	and	O
24	hypoxia	B
25	-	I
26	inducible	I
27	factor	I
28	1	I
29	,	O
30	which	O
31	transactivate	O
32	their	O
33	target	O
34	genes	O
35	,	O
36	such	O
37	as	O
38	CYP1A1	B
39	and	O
40	erythropoietin	B
41	,	O
42	in	O
43	response	O
44	to	O
45	xenobiotic	O
46	aromatic	O
47	hydrocarbons	O
48	and	O
49	to	O
50	low	O
51	O2	O
52	concentration	O
53	,	O
54	respectively	O
55	.	O
1	Pseudomonas	O
2	aeruginosa	O
3	strains	O
4	infecting	O
5	patients	O
6	with	O
7	cystic	O
8	fibrosis	O
9	(	O
10	CF	O
11	)	O
12	acquire	O
13	a	O
14	mucoid	O
15	phenotype	O
16	due	O
17	to	O
18	overproduction	O
19	of	O
20	alginate	O
21	.	O
1	The	O
2	CPK	B
3	-	I
4	MB	I
5	isoenzyme	O
6	showed	O
7	no	O
8	percentage	O
9	increase	O
10	of	O
11	total	O
12	CPK	B
13	higher	O
14	than	O
15	5	O
16	%,	O
17	measured	O
18	at	O
19	6	O
20	,	O
21	12	O
22	,	O
23	and	O
24	24	O
25	h	O
26	after	O
27	the	O
28	shock	O
29	,	O
30	independent	O
31	of	O
32	the	O
33	number	O
34	of	O
35	attempts	O
36	of	O
37	cardioversion	O
38	.	O
1	Transcription	O
2	factor	O
3	binding	O
4	sites	O
5	downstream	O
6	of	O
7	the	O
8	human	O
9	immunodeficiency	O
10	virus	O
11	type	O
12	1	O
13	transcription	O
14	start	O
15	site	O
16	are	O
17	important	O
18	for	O
19	virus	O
20	infectivity	O
21	.	O
1	The	O
2	frequency	O
3	of	O
4	positive	O
5	anti	B
6	-	I
7	GM1	I
8	antibody	I
9	titers	O
10	in	O
11	the	O
12	Guillain	O
13	-	O
14	Barre	O
15	syndrome	O
16	patients	O
17	with	O
18	PEN	O
19	19	O
20	isolates	O
21	was	O
22	higher	O
23	than	O
24	that	O
25	in	O
26	the	O
27	Guillain	O
28	-	O
29	Barre	O
30	syndrome	O
31	and	O
32	Fisher	O
33	'	O
34	s	O
35	syndrome	O
36	patients	O
37	without	O
38	PEN	O
39	19	O
40	isolates	O
41	.	O
1	NF	B
2	-	I
3	kappa	I
4	B	I
5	/	O
6	Rel	B
7	transcription	O
8	factors	O
9	participate	O
10	in	O
11	the	O
12	activation	O
13	of	O
14	numerous	O
15	genes	O
16	involved	O
17	in	O
18	immune	O
19	regulation	O
20	/	O
21	inflammation	O
22	including	O
23	cytokines	O
24	,	O
25	cell	O
26	surface	O
27	receptors	O
28	,	O
29	adhesion	O
30	molecules	O
31	,	O
32	and	O
33	acute	O
34	phase	O
35	proteins	O
36	.	O
1	In	O
2	summary	O
3	,	O
4	DDC	O
5	express	O
6	receptors	O
7	for	O
8	a	O
9	broad	O
10	panel	O
11	of	O
12	cytokines	O
13	,	O
14	even	O
15	receptors	O
16	for	O
17	cytokines	O
18	whose	O
19	effects	O
20	on	O
21	DC	O
22	are	O
23	still	O
24	unknown	O
25	(	O
26	i	O
27	.	O
28	e	O
29	.	O
1	Though	O
2	the	O
3	BACTEC	O
4	9000	O
5	MB	O
6	system	O
7	is	O
8	recommended	O
9	for	O
10	respiratory	O
11	specimens	O
12	,	O
13	we	O
14	demonstrated	O
15	that	O
16	it	O
17	can	O
18	be	O
19	successfully	O
20	used	O
21	also	O
22	for	O
23	recovery	O
24	of	O
25	mycobacteria	O
26	from	O
27	clinical	O
28	specimens	O
29	from	O
30	various	O
31	extrapulmonary	O
32	sites	O
33	.	O
1	Autoimmune	O
2	neutropenia	O
3	(	O
4	AIN	O
5	)	O
6	is	O
7	a	O
8	frequent	O
9	cause	O
10	of	O
11	chronic	O
12	neutropenia	O
13	especially	O
14	in	O
15	youngest	O
16	children	O
17	.	O
1	This	O
2	protein	O
3	,	O
4	designated	O
5	p532	B
6	based	O
7	on	O
8	its	O
9	predicted	O
10	molecular	O
11	weight	O
12	(	O
13	EMBO	O
14	J	O
15	15	O
16	:	O
17	5738	O
18	,	O
19	1996	O
20	),	O
21	contains	O
22	multiple	O
23	structural	O
24	domains	O
25	including	O
26	two	O
27	regions	O
28	of	O
29	seven	O
30	internal	O
31	repeats	O
32	highly	O
33	related	O
34	to	O
35	the	O
36	cell	O
37	cycle	O
38	regulator	O
39	RCC1	B
40	,	O
41	a	O
42	guanine	B
43	nucleotide	I
44	exchange	I
45	factor	I
46	for	O
47	the	O
48	small	B
49	GTP	I
50	-	I
51	binding	I
52	protein	I
53	Ran	I
54	,	O
55	seven	O
56	beta	O
57	-	O
58	repeat	O
59	domains	O
60	characteristic	O
61	of	O
62	the	O
63	beta	O
64	subunit	O
65	of	O
66	heterotrimeric	B
67	G	I
68	proteins	I
69	,	O
70	three	O
71	putative	O
72	SH3	B
73	binding	I
74	sites	I
75	,	O
76	a	O
77	putative	O
78	leucine	O
79	-	O
80	zipper	O
81	and	O
82	a	O
83	carboxy	B
84	-	I
85	terminal	I
86	HECT	I
87	domain	I
88	characteristic	O
89	of	O
90	E3	B
91	ubiquitin	I
92	-	I
93	protein	I
94	ligases	I
95	.	O
1	Thus	O
2	,	O
3	the	O
4	L45	O
5	sequence	O
6	between	O
7	kinase	O
8	subdomains	O
9	IV	O
10	and	O
11	V	O
12	specifies	O
13	TGF	B
14	-	I
15	beta	I
16	responsiveness	O
17	of	O
18	the	O
19	type	B
20	I	I
21	receptor	I
22	.	O
1	Prominent	O
2	protein	O
3	kinase	O
4	cascades	O
5	are	O
6	those	O
7	that	O
8	activate	O
9	mitogen	B
10	-	I
11	activated	I
12	protein	I
13	(	I
14	MAP	I
15	)	I
16	kinases	I
17	.	O
1	While	O
2	important	O
3	for	O
4	ligand	O
5	-	O
6	dependent	O
7	transactivation	O
8	,	O
9	this	O
10	interaction	O
11	surface	O
12	is	O
13	not	O
14	directly	O
15	involved	O
16	in	O
17	transrepression	O
18	of	O
19	AP	B
20	-	I
21	1	I
22	activity	O
23	.	O
1	Neither	O
2	of	O
3	these	O
4	proteins	O
5	,	O
6	individually	O
7	or	O
8	as	O
9	a	O
10	pair	O
11	,	O
12	can	O
13	bind	O
14	the	O
15	alpha	B
16	-	I
17	globin	I
18	3	I
19	'	I
20	UTR	I
21	unless	O
22	they	O
23	are	O
24	complexed	O
25	with	O
26	the	O
27	remaining	O
28	non	O
29	-	O
30	poly	O
31	(	O
32	C	O
33	)	O
34	binding	O
35	proteins	O
36	of	O
37	the	O
38	alpha	B
39	-	I
40	complex	I
41	.	O
1	A	O
2	2	O
3	years	O
4	and	O
5	9	O
6	months	O
7	old	O
8	female	O
9	patient	O
10	,	O
11	with	O
12	the	O
13	diagnosis	O
14	of	O
15	Weaver	O
16	syndrome	O
17	is	O
18	reported	O
19	.	O
1	Sustained	O
2	activation	O
3	of	O
4	p21	B
5	expression	O
6	is	O
7	proposed	O
8	to	O
9	be	O
10	a	O
11	distinguishing	O
12	feature	O
13	of	O
14	the	O
15	activity	O
16	of	O
17	NGF	B
18	that	O
19	contributes	O
20	to	O
21	PC12	O
22	growth	O
23	arrest	O
24	during	O
25	differentiation	O
1	It	O
2	is	O
3	present	O
4	in	O
5	the	O
6	nucleus	O
7	of	O
8	the	O
9	cells	O
10	in	O
11	which	O
12	it	O
13	is	O
14	expressed	O
15	and	O
16	can	O
17	phosphorylate	O
18	and	O
19	activate	O
20	the	O
21	cyclic	B
22	AMP	I
23	response	I
24	element	I
25	binding	I
26	proteins	I
27	CREB	I
28	and	O
29	CREM	B
30	tau	I
31	in	O
32	a	O
33	manner	O
34	analogous	O
35	to	O
36	protein	B
37	kinase	I
38	A	I
39	.	O
1	Both	O
2	of	O
3	these	O
4	dogs	O
5	had	O
6	low	O
7	serum	O
8	IgG	B
9	(	O
10	3	O
11	.	O
12	5	O
13	to	O
14	7	O
15	.	O
16	2	O
17	mg	O
18	/	O
19	ml	O
20	)	O
21	and	O
22	the	O
23	second	O
24	littermate	O
25	also	O
26	had	O
27	reduced	O
28	serum	O
29	IgA	B
30	(<	O
31	0	O
32	.	O
33	1	O
34	to	O
35	0	O
36	.	O
37	15	O
38	mg	O
39	/	O
40	ml	O
41	).	O
1	Neural	O
2	blockade	O
3	in	O
4	chronic	O
5	and	O
6	cancer	O
7	pain	O
8	.	O
1	Five	O
2	cell	O
3	strains	O
4	of	O
5	human	O
6	dermal	O
7	fibroblasts	O
8	were	O
9	each	O
10	treated	O
11	with	O
12	three	O
13	samples	O
14	of	O
15	burn	O
16	blister	O
17	fluid	O
18	and	O
19	the	O
20	effect	O
21	compared	O
22	with	O
23	the	O
24	rate	O
25	of	O
26	contraction	O
27	of	O
28	free	O
29	floating	O
30	fibroblast	O
31	populated	O
32	collagen	B
33	lattices	O
34	(	O
35	FPCL	O
36	).	O
1	Cell	O
2	49	O
3	,	O
4	753	O
5	-	O
6	761	O
7	].	O
1	The	O
2	Cut9	B
3	subunit	I
4	is	O
5	likely	O
6	to	O
7	be	O
8	a	O
9	target	O
10	for	O
11	regulating	O
12	APC	B
13	/	I
14	cyclosome	I
15	function	O
16	through	O
17	protein	O
18	-	O
19	protein	O
20	interactions	O
21	and	O
22	phosphorylation	O
23	.	O
1	The	O
2	position	O
3	,	O
4	transcription	O
5	orientation	O
6	,	O
7	and	O
8	imprinted	O
9	status	O
10	of	O
11	the	O
12	genes	O
13	immediately	O
14	flanking	O
15	Igf2r	B
16	have	O
17	been	O
18	assessed	O
19	.	O
1	We	O
2	describe	O
3	a	O
4	novel	O
5	zinc	B
6	finger	I
7	protein	I
8	,	O
9	dsRBP	B
10	-	I
11	ZFa	I
12	,	O
13	isolated	O
14	by	O
15	screening	O
16	an	O
17	expression	O
18	library	O
19	with	O
20	dsRNA	O
21	.	O
1	Consistent	O
2	with	O
3	this	O
4	model	O
5	,	O
6	a	O
7	synthetic	O
8	construct	O
9	containing	O
10	three	O
11	tandem	O
12	copies	O
13	of	O
14	the	O
15	native	O
16	LDL	B
17	receptor	I
18	SREBP	I
19	site	O
20	linked	O
21	to	O
22	a	O
23	single	O
24	Sp1	B
25	site	I
26	was	O
27	also	O
28	significantly	O
29	activated	O
30	in	O
31	a	O
32	buttonhead	B
33	-	O
34	independent	O
35	fashion	O
36	.	O
1	In	O
2	the	O
3	adult	O
4	mouse	O
5	,	O
6	ERR	B
7	alpha	I
8	is	O
9	most	O
10	highly	O
11	expressed	O
12	in	O
13	kidney	O
14	,	O
15	heart	O
16	,	O
17	and	O
18	brown	O
19	adipocytes	O
20	,	O
21	tissues	O
22	which	O
23	preferentially	O
24	metabolize	O
25	fatty	O
26	acids	O
27	.	O
1	Overexpression	O
2	of	O
3	CARP	B
4	in	O
5	cardiomyocytes	O
6	suppresses	O
7	cardiac	B
8	troponin	I
9	C	I
10	and	O
11	atrial	B
12	natriuretic	I
13	factor	I
14	transcription	O
15	.	O
1	Substrate	O
2	specificity	O
3	of	O
4	the	O
5	RNase	B
6	activity	O
7	of	O
8	yeast	B
9	RNA	I
10	polymerase	I
11	III	I
12	.	O
1	To	O
2	address	O
3	mechanisms	O
4	that	O
5	define	O
6	interactions	O
7	of	O
8	Site	B
9	II	I
10	regulatory	I
11	factors	I
12	with	O
13	this	O
14	cell	O
15	cycle	O
16	control	O
17	element	O
18	,	O
19	we	O
20	have	O
21	investigated	O
22	these	O
23	determinants	O
24	of	O
25	transcriptional	O
26	regulation	O
27	at	O
28	the	O
29	G1	O
30	/	O
31	S	O
32	phase	O
33	transition	O
34	in	O
35	FDC	O
36	-	O
37	P1	O
38	hematopoietic	O
39	progenitor	O
40	cells	O
41	.	O
1	S2F	B
2	,	O
3	a	O
4	leaf	O
5	-	O
6	specific	O
7	trans	O
8	-	O
9	acting	O
10	factor	O
11	,	O
12	binds	O
13	to	O
14	a	O
15	novel	O
16	cis	O
17	-	O
18	acting	O
19	element	O
20	and	O
21	differentially	O
22	activates	O
23	the	O
24	RPL21	B
25	gene	I
26	.	O
1	Transient	O
2	hyperammonaemia	O
3	in	O
4	an	O
5	adult	O
6	German	O
7	shepherd	O
8	dog	O
9	.	O
1	We	O
2	established	O
3	that	O
4	the	O
5	2	O
6	.	O
7	6	O
8	kb	O
9	mRNA	O
10	V	O
11	-	O
12	1	O
13	and	O
14	the	O
15	2	O
16	.	O
17	3	O
18	kb	O
19	GGT	B
20	mRNA	O
21	V	O
22	-	O
23	2	O
24	derive	O
25	,	O
26	by	O
27	alternate	O
28	splicing	O
29	,	O
30	from	O
31	a	O
32	primary	O
33	transcript	O
34	initiated	O
35	on	O
36	a	O
37	distal	O
38	promoter	O
39	on	O
40	the	O
41	rat	B
42	GGT	I
43	gene	I
44	.	O
1	Within	O
2	a	O
3	135	O
4	-	O
5	bp	O
6	core	O
7	homology	O
8	region	O
9	,	O
10	the	O
11	human	B
12	HS12	I
13	enhancers	I
14	are	O
15	approximately	O
16	90	O
17	%	O
18	identical	O
19	to	O
20	the	O
21	murine	O
22	homolog	O
23	and	O
24	include	O
25	several	O
26	motifs	O
27	previously	O
28	demonstrated	O
29	to	O
30	be	O
31	important	O
32	for	O
33	function	O
34	of	O
35	the	O
36	murine	O
37	enhancer	O
38	;	O
39	additional	O
40	segments	O
41	of	O
42	high	O
43	sequence	O
44	conservation	O
45	suggest	O
46	the	O
47	possibility	O
48	of	O
49	previously	O
50	unrecognized	O
51	functional	O
52	motifs	O
53	.	O
1	In	O
2	contrast	O
3	to	O
4	the	O
5	wild	O
6	-	O
7	type	O
8	protein	O
9	,	O
10	expression	O
11	of	O
12	p45	B
13	NF	I
14	-	I
15	E2	I
16	lacking	O
17	this	O
18	activation	O
19	domain	O
20	in	O
21	an	O
22	NF	B
23	-	I
24	E2	I
25	null	O
26	cell	O
27	line	O
28	fails	O
29	to	O
30	support	O
31	enhancer	O
32	-	O
33	dependent	O
34	transcription	O
35	in	O
36	transient	O
37	assays	O
38	.	O
1	When	O
2	the	O
3	downstream	O
4	operator	O
5	was	O
6	altered	O
7	,	O
8	there	O
9	was	O
10	a	O
11	fourfold	O
12	reduction	O
13	in	O
14	reporter	O
15	enzyme	O
16	levels	O
17	.	O
1	The	O
2	ORF3	O
3	mutant	O
4	produced	O
5	reduced	O
6	levels	O
7	of	O
8	tabtoxin	B
9	,	O
10	indicating	O
11	that	O
12	ORF3	O
13	may	O
14	have	O
15	a	O
16	role	O
17	in	O
18	T	B
19	beta	I
20	L	I
21	biosynthesis	O
22	.	O
1	However	O
2	,	O
3	the	O
4	published	O
5	reports	O
6	consist	O
7	of	O
8	a	O
9	small	O
10	number	O
11	of	O
12	patients	O
13	and	O
14	limited	O
15	data	O
16	.	O
1	The	O
2	distribution	O
3	of	O
4	cryptosporidia	O
5	in	O
6	the	O
7	intestine	O
8	and	O
9	number	O
10	of	O
11	cryptosporidia	O
12	per	O
13	ileal	O
14	villus	O
15	on	O
16	different	O
17	DPI	O
18	were	O
19	also	O
20	estimated	O
21	for	O
22	detailed	O
23	characterization	O
24	of	O
25	the	O
26	infection	O
27	in	O
28	kids	O
29	as	O
30	a	O
31	model	O
32	for	O
33	experimental	O
34	cryptosporidiosis	O
35	.	O
1	Proteasomes	O
2	are	O
3	the	O
4	multisubunit	O
5	protease	O
6	involved	O
7	in	O
8	the	O
9	generation	O
10	of	O
11	peptides	O
12	presented	O
13	by	O
14	MHC	B
15	class	I
16	I	I
17	molecules	I
18	.	O
1	The	O
2	9	O
3	;	O
4	22	O
5	chromosomal	O
6	translocation	O
7	characteristic	O
8	of	O
9	CML	O
10	results	O
11	in	O
12	a	O
13	fused	O
14	bcr	B
15	/	O
16	abl	B
17	gene	O
18	and	O
19	an	O
20	abnormal	O
21	fusion	O
22	protein	O
23	,	O
24	p210bcr	B
25	/	O
26	abl	B
27	.	O
1	Overexpression	O
2	of	O
3	BAG	B
4	-	I
5	1	I
6	also	O
7	protected	O
8	certain	O
9	cell	O
10	lines	O
11	from	O
12	heat	O
13	shock	O
14	-	O
15	induced	O
16	cell	O
17	death	O
18	.	O
1	The	O
2	recognition	O
3	specificity	O
4	of	O
5	the	O
6	p55	B
7	PDZ	I
8	domain	I
9	appears	O
10	to	O
11	be	O
12	unique	O
13	,	O
14	since	O
15	the	O
16	three	O
17	PDZ	B
18	domains	I
19	of	O
20	hDlg	B
21	(	O
22	human	O
23	lymphocyte	O
24	homologue	O
25	of	O
26	the	O
27	Drosophila	B
28	discs	I
29	large	I
30	tumor	I
31	suppressor	I
32	)	O
33	do	O
34	not	O
35	bind	O
36	the	O
37	cytoplasmic	O
38	domain	O
39	of	O
40	glycophorin	B
41	C	I
42	.	O
1	We	O
2	report	O
3	the	O
4	preliminary	O
5	biochemical	O
6	characterization	O
7	of	O
8	the	O
9	T	B
10	antigens	I
11	encoded	O
12	by	O
13	three	O
14	SV40	O
15	mutants	O
16	,	O
17	5030	O
18	,	O
19	5031	O
20	,	O
21	and	O
22	5061	O
23	,	O
24	each	O
25	of	O
26	which	O
27	have	O
28	altered	O
29	residues	O
30	within	O
31	or	O
32	near	O
33	the	O
34	ATP	O
35	binding	O
36	pocket	O
37	.	O
1	These	O
2	effects	O
3	were	O
4	abrogated	O
5	by	O
6	co	O
7	-	O
8	expression	O
9	of	O
10	kinase	B
11	-	I
12	deficient	I
13	PKC	I
14	zeta	I
15	and	O
16	inhibition	O
17	of	O
18	phosphatidylinositol	B
19	3	I
20	-	I
21	kinase	I
22	p85alpha	I
23	-	O
24	p110	B
25	by	O
26	wortmannin	O
27	,	O
28	LY294002	O
29	and	O
30	a	O
31	dominant	O
32	-	O
33	negative	O
34	mutant	O
35	of	O
36	p85alpha	B
37	.	O
1	Recent	O
2	studies	O
3	have	O
4	shown	O
5	that	O
6	the	O
7	Src	B
8	homology	I
9	-	I
10	2	I
11	(	O
12	SH2	B
13	)	O
14	domain	O
15	-	O
16	containing	O
17	protein	B
18	-	I
19	tyrosine	I
20	phosphatase	I
21	,	O
22	SHP	B
23	-	I
24	2	I
25	,	O
26	associates	O
27	with	O
28	the	O
29	cytoplasmic	O
30	domain	O
31	of	O
32	PECAM	B
33	-	I
34	1	I
35	as	O
36	it	O
37	becomes	O
38	tyrosine	O
39	-	O
40	phosphorylated	O
41	during	O
42	platelet	O
43	aggregation	O
44	:	O
45	a	O
46	process	O
47	that	O
48	can	O
49	be	O
50	mimicked	O
51	in	O
52	part	O
53	by	O
54	small	O
55	synthetic	O
56	phosphopeptides	O
57	corresponding	O
58	to	O
59	the	O
60	cytoplasmic	O
61	domain	O
62	of	O
63	PECAM	B
64	-	I
65	1	I
66	encompassing	O
67	tyrosine	O
68	residues	O
69	Tyr	O
70	-	O
71	663	O
72	or	O
73	Tyr	O
74	-	O
75	686	O
76	.	O
1	Furthermore	O
2	,	O
3	our	O
4	novel	O
5	observation	O
6	that	O
7	expression	O
8	of	O
9	a	O
10	highly	O
11	activated	O
12	FGFR3	B
13	kinase	I
14	domain	I
15	is	O
16	able	O
17	to	O
18	morphologically	O
19	transform	O
20	fibroblasts	O
21	suggests	O
22	that	O
23	dysregulation	O
24	of	O
25	FGFR3	B
26	has	O
27	the	O
28	potential	O
29	to	O
30	play	O
31	a	O
32	role	O
33	in	O
34	human	O
35	neoplasia	O
36	.	O
1	However	O
2	,	O
3	Cbf5p	B
4	was	O
5	found	O
6	to	O
7	be	O
8	nucleolar	O
9	and	O
10	is	O
11	highly	O
12	homologous	O
13	to	O
14	the	O
15	rat	B
16	nucleolar	I
17	protein	I
18	NAP57	I
19	,	O
20	which	O
21	coimmunoprecipitates	O
22	with	O
23	Nopp140	B
24	and	O
25	which	O
26	is	O
27	postulated	O
28	to	O
29	be	O
30	involved	O
31	in	O
32	nucleolar	O
33	-	O
34	cytoplasmic	O
35	shuttling	O
36	(	O
37	U	O
38	.	O
1	We	O
2	found	O
3	that	O
4	multiple	O
5	tumor	O
6	suppressor	O
7	genes	O
8	(	O
9	e	O
10	.	O
11	g	O
12	.,	O
13	p53	B
14	,	O
15	DCC	B
16	,	O
17	APC	B
18	,	O
19	MCC	B
20	,	O
21	BRCA1	B
22	,	O
23	and	O
24	WAF1	B
25	/	O
26	CIP1	B
27	)	O
28	were	O
29	inactivated	O
30	at	O
31	different	O
32	frequencies	O
33	via	O
34	various	O
35	mechanisms	O
36	[	O
37	e	O
38	.	O
39	g	O
40	.,	O
41	loss	O
42	of	O
43	heterozygosity	O
44	(	O
45	LOH	O
46	),	O
47	loss	O
48	of	O
49	expression	O
50	(	O
51	LOE	O
52	),	O
53	mutation	O
54	,	O
55	and	O
56	inactivation	O
57	by	O
58	cellular	O
59	binding	O
60	protein	O
61	].	O
1	A	O
2	data	O
3	base	O
4	homology	O
5	search	O
6	revealed	O
7	that	O
8	the	O
9	predicted	O
10	ER1	B
11	amino	O
12	acid	O
13	sequence	O
14	contains	O
15	three	O
16	regions	O
17	of	O
18	similarity	O
19	to	O
20	the	O
21	rat	O
22	and	O
23	human	O
24	proteins	O
25	encoded	O
26	by	O
27	the	O
28	metastasis	O
29	-	O
30	associated	O
31	gene	O
32	,	O
33	mta1	B
34	,	O
35	and	O
36	two	O
37	regions	O
38	of	O
39	similarity	O
40	to	O
41	the	O
42	Caenorhabditis	O
43	elegans	O
44	sequence	O
45	that	O
46	is	O
47	similar	O
48	to	O
49	mta1	B
50	.	O
1	The	O
2	sequenced	O
3	cDNA	O
4	predicts	O
5	a	O
6	704	O
7	-	O
8	amino	O
9	acid	O
10	protein	O
11	80	O
12	%	O
13	identical	O
14	to	O
15	human	B
16	progelatinase	I
17	B	I
18	.	O
1	Using	O
2	5	O
3	'	O
4	RACE	O
5	and	O
6	reverse	O
7	transcription	O
8	-	O
9	PCR	O
10	(	O
11	RT	O
12	-	O
13	PCR	O
14	)	O
15	methodologies	O
16	,	O
17	we	O
18	cloned	O
19	these	O
20	sequences	O
21	from	O
22	brain	O
23	and	O
24	placenta	O
25	and	O
26	found	O
27	this	O
28	material	O
29	to	O
30	be	O
31	composed	O
32	of	O
33	alternatively	O
34	spliced	O
35	exons	O
36	using	O
37	a	O
38	previously	O
39	reported	O
40	noncoding	O
41	exon	O
42	(	O
43	1A	O
44	)	O
45	and	O
46	a	O
47	novel	O
48	97	O
49	-	O
50	bp	O
51	noncoding	O
52	exon	O
53	(	O
54	1B	O
55	).	O
1	This	O
2	is	O
3	the	O
4	first	O
5	study	O
6	in	O
7	which	O
8	mutation	O
9	screening	O
10	has	O
11	been	O
12	performed	O
13	for	O
14	both	O
15	the	O
16	EXT1	B
17	and	O
18	EXT2	B
19	genes	I
20	prior	O
21	to	O
22	any	O
23	linkage	O
24	analysis	O
25	.	O
1	Serum	O
2	E2	O
3	concentrations	O
4	increased	O
5	numerically	O
6	two	O
7	-	O
8	to	O
9	threefold	O
10	from	O
11	d	O
12	56	O
13	to	O
14	140	O
15	in	O
16	controls	O
17	fed	O
18	MGA	O
19	,	O
20	compared	O
21	with	O
22	controls	O
23	not	O
24	fed	O
25	MGA	O
26	.	O
1	We	O
2	have	O
3	previously	O
4	reported	O
5	that	O
6	expression	O
7	of	O
8	a	O
9	tumour	O
10	derived	O
11	brk	B
12	cDNA	I
13	in	O
14	mouse	O
15	embryonic	O
16	fibroblasts	O
17	and	O
18	human	O
19	mammary	O
20	epithelial	O
21	cells	O
22	supports	O
23	anchorage	O
24	independent	O
25	growth	O
26	,	O
27	and	O
28	in	O
29	the	O
30	latter	O
31	potentiates	O
32	the	O
33	mitogenic	O
34	response	O
35	to	O
36	epidermal	B
37	growth	I
38	factor	I
39	.	O
1	One	O
2	skull	O
3	does	O
4	not	O
5	a	O
6	species	O
7	make	O
8	.	O
1	To	O
2	examine	O
3	the	O
4	basis	O
5	for	O
6	the	O
7	apparent	O
8	differences	O
9	in	O
10	postsegregational	O
11	killing	O
12	between	O
13	the	O
14	two	O
15	E	O
16	.	O
17	coli	O
18	strains	O
19	,	O
20	transformation	O
21	assays	O
22	were	O
23	carried	O
24	out	O
25	to	O
26	determine	O
27	the	O
28	relative	O
29	sensitivities	O
30	of	O
31	the	O
32	strains	O
33	to	O
34	the	O
35	ParE	B
36	toxin	I
37	protein	I
38	.	O
1	Interestingly	O
2	,	O
3	segment	O
4	nesting	O
5	differentially	O
6	increases	O
7	the	O
8	copy	O
9	number	O
10	of	O
11	genes	O
12	encoded	O
13	by	O
14	segment	O
15	W	O
16	,	O
17	suggesting	O
18	that	O
19	the	O
20	unusual	O
21	genomic	O
22	organization	O
23	of	O
24	PDVs	O
25	may	O
26	be	O
27	directly	O
28	linked	O
29	to	O
30	the	O
31	unique	O
32	functions	O
33	of	O
34	this	O
35	virus	O
36	in	O
37	its	O
38	obligate	O
39	mutualistic	O
40	association	O
41	with	O
42	parasitic	O
43	wasps	O
44	.	O
1	The	O
2	Scm	B
3	and	O
4	ph	B
5	proteins	O
6	share	O
7	a	O
8	homology	O
9	domain	O
10	with	O
11	38	O
12	%	O
13	identity	O
14	over	O
15	a	O
16	length	O
17	of	O
18	65	O
19	amino	O
20	acids	O
21	,	O
22	termed	O
23	the	O
24	SPM	O
25	domain	O
26	,	O
27	that	O
28	is	O
29	located	O
30	at	O
31	their	O
32	respective	O
33	C	O
34	termini	O
35	.	O
1	Likewise	O
2	,	O
3	rad6	B
4	-	I
5	delta	I
6	reduces	O
7	silencing	O
8	of	O
9	the	O
10	telomere	B
11	-	I
12	located	I
13	RNAP	I
14	II	I
15	-	I
16	transcribed	I
17	genes	I
18	URA3	I
19	and	O
20	ADE2	B
21	.	O
1	Recently	O
2	,	O
3	roles	O
4	also	O
5	have	O
6	been	O
7	suggested	O
8	for	O
9	the	O
10	nuclear	O
11	trans	O
12	-	O
13	factor	O
14	GATA	B
15	-	I
16	1	I
17	in	O
18	regulating	O
19	progenitor	O
20	cell	O
21	proliferation	O
22	.	O
1	F	B
2	-	I
3	box	I
4	proteins	I
5	are	O
6	receptors	O
7	that	O
8	recruit	O
9	phosphorylated	O
10	substrates	O
11	to	O
12	the	O
13	SCF	B
14	ubiquitin	I
15	-	O
16	ligase	B
17	complex	O
18	.	O
1	An	O
2	end	O
3	to	O
4	the	O
5	lottery	O
6	.	O
1	Furthermore	O
2	,	O
3	the	O
4	over	O
5	-	O
6	replication	O
7	phenotype	O
8	produced	O
9	by	O
10	this	O
11	mutant	B
12	p65cdc18	I
13	is	O
14	resistant	O
15	to	O
16	increased	O
17	mitotic	O
18	cyclin	B
19	/	O
20	CDK	B
21	activity	O
22	,	O
23	a	O
24	known	O
25	inhibitor	O
26	of	O
27	over	O
28	-	O
29	replication	O
30	.	O
1	Their	O
2	biosynthesis	O
3	proceeds	O
4	via	O
5	linear	O
6	precursors	O
7	that	O
8	become	O
9	branched	O
10	by	O
11	beta1	B
12	,	I
13	6	I
14	-	I
15	GlcNAc	I
16	transferases	I
17	(	O
18	IGnT6	O
19	,	O
20	GlcNAc	O
21	to	O
22	Gal	O
23	).	O
1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	Rat7p	B
9	/	O
10	Nup159p	B
11	is	O
12	anchored	O
13	within	O
14	the	O
15	NPC	O
16	through	O
17	its	O
18	coiled	O
19	-	O
20	coil	O
21	region	O
22	and	O
23	adjacent	O
24	sequences	O
25	.	O
1	In	O
2	a	O
3	group	O
4	of	O
5	13	O
6	patients	O
7	with	O
8	obliterative	O
9	arteriopathies	O
10	of	O
11	the	O
12	lower	O
13	limbs	O
14	the	O
15	plasma	O
16	levels	O
17	of	O
18	thrombomodulin	B
19	(	O
20	TM	B
21	),	O
22	betathromboglobulin	B
23	(	O
24	beta	B
25	-	I
26	TG	I
27	),	O
28	D	O
29	-	O
30	dimer	O
31	(	O
32	DD	O
33	)	O
34	and	O
35	plasminogen	B
36	activator	I
37	-	I
38	inhibitor	I
39	(	O
40	pAI	B
41	-	I
42	1	I
43	)	O
44	were	O
45	measured	O
46	,	O
47	and	O
48	compared	O
49	to	O
50	the	O
51	values	O
52	obtained	O
53	from	O
54	10	O
55	healthy	O
56	volunteers	O
57	.	O
1	We	O
2	have	O
3	now	O
4	shown	O
5	that	O
6	in	O
7	vivo	O
8	phosphorylation	O
9	of	O
10	14	B
11	-	I
12	3	I
13	-	I
14	3	I
15	zeta	I
16	at	O
17	the	O
18	CKIalpha	B
19	site	I
20	(	I
21	Thr	I
22	-	I
23	233	I
24	)	I
25	negatively	O
26	regulates	O
27	its	O
28	binding	O
29	to	O
30	c	B
31	-	I
32	Raf	I
33	,	O
34	and	O
35	may	O
36	be	O
37	important	O
38	in	O
39	Raf	B
40	-	O
41	mediated	O
42	signal	O
43	transduction	O
44	.	O
1	PKA	B
2	phosphorylated	O
3	WT1	B
4	at	O
5	Ser	O
6	-	O
7	365	O
8	and	O
9	Ser	O
10	-	O
11	393	O
12	in	O
13	vitro	O
14	,	O
15	as	O
16	well	O
17	as	O
18	at	O
19	additional	O
20	sites	O
21	,	O
22	and	O
23	this	O
24	phosphorylation	O
25	abolished	O
26	the	O
27	DNA	O
28	-	O
29	binding	O
30	activity	O
31	of	O
32	WT1	B
33	in	O
34	vitro	O
35	.	O
1	Restriction	O
2	enzyme	O
3	mapping	O
4	,	O
5	subcloning	O
6	,	O
7	and	O
8	DNA	O
9	sequencing	O
10	analysis	O
11	of	O
12	recombinant	O
13	phage	O
14	lambda	O
15	and	O
16	P1	O
17	clones	O
18	revealed	O
19	that	O
20	exons	O
21	encoding	O
22	the	O
23	1	O
24	.	O
25	9	O
26	-	O
27	kb	O
28	mouse	B
29	TS	I
30	mRNA	I
31	are	O
32	dispersed	O
33	over	O
34	>	O
35	150	O
36	kb	O
37	genomic	O
38	DNA	O
39	.	O
1	However	O
2	,	O
3	one	O
4	CAK	B
5	-	O
6	phosphorylated	O
7	phosphopeptide	O
8	comigrates	O
9	with	O
10	a	O
11	Cdc2	B
12	-	O
13	phosphorylated	O
14	phosphopeptide	O
15	previously	O
16	shown	O
17	to	O
18	be	O
19	mitosis	O
20	-	O
21	specific	O
22	,	O
23	suggesting	O
24	that	O
25	,	O
26	in	O
27	vitro	O
28	,	O
29	CAK	B
30	is	O
31	able	O
32	to	O
33	phosphorylate	O
34	at	O
35	least	O
36	one	O
37	site	O
38	that	O
39	is	O
40	also	O
41	phosphorylated	O
42	in	O
43	vivo	O
44	.	O
1	However	O
2	,	O
3	when	O
4	a	O
5	second	O
6	,	O
7	upstream	B
8	IRE	I
9	-	I
10	like	I
11	sequence	I
12	was	O
13	evaluated	O
14	by	O
15	EMSA	O
16	,	O
17	a	O
18	DNA	O
19	binding	O
20	pattern	O
21	distinct	O
22	from	O
23	that	O
24	seen	O
25	following	O
26	exposure	O
27	to	O
28	IFN	B
29	-	I
30	gamma	I
31	alone	O
32	was	O
33	observed	O
34	after	O
35	prolonged	O
36	stimulation	O
37	with	O
38	both	O
39	IFN	B
40	-	I
41	alpha	I
42	and	O
43	IFN	B
44	-	I
45	gamma	I
46	.	O
1	Mutational	O
2	analysis	O
3	shows	O
4	that	O
5	both	O
6	an	O
7	AP	B
8	-	I
9	1	I
10	like	I
11	sequence	I
12	(-	O
13	294	O
14	/-	O
15	285	O
16	,	O
17	TGAATCATCA	O
18	)	O
19	and	O
20	an	O
21	A	O
22	/	O
23	T	O
24	-	O
25	rich	O
26	myocyte	B
27	enhancer	I
28	factor	I
29	(	I
30	MEF	I
31	)-	I
32	2	I
33	like	I
34	sequence	I
35	(-	O
36	310	O
37	/-	O
38	298	O
39	,	O
40	TTAAAAATAAAAA	O
41	)	O
42	in	O
43	the	O
44	33	O
45	-	O
46	bp	O
47	region	O
48	are	O
49	necessary	O
50	for	O
51	the	O
52	OP	B
53	-	I
54	1	I
55	effect	O
56	.	O
1	This	O
2	protein	O
3	is	O
4	present	O
5	in	O
6	both	O
7	HeLa	O
8	nuclear	O
9	extracts	O
10	and	O
11	S100	B
12	extracts	O
13	but	O
14	absent	O
15	from	O
16	SR	B
17	protein	I
18	preparations	O
19	,	O
20	suggesting	O
21	that	O
22	it	O
23	is	O
24	not	O
25	a	O
26	classical	O
27	SR	B
28	protein	I
29	.	O
1	Chimeras	O
2	containing	O
3	IE1	B
4	peptides	I
5	dramatically	O
6	activated	O
7	transcription	O
8	of	O
9	the	O
10	basal	O
11	promoter	O
12	only	O
13	when	O
14	lac	B
15	operator	I
16	sequences	I
17	were	O
18	present	O
19	.	O
1	The	O
2	yeast	O
3	silent	B
4	information	I
5	regulator	I
6	Sir4p	I
7	anchors	O
8	and	O
9	partitions	O
10	plasmids	O
11	.	O
1	These	O
2	results	O
3	implicate	O
4	a	O
5	precursor	O
6	-	O
7	specific	O
8	base	O
9	-	O
10	paired	O
11	structure	O
12	involving	O
13	sequences	O
14	on	O
15	both	O
16	sides	O
17	of	O
18	the	O
19	mature	O
20	cleavage	O
21	site	O
22	in	O
23	the	O
24	3	O
25	'	O
26	processing	O
27	of	O
28	human	B
29	U2	I
30	RNA	I
31	.	O
1	Identification	O
2	of	O
3	dynein	B
4	heavy	I
5	chain	I
6	genes	I
7	expressed	O
8	in	O
9	human	O
10	and	O
11	mouse	O
12	testis	O
13	:	O
14	chromosomal	O
15	localization	O
16	of	O
17	an	O
18	axonemal	B
19	dynein	I
20	gene	I
21	.	O
1	Bitter	O
2	cassava	O
3	contains	O
4	cyanogenic	O
5	glycosides	O
6	;	O
7	processing	O
8	breaks	O
9	them	O
10	down	O
11	to	O
12	acetone	O
13	cyanohydrin	O
14	and	O
15	hydrogen	O
16	cyanide	O
17	.	O
1	The	O
2	proposed	O
3	mechanism	O
4	of	O
5	effect	O
6	states	O
7	that	O
8	mono	O
9	(	O
10	2	O
11	-	O
12	ethylhexyl	O
13	)	O
14	phthalate	O
15	(	O
16	MEHP	O
17	),	O
18	the	O
19	primary	O
20	hydrolysis	O
21	product	O
22	of	O
23	DEHP	O
24	,	O
25	mimics	O
26	the	O
27	inducing	O
28	prostaglandins	O
29	(	O
30	PG	O
31	)	O
32	PGD	O
33	(	O
34	2	O
35	),	O
36	9alpha	O
37	,	O
38	11betaPGF2	O
39	,	O
40	and	O
41	PGF2alpha	O
42	,	O
43	and	O
44	thromboxanes	O
45	in	O
46	the	O
47	lungs	O
48	,	O
49	thereby	O
50	increasing	O
51	the	O
52	risk	O
53	of	O
54	inducing	O
55	inflammation	O
56	in	O
57	the	O
58	airways	O
59	,	O
60	which	O
61	is	O
62	a	O
63	characteristic	O
64	of	O
65	asthma	O
66	.	O
1	The	O
2	author	O
3	analyzes	O
4	extensive	O
5	own	O
6	data	O
7	based	O
8	on	O
9	study	O
10	into	O
11	particular	O
12	features	O
13	of	O
14	cardiovascular	O
15	disorders	O
16	in	O
17	chronic	O
18	renal	O
19	impairement	O
20	with	O
21	making	O
22	use	O
23	of	O
24	modern	O
25	diagnostic	O
26	tools	O
27	.	O
1	In	O
2	this	O
3	paper	O
4	,	O
5	characterization	O
6	is	O
7	given	O
8	of	O
9	clinical	O
10	and	O
11	biochemical	O
12	features	O
13	of	O
14	VH	O
15	B	O
16	course	O
17	against	O
18	the	O
19	background	O
20	of	O
21	narcomania	O
22	.	O
1	447	O
2	microns	O
3	for	O
4	A	O
5	.	O
6	microcephalum	O
7	and	O
8	350	O
9	microns	O
10	for	O
11	A	O
12	.	O
13	wedli	O
14	),	O
15	and	O
16	fewer	O
17	testes	O
18	per	O
19	proglottis	O
20	(	O
21	44	O
22	-	O
23	73	O
24	vs	O
25	.	O
1	Two	O
2	sterol	O
3	regulatory	O
4	element	O
5	-	O
6	like	O
7	sequences	O
8	mediate	O
9	up	O
10	-	O
11	regulation	O
12	of	O
13	caveolin	B
14	gene	I
15	transcription	O
16	in	O
17	response	O
18	to	O
19	low	B
20	density	I
21	lipoprotein	I
22	free	O
23	cholesterol	O
24	.	O
1	First	O
2	,	O
3	two	O
4	MCTs	O
5	using	O
6	a	O
7	long	O
8	electrode	O
9	,	O
10	3	O
11	cm	O
12	in	O
13	size	O
14	,	O
15	were	O
16	performed	O
17	in	O
18	the	O
19	central	O
20	area	O
21	of	O
22	the	O
23	tumor	O
24	,	O
25	and	O
26	eight	O
27	MCTs	O
28	by	O
29	a	O
30	short	O
31	electrode	O
32	,	O
33	2	O
34	cm	O
35	in	O
36	size	O
37	,	O
38	were	O
39	done	O
40	in	O
41	the	O
42	peripheral	O
43	and	O
44	surrounding	O
45	area	O
46	of	O
47	the	O
48	tumor	O
49	.	O
1	Direct	O
2	proof	O
3	that	O
4	the	O
5	heightened	O
6	renal	O
7	cellular	O
8	apoptosis	O
9	in	O
10	PKD	O
11	is	O
12	not	O
13	occurring	O
14	through	O
15	p53	B
16	was	O
17	obtained	O
18	by	O
19	successive	O
20	matings	O
21	between	O
22	SBM	O
23	and	O
24	p53	B
25	(-/-)	O
26	mice	O
27	.	O
1	The	O
2	data	O
3	provide	O
4	evidence	O
5	both	O
6	for	O
7	a	O
8	signal	O
9	transduction	O
10	pathway	O
11	independent	O
12	of	O
13	JNK	B
14	,	O
15	ERK	B
16	,	O
17	and	O
18	p38	B
19	MAP	I
20	kinase	I
21	to	O
22	be	O
23	involved	O
24	in	O
25	the	O
26	induction	O
27	of	O
28	rhoB	B
29	by	O
30	genotoxic	O
31	stress	O
32	,	O
33	and	O
34	furthermore	O
35	,	O
36	indicate	O
37	autoregulation	O
38	of	O
39	rhoB	B
40	.	O
1	We	O
2	also	O
3	show	O
4	by	O
5	immunogold	O
6	electron	O
7	microscopy	O
8	immunocytochemistry	O
9	that	O
10	amphiphysin	B
11	I	I
12	is	O
13	localized	O
14	in	O
15	the	O
16	nerve	O
17	terminal	O
18	cytomatrix	O
19	and	O
20	is	O
21	partially	O
22	associated	O
23	with	O
24	endocytic	O
25	intermediates	O
26	.	O
1	Thus	O
2	,	O
3	dpp	B
4	and	O
5	omb	B
6	promote	O
7	both	O
8	dorsal	O
9	leg	O
10	cell	O
11	fate	O
12	as	O
13	well	O
14	as	O
15	transdetermination	O
16	-	O
17	competent	O
18	leg	O
19	disc	O
20	cells	O
21	.	O
1	AIDS	O
2	-	O
3	related	O
4	disseminated	O
5	histoplasmosis	O
6	in	O
7	San	O
8	Francisco	O
9	,	O
10	California	O
11	.	O
1	TNF	B
2	-	I
3	alpha	I
4	exposure	O
5	markedly	O
6	increased	O
7	activity	O
8	of	O
9	several	O
10	RNA	O
11	-	O
12	binding	O
13	proteins	O
14	,	O
15	especially	O
16	a	O
17	novel	O
18	Mr	O
19	50	O
20	,	O
21	000	O
22	-	O
23	55	O
24	,	O
25	000	O
26	RNA	O
27	-	O
28	binding	O
29	protein	O
30	.	O
1	We	O
2	speculate	O
3	that	O
4	the	O
5	human	O
6	papillomavirus	O
7	late	O
8	mRNAs	O
9	,	O
10	produced	O
11	from	O
12	several	O
13	hundred	O
14	copies	O
15	of	O
16	the	O
17	virus	O
18	genome	O
19	present	O
20	in	O
21	infected	O
22	cells	O
23	,	O
24	compete	O
25	with	O
26	the	O
27	c	B
28	-	I
29	fos	I
30	mRNAs	I
31	for	O
32	destabilizing	O
33	cellular	O
34	factors	O
35	and	O
36	that	O
37	this	O
38	may	O
39	lead	O
40	to	O
41	elevated	O
42	Fos	B
43	protein	I
44	levels	O
45	in	O
46	human	O
47	papillomavirus	O
48	infected	O
49	cells	O
50	.	O
1	The	O
2	proofreading	O
3	domain	O
4	of	O
5	Escherichia	B
6	coli	I
7	DNA	I
8	polymerase	I
9	I	I
10	and	O
11	other	O
12	DNA	B
13	and	I
14	/	I
15	or	I
16	RNA	I
17	exonuclease	I
18	domains	I
19	.	O
1	Responsibility	O
2	matters	O
3	--	O
4	this	O
5	is	O
6	a	O
7	scientific	O
8	council	O
1	Coexpression	O
2	of	O
3	mouse	O
4	PKR	B
5	(	I
6	1	I
7	-	I
8	515	I
9	)	I
10	WT	I
11	as	O
12	a	O
13	Gal4	B
14	DNA	O
15	-	O
16	binding	O
17	domain	O
18	fusion	O
19	with	O
20	either	O
21	the	O
22	catalytic	O
23	-	O
24	deficient	O
25	human	O
26	PKR	B
27	(	I
28	1	I
29	-	I
30	551	I
31	)	I
32	K296R	O
33	mutant	O
34	,	O
35	the	O
36	RNA	O
37	-	O
38	binding	O
39	-	O
40	deficient	O
41	human	O
42	PKR	B
43	(	I
44	1	I
45	-	I
46	551	I
47	)	I
48	K64E	I
49	/	I
50	K296R	I
51	double	O
52	mutant	O
53	,	O
54	or	O
55	wild	O
56	-	O
57	type	O
58	mouse	O
59	PKR	B
60	(	I
61	1	I
62	-	I
63	515	I
64	)	I
65	WT	I
66	as	O
67	full	O
68	-	O
69	length	O
70	PKR	B
71	-	O
72	Gal4	B
73	activation	O
74	domain	O
75	fusions	O
76	resulted	O
77	in	O
78	activation	O
79	of	O
80	the	O
81	HIS3	B
82	and	O
83	lacZ	B
84	reporters	O
85	.	O
1	These	O
2	defects	O
3	no	O
4	doubt	O
5	impair	O
6	the	O
7	folding	O
8	and	O
9	configuration	O
10	necessary	O
11	for	O
12	normal	O
13	processing	O
14	of	O
15	the	O
16	AVP	B
17	gene	I
18	precursor	I
19	.	O
1	Moreover	O
2	,	O
3	moderate	O
4	overexpression	O
5	of	O
6	Chk1	B
7	suppresses	O
8	the	O
9	phenotypes	O
10	of	O
11	cut5	B
12	and	O
13	crb2	B
14	mutants	I
15	.	O
1	Diet	O
2	therapy	O
3	with	O
4	soy	O
5	proteins	O
6	for	O
7	chronic	O
8	stomach	O
9	ulcers	O
1	Resistance	O
2	training	O
3	shifts	O
4	the	O
5	power	O
6	curve	O
7	in	O
8	a	O
9	positive	O
10	direction	O
11	when	O
12	the	O
13	measurements	O
14	are	O
15	determined	O
16	with	O
17	absolute	O
18	loads	O
19	,	O
20	but	O
21	the	O
22	increased	O
23	power	O
24	may	O
25	not	O
26	be	O
27	transferred	O
28	to	O
29	an	O
30	absolute	O
31	performance	O
32	task	O
33	like	O
34	the	O
35	SSP	O
36	.	O
1	We	O
2	have	O
3	previously	O
4	reported	O
5	that	O
6	depletion	O
7	of	O
8	protein	B
9	kinase	I
10	C	I
11	by	O
12	long	O
13	-	O
14	term	O
15	treatment	O
16	of	O
17	B16	O
18	mouse	O
19	melanoma	O
20	cells	O
21	with	O
22	phorbol	O
23	dibutyrate	O
24	(	O
25	PDBu	O
26	)	O
27	prevented	O
28	cell	O
29	density	O
30	-	O
31	dependent	O
32	melanogenesis	O
33	.	O
1	Replacement	O
2	of	O
3	residues	O
4	in	O
5	positions	O
6	+	O
7	3	O
8	(	O
9	His128Asn	O
10	)	O
11	and	O
12	+	O
13	2	O
14	(	O
15	Gln155Lys	O
16	)	O
17	of	O
18	the	O
19	reading	O
20	helices	O
21	of	O
22	fingers	O
23	2	O
24	and	O
25	3	O
26	,	O
27	respectively	O
28	,	O
29	prevented	O
30	binding	O
31	.	O
1	The	O
2	interaction	O
3	between	O
4	DDB	B
5	and	O
6	E2F1	B
7	can	O
8	also	O
9	be	O
10	detected	O
11	by	O
12	coimmunoprecipitation	O
13	experiments	O
14	.	O
1	Cell	O
2	factor	O
3	-	O
4	mediated	O
5	regulatory	O
6	interactions	O
7	are	O
8	involved	O
9	in	O
10	regulating	O
11	the	O
12	restricted	O
13	expression	O
14	of	O
15	the	O
16	HCMV	B
17	major	I
18	immediate	I
19	-	I
20	early	I
21	(	I
22	IE	I
23	)	I
24	gene	I
25	(	O
26	J	O
27	.	O
1	C	O
2	.	O
1	These	O
2	are	O
3	the	O
4	long	O
5	terminal	O
6	repeat	O
7	(	O
8	LTR	O
9	)	O
10	promoter	O
11	,	O
12	which	O
13	regulates	O
14	expression	O
15	of	O
16	the	O
17	viral	O
18	structural	O
19	proteins	O
20	,	O
21	and	O
22	a	O
23	second	O
24	internal	O
25	promoter	O
26	,	O
27	located	O
28	towards	O
29	the	O
30	3	O
31	'	O
32	end	O
33	of	O
34	the	O
35	env	B
36	gene	I
37	,	O
38	that	O
39	directs	O
40	expression	O
41	of	O
42	the	O
43	viral	O
44	auxiliary	O
45	proteins	O
46	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	affinities	O
6	of	O
7	CBF2	B
8	for	O
9	binding	O
10	to	O
11	the	O
12	LMP	B
13	-	I
14	1	I
15	,	O
16	LMP	B
17	-	I
18	2	I
19	,	O
20	and	O
21	CD23	B
22	promoters	I
23	were	O
24	also	O
25	measured	O
26	.	O
1	A	O
2	cAMP	O
3	-	O
4	responsive	O
5	element	O
6	-	O
7	like	O
8	(	O
9	CRE	O
10	-	O
11	like	O
12	,	O
13	TGACGTGA	O
14	)	O
15	promoter	O
16	sequence	O
17	and	O
18	a	O
19	protein	B
20	kinase	I
21	A	I
22	signaling	O
23	pathway	O
24	are	O
25	involved	O
26	in	O
27	this	O
28	induction	O
29	,	O
30	and	O
31	activation	O
32	of	O
33	both	O
34	CRE	B
35	binding	I
36	protein	I
37	(	O
38	CREB	B
39	)	O
40	and	O
41	activating	B
42	transcription	I
43	factor	I
44	-	I
45	2	I
46	(	O
47	ATF	B
48	-	I
49	2	I
50	)	O
51	is	O
52	required	O
53	in	O
54	the	O
55	above	O
56	process	O
57	.	O
1	IVOX	O
2	was	O
3	named	O
4	as	O
5	an	O
6	acronym	O
7	for	O
8	intravascular	O
9	oxygenator	O
10	.	O
1	A	O
2	.,	O
3	Swift	O
4	,	O
5	A	O
6	.	O
1	Lysine	B
2	-	I
3	ketoglutarate	I
4	reductase	I
5	and	O
6	saccharopine	B
7	dehydrogenase	I
8	from	O
9	Arabidopsis	O
10	thaliana	O
11	:	O
12	nucleotide	O
13	sequence	O
14	and	O
15	characterization	O
16	.	O
1	Patients	O
2	and	O
3	their	O
4	relatives	O
5	must	O
6	be	O
7	informed	O
8	about	O
9	the	O
10	available	O
11	effective	O
12	treatment	O
13	possibilities	O
14	and	O
15	about	O
16	the	O
17	right	O
18	moment	O
19	for	O
20	their	O
21	application	O
22	in	O
23	an	O
24	individual	O
25	patient	O
26	.	O
1	The	O
2	organization	O
3	of	O
4	SPP1	B
5	genes	I
6	involved	O
7	in	O
8	the	O
9	replication	O
10	,	O
11	DNA	O
12	packaging	O
13	and	O
14	phage	O
15	assembly	O
16	proteins	O
17	resembles	O
18	the	O
19	organization	O
20	of	O
21	genes	O
22	of	O
23	equivalent	O
24	regions	O
25	of	O
26	different	O
27	E	O
28	.	O
29	coli	O
30	double	O
31	-	O
32	stranded	O
33	DNA	O
34	phages	O
35	.	O
1	Our	O
2	results	O
3	showed	O
4	that	O
5	compared	O
6	to	O
7	the	O
8	primary	O
9	photon	O
10	fluence	O
11	,	O
12	the	O
13	extra	O
14	-	O
15	focal	O
16	photon	O
17	fluence	O
18	from	O
19	the	O
20	primary	O
21	collimator	O
22	and	O
23	the	O
24	flattening	O
25	filter	O
26	was	O
27	11	O
28	%-	O
29	16	O
30	%	O
31	at	O
32	the	O
33	isocenter	O
34	,	O
35	among	O
36	which	O
37	70	O
38	%	O
39	was	O
40	contributed	O
41	by	O
42	the	O
43	flattening	O
44	filter	O
45	.	O
1	The	O
2	functional	O
3	mature	O
4	domain	O
5	of	O
6	pediocin	B
7	AcH	I
8	(	I
9	Lys	I
10	+	I
11	1	I
12	to	I
13	Cys	I
14	+	I
15	44	I
16	)	I
17	is	O
18	targeted	O
19	into	O
20	the	O
21	E	O
22	.	O
23	coli	O
24	sec	O
25	machinery	O
26	and	O
27	secreted	O
28	to	O
29	the	O
30	periplasm	O
31	in	O
32	active	O
33	form	O
34	when	O
35	fused	O
36	in	O
37	frame	O
38	to	O
39	the	O
40	COOH	O
41	terminus	O
42	of	O
43	the	O
44	secretory	B
45	protein	I
46	maltose	I
47	-	I
48	binding	I
49	protein	I
50	(	O
51	MBP	B
52	).	O
1	Protein	B
2	C	I
3	deficiency	O
4	or	O
5	protein	B
6	S	I
7	deficiency	O
8	was	O
9	the	O
10	only	O
11	identified	O
12	risk	O
13	factor	O
14	for	O
15	5	O
16	.	O
17	4	O
18	%	O
19	(	O
20	2	O
21	patients	O
22	)	O
23	and	O
24	13	O
25	.	O
26	5	O
27	%	O
28	(	O
29	5	O
30	patients	O
31	),	O
32	respectively	O
33	,	O
34	of	O
35	these	O
36	37	O
37	children	O
38	.	O
1	Perhaps	O
2	in	O
3	addition	O
4	to	O
5	,	O
6	or	O
7	as	O
8	part	O
9	of	O
10	,	O
11	its	O
12	essential	O
13	function	O
14	in	O
15	late	O
16	mitosis	O
17	,	O
18	MOB1	B
19	is	O
20	required	O
21	for	O
22	a	O
23	cell	O
24	cycle	O
25	reset	O
26	function	O
27	necessary	O
28	for	O
29	the	O
30	initiation	O
31	of	O
32	the	O
33	spindle	O
34	pole	O
35	body	O
36	duplication	O
37	.	O
1	To	O
2	examine	O
3	the	O
4	role	O
5	of	O
6	this	O
7	CE2	O
8	element	O
9	in	O
10	regulating	O
11	Hoxa1	B
12	expression	O
13	in	O
14	vivo	O
15	,	O
16	transgenic	O
17	mice	O
18	were	O
19	generated	O
20	which	O
21	express	O
22	a	O
23	Hoxa1	B
24	beta	I
25	-	I
26	galactosidase	I
27	reporter	O
28	gene	O
29	that	O
30	contains	O
31	a	O
32	mutation	O
33	in	O
34	the	O
35	CE2	O
36	element	O
37	.	O
1	RESULTS	O
2	:	O
3	The	O
4	bovine	O
5	cDNA	O
6	insert	O
7	sequence	O
8	was	O
9	273	O
10	nucleotides	O
11	in	O
12	length	O
13	for	O
14	the	O
15	entire	O
16	mRNA	O
17	coding	O
18	region	O
19	,	O
20	212	O
21	nucleotides	O
22	in	O
23	the	O
24	5	O
25	'	O
26	untranslated	O
27	region	O
28	,	O
29	83	O
30	nucleotides	O
31	in	O
32	the	O
33	3	O
34	'	O
35	untranslated	O
36	region	O
37	and	O
38	a	O
39	poly	O
40	(	O
41	A	O
42	)	O
43	tail	O
44	.	O
1	We	O
2	have	O
3	previously	O
4	identified	O
5	a	O
6	liver	O
7	-	O
8	enriched	O
9	transcription	O
10	factor	O
11	,	O
12	HNF	B
13	-	I
14	6	I
15	,	O
16	which	O
17	is	O
18	required	O
19	for	O
20	HNF	B
21	-	I
22	3	I
23	beta	I
24	promoter	I
25	activity	O
26	and	O
27	also	O
28	recognizes	O
29	the	O
30	regulatory	O
31	region	O
32	of	O
33	numerous	O
34	hepatocyte	O
35	-	O
36	specific	O
37	genes	O
38	.	O
1	A	O
2	cDNA	O
3	clone	O
4	was	O
5	identified	O
6	encoding	O
7	a	O
8	second	O
9	GHS	B
10	-	I
11	R	I
12	-	I
13	related	I
14	gene	I
15	(	O
16	GPR39	B
17	).	O
1	In	O
2	vitro	O
3	DNase	B
4	I	I
5	footprinting	O
6	of	O
7	the	O
8	200	O
9	-	O
10	bp	O
11	proximal	O
12	region	O
13	of	O
14	the	O
15	promoter	O
16	with	O
17	a	O
18	murine	O
19	Hepa	O
20	1	O
21	-	O
22	6	O
23	cell	O
24	nuclear	O
25	extract	O
26	revealed	O
27	a	O
28	clear	O
29	footprint	O
30	of	O
31	a	O
32	region	O
33	corresponding	O
34	to	O
35	-	O
36	80	O
37	to	O
38	-	O
39	28	O
40	bp	O
41	of	O
42	the	O
43	murine	B
44	fVII	I
45	gene	I
46	,	O
47	suggesting	O
48	that	O
49	liver	O
50	factors	O
51	interact	O
52	with	O
53	this	O
54	region	O
55	of	O
56	the	O
57	DNA	O
58	.	O
1	Consistent	O
2	with	O
3	this	O
4	interpretation	O
5	,	O
6	a	O
7	mutant	O
8	form	O
9	of	O
10	XRN1	B
11	,	O
12	which	O
13	encodes	O
14	a	O
15	5	O
16	'-	O
17	3	O
18	'	O
19	exonuclease	O
20	,	O
21	was	O
22	identified	O
23	as	O
24	an	O
25	extragenic	O
26	suppressor	O
27	that	O
28	increases	O
29	the	O
30	half	O
31	-	O
32	life	O
33	of	O
34	rhis4	B
35	mRNA	I
36	,	O
37	leading	O
38	to	O
39	a	O
40	10	O
41	-	O
42	fold	O
43	increase	O
44	in	O
45	steady	O
46	-	O
47	state	O
48	mRNA	O
49	levels	O
50	compared	O
51	to	O
52	the	O
53	wild	B
54	-	I
55	type	I
56	HIS4	I
57	mRNA	I
58	level	O
59	.	O
1	Antibodies	O
2	raised	O
3	against	O
4	GST	B
5	mSH2	I
6	-	I
7	B	I
8	identified	O
9	a	O
10	cellular	O
11	protein	O
12	of	O
13	92	O
14	kDa	O
15	that	O
16	was	O
17	not	O
18	found	O
19	to	O
20	be	O
21	phosphorylated	O
22	on	O
23	Tyr	O
24	.	O
1	The	O
2	assay	O
3	exhibits	O
4	a	O
5	dynamic	O
6	range	O
7	of	O
8	0	O
9	.	O
10	1	O
11	-	O
12	100	O
13	micrograms	O
14	l	O
15	-	O
16	1	O
17	using	O
18	a	O
19	monoclonal	O
20	antibody	O
21	or	O
22	alternatively	O
23	10	O
24	micrograms	O
25	l	O
26	-	O
27	1	O
28	to	O
29	10	O
30	mg	O
31	l	O
32	-	O
33	1	O
34	using	O
35	commercially	O
36	available	O
37	antiserum	O
38	.	O
1	Expression	O
2	and	O
3	characterization	O
4	of	O
5	recombinant	B
6	single	I
7	-	I
8	chain	I
9	Fv	I
10	and	O
11	Fv	B
12	fragments	I
13	derived	O
14	from	O
15	a	O
16	set	O
17	of	O
18	catalytic	O
19	antibodies	O
20	.	O
1	The	O
2	ipsilateral	O
3	breast	O
4	tumor	O
5	relapse	O
6	rate	O
7	was	O
8	similar	O
9	between	O
10	the	O
11	PALP	O
12	and	O
13	MGDET	O
14	groups	O
15	.	O
1	Northern	O
2	analysis	O
3	indicated	O
4	differential	O
5	expression	O
6	by	O
7	tissue	O
8	with	O
9	highest	O
10	expression	O
11	in	O
12	the	O
13	heart	O
14	.	O
1	In	O
2	the	O
3	tissues	O
4	tested	O
5	,	O
6	except	O
7	brain	O
8	,	O
9	the	O
10	message	O
11	for	O
12	CLIP	B
13	-	I
14	170	I
15	was	O
16	more	O
17	abundant	O
18	than	O
19	that	O
20	for	O
21	Restin	B
22	.	O
1	BACKGROUND	O
2	:	O
3	Chemicals	O
4	vary	O
5	considerably	O
6	in	O
7	their	O
8	intrinsic	O
9	ability	O
10	to	O
11	cause	O
12	allergic	O
13	contact	O
14	dermatitis	O
15	.	O
1	The	O
2	cloned	O
3	alcR	B
4	gene	I
5	provided	O
6	in	O
7	trans	O
8	restored	O
9	these	O
10	siderophore	O
11	system	O
12	activities	O
13	to	O
14	the	O
15	mutants	O
16	.	O
1	Competitive	O
2	reverse	O
3	transcription	O
4	-	O
5	polymerase	O
6	chain	O
7	reaction	O
8	and	O
9	HPLC	O
10	analysis	O
11	showed	O
12	that	O
13	RUSH	B
14	-	I
15	1alpha	I
16	is	O
17	the	O
18	progesterone	O
19	-	O
20	dependent	O
21	splice	O
22	variant	O
23	.	O
1	TOR2	B
2	is	O
3	part	O
4	of	O
5	two	O
6	related	O
7	signaling	O
8	pathways	O
9	coordinating	O
10	cell	O
11	growth	O
12	in	O
13	Saccharomyces	O
14	cerevisiae	O
15	.	O
1	Simple	O
2	models	O
3	of	O
4	bimolecular	O
5	interaction	O
6	did	O
7	not	O
8	fully	O
9	account	O
10	for	O
11	the	O
12	kinetic	O
13	profiles	O
14	obtained	O
15	with	O
16	the	O
17	parental	O
18	antibodies	O
19	and	O
20	the	O
21	hybrids	O
22	,	O
23	and	O
24	this	O
25	complexity	O
26	suggested	O
27	the	O
28	existence	O
29	of	O
30	a	O
31	conformational	O
32	heterogeneity	O
33	in	O
34	these	O
35	molecules	O
36	.	O
1	To	O
2	elucidate	O
3	the	O
4	regulatory	O
5	mechanism	O
6	of	O
7	human	B
8	AM	I
9	gene	I
10	expression	O
11	,	O
12	functional	O
13	elements	O
14	of	O
15	5	O
16	'-	O
17	flanking	O
18	region	O
19	of	O
20	AM	B
21	gene	I
22	were	O
23	studied	O
24	in	O
25	human	O
26	aortic	O
27	endothelial	O
28	cells	O
29	(	O
30	HAEC	O
31	).	O
1	Despite	O
2	this	O
3	there	O
4	was	O
5	no	O
6	difference	O
7	in	O
8	the	O
9	intubating	O
10	conditions	O
11	at	O
12	one	O
13	minute	O
14	with	O
15	25	O
16	excellent	O
17	/	O
18	5	O
19	good	O
20	in	O
21	the	O
22	suxamethonium	O
23	group	O
24	and	O
25	27	O
26	excellent	O
27	/	O
28	3	O
29	good	O
30	in	O
31	the	O
32	rocuronium	O
33	group	O
34	.	O
1	Sp1	B
2	can	O
3	activate	O
4	transcription	O
5	through	O
6	immunoglobulin	B
7	kappa	I
8	-	I
9	chain	I
10	enhancer	I
11	or	O
12	P	B
13	-	I
14	selectin	I
15	promoter	I
16	NF	I
17	-	I
18	kappaB	I
19	sites	I
20	.	O
21	p50	B
22	homodimers	I
23	replace	O
24	Sp1	B
25	from	O
26	the	O
27	P	B
28	-	I
29	selectin	I
30	promoter	I
31	by	O
32	binding	O
33	site	O
34	competition	O
35	and	O
36	thereby	O
37	either	O
38	inhibit	O
39	basal	O
40	Sp1	B
41	-	O
42	driven	O
43	expression	O
44	or	O
45	,	O
46	in	O
47	concert	O
48	with	O
49	Bcl	B
50	-	I
51	3	I
52	,	O
53	stimulate	O
54	expression	O
55	.	O
1	For	O
2	the	O
3	5HT5A	B
4	receptor	I
5	the	O
6	addition	O
7	of	O
8	yohimbine	O
9	resulted	O
10	in	O
11	a	O
12	similar	O
13	but	O
14	smaller	O
15	effect	O
16	.	O
1	The	O
2	DSF	O
3	regimen	O
4	appears	O
5	to	O
6	have	O
7	significant	O
8	activity	O
9	in	O
10	patients	O
11	who	O
12	have	O
13	metastatic	O
14	pancreatic	O
15	islet	O
16	-	O
17	cell	O
18	carcinoma	O
19	,	O
20	and	O
21	patient	O
22	tolerance	O
23	of	O
24	the	O
25	regimen	O
26	is	O
27	excellent	O
28	,	O
29	thus	O
30	warranting	O
31	further	O
32	investigation	O
33	.	O
1	CONCLUSIONS	O
2	:	O
3	XCoe2	B
4	may	O
5	play	O
6	a	O
7	pivotal	O
8	role	O
9	in	O
10	the	O
11	transcriptional	O
12	cascade	O
13	that	O
14	specifies	O
15	primary	O
16	neurons	O
17	in	O
18	Xenopus	O
19	embryos	O
20	:	O
21	by	O
22	maintaining	O
23	Delta	B
24	-	O
25	Notch	B
26	signalling	O
27	,	O
28	XCoe2	B
29	stabilises	O
30	the	O
31	higher	O
32	neural	O
33	potential	O
34	of	O
35	selected	O
36	progenitor	O
37	cells	O
38	that	O
39	express	O
40	X	B
41	-	I
42	ngnr	I
43	-	I
44	1	I
45	,	O
46	ensuring	O
47	the	O
48	transition	O
49	between	O
50	neural	O
51	competence	O
52	and	O
53	irreversible	O
54	commitment	O
55	to	O
56	a	O
57	neural	O
58	fate	O
59	;	O
60	and	O
61	it	O
62	promotes	O
63	neuronal	O
64	differentiation	O
65	by	O
66	activating	O
67	XNeuroD	B
68	expression	O
69	,	O
70	directly	O
71	or	O
72	indirectly	O
73	.	O
1	RESULTS	O
2	:	O
3	Patients	O
4	in	O
5	Group	O
6	A	O
7	had	O
8	a	O
9	higher	O
10	incidence	O
11	of	O
12	posterolateral	O
13	wall	O
14	motion	O
15	abnormalities	O
16	(	O
17	p	O
18	<	O
19	0	O
20	.	O
21	001	O
22	)	O
23	on	O
24	radionuclide	O
25	ventriculography	O
26	,	O
27	a	O
28	larger	O
29	infarct	O
30	area	O
31	(	O
32	as	O
33	evidenced	O
34	by	O
35	higher	O
36	peak	O
37	creatine	B
38	kinase	I
39	levels	O
40	)	O
41	(	O
42	p	O
43	<	O
44	0	O
45	.	O
46	02	O
47	)	O
48	and	O
49	a	O
50	lower	O
51	left	O
52	ventricular	O
53	ejection	O
54	fraction	O
55	(	O
56	LVEF	O
57	)	O
58	at	O
59	hospital	O
60	discharge	O
61	(	O
62	p	O
63	<	O
64	0	O
65	.	O
66	008	O
67	)	O
68	than	O
69	those	O
70	in	O
71	Group	O
72	B	O
73	.	O
1	We	O
2	further	O
3	show	O
4	that	O
5	proteolytic	O
6	targeting	O
7	by	O
8	calpain	B
9	II	I
10	and	O
11	the	O
12	proteasome	O
13	involves	O
14	different	O
15	structural	O
16	elements	O
17	of	O
18	YY1	B
19	.	O
1	If	O
2	the	O
3	haemoglobin	B
4	concentration	O
5	(	O
6	Hb	B
7	)	O
8	was	O
9	less	O
10	than	O
11	12	O
12	g	O
13	dL	O
14	-	O
15	1	O
16	they	O
17	were	O
18	given	O
19	a	O
20	four	O
21	week	O
22	course	O
23	of	O
24	ferrous	O
25	sulphate	O
26	.	O
1	These	O
2	results	O
3	indicate	O
4	that	O
5	TGF	B
6	-	I
7	betaf	I
8	potentiates	O
9	the	O
10	c	B
11	-	I
12	fos	I
13	SRE	O
14	activated	O
15	by	O
16	PKC	B
17	through	O
18	the	O
19	SRF	B
20	binding	I
21	site	I
22	.	O
1	RT	O
2	-	O
3	PCR	O
4	indicated	O
5	that	O
6	p21	B
7	mRNA	I
8	was	O
9	induced	O
10	1	O
11	.	O
12	4	O
13	-,	O
14	2	O
15	.	O
16	0	O
17	-,	O
18	and	O
19	3	O
20	.	O
21	1	O
22	-	O
23	fold	O
24	in	O
25	the	O
26	2	O
27	-	O
28	day	O
29	neonatal	O
30	,	O
31	7	O
32	-	O
33	day	O
34	neonatal	O
35	,	O
36	and	O
37	adult	O
38	stages	O
39	,	O
40	respectively	O
41	,	O
42	compared	O
43	to	O
44	the	O
45	17	O
46	-	O
47	day	O
48	fetal	O
49	stage	O
50	.	O
1	BACKGROUND	O
2	:	O
3	Defensins	B
4	,	O
5	also	O
6	known	O
7	as	O
8	human	B
9	neutrophil	I
10	peptides	I
11	,	O
12	are	O
13	antimicrobial	O
14	peptides	O
15	present	O
16	in	O
17	the	O
18	azurophil	O
19	granules	O
20	of	O
21	neutrophils	O
22	.	O
1	The	O
2	spontaneous	O
3	mutation	O
4	blocking	O
5	pca	B
6	gene	I
7	expression	O
8	was	O
9	located	O
10	in	O
11	the	O
12	promoter	O
13	for	O
14	the	O
15	pca	B
16	operon	I
17	.	O
1	Azithromycin	O
2	is	O
3	a	O
4	new	O
5	generation	O
6	macrolide	O
7	antibiotic	O
8	with	O
9	unusual	O
10	and	O
11	favorable	O
12	pharmacokinetics	O
13	,	O
14	and	O
15	seems	O
16	to	O
17	be	O
18	a	O
19	very	O
20	promising	O
21	agent	O
22	for	O
23	innovative	O
24	anti	O
25	-	O
26	H	O
27	.	O
28	pylori	O
29	regimens	O
30	.	O
1	The	O
2	study	O
3	enrolled	O
4	994	O
5	people	O
6	co	O
7	-	O
8	infected	O
9	with	O
10	CMV	O
11	and	O
12	HIV	O
13	,	O
14	with	O
15	at	O
16	least	O
17	one	O
18	CD4	B
19	count	O
20	recorded	O
21	<	O
22	100	O
23	x	O
24	10	O
25	(	O
26	6	O
27	)	O
28	cells	O
29	/	O
30	l	O
31	.	O
1	BACKGROUND	O
2	AND	O
3	OBJECTIVES	O
4	:	O
5	The	O
6	sexually	O
7	transmitted	O
8	diseases	O
9	(	O
10	STD	O
11	)	O
12	control	O
13	program	O
14	for	O
15	female	O
16	sex	O
17	workers	O
18	(	O
19	FSW	O
20	)	O
21	in	O
22	Lima	O
23	,	O
24	Peru	O
25	,	O
26	provided	O
27	periodic	O
28	serological	O
29	tests	O
30	for	O
31	syphilis	O
32	and	O
33	cervical	O
34	smears	O
35	for	O
36	gonococci	O
37	,	O
38	but	O
39	not	O
40	medication	O
41	for	O
42	STD	O
43	or	O
44	condoms	O
45	.	O
1	These	O
2	changes	O
3	correlate	O
4	directly	O
5	with	O
6	an	O
7	increase	O
8	in	O
9	the	O
10	acetylation	O
11	levels	O
12	of	O
13	all	O
14	four	O
15	core	B
16	histones	I
17	in	O
18	vivo	O
19	.	O
1	The	O
2	hp55	B
3	gamma	I
4	protein	I
5	interacts	O
6	strongly	O
7	with	O
8	the	O
9	activated	O
10	IGFIR	B
11	but	O
12	not	O
13	with	O
14	the	O
15	kinase	O
16	-	O
17	negative	O
18	mutant	O
19	receptor	O
20	.	O
21	hp55	B
22	gamma	I
23	also	O
24	interacts	O
25	with	O
26	the	O
27	insulin	B
28	receptor	I
29	(	O
30	IR	B
31	)	O
32	in	O
33	the	O
34	yeast	O
35	two	O
36	-	O
37	hybrid	O
38	system	O
39	.	O
1	Full	B
2	-	I
3	length	I
4	FLAP	I
5	clones	O
6	were	O
7	isolated	O
8	from	O
9	a	O
10	mouse	O
11	skeletal	O
12	muscle	O
13	cDNA	O
14	library	O
15	.	O
1	Flap	O
2	survival	O
3	depends	O
4	on	O
5	the	O
6	development	O
7	of	O
8	a	O
9	small	O
10	number	O
11	of	O
12	vascular	O
13	connections	O
14	between	O
15	vessels	O
16	arising	O
17	from	O
18	the	O
19	pedicle	O
20	and	O
21	preexisting	O
22	dermal	O
23	vessels	O
24	.	O
1	In	O
2	vitro	O
3	binding	O
4	studies	O
5	using	O
6	GST	B
7	fusion	O
8	proteins	O
9	and	O
10	yeast	O
11	extracts	O
12	defined	O
13	distinct	O
14	binding	O
15	sites	O
16	on	O
17	yAP180A	B
18	for	O
19	Pan1p	B
20	and	O
21	clathrin	B
22	.	O
23	yAP180	B
24	proteins	I
25	and	O
26	Pan1p	B
27	,	O
28	like	O
29	actin	B
30	,	O
31	localize	O
32	to	O
33	peripheral	O
34	patches	O
35	along	O
36	the	O
37	plasma	O
38	membrane	O
39	.	O
1	Two	O
2	differentially	O
3	expressed	O
4	LNX	B
5	messages	I
6	encode	O
7	overlapping	O
8	proteins	O
9	with	O
10	predicted	O
11	molecular	O
12	masses	O
13	of	O
14	80	B
15	kDa	I
16	(	I
17	LNX	I
18	)	I
19	and	O
20	70	O
21	kDa	O
22	(	O
23	LNX	O
24	-	O
25	b	O
26	).	O
1	Analysis	O
2	of	O
3	promoter	O
4	and	O
5	androgen	O
6	regulatory	O
7	sequences	O
8	required	O
9	for	O
10	optimal	O
11	transcription	O
12	of	O
13	the	O
14	rat	O
15	androgen	B
16	-	I
17	binding	I
18	protein	I
19	gene	O
20	.	O
1	Furthermore	O
2	,	O
3	in	O
4	the	O
5	ischemia	O
6	/	O
7	angiotension	B
8	II	I
9	-	O
10	induced	O
11	AHF	O
12	model	O
13	,	O
14	NIC	O
15	decreased	O
16	left	O
17	ventricular	O
18	end	O
19	-	O
20	diastolic	O
21	pressure	O
22	(	O
23	LVEDP	O
24	).	O
1	ATP	O
2	-	O
3	dependent	O
4	assembly	O
5	of	O
6	a	O
7	ternary	O
8	complex	O
9	consisting	O
10	of	O
11	a	O
12	DNA	O
13	mismatch	O
14	and	O
15	the	O
16	yeast	O
17	MSH2	B
18	-	O
19	MSH6	B
20	and	O
21	MLH1	B
22	-	O
23	PMS1	B
24	protein	O
25	complexes	O
26	.	O
1	We	O
2	recently	O
3	characterized	O
4	a	O
5	single	O
6	yeast	B
7	hnRNP	I
8	methyltransferase	I
9	(	O
10	HMT1	B
11	).	O
1	We	O
2	recently	O
3	characterized	O
4	a	O
5	single	O
6	yeast	B
7	hnRNP	I
8	methyltransferase	I
9	(	O
10	HMT1	B
11	).	O
1	Recombinant	B
2	HRMT1L2	I
3	protein	I
4	encoded	O
5	by	O
6	the	O
7	most	O
8	common	O
9	5	O
10	'-	O
11	variant	O
12	exhibited	O
13	methyltransferase	O
14	activity	O
15	in	O
16	vitro	O
17	.	O
1	Furthermore	O
2	,	O
3	interactions	O
4	were	O
5	identified	O
6	between	O
7	endogenous	B
8	E	I
9	-	I
10	cadherin	I
11	and	O
12	the	O
13	chimera	O
14	containing	O
15	the	O
16	E	B
17	-	I
18	cadherin	I
19	extracellular	I
20	domain	I
21	and	O
22	the	O
23	desmoglein	B
24	1	I
25	intracellular	I
26	domain	I
27	providing	O
28	in	O
29	vivo	O
30	evidence	O
31	for	O
32	previously	O
33	predicted	O
34	lateral	O
35	interactions	O
36	of	O
37	E	B
38	-	I
39	cadherin	I
40	extracellular	I
41	domains	I
42	.	O
1	The	O
2	ether	O
3	phospholipid	O
4	1	O
5	-	O
6	O	O
7	-	O
8	octadecyl	O
9	-	O
10	2	O
11	-	O
12	O	O
13	-	O
14	methyl	O
15	-	O
16	rac	O
17	-	O
18	glycero	O
19	-	O
20	3	O
21	-	O
22	phosphocholine	O
23	(	O
24	ET	O
25	-	O
26	18	O
27	-	O
28	OCH3	O
29	;	O
30	edelfosine	O
31	)	O
32	is	O
33	a	O
34	potent	O
35	inducer	O
36	of	O
37	apoptosis	O
38	in	O
39	human	O
40	tumor	O
41	cells	O
42	.	O
1	Serum	O
2	levels	O
3	of	O
4	testosterone	O
5	also	O
6	showed	O
7	no	O
8	significant	O
9	changes	O
10	by	O
11	exposure	O
12	to	O
13	p	O
14	,	O
15	p	O
16	'-	O
17	DDE	O
18	under	O
19	the	O
20	conditions	O
21	of	O
22	this	O
23	study	O
24	.	O
1	Their	O
2	use	O
3	resulted	O
4	in	O
5	a	O
6	sensitivity	O
7	of	O
8	73	O
9	%	O
10	and	O
11	a	O
12	specificity	O
13	of	O
14	74	O
15	%	O
16	with	O
17	regard	O
18	to	O
19	predictability	O
20	of	O
21	ALT	B
22	levels	O
23	increasing	O
24	during	O
25	the	O
26	trial	O
27	.	O
1	The	O
2	N	O
3	-	O
4	syndecan	O
5	-	O
6	dependent	O
7	neurite	O
8	outgrowth	O
9	is	O
10	inhibited	O
11	by	O
12	the	O
13	tyrosine	B
14	kinase	I
15	inhibitors	O
16	herbimycin	O
17	A	O
18	and	O
19	PP1	B
20	.	O
1	The	O
2	pharmacokinetic	O
3	patterns	O
4	of	O
5	estradiol	O
6	(	O
7	CAS	O
8	50	O
9	-	O
10	28	O
11	-	O
12	2	O
13	)	O
14	and	O
15	of	O
16	estrone	O
17	(	O
18	CAS	O
19	53	O
20	-	O
21	16	O
22	-	O
23	7	O
24	)	O
25	were	O
26	investigated	O
27	in	O
28	18	O
29	women	O
30	in	O
31	natural	O
32	or	O
33	surgical	O
34	menopause	O
35	during	O
36	the	O
37	application	O
38	of	O
39	a	O
40	new	O
41	estradiol	O
42	transdermal	O
43	patch	O
44	with	O
45	active	O
46	matrix	O
47	and	O
48	without	O
49	absorption	O
50	enhancers	O
51	designed	O
52	for	O
53	epicutaneous	O
54	applications	O
55	of	O
56	7	O
57	days	O
58	(	O
59	hereinafter	O
60	called	O
61	""""	O
62	patch	O
63	7D	O
64	""")."	O
1	Among	O
2	the	O
3	H	B
4	/	I
5	ACA	I
6	snoRNAs	I
7	associated	O
8	with	O
9	Gar1p	B
10	,	O
11	one	O
12	can	O
13	distinguish	O
14	a	O
15	large	O
16	group	O
17	of	O
18	snoRNAs	O
19	that	O
20	are	O
21	not	O
22	essential	O
23	in	O
24	yeast	O
25	and	O
26	serve	O
27	as	O
28	guides	O
29	for	O
30	pseudouridine	O
31	synthesis	O
32	onto	O
33	the	O
34	pre	O
35	-	O
36	rRNA	O
37	molecule	O
38	.	O
1	Rhesus	O
2	macaques	O
3	and	O
4	BALB	O
5	/	O
6	c	O
7	mice	O
8	inoculated	O
9	with	O
10	the	O
11	Mengo	O
12	virus	O
13	SIV	O
14	recombinants	O
15	failed	O
16	to	O
17	develop	O
18	CTL	O
19	responses	O
20	against	O
21	the	O
22	SIV	O
23	gene	O
24	products	O
25	,	O
26	while	O
27	one	O
28	of	O
29	the	O
30	HIV	B
31	-	I
32	Nef	I
33	recombinants	I
34	induced	O
35	a	O
36	weak	O
37	CTL	O
38	response	O
39	in	O
40	mice	O
41	directed	O
42	to	O
43	an	O
44	HIV1	B
45	Nef	I
46	peptide	I
47	spanning	O
48	positions	O
49	182	O
50	-	O
51	198	O
52	.	O
1	Similarly	O
2	,	O
3	PCDFs	O
4	/	O
5	PCDDs	O
6	ratio	O
7	in	O
8	ESP	O
9	ash	O
10	was	O
11	lower	O
12	than	O
13	that	O
14	in	O
15	boiler	O
16	ash	O
17	.	O
1	Localization	O
2	of	O
3	67	O
4	exons	O
5	on	O
6	a	O
7	YAC	O
8	contig	O
9	spanning	O
10	1	O
11	.	O
12	5	O
13	Mb	O
14	around	O
15	the	O
16	multidrug	B
17	resistance	I
18	gene	I
19	region	I
20	of	O
21	human	O
22	chromosome	O
23	7q21	O
24	.	O
25	1	O
26	.	O
1	Many	O
2	cytokine	O
3	receptors	O
4	employ	O
5	Janus	B
6	protein	I
7	tyrosine	I
8	kinases	I
9	(	O
10	Jaks	B
11	)	O
12	and	O
13	signal	B
14	transducers	I
15	and	I
16	activators	I
17	of	I
18	transcription	I
19	(	O
20	Stats	B
21	)	O
22	for	O
23	nuclear	O
24	signaling	O
25	.	O
1	In	O
2	angiodysplasia	O
3	,	O
4	ectatic	O
5	vessels	O
6	in	O
7	the	O
8	mucosa	O
9	appeared	O
10	to	O
11	contain	O
12	less	O
13	collagen	B
14	type	I
15	IV	I
16	than	O
17	similarly	O
18	sized	O
19	vessels	O
20	in	O
21	the	O
22	submucosa	O
23	,	O
24	and	O
25	perforating	O
26	vessels	O
27	appeared	O
28	in	O
29	many	O
30	cases	O
31	to	O
32	lose	O
33	staining	O
34	at	O
35	the	O
36	level	O
37	of	O
38	the	O
39	muscularis	O
40	mucosae	O
41	.	O
1	To	O
2	clarify	O
3	whether	O
4	seizure	O
5	-	O
6	offset	O
7	patterns	O
8	are	O
9	reliable	O
10	in	O
11	predicting	O
12	seizure	O
13	outcome	O
14	,	O
15	we	O
16	studied	O
17	SEEG	O
18	/	O
19	ECoG	O
20	in	O
21	a	O
22	similar	O
23	group	O
24	of	O
25	patients	O
26	with	O
27	temporal	O
28	lobe	O
29	epilepsy	O
30	(	O
31	TLE	O
32	).	O
1	The	O
2	DNA	O
3	binding	O
4	activities	O
5	of	O
6	the	O
7	three	O
8	repressor	O
9	preparations	O
10	were	O
11	studied	O
12	using	O
13	fragments	O
14	containing	O
15	CIRs	O
16	(	O
17	CIR3	O
18	-	O
19	CIR6	O
20	)	O
21	from	O
22	the	O
23	essential	O
24	early	O
25	region	O
26	as	O
27	templates	O
28	for	O
29	DNase	B
30	I	I
31	footprinting	O
32	.	O
1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	suggest	O
7	that	O
8	silymarin	O
9	may	O
10	exert	O
11	a	O
12	strong	O
13	anticarcinogenic	O
14	effect	O
15	against	O
16	PCA	O
17	and	O
18	that	O
19	this	O
20	effect	O
21	is	O
22	likely	O
23	to	O
24	involve	O
25	impairment	O
26	of	O
27	erbB1	B
28	-	O
29	SHC	B
30	-	O
31	mediated	O
32	signaling	O
33	pathway	O
34	,	O
35	induction	O
36	of	O
37	CDKIs	B
38	,	O
39	and	O
40	a	O
41	resultant	O
42	G1	O
43	arrest	O
44	.	O
1	We	O
2	established	O
3	the	O
4	radiosensitive	O
5	cell	O
6	line	O
7	SX9	O
8	from	O
9	mammary	O
10	carcinoma	O
11	cell	O
12	line	O
13	FM3A	O
14	.	O
1	Results	O
2	showed	O
3	that	O
4	the	O
5	mean	O
6	bond	O
7	strength	O
8	of	O
9	H	O
10	.	O
11	T	O
12	.	O
13	V	O
14	.	O
15	specimens	O
16	ranged	O
17	from	O
18	9	O
19	.	O
20	6	O
21	to	O
22	13	O
23	.	O
24	12	O
25	kg	O
26	/	O
27	cm2	O
28	,	O
29	while	O
30	the	O
31	mean	O
32	bond	O
33	strength	O
34	of	O
35	R	O
36	.	O
37	T	O
38	.	O
39	V	O
40	.	O
41	specimens	O
42	ranged	O
43	from	O
44	0	O
45	.	O
46	36	O
47	to	O
48	1	O
49	.	O
50	75	O
51	kg	O
52	/	O
53	cm2	O
54	.	O
1	OBJECTIVES	O
2	:	O
3	To	O
4	measure	O
5	coagulation	B
6	factor	I
7	VIII	I
8	:	I
9	coagulant	I
10	(	O
11	F	B
12	.	I
13	VIII	I
14	:	I
15	C	I
16	)	O
17	and	O
18	C1	B
19	-	I
20	esterase	I
21	inhibitor	I
22	(	O
23	C1	B
24	-	I
25	INH	I
26	),	O
27	hemostasis	O
28	-	O
29	associated	O
30	acute	O
31	-	O
32	phase	O
33	reactant	O
34	proteins	O
35	and	O
36	coagulation	B
37	factors	I
38	VII	I
39	(	O
40	F	B
41	.	I
42	VII	I
43	),	O
44	IX	O
45	(	O
46	F	B
47	.	I
48	IX	I
49	),	O
50	and	O
51	X	O
52	(	O
53	F	B
54	.	I
55	X	I
56	),	O
57	hemostasis	O
58	proteins	O
59	not	O
60	associated	O
61	with	O
62	an	O
63	acute	O
64	-	O
65	phase	O
66	response	O
67	,	O
68	in	O
69	a	O
70	select	O
71	population	O
72	of	O
73	horses	O
74	with	O
75	colic	O
76	and	O
77	hemostasis	O
78	abnormalities	O
79	,	O
80	and	O
81	presumed	O
82	to	O
83	have	O
84	acute	O
85	-	O
86	phase	O
87	changes	O
88	.	O
1	DESIGN	O
2	AND	O
3	METHODS	O
4	:	O
5	Case	O
6	study	O
7	.	O
1	Our	O
2	data	O
3	showed	O
4	that	O
5	activation	O
6	of	O
7	the	O
8	raf	B
9	-	O
10	ERK	B
11	pathway	O
12	led	O
13	to	O
14	activation	O
15	of	O
16	TF	B
17	expression	O
18	in	O
19	breast	O
20	carcinoma	O
21	cells	O
22	and	O
23	suggested	O
24	that	O
25	constitutive	O
26	activation	O
27	of	O
28	this	O
29	pathway	O
30	leads	O
31	to	O
32	high	O
33	TF	B
34	expression	O
35	in	O
36	MDA	O
37	-	O
38	MB	O
39	-	O
40	231	O
41	cells	O
42	.	O
1	RESULTS	O
2	:	O
3	Acetabular	O
4	index	O
5	returned	O
6	to	O
7	normal	O
8	gradually	O
9	as	O
10	the	O
11	time	O
12	went	O
13	by	O
14	and	O
15	significantly	O
16	within	O
17	one	O
18	year	O
19	after	O
20	the	O
21	reduction	O
22	of	O
23	developmental	O
24	dislocation	O
25	of	O
26	the	O
27	hip	O
28	.	O
1	Consequently	O
2	,	O
3	it	O
4	is	O
5	not	O
6	known	O
7	how	O
8	knee	O
9	loading	O
10	changes	O
11	following	O
12	ACL	O
13	transection	O
14	,	O
15	and	O
16	how	O
17	it	O
18	contributes	O
19	to	O
20	cartilage	O
21	degeneration	O
22	.	O
1	Roles	O
2	of	O
3	the	O
4	Candida	B
5	albicans	I
6	mitogen	I
7	-	I
8	activated	I
9	protein	I
10	kinase	I
11	homolog	I
12	,	O
13	Cek1p	B
14	,	O
15	in	O
16	hyphal	O
17	development	O
18	and	O
19	systemic	O
20	candidiasis	O
21	.	O
1	We	O
2	provide	O
3	community	O
4	metabolic	O
5	data	O
6	that	O
7	indicate	O
8	that	O
9	large	O
10	changes	O
11	in	O
12	CO2	O
13	concentration	O
14	can	O
15	occur	O
16	in	O
17	coral	O
18	reef	O
19	waters	O
20	via	O
21	biogeochemical	O
22	processes	O
23	not	O
24	directly	O
25	associated	O
26	with	O
27	photosynthesis	O
28	,	O
29	respiration	O
30	,	O
31	calcification	O
32	,	O
33	and	O
34	CaCO3	O
35	dissolution	O
36	.	O
1	In	O
2	contrast	O
3	to	O
4	other	O
5	known	O
6	retroviruses	O
7	,	O
8	the	O
9	FV	B
10	pol	I
11	genes	I
12	are	O
13	expressed	O
14	via	O
15	spliced	O
16	transcripts	O
17	.	O
1	Fregnac	O
2	,	O
3	M	O
4	.	O
1	Identical	O
2	results	O
3	were	O
4	obtained	O
5	when	O
6	transfections	O
7	and	O
8	mobility	O
9	shift	O
10	assays	O
11	were	O
12	performed	O
13	in	O
14	primary	O
15	rat	O
16	hepatocytes	O
17	in	O
18	which	O
19	the	O
20	endogenous	O
21	ALS	B
22	gene	I
23	is	O
24	expressed	O
25	.	O
1	CONCLUSION	O
2	:	O
3	In	O
4	women	O
5	who	O
6	want	O
7	or	O
8	require	O
9	conservative	O
10	management	O
11	of	O
12	grade	O
13	4	O
14	prolapse	O
15	and	O
16	are	O
17	unable	O
18	to	O
19	retain	O
20	a	O
21	single	O
22	pessary	O
23	,	O
24	the	O
25	placement	O
26	of	O
27	two	O
28	pessaries	O
29	often	O
30	will	O
31	be	O
32	successful	O
33	.	O
1	Rev	B
2	-	O
3	erbAalpha	B
4	/	I
5	beta	I
6	),	O
7	Mxi	B
8	-	I
9	1	I
10	and	O
11	Mad	B
12	bHLH	O
13	-	O
14	zip	O
15	proteins	O
16	and	O
17	the	O
18	oncoproteins	O
19	PLZF	B
20	and	O
21	LAZ3	B
22	/	O
23	BCL6	B
24	is	O
25	mediated	O
26	by	O
27	the	O
28	corepressors	O
29	N	B
30	-	I
31	CoR	I
32	and	O
33	SMRT	B
34	.	O
1	The	O
2	identified	O
3	isolates	O
4	of	O
5	CSF	O
6	(	O
7	20	O
8	of	O
9	29	O
10	)	O
11	were	O
12	:	O
13	ECHO	O
14	30	O
15	(	O
16	9	O
17	),	O
18	ECHO	O
19	11	O
20	(	O
21	7	O
22	),	O
23	ECHO	O
24	9	O
25	(	O
26	3	O
27	)	O
28	and	O
29	ECHO	O
30	7	O
31	(	O
32	1	O
33	).	O
1	A	O
2	deproteinization	O
3	procedure	O
4	was	O
5	coupled	O
6	with	O
7	a	O
8	reversed	O
9	-	O
10	phase	O
11	HPLC	O
12	separation	O
13	using	O
14	a	O
15	250x4	O
16	.	O
17	6	O
18	mm	O
19	I	O
20	.	O
21	D	O
22	.	O
1	A	O
2	phylogenetic	O
3	analysis	O
4	of	O
5	the	O
6	reverse	B
7	transcriptase	I
8	domain	I
9	confirms	O
10	our	O
11	differential	O
12	genetic	O
13	assessment	O
14	that	O
15	Cyclops	B
16	from	O
17	pea	O
18	is	O
19	a	O
20	novel	O
21	element	O
22	with	O
23	no	O
24	specific	O
25	relationship	O
26	to	O
27	the	O
28	previously	O
29	described	O
30	Gypsy	B
31	-	I
32	like	I
33	elements	I
34	from	O
35	plants	O
36	.	O
1	In	O
2	addition	O
3	,	O
4	insulin	B
5	induced	O
6	AP	B
7	-	I
8	1	I
9	DNA	O
10	binding	O
11	activity	O
12	,	O
13	this	O
14	effect	O
15	being	O
16	totally	O
17	prevented	O
18	in	O
19	the	O
20	presence	O
21	of	O
22	MEK	B
23	-	I
24	1	I
25	inhibitor	O
26	.	O
1	Essentially	O
2	,	O
3	2	O
4	'-	O
5	O	O
6	-	O
7	methyl	O
8	oligoribonucleotides	O
9	(	O
10	2	O
11	'	O
12	OMeRNA	O
13	)	O
14	were	O
15	delivered	O
16	to	O
17	the	O
18	nuclei	O
19	of	O
20	primary	O
21	mdx	O
22	myoblasts	O
23	in	O
24	culture	O
25	.	O
1	We	O
2	characterized	O
3	the	O
4	structure	O
5	of	O
6	this	O
7	leader	O
8	mRNA	O
9	by	O
10	using	O
11	the	O
12	program	O
13	Mfold	O
14	and	O
15	a	O
16	combination	O
17	of	O
18	nested	O
19	and	O
20	internal	O
21	deletions	O
22	transcriptionally	O
23	fused	O
24	to	O
25	a	O
26	promoterless	O
27	lac	B
28	operon	I
29	.	O
1	Routine	O
2	blood	O
3	examination	O
4	showed	O
5	leukocytosis	O
6	,	O
7	thrombocytopenia	O
8	,	O
9	positive	O
10	CRP	B
11	,	O
12	and	O
13	elevated	O
14	myocardial	O
15	enzymes	O
16	.	O
1	Previous	O
2	studies	O
3	have	O
4	suggested	O
5	that	O
6	moderate	O
7	cooling	O
8	increases	O
9	the	O
10	responsiveness	O
11	of	O
12	vascular	B
13	alpha2	I
14	-	I
15	adrenoceptors	I
16	.	O
1	We	O
2	have	O
3	applied	O
4	the	O
5	mRNA	O
6	differential	O
7	display	O
8	method	O
9	to	O
10	compare	O
11	and	O
12	analyze	O
13	mRNAs	O
14	prepared	O
15	from	O
16	five	O
17	normal	O
18	nasopharyngeal	O
19	epithelial	O
20	cell	O
21	cultures	O
22	and	O
23	five	O
24	nasopharyngeal	O
25	carcinoma	O
26	cell	O
27	lines	O
28	.	O
1	We	O
2	found	O
3	the	O
4	following	O
5	:	O
6	Specific	O
7	mutations	O
8	affected	O
9	the	O
10	precise	O
11	carbohydrate	O
12	structure	O
13	and	O
14	folding	O
15	of	O
16	the	O
17	HA	B
18	trimer	I
19	.	O
1	The	O
2	pre	O
3	-	O
4	mRNA	O
5	splicing	O
6	factor	O
7	U2AF	B
8	(	O
9	U2	B
10	small	I
11	nuclear	I
12	ribonucleoprotein	I
13	particle	I
14	[	I
15	snRNP	I
16	]	I
17	auxiliary	I
18	factor	I
19	)	O
20	plays	O
21	a	O
22	critical	O
23	role	O
24	in	O
25	3	O
26	'	O
27	splice	O
28	site	O
29	selection	O
30	.	O
1	The	O
2	virus	O
3	-	O
4	associated	O
5	VAI	B
6	RNA	O
7	of	O
8	adenovirus	O
9	is	O
10	a	O
11	small	O
12	highly	O
13	structured	O
14	RNA	O
15	that	O
16	is	O
17	required	O
18	for	O
19	the	O
20	efficient	O
21	translation	O
22	of	O
23	cellular	O
24	and	O
25	viral	O
26	mRNAs	O
27	at	O
28	late	O
29	times	O
30	after	O
31	infection	O
32	.	O
1	Atmospheric	O
2	benzene	O
3	,	O
4	urinary	O
5	muconic	O
6	acid	O
7	(	O
8	tt	O
9	-	O
10	MA	O
11	)	O
12	and	O
13	leukocyte	B
14	alkaline	I
15	phosphatase	I
16	activity	O
17	(	O
18	LAPA	O
19	)	O
20	were	O
21	evaluated	O
22	among	O
23	66	O
24	car	O
25	mechanics	O
26	,	O
27	34	O
28	road	O
29	tanker	O
30	drivers	O
31	,	O
32	and	O
33	28	O
34	nonexposed	O
35	workers	O
36	.	O
1	It	O
2	contains	O
3	a	O
4	5	O
5	'-	O
6	noncoding	O
7	region	O
8	(	O
9	NCR	O
10	)	O
11	of	O
12	73	O
13	nucleotides	O
14	,	O
15	five	O
16	open	O
17	reading	O
18	frames	O
19	(	O
20	ORFs	O
21	1	O
22	to	O
23	5	O
24	)	O
25	which	O
26	encode	O
27	proteins	O
28	with	O
29	M	O
30	(	O
31	r	O
32	)	O
33	160	O
34	kDa	O
35	RNA	O
36	-	O
37	dependent	O
38	RNA	O
39	polymerase	O
40	(	O
41	ORF1	O
42	),	O
43	26	O
44	kDa	O
45	movement	O
46	protein	O
47	1	O
48	(	O
49	ORF2	O
50	),	O
51	13	O
52	kDa	O
53	movement	O
54	protein	O
55	2	O
56	(	O
57	ORF3	O
58	),	O
59	10	O
60	kDa	O
61	movement	O
62	protein	O
63	3	O
64	(	O
65	ORF4	O
66	),	O
67	24	O
68	kDa	O
69	coat	O
70	protein	O
71	(	O
72	OFR5	O
73	),	O
74	and	O
75	a	O
76	3	O
77	'	O
78	NCR	O
79	of	O
80	76	O
81	nucleotides	O
82	.	O
1	These	O
2	genes	O
3	may	O
4	represent	O
5	interesting	O
6	targets	O
7	for	O
8	new	O
9	therapeutic	O
10	strategies	O
11	.	O
1	It	O
2	could	O
3	also	O
4	inhibit	O
5	C1q	B
6	-	O
7	dependent	O
8	haemolysis	O
9	of	O
10	both	O
11	IgG	B
12	-	O
13	and	O
14	IgM	B
15	-	O
16	sensitized	O
17	erythrocytes	O
18	.	O
1	Binding	O
2	affinities	O
3	of	O
4	different	O
5	nucleotide	O
6	mono	O
7	-,	O
8	di	O
9	-	O
10	and	O
11	triphosphates	O
12	and	O
13	non	O
14	-	O
15	hydrolyzable	O
16	analogs	O
17	indicate	O
18	that	O
19	the	O
20	beta	O
21	-	O
22	phosphate	O
23	moiety	O
24	is	O
25	required	O
26	for	O
27	substrate	O
28	binding	O
29	.	O
1	The	O
2	intron	O
3	8	O
4	enhancer	O
5	region	O
6	was	O
7	not	O
8	activated	O
9	by	O
10	GATA	B
11	-	I
12	1	I
13	together	O
14	with	O
15	Sp1	B
16	in	O
17	transactivation	O
18	experiments	O
19	in	O
20	COS	O
21	-	O
22	1	O
23	cells	O
24	indicating	O
25	the	O
26	involvement	O
27	of	O
28	a	O
29	related	O
30	Sp1	B
31	protein	I
32	or	O
33	of	O
34	another	O
35	unidentified	O
36	erythroid	O
37	factor	O
38	.	O
1	The	O
2	cleavage	O
3	of	O
4	Fak	B
5	by	O
6	caspases	B
7	may	O
8	thus	O
9	play	O
10	an	O
11	important	O
12	role	O
13	in	O
14	the	O
15	execution	O
16	of	O
17	the	O
18	suicide	O
19	program	O
20	by	O
21	disabling	O
22	the	O
23	anti	O
24	-	O
25	apoptotic	O
26	function	O
27	of	O
28	Fak	B
29	.	O
1	It	O
2	can	O
3	also	O
4	be	O
5	used	O
6	to	O
7	examine	O
8	various	O
9	laryngeal	O
10	parameters	O
11	obtained	O
12	from	O
13	videotaped	O
14	endoscopic	O
15	and	O
16	stroboscopic	O
17	examinations	O
18	.	O
1	Interestingly	O
2	,	O
3	PKA	B
4	activity	O
5	is	O
6	dispensable	O
7	in	O
8	a	O
9	strain	O
10	lacking	O
11	Msn2p	B
12	and	O
13	Msn4p	B
14	activity	O
15	.	O
1	Recently	O
2	,	O
3	a	O
4	human	B
5	transcription	I
6	elongation	I
7	factor	I
8	P	I
9	-	I
10	TEFb	I
11	,	O
12	consisting	O
13	of	O
14	CDK9	B
15	kinase	I
16	,	O
17	cyclin	B
18	T	I
19	and	O
20	other	O
21	associated	O
22	factors	O
23	,	O
24	has	O
25	been	O
26	shown	O
27	to	O
28	interact	O
29	with	O
30	Tat	B
31	to	O
32	restore	O
33	Tat	B
34	activation	O
35	in	O
36	HeLa	O
37	nuclear	O
38	extract	O
39	depleted	O
40	of	O
41	P	B
42	-	I
43	TEFb	I
44	.	O
1	Blocked	O
2	shift	O
3	/	O
4	supershift	O
5	analysis	O
6	indicates	O
7	that	O
8	Fos	B
9	family	I
10	member	O
11	proteins	O
12	especially	O
13	Fra	B
14	-	I
15	1	I
16	and	O
17	Fra	B
18	-	I
19	2	I
20	are	O
21	related	O
22	to	O
23	progression	O
24	and	O
25	no	O
26	changes	O
27	found	O
28	in	O
29	the	O
30	Jun	B
31	family	I
32	member	O
33	proteins	O
34	although	O
35	they	O
36	are	O
37	present	O
38	in	O
39	the	O
40	AP	B
41	-	I
42	1	I
43	/	I
44	DNA	I
45	binding	I
46	complex	I
47	.	O
1	Initially	O
2	,	O
3	we	O
4	observed	O
5	that	O
6	unmutated	O
7	p53	B
8	is	O
9	strongly	O
10	expressed	O
11	in	O
12	premalignant	O
13	mammary	O
14	glands	O
15	and	O
16	in	O
17	mammary	O
18	tumors	O
19	derived	O
20	from	O
21	the	O
22	MMTV	O
23	-	O
24	c	B
25	-	I
26	myc	I
27	strain	O
28	.	O
1	Five	O
2	additional	O
3	copies	O
4	of	O
5	Lian	B
6	elements	I
7	were	O
8	isolated	O
9	,	O
10	mapped	O
11	by	O
12	restriction	O
13	digestion	O
14	,	O
15	and	O
16	partially	O
17	sequenced	O
18	.	O
1	Fowlpox	O
2	virus	O
3	encodes	O
4	nonessential	O
5	homologs	O
6	of	O
7	cellular	B
8	alpha	I
9	-	I
10	SNAP	I
11	,	O
12	PC	B
13	-	I
14	1	I
15	,	O
16	and	O
17	an	O
18	orphan	O
19	human	O
20	homolog	O
21	of	O
22	a	O
23	secreted	O
24	nematode	O
25	protein	O
26	.	O
1	Clinical	O
2	implication	O
3	of	O
4	protein	O
5	levels	O
6	of	O
7	IL	B
8	-	I
9	5	I
10	in	O
11	induced	O
12	sputum	O
13	in	O
14	asthmatic	O
15	patients	O
16	.	O
1	To	O
2	better	O
3	understand	O
4	the	O
5	role	O
6	of	O
7	Ets	B
8	proteins	I
9	in	O
10	Ras	B
11	transformation	O
12	,	O
13	we	O
14	have	O
15	now	O
16	analyzed	O
17	the	O
18	effects	O
19	of	O
20	stably	O
21	expressing	O
22	a	O
23	variety	O
24	of	O
25	Ets2	B
26	constructs	I
27	in	O
28	Ras	B
29	-	O
30	transformed	O
31	NIH3T3	O
32	(	O
33	DT	O
34	)	O
35	cells	O
36	.	O
1	We	O
2	demonstrate	O
3	that	O
4	Ddc1p	B
5	interacts	O
6	physically	O
7	in	O
8	vivo	O
9	with	O
10	Mec3p	B
11	,	O
12	and	O
13	this	O
14	interaction	O
15	requires	O
16	Rad17p	B
17	.	O
1	""""	O
2	Complex	O
3	partial	O
4	""""	O
5	seizures	O
6	.	O
1	One	O
2	is	O
3	to	O
4	act	O
5	within	O
6	the	O
7	visceral	O
8	endoderm	O
9	to	O
10	promote	O
11	proper	O
12	streak	O
13	morphogenesis	O
14	.	O
1	We	O
2	then	O
3	studied	O
4	four	O
5	unrelated	O
6	Japanese	O
7	families	O
8	with	O
9	GSD	O
10	-	O
11	Ib	O
12	,	O
13	and	O
14	found	O
15	three	O
16	novel	O
17	mutations	O
18	:	O
19	a	O
20	four	O
21	-	O
22	base	O
23	deletion	O
24	/	O
25	two	O
26	-	O
27	base	O
28	insertion	O
29	,	O
30	a	O
31	point	O
32	mutation	O
33	within	O
34	a	O
35	consensus	O
36	splicing	O
37	donor	O
38	site	O
39	,	O
40	and	O
41	a	O
42	missense	O
43	mutation	O
44	(	O
45	W118R	O
46	).	O
1	METHOD	O
2	:	O
3	50	O
4	consecutive	O
5	children	O
6	aged	O
7	from	O
8	6	O
9	months	O
10	to	O
11	17	O
12	years	O
13	were	O
14	included	O
15	into	O
16	the	O
17	study	O
18	which	O
19	comprised	O
20	questionnaires	O
21	of	O
22	patient	O
23	and	O
24	family	O
25	histories	O
26	,	O
27	serological	O
28	screening	O
29	tests	O
30	for	O
31	common	O
32	inhalational	O
33	allergens	O
34	(	O
35	CAP	O
36	SX1	O
37	),	O
38	and	O
39	determination	O
40	of	O
41	total	O
42	serum	B
43	immunoglobulin	I
44	E	I
45	(	O
46	IgE	B
47	)	O
48	and	O
49	of	O
50	latex	O
51	-	O
52	specific	O
53	serum	B
54	IgE	I
55	by	O
56	solid	O
57	-	O
58	phase	O
59	immunoassays	O
60	.	O
1	In	O
2	particular	O
3	,	O
4	the	O
5	potential	O
6	for	O
7	prostate	O
8	cancer	O
9	chemoprevention	O
10	using	O
11	nonsteroidal	O
12	anti	O
13	-	O
14	inflammatory	O
15	drugs	O
16	(	O
17	cyclo	B
18	-	I
19	oxygenase	I
20	inhibitors	O
21	;	O
22	NSAIDs	O
23	)	O
24	has	O
25	received	O
26	little	O
27	attention	O
28	.	O
1	Our	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	crucial	O
7	role	O
8	of	O
9	the	O
10	mutations	O
11	activating	O
12	v	B
13	-	I
14	erbA	I
15	as	O
16	an	O
17	oncogene	O
18	is	O
19	to	O
20	'	O
21	freeze	O
22	'	O
23	c	B
24	-	I
25	ErbA	I
26	/	O
27	TRalpha	B
28	in	O
29	its	O
30	non	O
31	-	O
32	liganded	O
33	,	O
34	repressive	O
35	conformation	O
36	and	O
37	to	O
38	facilitate	O
39	its	O
40	overexpression	O
41	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	describe	O
7	a	O
8	mammalian	O
9	cell	O
10	-	O
11	free	O
12	transcription	O
13	system	O
14	reconstituted	O
15	with	O
16	only	O
17	recombinant	O
18	proteins	O
19	and	O
20	epitope	O
21	-	O
22	tagged	O
23	multiprotein	O
24	complexes	O
25	.	O
1	This	O
2	repressor	O
3	is	O
4	however	O
5	unlikely	O
6	to	O
7	mediate	O
8	spi	B
9	2	I
10	.	I
11	3	I
12	3	I
13	'	I
14	UTR	I
15	silencer	I
16	action	O
17	since	O
18	it	O
19	was	O
20	not	O
21	detected	O
22	in	O
23	rat	O
24	hepatocytes	O
25	.	O
1	A	O
2	prerequisite	O
3	for	O
4	the	O
5	synthesis	O
6	of	O
7	sialylated	O
8	glycoconjugates	O
9	is	O
10	the	O
11	activated	O
12	sugar	O
13	-	O
14	nucleotide	O
15	cytidine	O
16	5	O
17	'-	O
18	monophosphate	O
19	N	O
20	-	O
21	acetylneuraminic	O
22	acid	O
23	(	O
24	CMP	O
25	-	O
26	Neu5Ac	O
27	),	O
28	which	O
29	provides	O
30	a	O
31	substrate	O
32	for	O
33	Golgi	B
34	sialyltransferases	I
35	.	O
1	When	O
2	cysteine	O
3	is	O
4	scanned	O
5	through	O
6	the	O
7	helices	O
8	,	O
9	characteristic	O
10	repeating	O
11	patterns	O
12	of	O
13	solvent	O
14	exposure	O
15	and	O
16	burial	O
17	are	O
18	observed	O
19	.	O
1	The	O
2	complement	B
3	C3a	I
4	anaphylatoxin	I
5	receptor	I
6	(	O
7	C3aR	B
8	)	O
9	is	O
10	a	O
11	seven	B
12	-	I
13	transmembrane	I
14	G	I
15	-	I
16	protein	I
17	coupled	I
18	chemoattractant	I
19	receptor	I
20	that	O
21	on	O
22	binding	O
23	the	O
24	C3a	B
25	peptide	I
26	ligand	I
27	mediates	O
28	numerous	O
29	cellular	O
30	responses	O
31	,	O
32	including	O
33	histamine	O
34	release	O
35	from	O
36	mast	O
37	cells	O
38	.	O
39	smooth	O
40	muscle	O
41	contraction	O
42	,	O
43	and	O
44	the	O
45	directed	O
46	migration	O
47	of	O
48	eosinophils	O
49	.	O
1	The	O
2	heterogeneous	O
3	nuclear	B
4	ribonucleoprotein	I
5	C	I
6	protein	I
7	tetramer	I
8	binds	O
9	U1	B
10	,	O
11	U2	B
12	,	O
13	and	O
14	U6	B
15	snRNAs	I
16	through	O
17	its	O
18	high	O
19	affinity	O
20	RNA	O
21	binding	O
22	domain	O
23	(	O
24	the	O
25	bZIP	O
26	-	O
27	like	O
28	motif	O
29	).	O
1	On	O
2	the	O
3	comparison	O
4	of	O
5	correlated	O
6	proportions	O
7	for	O
8	clustered	O
9	data	O
10	.	O
1	The	O
2	mutant	O
3	protein	O
4	is	O
5	present	O
6	at	O
7	levels	O
8	slightly	O
9	greater	O
10	than	O
11	wild	O
12	-	O
13	type	O
14	,	O
15	but	O
16	exhibits	O
17	the	O
18	same	O
19	tissue	O
20	distribution	O
21	as	O
22	wild	O
23	-	O
24	type	O
25	protein	O
26	,	O
27	and	O
28	has	O
29	approximately	O
30	normal	O
31	affinity	O
32	for	O
33	known	O
34	target	O
35	sequences	O
36	(	O
37	though	O
38	no	O
39	DNA	O
40	targets	O
41	identified	O
42	to	O
43	date	O
44	require	O
45	the	O
46	first	O
47	cut	O
48	repeat	O
49	for	O
50	binding	O
51	).	O
1	Reverse	B
2	transcriptase	I
3	-	O
4	polymerase	O
5	chain	O
6	reaction	O
7	(	O
8	RT	B
9	-	O
10	PCR	O
11	)	O
12	was	O
13	performed	O
14	using	O
15	eyestalk	O
16	complementary	O
17	DNA	O
18	of	O
19	the	O
20	sand	O
21	shrimp	O
22	Metapenaeus	O
23	ensis	O
24	.	O
1	The	O
2	IE13	O
3	.	O
4	1	O
5	cell	O
6	line	O
7	was	O
8	able	O
9	to	O
10	complement	O
11	a	O
12	recombinant	O
13	virus	O
14	in	O
15	which	O
16	both	O
17	copies	O
18	of	O
19	the	O
20	IE	B
21	gene	I
22	were	O
23	replaced	O
24	by	O
25	insertion	O
26	of	O
27	the	O
28	Escherichia	B
29	coli	I
30	lacZ	I
31	gene	I
32	.	O
1	DNase	B
2	I	I
3	footprinting	O
4	and	O
5	electrophoretic	O
6	mobility	O
7	shift	O
8	analyses	O
9	revealed	O
10	two	O
11	hepatocyte	B
12	nuclear	I
13	factor	I
14	-	I
15	1	I
16	(	O
17	HNF1	B
18	),	O
19	three	O
20	CCAAT	B
21	/	I
22	enhancer	I
23	-	I
24	binding	I
25	protein	I
26	(	O
27	C	B
28	/	I
29	EBP	I
30	),	O
31	and	O
32	one	O
33	consensus	O
34	palindromic	O
35	thyroid	O
36	hormone	O
37	response	O
38	elements	O
39	within	O
40	the	O
41	first	O
42	215	O
43	base	O
44	pairs	O
45	(	O
46	bp	O
47	)	O
48	of	O
49	the	O
50	promoter	O
51	sequence	O
52	of	O
53	rat	B
54	Std	I
55	.	O
1	Purified	O
2	Hsk1	B
3	phosphorylates	O
4	the	O
5	Cdc19	B
6	(	O
7	Mcm2	B
8	)	O
9	subunit	O
10	of	O
11	the	O
12	six	B
13	-	I
14	member	I
15	minichromosome	I
16	maintenance	I
17	protein	I
18	complex	I
19	purified	O
20	from	O
21	fission	O
22	yeast	O
23	.	O
1	Persistent	O
2	activation	O
3	of	O
4	mitogen	B
5	-	I
6	activated	I
7	protein	I
8	kinases	I
9	p42	I
10	and	O
11	p44	B
12	and	O
13	ets	B
14	-	I
15	2	I
16	phosphorylation	O
17	in	O
18	response	O
19	to	O
20	colony	B
21	-	I
22	stimulating	I
23	factor	I
24	1	I
25	/	O
26	c	B
27	-	I
28	fms	I
29	signaling	O
30	.	O
1	Tumor	B
2	necrosis	I
3	factor	I
4	signaling	O
5	to	O
6	stress	B
7	-	I
8	activated	I
9	protein	I
10	kinase	I
11	(	O
12	SAPK	B
13	)/	O
14	Jun	B
15	NH2	I
16	-	I
17	terminal	I
18	kinase	I
19	(	O
20	JNK	B
21	)	O
22	and	O
23	p38	B
24	.	O
1	After	O
2	that	O
3	report	O
4	,	O
5	carboxypeptidase	B
6	D	I
7	(	O
8	CPD	B
9	)	O
10	was	O
11	subsequently	O
12	purified	O
13	from	O
14	bovine	O
15	pituitary	O
16	and	O
17	characterized	O
18	as	O
19	a	O
20	novel	O
21	carboxypeptidase	B
22	E	I
23	(	O
24	CPE	B
25	)-	O
26	like	O
27	enzyme	O
28	,	O
29	with	O
30	many	O
31	characteristics	O
32	in	O
33	common	O
34	with	O
35	duck	O
36	gp180	B
37	(	O
38	Song	O
39	,	O
40	L	O
41	.,	O
42	Fricker	O
43	,	O
44	L	O
45	.	O
46	D	O
47	.,	O
48	1995	O
49	.	O
1	The	O
2	histopathology	O
3	and	O
4	neovascularization	O
5	did	O
6	not	O
7	appreciably	O
8	differ	O
9	between	O
10	xenograft	O
11	tumors	O
12	derived	O
13	from	O
14	FGF4	B
15	over	O
16	-	O
17	expressing	O
18	versus	O
19	control	O
20	transfectants	O
21	.	O
1	TBP	B
2	can	O
3	be	O
4	phosphorylated	O
5	in	O
6	vitro	O
7	by	O
8	extracts	O
9	of	O
10	U937	O
11	cells	O
12	or	O
13	by	O
14	bacterially	O
15	expressed	O
16	activated	O
17	ERK2	B
18	;	O
19	the	O
20	phosphorylation	O
21	sites	O
22	were	O
23	mapped	O
24	to	O
25	ERK	B
26	kinase	I
27	consensus	I
28	sites	I
29	in	O
30	the	O
31	TBP	B
32	amino	I
33	-	I
34	terminal	I
35	domain	I
36	.	O
1	These	O
2	sequence	O
3	analyses	O
4	suggest	O
5	that	O
6	xIRS	B
7	-	I
8	u	I
9	is	O
10	a	O
11	novel	O
12	member	O
13	of	O
14	the	O
15	IRS	B
16	family	I
17	rather	O
18	than	O
19	a	O
20	Xenopus	O
21	homolog	O
22	of	O
23	an	O
24	existing	O
25	member	O
26	.	O
1	Seventy	O
2	-	O
3	five	O
4	percent	O
5	of	O
6	children	O
7	who	O
8	received	O
9	a	O
10	second	O
11	transplant	O
12	for	O
13	HCV	O
14	hepatitis	O
15	had	O
16	early	O
17	histologic	O
18	recurrence	O
19	that	O
20	led	O
21	to	O
22	liver	O
23	failure	O
24	and	O
25	death	O
26	.	O
1	Regulation	O
2	of	O
3	embryonic	O
4	growth	O
5	and	O
6	lysosomal	O
7	targeting	O
8	by	O
9	the	O
10	imprinted	O
11	Igf2	B
12	/	O
13	Mpr	B
14	gene	O
15	.	O
1	Tyrosine	O
2	phosphorylated	O
3	STATs	B
4	dimerize	O
5	and	O
6	translocate	O
7	into	O
8	the	O
9	nucleus	O
10	to	O
11	activate	O
12	specific	O
13	genes	O
14	.	O
1	Nonsynonymous	O
2	substitution	O
3	in	O
4	abalone	O
5	sperm	O
6	fertilization	O
7	genes	O
8	exceeds	O
9	substitution	O
10	in	O
11	introns	O
12	and	O
13	mitochondrial	O
14	DNA	O
15	.	O
1	CONCLUSION	O
2	:	O
3	Although	O
4	quantitative	O
5	and	O
6	qualitative	O
7	criteria	O
8	for	O
9	diagnosing	O
10	fatty	O
11	liver	O
12	on	O
13	helical	O
14	CT	O
15	can	O
16	be	O
17	determined	O
18	,	O
19	they	O
20	are	O
21	protocol	O
22	-	O
23	specific	O
24	.	O
1	Alternatively	O
2	,	O
3	the	O
4	similarity	O
5	in	O
6	apparent	O
7	regulatory	O
8	action	O
9	of	O
10	the	O
11	genes	O
12	may	O
13	indicate	O
14	allelic	O
15	differences	O
16	wherein	O
17	the	O
18	IS1112C	B
19	Rf3	I
20	allele	I
21	may	O
22	differ	O
23	from	O
24	alleles	O
25	of	O
26	maintainer	O
27	lines	O
28	by	O
29	the	O
30	capability	O
31	to	O
32	regulate	O
33	both	O
34	orf107	B
35	and	O
36	urf209	B
37	processing	O
38	activities	O
39	.	O
1	A	O
2	further	O
3	mechanism	O
4	increasing	O
5	specific	O
6	activation	O
7	was	O
8	cooperation	O
9	of	O
10	receptors	O
11	at	O
12	multiple	O
13	and	O
14	weak	O
15	HREs	O
16	,	O
17	which	O
18	was	O
19	accentuated	O
20	in	O
21	the	O
22	presence	O
23	of	O
24	both	O
25	the	O
26	AR	B
27	N	O
28	terminus	O
29	and	O
30	ligand	O
31	binding	O
32	domain	O
33	.	O
1	Likewise	O
2	,	O
3	at	O
4	150	O
5	degrees	O
6	C	O
7	with	O
8	2	O
9	%	O
10	APS	O
11	the	O
12	surface	O
13	density	O
14	of	O
15	NH2	O
16	groups	O
17	reached	O
18	a	O
19	maximum	O
20	at	O
21	24	O
22	hr	O
23	and	O
24	remained	O
25	relatively	O
26	constant	O
27	up	O
28	to	O
29	96	O
30	hr	O
31	.	O
1	Studies	O
2	using	O
3	the	O
4	yeast	O
5	two	O
6	-	O
7	hybrid	O
8	system	O
9	also	O
10	did	O
11	not	O
12	provide	O
13	evidence	O
14	for	O
15	the	O
16	formation	O
17	of	O
18	a	O
19	VDR	B
20	-	O
21	TR	B
22	protein	O
23	-	O
24	protein	O
25	interaction	O
26	.	O
1	Our	O
2	results	O
3	show	O
4	that	O
5	,	O
6	from	O
7	a	O
8	thermodynamical	O
9	standpoint	O
10	,	O
11	melatonin	O
12	may	O
13	directly	O
14	scavenge	O
15	hydroxyl	O
16	radicals	O
17	both	O
18	in	O
19	vacuum	O
20	and	O
21	in	O
22	aqueous	O
23	solution	O
24	.	O
1	This	O
2	sequence	O
3	,	O
4	Thr	O
5	-	O
6	Gly	O
7	-	O
8	X	O
9	-	O
10	X	O
11	-	O
12	Gly	O
13	-	O
14	Asp	O
15	-	O
16	Gly	O
17	-	O
18	Lys	O
19	-	O
20	Ile	O
21	-	O
22	Phe	O
23	,	O
24	forms	O
25	part	O
26	of	O
27	the	O
28	B	O
29	-	O
30	loop	O
31	and	O
32	is	O
33	conserved	O
34	in	O
35	a	O
36	wide	O
37	variety	O
38	of	O
39	organisms	O
40	that	O
41	include	O
42	bacteria	O
43	,	O
44	algae	O
45	and	O
46	archeabacteria	O
47	.	O
1	We	O
2	did	O
3	not	O
4	observe	O
5	any	O
6	changes	O
7	in	O
8	Bcl	B
9	-	I
10	2	I
11	or	O
12	Bcl	B
13	-	I
14	2	I
15	-	I
16	related	I
17	proteins	I
18	(	O
19	Bcl	B
20	-	I
21	x	I
22	,	O
23	Bax	B
24	,	O
25	and	O
26	Bad	B
27	)	O
28	in	O
29	control	O
30	or	O
31	KCREB	B
32	-	O
33	transfected	O
34	cells	O
35	before	O
36	or	O
37	after	O
38	treatment	O
39	with	O
40	Tg	O
41	.	O
1	Tyrosine	O
2	112	O
3	of	O
4	latent	B
5	membrane	I
6	protein	I
7	2A	I
8	is	O
9	essential	O
10	for	O
11	protein	B
12	tyrosine	I
13	kinase	I
14	loading	O
15	and	O
16	regulation	O
17	of	O
18	Epstein	O
19	-	O
20	Barr	O
21	virus	O
22	latency	O
23	.	O
1	Second	O
2	,	O
3	the	O
4	wild	B
5	-	I
6	type	I
7	m8	I
8	3	I
9	'	I
10	UTR	I
11	strongly	O
12	reduces	O
13	accumulation	O
14	of	O
15	heterologous	O
16	transcripts	O
17	in	O
18	vivo	O
19	,	O
20	an	O
21	activity	O
22	that	O
23	requires	O
24	its	O
25	K	O
26	box	O
27	sequences	O
28	.	O
1	MEKs	B
2	and	O
3	ERKs	B
4	inhibited	O
5	IL	B
6	-	I
7	6	I
8	activation	O
9	of	O
10	Stat3	B
11	harboring	O
12	a	O
13	mutation	O
14	at	O
15	serine	O
16	-	O
17	727	O
18	,	O
19	the	O
20	major	O
21	site	O
22	for	O
23	serine	O
24	phosphorylation	O
25	,	O
26	similar	O
27	to	O
28	inhibition	O
29	of	O
30	wild	B
31	-	I
32	type	I
33	Stat3	I
34	,	O
35	and	O
36	inhibited	O
37	Janus	B
38	kinases	I
39	Jak1	I
40	and	O
41	Jak2	B
42	upstream	O
43	of	O
44	Stat3	B
45	in	O
46	the	O
47	Jak	B
48	-	O
49	STAT	B
50	-	O
51	signaling	O
52	pathway	O
53	.	O
1	Transfection	O
2	and	O
3	in	O
4	vitro	O
5	binding	O
6	studies	O
7	identified	O
8	within	O
9	HEFT1	B
10	a	I
11	promoter	I
12	whose	O
13	basal	O
14	activity	O
15	required	O
16	a	O
17	GC	O
18	box	O
19	activated	O
20	by	O
21	Sp1	B
22	or	O
23	Sp3	B
24	.	O
1	Plasma	O
2	was	O
3	tested	O
4	before	O
5	and	O
6	after	O
7	(	O
8	14	O
9	+/-	O
10	7	O
11	.	O
12	5	O
13	[	O
14	SD	O
15	]	O
16	days	O
17	)	O
18	surgery	O
19	for	O
20	IgG	B
21	antibodies	I
22	to	O
23	the	O
24	complex	O
25	of	O
26	heparin	B
27	/	I
28	platelet	I
29	factor	I
30	4	I
31	,	O
32	using	O
33	a	O
34	standardized	O
35	,	O
36	validated	O
37	enzyme	O
38	-	O
39	linked	O
40	immunosorbent	O
41	assay	O
42	(	O
43	ELISA	O
44	).	O
1	The	O
2	effect	O
3	of	O
4	independent	O
5	predictors	O
6	on	O
7	survival	O
8	was	O
9	examined	O
10	in	O
11	a	O
12	Cox	O
13	regression	O
14	model	O
15	with	O
16	adjustment	O
17	for	O
18	existing	O
19	illnesses	O
20	.	O
1	The	O
2	effects	O
3	of	O
4	high	O
5	intensity	O
6	light	O
7	emissions	O
8	,	O
9	produced	O
10	by	O
11	a	O
12	novel	O
13	pulsed	O
14	power	O
15	energization	O
16	technique	O
17	(	O
18	PPET	O
19	),	O
20	on	O
21	the	O
22	survival	O
23	of	O
24	bacterial	O
25	populations	O
26	of	O
27	verocytotoxigenic	O
28	Escherichia	O
29	coli	O
30	(	O
31	serotype	O
32	0157	O
33	:	O
34	H7	O
35	)	O
36	and	O
37	Listeria	O
38	monocytogenes	O
39	(	O
40	serotype	O
41	4b	O
42	)	O
43	were	O
44	investigated	O
45	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	Thr115	O
6	may	O
7	play	O
8	an	O
9	important	O
10	role	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	MyoD	B
16	function	O
17	under	O
18	conditions	O
19	of	O
20	high	O
21	mitogenesis	O
22	.	O
1	This	O
2	and	O
3	previous	O
4	results	O
5	suggest	O
6	that	O
7	the	O
8	CRE	O
9	and	O
10	Sp1	B
11	site	I
12	may	O
13	synergistically	O
14	activate	O
15	TH	B
16	transcription	O
17	in	O
18	a	O
19	promoter	O
20	context	O
21	-	O
22	dependent	O
23	manner	O
24	.	O
1	T7	O
2	transcription	O
3	could	O
4	be	O
5	manipulated	O
6	to	O
7	achieve	O
8	different	O
9	levels	O
10	of	O
11	constitutive	O
12	expression	O
13	,	O
14	through	O
15	the	O
16	use	O
17	of	O
18	promoter	O
19	mutations	O
20	.	O
1	The	O
2	hBRAG	B
3	gene	I
4	was	O
5	localized	O
6	to	O
7	the	O
8	long	O
9	arm	O
10	of	O
11	chromosome	O
12	10	O
13	(	O
14	10q26	O
15	).	O
1	Here	O
2	,	O
3	we	O
4	report	O
5	that	O
6	swa5	B
7	-	I
8	1	I
9	is	O
10	a	O
11	new	O
12	temperature	O
13	-	O
14	sensitive	O
15	allele	O
16	of	O
17	the	O
18	clathrin	B
19	heavy	I
20	chain	I
21	gene	I
22	(	O
23	chc1	B
24	-	I
25	5	I
26	),	O
27	which	O
28	carries	O
29	a	O
30	frameshift	O
31	mutation	O
32	near	O
33	the	O
34	3	O
35	'	O
36	end	O
37	of	O
38	the	O
39	CHC1	B
40	open	O
41	reading	O
42	frame	O
43	.	O
1	However	O
2	,	O
3	while	O
4	IL	B
5	-	I
6	1beta	I
7	and	O
8	TNF	B
9	-	I
10	alpha	I
11	both	O
12	induced	O
13	nuclear	O
14	binding	O
15	of	O
16	the	O
17	Rel	B
18	proteins	I
19	p50	I
20	and	O
21	p65	B
22	to	O
23	an	O
24	NF	B
25	-	I
26	kappaB	I
27	consensus	I
28	oligonucleotide	I
29	in	O
30	gel	O
31	shift	O
32	assays	O
33	and	O
34	caused	O
35	transient	O
36	degradation	O
37	of	O
38	inhibitor	B
39	of	I
40	NF	I
41	-	I
42	kappaB	I
43	-	I
44	alpha	I
45	(	O
46	IkappaB	B
47	-	I
48	alpha	I
49	)	O
50	in	O
51	the	O
52	cytoplasm	O
53	of	O
54	myofibroblasts	O
55	,	O
56	only	O
57	IL	B
58	-	I
59	1beta	I
60	upregulated	O
61	PDGF	B
62	-	I
63	Ralpha	I
64	.	O
1	Phosphocreatine	O
2	hydrolysis	O
3	during	O
4	submaximal	O
5	exercise	O
6	:	O
7	the	O
8	effect	O
9	of	O
10	FIO2	O
11	.	O
1	Pseudocontact	O
2	shifts	O
3	arise	O
4	from	O
5	the	O
6	isotropic	O
7	reorientational	O
8	average	O
9	of	O
10	the	O
11	dipolar	O
12	coupling	O
13	between	O
14	unpaired	O
15	electron	O
16	and	O
17	nuclei	O
18	,	O
19	in	O
20	the	O
21	presence	O
22	of	O
23	magnetic	O
24	susceptibility	O
25	anisotropy	O
26	.	O
1	The	O
2	interaction	O
3	of	O
4	U1	B
5	-	I
6	70K	I
7	with	O
8	the	O
9	SRZ	B
10	proteins	I
11	is	O
12	confirmed	O
13	further	O
14	in	O
15	vitro	O
16	using	O
17	a	O
18	blot	O
19	overlay	O
20	assay	O
21	.	O
1	Interestingly	O
2	,	O
3	an	O
4	antibody	O
5	against	O
6	N	B
7	-	I
8	SMase	I
9	can	O
10	abrogate	O
11	Ox	B
12	-	I
13	LDL	I
14	-	O
15	and	O
16	TNF	B
17	-	I
18	alpha	I
19	-	O
20	induced	O
21	apoptosis	O
22	and	O
23	therefore	O
24	may	O
25	be	O
26	useful	O
27	for	O
28	in	O
29	vivo	O
30	studies	O
31	of	O
32	apoptosis	O
33	in	O
34	experimental	O
35	animals	O
36	.	O
1	The	O
2	murine	B
3	facilitative	I
4	glucose	I
5	transporter	I
6	isoform	I
7	3	I
8	(	O
9	Glut	B
10	3	I
11	)	O
12	is	O
13	developmentally	O
14	regulated	O
15	and	O
16	is	O
17	predominantly	O
18	expressed	O
19	in	O
20	neurons	O
21	and	O
22	trophoblasts	O
23	.	O
1	Cotransfection	O
2	of	O
3	the	O
4	helicase	B
5	-	O
6	primase	B
7	proteins	O
8	,	O
9	one	O
10	of	O
11	which	O
12	was	O
13	fused	O
14	to	O
15	a	O
16	heterologous	O
17	activation	O
18	domain	O
19	,	O
20	led	O
21	to	O
22	Zta	B
23	-	O
24	dependent	O
25	superactivation	O
26	of	O
27	CAT	B
28	expression	O
29	.	O
1	This	O
2	domain	O
3	,	O
4	although	O
5	adjacent	O
6	to	O
7	the	O
8	5	O
9	'	O
10	edge	O
11	of	O
12	the	O
13	SD	O
14	sequence	O
15	,	O
16	does	O
17	not	O
18	inhibit	O
19	ribosome	O
20	binding	O
21	as	O
22	long	O
23	as	O
24	the	O
25	single	O
26	-	O
27	stranded	O
28	region	O
29	of	O
30	domain	O
31	3	O
32	is	O
33	present	O
34	.	O
1	EGFR	B
2	levels	O
3	were	O
4	found	O
5	to	O
6	be	O
7	elevated	O
8	5	O
9	-,	O
10	3	O
11	.	O
1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	portion	O
6	of	O
7	UKLF	B
8	contains	O
9	three	O
10	zinc	O
11	fingers	O
12	of	O
13	the	O
14	Cys2	O
15	-	O
16	His2	O
17	type	O
18	and	O
19	binds	O
20	in	O
21	vitro	O
22	to	O
23	the	O
24	CACCC	O
25	motif	O
26	of	O
27	the	O
28	beta	B
29	-	I
30	globin	I
31	promoter	I
32	and	O
33	to	O
34	the	O
35	Sp1	B
36	recognition	I
37	sequence	I
38	.	O
1	A	O
2	simple	O
3	analytical	O
4	method	O
5	for	O
6	l	O
7	-	O
8	menthol	O
9	by	O
10	high	O
11	-	O
12	performance	O
13	liquid	O
14	chromatography	O
15	with	O
16	a	O
17	polarized	O
18	photometric	O
19	detector	O
20	was	O
21	established	O
22	.	O
1	The	O
2	predicted	O
3	domain	O
4	structures	O
5	of	O
6	FkbB	B
7	and	O
8	FkbC	B
9	are	O
10	analogous	O
11	to	O
12	that	O
13	of	O
14	FkbA	B
15	and	O
16	comprise	O
17	30	O
18	fatty	B
19	-	I
20	acid	I
21	-	I
22	synthase	I
23	(	O
24	FAS	B
25	)-	O
26	like	O
27	domains	O
28	arranged	O
29	in	O
30	6	O
31	modules	O
32	.	O
1	Analysis	O
2	of	O
3	Msy2	B
4	mRNA	I
5	expression	O
6	in	O
7	prepubertal	O
8	and	O
9	adult	O
10	mouse	O
11	testes	O
12	,	O
13	and	O
14	in	O
15	isolated	O
16	populations	O
17	of	O
18	germ	O
19	cells	O
20	,	O
21	reveals	O
22	maximal	O
23	expression	O
24	in	O
25	postmeiotic	O
26	round	O
27	spermatids	O
28	,	O
29	a	O
30	cell	O
31	type	O
32	with	O
33	abundant	O
34	amounts	O
35	of	O
36	stored	O
37	messenger	O
38	ribonucleoproteins	O
39	.	O
1	633	O
2	+/-	O
3	258	O
4	aggregates	O
5	/	O
6	ml	O
7	at	O
8	0	O
9	rpm	O
10	;	O
11	P	O
12	<	O
13	0	O
14	.	O
15	001	O
16	).	O
1	Finally	O
2	,	O
3	using	O
4	in	O
5	vitro	O
6	binding	O
7	studies	O
8	,	O
9	we	O
10	showed	O
11	that	O
12	SREBP2	B
13	was	O
14	able	O
15	to	O
16	displace	O
17	ADD1	B
18	/	O
19	SREBP1	B
20	binding	O
21	from	O
22	the	O
23	sterol	O
24	regulatory	O
25	element	O
26	(	O
27	SRE	O
28	)	O
29	site	O
30	.	O
1	Northern	O
2	blot	O
3	analyses	O
4	show	O
5	that	O
6	the	O
7	hBub1	B
8	mRNA	I
9	level	O
10	is	O
11	abundantly	O
12	expressed	O
13	in	O
14	tissues	O
15	or	O
16	cells	O
17	with	O
18	a	O
19	high	O
20	mitotic	O
21	index	O
22	.	O
1	Ligand	O
2	binding	O
3	to	O
4	the	O
5	receptor	O
6	complex	O
7	leads	O
8	to	O
9	tyrosine	O
10	phosphorylation	O
11	and	O
12	activation	O
13	of	O
14	Janus	B
15	kinases	I
16	(	O
17	Jak	B
18	),	O
19	phosphorylation	O
20	of	O
21	the	O
22	signal	B
23	transducing	I
24	subunit	I
25	gp130	I
26	,	O
27	followed	O
28	by	O
29	recruitment	O
30	and	O
31	phosphorylation	O
32	of	O
33	the	O
34	signal	B
35	transducer	I
36	and	I
37	activator	I
38	of	I
39	transcription	I
40	factors	I
41	STAT3	I
42	and	O
43	STAT1	B
44	and	O
45	the	O
46	src	B
47	homology	I
48	domain	I
49	(	O
50	SH2	B
51	)-	O
52	containing	O
53	protein	B
54	tyrosine	I
55	phosphatase	I
56	(	O
57	SHP2	B
58	).	O
1	An	O
2	electrophoretic	O
3	mobility	O
4	shift	O
5	assay	O
6	was	O
7	performed	O
8	to	O
9	characterize	O
10	the	O
11	binding	O
12	property	O
13	of	O
14	TR2	B
15	and	O
16	its	O
17	truncated	O
18	isoform	O
19	.	O
1	We	O
2	have	O
3	generated	O
4	a	O
5	computer	O
6	model	O
7	of	O
8	the	O
9	C	O
10	-	O
11	terminal	O
12	domain	O
13	of	O
14	the	O
15	434	O
16	repressor	O
17	based	O
18	on	O
19	the	O
20	crystal	O
21	structure	O
22	of	O
23	the	O
24	homologous	B
25	UmuD	I
26	'	I
27	protein	I
28	.	O
1	One	O
2	of	O
3	these	O
4	fragments	O
5	shows	O
6	the	O
7	highest	O
8	amino	O
9	acid	O
10	sequence	O
11	homology	O
12	to	O
13	the	O
14	insect	O
15	ecdysone	O
16	inducible	O
17	gene	B
18	E75	I
19	.	O
1	The	O
2	full	O
3	-	O
4	length	O
5	N	B
6	gene	I
7	,	O
8	encoded	O
9	by	O
10	open	O
11	reading	O
12	frame	O
13	7	O
14	,	O
15	was	O
16	cloned	O
17	from	O
18	the	O
19	Canadian	O
20	PRRS	O
21	virus	O
22	,	O
23	PA	O
24	-	O
25	8	O
26	.	O
1	Based	O
2	on	O
3	sequence	O
4	homology	O
5	,	O
6	the	O
7	genes	O
8	were	O
9	identified	O
10	as	O
11	TEF	B
12	,	O
13	encoding	O
14	translation	B
15	elongation	I
16	factor	I
17	-	I
18	1	I
19	alpha	I
20	and	O
21	RPS7	B
22	,	O
23	encoding	O
24	ribosomal	O
25	protein	O
26	S7	B
27	.	O
1	Dose	O
2	of	O
3	20	O
4	ig	O
5	were	O
6	administered	O
7	within	O
8	a	O
9	scheme	O
10	from	O
11	0	O
12	.	O
13	1	O
14	to	O
15	6	O
16	months	O
17	in	O
18	order	O
19	to	O
20	study	O
21	its	O
22	immunogenicity	O
23	,	O
24	which	O
25	was	O
26	evaluated	O
27	at	O
28	2	O
29	,	O
30	7	O
31	,	O
32	and	O
33	12	O
34	months	O
35	after	O
36	the	O
37	first	O
38	dose	O
39	.	O
1	The	O
2	various	O
3	available	O
4	data	O
5	strongly	O
6	suggesting	O
7	an	O
8	environmental	O
9	toxic	O
10	origin	O
11	for	O
12	the	O
13	""""	O
14	sperm	O
15	fall	O
16	""""	O
17	will	O
18	be	O
19	presented	O
20	as	O
21	well	O
22	as	O
23	the	O
24	most	O
25	frequently	O
26	suspected	O
27	class	O
28	of	O
29	substances	O
30	,	O
31	the	O
32	xenoestrogens	O
33	.	O
1	Its	O
2	interaction	O
3	with	O
4	RFX5	B
5	and	O
6	RFXAP	B
7	is	O
8	essential	O
9	for	O
10	binding	O
11	of	O
12	the	O
13	RFX	B
14	complex	I
15	to	O
16	MHC	B
17	-	I
18	II	I
19	promoters	I
20	.	O
1	Copyright	O
2	1998	O
3	Academic	O
4	Press	O
5	.	O
1	Rather	O
2	,	O
3	usp	B
4	is	O
5	required	O
6	in	O
7	late	O
8	third	O
9	instar	O
10	larvae	O
11	for	O
12	appropriate	O
13	developmental	O
14	and	O
15	transcriptional	O
16	responses	O
17	to	O
18	the	O
19	ecdysone	O
20	pulse	O
21	that	O
22	triggers	O
23	puparium	O
24	formation	O
25	.	O
1	GH	B
2	failed	O
3	to	O
4	stimulate	O
5	phosphorylation	O
6	or	O
7	activation	O
8	of	O
9	Jun	B
10	N	I
11	-	I
12	terminal	I
13	kinase	I
14	under	O
15	the	O
16	conditions	O
17	used	O
18	.	O
1	We	O
2	detected	O
3	no	O
4	effect	O
5	of	O
6	deleting	O
7	YCL024W	B
8	,	O
9	either	O
10	alone	O
11	or	O
12	in	O
13	combination	O
14	with	O
15	deletion	O
16	of	O
17	GIN4	B
18	.	O
1	Low	O
2	PbrO2	O
3	readings	O
4	,	O
5	however	O
6	,	O
7	could	O
8	be	O
9	caused	O
10	by	O
11	local	O
12	microhemorrhages	O
13	,	O
14	undetectable	O
15	on	O
16	CT	O
17	or	O
18	MRI	O
19	.	O
1	PURPOSE	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	effects	O
7	of	O
8	hypercholesterolemia	O
9	and	O
10	atherosclerosis	O
11	-	O
12	induced	O
13	chronic	O
14	cavernosal	O
15	arterial	O
16	insufficiency	O
17	on	O
18	cavernosal	O
19	smooth	O
20	muscle	O
21	tone	O
22	,	O
23	nitric	B
24	oxide	I
25	synthase	I
26	(	O
27	NOS	B
28	)	O
29	activity	O
30	and	O
31	cavernosal	O
32	tissue	O
33	synthesis	O
34	of	O
35	constrictor	O
36	eicosanoids	O
37	.	O
1	(	O
2	1992	O
3	)	O
4	Biochemistry	O
5	31	O
6	,	O
7	3351	O
8	-	O
9	3358	O
10	].	O
1	Levels	O
2	of	O
3	serum	O
4	IgE	B
5	were	O
6	measured	O
7	monthly	O
8	,	O
9	and	O
10	nasal	O
11	IgE	B
12	was	O
13	measured	O
14	at	O
15	the	O
16	height	O
17	and	O
18	end	O
19	of	O
20	the	O
21	season	O
22	.	O
1	The	O
2	mapping	O
3	was	O
4	completed	O
5	with	O
6	Southern	O
7	blotting	O
8	and	O
9	restriction	O
10	analysis	O
11	.	O
1	Thus	O
2	,	O
3	hypoxia	O
4	-	O
5	inducible	O
6	nuclear	O
7	import	O
8	and	O
9	transactivation	O
10	by	O
11	recruitment	O
12	of	O
13	CBP	B
14	can	O
15	be	O
16	functionally	O
17	separated	O
18	from	O
19	one	O
20	another	O
21	and	O
22	play	O
23	critical	O
24	roles	O
25	in	O
26	signal	O
27	transduction	O
28	by	O
29	HIF	B
30	-	I
31	1alpha	I
32	.	O
1	A	O
2	synergistic	O
3	effect	O
4	on	O
5	HCK	B
6	promoter	I
7	activity	O
8	was	O
9	observed	O
10	at	O
11	high	O
12	concentrations	O
13	of	O
14	Sp1	B
15	.	O
1	Low	O
2	-	O
3	grade	O
4	gastric	O
5	MALT	O
6	lymphoma	O
7	and	O
8	helicobacter	O
9	heilmannii	O
10	(	O
11	Gastrospirillum	O
12	hominis	O
1	Over	O
2	-	O
3	expression	O
4	of	O
5	the	O
6	cofactor	O
7	p300	B
8	,	O
9	which	O
10	functions	O
11	as	O
12	a	O
13	coactivator	O
14	of	O
15	myoD	B
16	-	O
17	mediated	O
18	transcription	O
19	,	O
20	alleviated	O
21	repression	O
22	by	O
23	COUP	B
24	-	I
25	TF	I
26	II	I
27	.	O
1	Retroviral	B
2	nucleocapsid	I
3	proteins	I
4	(	O
5	NCPs	B
6	)	O
7	are	O
8	CCHC	B
9	-	I
10	type	I
11	zinc	I
12	finger	I
13	proteins	I
14	that	O
15	mediate	O
16	virion	O
17	RNA	O
18	binding	O
19	activities	O
20	associated	O
21	with	O
22	retrovirus	O
23	assembly	O
24	and	O
25	genomic	O
26	RNA	O
27	encapsidation	O
28	.	O
1	We	O
2	have	O
3	identified	O
4	two	O
5	overlapping	O
6	expressed	O
7	sequence	O
8	tag	O
9	clones	O
10	,	O
11	which	O
12	contain	O
13	the	O
14	missing	O
15	4	O
16	.	O
17	4	O
18	-	O
19	kb	O
20	3	O
21	'-	O
22	UTR	O
23	of	O
24	the	O
25	human	B
26	D2	I
27	(	O
28	hD2	B
29	)	O
30	cDNA	O
31	.	O
1	RESULTS	O
2	:	O
3	During	O
4	the	O
5	7	O
6	-	O
7	year	O
8	period	O
9	,	O
10	10	O
11	,	O
12	331	O
13	symptomatic	O
14	duodenal	O
15	ulcer	O
16	diseases	O
17	were	O
18	diagnosed	O
19	.	O
1	Jembrana	O
2	disease	O
3	virus	O
4	(	O
5	JDV	O
6	)	O
7	is	O
8	a	O
9	newly	O
10	identified	O
11	bovine	O
12	lentivirus	O
13	that	O
14	is	O
15	closely	O
16	related	O
17	to	O
18	the	O
19	bovine	O
20	immunodeficiency	O
21	virus	O
22	(	O
23	BIV	O
24	).	O
1	This	O
2	survey	O
3	included	O
4	3000	O
5	randomly	O
6	selected	O
7	Norwegians	O
8	above	O
9	18	O
10	years	O
11	of	O
12	age	O
13	who	O
14	received	O
15	the	O
16	European	O
17	Organization	O
18	for	O
19	Research	O
20	and	O
21	Treatment	O
22	of	O
23	Cancer	O
24	Core	O
25	Quality	O
26	of	O
27	Life	O
28	Questionnaire	O
29	(	O
30	EORTC	O
31	QLQ	O
32	-	O
33	C30	O
34	(+	O
35	3	O
36	)	O
37	by	O
38	mail	O
39	.	O
1	The	O
2	human	B
3	SHBG	I
4	proximal	I
5	promoter	I
6	was	O
7	analyzed	O
8	by	O
9	DNase	B
10	I	I
11	footprinting	O
12	,	O
13	and	O
14	the	O
15	functional	O
16	significance	O
17	of	O
18	6	O
19	footprinted	O
20	regions	O
21	(	O
22	FP1	O
23	-	O
24	FP6	O
25	)	O
26	within	O
27	the	O
28	proximal	O
29	promoter	O
30	was	O
31	studied	O
32	in	O
33	human	O
34	HepG2	O
35	hepatoblastoma	O
36	cells	O
37	.	O
1	Wild	O
2	type	O
3	HA	B
4	-	O
5	p190	B
6	induced	O
7	a	O
8	phenotype	O
9	of	O
10	rounded	O
11	cells	O
12	with	O
13	long	O
14	,	O
15	beaded	O
16	extensions	O
17	similar	O
18	to	O
19	that	O
20	seen	O
21	when	O
22	Rho	B
23	function	O
24	is	O
25	disrupted	O
26	by	O
27	ADP	O
28	-	O
29	ribosylation	O
30	.	O
1	Dry	O
2	matter	O
3	intake	O
4	,	O
5	apparent	O
6	nutrient	O
7	digestibilities	O
8	,	O
9	serum	O
10	chemistry	O
11	profiles	O
12	,	O
13	sphingolipid	O
14	concentrations	O
15	,	O
16	and	O
17	persistency	O
18	of	O
19	FB1	O
20	in	O
21	tissues	O
22	were	O
23	evaluated	O
24	.	O
1	Furthermore	O
2	,	O
3	RING1	B
4	overexpression	O
5	results	O
6	in	O
7	enhanced	O
8	expression	O
9	of	O
10	the	O
11	proto	O
12	-	O
13	oncogenes	O
14	c	B
15	-	I
16	jun	I
17	and	O
18	c	B
19	-	I
20	fos	I
21	.	O
1	Recent	O
2	studies	O
3	have	O
4	suggested	O
5	that	O
6	Y319	O
7	also	O
8	positively	O
9	regulate	O
10	ZAP	B
11	-	I
12	70	I
13	function	O
14	.	O
1	These	O
2	findings	O
3	suggest	O
4	that	O
5	late	O
6	MYO	O
7	/	O
8	M	O
9	is	O
10	more	O
11	useful	O
12	than	O
13	washout	O
14	rate	O
15	to	O
16	assess	O
17	the	O
18	effect	O
19	of	O
20	treatment	O
21	on	O
22	heart	O
23	failure	O
24	due	O
25	to	O
26	DCM	O
27	.	O
1	With	O
2	regard	O
3	to	O
4	the	O
5	optimal	O
6	threshold	O
7	values	O
8	,	O
9	sensitivity	O
10	and	O
11	specificity	O
12	were	O
13	100	O
14	%/	O
15	97	O
16	%	O
17	and	O
18	95	O
19	%/	O
20	95	O
21	%	O
22	with	O
23	FDG	O
24	PET	O
25	,	O
26	compared	O
27	to	O
28	86	O
29	%/	O
30	92	O
31	%	O
32	and	O
33	77	O
34	%/	O
35	82	O
36	%	O
37	with	O
38	IS	O
39	,	O
40	respectively	O
41	.	O
1	The	O
2	orbitofrontal	O
3	,	O
4	cingulate	O
5	,	O
6	and	O
7	anteromedial	O
8	part	O
9	of	O
10	the	O
11	dorsal	O
12	premotor	O
13	areas	O
14	were	O
15	preferentially	O
16	activated	O
17	by	O
18	the	O
19	self	O
20	-	O
21	initiated	O
22	hand	O
23	movement	O
24	task	O
25	(	O
26	SELF	O
27	).	O
1	The	O
2	active	O
3	site	O
4	includes	O
5	the	O
6	acidic	O
7	triad	O
8	Asp53	O
9	(	O
10	the	O
11	site	O
12	of	O
13	phosphorylation	O
14	),	O
15	Asp10	O
16	and	O
17	Glu9	O
18	.	O
1	MPO	B
2	was	O
3	labeled	O
4	with	O
5	1	O
6	mCi	O
7	125I	O
8	by	O
9	a	O
10	technique	O
11	of	O
12	self	O
13	-	O
14	labeling	O
15	in	O
16	the	O
17	presence	O
18	of	O
19	10	O
20	(-	O
21	4	O
22	)	O
23	M	O
24	hydrogen	O
25	peroxide	O
26	.	O
1	Therefore	O
2	,	O
3	in	O
4	order	O
5	to	O
6	search	O
7	for	O
8	the	O
9	latent	O
10	genes	O
11	,	O
12	we	O
13	used	O
14	allotype	O
15	-	O
16	specific	O
17	oligonucleotides	O
18	for	O
19	b5	O
20	,	O
21	b6	O
22	and	O
23	b9	O
24	to	O
25	probe	O
26	DNAs	O
27	from	O
28	both	O
29	normal	O
30	and	O
31	T	O
32	.	O
33	brucei	O
34	-	O
35	infected	O
36	rabbits	O
37	by	O
38	Southern	O
39	blotting	O
40	.	O
1	However	O
2	,	O
3	serial	O
4	passages	O
5	of	O
6	fetal	O
7	lamb	O
8	kidney	O
9	(	O
10	FLK	O
11	)	O
12	cells	O
13	,	O
14	which	O
15	are	O
16	sensitive	O
17	to	O
18	infection	O
19	with	O
20	BLV	O
21	,	O
22	after	O
23	transient	O
24	transfection	O
25	revealed	O
26	that	O
27	mutation	O
28	of	O
29	a	O
30	second	O
31	tyrosine	O
32	residue	O
33	in	O
34	the	O
35	N	O
36	-	O
37	terminal	O
38	motif	O
39	completely	O
40	prevented	O
41	the	O
42	propagation	O
43	of	O
44	the	O
45	virus	O
46	.	O
1	In	O
2	the	O
3	second	O
4	experiment	O
5	,	O
6	a	O
7	stable	O
8	nickel	O
9	isotope	O
10	,	O
11	61Ni	O
12	,	O
13	was	O
14	given	O
15	in	O
16	drinking	O
17	water	O
18	to	O
19	20	O
20	nickel	O
21	-	O
22	sensitized	O
23	women	O
24	and	O
25	20	O
26	age	O
27	-	O
28	matched	O
29	controls	O
30	,	O
31	both	O
32	groups	O
33	having	O
34	vesicular	O
35	hand	O
36	eczema	O
37	of	O
38	the	O
39	pompholyx	O
40	type	O
41	.	O
1	BACKGROUND	O
2	:	O
3	Diazepam	O
4	,	O
5	one	O
6	of	O
7	the	O
8	benzodiazepine	O
9	group	O
10	of	O
11	tranquilizers	O
12	,	O
13	is	O
14	used	O
15	as	O
16	an	O
17	adjunctive	O
18	drug	O
19	for	O
20	sedation	O
21	and	O
22	for	O
23	relief	O
24	of	O
25	anxiety	O
26	in	O
27	the	O
28	treatment	O
29	of	O
30	epilepsy	O
31	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	regulation	O
6	of	O
7	Glvr	B
8	-	I
9	1	I
10	gene	I
11	expression	O
12	also	O
13	has	O
14	potential	O
15	applications	O
16	to	O
17	gene	O
18	therapy	O
19	,	O
20	since	O
21	retroviral	O
22	vectors	O
23	carrying	O
24	gibbon	B
25	ape	I
26	leukemia	I
27	virus	I
28	envelope	I
29	proteins	I
30	are	O
31	used	O
32	for	O
33	gene	O
34	delivery	O
35	into	O
36	different	O
37	cell	O
38	types	O
39	.	O
1	E1	B
2	,	O
3	a	O
4	DNA	B
5	helicase	I
6	,	O
7	collaborates	O
8	with	O
9	the	O
10	HPV	B
11	E2	I
12	protein	I
13	in	O
14	ori	O
15	-	O
16	dependent	O
17	replication	O
18	.	O
1	Unilateral	O
2	naris	O
3	occlusion	O
4	and	O
5	the	O
6	rat	O
7	accessory	O
8	olfactory	O
9	bulb	O
10	.	O
1	Sp1	B
2	'	O
3	s	O
4	role	O
5	in	O
6	transactivation	O
7	of	O
8	the	O
9	pgp2	B
10	/	O
11	mdr1b	B
12	promoter	O
13	was	O
14	tested	O
15	in	O
16	Drosophila	O
17	Schneider	O
18	cells	O
19	.	O
1	The	O
2	pattern	O
3	of	O
4	RNase	B
5	E	I
6	digestion	O
7	of	O
8	finP305	B
9	RNA	I
10	differed	O
11	from	O
12	FinP	B
13	,	O
14	and	O
15	GST	B
16	-	O
17	FinO	B
18	did	O
19	not	O
20	protect	O
21	finP305	B
22	RNA	I
23	from	O
24	cleavage	O
25	in	O
26	vitro	O
27	.	O
1	C3	B
2	toxin	I
3	completely	O
4	inhibited	O
5	RhoA	B
6	function	O
7	,	O
8	partially	O
9	inhibited	O
10	SRE	O
11	:	O
12	Luc	B
13	activity	O
14	,	O
15	but	O
16	had	O
17	no	O
18	effect	O
19	on	O
20	LPA	O
21	-	O
22	stimulated	O
23	c	B
24	-	I
25	Fos	I
26	expression	O
27	.	O
1	The	O
2	role	O
3	of	O
4	intraoperative	O
5	echocardiography	O
6	in	O
7	surgery	O
8	of	O
9	the	O
10	heart	O
11	and	O
12	large	O
13	vessels	O
1	In	O
2	protocol	O
3	2	O
4	,	O
5	eight	O
6	different	O
7	subjects	O
8	performed	O
9	Con	O
10	and	O
11	Ecc	O
12	arm	O
13	curls	O
14	to	O
15	fatigue	O
16	,	O
17	followed	O
18	by	O
19	postexercise	O
20	muscle	O
21	ischemia	O
22	,	O
23	by	O
24	using	O
25	the	O
26	same	O
27	resistance	O
28	as	O
29	in	O
30	protocol	O
31	1	O
32	.	O
1	Although	O
2	both	O
3	transcripts	O
4	share	O
5	the	O
6	first	O
7	nine	O
8	exons	O
9	,	O
10	exon	O
11	10	O
12	of	O
13	ZIS	B
14	-	I
15	2	I
16	is	O
17	lacking	O
18	in	O
19	ZIS	B
20	-	I
21	1	I
22	,	O
23	and	O
24	instead	O
25	,	O
26	exon	O
27	11	O
28	(	O
29	10th	O
30	exon	O
31	)	O
32	of	O
33	ZIS	B
34	-	I
35	1	I
36	is	O
37	larger	O
38	in	O
39	size	O
40	,	O
41	leading	O
42	to	O
43	the	O
44	longer	O
45	3	O
46	'-	O
47	UTR	O
48	.	O
1	IFN	B
2	-	I
3	gamma	I
4	was	O
5	elevated	O
6	during	O
7	active	O
8	TB	O
9	when	O
10	compared	O
11	with	O
12	healthy	O
13	controls	O
14	,	O
15	declining	O
16	during	O
17	and	O
18	after	O
19	treatment	O
20	.	O
1	If	O
2	no	O
3	alloantibodies	O
4	are	O
5	detected	O
6	,	O
7	further	O
8	analysis	O
9	to	O
10	define	O
11	a	O
12	role	O
13	of	O
14	drug	O
15	-	O
16	related	O
17	or	O
18	autoantibodies	O
19	is	O
20	required	O
21	.	O
1	Electronic	O
2	structure	O
3	of	O
4	delta	O
5	-	O
6	plutonium	O
7	and	O
8	of	O
9	single	O
10	Al	O
11	,	O
12	Ga	O
13	,	O
14	and	O
15	Sc	O
16	impurities	O
17	in	O
18	delta	O
19	-	O
20	plutonium	O
21	.	O
1	II	O
2	.	O
1	The	O
2	history	O
3	of	O
4	exposure	O
5	and	O
6	carboxyhemoglobin	B
7	levels	O
8	should	O
9	alert	O
10	the	O
11	physician	O
12	to	O
13	this	O
14	diagnosis	O
15	.	O
1	The	O
2	case	O
3	for	O
4	neutrinos	O
5	from	O
6	SN	O
7	1987A	O
8	.	O
1	Direct	O
2	approach	O
3	to	O
4	the	O
5	study	O
6	of	O
7	soliton	O
8	perturbations	O
9	.	O
1	However	O
2	,	O
3	after	O
4	PRK	O
5	at	O
6	5	O
7	weeks	O
8	of	O
9	age	O
10	,	O
11	partial	O
12	retreatment	O
13	may	O
14	be	O
15	necessary	O
16	due	O
17	to	O
18	regression	O
19	of	O
20	the	O
21	PRK	O
22	effect	O
23	.	O
1	Molecular	O
2	cloning	O
3	of	O
4	human	O
5	cDNA	O
6	encoding	O
7	a	O
8	novel	O
9	beta1	B
10	,	I
11	6	I
12	-	I
13	N	I
14	-	I
15	acetylglucosaminyltransferase	I
16	forming	O
17	core	O
18	2	O
19	and	O
20	core	O
21	4	O
22	.	O
1	In	O
2	concert	O
3	with	O
4	the	O
5	coactivator	O
6	CREB	B
7	binding	I
8	protein	I
9	/	O
10	p300	B
11	,	O
12	which	O
13	interacts	O
14	with	O
15	GABPalpha	B
16	,	O
17	the	O
18	binding	O
19	of	O
20	GABPalpha	B
21	and	I
22	-	I
23	beta	I
24	to	O
25	the	O
26	dyad	O
27	symmetry	O
28	element	O
29	controls	O
30	the	O
31	induction	O
32	of	O
33	IL	B
34	-	I
35	16	I
36	promoter	I
37	in	O
38	T	O
39	cells	O
40	.	O
1	TPO	B
2	by	O
3	itself	O
4	did	O
5	not	O
6	activate	O
7	ERK1	B
8	,	O
9	ERK2	B
10	and	O
11	protein	B
12	kinase	I
13	C	I
14	(	O
15	PKC	B
16	),	O
17	whereas	O
18	TPO	B
19	directly	O
20	enhanced	O
21	the	O
22	PKC	B
23	-	O
24	dependent	O
25	activation	O
26	of	O
27	ERKs	B
28	induced	O
29	by	O
30	other	O
31	agonists	O
32	including	O
33	thrombin	B
34	and	O
35	phorbol	O
36	esters	O
37	,	O
38	without	O
39	affecting	O
40	the	O
41	PKC	B
42	activation	O
43	by	O
44	those	O
45	agonists	O
46	.	O
1	Observation	O
2	of	O
3	dipolar	O
4	interactions	O
5	between	O
6	Pb0	O
7	defects	O
8	at	O
9	the	O
10	(	O
11	111	O
12	)	O
13	Si	O
14	/	O
15	SiO2	O
16	interface	O
17	.	O
1	Chirality	O
2	-	O
3	glass	O
4	and	O
5	spin	O
6	-	O
7	glass	O
8	correlations	O
9	in	O
10	the	O
11	two	O
12	-	O
13	dimensional	O
14	random	O
15	-	O
16	bond	O
17	XY	O
18	model	O
19	.	O
1	Far	O
2	-	O
3	infrared	O
4	hopping	O
5	conductivity	O
6	in	O
7	the	O
8	CuO	O
9	chains	O
10	of	O
11	a	O
12	single	O
13	-	O
14	domain	O
15	YBa2Cu3O7	O
16	-	O
17	delta	O
18	crystal	O
19	.	O
1	Factors	O
2	influencing	O
3	direct	O
4	-	O
5	immersion	O
6	(	O
7	DI	O
8	)-	O
9	SPME	O
10	process	O
11	were	O
12	also	O
13	checked	O
14	and	O
15	chosen	O
16	experimentally	O
17	.	O
1	In	O
2	addition	O
3	,	O
4	a	O
5	potent	O
6	splicing	O
7	enhancer	O
8	sequence	O
9	isolated	O
10	in	O
11	the	O
12	selection	O
13	specifically	O
14	binds	O
15	a	O
16	20	B
17	-	I
18	kDa	I
19	SR	I
20	protein	I
21	.	O
1	Proteins	O
2	known	O
3	to	O
4	bind	O
5	the	O
6	PEPCK	B
7	CRE	O
8	include	O
9	the	O
10	CRE	B
11	-	I
12	binding	I
13	protein	I
14	(	O
15	CREB	B
16	)	O
17	and	O
18	members	O
19	of	O
20	the	O
21	CCAAT	B
22	/	I
23	enhancer	I
24	-	I
25	binding	I
26	protein	I
27	(	O
28	C	B
29	/	I
30	EBP	I
31	)	O
32	family	O
33	.	O
1	Several	O
2	secondary	O
3	structure	O
4	elements	O
5	were	O
6	identified	O
7	.	O
1	Most	O
2	other	O
3	end	O
4	points	O
5	were	O
6	highly	O
7	significant	O
8	,	O
9	and	O
10	death	O
11	,	O
12	which	O
13	was	O
14	monitored	O
15	across	O
16	the	O
17	U	O
18	.	O
19	S	O
20	.	O
21	program	O
22	,	O
23	was	O
24	different	O
25	with	O
26	p	O
27	<	O
28	0	O
29	.	O
30	0001	O
31	.	O
1	Results	O
2	demonstrated	O
3	that	O
4	the	O
5	presence	O
6	of	O
7	myofibroblasts	O
8	varied	O
9	considerably	O
10	from	O
11	case	O
12	to	O
13	case	O
14	and	O
15	was	O
16	always	O
17	related	O
18	to	O
19	smooth	O
20	muscle	O
21	cell	O
22	dispersion	O
23	,	O
24	which	O
25	occurred	O
26	around	O
27	medium	O
28	-	O
29	sized	O
30	damaged	O
31	portal	O
32	vein	O
33	branches	O
34	.	O
1	Fifty	O
2	-	O
3	seven	O
4	patients	O
5	aged	O
6	<	O
7	55	O
8	years	O
9	with	O
10	acute	O
11	lymphoblastic	O
12	leukemia	O
13	(	O
14	ALL	O
15	)	O
16	in	O
17	second	O
18	or	O
19	third	O
20	bone	O
21	marrow	O
22	(	O
23	BM	O
24	)	O
25	relapse	O
26	or	O
27	refractory	O
28	to	O
29	first	O
30	-	O
31	line	O
32	therapy	O
33	were	O
34	enrolled	O
35	in	O
36	an	O
37	Italian	O
38	cooperative	O
39	study	O
40	.	O
1	The	O
2	dorsal	O
3	nerves	O
4	of	O
5	the	O
6	penis	O
7	were	O
8	anesthetized	O
9	bilaterally	O
10	with	O
11	lidocaine	O
12	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	investigated	O
7	the	O
8	signal	O
9	transduction	O
10	pathways	O
11	that	O
12	are	O
13	involved	O
14	in	O
15	OM	B
16	-	O
17	induced	O
18	LDLR	B
19	transcription	O
20	.	O
1	Spectroscopy	O
2	of	O
3	negative	O
4	ions	O
5	utilizing	O
6	multiphoton	O
7	detachment	O
8	in	O
9	a	O
10	Raman	O
11	coupling	O
12	regime	O
13	.	O
1	Acoustic	O
2	transmission	O
3	spectra	O
4	in	O
5	the	O
6	Penrose	O
7	lattice	O
8	.	O
1	Basal	O
2	midexpiratory	O
3	lower	O
4	esophageal	O
5	sphincter	O
6	pressure	O
7	was	O
8	similar	O
9	in	O
10	the	O
11	study	O
12	group	O
13	(	O
14	mean	O
15	[	O
16	SD	O
17	]	O
18	20	O
19	.	O
20	1	O
21	[	O
22	9	O
23	.	O
24	1	O
25	]	O
26	mmHg	O
27	)	O
28	and	O
29	controls	O
30	(	O
31	17	O
32	.	O
33	6	O
34	[	O
35	6	O
36	.	O
37	0	O
38	]	O
39	mmHg	O
40	);	O
41	the	O
42	pressure	O
43	did	O
44	not	O
45	change	O
46	following	O
47	EVS	O
48	or	O
49	EVL	O
50	.	O
1	However	O
2	,	O
3	in	O
4	those	O
5	studies	O
6	due	O
7	to	O
8	the	O
9	presence	O
10	of	O
11	thiol	O
12	agents	O
13	in	O
14	the	O
15	PKC	B
16	preparations	O
17	,	O
18	the	O
19	sensitive	O
20	reaction	O
21	of	O
22	BPO	O
23	with	O
24	redox	O
25	-	O
26	active	O
27	cysteine	O
28	residues	O
29	in	O
30	PKC	B
31	was	O
32	not	O
33	observed	O
34	.	O
1	The	O
2	costs	O
3	were	O
4	DM	O
5	11	O
6	,	O
7	562	O
8	for	O
9	a	O
10	PE	O
11	,	O
12	DM	O
13	12	O
14	,	O
15	477	O
16	for	O
17	a	O
18	VR	O
19	and	O
20	DM	O
21	7	O
22	,	O
23	532	O
24	for	O
25	a	O
26	MR	O
27	.	O
1	Each	O
2	of	O
3	these	O
4	genes	O
5	contains	O
6	a	O
7	putative	O
8	upstream	O
9	ORF	O
10	,	O
11	while	O
12	STA2	B
13	has	O
14	two	O
15	additional	O
16	in	O
17	-	O
18	frame	O
19	AUG	O
20	codons	O
21	5	O
22	'	O
23	to	O
24	the	O
25	major	O
26	cistron	O
27	.	O
1	RT	O
2	-	O
3	PCR	O
4	was	O
5	performed	O
6	using	O
7	previously	O
8	reported	O
9	degenerate	O
10	oligonucleotide	O
11	primers	O
12	to	O
13	the	O
14	ligand	O
15	binding	O
16	domain	O
17	(	O
18	LBD	O
19	)	O
20	of	O
21	known	O
22	beta	B
23	integrin	I
24	subunits	I
25	and	O
26	Bge	B
27	cDNA	I
28	.	O
1	Primary	O
2	and	O
3	secondary	O
4	structural	O
5	elements	O
6	required	O
7	for	O
8	synthesis	O
9	of	O
10	barley	O
11	yellow	O
12	dwarf	O
13	virus	O
14	subgenomic	O
15	RNA1	O
16	.	O
1	The	O
2	MSY2	B
3	associated	O
4	kinase	O
5	is	O
6	not	O
7	casein	B
8	kinase	I
9	2	I
10	,	O
11	the	O
12	kinase	O
13	believed	O
14	to	O
15	phosphorylate	O
16	mRNP3	B
17	+	I
18	4	I
19	in	O
20	oocytes	O
21	,	O
22	but	O
23	a	O
24	yet	O
25	unidentified	O
26	kinase	O
27	.	O
1	These	O
2	data	O
3	provide	O
4	the	O
5	molecular	O
6	tools	O
7	for	O
8	the	O
9	final	O
10	identification	O
11	of	O
12	the	O
13	MKS	B
14	and	O
15	the	O
16	MUL	B
17	genes	I
18	.	O
1	Comparison	O
2	of	O
3	frequencies	O
4	of	O
5	atrial	O
6	fibrillation	O
7	after	O
8	coronary	O
9	artery	O
10	bypass	O
11	grafting	O
12	with	O
13	and	O
14	without	O
15	the	O
16	use	O
17	of	O
18	cardiopulmonary	O
19	bypass	O
20	.	O
1	The	O
2	results	O
3	of	O
4	supershift	O
5	analysis	O
6	using	O
7	specific	O
8	antibodies	O
9	against	O
10	transcription	O
11	factors	O
12	suggested	O
13	that	O
14	both	O
15	binding	O
16	complexes	O
17	contained	O
18	the	O
19	NF	B
20	-	I
21	kappaB	I
22	components	O
23	p50	B
24	and	O
25	p65	B
26	,	O
27	and	O
28	did	O
29	not	O
30	contain	O
31	other	O
32	NF	B
33	-	I
34	kappaB	I
35	proteins	I
36	(	O
37	p52	B
38	,	O
39	c	B
40	-	I
41	Rel	I
42	,	O
43	Rel	B
44	B	I
45	),	O
46	AP	B
47	-	I
48	1	I
49	proteins	I
50	(	O
51	c	B
52	-	I
53	Fos	I
54	,	O
55	C	B
56	-	I
57	Jun	I
58	),	O
59	CREB	B
60	or	O
61	C	B
62	/	I
63	EBPbeta	I
64	(	O
65	NF	B
66	-	I
67	IL6	I
68	).	O
1	A	O
2	set	O
3	of	O
4	peptides	O
5	corresponding	O
6	to	O
7	the	O
8	individual	O
9	elements	O
10	of	O
11	secondary	O
12	structure	O
13	derived	O
14	from	O
15	the	O
16	N	O
17	-	O
18	terminal	O
19	domain	O
20	of	O
21	the	O
22	ribosomal	B
23	protein	I
24	L9	I
25	have	O
26	been	O
27	synthesized	O
28	.	O
1	These	O
2	results	O
3	continue	O
4	to	O
5	support	O
6	the	O
7	hypothesis	O
8	that	O
9	HS2	O
10	,	O
11	HS3	O
12	,	O
13	and	O
14	HS4	O
15	act	O
16	as	O
17	a	O
18	single	O
19	,	O
20	integral	O
21	unit	O
22	to	O
23	regulate	O
24	human	B
25	globin	I
26	gene	I
27	transcription	O
28	as	O
29	a	O
30	holocomplex	O
31	,	O
32	but	O
33	they	O
34	can	O
35	also	O
36	be	O
37	interpreted	O
38	to	O
39	say	O
40	that	O
41	formation	O
42	of	O
43	a	O
44	DNase	B
45	I	I
46	hypersensitive	O
47	holocomplex	O
48	alone	O
49	is	O
50	not	O
51	sufficient	O
52	for	O
53	mediating	O
54	high	O
55	-	O
56	level	O
57	globin	B
58	gene	I
59	transcription	O
60	.	O
1	KEY	O
2	WORDS	O
3	:	O
4	Melaleuca	O
5	;	O
6	Lake	O
7	Okeechobee	O
8	;	O
9	Littoral	O
10	zone	O
11	;	O
12	Water	O
13	level	O
14	;	O
15	Regulation	O
16	schedule	O
1	The	O
2	following	O
3	data	O
4	were	O
5	recorded	O
6	at	O
7	arrival	O
8	in	O
9	the	O
10	intensive	O
11	care	O
12	unit	O
13	6	O
14	,	O
15	12	O
16	,	O
17	24	O
18	,	O
19	and	O
20	48	O
21	hours	O
22	after	O
23	termination	O
24	of	O
25	CPB	O
26	:	O
27	heart	O
28	rate	O
29	,	O
30	blood	O
31	pressure	O
32	,	O
33	left	O
34	atrial	O
35	pressure	O
36	,	O
37	central	O
38	-	O
39	peripheral	O
40	temperature	O
41	difference	O
42	,	O
43	arterial	O
44	-	O
45	central	O
46	venous	O
47	oxygen	O
48	saturation	O
49	difference	O
50	,	O
51	urine	O
52	output	O
53	,	O
54	serum	O
55	creatinine	O
56	,	O
57	lactate	O
58	and	O
59	neutrophil	B
60	elastase	I
61	levels	O
62	,	O
63	the	O
64	Doppler	O
65	echocardiographic	O
66	factors	O
67	shortening	O
68	fraction	O
69	and	O
70	preejection	O
71	period	O
72	/	O
73	left	O
74	-	O
75	ventricular	O
76	ejection	O
77	time	O
78	,	O
79	and	O
80	cumulative	O
81	doses	O
82	of	O
83	catecholamines	O
84	(	O
85	epinephrine	O
86	),	O
87	enoximone	O
88	,	O
89	and	O
90	furosemide	O
91	.	O
1	MDS1	B
2	/	O
3	EVI1	B
4	,	O
5	located	O
6	on	O
7	chromosome	O
8	3	O
9	band	O
10	q26	O
11	,	O
12	encodes	O
13	a	O
14	zinc	B
15	-	I
16	finger	I
17	DNA	I
18	-	I
19	binding	I
20	transcription	I
21	activator	I
22	not	O
23	detected	O
24	in	O
25	normal	O
26	hematopoietic	O
27	cells	O
28	but	O
29	expressed	O
30	in	O
31	several	O
32	normal	O
33	tissues	O
34	.	O
1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	binding	O
7	sites	O
8	for	O
9	the	O
10	repressor	B
11	proteins	I
12	BP1	I
13	and	O
14	BP2	B
15	in	O
16	the	O
17	upstream	O
18	portion	O
19	of	O
20	the	O
21	beta	B
22	globin	I
23	gene	I
24	flanking	I
25	region	I
26	led	O
27	to	O
28	a	O
29	4	O
30	-	O
31	6	O
32	fold	O
33	increase	O
34	in	O
35	promoter	O
36	activity	O
37	.	O
1	Schwab	O
2	and	O
3	England	O
4	ADL	O
5	scores	O
6	in	O
7	the	O
8	""""	O
9	off	O
10	""""	O
11	state	O
12	were	O
13	improved	O
14	by	O
15	18	O
16	%	O
17	and	O
18	in	O
19	the	O
20	""""	O
21	on	O
22	""""	O
23	state	O
24	the	O
25	scores	O
26	declined	O
27	by	O
28	2	O
29	%.	O
1	Four	O
2	CsA	O
3	-	O
4	treated	O
5	patients	O
6	developed	O
7	persistently	O
8	elevated	O
9	UAER	O
10	>	O
11	30	O
12	mg	O
13	/	O
14	24	O
15	h	O
16	(	O
17	n	O
18	=	O
19	3	O
20	with	O
21	microalbuminuria	O
22	),	O
23	whereas	O
24	all	O
25	the	O
26	17	O
27	placebo	O
28	-	O
29	treated	O
30	patients	O
31	had	O
32	normal	O
33	UAER	O
34	(<	O
35	30	O
36	mg	O
37	/	O
38	24	O
39	h	O
40	)	O
41	after	O
42	7	O
43	years	O
44	of	O
45	follow	O
46	-	O
47	up	O
48	.	O
1	In	O
2	contrast	O
3	,	O
4	no	O
5	change	O
6	was	O
7	detected	O
8	in	O
9	the	O
10	phenotype	O
11	of	O
12	'	O
13	unstressed	O
14	'	O
15	clones	O
16	,	O
17	with	O
18	respect	O
19	to	O
20	any	O
21	of	O
22	the	O
23	following	O
24	parameters	O
25	:	O
26	proliferation	O
27	rate	O
28	in	O
29	monolayer	O
30	,	O
31	serum	O
32	-	O
33	dependence	O
34	for	O
35	proliferation	O
36	or	O
37	survival	O
38	,	O
39	tumorigenicity	O
40	,	O
41	cellular	O
42	morphology	O
43	,	O
44	or	O
45	tissue	O
46	-	O
47	specific	O
48	differentiation	O
49	markers	O
50	.	O
1	Type	O
2	I	O
3	cysts	O
4	(	O
5	with	O
6	a	O
7	high	O
8	K	O
9	+/	O
10	Na	O
11	+	O
12	ratio	O
13	)	O
14	tend	O
15	to	O
16	have	O
17	higher	O
18	total	O
19	PSA	B
20	than	O
21	Type	O
22	II	O
23	cysts	O
24	.	O
1	Ultrasonography	O
2	provides	O
3	excellent	O
4	intraoperative	O
5	evaluation	O
6	of	O
7	spinal	O
8	cord	O
9	injury	O
10	.	O
1	We	O
2	have	O
3	screened	O
4	the	O
5	elastin	B
6	gene	I
7	for	O
8	mutations	O
9	responsible	O
10	for	O
11	supravalvular	O
12	aortic	O
13	stenosis	O
14	(	O
15	SVAS	O
16	)	O
17	in	O
18	two	O
19	large	O
20	,	O
21	independently	O
22	collected	O
23	families	O
24	with	O
25	isolated	O
26	(	O
27	nonsyndromic	O
28	)	O
29	SVAS	O
30	.	O
1	Spatiotemporal	O
2	expression	O
3	of	O
4	the	O
5	PAX3	B
6	gene	I
7	is	O
8	tightly	O
9	regulated	O
10	during	O
11	development	O
12	.	O
1	One	O
2	such	O
3	element	O
4	,	O
5	1P	O
6	,	O
7	was	O
8	employed	O
9	to	O
10	clone	O
11	from	O
12	a	O
13	rat	O
14	pituitary	O
15	cDNA	O
16	expression	O
17	library	O
18	a	O
19	novel	O
20	417	B
21	-	I
22	amino	I
23	acid	I
24	WD	I
25	protein	I
26	,	O
27	designated	O
28	PREB	B
29	(	I
30	PRL	I
31	regulatory	I
32	element	I
33	binding	I
34	)	I
35	protein	I
36	.	O
1	The	O
2	catalytic	O
3	site	O
4	has	O
5	an	O
6	S1	O
7	pocket	O
8	lined	O
9	with	O
10	conserved	O
11	hydrophobic	O
12	residues	O
13	to	O
14	accommodate	O
15	the	O
16	pyroglutamyl	O
17	residue	O
18	.	O
1	CCAAT	B
2	displacement	I
3	protein	I
4	binds	O
5	to	O
6	and	O
7	negatively	O
8	regulates	O
9	human	O
10	papillomavirus	O
11	type	O
12	6	O
13	E6	B
14	,	O
15	E7	B
16	,	O
17	and	O
18	E1	B
19	promoters	O
20	.	O
1	As	O
2	such	O
3	the	O
4	findings	O
5	support	O
6	existing	O
7	studies	O
8	that	O
9	have	O
10	identified	O
11	given	O
12	social	O
13	characteristics	O
14	of	O
15	drink	O
16	drivers	O
17	.	O
1	Analysis	O
2	of	O
3	lacZ	B
4	transcriptional	I
5	fusions	I
6	shows	O
7	that	O
8	the	O
9	KdgR	B
10	-	I
11	binding	I
12	sites	I
13	negatively	O
14	affect	O
15	the	O
16	expression	O
17	of	O
18	rsmB	B
19	.	O
1	Many	O
2	eukaryotic	O
3	cell	O
4	surface	O
5	proteins	O
6	are	O
7	anchored	O
8	in	O
9	the	O
10	lipid	O
11	bilayer	O
12	through	O
13	glycosylphosphatidylinositol	O
14	(	O
15	GPI	O
16	).	O
1	Bacteria	O
2	can	O
3	also	O
4	cause	O
5	a	O
6	labyrinthitis	O
7	acting	O
8	directly	O
9	on	O
10	the	O
11	inner	O
12	ear	O
13	:	O
14	among	O
15	these	O
16	,	O
17	Treponemas	O
18	Pallidum	O
19	,	O
20	a	O
21	spirochaete	O
22	which	O
23	causes	O
24	syphilis	O
25	and	O
26	Borrelia	O
27	Burgdorferi	O
28	,	O
29	a	O
30	spirochaete	O
31	that	O
32	causes	O
33	Lyme	O
34	Disease	O
35	,	O
36	must	O
37	be	O
38	mentioned	O
39	.	O
1	We	O
2	found	O
3	that	O
4	the	O
5	expression	O
6	of	O
7	the	O
8	protein	O
9	was	O
10	maximum	O
11	in	O
12	mitosis	O
13	and	O
14	minimum	O
15	in	O
16	G1	O
17	,	O
18	which	O
19	correlated	O
20	with	O
21	the	O
22	expression	O
23	of	O
24	its	O
25	messenger	O
26	RNA	O
27	.	O
1	Mechanistically	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	the	O
7	GRR	O
8	appears	O
9	to	O
10	stop	O
11	further	O
12	degradation	O
13	of	O
14	p50	B
15	and	O
16	to	O
17	stabilize	O
18	the	O
19	molecule	O
20	.	O
1	Concomitantly	O
2	,	O
3	the	O
4	total	O
5	cellular	O
6	level	O
7	of	O
8	p21	B
9	increased	O
10	severalfold	O
11	via	O
12	a	O
13	posttranscriptional	O
14	mechanism	O
15	.	O
1	We	O
2	show	O
3	here	O
4	that	O
5	,	O
6	despite	O
7	their	O
8	structural	O
9	and	O
10	functional	O
11	similarities	O
12	,	O
13	the	O
14	pop1	B
15	and	O
16	pop2	B
17	genes	I
18	fail	O
19	to	O
20	complement	O
21	each	O
22	other	O
23	'	O
24	s	O
25	deletion	O
26	phenotypes	O
27	,	O
28	indicating	O
29	that	O
30	they	O
31	perform	O
32	non	O
33	-	O
34	redundant	O
35	,	O
36	but	O
37	potentially	O
38	interdependent	O
39	,	O
40	functions	O
41	in	O
42	proteolysis	O
43	.	O
1	Significantly	O
2	greater	O
3	improvement	O
4	(	O
5	p	O
6	<	O
7	0	O
8	.	O
9	05	O
10	)	O
11	in	O
12	the	O
13	sertraline	O
14	group	O
15	first	O
16	became	O
17	apparent	O
18	by	O
19	the	O
20	end	O
21	of	O
22	week	O
23	3	O
24	on	O
25	the	O
26	Y	O
27	-	O
28	BOCS	O
29	and	O
30	the	O
31	CGI	O
32	Improvement	O
33	scale	O
34	,	O
35	and	O
36	by	O
37	the	O
38	end	O
39	of	O
40	weeks	O
41	6	O
42	and	O
43	8	O
44	,	O
45	respectively	O
46	,	O
47	on	O
48	the	O
49	NIMH	O
50	and	O
51	CGI	O
52	Severity	O
53	scale	O
54	.	O
1	Stress	B
2	-	I
3	inducible	I
4	protein	I
5	kinases	I
6	capable	O
7	of	O
8	activating	O
9	c	B
10	-	I
11	jun	I
12	expression	O
13	include	O
14	stress	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	/	O
20	c	B
21	-	I
22	Jun	I
23	N	I
24	-	I
25	terminal	I
26	protein	I
27	kinase	I
28	(	O
29	SAPK	B
30	/	O
31	JNK	B
32	)	O
33	and	O
34	p38	B
35	members	O
36	of	O
37	the	O
38	mitogen	B
39	-	I
40	activated	I
41	protein	I
42	kinase	I
43	(	O
44	MAPK	B
45	)	O
46	superfamily	O
47	of	O
48	signaling	O
49	molecules	O
50	.	O
1	Chronotherapeutics	O
2	in	O
3	cardiovascular	O
4	disease	O
5	.	O
1	Group	O
2	psychometric	O
3	functions	O
4	for	O
5	listeners	O
6	with	O
7	hearing	O
8	loss	O
9	do	O
10	not	O
11	show	O
12	a	O
13	decrease	O
14	in	O
15	performance	O
16	at	O
17	the	O
18	largest	O
19	values	O
20	of	O
21	delta	O
22	f	O
23	included	O
24	in	O
25	this	O
26	study	O
27	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	report	O
7	the	O
8	isolation	O
9	and	O
10	characterization	O
11	of	O
12	the	O
13	entire	O
14	rat	B
15	GSTA3	I
16	(	O
17	rGST	B
18	Yc1	I
19	)	O
20	subunit	O
21	gene	O
22	.	O
1	Calcinosis	O
2	cutis	O
3	following	O
4	intravenous	O
5	infusion	O
6	of	O
7	calcium	O
8	gluconate	O
9	.	O
1	Finally	O
2	,	O
3	we	O
4	determined	O
5	the	O
6	genomic	O
7	organization	O
8	of	O
9	the	O
10	human	B
11	TrxR2	I
12	gene	I
13	,	O
14	which	O
15	consists	O
16	of	O
17	18	O
18	exons	O
19	spanning	O
20	about	O
21	67	O
22	kb	O
23	,	O
24	and	O
25	its	O
26	chromosomal	O
27	localization	O
28	at	O
29	position	O
30	22q11	O
31	.	O
32	2	O
33	.	O
1	The	O
2	binding	O
3	of	O
4	PH	B
5	domains	I
6	to	O
7	Gbetagamma	B
8	was	O
9	inhibited	O
10	by	O
11	preincubation	O
12	of	O
13	Gbetagamma	B
14	with	O
15	the	O
16	GDP	O
17	-	O
18	bound	O
19	but	O
20	not	O
21	the	O
22	GTP	O
23	-	O
24	bound	O
25	form	O
26	of	O
27	Gialpha	B
28	.	O
1	In	O
2	XO	O
3	males	O
4	,	O
5	two	O
6	her	B
7	-	I
8	1	I
9	mRNAs	I
10	,	O
11	her	B
12	-	I
13	1a	I
14	and	O
15	her	B
16	-	I
17	1b	I
18	,	O
19	are	O
20	transcribed	O
21	from	O
22	two	O
23	separate	O
24	promoters	O
25	:	O
26	P1	O
27	,	O
28	located	O
29	in	O
30	the	O
31	5	O
32	'-	O
33	flanking	O
34	region	O
35	,	O
36	and	O
37	P2	O
38	,	O
39	located	O
40	in	O
41	the	O
42	large	O
43	second	O
44	intron	O
45	.	O
1	Induction	O
2	of	O
3	Fas	B
4	ligand	I
5	expression	O
6	by	O
7	HIV	O
8	involves	O
9	the	O
10	interaction	O
11	of	O
12	Nef	B
13	with	O
14	the	O
15	T	B
16	cell	I
17	receptor	I
18	zeta	I
19	chain	I
20	.	O
1	Two	O
2	-	O
3	dimensional	O
4	gel	O
5	electrophoresis	O
6	of	O
7	anti	B
8	-	I
9	p59fyn	I
10	immunoprecipitates	O
11	obtained	O
12	from	O
13	non	O
14	-	O
15	transformed	O
16	resting	O
17	human	O
18	T	O
19	lymphocytes	O
20	resulted	O
21	in	O
22	the	O
23	identification	O
24	of	O
25	an	O
26	oligomeric	O
27	protein	O
28	complex	O
29	which	O
30	is	O
31	constitutively	O
32	formed	O
33	between	O
34	Fyn	B
35	and	O
36	several	O
37	additional	O
38	phosphoproteins	O
39	(	O
40	pp43	B
41	,	O
42	pp72	B
43	,	O
44	pp85	B
45	,	O
46	the	O
47	protein	B
48	tyrosine	I
49	kinase	I
50	Pyk2	I
51	,	O
52	as	O
53	well	O
54	as	O
55	the	O
56	two	O
57	recently	O
58	cloned	O
59	adaptor	O
60	proteins	O
61	,	O
62	SKAP55	B
63	and	O
64	SLAP	B
65	-	I
66	130	I
67	).	O
1	Total	O
2	serum	O
3	calcium	O
4	was	O
5	7	O
6	.	O
7	8	O
8	+/-	O
9	0	O
10	.	O
11	8	O
12	mg	O
13	/	O
14	dl	O
15	,	O
16	whereas	O
17	ionized	O
18	calcium	O
19	was	O
20	5	O
21	.	O
22	7	O
23	+/-	O
24	0	O
25	.	O
26	7	O
27	mg	O
28	/	O
29	dl	O
30	,	O
31	phosphorus	O
32	3	O
33	.	O
34	2	O
35	+/-	O
36	1	O
37	.	O
38	2	O
39	mg	O
40	/	O
41	dl	O
42	,	O
43	and	O
44	alkaline	B
45	phosphatase	I
46	149	O
47	+/-	O
48	48	O
49	.	O
50	6	O
51	U	O
52	/	O
53	liter	O
54	.	O
1	Canadian	O
2	survey	O
3	reveals	O
4	widespread	O
5	dissatisfaction	O
6	among	O
7	physicians	O
8	.	O
1	Members	O
2	of	O
3	the	O
4	mitogen	B
5	activated	I
6	protein	I
7	(	I
8	MAP	I
9	)	I
10	kinase	I
11	family	I
12	,	O
13	extracellular	B
14	signal	I
15	-	I
16	regulated	I
17	kinase	I
18	,	O
19	stress	B
20	-	I
21	activated	I
22	protein	I
23	kinase	I
24	-	I
25	1	I
26	/	O
27	c	B
28	-	I
29	Jun	I
30	NH2	I
31	-	I
32	terminal	I
33	kinase	I
34	,	O
35	and	O
36	p38	B
37	,	O
38	are	O
39	central	O
40	elements	O
41	that	O
42	transduce	O
43	the	O
44	signal	O
45	generated	O
46	by	O
47	growth	O
48	factors	O
49	,	O
50	cytokines	O
51	,	O
52	and	O
53	stressing	O
54	agents	O
55	.	O
1	We	O
2	also	O
3	observed	O
4	that	O
5	cell	O
6	surface	O
7	CD4	B
8	(-)	O
9	CD8	B
10	(-)	O
11	CD3	B
12	(-)	O
13	cells	O
14	with	O
15	rearranged	B
16	TCR	I
17	genes	I
18	developed	O
19	from	O
20	Id3	B
21	-	O
22	transduced	O
23	but	O
24	not	O
25	from	O
26	control	O
27	-	O
28	transduced	O
29	pre	O
30	-	O
31	T	O
32	cells	O
33	in	O
34	an	O
35	FTOC	O
36	.	O
1	RESULTS	O
2	:	O
3	Each	O
4	year	O
5	,	O
6	on	O
7	average	O
8	39	O
9	%	O
10	of	O
11	cases	O
12	seen	O
13	in	O
14	Sardinia	O
15	are	O
16	notified	O
17	;	O
18	646	O
19	(	O
20	40	O
21	%)	O
22	of	O
23	the	O
24	1591	O
25	patients	O
26	notified	O
27	during	O
28	the	O
29	study	O
30	period	O
31	were	O
32	never	O
33	seen	O
34	by	O
35	regional	O
36	medical	O
37	centres	O
38	.	O
1	The	O
2	hTERT	B
3	gene	I
4	encompasses	O
5	more	O
6	than	O
7	37kb	O
8	and	O
9	consists	O
10	of	O
11	16	O
12	exons	O
13	.	O
1	In	O
2	reperfusion	O
3	B	O
4	,	O
5	only	O
6	the	O
7	diabetic	O
8	group	O
9	demonstrated	O
10	a	O
11	significant	O
12	increase	O
13	in	O
14	IL	B
15	-	I
16	8	I
17	concentrations	O
18	at	O
19	1	O
20	and	O
21	15	O
22	min	O
23	compared	O
24	to	O
25	nondiabetics	O
26	.	O
1	CDK4	B
2	kinase	I
3	activities	O
4	were	O
5	unaffected	O
6	,	O
7	as	O
8	were	O
9	the	O
10	levels	O
11	of	O
12	the	O
13	CDK	B
14	inhibitor	O
15	p21Cip1	B
16	present	O
17	in	O
18	cyclin	B
19	E	I
20	immunocomplexes	I
21	.	O
1	The	O
2	recombinant	O
3	purified	O
4	protein	O
5	expressed	O
6	in	O
7	the	O
8	baculovirus	O
9	system	O
10	had	O
11	an	O
12	approximate	O
13	molecular	O
14	size	O
15	20	O
16	kDa	O
17	with	O
18	amino	O
19	-	O
20	terminal	O
21	sequence	O
22	of	O
23	AVQGP	O
24	.	O
1	The	O
2	kinetics	O
3	of	O
4	kinase	O
5	activity	O
6	within	O
7	these	O
8	complexes	O
9	compared	O
10	to	O
11	CheA	B
12	alone	O
13	indicate	O
14	approximately	O
15	a	O
16	50	O
17	%	O
18	decrease	O
19	in	O
20	the	O
21	KM	O
22	for	O
23	ATP	O
24	and	O
25	a	O
26	100	O
27	-	O
28	fold	O
29	increase	O
30	in	O
31	the	O
32	Vmax	O
33	.	O
1	Developmental	O
2	follow	O
3	-	O
4	up	O
5	at	O
6	age	O
7	2	O
8	years	O
9	was	O
10	performed	O
11	.	O
1	However	O
2	,	O
3	neu	B
4	differentiation	O
5	factor	O
6	-	O
7	induced	O
8	heterodimers	O
9	of	O
10	ErbB2	B
11	and	O
12	ErbB4	B
13	activated	O
14	Stat5	B
15	.	O
1	Nevertheless	O
2	,	O
3	they	O
4	are	O
5	functionally	O
6	distinct	O
7	in	O
8	that	O
9	FcalphaRI	B
10	binds	O
11	human	B
12	IgA	I
13	(	O
14	hIgA	B
15	)	O
16	but	O
17	not	O
18	bovine	B
19	IgG2	I
20	(	O
21	bIgG2	B
22	),	O
23	whereas	O
24	bFcgamma2R	B
25	binds	O
26	bIgG2	B
27	but	O
28	not	O
29	hIgA	B
30	.	O
1	Vac1p	B
2	was	O
3	found	O
4	to	O
5	bind	O
6	the	O
7	Sec1p	B
8	homologue	I
9	Vps45p	I
10	.	O
1	In	O
2	co	O
3	-	O
4	transfection	O
5	studies	O
6	,	O
7	the	O
8	expression	O
9	of	O
10	c	B
11	-	I
12	Jun	I
13	plus	O
14	c	B
15	-	I
16	Fos	I
17	enhanced	O
18	the	O
19	transactivation	O
20	of	O
21	oIFNtau	B
22	-	O
23	CAT	B
24	but	O
25	the	O
26	expression	O
27	of	O
28	GATA	B
29	-	I
30	1	I
31	,	O
32	GATA	B
33	-	I
34	2	I
35	or	O
36	GATA	B
37	-	I
38	3	I
39	did	O
40	not	O
41	.	O
1	To	O
2	identify	O
3	these	O
4	sites	O
5	,	O
6	Cdk2	B
7	-	O
8	phosphorylated	O
9	MARCKS	B
10	was	O
11	digested	O
12	with	O
13	lysyl	B
14	endoprotease	I
15	and	O
16	analysed	O
17	by	O
18	electrospray	O
19	MS	O
20	.	O
1	In	O
2	addition	O
3	,	O
4	we	O
5	show	O
6	that	O
7	the	O
8	expression	O
9	of	O
10	individual	O
11	members	O
12	of	O
13	one	O
14	subfamily	O
15	of	O
16	KRAB	B
17	zinc	I
18	finger	I
19	genes	I
20	is	O
21	restricted	O
22	to	O
23	specific	O
24	hematopoietic	O
25	cell	O
26	lineages	O
27	.	O
1	Binding	O
2	affinities	O
3	of	O
4	these	O
5	recombinant	O
6	phages	O
7	as	O
8	determined	O
9	by	O
10	the	O
11	retention	O
12	of	O
13	these	O
14	phages	O
15	by	O
16	a	O
17	His	O
18	-	O
19	tag	O
20	immobilized	O
21	gp17	B
22	column	O
23	,	O
24	and	O
25	by	O
26	co	O
27	-	O
28	immunoprecipitation	O
29	with	O
30	purified	O
31	terminase	B
32	supported	O
33	the	O
34	specific	O
35	nature	O
36	of	O
37	the	O
38	portal	B
39	protein	I
40	and	O
41	terminase	B
42	interaction	I
43	sites	I
44	.	O
1	The	O
2	hybrid	O
3	viruses	O
4	were	O
5	found	O
6	to	O
7	accumulate	O
8	to	O
9	high	O
10	levels	O
11	in	O
12	infected	O
13	plants	O
14	,	O
15	to	O
16	form	O
17	stable	O
18	virions	O
19	,	O
20	and	O
21	to	O
22	be	O
23	mechanically	O
24	transmissible	O
25	.	O
1	cDNA	O
2	and	O
3	structural	O
4	organization	O
5	of	O
6	the	O
7	gene	B
8	Pole1	I
9	for	O
10	the	O
11	mouse	B
12	DNA	I
13	polymerase	I
14	epsilon	I
15	catalytic	I
16	subunit	I
17	.	O
1	Optimal	O
2	monitoring	O
3	of	O
4	ODA	O
5	remains	O
6	undefined	O
7	.	O
1	The	O
2	Aa	B
3	-	I
4	Pri2	I
5	gene	I
6	,	O
7	specifically	O
8	expressed	O
9	during	O
10	basidiocarp	O
11	differentiation	O
12	of	O
13	the	O
14	mushroom	O
15	Agrocybe	O
16	aegerita	O
17	,	O
18	was	O
19	cloned	O
20	.	O
1	CONCLUSION	O
2	:	O
3	NBP	O
4	pre	O
5	-	O
6	treatment	O
7	or	O
8	post	O
9	-	O
10	treatment	O
11	markedly	O
12	enhanced	O
13	the	O
14	rCBF	O
15	to	O
16	striatum	O
17	in	O
18	RMCAO	O
19	rats	O
20	.	O
1	Progression	O
2	after	O
3	first	O
4	-	O
5	line	O
6	chemotherapy	O
7	was	O
8	associated	O
9	with	O
10	significantly	O
11	worse	O
12	survival	O
13	for	O
14	patients	O
15	with	O
16	metastasis	O
17	.	O
1	Mutations	O
2	within	O
3	human	O
4	UTR1	O
5	modulate	O
6	NRF	B
7	-	I
8	1	I
9	expression	O
10	by	O
11	interfering	O
12	with	O
13	mRNA	O
14	translational	O
15	efficiency	O
16	in	O
17	transfected	O
18	cells	O
19	and	O
20	in	O
21	an	O
22	in	O
23	vitro	O
24	translation	O
25	system	O
26	.	O
1	Green	O
2	fluorescent	O
3	protein	O
4	-	O
5	tagged	O
6	UNC	B
7	-	I
8	49B	I
9	and	O
10	UNC	B
11	-	I
12	49C	I
13	subunits	I
14	are	O
15	coexpressed	O
16	in	O
17	muscle	O
18	cells	O
19	and	O
20	are	O
21	colocalized	O
22	to	O
23	synaptic	O
24	regions	O
25	.	O
1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	investigate	O
9	the	O
10	spontaneous	O
11	reports	O
12	of	O
13	suspected	O
14	adverse	O
15	drug	O
16	reactions	O
17	,	O
18	observed	O
19	in	O
20	elderly	O
21	patients	O
22	(	O
23	over	O
24	65	O
25	years	O
26	of	O
27	age	O
28	)	O
29	in	O
30	Sicily	O
31	(	O
32	Italy	O
33	)	O
34	during	O
35	the	O
36	period	O
37	from	O
38	1	O
39	January	O
40	1995	O
41	to	O
42	31	O
43	December	O
44	1997	O
45	.	O
1	Forty	O
2	-	O
3	eight	O
4	sequences	O
5	,	O
6	30	O
7	not	O
8	previously	O
9	identified	O
10	as	O
11	IR	O
12	-	O
13	responsive	O
14	,	O
15	were	O
16	significantly	O
17	regulated	O
18	by	O
19	IR	O
20	.	O
1	The	O
2	penicillin	B
3	binding	I
4	proteins	I
5	(	O
6	PBPs	B
7	)	O
8	synthesize	O
9	and	O
10	remodel	O
11	peptidoglycan	O
12	,	O
13	the	O
14	structural	O
15	component	O
16	of	O
17	the	O
18	bacterial	O
19	cell	O
20	wall	O
21	.	O
1	The	O
2	percentages	O
3	of	O
4	recovery	O
5	decreased	O
6	with	O
7	storage	O
8	time	O
9	,	O
10	although	O
11	the	O
12	addition	O
13	of	O
14	dispersant	O
15	(	O
16	Tris	O
17	-	O
18	Tween	O
19	80	O
20	)	O
21	before	O
22	storage	O
23	appeared	O
24	to	O
25	partially	O
26	prevent	O
27	adhesion	O
28	.	O
1	The	O
2	activation	O
3	of	O
4	the	O
5	HIV	O
6	promoter	O
7	required	O
8	the	O
9	nuclear	O
10	localization	O
11	of	O
12	c	B
13	-	I
14	Abl	I
15	and	O
16	could	O
17	be	O
18	correlated	O
19	with	O
20	increased	O
21	tyrosine	O
22	phosphorylation	O
23	of	O
24	RNA	B
25	polymerase	I
26	II	I
27	.	O
1	DDP1	B
2	also	O
3	localizes	O
4	to	O
5	heterochromatin	O
6	in	O
7	interphase	O
8	nuclei	O
9	of	O
10	larval	O
11	neuroblasts	O
12	.	O
1	Sequence	O
2	of	O
3	10q24	B
4	locus	I
5	surrounding	O
6	the	O
7	HOX11	B
8	oncogene	I
9	reveals	O
10	a	O
11	new	O
12	gene	O
13	HUG1	B
14	expressed	O
15	in	O
16	a	O
17	T	O
18	-	O
19	ALL	O
20	cell	O
21	line	O
22	.	O
1	G	O
2	-	O
3	box	O
4	-	O
5	directed	O
6	expression	O
7	in	O
8	leaves	O
9	required	O
10	the	O
11	presence	O
12	of	O
13	an	O
14	enhancer	O
15	region	O
16	from	O
17	the	O
18	cauliflower	O
19	mosaic	O
20	virus	O
21	(	O
22	CaMV	O
23	)	O
24	35S	B
25	promoter	I
26	.	O
1	However	O
2	,	O
3	the	O
4	favored	O
5	,	O
6	parallel	O
7	beta	O
8	helix	O
9	model	O
10	is	O
11	a	O
12	compact	O
13	coil	O
14	of	O
15	ten	O
16	helically	O
17	arranged	O
18	beta	O
19	strands	O
20	forming	O
21	two	O
22	parallel	O
23	beta	O
24	sheet	O
25	faces	O
26	.	O
1	This	O
2	is	O
3	predicted	O
4	to	O
5	encode	O
6	a	O
7	315	O
8	-	O
9	residue	O
10	protein	O
11	containing	O
12	seven	O
13	hydrophobic	O
14	helical	O
15	regions	O
16	and	O
17	a	O
18	17	O
19	amino	O
20	acid	O
21	motif	O
22	characteristic	O
23	of	O
24	the	O
25	R7G	B
26	family	I
27	of	O
28	G	B
29	-	I
30	protein	I
31	coupled	I
32	membrane	I
33	-	I
34	bound	I
35	receptors	I
36	.	O
1	Using	O
2	Scheffe	O
3	'	O
4	s	O
5	procedure	O
6	as	O
7	an	O
8	illustration	O
9	,	O
10	comparisons	O
11	are	O
12	made	O
13	to	O
14	usual	O
15	sample	O
16	size	O
17	methods	O
18	that	O
19	incorrectly	O
20	ignore	O
21	the	O
22	stochastic	O
23	nature	O
24	of	O
25	S2p	O
26	.	O
1	The	O
2	crystal	O
3	structure	O
4	of	O
5	the	O
6	VP16	B
7	core	I
8	has	O
9	been	O
10	determined	O
11	at	O
12	2	O
13	.	O
14	1	O
15	A	O
16	resolution	O
17	.	O
1	The	O
2	latter	O
3	method	O
4	adds	O
5	clamping	O
6	of	O
7	the	O
8	inferior	O
9	vena	O
10	cava	O
11	,	O
12	which	O
13	results	O
14	in	O
15	hypotension	O
16	,	O
17	requiring	O
18	invasive	O
19	anesthetic	O
20	management	O
21	.	O
1	Simian	O
2	parainfluenza	O
3	virus	O
4	5	O
5	(	O
6	SV5	O
7	)	O
8	is	O
9	a	O
10	prototype	O
11	of	O
12	the	O
13	Paramyxoviridae	O
14	family	O
15	of	O
16	nonsegmented	O
17	negative	O
18	-	O
19	sense	O
20	RNA	O
21	viruses	O
22	.	O
1	To	O
2	investigate	O
3	the	O
4	functions	O
5	of	O
6	GE	O
7	,	O
8	IG	O
9	,	O
10	and	O
11	GS	O
12	sequences	O
13	in	O
14	transcription	O
15	,	O
16	we	O
17	constructed	O
18	plasmids	O
19	containing	O
20	cDNAs	O
21	of	O
22	the	O
23	full	O
24	-	O
25	length	O
26	SV5	O
27	genome	O
28	in	O
29	which	O
30	the	O
31	gene	O
32	junction	O
33	sequences	O
34	(	O
35	GE	O
36	,	O
37	IG	O
38	,	O
39	and	O
40	GS	O
41	sequences	O
42	)	O
43	located	O
44	between	O
45	the	O
46	hemagglutinin	B
47	-	I
48	neuraminidase	I
49	(	O
50	HN	B
51	)	O
52	and	O
53	the	O
54	polymerase	B
55	(	I
56	L	I
57	)	I
58	genes	I
59	were	O
60	replaced	O
61	with	O
62	the	O
63	counterpart	O
64	sequences	O
65	from	O
66	other	O
67	gene	O
68	junctions	O
69	.	O
1	Identification	O
2	of	O
3	a	O
4	spliced	O
5	gene	O
6	from	O
7	Kaposi	O
8	'	O
9	s	O
10	sarcoma	O
11	-	O
12	associated	O
13	herpesvirus	O
14	encoding	O
15	a	O
16	protein	O
17	with	O
18	similarities	O
19	to	O
20	latent	B
21	membrane	I
22	proteins	I
23	1	I
24	and	I
25	2A	I
26	of	I
27	Epstein	I
28	-	I
29	Barr	I
30	virus	I
31	.	O
1	Auditory	O
2	clicks	O
3	were	O
4	given	O
5	at	O
6	a	O
7	rate	O
8	of	O
9	20	O
10	s	O
11	(-	O
12	1	O
13	).	O
1	Comparison	O
2	with	O
3	the	O
4	bHLH	B
5	/	O
6	PAS	B
7	family	O
8	genes	O
9	revealed	O
10	that	O
11	the	O
12	intron	O
13	/	O
14	exon	O
15	splice	O
16	pattern	O
17	of	O
18	mBMAL1	B
19	most	O
20	closely	O
21	matches	O
22	that	O
23	of	O
24	the	O
25	mAhr	B
26	,	O
27	which	O
28	suggests	O
29	that	O
30	BMAL1	B
31	and	O
32	Ahr	B
33	belong	O
34	to	O
35	the	O
36	same	O
37	subclass	O
38	and	O
39	may	O
40	be	O
41	derived	O
42	from	O
43	a	O
44	common	O
45	primordial	O
46	gene	O
47	.	O
1	This	O
2	sequence	O
3	also	O
4	confers	O
5	VDR	B
6	and	O
7	vitamin	O
8	D	O
9	responsiveness	O
10	to	O
11	a	O
12	heterologous	O
13	promoter	O
14	.	O
1	Chemical	O
2	stability	O
3	tests	O
4	and	O
5	site	O
6	-	O
7	specific	O
8	mutagenesis	O
9	identified	O
10	amino	O
11	acids	O
12	H219	O
13	and	O
14	D63	O
15	of	O
16	RegS	B
17	and	O
18	RegR	B
19	,	O
20	respectively	O
21	,	O
22	as	O
23	the	O
24	phosphorylated	O
25	residues	O
26	.	O
1	Role	O
2	of	O
3	secondary	O
4	structure	O
5	in	O
6	discrimination	O
7	between	O
8	constitutive	O
9	and	O
10	inducible	O
11	activators	O
12	.	O
1	The	O
2	in	O
3	vitro	O
4	relaxivity	O
5	of	O
6	the	O
7	complex	O
8	is	O
9	16	O
10	.	O
11	24	O
12	s	O
13	(-	O
14	1	O
15	)	O
16	mM	O
17	(-	O
18	1	O
19	).	O
1	Bacterial	O
2	recovery	O
3	of	O
4	SA	O
5	from	O
6	the	O
7	liver	O
8	/	O
9	spleen	O
10	and	O
11	the	O
12	cecal	O
13	tonsil	O
14	in	O
15	contact	O
16	poults	O
17	and	O
18	SG	O
19	from	O
20	contact	O
21	chicks	O
22	treated	O
23	with	O
24	ILK	B
25	was	O
26	dramatically	O
27	reduced	O
28	when	O
29	compared	O
30	to	O
31	non	O
32	-	O
33	treated	O
34	contact	O
35	poults	O
36	and	O
37	chicks	O
38	.	O
1	A	O
2	decrease	O
3	in	O
4	insulin	B
5	-	O
6	induced	O
7	receptor	O
8	kinase	O
9	activity	O
10	was	O
11	observed	O
12	for	O
13	solubilized	O
14	chimeric	O
15	receptors	O
16	.	O
1	Repair	O
2	of	O
3	double	O
4	-	O
5	strand	O
6	breaks	O
7	(	O
8	DSBs	O
9	)	O
10	in	O
11	chromosomal	O
12	DNA	O
13	by	O
14	nonhomologous	O
15	end	O
16	-	O
17	joining	O
18	(	O
19	NHEJ	O
20	)	O
21	is	O
22	not	O
23	well	O
24	characterized	O
25	in	O
26	the	O
27	yeast	O
28	Saccharomyces	O
29	cerevisiae	O
30	.	O
1	The	O
2	C	O
3	-	O
4	terminal	O
5	mutants	O
6	were	O
7	strongly	O
8	dominant	O
9	over	O
10	TraR	B
11	,	O
12	suggesting	O
13	that	O
14	they	O
15	can	O
16	form	O
17	heteromultimers	O
18	with	O
19	the	O
20	wild	O
21	-	O
22	type	O
23	activator	O
24	.	O
1	Identity	O
2	elements	O
3	in	O
4	tRNA	O
5	for	O
6	mono	O
7	-	O
8	and	O
9	dimethylation	O
10	reactions	O
11	by	O
12	the	O
13	recombinant	B
14	pfTrm1p	I
15	were	O
16	identified	O
17	using	O
18	in	O
19	vitro	O
20	T7	O
21	transcripts	O
22	of	O
23	33	O
24	variants	O
25	of	O
26	tRNA	B
27	(	I
28	Asp	I
29	)	I
30	and	O
31	tRNA	B
32	(	I
33	Phe	I
34	)	I
35	from	O
36	yeast	O
37	.	O
1	Analysis	O
2	of	O
3	cell	O
4	cycle	O
5	proteins	O
6	showed	O
7	that	O
8	24	O
9	h	O
10	of	O
11	lovastatin	O
12	treatment	O
13	in	O
14	the	O
15	control	O
16	cells	O
17	caused	O
18	an	O
19	elevation	O
20	in	O
21	the	O
22	levels	O
23	of	O
24	the	O
25	cyclin	B
26	-	I
27	dependent	I
28	kinase	I
29	inhibitor	O
30	p27	B
31	(	O
32	kip1	B
33	),	O
34	inhibition	O
35	of	O
36	both	O
37	cyclin	B
38	E	I
39	-	I
40	and	I
41	cyclin	I
42	A	I
43	-	I
44	dependent	I
45	kinase	I
46	activity	O
47	,	O
48	and	O
49	decreased	O
50	levels	O
51	of	O
52	hyperphosphorylated	O
53	retinoblastoma	B
54	protein	I
55	(	O
56	pRb	B
57	).	O
1	RESULTS	O
2	:	O
3	Circulating	O
4	leptin	B
5	concentrations	O
6	in	O
7	AN	O
8	were	O
9	3	O
10	.	O
11	5	O
12	+/-	O
13	0	O
14	.	O
15	5	O
16	versus	O
17	7	O
18	.	O
19	6	O
20	+/-	O
21	1	O
22	.	O
23	2	O
24	ng	O
25	/	O
26	ml	O
27	in	O
28	control	O
29	subjects	O
30	.	O
1	Copyright	O
2	1999	O
3	Academic	O
4	Press	O
5	.	O
1	In	O
2	the	O
3	course	O
4	of	O
5	investigating	O
6	the	O
7	mechanisms	O
8	by	O
9	which	O
10	OF5	B
11	and	O
12	OF3	B
13	regulated	O
14	CYP11A1	B
15	transcription	O
16	,	O
17	we	O
18	found	O
19	that	O
20	OF5	B
21	and	O
22	OF3	B
23	bound	O
24	Sp1	B
25	and	O
26	Sp3	B
27	in	O
28	JEG	O
29	-	O
30	3	O
31	cells	O
32	.	O
1	Transformation	O
2	blocks	O
3	differentiation	O
4	-	O
5	induced	O
6	inhibition	O
7	of	O
8	serum	B
9	response	I
10	factor	I
11	interactions	O
12	with	O
13	serum	O
14	response	O
15	elements	O
16	.	O
1	The	O
2	interaction	O
3	of	O
4	zf4	B
5	-	I
6	6	I
7	with	O
8	full	B
9	-	I
10	length	I
11	5	I
12	S	I
13	RNA	I
14	was	O
15	far	O
16	more	O
17	sensitive	O
18	to	O
19	non	O
20	-	O
21	specific	O
22	competitor	O
23	concentration	O
24	than	O
25	was	O
26	the	O
27	zf4	B
28	-	I
29	7	I
30	:	O
31	5	B
32	S	I
33	RNA	I
34	interaction	O
35	,	O
36	suggesting	O
37	that	O
38	finger	O
39	seven	O
40	contributes	O
41	to	O
42	both	O
43	affinity	O
44	and	O
45	specificity	O
46	in	O
47	this	O
48	protein	O
49	:	O
50	RNA	O
51	interaction	O
52	.	O
1	The	O
2	STAT	B
3	protein	I
4	accumulation	O
5	resulting	O
6	from	O
7	C	B
8	/	I
9	EBP	I
10	expression	O
11	was	O
12	tightly	O
13	coupled	O
14	to	O
15	the	O
16	morphological	O
17	conversion	O
18	of	O
19	fibroblasts	O
20	to	O
21	adipocytes	O
22	and	O
23	represents	O
24	an	O
25	expression	O
26	profile	O
27	identical	O
28	to	O
29	that	O
30	reported	O
31	for	O
32	mature	O
33	adipocytes	O
34	in	O
35	vivo	O
36	.	O
1	The	O
2	present	O
3	investigation	O
4	conducted	O
5	in	O
6	a	O
7	population	O
8	of	O
9	258	O
10	dentally	O
11	aware	O
12	individuals	O
13	in	O
14	the	O
15	age	O
16	range	O
17	20	O
18	-	O
19	69	O
20	years	O
21	,	O
22	was	O
23	initiated	O
24	to	O
25	elucidate	O
26	the	O
27	relationship	O
28	between	O
29	tobacco	O
30	smoking	O
31	and	O
32	supragingival	O
33	calculus	O
34	,	O
35	taking	O
36	into	O
37	account	O
38	possible	O
39	confounding	O
40	factors	O
41	such	O
42	as	O
43	age	O
44	,	O
45	gender	O
46	,	O
47	oral	O
48	hygiene	O
49	and	O
50	gingival	O
51	inflammation	O
52	.	O
1	These	O
2	cells	O
3	were	O
4	able	O
5	to	O
6	present	O
7	influenza	O
8	virus	O
9	particles	O
10	to	O
11	HLA	B
12	-	I
13	DR1	I
14	-	O
15	restricted	O
16	T	O
17	cell	O
18	clones	O
19	.	O
1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	demonstrate	O
8	that	O
9	expression	O
10	of	O
11	TD	B
12	-	I
13	IkappaBalpha	I
14	blocked	O
15	phorbol	O
16	myristate	O
17	acetate	B
18	-	I
19	phytohemagglutinin	I
20	or	O
21	tumor	B
22	necrosis	I
23	factor	I
24	alpha	I
25	-	O
26	induced	O
27	IkappaBalpha	B
28	gene	I
29	transcription	O
30	and	O
31	abolished	O
32	NF	B
33	-	I
34	kappaB	I
35	DNA	O
36	binding	O
37	activity	O
38	,	O
39	due	O
40	to	O
41	the	O
42	continued	O
43	cytoplasmic	O
44	sequestration	O
45	of	O
46	RelA	B
47	(	O
48	p65	B
49	)	O
50	by	O
51	TD	B
52	-	I
53	IkappaBalpha	I
54	.	O
1	CONCLUSIONS	O
2	:	O
3	In	O
4	healthy	O
5	individuals	O
6	,	O
7	whole	O
8	body	O
9	insulin	B
10	sensitivity	O
11	is	O
12	related	O
13	,	O
14	or	O
15	""""	O
16	coupled	O
17	,	O
18	""""	O
19	to	O
20	the	O
21	anaerobic	O
22	threshold	O
23	.	O
1	In	O
2	contrast	O
3	,	O
4	the	O
5	xtRNA	B
6	(	O
7	Sec	B
8	)	O
9	gene	O
10	needs	O
11	the	O
12	binding	O
13	of	O
14	the	O
15	seven	O
16	Staf	B
17	zinc	I
18	fingers	I
19	,	O
20	but	O
21	not	O
22	Oct	B
23	-	I
24	1	I
25	,	O
26	for	O
27	optimal	O
28	transcriptional	O
29	capacity	O
30	.	O
1	Independent	O
2	protrudor	O
3	muscle	O
4	stimulation	O
5	increased	O
6	VI	O
7	,	O
8	max	O
9	(	O
10	peak	O
11	increase	O
12	61	O
13	%,	O
14	P	O
15	<	O
16	0	O
17	.	O
18	05	O
19	),	O
20	did	O
21	not	O
22	change	O
23	Pcrit	O
24	,	O
25	and	O
26	decreased	O
27	Rn	O
28	(	O
29	peak	O
30	decrease	O
31	of	O
32	41	O
33	%,	O
34	P	O
35	<	O
36	0	O
37	.	O
38	05	O
39	).	O
1	After	O
2	10	O
3	months	O
4	of	O
5	treatment	O
6	with	O
7	the	O
8	conjugated	O
9	estrogen	O
10	,	O
11	both	O
12	his	O
13	height	O
14	and	O
15	weight	O
16	showed	O
17	improvement	O
18	,	O
19	while	O
20	his	O
21	bone	O
22	mineral	O
23	density	O
24	and	O
25	bone	O
26	age	O
27	were	O
28	increased	O
29	.	O
1	Role	O
2	of	O
3	the	O
4	3	O
5	'	O
6	untranslated	O
7	region	O
8	of	O
9	baculovirus	B
10	p10	I
11	mRNA	I
12	in	O
13	high	O
14	-	O
15	level	O
16	expression	O
17	of	O
18	foreign	O
19	genes	O
20	.	O
1	RESULTS	O
2	:	O
3	CK	B
4	-	O
5	MB	B
6	elevation	O
7	was	O
8	detected	O
9	in	O
10	313	O
11	patients	O
12	(	O
13	18	O
14	.	O
15	7	O
16	%),	O
17	with	O
18	1	O
19	-	O
20	3x	O
21	in	O
22	12	O
23	.	O
24	8	O
25	%,	O
26	3	O
27	-	O
28	5x	O
29	in	O
30	3	O
31	.	O
32	5	O
33	%	O
34	and	O
35	>	O
36	5x	O
37	normal	O
38	in	O
39	2	O
40	.	O
41	4	O
42	%	O
43	of	O
44	patients	O
45	.	O
1	Thus	O
2	,	O
3	NART	O
4	-	O
5	R	O
6	performance	O
7	may	O
8	not	O
9	be	O
10	a	O
11	valid	O
12	estimate	O
13	of	O
14	baseline	O
15	IQ	O
16	for	O
17	patients	O
18	with	O
19	neurologic	O
20	disorders	O
21	with	O
22	suspected	O
23	language	O
24	impairment	O
25	.	O
1	Activated	O
2	areas	O
3	have	O
4	been	O
5	identified	O
6	by	O
7	means	O
8	of	O
9	cross	O
10	-	O
11	correlation	O
12	analysis	O
13	.	O
1	Galoyan	O
2	has	O
3	summarized	O
4	the	O
5	results	O
6	of	O
7	his	O
8	discovery	O
9	of	O
10	cardioactive	O
11	neurohormones	O
12	.	O
1	Using	O
2	transgenic	O
3	Xenopus	O
4	embryos	O
5	,	O
6	we	O
7	demonstrate	O
8	that	O
9	the	O
10	integrity	O
11	of	O
12	these	O
13	two	O
14	sequences	O
15	is	O
16	necessary	O
17	for	O
18	correct	O
19	spatial	O
20	expression	O
21	of	O
22	a	O
23	Xbra2	B
24	promoter	I
25	-	I
26	driven	I
27	reporter	I
28	gene	I
29	.	O
1	In	O
2	order	O
3	to	O
4	screen	O
5	for	O
6	such	O
7	cofactors	O
8	,	O
9	we	O
10	have	O
11	used	O
12	a	O
13	transcriptionally	O
14	inactive	O
15	mutant	O
16	of	O
17	Xenopus	B
18	MEF2D	I
19	in	O
20	a	O
21	yeast	O
22	two	O
23	-	O
24	hybrid	O
25	screen	O
26	.	O
1	ATF1	B
2	transcription	O
3	is	O
4	negatively	O
5	regulated	O
6	by	O
7	unsaturated	O
8	fatty	O
9	acids	O
10	and	O
11	oxygen	O
12	.	O
1	In	O
2	fact	O
3	,	O
4	SPT	B
5	activity	O
6	in	O
7	the	O
8	fly	O
9	expressing	O
10	epitope	O
11	-	O
12	tagged	O
13	Lace	B
14	was	O
15	absorbed	O
16	by	O
17	epitope	O
18	-	O
19	specific	O
20	antibody	O
21	.	O
1	Serum	O
2	concentrations	O
3	of	O
4	bone	B
5	specific	I
6	alkaline	I
7	phosphatase	I
8	(	O
9	BALP	B
10	)	O
11	and	O
12	osteocalcin	B
13	(	O
14	bone	B
15	Gla	I
16	protein	I
17	,	O
18	BGP	B
19	),	O
20	urinary	O
21	levels	O
22	of	O
23	pyridinoline	O
24	(	O
25	Pyr	O
26	)	O
27	and	O
28	deoxypyridinoline	O
29	(	O
30	Dpyr	O
31	)	O
32	and	O
33	computed	O
34	tomography	O
35	(	O
36	CT	O
37	)	O
38	measurements	O
39	of	O
40	the	O
41	cross	O
42	-	O
43	sectional	O
44	areas	O
45	of	O
46	the	O
47	vertebrae	O
48	and	O
49	the	O
50	femurs	O
51	,	O
52	the	O
53	apparent	O
54	density	O
55	of	O
56	cancellous	O
57	bone	O
58	in	O
59	the	O
60	vertebrae	O
61	,	O
62	and	O
63	the	O
64	volume	O
65	and	O
66	the	O
67	material	O
68	density	O
69	of	O
70	cortical	O
71	bone	O
72	in	O
73	the	O
74	femurs	O
75	were	O
76	determined	O
77	in	O
78	126	O
79	boys	O
80	and	O
81	143	O
82	girls	O
83	,	O
84	ages	O
85	7	O
86	-	O
87	18	O
88	years	O
89	.	O
1	This	O
2	cluster	O
3	consisted	O
4	of	O
5	four	O
6	apparently	O
7	unrelated	O
8	ESTs	O
9	and	O
10	two	O
11	genes	O
12	,	O
13	pregnancy	B
14	-	I
15	associated	I
16	plasma	I
17	protein	I
18	-	I
19	A	I
20	(	O
21	PAPP	B
22	-	I
23	A	I
24	)	O
25	and	O
26	a	O
27	novel	O
28	gene	O
29	(	O
30	tentatively	O
31	named	O
32	EST	B
33	-	I
34	YD1	I
35	).	O
1	We	O
2	propose	O
3	that	O
4	Gly84	O
5	is	O
6	part	O
7	of	O
8	a	O
9	putative	O
10	""""	O
11	oxyanion	O
12	hole	O
13	""""	O
14	involved	O
15	in	O
16	the	O
17	stabilization	O
18	of	O
19	the	O
20	transition	O
21	state	O
22	similar	O
23	to	O
24	the	O
25	C	B
26	group	I
27	of	O
28	the	O
29	esterase	B
30	/	O
31	lipase	B
32	family	O
33	.	O
1	Since	O
2	sildenafil	O
3	came	O
4	on	O
5	the	O
6	market	O
7	,	O
8	it	O
9	seems	O
10	that	O
11	the	O
12	place	O
13	of	O
14	MUSE	O
15	is	O
16	reduced	O
17	because	O
18	comparative	O
19	studies	O
20	give	O
21	better	O
22	results	O
23	for	O
24	sildenafil	O
25	than	O
26	MUSE	O
27	(	O
28	70	O
29	%	O
30	vs	O
31	40	O
32	%)	O
33	and	O
34	of	O
35	course	O
36	with	O
37	a	O
38	better	O
39	acceptance	O
40	.	O
1	Ribonuclease	O
2	protection	O
3	assays	O
4	revealed	O
5	that	O
6	hmg1	B
7	and	O
8	hmg2	B
9	are	O
10	differentially	O
11	expressed	O
12	in	O
13	a	O
14	developmentally	O
15	-	O
16	and	O
17	spatially	O
18	-	O
19	modulated	O
20	manner	O
21	during	O
22	morphogenesis	O
23	of	O
24	specialized	O
25	terpenoid	O
26	-	O
27	containing	O
28	pigment	O
29	glands	O
30	in	O
31	embryos	O
32	.	O
1	A	O
2	total	O
3	of	O
4	174	O
5	primer	O
6	pairs	O
7	gave	O
8	interpretable	O
9	banding	O
10	patterns	O
11	,	O
12	137	O
13	(	O
14	79	O
15	%)	O
16	of	O
17	which	O
18	revealed	O
19	at	O
20	least	O
21	two	O
22	alleles	O
23	on	O
24	native	O
25	polyacrylamide	O
26	gels	O
27	.	O
1	Immunofluoresence	O
2	data	O
3	indicated	O
4	that	O
5	once	O
6	bound	O
7	to	O
8	the	O
9	mutant	O
10	receptor	O
11	,	O
12	fluorescent	O
13	-	O
14	labeled	O
15	RAP	B
16	co	O
17	-	O
18	localized	O
19	with	O
20	markers	O
21	of	O
22	the	O
23	endosomal	O
24	pathway	O
25	,	O
26	whereas	O
27	,	O
28	in	O
29	cells	O
30	expressing	O
31	the	O
32	wild	O
33	-	O
34	type	O
35	receptor	O
36	,	O
37	RAP	B
38	fluorescence	O
39	co	O
40	-	O
41	localized	O
42	with	O
43	lysosomal	O
44	markers	O
45	.	O
1	Our	O
2	results	O
3	implicate	O
4	TGF	B
5	-	I
6	beta	I
7	RII	I
8	as	O
9	a	O
10	direct	O
11	target	O
12	of	O
13	EWS	B
14	-	O
15	FLI1	B
16	.	O
1	Secondly	O
2	,	O
3	an	O
4	ethanol	O
5	repression	O
6	autoregulation	O
7	(	O
8	ERA	O
9	)/	O
10	twelve	O
11	-	O
12	fold	O
13	TA	O
14	repeat	O
15	(	O
16	TAB	O
17	)	O
18	repressor	O
19	element	O
20	was	O
21	identified	O
22	within	O
23	the	O
24	promoter	O
25	region	O
26	of	O
27	the	O
28	GLK1	B
29	gene	I
30	.	O
1	A	O
2	local	O
3	,	O
4	high	O
5	-	O
6	density	O
7	,	O
8	single	O
9	-	O
10	nucleotide	O
11	polymorphism	O
12	map	O
13	used	O
14	to	O
15	clone	O
16	Caenorhabditis	B
17	elegans	I
18	cdf	I
19	-	I
20	1	I
21	.	O
1	Modification	O
2	of	O
3	dopamine	B
4	D2	I
5	receptor	I
6	activity	O
7	by	O
8	pergolide	O
9	in	O
10	Parkinson	O
11	'	O
12	s	O
13	disease	O
14	:	O
15	an	O
16	in	O
17	vivo	O
18	study	O
19	by	O
20	PET	O
21	.	O
1	Aggregation	O
2	of	O
3	vHnf1	B
4	-	O
5	deficient	O
6	embryonic	O
7	stem	O
8	cells	O
9	with	O
10	wild	O
11	-	O
12	type	O
13	tetraploid	O
14	embryos	O
15	,	O
16	which	O
17	contribute	O
18	exclusively	O
19	to	O
20	extraembryonic	O
21	tissues	O
22	,	O
23	rescues	O
24	periimplantation	O
25	lethality	O
26	and	O
27	allows	O
28	development	O
29	to	O
30	progress	O
31	to	O
32	early	O
33	organogenesis	O
34	.	O
1	The	O
2	expression	O
3	analysis	O
4	of	O
5	the	O
6	KlHIS4	B
7	gene	I
8	under	O
9	phosphate	O
10	starvation	O
11	or	O
12	high	O
13	adenine	O
14	supply	O
15	shows	O
16	that	O
17	factors	O
18	,	O
19	such	O
20	as	O
21	Bas1	B
22	or	O
23	Bas2	B
24	,	O
25	involved	O
26	in	O
27	the	O
28	basal	O
29	control	O
30	may	O
31	also	O
32	operate	O
33	in	O
34	a	O
35	different	O
36	way	O
37	in	O
38	K	O
39	.	O
40	lactis	O
41	.	O
1	Paleoceanographic	O
2	data	O
3	from	O
4	the	O
5	Laurentian	O
6	Fan	O
7	,	O
8	used	O
9	as	O
10	a	O
11	proxy	O
12	for	O
13	sea	O
14	surface	O
15	temperature	O
16	,	O
17	reveal	O
18	that	O
19	surface	O
20	slope	O
21	waters	O
22	north	O
23	of	O
24	the	O
25	Gulf	O
26	Stream	O
27	experienced	O
28	warming	O
29	during	O
30	the	O
31	Little	O
32	Ice	O
33	Age	O
34	of	O
35	the	O
36	16th	O
37	to	O
38	19th	O
39	centuries	O
40	and	O
41	support	O
42	the	O
43	notion	O
44	of	O
45	an	O
46	NAO	O
47	-	O
48	driven	O
49	coupled	O
50	system	O
51	.	O
1	The	O
2	factor	O
3	designated	O
4	B	O
5	formed	O
6	a	O
7	complex	O
8	centered	O
9	on	O
10	the	O
11	sequence	O
12	TGTGGT	O
13	,	O
14	a	O
15	core	O
16	motif	O
17	recognized	O
18	by	O
19	members	O
20	of	O
21	the	O
22	AML	B
23	/	I
24	CBFalpha	I
25	transcription	I
26	factor	I
27	family	I
28	.	O
1	Furthermore	O
2	,	O
3	overexpression	O
4	of	O
5	AML3	B
6	/	O
7	CBFalpha1	B
8	could	O
9	rescue	O
10	the	O
11	AML1	B
12	-	O
13	ETO	B
14	repression	O
15	.	O
1	The	O
2	ORs	O
3	of	O
4	GC	O
5	,	O
6	adjusted	O
7	for	O
8	age	O
9	and	O
10	sex	O
11	,	O
12	varied	O
13	from	O
14	17	O
15	.	O
16	1	O
17	,	O
18	for	O
19	those	O
20	with	O
21	baseline	O
22	diagnoses	O
23	of	O
24	superficial	O
25	intestinal	O
26	metaplasia	O
27	(	O
28	IM	O
29	),	O
30	to	O
31	29	O
32	.	O
33	3	O
34	,	O
35	for	O
36	those	O
37	with	O
38	deep	O
39	IM	O
40	or	O
41	mild	O
42	dysplasia	O
43	(	O
44	DYS	O
45	)	O
46	or	O
47	IM	O
48	with	O
49	glandular	O
50	atrophy	O
51	and	O
52	neck	O
53	hyperplasia	O
54	,	O
55	to	O
56	104	O
57	.	O
58	2	O
59	,	O
60	for	O
61	those	O
62	with	O
63	moderate	O
64	or	O
65	severe	O
66	DYS	O
67	,	O
68	as	O
69	compared	O
70	with	O
71	subjects	O
72	with	O
73	superficial	O
74	gastritis	O
75	(	O
76	SG	O
77	)	O
78	or	O
79	chronic	O
80	atrophic	O
81	gastritis	O
82	(	O
83	CAG	O
84	)	O
85	at	O
86	baseline	O
87	.	O
1	Thus	O
2	,	O
3	the	O
4	nematode	O
5	genes	O
6	could	O
7	be	O
8	the	O
9	homologs	B
10	of	I
11	Hh	I
12	molecules	I
13	in	O
14	other	O
15	phyla	O
16	.	O
1	We	O
2	have	O
3	examined	O
4	the	O
5	regulation	O
6	of	O
7	the	O
8	FGFR	B
9	-	I
10	1	I
11	gene	I
12	(	O
13	cek	B
14	-	I
15	1	I
16	)	O
17	in	O
18	avian	O
19	myogenic	O
20	cultures	O
21	by	O
22	immunocytochemistry	O
23	and	O
24	Northern	O
25	blot	O
26	analysis	O
27	.	O
1	Rac	B
2	causes	O
3	uncapping	O
4	of	O
5	actin	B
6	filaments	I
7	(	O
8	F	B
9	-	I
10	actin	I
11	)	O
12	at	O
13	the	O
14	plus	O
15	-	O
16	ends	O
17	,	O
18	through	O
19	phosphatidylinositol	O
20	4	O
21	,	O
22	5	O
23	bisphosphate	O
24	(	O
25	PIP2	O
26	),	O
27	and	O
28	eventually	O
29	induces	O
30	membrane	O
31	ruffling	O
32	.	O
1	In	O
2	assays	O
3	with	O
4	purified	O
5	enzymes	O
6	,	O
7	wild	O
8	-	O
9	type	O
10	but	O
11	not	O
12	PTPS	B
13	-	O
14	S19A	B
15	was	O
16	a	O
17	specific	O
18	substrate	O
19	for	O
20	the	O
21	cGMP	B
22	-	I
23	dependent	I
24	protein	I
25	kinase	I
26	(	I
27	cGK	I
28	)	I
29	type	I
30	I	I
31	and	I
32	II	I
33	.	O
1	The	O
2	first	O
3	algorithm	O
4	,	O
5	FOREPROJ	O
6	,	O
7	is	O
8	a	O
9	fast	O
10	-	O
11	forward	O
12	projection	O
13	algorithm	O
14	that	O
15	allows	O
16	calculation	O
17	of	O
18	the	O
19	3	O
20	-	O
21	D	O
22	attenuation	O
23	correction	O
24	factors	O
25	(	O
26	ACF	O
27	'	O
28	s	O
29	)	O
30	directly	O
31	from	O
32	a	O
33	two	O
34	-	O
35	dimensional	O
36	(	O
37	2	O
38	-	O
39	D	O
40	)	O
41	transmission	O
42	scan	O
43	,	O
44	without	O
45	first	O
46	reconstructing	O
47	the	O
48	attenuation	O
49	map	O
50	and	O
51	then	O
52	performing	O
53	a	O
54	3	O
55	-	O
56	D	O
57	forward	O
58	projection	O
59	.	O
1	RT	O
2	-	O
3	PCR	O
4	and	O
5	in	O
6	situ	O
7	hybridization	O
8	analyses	O
9	of	O
10	a	O
11	time	O
12	course	O
13	of	O
14	juvenile	O
15	testis	O
16	development	O
17	indicate	O
18	that	O
19	Spo11	B
20	expression	O
21	begins	O
22	in	O
23	early	O
24	meiotic	O
25	Prophase	O
26	I	O
27	,	O
28	prior	O
29	to	O
30	the	O
31	pachytene	O
32	stage	O
33	,	O
34	with	O
35	increasing	O
36	accumulation	O
37	of	O
38	mRNA	O
39	through	O
40	the	O
41	pachytene	O
42	stage	O
43	.	O
1	Animals	O
2	were	O
3	put	O
4	to	O
5	death	O
6	8	O
7	weeks	O
8	later	O
9	and	O
10	the	O
11	grafts	O
12	were	O
13	sterilely	O
14	explanted	O
15	and	O
16	analyzed	O
17	via	O
18	microbiologic	O
19	culture	O
20	and	O
21	standard	O
22	histologic	O
23	procedures	O
24	for	O
25	evidence	O
26	of	O
27	infection	O
28	.	O
1	Oseltamivir	O
2	(	O
3	GS4104	O
4	),	O
5	which	O
6	can	O
7	be	O
8	administered	O
9	orally	O
10	,	O
11	is	O
12	the	O
13	prodrug	O
14	of	O
15	GS4071	O
16	,	O
17	a	O
18	potent	O
19	and	O
20	selective	O
21	inhibitor	O
22	of	O
23	influenzavirus	B
24	neuraminidases	I
25	.	O
1	Albumin	O
2	expression	O
3	is	O
4	maintained	O
5	in	O
6	the	O
7	liver	O
8	by	O
9	a	O
10	combination	O
11	of	O
12	liver	O
13	-	O
14	enriched	O
15	transcription	O
16	factors	O
17	such	O
18	as	O
19	CAAT	B
20	enhancer	I
21	-	I
22	binding	I
23	protein	I
24	(	I
25	C	I
26	/	I
27	EBP	I
28	)	I
29	alpha	I
30	and	O
31	C	B
32	/	I
33	EBPbeta	I
34	.	O
1	Amyloid	B
2	beta	I
3	-	I
4	protein	I
5	(	O
6	Abeta	B
7	)	O
8	is	O
9	the	O
10	main	O
11	constituent	O
12	of	O
13	amyloid	O
14	fibrils	O
15	found	O
16	in	O
17	senile	O
18	plaques	O
19	and	O
20	cerebral	O
21	vessels	O
22	in	O
23	Alzheimer	O
24	'	O
25	s	O
26	disease	O
27	(	O
28	AD	O
29	)	O
30	and	O
31	is	O
32	derived	O
33	by	O
34	proteolysis	O
35	from	O
36	the	O
37	beta	B
38	-	I
39	amyloid	I
40	precursor	I
41	protein	I
42	(	O
43	APP	B
44	).	O
1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	presence	O
7	or	O
8	absence	O
9	per	O
10	se	O
11	of	O
12	keratan	O
13	sulfate	O
14	on	O
15	native	O
16	G1	O
17	-	O
18	G2	O
19	does	O
20	not	O
21	affect	O
22	the	O
23	activity	O
24	of	O
25	atrolysin	O
26	C	O
27	toward	O
28	the	O
29	two	O
30	sites	O
31	.	O
1	Despite	O
2	i	O
3	.	O
4	v	O
5	.	O
6	steroid	O
7	therapy	O
8	,	O
9	[	O
10	NOexh	O
11	]	O
12	remained	O
13	elevated	O
14	throughout	O
15	recovery	O
16	(	O
17	37	O
18	.	O
19	9	O
20	+/-	O
21	4	O
22	.	O
23	8	O
24	ppb	O
25	,	O
26	p	O
27	<	O
28	0	O
29	.	O
30	001	O
31	)	O
32	until	O
33	discharge	O
34	(	O
35	40	O
36	.	O
37	9	O
38	+/-	O
39	4	O
40	.	O
41	3	O
42	ppb	O
43	,	O
44	p	O
45	<	O
46	0	O
47	.	O
48	001	O
49	).	O
1	FZD4	B
2	is	O
3	homologous	O
4	to	O
5	FZD9	B
6	and	O
7	FZD10	B
8	,	O
9	and	O
10	overall	O
11	amino	O
12	acid	O
13	identity	O
14	is	O
15	as	O
16	follows	O
17	:	O
18	FZD4	B
19	vs	O
20	FZD9	B
21	,	O
22	51	O
23	.	O
24	6	O
25	%;	O
26	FZD4	B
27	vs	O
28	FZD10	B
29	,	O
30	51	O
31	.	O
32	2	O
33	%;	O
34	FZD9	B
35	vs	O
36	FZD10	B
37	,	O
38	65	O
39	.	O
40	7	O
41	%.	O
1	Phosphatidylinositol	B
2	3	I
3	-	I
4	kinase	I
5	requirement	O
6	in	O
7	activation	O
8	of	O
9	the	O
10	ras	B
11	/	O
12	C	B
13	-	I
14	raf	I
15	-	I
16	1	I
17	/	O
18	MEK	B
19	/	O
20	ERK	B
21	and	O
22	p70	B
23	(	O
24	s6k	B
25	)	O
26	signaling	O
27	cascade	O
28	by	O
29	the	O
30	insulinomimetic	O
31	agent	O
32	vanadyl	O
33	sulfate	O
34	.	O
1	PURPOSE	O
2	:	O
3	Previous	O
4	WR	O
5	-	O
6	2721	O
7	human	O
8	pharmacokinetic	O
9	studies	O
10	were	O
11	limited	O
12	to	O
13	plasma	O
14	levels	O
15	in	O
16	patients	O
17	receiving	O
18	platinum	O
19	-	O
20	based	O
21	compounds	O
22	,	O
23	and	O
24	none	O
25	includes	O
26	the	O
27	effects	O
28	of	O
29	WR	O
30	-	O
31	2721	O
32	on	O
33	endogenous	O
34	thiols	O
35	.	O
1	With	O
2	regard	O
3	to	O
4	nonhematologic	O
5	toxicities	O
6	,	O
7	diarrhea	O
8	,	O
9	infection	O
10	and	O
11	elevated	O
12	serum	B
13	alkaline	I
14	phosphatase	I
15	of	O
16	grade	O
17	3	O
18	or	O
19	over	O
20	were	O
21	observed	O
22	in	O
23	2	O
24	%	O
25	of	O
26	cycles	O
27	,	O
28	but	O
29	were	O
30	tolerable	O
31	and	O
32	reversible	O
33	.	O
1	LHbeta	B
2	is	O
3	expressed	O
4	in	O
5	pituitary	O
6	gonadotrope	O
7	cells	O
8	and	O
9	CGbeta	B
10	is	O
11	expressed	O
12	in	O
13	placental	O
14	trophoblast	O
15	cells	O
16	.	O
1	Human	B
2	LTBP	I
3	-	I
4	1	I
5	is	O
6	known	O
7	to	O
8	exist	O
9	in	O
10	different	O
11	forms	O
12	.	O
1	CONCLUSIONS	O
2	:	O
3	In	O
4	addition	O
5	to	O
6	the	O
7	superiority	O
8	of	O
9	octafluoropropane	O
10	-	O
11	filled	O
12	microspheres	O
13	to	O
14	air	O
15	-	O
16	filled	O
17	microspheres	O
18	for	O
19	LV	O
20	opacification	O
21	,	O
22	the	O
23	efficacy	O
24	of	O
25	OCTA	O
26	is	O
27	relatively	O
28	unaffected	O
29	by	O
30	impaired	O
31	LV	O
32	function	O
33	and	O
34	is	O
35	less	O
36	susceptible	O
37	to	O
38	the	O
39	effects	O
40	of	O
41	poor	O
42	echogenicity	O
43	than	O
44	AIR	O
45	.	O
1	CONCLUSIONS	O
2	:	O
3	The	O
4	largest	O
5	value	O
6	of	O
7	the	O
8	joint	O
9	space	O
10	may	O
11	be	O
12	used	O
13	when	O
14	evaluating	O
15	rheumatoid	O
16	AC	O
17	joint	O
18	space	O
19	.	O
1	An	O
2	analysis	O
3	of	O
4	sequence	O
5	of	O
6	the	O
7	mutant	B
8	recN	I
9	gene	I
10	revealed	O
11	a	O
12	G	O
13	:	O
14	C	O
15	to	O
16	T	O
17	:	O
18	A	O
19	transversion	O
20	near	O
21	the	O
22	3	O
23	'	O
24	end	O
25	of	O
26	the	O
27	coding	O
28	region	O
29	.	O
1	Moreover	O
2	,	O
3	a	O
4	recombinant	O
5	Ad	O
6	expressing	O
7	Ad5	B
8	E4orf6	I
9	/	I
10	7	I
11	induced	O
12	apoptosis	O
13	in	O
14	rat	O
15	cells	O
16	when	O
17	coinfected	O
18	with	O
19	wild	O
20	-	O
21	type	O
22	p53	B
23	-	O
24	expressing	O
25	Ad	O
26	.	O
1	Macroscopic	O
2	researches	O
3	on	O
4	heart	O
5	vascularization	O
6	have	O
7	indicated	O
8	that	O
9	the	O
10	angioarchitecture	O
11	of	O
12	the	O
13	conducting	O
14	system	O
15	differs	O
16	from	O
17	that	O
18	of	O
19	the	O
20	normal	O
21	myocardium	O
22	.	O
1	However	O
2	,	O
3	reoperation	O
4	for	O
5	bulky	O
6	cervical	O
7	disease	O
8	(	O
9	group	O
10	3	O
11	)	O
12	rarely	O
13	results	O
14	in	O
15	normal	O
16	calcitonin	B
17	levels	O
18	and	O
19	is	O
20	associated	O
21	with	O
22	a	O
23	high	O
24	incidence	O
25	of	O
26	permanent	O
27	hypoparathyroidism	O
28	.	O
1	We	O
2	present	O
3	a	O
4	case	O
5	of	O
6	carcinoma	O
7	of	O
8	the	O
9	breast	O
10	presenting	O
11	concurrently	O
12	with	O
13	SSc	O
14	that	O
15	subsequently	O
16	progressed	O
17	to	O
18	dialysis	O
19	-	O
20	dependent	O
21	renal	O
22	failure	O
23	in	O
24	just	O
25	1	O
26	month	O
27	.	O
1	PURPOSE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	disease	O
7	-	O
8	free	O
9	survival	O
10	(	O
11	DFS	O
12	)	O
13	and	O
14	overall	O
15	survival	O
16	(	O
17	OS	O
18	),	O
19	prognostic	O
20	factors	O
21	,	O
22	and	O
23	treatment	O
24	-	O
25	related	O
26	mortality	O
27	of	O
28	women	O
29	with	O
30	stage	O
31	IIIB	O
32	inflammatory	O
33	breast	O
34	cancer	O
35	(	O
36	IBC	O
37	)	O
38	treated	O
39	with	O
40	combined	O
41	modality	O
42	therapy	O
43	(	O
44	CMT	O
45	)	O
46	and	O
47	high	O
48	-	O
49	dose	O
50	chemotherapy	O
51	(	O
52	HDCT	O
53	)	O
54	with	O
55	autologous	O
56	stem	O
57	-	O
58	cell	O
59	transplantation	O
60	.	O
1	The	O
2	GPI	O
3	anchor	O
4	moiety	O
5	is	O
6	either	O
7	absent	O
8	or	O
9	present	O
10	at	O
11	a	O
12	very	O
13	low	O
14	level	O
15	in	O
16	the	O
17	polypeptide	O
18	expressed	O
19	from	O
20	the	O
21	cDNA	O
22	that	O
23	contained	O
24	both	O
25	the	O
26	signal	O
27	peptide	O
28	and	O
29	GPI	O
30	signal	O
31	sequences	O
32	.	O
1	They	O
2	self	O
3	-	O
4	completed	O
5	the	O
6	SF	O
7	-	O
8	36	O
9	questionnaire	O
10	and	O
11	their	O
12	QoL	O
13	was	O
14	described	O
15	and	O
16	retrospectively	O
17	compared	O
18	to	O
19	that	O
20	of	O
21	historical	O
22	controls	O
23	.	O
1	Here	O
2	,	O
3	we	O
4	describe	O
5	a	O
6	tyrosine	O
7	-	O
8	phosphorylated	O
9	nuclear	O
10	protein	O
11	,	O
12	YT521	B
13	-	I
14	B	I
15	,	O
16	and	O
17	show	O
18	that	O
19	it	O
20	interacts	O
21	with	O
22	the	O
23	nuclear	B
24	transcriptosomal	I
25	component	I
26	scaffold	I
27	attachment	I
28	factor	I
29	B	I
30	,	O
31	and	O
32	the	O
33	68	B
34	-	I
35	kDa	I
36	Src	I
37	substrate	O
38	associated	O
39	during	O
40	mitosis	O
41	,	O
42	Sam68	B
43	.	O
1	These	O
2	mutants	O
3	all	O
4	failed	O
5	to	O
6	interact	O
7	with	O
8	the	O
9	TraR	B
10	fusion	I
11	in	O
12	the	O
13	two	O
14	-	O
15	hybrid	O
16	system	O
17	.	O
1	With	O
2	constructs	O
3	containing	O
4	the	O
5	binding	O
6	site	O
7	of	O
8	one	O
9	gene	O
10	fused	O
11	to	O
12	the	O
13	promoter	O
14	of	O
15	the	O
16	other	O
17	,	O
18	we	O
19	demonstrated	O
20	that	O
21	the	O
22	positional	O
23	requirements	O
24	are	O
25	a	O
26	function	O
27	of	O
28	the	O
29	specific	O
30	binding	O
31	site	O
32	,	O
33	not	O
34	the	O
35	promoter	O
36	.	O
1	The	O
2	proliferation	O
3	-	O
4	specific	O
5	HNF	B
6	-	I
7	3	I
8	/	O
9	fork	B
10	head	I
11	homolog	I
12	-	I
13	11B	I
14	protein	O
15	(	O
16	HFH	B
17	-	I
18	11B	I
19	;	O
20	also	O
21	known	O
22	as	O
23	Trident	B
24	and	O
25	Win	B
26	)	O
27	is	O
28	a	O
29	family	O
30	member	O
31	of	O
32	the	O
33	winged	B
34	helix	I
35	/	O
36	fork	B
37	head	I
38	transcription	O
39	factors	O
40	and	O
41	in	O
42	regenerating	O
43	liver	O
44	its	O
45	expression	O
46	is	O
47	reactivated	O
48	prior	O
49	to	O
50	hepatocyte	O
51	entry	O
52	into	O
53	DNA	O
54	replication	O
55	(	O
56	S	O
57	phase	O
58	).	O
1	We	O
2	determined	O
3	whether	O
4	a	O
5	single	O
6	injection	O
7	of	O
8	slow	O
9	-	O
10	release	O
11	estradiol	O
12	-	O
13	17beta	O
14	(	O
15	SRE2	O
16	)	O
17	would	O
18	induce	O
19	pseudopregnancy	O
20	in	O
21	gilts	O
22	and	O
23	whether	O
24	PGF2alpha	O
25	would	O
26	regress	O
27	the	O
28	corpora	O
29	lutea	O
30	(	O
31	CL	O
32	)	O
33	of	O
34	pseudopregnancy	O
35	.	O
1	The	O
2	level	O
3	of	O
4	serum	B
5	creatine	I
6	kinase	I
7	was	O
8	significantly	O
9	high	O
10	2	O
11	days	O
12	after	O
13	ESWIB	O
14	,	O
15	but	O
16	it	O
17	recovered	O
18	in	O
19	a	O
20	week	O
21	.	O
1	Among	O
2	the	O
3	remaining	O
4	22	O
5	sites	O
6	,	O
7	six	O
8	are	O
9	in	O
10	the	O
11	promoters	O
12	of	O
13	known	O
14	alpha	O
15	-	O
16	specific	O
17	genes	O
18	and	O
19	two	O
20	other	O
21	sites	O
22	have	O
23	an	O
24	alpha2	B
25	-	O
26	Mcm1	B
27	-	O
28	dependent	O
29	role	O
30	in	O
31	determining	O
32	the	O
33	direction	O
34	of	O
35	mating	O
36	type	O
37	switching	O
38	.	O
1	Activation	O
2	of	O
3	T	O
4	cells	O
5	via	O
6	the	O
7	TCR	B
8	and	O
9	other	O
10	costimulatory	O
11	receptors	O
12	triggers	O
13	a	O
14	number	O
15	of	O
16	signaling	O
17	cascades	O
18	.	O
1	Results	O
2	confirmed	O
3	that	O
4	stress	O
5	produced	O
6	CA3	O
7	dendritic	O
8	atrophy	O
9	and	O
10	tianeptine	O
11	prevented	O
12	it	O
13	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	both	O
6	transcription	O
7	activators	O
8	depend	O
9	on	O
10	or	O
11	interact	O
12	with	O
13	different	O
14	subunits	O
15	of	O
16	RNA	B
17	polymerase	I
18	,	O
19	although	O
20	their	O
21	role	O
22	in	O
23	formation	O
24	of	O
25	proper	O
26	DNA	O
27	geometry	O
28	may	O
29	also	O
30	be	O
31	crucial	O
32	.	O
1	Skin	O
2	pH	O
3	changes	O
4	associated	O
5	with	O
6	iontophoresis	O
7	.	O
1	Phosphorylation	O
2	of	O
3	myosin	B
4	-	I
5	binding	I
6	subunit	I
7	(	O
8	MBS	B
9	)	O
10	of	O
11	myosin	B
12	phosphatase	I
13	by	O
14	Rho	B
15	-	I
16	kinase	I
17	in	O
18	vivo	O
19	.	O
1	Cytoprotection	O
2	with	O
3	amifostine	O
4	in	O
5	radiotherapy	O
6	or	O
7	radio	O
8	-	O
9	chemotherapy	O
10	of	O
11	head	O
12	and	O
13	neck	O
14	tumors	O
1	Patients	O
2	with	O
3	types	O
4	I	O
5	and	O
6	III	O
7	MPGN	O
8	did	O
9	not	O
10	differ	O
11	in	O
12	age	O
13	at	O
14	apparent	O
15	onset	O
16	,	O
17	age	O
18	at	O
19	diagnosis	O
20	,	O
21	or	O
22	interval	O
23	from	O
24	apparent	O
25	onset	O
26	of	O
27	symptoms	O
28	to	O
29	diagnosis	O
30	(	O
31	biopsy	O
32	).	O
1	Recombinant	B
2	prenylcysteine	I
3	lyase	I
4	was	O
5	produced	O
6	in	O
7	a	O
8	baculovirus	O
9	-	O
10	Sf9	O
11	expression	O
12	system	O
13	.	O
1	In	O
2	gel	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	low	O
8	binding	O
9	activity	O
10	of	O
11	CBF	B
12	to	O
13	the	O
14	wild	B
15	-	I
16	type	I
17	AtpC	I
18	promoter	I
19	sequence	I
20	was	O
21	observed	O
22	with	O
23	nuclear	O
24	extracts	O
25	from	O
26	tissue	O
27	with	O
28	low	O
29	AtpC	B
30	expression	O
31	levels	O
32	,	O
33	i	O
34	.	O
35	e	O
36	.	O
37	extracts	O
38	from	O
39	etiolated	O
40	and	O
41	photobleached	O
42	seedlings	O
43	,	O
44	whereas	O
45	high	O
46	binding	O
47	activity	O
48	was	O
49	detectable	O
50	with	O
51	extracts	O
52	from	O
53	tissues	O
54	with	O
55	high	O
56	AtpC	B
57	expression	O
58	levels	O
59	,	O
60	i	O
61	.	O
62	e	O
63	.	O
64	extracts	O
65	from	O
66	light	O
67	-	O
68	grown	O
69	seedlings	O
70	and	O
71	etiolated	O
72	seedlings	O
73	treated	O
74	with	O
75	cytokinin	B
76	.	O
1	Mycoplasma	O
2	hominis	O
3	infections	O
4	are	O
5	easily	O
6	missed	O
7	because	O
8	conventional	O
9	methods	O
10	for	O
11	bacterial	O
12	detection	O
13	may	O
14	fail	O
15	.	O
1	Demyelinating	O
2	diseases	O
3	involving	O
4	the	O
5	grey	O
6	matter	O
7	were	O
8	very	O
9	rare	O
10	,	O
11	but	O
12	we	O
13	must	O
14	consider	O
15	the	O
16	presence	O
17	of	O
18	symmetrical	O
19	thalamic	O
20	involvement	O
21	in	O
22	patients	O
23	with	O
24	ADEM	O
25	.	O
1	To	O
2	define	O
3	the	O
4	minimal	O
5	VDRE	O
6	binding	O
7	domain	O
8	for	O
9	human	B
10	VDR	I
11	(	O
12	hVDR	B
13	),	O
14	a	O
15	series	O
16	of	O
17	C	O
18	-	O
19	terminally	O
20	truncated	O
21	hVDR	B
22	mutants	I
23	(	O
24	Delta134	O
25	,	O
26	Delta113	O
27	,	O
28	Delta102	O
29	,	O
30	Delta90	O
31	,	O
32	Delta84	O
33	,	O
34	Delta80	O
35	,	O
36	and	O
37	Delta60	O
38	)	O
39	was	O
40	generated	O
41	and	O
42	expressed	O
43	in	O
44	bacteria	O
45	.	O
1	A	O
2	key	O
3	event	O
4	in	O
5	this	O
6	process	O
7	is	O
8	the	O
9	selective	O
10	recognition	O
11	of	O
12	the	O
13	target	O
14	membrane	O
15	by	O
16	the	O
17	vesicle	O
18	and	O
19	the	O
20	current	O
21	view	O
22	is	O
23	that	O
24	SNARE	B
25	protein	I
26	interactions	O
27	likely	O
28	play	O
29	a	O
30	central	O
31	role	O
32	in	O
33	vesicle	O
34	-	O
35	target	O
36	recognition	O
37	and	O
38	or	O
39	membrane	O
40	fusion	O
41	.	O
1	The	O
2	potential	O
3	for	O
4	highly	O
5	reactive	O
6	nanoparticles	O
7	(	O
8	RNP	O
9	)	O
10	to	O
11	absorb	O
12	destructively	O
13	,	O
14	i	O
15	.	O
16	e	O
17	.	O
18	to	O
19	neutralize	O
20	highly	O
21	toxic	O
22	substances	O
23	such	O
24	as	O
25	the	O
26	warfare	O
27	agents	O
28	GA	O
29	,	O
30	GB	O
31	,	O
32	HD	O
33	and	O
34	VX	O
35	,	O
36	has	O
37	been	O
38	demonstrated	O
39	in	O
40	the	O
41	laboratory	O
42	.	O
1	There	O
2	were	O
3	minimal	O
4	negative	O
5	effects	O
6	on	O
7	hematological	O
8	parameters	O
9	,	O
10	acid	O
11	-	O
12	base	O
13	status	O
14	,	O
15	and	O
16	blood	O
17	gases	O
18	.	O
1	The	O
2	RET	B
3	/	O
4	PTC3	B
5	rearrangement	O
6	is	O
7	formed	O
8	by	O
9	fusion	O
10	of	O
11	the	O
12	ELE1	B
13	and	O
14	RET	B
15	genes	I
16	,	O
17	and	O
18	is	O
19	highly	O
20	prevalent	O
21	in	O
22	radiation	O
23	-	O
24	induced	O
25	post	O
26	-	O
27	Chernobyl	O
28	papillary	O
29	thyroid	O
30	carcinomas	O
31	.	O
1	Higher	O
2	CYP3A23	B
3	basal	O
4	activity	O
5	appears	O
6	to	O
7	be	O
8	due	O
9	to	O
10	an	O
11	E	O
12	-	O
13	box	O
14	in	O
15	3A23SiteA	B
16	that	O
17	interacts	O
18	with	O
19	USF1	B
20	,	O
21	a	O
22	ubiquitous	O
23	bHLH	B
24	/	I
25	leucine	I
26	zipper	I
27	transcription	I
28	factor	I
29	.	O
1	In	O
2	addition	O
3	,	O
4	using	O
5	biochemical	O
6	activity	O
7	assays	O
8	for	O
9	Rho	B
10	-	O
11	like	O
12	GTPases	B
13	,	O
14	we	O
15	show	O
16	that	O
17	the	O
18	expression	O
19	of	O
20	beta1A	B
21	,	O
22	beta1D	B
23	,	O
24	or	O
25	IL2R	B
26	-	O
27	beta1A	B
28	in	O
29	GE11	O
30	or	O
31	GD25	O
32	cells	O
33	triggers	O
34	activation	O
35	of	O
36	both	O
37	RhoA	B
38	and	O
39	Rac1	B
40	,	O
41	but	O
42	not	O
43	of	O
44	Cdc42	B
45	.	O
1	These	O
2	synergistic	O
3	effects	O
4	were	O
5	strongly	O
6	Jem	B
7	-	I
8	1	I
9	dose	O
10	-	O
11	dependent	O
12	.	O
1	In	O
2	this	O
3	study	O
4	26	O
5	patients	O
6	(	O
7	20	O
8	females	O
9	and	O
10	6	O
11	males	O
12	)	O
13	were	O
14	evaluated	O
15	.	O
1	STUDY	O
2	DESIGN	O
3	AND	O
4	METHODS	O
5	:	O
6	A	O
7	study	O
8	was	O
9	initiated	O
10	to	O
11	compare	O
12	the	O
13	collection	O
14	of	O
15	PBPCs	O
16	with	O
17	the	O
18	new	O
19	device	O
20	,	O
21	the	O
22	AutoPBSC	O
23	(	O
24	version	O
25	[	O
26	V	O
27	]	O
28	6	O
29	.	O
30	0	O
31	with	O
32	AutoPBSC	O
33	tubing	O
34	set	O
35	),	O
36	and	O
37	that	O
38	with	O
39	the	O
40	MNC	O
41	(	O
42	mononuclear	O
43	cell	O
44	)	O
45	procedure	O
46	(	O
47	V4	O
48	.	O
49	7	O
50	with	O
51	white	O
52	cell	O
53	tubing	O
54	set	O
55	),	O
56	for	O
57	patients	O
58	and	O
59	healthy	O
60	donors	O
61	.	O
1	Consistent	O
2	with	O
3	this	O
4	finding	O
5	,	O
6	beta	B
7	-	I
8	catenin	I
9	interacted	O
10	directly	O
11	with	O
12	the	O
13	RA	B
14	receptor	I
15	(	O
16	RAR	B
17	)	O
18	in	O
19	a	O
20	retinoid	O
21	-	O
22	dependent	O
23	manner	O
24	,	O
25	but	O
26	not	O
27	with	O
28	the	O
29	retinoid	B
30	X	I
31	receptor	I
32	(	O
33	RXR	B
34	),	O
35	and	O
36	RAR	B
37	competed	O
38	with	O
39	TCF	B
40	for	O
41	beta	B
42	-	I
43	catenin	I
44	binding	O
45	.	O
1	Thrombolysis	O
2	was	O
3	followed	O
4	by	O
5	a	O
6	similar	O
7	increase	O
8	of	O
9	platelet	O
10	activity	O
11	with	O
12	maximal	O
13	values	O
14	reached	O
15	at	O
16	the	O
17	3rd	O
18	hour	O
19	in	O
20	both	O
21	groups	O
22	(	O
23	196	O
24	+/-	O
25	43	O
26	IU	O
27	/	O
28	ml	O
29	in	O
30	Group	O
31	1	O
32	and	O
33	192	O
34	+/-	O
35	39	O
36	in	O
37	Group	O
38	2	O
39	:	O
40	p	O
41	&	O
42	lt	O
43	;	O
44	001versus	O
45	baseline	O
46	and	O
47	p	O
48	NS	O
49	between	O
50	the	O
51	groups	O
52	).	O
1	Consistent	O
2	with	O
3	this	O
4	finding	O
5	,	O
6	wild	B
7	-	I
8	type	I
9	SAGA	I
10	inhibits	O
11	TBP	B
12	binding	O
13	to	O
14	the	O
15	HIS3	B
16	promoter	I
17	in	O
18	vitro	O
19	,	O
20	while	O
21	SAGA	B
22	lacking	O
23	Spt3	B
24	or	O
25	Spt8	B
26	is	O
27	not	O
28	inhibitory	O
29	.	O
1	However	O
2	,	O
3	no	O
4	genetic	O
5	alteration	O
6	was	O
7	detected	O
8	in	O
9	any	O
10	of	O
11	the	O
12	cancers	O
13	examined	O
14	.	O
1	Cloning	O
2	and	O
3	sequencing	O
4	of	O
5	the	O
6	upstream	O
7	region	O
8	of	O
9	pepX	B
10	revealed	O
11	the	O
12	presence	O
13	of	O
14	two	O
15	ORFs	O
16	of	O
17	360	O
18	and	O
19	1	O
20	,	O
21	338	O
22	bp	O
23	that	O
24	were	O
25	shown	O
26	to	O
27	be	O
28	able	O
29	to	O
30	encode	O
31	proteins	O
32	with	O
33	high	O
34	homology	O
35	to	O
36	GlnR	B
37	and	O
38	GlnA	B
39	proteins	I
40	,	O
41	respectively	O
42	.	O
1	Histological	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	neuronal	O
7	loss	O
8	in	O
9	the	O
10	DHED	O
11	-	O
12	treated	O
13	group	O
14	was	O
15	notably	O
16	reduced	O
17	in	O
18	the	O
19	hippocampal	O
20	area	O
21	(	O
22	CA1	O
23	)	O
24	of	O
25	ischemic	O
26	rats	O
27	and	O
28	in	O
29	the	O
30	dentate	O
31	gyrus	O
32	and	O
33	hippocampal	O
34	area	O
35	(	O
36	CA1	O
37	and	O
38	CA3	O
39	)	O
40	of	O
41	EC	O
42	-	O
43	lesioned	O
44	rats	O
45	compared	O
46	with	O
47	the	O
48	nontreated	O
49	group	O
50	.	O
1	The	O
2	extents	O
3	of	O
4	phosphorylation	O
5	of	O
6	Ser44	O
7	and	O
8	Ser64	O
9	were	O
10	1	O
11	:	O
12	1	O
13	,	O
14	whereas	O
15	those	O
16	of	O
17	the	O
18	four	O
19	minor	O
20	sites	O
21	all	O
22	together	O
23	were	O
24	<	O
25	30	O
26	%	O
27	of	O
28	the	O
29	major	O
30	one	O
31	.	O
1	Maximum	O
2	induction	O
3	of	O
4	AP	B
5	-	I
6	1	I
7	was	O
8	reached	O
9	at	O
10	a	O
11	concentration	O
12	of	O
13	250	O
14	nmol	O
15	/	O
16	L	O
17	of	O
18	CalC	O
19	.	O
1	Animal	O
2	studies	O
3	showed	O
4	that	O
5	beam	O
6	equalization	O
7	significantly	O
8	improved	O
9	fluoroscopic	O
10	and	O
11	angiographic	O
12	image	O
13	quality	O
14	.	O
1	The	O
2	prevalence	O
3	of	O
4	hepatitis	O
5	C	O
6	virus	O
7	(	O
8	HCV	O
9	)	O
10	infection	O
11	is	O
12	relatively	O
13	low	O
14	in	O
15	childhood	O
16	,	O
17	with	O
18	anti	B
19	-	I
20	HCV	I
21	prevalence	O
22	rates	O
23	of	O
24	0	O
25	.	O
26	1	O
27	-	O
28	0	O
29	.	O
30	4	O
31	%	O
32	in	O
33	the	O
34	Western	O
35	world	O
36	.	O
1	Clear	O
2	and	O
3	evidenced	O
4	-	O
5	based	O
6	information	O
7	should	O
8	be	O
9	provided	O
10	to	O
11	patients	O
12	as	O
13	to	O
14	the	O
15	means	O
16	of	O
17	prevention	O
18	with	O
19	special	O
20	attention	O
21	to	O
22	individual	O
23	risk	O
24	groups	O
25	such	O
26	as	O
27	IV	O
28	drug	O
29	abusers	O
30	.	O
1	Compared	O
2	to	O
3	those	O
4	with	O
5	normal	O
6	renal	O
7	functions	O
8	,	O
9	these	O
10	patients	O
11	were	O
12	older	O
13	(	O
14	P	O
15	<	O
16	or	O
17	=	O
18	0	O
19	.	O
20	01	O
21	),	O
22	had	O
23	significantly	O
24	elevated	O
25	blood	O
26	pressures	O
27	(	O
28	P	O
29	<	O
30	0	O
31	.	O
32	01	O
33	or	O
34	P	O
35	=	O
36	0	O
37	.	O
38	0001	O
39	),	O
40	and	O
41	in	O
42	the	O
43	case	O
44	of	O
45	Type	O
46	1	O
47	DM	O
48	,	O
49	with	O
50	a	O
51	higher	O
52	body	O
53	mass	O
54	index	O
55	(	O
56	P	O
57	=	O
58	0	O
59	.	O
60	0001	O
61	)	O
62	and	O
63	waist	O
64	-	O
65	hip	O
66	ratio	O
67	(	O
68	P	O
69	<	O
70	0	O
71	.	O
72	01	O
73	).	O
1	Angiotensin	B
2	II	I
3	induces	O
4	nuclear	B
5	factor	I
6	(	I
7	NF	I
8	)-	I
9	kappaB1	I
10	isoforms	I
11	to	O
12	bind	O
13	the	O
14	angiotensinogen	B
15	gene	I
16	acute	O
17	-	O
18	phase	O
19	response	O
20	element	O
21	:	O
22	a	O
23	stimulus	O
24	-	O
25	specific	O
26	pathway	O
27	for	O
28	NF	B
29	-	I
30	kappaB	I
31	activation	O
32	.	O
1	Downstream	O
2	of	O
3	the	O
4	G	O
5	-	O
6	A	O
7	anastomosis	O
8	,	O
9	the	O
10	RD	O
11	,	O
12	CC	O
13	,	O
14	E	O
15	(	O
16	p	O
17	)	O
18	and	O
19	loop	O
20	areas	O
21	were	O
22	significantly	O
23	different	O
24	from	O
25	REF	O
26	,	O
27	but	O
28	significantly	O
29	different	O
30	from	O
31	A	O
32	-	O
33	A	O
34	.	O
1	Eastern	O
2	Cooperative	O
3	Oncology	O
4	Group	O
5	trial	O
6	E3186	O
7	was	O
8	initiated	O
9	to	O
10	explore	O
11	this	O
12	question	O
13	.	O
1	Sequence	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	5	O
7	'-	O
8	flanking	O
9	region	O
10	upstream	O
11	to	O
12	the	O
13	ATG	O
14	codon	O
15	did	O
16	not	O
17	contain	O
18	a	O
19	conventional	O
20	TATA	O
21	box	O
22	.	O
1	Differential	O
2	expression	O
3	and	O
4	regulation	O
5	by	O
6	20	O
7	-	O
8	hydroxyecdysone	O
9	of	O
10	mosquito	O
11	ultraspiracle	O
12	isoforms	O
13	.	O
1	Multivariate	O
2	predictors	O
3	were	O
4	concentric	O
5	remodeling	O
6	(	O
7	P	O
8	<	O
9	0	O
10	.	O
11	0001	O
12	;	O
13	odds	O
14	ratio	O
15	,	O
16	13	O
17	.	O
18	5	O
19	),	O
20	left	O
21	ventricular	O
22	ejection	O
23	fraction	O
24	>	O
25	2	O
26	SD	O
27	above	O
28	normal	O
29	(	O
30	P	O
31	<	O
32	0	O
33	.	O
34	0001	O
35	),	O
36	and	O
37	single	O
38	-	O
39	vessel	O
40	left	O
41	circumflex	O
42	disease	O
43	(	O
44	P	O
45	<	O
46	0	O
47	.	O
48	0007	O
49	;	O
50	odds	O
51	ratio	O
52	,	O
53	7	O
54	.	O
55	6	O
56	).	O
1	The	O
2	case	O
3	for	O
4	completing	O
5	the	O
6	lymphadenectomy	O
7	when	O
8	positive	O
9	lymph	O
10	nodes	O
11	are	O
12	found	O
13	during	O
14	radical	O
15	hysterectomy	O
16	for	O
17	cervical	O
18	carcinoma	O
19	.	O
1	The	O
2	RNA	O
3	aptamer	O
4	contains	O
5	three	O
6	stems	O
7	separated	O
8	by	O
9	a	O
10	pair	O
11	of	O
12	two	O
13	-	O
14	base	O
15	bulges	O
16	,	O
17	and	O
18	adopts	O
19	an	O
20	unanticipated	O
21	fold	O
22	in	O
23	which	O
24	both	O
25	junctional	O
26	sites	O
27	are	O
28	anchored	O
29	through	O
30	base	O
31	triple	O
32	formation	O
33	.	O
1	All	O
2	clones	O
3	and	O
4	strains	O
5	produced	O
6	have	O
7	been	O
8	deposited	O
9	in	O
10	the	O
11	EUROFAN	O
12	genetic	O
13	stock	O
14	centre	O
15	(	O
16	EUROSCARF	O
17	,	O
18	Frankfurt	O
19	).	O
1	Two	O
2	episodes	O
3	of	O
4	peritonitis	O
5	occurred	O
6	while	O
7	the	O
8	patient	O
9	received	O
10	CAPD	O
11	(	O
12	1	O
13	episode	O
14	/	O
15	3	O
16	.	O
17	5	O
18	patient	O
19	-	O
20	months	O
21	).	O
1	Induction	O
2	was	O
3	reversed	O
4	by	O
5	coexpression	O
6	of	O
7	A	B
8	-	I
9	Fos	I
10	,	O
11	a	O
12	dominant	O
13	negative	O
14	to	O
15	AP	B
16	-	I
17	1	I
18	.	O
1	High	O
2	resolution	O
3	computed	O
4	tomography	O
5	of	O
6	the	O
7	lungs	O
8	in	O
9	patients	O
10	with	O
11	rheumatoid	O
12	arthritis	O
13	.	O
1	However	O
2	,	O
3	its	O
4	participation	O
5	in	O
6	collagen	B
7	binding	O
8	has	O
9	not	O
10	been	O
11	shown	O
12	.	O
1	We	O
2	have	O
3	addressed	O
4	these	O
5	issues	O
6	by	O
7	reconstituting	O
8	and	O
9	characterizing	O
10	the	O
11	KRAB	B
12	:	O
13	KAP	B
14	-	I
15	1	I
16	-	O
17	RBCC	B
18	interaction	O
19	using	O
20	purified	O
21	components	O
22	.	O
1	JPEG	O
2	53	O
3	,	O
4	resulting	O
5	in	O
6	a	O
7	compression	O
8	ratio	O
9	of	O
10	1	O
11	:	O
12	21	O
13	,	O
14	does	O
15	not	O
16	compromise	O
17	the	O
18	diagnostic	O
19	performance	O
20	in	O
21	general	O
22	.	O
1	An	O
2	increase	O
3	in	O
4	the	O
5	level	O
6	of	O
7	serum	O
8	enzymes	O
9	,	O
10	such	O
11	as	O
12	aspartate	B
13	transaminase	I
14	,	O
15	alkaline	B
16	phosphatase	I
17	,	O
18	creatine	B
19	phosphokinase	I
20	,	O
21	lactate	B
22	dehydrogenase	I
23	after	O
24	D	O
25	.	O
26	russelli	O
27	venom	O
28	injection	O
29	in	O
30	albino	O
31	rats	O
32	is	O
33	indicative	O
34	of	O
35	cell	O
36	or	O
37	tissue	O
38	damage	O
39	.	O
1	We	O
2	show	O
3	that	O
4	stabilization	O
5	of	O
6	the	O
7	hairpin	O
8	reduced	O
9	the	O
10	amount	O
11	of	O
12	tRNA	O
13	primer	O
14	that	O
15	is	O
16	annealed	O
17	to	O
18	the	O
19	PBS	O
20	.	O
1	ZK7	B
2	and	O
3	HZF16	B
4	genes	I
5	appear	O
6	to	O
7	be	O
8	the	O
9	splice	O
10	variants	O
11	transcribed	O
12	from	O
13	the	O
14	same	O
15	gene	O
16	.	O
1	No	O
2	definite	O
3	conclusions	O
4	are	O
5	possible	O
6	because	O
7	of	O
8	the	O
9	small	O
10	number	O
11	of	O
12	patients	O
13	involved	O
14	in	O
15	this	O
16	phase	O
17	II	O
18	trial	O
19	.	O
1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	investigated	O
7	the	O
8	molecular	O
9	mechanisms	O
10	underlying	O
11	the	O
12	inducible	O
13	expression	O
14	of	O
15	the	O
16	flt	B
17	-	I
18	1	I
19	gene	I
20	during	O
21	the	O
22	activation	O
23	of	O
24	THP	O
25	-	O
26	1	O
27	cells	O
28	.	O
1	Protein	O
2	sequence	O
3	analysis	O
4	reveals	O
5	that	O
6	MAN1	B
7	shares	O
8	a	O
9	conserved	O
10	globular	O
11	domain	O
12	of	O
13	approximately	O
14	40	O
15	amino	O
16	acids	O
17	,	O
18	which	O
19	we	O
20	term	O
21	the	O
22	LEM	B
23	module	I
24	,	O
25	with	O
26	inner	O
27	nuclear	O
28	membrane	O
29	proteins	O
30	lamina	B
31	-	I
32	associated	I
33	polypeptide	I
34	2	I
35	and	O
36	emerin	B
37	.	O
1	For	O
2	each	O
3	night	O
4	,	O
5	the	O
6	diary	O
7	allowed	O
8	the	O
9	subjective	O
10	measurement	O
11	of	O
12	bedtime	O
13	,	O
14	wake	O
15	time	O
16	,	O
17	time	O
18	in	O
19	bed	O
20	(	O
21	TIB	O
22	),	O
23	sleep	O
24	efficiency	O
25	,	O
26	number	O
27	of	O
28	minutes	O
29	of	O
30	wake	O
31	after	O
32	sleep	O
33	onset	O
34	(	O
35	WASO	O
36	),	O
37	alertness	O
38	on	O
39	awakening	O
40	,	O
41	and	O
42	percentage	O
43	of	O
44	morning	O
45	needing	O
46	an	O
47	alarm	O
48	(	O
49	or	O
50	a	O
51	person	O
52	functioning	O
53	as	O
54	one	O
55	).	O
1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O
1	Structural	O
2	changes	O
3	in	O
4	the	O
5	kinetically	O
6	more	O
7	damaged	O
8	E44D	O
9	mutant	O
10	detected	O
11	in	O
12	(	O
13	1	O
14	)	O
15	H	O
16	-(	O
17	15	O
18	)	O
19	N	O
20	HSQC	O
21	spectra	O
22	were	O
23	largely	O
24	limited	O
25	to	O
26	the	O
27	loop	O
28	I	O
29	-	O
30	helix	O
31	I	O
32	motif	O
33	,	O
34	suggesting	O
35	that	O
36	Glu	O
37	-	O
38	44	O
39	stabilizes	O
40	the	O
41	active	O
42	site	O
43	region	O
44	.	O
1	We	O
2	present	O
3	evidence	O
4	that	O
5	the	O
6	upstream	O
7	open	O
8	reading	O
9	frame	O
10	(	O
11	uORF	O
12	)	O
13	represses	O
14	the	O
15	translation	O
16	of	O
17	the	O
18	downstream	O
19	major	O
20	open	O
21	reading	O
22	frame	O
23	(	O
24	mORF	O
25	).	O
1	No	O
2	somatic	O
3	mutations	O
4	were	O
5	found	O
6	in	O
7	any	O
8	of	O
9	the	O
10	samples	O
11	,	O
12	suggesting	O
13	that	O
14	ING1	B
15	is	O
16	not	O
17	a	O
18	tumor	O
19	suppressor	O
20	gene	O
21	target	O
22	in	O
23	head	O
24	and	O
25	neck	O
26	cancer	O
27	.	O
1	EMSA	O
2	showed	O
3	that	O
4	nuclear	O
5	proteins	O
6	from	O
7	PC12	O
8	but	O
9	not	O
10	C6	O
11	or	O
12	Rat2	O
13	cells	O
14	bind	O
15	the	O
16	CRE	O
17	as	O
18	a	O
19	complex	O
20	containing	O
21	activating	B
22	transcription	I
23	factor	I
24	(	I
25	ATF	I
26	)-	I
27	4	I
28	and	O
29	CCAAT	B
30	enhancer	I
31	-	I
32	binding	I
33	protein	I
34	beta	I
35	,	O
36	while	O
37	both	O
38	PC12	O
39	and	O
40	C6	O
41	cell	O
42	nuclear	O
43	extracts	O
44	were	O
45	recruited	O
46	by	O
47	the	O
48	CCAAT	O
49	-	O
50	box	O
51	as	O
52	a	O
53	complex	O
54	containing	O
55	nuclear	B
56	factor	I
57	Y	I
58	.	O
1	LPO	O
2	and	O
3	SOD	B
4	levels	O
5	were	O
6	measured	O
7	at	O
8	five	O
9	points	O
10	before	O
11	and	O
12	during	O
13	the	O
14	operation	O
15	.	O
1	Sulfhydryl	O
2	titration	O
3	with	O
4	iodoacetamide	O
5	,	O
6	monitored	O
7	by	O
8	quantitating	O
9	the	O
10	residual	O
11	thiols	O
12	after	O
13	reaction	O
14	with	O
15	a	O
16	maleimide	O
17	derivative	O
18	of	O
19	biotin	O
20	,	O
21	revealed	O
22	a	O
23	striking	O
24	difference	O
25	in	O
26	the	O
27	apparent	O
28	pK	O
29	(	O
30	a	O
31	)	O
32	values	O
33	of	O
34	the	O
35	cysteines	O
36	at	O
37	the	O
38	two	O
39	splice	O
40	junctions	O
41	.	O
1	Covalent	O
2	modification	O
3	of	O
4	the	O
5	transactivator	O
6	protein	O
7	IE2	B
8	-	O
9	p86	B
10	of	O
11	human	O
12	cytomegalovirus	O
13	by	O
14	conjugation	O
15	to	O
16	the	O
17	ubiquitin	B
18	-	I
19	homologous	I
20	proteins	I
21	SUMO	I
22	-	I
23	1	I
24	and	O
25	hSMT3b	B
26	.	O
1	Mouse	B
2	growth	I
3	hormone	I
4	transcription	I
5	factor	I
6	Zn	I
7	-	I
8	16	I
9	:	O
10	unique	O
11	bipartite	O
12	structure	O
13	containing	O
14	tandemly	O
15	repeated	O
16	zinc	O
17	finger	O
18	domains	O
19	not	O
20	reported	O
21	in	O
22	rat	B
23	Zn	I
24	-	I
25	15	I
26	.	O
1	First	O
2	,	O
3	human	O
4	erythroid	O
5	K562	O
6	cells	O
7	stably	O
8	integrated	O
9	with	O
10	various	O
11	HS	B
12	-	I
13	40	I
14	mutants	I
15	cis	O
16	linked	O
17	to	O
18	a	O
19	human	B
20	alpha	I
21	-	I
22	globin	I
23	promoter	I
24	-	O
25	growth	B
26	hormone	I
27	hybrid	O
28	gene	O
29	were	O
30	analyzed	O
31	by	O
32	genomic	O
33	footprinting	O
34	and	O
35	expression	O
36	analysis	O
37	.	O
1	Its	O
2	cognate	O
3	binding	O
4	protein	O
5	,	O
6	REST	B
7	/	O
8	NRSF	B
9	,	O
10	is	O
11	an	O
12	essential	O
13	transcription	O
14	factor	O
15	;	O
16	its	O
17	null	O
18	mutations	O
19	result	O
20	in	O
21	embryonic	O
22	lethality	O
23	,	O
24	and	O
25	its	O
26	dominant	O
27	negative	O
28	mutants	O
29	produce	O
30	aberrant	O
31	expression	O
32	of	O
33	neuron	O
34	-	O
35	specific	O
36	genes	O
37	.	O
1	Removal	O
2	of	O
3	all	O
4	core	B
5	histone	I
6	tail	O
7	domains	O
8	by	O
9	limited	O
10	trypsin	B
11	proteolysis	O
12	or	O
13	acetylation	O
14	of	O
15	the	O
16	core	B
17	histone	I
18	tails	O
19	significantly	O
20	relieves	O
21	this	O
22	inhibition	O
23	and	O
24	allows	O
25	TFIIIA	B
26	to	O
27	exhibit	O
28	high	O
29	-	O
30	affinity	O
31	binding	O
32	to	O
33	nucleosomal	O
34	DNA	O
35	.	O
1	OUTCOME	O
2	:	O
3	Acetylcholine	B
4	receptor	I
5	antibodies	I
6	and	O
7	single	O
8	-	O
9	fibre	O
10	electromyogram	O
11	were	O
12	useful	O
13	in	O
14	the	O
15	diagnosis	O
16	of	O
17	myasthenia	O
18	gravis	O
19	.	O
1	In	O
2	two	O
3	-	O
4	field	O
5	nodal	O
6	dissection	O
7	,	O
8	two	O
9	components	O
10	are	O
11	included	O
12	with	O
13	(	O
14	modern	O
15	two	O
16	-	O
17	field	O
18	)	O
19	or	O
20	without	O
21	(	O
22	traditional	O
23	two	O
24	-	O
25	field	O
26	)	O
27	nodal	O
28	dissection	O
29	around	O
30	both	O
31	recurrent	O
32	laryngeal	O
33	nerve	O
34	chains	O
35	in	O
36	the	O
37	upper	O
38	mediastinum	O
39	.	O
1	Static	O
2	and	O
3	dynamic	O
4	compliance	O
5	was	O
6	measured	O
7	after	O
8	induction	O
9	of	O
10	anesthesia	O
11	,	O
12	before	O
13	and	O
14	immediately	O
15	after	O
16	filtration	O
17	in	O
18	the	O
19	operating	O
20	theater	O
21	,	O
22	1	O
23	hour	O
24	after	O
25	return	O
26	to	O
27	the	O
28	pediatric	O
29	intensive	O
30	care	O
31	unit	O
32	,	O
33	and	O
34	24	O
35	hours	O
36	after	O
37	the	O
38	operation	O
39	.	O
1	Together	O
2	,	O
3	these	O
4	data	O
5	identify	O
6	ERK2	B
7	as	O
8	a	O
9	specific	O
10	and	O
11	direct	O
12	target	O
13	of	O
14	HePTP	B
15	and	O
16	are	O
17	consistent	O
18	with	O
19	a	O
20	model	O
21	in	O
22	which	O
23	HePTP	B
24	negatively	O
25	regulates	O
26	ERK2	B
27	activity	O
28	as	O
29	part	O
30	of	O
31	a	O
32	feedback	O
33	mechanism	O
34	.	O
1	Strontium	O
2	nitrate	O
3	mixed	O
4	with	O
5	glycolic	O
6	acid	O
7	,	O
8	in	O
9	comparison	O
10	with	O
11	glycolic	O
12	acid	O
13	alone	O
14	,	O
15	markedly	O
16	(	O
17	p	O
18	<	O
19	0	O
20	.	O
21	01	O
22	)	O
23	shortened	O
24	the	O
25	duration	O
26	of	O
27	the	O
28	irritation	O
29	sensation	O
30	from	O
31	24	O
32	.	O
33	4	O
34	+/-	O
35	4	O
36	.	O
37	1	O
38	(	O
39	mean	O
40	+/-	O
41	SEM	O
42	)	O
43	min	O
44	to	O
45	8	O
46	.	O
47	9	O
48	+/-	O
49	3	O
50	.	O
51	7	O
52	(	O
53	mean	O
54	+/-	O
55	SEM	O
56	)	O
57	min	O
58	,	O
59	and	O
60	significantly	O
61	(	O
62	p	O
63	<	O
64	0	O
65	.	O
66	05	O
67	)	O
68	reduced	O
69	the	O
70	mean	O
71	magnitude	O
72	of	O
73	the	O
74	irritation	O
75	sensation	O
76	at	O
77	all	O
78	time	O
79	points	O
80	(	O
81	overall	O
82	).	O
1	We	O
2	also	O
3	show	O
4	that	O
5	zygotically	O
6	activated	O
7	Xretpos	O
8	transcripts	O
9	are	O
10	restricted	O
11	to	O
12	ventro	O
13	-	O
14	posterior	O
15	specific	O
16	regions	O
17	and	O
18	induced	O
19	by	O
20	UV	O
21	-	O
22	irradiation	O
23	and	O
24	BMP	B
25	-	I
26	4	I
27	overexpression	O
28	in	O
29	cycloheximide	O
30	-	O
31	dependent	O
32	way	O
33	.	O
34	genesis	O
35	26	O
36	:	O
37	198	O
38	-	O
39	207	O
40	,	O
41	2000	O
42	.	O
1	However	O
2	,	O
3	when	O
4	,	O
5	where	O
6	and	O
7	how	O
8	the	O
9	DSPP	B
10	is	O
11	cleaved	O
12	into	O
13	DSP	B
14	and	O
15	DPP	B
16	is	O
17	not	O
18	clear	O
19	.	O
1	Approximately	O
2	20	O
3	%	O
4	of	O
5	ALCLs	O
6	that	O
7	express	O
8	ALK	B
9	do	O
10	not	O
11	contain	O
12	the	O
13	t	O
14	(	O
15	2	O
16	;	O
17	5	O
18	),	O
19	suggesting	O
20	that	O
21	other	O
22	genetic	O
23	abnormalities	O
24	can	O
25	result	O
26	in	O
27	aberrant	O
28	ALK	B
29	expression	O
30	.	O
1	Following	O
2	the	O
3	observation	O
4	that	O
5	non	O
6	-	O
7	organ	O
8	-	O
9	specific	O
10	antibodies	O
11	are	O
12	related	O
13	with	O
14	pregnancy	O
15	loss	O
16	and	O
17	preeclampsia	O
18	,	O
19	the	O
20	role	O
21	of	O
22	organ	O
23	-	O
24	specific	O
25	antibodies	O
26	is	O
27	currently	O
28	being	O
29	extensively	O
30	investigated	O
31	.	O
1	Manganese	O
2	ions	O
3	were	O
4	found	O
5	to	O
6	be	O
7	essential	O
8	for	O
9	autophosphorylation	O
10	of	O
11	BGLF4	B
12	,	O
13	and	O
14	magnesium	O
15	can	O
16	stimulate	O
17	the	O
18	activity	O
19	.	O
1	An	O
2	amino	O
3	-	O
4	acid	O
5	sequence	O
6	comparison	O
7	revealed	O
8	that	O
9	Bacillus	B
10	YM55	I
11	-	I
12	1	I
13	aspartase	I
14	shared	O
15	71	O
16	%	O
17	homology	O
18	with	O
19	Bacillus	B
20	subtilis	I
21	aspartase	I
22	and	O
23	49	O
24	%	O
25	with	O
26	Escherichia	O
27	coli	O
28	and	O
29	Pseudomonas	B
30	fluorescens	I
31	aspartases	I
32	.	O
1	Unique	O
2	to	O
3	this	O
4	system	O
5	,	O
6	the	O
7	activity	O
8	of	O
9	TraR	B
10	is	O
11	negatively	O
12	modulated	O
13	by	O
14	an	O
15	antiactivator	O
16	called	O
17	TraM	B
18	.	O
1	Here	O
2	we	O
3	show	O
4	that	O
5	IIIa	O
6	pre	O
7	-	O
8	mRNA	O
9	splicing	O
10	is	O
11	activated	O
12	more	O
13	than	O
14	200	O
15	-	O
16	fold	O
17	in	O
18	nuclear	O
19	extracts	O
20	prepared	O
21	from	O
22	late	O
23	adenovirus	O
24	-	O
25	infected	O
26	cells	O
27	(	O
28	Ad	O
29	-	O
30	NE	O
31	)	O
32	compared	O
33	to	O
34	uninfected	O
35	HeLa	O
36	cell	O
37	nuclear	O
38	extracts	O
39	(	O
40	HeLa	O
41	-	O
42	NE	O
43	).	O
1	D	B
2	-	I
3	cyclin	I
4	-	O
5	cdk	B
6	activity	O
7	is	O
8	required	O
9	for	O
10	Rb	B
11	phosphorylation	O
12	in	O
13	v	B
14	-	I
15	Jun	I
16	-	O
17	transformed	O
18	cells	O
19	,	O
20	since	O
21	ectopic	O
22	expression	O
23	of	O
24	the	O
25	cdk4	B
26	-	O
27	and	O
28	cdk6	B
29	-	O
30	specific	O
31	inhibitor	O
32	p16	B
33	(	O
34	INK4A	B
35	)	O
36	inhibits	O
37	both	O
38	DNA	O
39	synthesis	O
40	and	O
41	cell	O
42	proliferation	O
43	.	O
1	These	O
2	data	O
3	indicate	O
4	that	O
5	expansion	O
6	of	O
7	the	O
8	dodecamer	O
9	repeat	O
10	located	O
11	in	O
12	the	O
13	proximal	O
14	promoter	O
15	of	O
16	CSTB	B
17	severely	O
18	disrupts	O
19	the	O
20	function	O
21	of	O
22	the	O
23	promoter	O
24	and	O
25	thereby	O
26	reduces	O
27	transcription	O
28	of	O
29	CSTB	B
30	.	O
1	Analysis	O
2	of	O
3	the	O
4	5	O
5	'	O
6	end	O
7	of	O
8	the	O
9	mouse	B
10	Elavl1	I
11	(	O
12	mHuA	B
13	)	O
14	gene	O
15	reveals	O
16	a	O
17	transcriptional	O
18	regulatory	O
19	element	O
20	and	O
21	evidence	O
22	for	O
23	conserved	O
24	genomic	O
25	organization	O
26	.	O
27	mHuA	B
28	(	O
29	Elavl1	B
30	)	O
31	belongs	O
32	to	O
33	a	O
34	highly	O
35	conserved	O
36	family	O
37	of	O
38	genes	O
39	encoding	O
40	RNA	O
41	-	O
42	binding	O
43	proteins	O
44	and	O
45	has	O
46	been	O
47	linked	O
48	to	O
49	cell	O
50	growth	O
51	and	O
52	proliferation	O
53	through	O
54	its	O
55	regulation	O
56	of	O
57	mRNA	O
58	stability	O
59	.	O
1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	revealed	O
6	that	O
7	Sp1	B
8	binds	O
9	to	O
10	two	O
11	different	O
12	regions	O
13	in	O
14	the	O
15	proximal	O
16	promoter	O
17	,	O
18	a	O
19	typical	O
20	Sp1	B
21	site	I
22	located	O
23	at	O
24	(-	O
25	38	O
26	;	O
27	-	O
28	33	O
29	)	O
30	and	O
31	a	O
32	G	O
33	/	O
34	C	O
35	-	O
36	rich	O
37	region	O
38	between	O
39	(-	O
40	67	O
41	;	O
42	-	O
43	62	O
44	).	O
1	Fgd3	B
2	and	O
3	FGD1	B
4	share	O
5	a	O
6	high	O
7	degree	O
8	of	O
9	sequence	O
10	identity	O
11	that	O
12	spans	O
13	>	O
14	560	O
15	contiguous	O
16	amino	O
17	acid	O
18	residues	O
19	.	O
1	Here	O
2	we	O
3	describe	O
4	the	O
5	cloning	O
6	,	O
7	tissue	O
8	-	O
9	specific	O
10	expression	O
11	pattern	O
12	,	O
13	and	O
14	functional	O
15	characterization	O
16	of	O
17	two	O
18	novel	O
19	TEF	B
20	-	I
21	1	I
22	isoforms	I
23	,	O
24	TEF	B
25	-	I
26	1beta	I
27	and	O
28	TEF	B
29	-	I
30	1gamma	I
31	.	O
1	Therefore	O
2	the	O
3	binding	O
4	sites	O
5	for	O
6	liver	O
7	-	O
8	enriched	O
9	factors	O
10	,	O
11	present	O
12	in	O
13	the	O
14	hamster	B
15	CYP7A1	I
16	proximal	I
17	promoter	I
18	in	O
19	close	O
20	vicinity	O
21	and	O
22	conserved	O
23	between	O
24	species	O
25	,	O
26	constitute	O
27	a	O
28	regulatory	O
29	unit	O
30	important	O
31	for	O
32	basal	O
33	hepatic	O
34	expression	O
35	and	O
36	tissue	O
37	restriction	O
38	of	O
39	the	O
40	action	O
41	of	O
42	hormones	O
43	such	O
44	as	O
45	insulin	B
46	.	O
1	Although	O
2	MAP	B
3	(	I
4	mitogen	I
5	-	I
6	activated	I
7	protein	I
8	)	I
9	kinases	I
10	are	O
11	implicated	O
12	in	O
13	cell	O
14	proliferation	O
15	and	O
16	differentiation	O
17	in	O
18	many	O
19	cell	O
20	types	O
21	,	O
22	the	O
23	role	O
24	of	O
25	MAP	B
26	kinases	I
27	in	O
28	cardiac	O
29	hypertrophy	O
30	remains	O
31	unclear	O
32	.	O
1	Patients	O
2	enrolled	O
3	in	O
4	the	O
5	Integrilin	O
6	to	O
7	Minimize	O
8	Platelet	O
9	Aggregation	O
10	and	O
11	Coronary	O
12	Thrombosis	O
13	-	O
14	II	O
15	(	O
16	IMPACT	O
17	-	O
18	II	O
19	)	O
20	trial	O
21	were	O
22	analyzed	O
23	.	O
1	To	O
2	investigate	O
3	the	O
4	molecular	O
5	mechanisms	O
6	of	O
7	this	O
8	Tax	B
9	-	O
10	mediated	O
11	inhibition	O
12	,	O
13	we	O
14	analyzed	O
15	its	O
16	effect	O
17	on	O
18	the	O
19	transcriptional	O
20	activity	O
21	of	O
22	the	O
23	myogenic	O
24	MyoD	B
25	protein	I
26	,	O
27	which	O
28	was	O
29	used	O
30	as	O
31	a	O
32	paradigm	O
33	of	O
34	bHLH	B
35	factors	I
36	.	O
1	Phosphorylation	O
2	and	O
3	spindle	O
4	pole	O
5	body	O
6	localization	O
7	of	O
8	the	O
9	Cdc15p	B
10	mitotic	I
11	regulatory	I
12	protein	I
13	kinase	I
14	in	I
15	budding	I
16	yeast	I
17	.	O
1	The	O
2	evolution	O
3	of	O
4	the	O
5	CCR5	B
6	cis	I
7	-	I
8	regulatory	I
9	region	I
10	versus	O
11	the	O
12	open	O
13	reading	O
14	frame	O
15	as	O
16	well	O
17	as	O
18	among	O
19	different	O
20	domains	O
21	of	O
22	the	O
23	open	O
24	reading	O
25	frame	O
26	differed	O
27	from	O
28	one	O
29	another	O
30	.	O
1	(	O
2	1998	O
3	)	O
4	J	O
5	.	O
1	Thus	O
2	,	O
3	growth	O
4	factor	O
5	activation	O
6	of	O
7	ER	B
8	can	O
9	mediate	O
10	transactivation	O
11	vs	O
12	ER	B
13	/	O
14	Sp1	B
15	binding	O
16	to	O
17	GC	O
18	-	O
19	rich	O
20	sites	O
21	and	O
22	represents	O
23	a	O
24	novel	O
25	pathway	O
26	for	O
27	ligand	O
28	-	O
29	independent	O
30	ER	B
31	action	O
32	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	transcription	O
6	of	O
7	c	B
8	-	I
9	IAP2	I
10	promoter	I
11	was	O
12	strongly	O
13	up	O
14	-	O
15	regulated	O
16	when	O
17	CD40	B
18	or	O
19	Epstein	B
20	-	I
21	Barr	I
22	virus	I
23	latent	I
24	membrane	I
25	protein	I
26	1	I
27	was	O
28	overexpressed	O
29	.	O
1	Recently	O
2	,	O
3	a	O
4	mutation	O
5	in	O
6	the	O
7	amino	O
8	-	O
9	terminus	O
10	of	O
11	IB1	B
12	was	O
13	associated	O
14	with	O
15	diabetes	O
16	.	O
1	CONCLUSION	O
2	:	O
3	More	O
4	than	O
5	50	O
6	%	O
7	of	O
8	patients	O
9	with	O
10	perennial	O
11	rhinitis	O
12	and	O
13	CRS	O
14	do	O
15	not	O
16	improve	O
17	after	O
18	surgery	O
19	,	O
20	a	O
21	response	O
22	that	O
23	may	O
24	be	O
25	predicted	O
26	by	O
27	more	O
28	cells	O
29	expressing	O
30	IL	B
31	-	I
32	5	I
33	mRNA	I
34	in	O
35	the	O
36	ethmoid	O
37	sinuses	O
38	.	O
1	The	O
2	second	O
3	functional	O
4	pair	O
5	of	O
6	CreA	B
7	sites	I
8	is	O
9	located	O
10	between	O
11	the	O
12	two	O
13	transcription	O
14	initiation	O
15	sites	O
16	.	O
1	The	O
2	complete	O
3	cDNA	O
4	sequence	O
5	of	O
6	human	B
7	betaV	I
8	spectrin	I
9	is	O
10	available	O
11	from	O
12	GenBank	O
13	(	O
14	TM	O
15	)	O
16	as	O
17	accession	O
18	number	O
19	.	O
1	Recombination	O
2	,	O
3	replication	O
4	,	O
5	repair	O
6	:	O
7	from	O
8	complexity	O
9	to	O
10	harmony	O
11	.	O
1	The	O
2	somatoform	O
3	conundrum	O
4	:	O
5	a	O
6	question	O
7	of	O
8	nosological	O
9	valves	O
10	.	O
1	The	O
2	CRE	O
3	,	O
4	5	O
5	'-	O
6	TGACGTCA	O
7	-	O
8	3	O
9	',	O
10	has	O
11	been	O
12	described	O
13	as	O
14	the	O
15	consensus	O
16	sequence	O
17	for	O
18	the	O
19	cis	O
20	-	O
21	element	O
22	that	O
23	directs	O
24	cAMP	O
25	-	O
26	regulated	O
27	gene	O
28	expression	O
29	.	O
1	A	O
2	cause	O
3	of	O
4	increase	O
5	of	O
6	alkaline	B
7	phosphatase	I
8	in	O
9	children	O
1	Retroviral	O
2	transduction	O
3	of	O
4	T	B
5	/	I
6	T	I
7	(	I
8	L	I
9	)	I
10	causes	O
11	a	O
12	rapidly	O
13	fatal	O
14	myeloproliferative	O
15	disease	O
16	in	O
17	a	O
18	murine	O
19	bone	O
20	marrow	O
21	transplant	O
22	(	O
23	BMT	O
24	)	O
25	model	O
26	,	O
27	whereas	O
28	T	B
29	/	I
30	T	I
31	(	I
32	F	I
33	)	I
34	causes	O
35	a	O
36	long	O
37	-	O
38	latency	O
39	,	O
40	pre	O
41	-	O
42	B	O
43	-	O
44	cell	O
45	lymphoblastic	O
46	lymphoma	O
47	.	O
1	Ab	O
2	-	O
3	MLV	O
4	strains	O
5	expressing	O
6	P70	B
7	/	O
8	S2	B
9	failed	O
10	to	O
11	transform	O
12	NIH	O
13	3T3	O
14	cells	O
15	and	O
16	demonstrated	O
17	a	O
18	greatly	O
19	reduced	O
20	capacity	O
21	to	O
22	mediate	O
23	signaling	O
24	events	O
25	associated	O
26	with	O
27	the	O
28	Ras	B
29	-	O
30	dependent	O
31	mitogen	B
32	-	I
33	activated	I
34	protein	I
35	(	I
36	MAP	I
37	)	I
38	kinase	I
39	pathway	O
40	.	O
1	Co	O
2	-	O
3	immunoprecipitation	O
4	and	O
5	DNA	O
6	affinity	O
7	chromatography	O
8	prove	O
9	that	O
10	Sp1	B
11	heterodimerizes	O
12	with	O
13	ZBP	B
14	-	I
15	89	I
16	when	O
17	bound	O
18	to	O
19	the	O
20	silencer	O
21	element	O
22	to	O
23	yield	O
24	a	O
25	DNA	O
26	-	O
27	protein	O
28	complex	O
29	whose	O
30	mobility	O
31	is	O
32	indistinguishable	O
33	from	O
34	that	O
35	displayed	O
36	by	O
37	HeLa	O
38	nuclear	O
39	extract	O
40	in	O
41	band	O
42	shift	O
43	assays	O
44	.	O
1	The	O
2	ZNF274	B
3	gene	I
4	is	O
5	mapped	O
6	distal	O
7	to	O
8	marker	O
9	RP	O
10	S28	O
11	1	O
12	in	O
13	the	O
14	human	O
15	chromosome	O
16	19qter	O
17	region	O
18	,	O
19	by	O
20	RH	O
21	mapping	O
22	.	O
1	Identification	O
2	of	O
3	a	O
4	novel	O
5	E2F3	B
6	product	I
7	suggests	O
8	a	O
9	mechanism	O
10	for	O
11	determining	O
12	specificity	O
13	of	O
14	repression	O
15	by	O
16	Rb	B
17	proteins	I
18	.	O
1	Overexpressing	O
2	the	O
3	coactivator	O
4	,	O
5	SRC1a	B
6	or	O
7	GRIP1	B
8	,	O
9	further	O
10	enhances	O
11	ERRalpha1	B
12	-	O
13	induced	O
14	transcriptional	O
15	activity	O
16	.	O
1	Estrogen	B
2	receptor	I
3	-	I
4	related	I
5	receptor	I
6	alpha	I
7	1	I
8	interacts	O
9	with	O
10	coactivator	O
11	and	O
12	constitutively	O
13	activates	O
14	the	O
15	estrogen	O
16	response	O
17	elements	O
18	of	O
19	the	O
20	human	B
21	lactoferrin	I
22	gene	I
23	.	O
1	We	O
2	examine	O
3	current	O
4	models	O
5	of	O
6	the	O
7	effects	O
8	of	O
9	aging	O
10	on	O
11	mean	O
12	response	O
13	time	O
14	and	O
15	show	O
16	how	O
17	they	O
18	might	O
19	be	O
20	reinterpreted	O
21	.	O
1	Comparison	O
2	of	O
3	sequences	O
4	from	O
5	-	O
6	215	O
7	to	O
8	+	O
9	1	O
10	bp	O
11	identified	O
12	consensus	O
13	binding	O
14	sites	O
15	for	O
16	the	O
17	homeodomain	B
18	transcription	I
19	factor	I
20	thyroid	I
21	transcription	I
22	factor	I
23	-	I
24	1	I
25	(	O
26	TTF	B
27	-	I
28	1	I
29	).	O
1	The	O
2	method	O
3	is	O
4	applied	O
5	to	O
6	determine	O
7	aberration	O
8	constants	O
9	of	O
10	a	O
11	CM300	O
12	FEG	O
13	/	O
14	UT	O
15	microscope	O
16	with	O
17	correction	O
18	of	O
19	the	O
20	three	O
21	-	O
22	fold	O
23	astigmatism	O
24	.	O
1	The	O
2	interaction	O
3	does	O
4	not	O
5	depend	O
6	on	O
7	the	O
8	presence	O
9	of	O
10	the	O
11	correct	O
12	amino	O
13	-	O
14	terminal	O
15	DNA	O
16	binding	O
17	domain	O
18	or	O
19	the	O
20	amino	O
21	acid	O
22	sequences	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	and	O
29	the	O
30	last	O
31	ten	O
32	amino	O
33	acids	O
34	.	O
1	Since	O
2	proteins	O
3	containing	O
4	TPR	O
5	elements	O
6	are	O
7	typically	O
8	involved	O
9	in	O
10	multiple	O
11	protein	O
12	-	O
13	protein	O
14	interactions	O
15	,	O
16	we	O
17	suggest	O
18	that	O
19	the	O
20	102kD	O
21	protein	O
22	interacts	O
23	within	O
24	the	O
25	tri	O
26	-	O
27	snRNP	O
28	with	O
29	both	O
30	the	O
31	U5	B
32	and	O
33	U4	B
34	/	O
35	U6	B
36	snRNPs	O
37	,	O
38	thus	O
39	bridging	O
40	the	O
41	two	O
42	particles	O
43	.	O
1	Regulation	O
2	of	O
3	mitochondrial	O
4	single	O
5	-	O
6	stranded	O
7	DNA	O
8	-	O
9	binding	O
10	protein	O
11	gene	O
12	expression	O
13	links	O
14	nuclear	O
15	and	O
16	mitochondrial	O
17	DNA	O
18	replication	O
19	in	O
20	drosophila	O
21	.	O
1	Genetic	O
2	and	O
3	molecular	O
4	complexity	O
5	of	O
6	the	O
7	position	O
8	effect	O
9	variegation	O
10	modifier	O
11	mod	B
12	(	O
13	mdg4	B
14	)	O
15	in	O
16	Drosophila	O
17	.	O
18	mod	B
19	(	O
20	mdg4	B
21	),	O
22	also	O
23	known	O
24	as	O
25	E	B
26	(	I
27	var	I
28	)	I
29	3	I
30	-	I
31	93D	I
32	,	O
33	is	O
34	involved	O
35	in	O
36	a	O
37	variety	O
38	of	O
39	processes	O
40	,	O
41	such	O
42	as	O
43	gene	O
44	silencing	O
45	in	O
46	position	O
47	effect	O
48	variegation	O
49	(	O
50	PEV	O
51	),	O
52	the	O
53	control	O
54	of	O
55	gypsy	B
56	insulator	I
57	sequences	I
58	,	O
59	regulation	O
60	of	O
61	homeotic	B
62	gene	I
63	expression	O
64	,	O
65	and	O
66	programmed	O
67	cell	O
68	death	O
69	.	O
1	M	O
2	.	O
1	Jkappa	B
2	DNA	I
3	-	I
4	binding	I
5	sites	I
6	were	O
7	not	O
8	required	O
9	for	O
10	this	O
11	activation	O
12	,	O
13	and	O
14	a	O
15	mutant	B
16	EBNA	I
17	-	I
18	3C	I
19	protein	I
20	unable	O
21	to	O
22	bind	O
23	Jkappa	B
24	activated	O
25	transcription	O
26	as	O
27	efficiently	O
28	as	O
29	wild	B
30	-	I
31	type	I
32	EBNA	I
33	-	I
34	3C	I
35	,	O
36	indicating	O
37	that	O
38	EBNA	B
39	-	I
40	3C	I
41	can	O
42	regulate	O
43	transcription	O
44	through	O
45	a	O
46	mechanism	O
47	that	O
48	is	O
49	independent	O
50	of	O
51	Jkappa	B
52	.	O
1	Vancomycin	O
2	data	O
3	were	O
4	analyzed	O
5	according	O
6	to	O
7	a	O
8	one	O
9	-	O
10	compartment	O
11	open	O
12	model	O
13	with	O
14	use	O
15	of	O
16	NONMEM	O
17	population	O
18	pharmacokinetic	O
19	software	O
20	.	O
1	Update	O
2	on	O
3	maternal	O
4	-	O
5	fetal	O
6	infections	O
7	by	O
8	hepatitis	O
9	C	O
10	,	O
11	HIV	O
12	and	O
13	cytomegalovirus	O
1	Mutational	O
2	analysis	O
3	of	O
4	mammalian	B
5	translation	I
6	initiation	I
7	factor	I
8	5	I
9	(	O
10	eIF5	B
11	):	O
12	role	O
13	of	O
14	interaction	O
15	between	O
16	the	O
17	beta	O
18	subunit	O
19	of	O
20	eIF2	B
21	and	O
22	eIF5	B
23	in	O
24	eIF5	B
25	function	O
26	in	O
27	vitro	O
28	and	O
29	in	O
30	vivo	O
31	.	O
1	In	O
2	contrast	O
3	,	O
4	mutations	O
5	affecting	O
6	the	O
7	other	O
8	two	O
9	Nim1p	B
10	-	I
11	related	I
12	kinases	I
13	in	O
14	S	O
15	.	O
16	cerevisiae	O
17	,	O
18	Hsl1p	B
19	and	O
20	Kcc4p	B
21	,	O
22	produce	O
23	no	O
24	detectable	O
25	effect	O
26	on	O
27	septin	B
28	organization	O
29	.	O
1	Among	O
2	non	O
3	-	O
4	cirrhotics	O
5	,	O
6	lack	O
7	of	O
8	portal	O
9	vein	O
10	visualisation	O
11	had	O
12	a	O
13	90	O
14	%	O
15	sensitivity	O
16	,	O
17	88	O
18	%	O
19	specificity	O
20	,	O
21	94	O
22	%	O
23	negative	O
24	predictive	O
25	value	O
26	,	O
27	and	O
28	83	O
29	%	O
30	positive	O
31	predictive	O
32	value	O
33	in	O
34	the	O
35	diagnosis	O
36	of	O
37	pre	O
38	-	O
39	sinusoidal	O
40	portal	O
41	hypertension	O
42	.	O
1	HFA	O
2	134a	O
3	had	O
4	a	O
5	greater	O
6	tendency	O
7	to	O
8	take	O
9	up	O
10	moisture	O
11	from	O
12	the	O
13	environment	O
14	than	O
15	did	O
16	HFA	O
17	227	O
18	.	O
1	These	O
2	natural	O
3	antisense	O
4	S	B
5	transcripts	I
6	co	O
7	-	O
8	exist	O
9	with	O
10	several	O
11	less	O
12	abundant	O
13	sense	O
14	S	B
15	transcripts	I
16	.	O
1	The	O
2	patients	O
3	who	O
4	presented	O
5	with	O
6	mucocutaneous	O
7	disease	O
8	also	O
9	had	O
10	low	O
11	CD4	B
12	+	I
13	T	O
14	lymphocyte	O
15	counts	O
16	,	O
17	and	O
18	most	O
19	of	O
20	them	O
21	had	O
22	AIDS	O
23	defining	O
24	illnesses	O
25	.	O
1	Double	O
2	-	O
3	blind	O
4	,	O
5	placebo	O
6	-	O
7	controlled	O
8	trial	O
9	.	O
1	Here	O
2	,	O
3	it	O
4	is	O
5	shown	O
6	that	O
7	TAFII250	B
8	,	O
9	the	O
10	largest	O
11	subunit	O
12	of	O
13	TFIID	B
14	,	O
15	contains	O
16	two	O
17	tandem	O
18	bromodomain	O
19	modules	O
20	that	O
21	bind	O
22	selectively	O
23	to	O
24	multiply	O
25	acetylated	O
26	histone	B
27	H4	I
28	peptides	I
29	.	O
1	Therefore	O
2	,	O
3	analogs	O
4	of	O
5	vitamin	O
6	D3	O
7	have	O
8	been	O
9	investigated	O
10	in	O
11	a	O
12	number	O
13	of	O
14	trials	O
15	showing	O
16	improvement	O
17	of	O
18	psoriasis	O
19	.	O
1	Iodine	O
2	deficiency	O
3	disorders	O
4	in	O
5	Bangladesh	O
6	.	O
1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	the	O
7	zinc	B
8	finger	I
9	protein	I
10	Gis1	I
11	acts	O
12	as	O
13	a	O
14	dosage	O
15	-	O
16	dependent	O
17	suppressor	O
18	of	O
19	the	O
20	rim15Delta	B
21	defect	O
22	in	O
23	nutrient	O
24	limitation	O
25	-	O
26	induced	O
27	transcriptional	O
28	derepression	O
29	of	O
30	SSA3	B
31	.	O
1	Consistent	O
2	with	O
3	our	O
4	model	O
5	,	O
6	CTCF	B
7	binding	O
8	is	O
9	abolished	O
10	by	O
11	DNA	O
12	methylation	O
13	.	O
1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	efficacy	O
7	and	O
8	safety	O
9	of	O
10	amphotericin	O
11	B	O
12	oral	O
13	suspension	O
14	(	O
15	ABOS	O
16	)	O
17	for	O
18	the	O
19	treatment	O
20	of	O
21	fluconazole	O
22	refractory	O
23	oral	O
24	candidiasis	O
25	in	O
26	persons	O
27	with	O
28	HIV	O
29	infection	O
30	.	O
1	Mucin	B
2	gene	I
3	expression	O
4	has	O
5	been	O
6	shown	O
7	to	O
8	be	O
9	altered	O
10	in	O
11	many	O
12	intestinal	O
13	diseases	O
14	and	O
15	especially	O
16	cancers	O
17	of	O
18	the	O
19	gastrointestinal	O
20	tract	O
21	.	O
1	The	O
2	experimentally	O
3	mapped	O
4	regions	O
5	of	O
6	RPB5	B
7	involved	O
8	in	O
9	these	O
10	interactions	O
11	correspond	O
12	to	O
13	distinct	O
14	and	O
15	surface	O
16	-	O
17	exposed	O
18	alpha	O
19	-	O
20	helical	O
21	structures	O
22	.	O
1	The	O
2	model	O
3	indicates	O
4	that	O
5	a	O
6	0	O
7	.	O
8	076	O
9	%	O
10	reduction	O
11	in	O
12	cigarette	O
13	consumption	O
14	is	O
15	associated	O
16	with	O
17	the	O
18	availability	O
19	of	O
20	nicotine	O
21	patches	O
22	after	O
23	1992	O
24	.	O
1	OBJECTIVE	O
2	:	O
3	This	O
4	study	O
5	was	O
6	conducted	O
7	to	O
8	assess	O
9	the	O
10	relative	O
11	roles	O
12	of	O
13	99mTc	O
14	-	O
15	sestamibi	O
16	scintimammography	O
17	and	O
18	sonography	O
19	in	O
20	the	O
21	evaluation	O
22	of	O
23	breast	O
24	lesions	O
25	that	O
26	are	O
27	indeterminate	O
28	or	O
29	suspicious	O
30	on	O
31	mammography	O
32	or	O
33	clinical	O
34	examination	O
35	.	O
1	Genomic	O
2	DNA	O
3	sequencing	O
4	in	O
5	the	O
6	vicinity	O
7	of	O
8	methylmalonyl	B
9	-	I
10	CoA	I
11	mutase	I
12	gene	I
13	(	O
14	mutAB	B
15	)	O
16	from	O
17	a	O
18	rifamycin	O
19	SV	O
20	-	O
21	producing	O
22	Amycolatopsis	O
23	mediterranei	O
24	U32	O
25	allowed	O
26	us	O
27	to	O
28	clone	O
29	,	O
30	sequence	O
31	,	O
32	and	O
33	identify	O
34	a	O
35	gene	O
36	encoding	O
37	a	O
38	novel	O
39	serine	B
40	/	I
41	threonine	I
42	protein	I
43	kinase	I
44	(	O
45	amk	B
46	).	O
1	In	O
2	contrast	O
3	,	O
4	H	B
5	-	I
6	NS	I
7	negative	O
8	regulation	O
9	operated	O
10	only	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	Fur	B
16	.	O
1	Karger	O
2	AG	O
3	,	O
4	Basel	O
1	Characterization	O
2	of	O
3	polymorphic	O
4	TNRs	O
5	in	O
6	novel	O
7	and	O
8	even	O
9	known	O
10	genes	O
11	expressed	O
12	in	O
13	human	O
14	spinal	O
15	cord	O
16	is	O
17	likely	O
18	to	O
19	help	O
20	in	O
21	the	O
22	identification	O
23	of	O
24	new	O
25	candidates	O
26	for	O
27	genes	O
28	involved	O
29	in	O
30	neurodegenerative	O
31	disorders	O
32	.	O
1	Improving	O
2	fissure	O
3	sealant	O
4	quality	O
5	:	O
6	mechanical	O
7	preparation	O
8	and	O
9	filling	O
10	level	O
11	.	O
1	The	O
2	Menopause	O
3	-	O
4	Rating	O
5	-	O
6	Scale	O
7	(	O
8	MRS	O
9	I	O
10	)	O
11	was	O
12	used	O
13	in	O
14	clinical	O
15	practice	O
16	since	O
17	1992	O
18	.	O
1	In	O
2	addition	O
3	,	O
4	the	O
5	mouse	O
6	ortholog	O
7	(	O
8	Mharp	B
9	/	O
10	Smarcal1	B
11	)	O
12	was	O
13	cloned	O
14	,	O
15	and	O
16	the	O
17	Caenorhabditis	O
18	elegans	O
19	ortholog	O
20	(	O
21	CEHARP	B
22	)	O
23	was	O
24	identified	O
25	in	O
26	the	O
27	GenBank	O
28	database	O
29	.	O
1	The	O
2	presence	O
3	of	O
4	such	O
5	a	O
6	putative	O
7	RNA	O
8	-	O
9	binding	O
10	domain	O
11	suggests	O
12	a	O
13	mechanism	O
14	for	O
15	the	O
16	observed	O
17	autoregulation	O
18	of	O
19	bacteriophage	O
20	T4	B
21	DNA	I
22	polymerase	I
23	synthesis	O
24	by	O
25	binding	O
26	to	O
27	its	O
28	own	O
29	mRNA	O
30	.	O
1	In	O
2	reconstitution	O
3	experiments	O
4	,	O
5	we	O
6	first	O
7	showed	O
8	that	O
9	expression	O
10	in	O
11	the	O
12	RAW	O
13	264	O
14	.	O
15	7	O
16	cell	O
17	line	O
18	of	O
19	C	B
20	-	I
21	terminal	I
22	Src	I
23	kinase	I
24	(	O
25	Csk	B
26	)	O
27	inhibited	O
28	and	O
29	that	O
30	of	O
31	a	O
32	membrane	O
33	-	O
34	anchored	O
35	,	O
36	gain	O
37	-	O
38	of	O
39	-	O
40	function	O
41	Csk	B
42	abolished	O
43	the	O
44	Fc	B
45	gamma	I
46	R	I
47	-	O
48	mediated	O
49	signaling	O
50	that	O
51	leads	O
52	to	O
53	phagocytosis	O
54	in	O
55	a	O
56	kinase	O
57	-	O
58	dependent	O
59	manner	O
60	.	O
1	We	O
2	also	O
3	found	O
4	that	O
5	environmental	O
6	conditions	O
7	for	O
8	meiosis	O
9	finely	O
10	regulate	O
11	the	O
12	transcript	O
13	levels	O
14	of	O
15	KIN28	B
16	and	O
17	CCL1	B
18	,	O
19	such	O
20	that	O
21	nitrogen	O
22	starvation	O
23	first	O
24	elevates	O
25	them	O
26	but	O
27	subsequent	O
28	alkalization	O
29	of	O
30	medium	O
31	decreases	O
32	them	O
33	.	O
1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	N	O
6	-	O
7	glycans	O
8	flanking	O
9	the	O
10	receptor	O
11	-	O
12	binding	O
13	site	O
14	of	O
15	the	O
16	HA	B
17	molecule	I
18	are	O
19	potent	O
20	regulators	O
21	of	O
22	influenza	O
23	virus	O
24	growth	O
25	,	O
26	with	O
27	the	O
28	glycan	O
29	at	O
30	Asn149	O
31	being	O
32	dominant	O
33	and	O
34	that	O
35	at	O
36	Asn123	O
37	being	O
38	less	O
39	effective	O
40	.	O
1	In	O
2	the	O
3	premating	O
4	period	O
5	male	O
6	rate	O
7	of	O
8	aggression	O
9	was	O
10	not	O
11	significantly	O
12	correlated	O
13	with	O
14	testosterone	O
15	level	O
16	.	O
1	G	O
2	.,	O
3	and	O
4	Hyde	O
5	,	O
6	C	O
7	.	O
1	The	O
2	ATR	O
3	-	O
4	X	O
5	syndrome	O
6	results	O
7	from	O
8	mutations	O
9	of	O
10	the	O
11	XH2	B
12	gene	I
13	,	O
14	located	O
15	on	O
16	the	O
17	X	O
18	chromosome	O
19	(	O
20	Xq13	O
21	.	O
22	3	O
23	)	O
24	and	O
25	coding	O
26	for	O
27	a	O
28	transacting	O
29	factor	O
30	which	O
31	regulates	O
32	gene	O
33	expression	O
34	.	O
1	A	O
2	murine	O
3	expressed	O
4	sequence	O
5	tag	O
6	(	O
7	EST	O
8	)	O
9	showing	O
10	homology	O
11	with	O
12	erythropoietin	B
13	receptor	I
14	(	O
15	EPOR	B
16	)	O
17	was	O
18	identified	O
19	in	O
20	the	O
21	EST	O
22	database	O
23	.	O
1	When	O
2	the	O
3	LCx	O
4	was	O
5	partially	O
6	occluded	O
7	,	O
8	mild	O
9	PM	O
10	-	O
11	induced	O
12	tachycardia	O
13	resulted	O
14	in	O
15	decreased	O
16	AoP	O
17	(	O
18	P	O
19	=	O
20	0	O
21	.	O
22	045	O
23	)	O
24	as	O
25	well	O
26	as	O
27	in	O
28	decreased	O
29	SV	O
30	(	O
31	P	O
32	=	O
33	0	O
34	.	O
35	048	O
36	);	O
37	the	O
38	LVEDP	O
39	remained	O
40	high	O
41	(	O
42	P	O
43	=	O
44	0	O
45	.	O
46	002	O
47	).	O
1	With	O
2	the	O
3	human	B
4	Rhotekin	I
5	cDNA	I
6	as	O
7	a	O
8	probe	O
9	,	O
10	Northern	O
11	hybridization	O
12	revealed	O
13	that	O
14	a	O
15	4	O
16	.	O
17	0	O
18	-	O
19	kb	O
20	transcript	O
21	was	O
22	expressed	O
23	at	O
24	a	O
25	high	O
26	level	O
27	in	O
28	prostate	O
29	and	O
30	at	O
31	a	O
32	middle	O
33	level	O
34	in	O
35	13	O
36	of	O
37	16	O
38	tissues	O
39	examined	O
40	,	O
41	but	O
42	it	O
43	cannot	O
44	be	O
45	detected	O
46	in	O
47	liver	O
48	and	O
49	lung	O
50	tissues	O
51	.	O
1	Testing	O
2	for	O
3	serum	B
4	IgM	I
5	binding	O
6	to	O
7	GM1	O
8	ganglioside	O
9	in	O
10	clinical	O
11	practice	O
12	.	O
1	Endonuclease	B
2	III	I
3	(	O
4	Nth	B
5	)	O
6	of	O
7	Escherichia	O
8	coli	O
9	is	O
10	a	O
11	DNA	B
12	glycosylase	I
13	essential	O
14	for	O
15	the	O
16	removal	O
17	of	O
18	oxidised	O
19	pyrimidine	O
20	base	O
21	residues	O
22	from	O
23	DNA	O
24	.	O
1	Furthermore	O
2	,	O
3	this	O
4	study	O
5	looks	O
6	at	O
7	the	O
8	impact	O
9	of	O
10	synthesis	O
11	conditions	O
12	on	O
13	block	O
14	length	O
15	and	O
16	crystallinity	O
17	,	O
18	and	O
19	the	O
20	impact	O
21	of	O
22	the	O
23	blocking	O
24	on	O
25	both	O
26	,	O
27	crystallinity	O
28	and	O
29	solubility	O
30	of	O
31	the	O
32	polymers	O
33	.	O
1	Both	O
2	the	O
3	MVBF	O
4	and	O
5	the	O
6	maximum	O
7	EMG	O
8	activity	O
9	in	O
10	the	O
11	right	O
12	masseter	O
13	and	O
14	the	O
15	left	O
16	anterior	O
17	temporalis	O
18	muscles	O
19	were	O
20	significantly	O
21	decreased	O
22	during	O
23	muscle	O
24	pain	O
25	when	O
26	the	O
27	subjects	O
28	bit	O
29	on	O
30	the	O
31	painful	O
32	side	O
33	.	O
1	The	O
2	detection	O
3	success	O
4	rate	O
5	was	O
6	determined	O
7	for	O
8	different	O
9	markers	O
10	using	O
11	this	O
12	MEK	B
13	.	O
1	ACE	B
2	-	I
3	2	I
4	has	O
5	a	O
6	hydrophobic	O
7	C	O
8	terminus	O
9	of	O
10	H	O
11	type	O
12	.	O
1	Members	O
2	of	O
3	the	O
4	titin	B
5	/	O
6	myosin	B
7	light	I
8	chain	I
9	kinase	I
10	family	O
11	play	O
12	an	O
13	essential	O
14	role	O
15	in	O
16	the	O
17	organization	O
18	of	O
19	the	O
20	actin	B
21	/	O
22	myosin	B
23	cytoskeleton	O
24	,	O
25	especially	O
26	in	O
27	sarcomere	O
28	assembly	O
29	and	O
30	function	O
31	.	O
1	Furthermore	O
2	,	O
3	a	O
4	pTyr317	B
5	Shc	I
6	phosphopeptide	I
7	selectively	O
8	recognized	O
9	Grb2	B
10	,	O
11	Sos1	B
12	,	O
13	SHIP	B
14	,	O
15	and	O
16	the	O
17	p85	B
18	subunit	I
19	of	O
20	phosphatidylinositol	B
21	3	I
22	'	I
23	kinase	I
24	from	O
25	mast	O
26	cells	O
27	,	O
28	as	O
29	characterized	O
30	by	O
31	mass	O
32	spectrometry	O
33	.	O
1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	mouse	B
6	cytosolic	I
7	chaperonin	I
8	subunit	I
9	gene	I
10	Ccta	I
11	/	I
12	t	I
13	-	I
14	complex	I
15	polypeptide	I
16	1	I
17	by	O
18	selenocysteine	B
19	tRNA	I
20	gene	I
21	transcription	I
22	activating	I
23	factor	I
24	family	I
25	zinc	I
26	finger	I
27	proteins	I
28	.	O
1	PARTICIPANTS	O
2	:	O
3	Convenience	O
4	sample	O
5	of	O
6	ambulatory	O
7	outpatients	O
8	with	O
9	hereditary	O
10	motor	O
11	and	O
12	sensory	O
13	neuropathy	O
14	,	O
15	type	O
16	I	O
17	(	O
18	n	O
19	=	O
20	9	O
21	),	O
22	myotonic	O
23	muscular	O
24	dystrophy	O
25	(	O
26	n	O
27	=	O
28	10	O
29	),	O
30	and	O
31	able	O
32	-	O
33	bodied	O
34	controls	O
35	(	O
36	n	O
37	=	O
38	11	O
39	).	O
1	Neither	O
2	is	O
3	it	O
4	a	O
5	major	O
6	cause	O
7	of	O
8	rehydration	O
9	-	O
10	induced	O
11	renal	O
12	Na	O
13	retention	O
14	.	O
1	Degenerate	O
2	primers	O
3	homologous	O
4	to	O
5	highly	O
6	conserved	O
7	regions	O
8	of	O
9	known	O
10	CYP3A	B
11	sequences	I
12	were	O
13	used	O
14	for	O
15	initial	O
16	RT	O
17	-	O
18	PCRs	O
19	.	O
1	In	O
2	a	O
3	gel	O
4	retardation	O
5	assay	O
6	using	O
7	HepG2	O
8	nuclear	O
9	extracts	O
10	,	O
11	the	O
12	5	O
13	'	O
14	flanking	O
15	sequence	O
16	from	O
17	-	O
18	74	O
19	to	O
20	-	O
21	46	O
22	showed	O
23	a	O
24	shifted	O
25	band	O
26	.	O
1	Since	O
2	the	O
3	RINX	B
4	gene	I
5	is	O
6	likely	O
7	an	O
8	ortholog	O
9	of	O
10	the	O
11	goldfish	B
12	Vsx1	I
13	gene	I
14	,	O
15	it	O
16	has	O
17	been	O
18	named	O
19	VSX1	B
20	by	O
21	the	O
22	Human	O
23	Gene	O
24	Nomenclature	O
25	Committee	O
26	.	O
1	The	O
2	present	O
3	study	O
4	was	O
5	designed	O
6	to	O
7	evaluate	O
8	the	O
9	sensitivity	O
10	and	O
11	specificity	O
12	of	O
13	AMP	O
14	CT	O
15	(	O
16	Gen	O
17	-	O
18	Probe	O
19	Incorporated	O
20	,	O
21	San	O
22	Diego	O
23	,	O
24	CA	O
25	,	O
26	USA	O
27	)	O
28	on	O
29	urogenital	O
30	specimens	O
31	taken	O
32	from	O
33	symptomatic	O
34	patients	O
35	and	O
36	on	O
37	first	O
38	void	O
39	urine	O
40	(	O
41	FVU	O
42	)	O
43	specimens	O
44	from	O
45	asymptomatic	O
46	patients	O
47	.	O
1	The	O
2	linear	O
3	plasmid	O
4	pCLU1	O
5	from	O
6	the	O
7	yeast	O
8	Kluyveromyces	O
9	lactis	O
10	normally	O
11	replicates	O
12	in	O
13	the	O
14	cytoplasm	O
15	,	O
16	with	O
17	the	O
18	aid	O
19	of	O
20	the	O
21	helper	O
22	linear	O
23	plasmid	O
24	pGKL2	O
25	,	O
26	using	O
27	terminal	B
28	protein	I
29	(	O
30	TP	B
31	)	O
32	as	O
33	a	O
34	primer	O
35	.	O
1	The	O
2	two	O
3	main	O
4	experimental	O
5	variables	O
6	were	O
7	the	O
8	attended	O
9	hemifield	O
10	(	O
11	left	O
12	or	O
13	right	O
14	)	O
15	and	O
16	the	O
17	proportion	O
18	of	O
19	trials	O
20	requiring	O
21	a	O
22	shift	O
23	within	O
24	that	O
25	hemifield	O
26	(	O
27	20	O
28	%	O
29	or	O
30	80	O
31	%).	O
1	Biochemical	O
2	examinations	O
3	of	O
4	calcium	O
5	-	O
6	phosphorus	O
7	metabolism	O
8	included	O
9	ions	O
10	and	O
11	PTH	B
12	concentrations	O
13	in	O
14	blood	O
15	serum	O
16	,	O
17	and	O
18	the	O
19	activity	O
20	of	O
21	bone	O
22	isoenzyme	O
23	of	O
24	AP	B
25	.	O
1	8	O
2	%	O
3	(	O
4	95	O
5	%	O
6	CI	O
7	,	O
8	21	O
9	.	O
10	3	O
11	-	O
12	44	O
13	.	O
14	3	O
15	%).	O
1	CONCLUSIONS	O
2	:	O
3	In	O
4	essential	O
5	hypertension	O
6	an	O
7	acute	O
8	protein	O
9	load	O
10	induces	O
11	a	O
12	decrease	O
13	in	O
14	GFR	O
15	that	O
16	may	O
17	normalize	O
18	under	O
19	antihypertensive	O
20	treatment	O
21	.	O
1	Twenty	O
2	eligible	O
3	patients	O
4	with	O
5	cirrhosis	O
6	were	O
7	randomized	O
8	into	O
9	two	O
10	groups	O
11	:	O
12	10	O
13	patients	O
14	treated	O
15	with	O
16	6	O
17	million	O
18	units	O
19	of	O
20	natural	O
21	IFN	B
22	-	I
23	beta	I
24	twice	O
25	a	O
26	week	O
27	for	O
28	36	O
29	months	O
30	and	O
31	10	O
32	patients	O
33	without	O
34	IFN	B
35	therapy	O
36	.	O
1	Logistic	O
2	regression	O
3	analysis	O
4	revealed	O
5	that	O
6	physicians	O
7	were	O
8	3	O
9	.	O
10	6	O
11	times	O
12	more	O
13	likely	O
14	to	O
15	detect	O
16	thin	O
17	lesions	O
18	(</=	O
19	0	O
20	.	O
21	75	O
22	mm	O
23	)	O
24	compared	O
25	with	O
26	nonphysician	O
27	detectors	O
28	(	O
29	95	O
30	%	O
31	confidence	O
32	interval	O
33	[	O
34	95	O
35	%	O
36	CI	O
37	],	O
38	2	O
39	.	O
40	1	O
41	,	O
42	6	O
43	.	O
44	5	O
45	;	O
46	P	O
47	=	O
48	0	O
49	.	O
50	0001	O
51	).	O
1	Measurements	O
2	were	O
3	compared	O
4	with	O
5	two	O
6	computerised	O
7	treatment	O
8	planning	O
9	systems	O
10	--	O
11	Theraplan	O
12	VO5B	O
13	and	O
14	ADAC	O
15	Pinnacle3	O
16	V4	O
17	.	O
18	0b	O
19	.	O
1	Mutations	O
2	in	O
3	the	O
4	RP2	B
5	locus	I
6	at	I
7	Xp11	I
8	.	I
9	3	I
10	were	O
11	found	O
12	in	O
13	a	O
14	further	O
15	10	O
16	-	O
17	20	O
18	%	O
19	of	O
20	XLRP	O
21	patients	O
22	,	O
23	as	O
24	predicted	O
25	from	O
26	linkage	O
27	studies	O
28	.	O
1	The	O
2	limit	O
3	between	O
4	the	O
5	cecum	O
6	and	O
7	the	O
8	ascending	O
9	colon	O
10	was	O
11	externally	O
12	marked	O
13	by	O
14	the	O
15	sulcus	O
16	cecocolicus	O
17	dorsalis	O
18	and	O
19	ventralis	O
20	.	O
1	Despite	O
2	these	O
3	limitations	O
4	the	O
5	CHIME	O
6	monitor	O
7	provides	O
8	an	O
9	opportunity	O
10	to	O
11	record	O
12	physiological	O
13	data	O
14	previously	O
15	unavailable	O
16	in	O
17	the	O
18	home	O
19	.	O
1	(	O
2	iii	O
3	)	O
4	In	O
5	these	O
6	cells	O
7	,	O
8	PKCbeta	B
9	plays	O
10	a	O
11	unique	O
12	Ras	B
13	-	O
14	independent	O
15	role	O
16	in	O
17	mediating	O
18	insulin	B
19	but	O
20	not	O
21	EGF	B
22	or	O
23	other	O
24	growth	O
25	factor	O
26	mitogenic	O
27	signals	O
28	.	O
1	Sequence	O
2	analysis	O
3	reveals	O
4	that	O
5	the	O
6	newly	O
7	discovered	O
8	oasA2	B
9	gene	I
10	represents	O
11	a	O
12	pseudogene	O
13	that	O
14	is	O
15	still	O
16	transcribed	O
17	,	O
18	but	O
19	is	O
20	not	O
21	functionally	O
22	translated	O
23	.	O
1	Two	O
2	distinct	O
3	recessive	O
4	susceptibility	O
5	loci	O
6	for	O
7	vasculitis	O
8	were	O
9	mapped	O
10	on	O
11	chromosome	O
12	(	O
13	Chr	O
14	)	O
15	4	O
16	at	O
17	D4Mit89	B
18	and	O
19	D4Mit147	B
20	in	O
21	both	O
22	progenies	O
23	.	O
1	TNF	B
2	-	I
3	alpha	I
4	induced	O
5	a	O
6	dose	O
7	-	O
8	and	O
9	time	O
10	-	O
11	dependent	O
12	increase	O
13	in	O
14	cyclooxygenase	B
15	-	I
16	2	I
17	(	O
18	COX	B
19	-	I
20	2	I
21	)	O
22	expression	O
23	and	O
24	PGE2	O
25	formation	O
26	in	O
27	human	O
28	NCI	O
29	-	O
30	H292	O
31	epithelial	O
32	cells	O
33	.	O
1	Mis3	B
2	is	O
3	needed	O
4	for	O
5	the	O
6	formation	O
7	of	O
8	18S	B
9	ribosome	I
10	RNA	I
11	,	O
12	and	O
13	may	O
14	hence	O
15	direct	O
16	the	O
17	level	O
18	of	O
19	proteins	O
20	required	O
21	for	O
22	the	O
23	coupling	O
24	.	O
1	Mobilization	O
2	with	O
3	cyclophosphamide	O
4	and	O
5	granulocyte	B
6	-	I
7	colony	I
8	stimulating	I
9	factor	I
10	was	O
11	effective	O
12	in	O
13	terms	O
14	of	O
15	CD34	B
16	+	I
17	cell	O
18	shift	O
19	to	O
20	peripheral	O
21	blood	O
22	and	O
23	the	O
24	good	O
25	quality	O
26	autograft	O
27	reliably	O
28	led	O
29	to	O
30	haematopoetic	O
31	recovery	O
32	after	O
33	megachemotherapy	O
34	.	O
1	A	O
2	2	O
3	.	O
4	3	O
5	-	O
6	kb	O
7	full	O
8	-	O
9	length	O
10	cDNA	O
11	clone	O
12	of	O
13	an	O
14	Atlantic	B
15	halibut	I
16	Mx	I
17	gene	I
18	was	O
19	isolated	O
20	from	O
21	a	O
22	liver	O
23	cDNA	O
24	library	O
25	.	O
1	PLUS	O
2	-	O
3	3	O
4	is	O
5	a	O
6	new	O
7	Swedish	O
8	protocol	O
9	of	O
10	natural	O
11	speech	O
12	in	O
13	3	O
14	-	O
15	year	O
16	-	O
17	old	O
18	children	O
19	.	O
1	Multiparity	O
2	had	O
3	a	O
4	protective	O
5	effect	O
6	with	O
7	0	O
8	.	O
9	66	O
10	less	O
11	risk	O
12	(	O
13	95	O
14	%	O
15	CI	O
16	0	O
17	.	O
18	44	O
19	-	O
20	0	O
21	.	O
22	99	O
23	).	O
1	On	O
2	long	O
3	-	O
4	term	O
5	follow	O
6	-	O
7	up	O
8	,	O
9	there	O
10	was	O
11	no	O
12	significant	O
13	difference	O
14	in	O
15	the	O
16	incidence	O
17	of	O
18	hospitalizations	O
19	(	O
20	1	O
21	per	O
22	2	O
23	.	O
24	1	O
25	vs	O
26	.	O
1	Linking	O
2	continuous	O
3	community	O
4	-	O
5	based	O
6	morbidity	O
7	recording	O
8	of	O
9	influenza	O
10	-	O
11	like	O
12	illness	O
13	(	O
14	ILI	O
15	)	O
16	with	O
17	virological	O
18	sampling	O
19	has	O
20	consistently	O
21	proved	O
22	its	O
23	value	O
24	as	O
25	one	O
26	of	O
27	the	O
28	earliest	O
29	indicators	O
30	of	O
31	circulating	O
32	influenza	O
33	activity	O
34	.	O
1	The	O
2	article	O
3	deals	O
4	with	O
5	the	O
6	diagnosing	O
7	and	O
8	correction	O
9	of	O
10	reversible	O
11	ischemia	O
12	of	O
13	the	O
14	intestine	O
15	.	O
1	The	O
2	amino	O
3	acid	O
4	sequence	O
5	of	O
6	matrilysin	B
7	-	I
8	2	I
9	also	O
10	contains	O
11	a	O
12	threonine	O
13	residue	O
14	adjacent	O
15	to	O
16	the	O
17	Zn	O
18	-	O
19	binding	O
20	site	O
21	that	O
22	has	O
23	been	O
24	defined	O
25	as	O
26	a	O
27	specific	O
28	feature	O
29	of	O
30	matrilysin	B
31	.	O
1	Coexisting	O
2	vertical	O
3	and	O
4	horizontal	O
5	one	O
6	and	O
7	a	O
8	half	O
9	syndromes	O
10	.	O
1	As	O
2	in	O
3	the	O
4	other	O
5	three	O
6	members	O
7	whose	O
8	gene	O
9	expression	O
10	is	O
11	altered	O
12	during	O
13	tumorigenesis	O
14	,	O
15	PI12	B
16	expression	O
17	was	O
18	found	O
19	to	O
20	be	O
21	down	O
22	-	O
23	regulated	O
24	in	O
25	tumor	O
26	brain	O
27	tissues	O
28	and	O
29	in	O
30	two	O
31	brain	O
32	cancer	O
33	cell	O
34	lines	O
35	:	O
36	U	O
37	-	O
38	87	O
39	MG	O
40	and	O
41	H4	O
42	.	O
1	Northern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	that	O
6	the	O
7	STORP	B
8	gene	I
9	has	O
10	a	O
11	ubiquitous	O
12	pattern	O
13	of	O
14	expression	O
15	similar	O
16	to	O
17	that	O
18	of	O
19	the	O
20	PML	B
21	gene	I
22	.	O
1	In	O
2	the	O
3	TLE	O
4	patients	O
5	the	O
6	NAA	O
7	:	O
8	Cr	O
9	ratios	O
10	were	O
11	reduced	O
12	in	O
13	the	O
14	seizure	O
15	focus	O
16	,	O
17	while	O
18	in	O
19	the	O
20	FLE	O
21	patients	O
22	they	O
23	were	O
24	not	O
25	always	O
26	reduced	O
27	in	O
28	the	O
29	seizure	O
30	focus	O
31	.	O
1	We	O
2	found	O
3	that	O
4	the	O
5	amplitude	O
6	of	O
7	the	O
8	cortical	O
9	evoked	O
10	potentials	O
11	(	O
12	amplitude	O
13	of	O
14	the	O
15	N2	O
16	/	O
17	P2	O
18	peak	O
19	)	O
20	increased	O
21	from	O
22	5	O
23	.	O
24	1	O
25	+/-	O
26	0	O
27	.	O
28	7	O
29	microV	O
30	at	O
31	5	O
32	mA	O
33	to	O
34	16	O
35	.	O
36	3	O
37	+/-	O
38	1	O
39	.	O
40	1	O
41	microV	O
42	at	O
43	20	O
44	mA	O
45	.	O
1	Studying	O
2	intracellular	O
3	signaling	O
4	pathways	O
5	,	O
6	which	O
7	may	O
8	be	O
9	involved	O
10	in	O
11	malignant	O
12	transformation	O
13	of	O
14	Ret	B
15	-	I
16	9bp	I
17	expressing	O
18	NIH3T3	O
19	cells	O
20	,	O
21	we	O
22	could	O
23	demonstrate	O
24	Ret	B
25	-	I
26	9bp	I
27	dependent	O
28	phosphorylation	O
29	of	O
30	insulin	B
31	receptor	I
32	substrate	I
33	-	I
34	2	I
35	(	O
36	IRS	B
37	-	I
38	2	I
39	)	O
40	with	O
41	consecutive	O
42	activation	O
43	of	O
44	phosphatidylinositol	B
45	3	I
46	-	I
47	kinase	I
48	(	O
49	PI	B
50	3	I
51	-	I
52	kinase	I
53	)	O
54	and	O
55	protein	B
56	kinase	I
57	B	I
58	(	O
59	PKB	B
60	/	O
61	AKT	B
62	).	O
1	Phylogenetic	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	ToLCV	O
7	isolates	O
8	from	O
9	Bangalore	O
10	constitute	O
11	a	O
12	group	O
13	of	O
14	viruses	O
15	separated	O
16	from	O
17	those	O
18	of	O
19	Northern	O
20	India	O
21	.	O
1	These	O
2	results	O
3	suggest	O
4	that	O
5	Cdc42p	B
6	is	O
7	in	O
8	fact	O
9	required	O
10	for	O
11	pheromone	O
12	response	O
13	and	O
14	that	O
15	interaction	O
16	with	O
17	the	O
18	PAK	B
19	Ste20p	I
20	is	O
21	critical	O
22	for	O
23	that	O
24	role	O
25	.	O
1	Studies	O
2	suggest	O
3	that	O
4	the	O
5	DGOR	O
6	without	O
7	acid	O
8	reflux	O
9	may	O
10	result	O
11	in	O
12	symptoms	O
13	but	O
14	unless	O
15	acid	O
16	reflux	O
17	is	O
18	present	O
19	simultaneously	O
20	,	O
21	it	O
22	does	O
23	not	O
24	cause	O
25	oesophagitis	O
26	.	O
1	The	O
2	variable	O
3	phenotype	O
4	of	O
5	the	O
6	allotetraploids	O
7	could	O
8	not	O
9	be	O
10	explained	O
11	by	O
12	cytological	O
13	abnormalities	O
14	.	O
1	We	O
2	have	O
3	demonstrated	O
4	that	O
5	the	O
6	activity	O
7	of	O
8	ILK	B
9	is	O
10	constitutively	O
11	elevated	O
12	in	O
13	PTEN	B
14	mutant	I
15	cells	O
16	.	O
1	Primary	O
2	adrenal	O
3	hypersensitivity	O
4	to	O
5	ACTH	B
6	drive	O
7	in	O
8	obesity	O
9	has	O
10	also	O
11	been	O
12	suggested	O
13	.	O
1	In	O
2	addition	O
3	,	O
4	a	O
5	noncanonical	O
6	C	B
7	/	I
8	EBP	I
9	-	I
10	binding	I
11	site	I
12	within	O
13	the	O
14	Gadd45gamma	B
15	promoter	I
16	where	O
17	C	B
18	/	I
19	EBPbeta	I
20	and	O
21	C	B
22	/	I
23	EBPdelta	I
24	could	O
25	bind	O
26	,	O
27	was	O
28	identified	O
29	by	O
30	electrophoretic	O
31	mobility	O
32	shift	O
33	assay	O
34	(	O
35	EMSA	O
36	)	O
37	and	O
38	reporter	O
39	gene	O
40	analysis	O
41	.	O
1	Src	B
2	activation	O
3	induced	O
4	by	O
5	FGF1	B
6	was	O
7	blocked	O
8	by	O
9	the	O
10	SH2	B
11	domain	I
12	of	O
13	Src	B
14	and	O
15	PP2	B
16	,	O
17	a	O
18	specific	O
19	inhibitor	O
20	of	O
21	Src	B
22	.	O
1	We	O
2	could	O
3	demonstrate	O
4	the	O
5	involvement	O
6	of	O
7	cAMP	B
8	-	I
9	dependent	I
10	protein	I
11	kinase	I
12	(	O
13	PKA	B
14	)	O
15	in	O
16	the	O
17	phosphorylation	O
18	of	O
19	CDC25Mm	B
20	in	O
21	fibroblasts	O
22	overexpressing	O
23	this	O
24	RasGEF	B
25	as	O
26	well	O
27	as	O
28	in	O
29	mouse	O
30	brain	O
31	synaptosomal	O
32	membranes	O
33	.	O
1	L	O
2	/	O
3	H	O
4	>	O
5	0	O
6	.	O
7	61	O
8	(	O
9	chi	O
10	(	O
11	2	O
12	)=	O
13	10	O
14	.	O
15	8	O
16	;	O
17	P	O
18	:<	O
19	0	O
20	.	O
21	001	O
22	)	O
23	and	O
24	a	O
25	restrictive	O
26	filling	O
27	pattern	O
28	(	O
29	chi	O
30	(	O
31	2	O
32	)=	O
33	3	O
34	.	O
35	6	O
36	;	O
37	P	O
38	:<	O
39	0	O
40	.	O
41	05	O
42	)	O
43	were	O
44	independent	O
45	predictors	O
46	of	O
47	events	O
48	.	O
1	When	O
2	cotransfected	O
3	in	O
4	fibroblasts	O
5	with	O
6	a	O
7	C	B
8	/	I
9	EBP	I
10	alpha	I
11	expression	O
12	vector	O
13	,	O
14	reporter	O
15	gene	O
16	expression	O
17	increased	O
18	3	O
19	-	O
20	fold	O
21	only	O
22	in	O
23	the	O
24	wild	O
25	-	O
26	type	O
27	constructs	O
28	.	O
1	This	O
2	interaction	O
3	inhibits	O
4	the	O
5	histone	B
6	acetyltransferase	I
7	activity	O
8	of	O
9	p300	B
10	,	O
11	resulting	O
12	in	O
13	drastic	O
14	reduction	O
15	of	O
16	nucleosomal	O
17	histone	B
18	acetylation	O
19	and	O
20	alteration	O
21	of	O
22	chromatin	O
23	structure	O
24	.	O
1	Hyperactivation	O
2	of	O
3	Cdc2	B
4	in	O
5	fission	O
6	yeast	O
7	causes	O
8	cells	O
9	to	O
10	undergo	O
11	a	O
12	lethal	O
13	premature	O
14	mitosis	O
15	called	O
16	mitotic	O
17	catastrophe	O
18	.	O
1	While	O
2	Pt	B
3	;	I
4	cycH	I
5	;	I
6	1	I
7	and	O
8	Os	B
9	;	I
10	cycH	I
11	;	I
12	1	I
13	were	O
14	expressed	O
15	in	O
16	all	O
17	tissues	O
18	examined	O
19	,	O
20	the	O
21	transcripts	O
22	accumulated	O
23	abundantly	O
24	in	O
25	dividing	O
26	cells	O
27	.	O
1	The	O
2	major	O
3	neurological	O
4	manifestations	O
5	of	O
6	brain	O
7	injury	O
8	in	O
9	these	O
10	babies	O
11	are	O
12	spastic	O
13	motor	O
14	deficits	O
15	.	O
1	For	O
2	this	O
3	purpose	O
4	,	O
5	the	O
6	writhing	O
7	test	O
8	,	O
9	capsaicin	O
10	and	O
11	formalin	O
12	induced	O
13	-	O
14	pain	O
15	in	O
16	mice	O
17	were	O
18	used	O
19	.	O
1	Prominent	O
2	findings	O
3	were	O
4	chronic	O
5	pancreatitis	O
6	with	O
7	acinar	O
8	and	O
9	ductal	O
10	plugs	O
11	,	O
12	granulomatous	O
13	and	O
14	necrotizing	O
15	peripancreatic	O
16	steatitis	O
17	,	O
18	degenerative	O
19	myopathy	O
20	,	O
21	testicular	O
22	atrophy	O
23	,	O
24	candidiasis	O
25	and	O
26	bacterial	O
27	necrotizing	O
28	glossitis	O
29	.	O
1	METHODS	O
2	AND	O
3	RESULTS	O
4	:	O
5	Studies	O
6	were	O
7	undertaken	O
8	in	O
9	9	O
10	isolated	O
11	guinea	O
12	pig	O
13	hearts	O
14	,	O
15	which	O
16	demonstrated	O
17	reverse	O
18	use	O
19	-	O
20	dependent	O
21	prolongation	O
22	of	O
23	cardiac	O
24	repolarization	O
25	by	O
26	100	O
27	nmol	O
28	/	O
29	L	O
30	domperidone	O
31	.	O
1	The	O
2	N	O
3	-	O
4	terminal	O
5	small	O
6	segment	O
7	of	O
8	yeast	B
9	TAF145	I
10	(	O
11	yTAF145	B
12	)	O
13	binds	O
14	to	O
15	TBP	B
16	and	O
17	thereby	O
18	inhibits	O
19	TBP	B
20	function	O
21	.	O
1	CONCLUSIONS	O
2	:	O
3	LSCC	O
4	malformation	O
5	,	O
6	like	O
7	other	O
8	inner	O
9	ear	O
10	malformations	O
11	such	O
12	as	O
13	large	O
14	vestibular	O
15	aqueduct	O
16	and	O
17	X	O
18	-	O
19	linked	O
20	mixed	O
21	deafness	O
22	with	O
23	perilymph	O
24	gusher	O
25	,	O
26	can	O
27	be	O
28	associated	O
29	with	O
30	CHL	O
31	,	O
32	SNHL	O
33	,	O
34	or	O
35	normal	O
36	hearing	O
37	.	O
1	Furthermore	O
2	,	O
3	loss	O
4	of	O
5	methylation	O
6	also	O
7	greatly	O
8	reduced	O
9	the	O
10	association	O
11	of	O
12	another	O
13	yeast	O
14	B	O
15	-	O
16	type	O
17	subunit	O
18	,	O
19	Rts1p	B
20	.	O
1	Together	O
2	,	O
3	these	O
4	results	O
5	indicate	O
6	that	O
7	IL	B
8	-	I
9	1	I
10	beta	I
11	induces	O
12	VEGF	B
13	gene	I
14	expression	O
15	at	O
16	both	O
17	transcriptional	O
18	and	O
19	post	O
20	-	O
21	transcriptional	O
22	levels	O
23	,	O
24	and	O
25	IL	B
26	-	I
27	1	I
28	beta	I
29	evokes	O
30	p38	B
31	MAPK	O
32	and	O
33	JNK	B
34	signalings	O
35	,	O
36	which	O
37	in	O
38	turn	O
39	stimulate	O
40	the	O
41	transcription	O
42	of	O
43	the	O
44	VEGF	B
45	gene	I
46	through	O
47	Sp1	B
48	-	I
49	binding	I
50	sites	I
51	.	O
1	Lys	O
2	(	O
3	193	O
4	)	O
5	and	O
6	Arg	O
7	(	O
8	194	O
9	),	O
10	located	O
11	at	O
12	the	O
13	COOH	O
14	-	O
15	terminal	O
16	end	O
17	of	O
18	HD	B
19	,	O
20	are	O
21	essential	O
22	for	O
23	dimerization	O
24	.	O
1	The	O
2	present	O
3	study	O
4	shows	O
5	that	O
6	phosphatidylinositol	B
7	3	I
8	-	I
9	kinase	I
10	-	O
11	dependent	O
12	p38	B
13	kinase	I
14	activation	O
15	regulates	O
16	Akt	B
17	phosphorylation	O
18	and	O
19	activity	O
20	in	O
21	human	O
22	neutrophils	O
23	.	O
1	These	O
2	probable	O
3	border	O
4	sequences	O
5	are	O
6	closely	O
7	related	O
8	to	O
9	those	O
10	of	O
11	other	O
12	known	O
13	T	O
14	-	O
15	regions	O
16	and	O
17	define	O
18	a	O
19	second	O
20	T	O
21	-	O
22	region	O
23	of	O
24	pTiChry5	O
25	,	O
26	called	O
27	T	O
28	-	O
29	right	O
30	(	O
31	TR	O
32	),	O
33	that	O
34	confers	O
35	production	O
36	of	O
37	the	O
38	Amadoriopines	O
39	.	O
1	High	O
2	expression	O
3	of	O
4	the	O
5	peroxisome	B
6	proliferator	I
7	-	I
8	activated	I
9	receptor	I
10	alpha	I
11	(	O
12	PPARalpha	B
13	)	O
14	differentiates	O
15	brown	O
16	fat	O
17	from	O
18	white	O
19	,	O
20	and	O
21	is	O
22	related	O
23	to	O
24	its	O
25	high	O
26	capacity	O
27	of	O
28	lipid	O
29	oxidation	O
30	.	O
1	This	O
2	-	O
3	2485	O
4	/-	O
5	2458	O
6	element	O
7	bound	O
8	PPARalpha	B
9	and	O
10	PPARgamma	B
11	from	O
12	brown	O
13	fat	O
14	nuclei	O
15	.	O
1	RESULTS	O
2	:	O
3	Twenty	O
4	-	O
5	two	O
6	(	O
7	26	O
8	%)	O
9	patients	O
10	had	O
11	PHG	O
12	before	O
13	(	O
14	group	O
15	A	O
16	)	O
17	and	O
18	64	O
19	(	O
20	74	O
21	%)	O
22	developed	O
23	PHG	O
24	after	O
25	variceal	O
26	eradication	O
27	(	O
28	group	O
29	B	O
30	).	O
1	The	O
2	entire	O
3	human	B
4	teneurin	I
5	-	I
6	1	I
7	(	O
8	TEN1	B
9	)	O
10	gene	O
11	is	O
12	contained	O
13	in	O
14	eight	O
15	PAC	O
16	clones	O
17	representing	O
18	part	O
19	of	O
20	the	O
21	chromosomal	O
22	locus	O
23	Xq25	O
24	.	O
1	In	O
2	general	O
3	lookback	O
4	,	O
5	all	O
6	patients	O
7	who	O
8	received	O
9	blood	O
10	before	O
11	being	O
12	tested	O
13	for	O
14	hepatitis	O
15	C	O
16	are	O
17	advised	O
18	to	O
19	undergo	O
20	testing	O
21	.	O
1	The	O
2	proposed	O
3	algorithm	O
4	consists	O
5	of	O
6	several	O
7	steps	O
8	.	O
1	Tobramycin	O
2	-	O
3	loaded	O
4	SLN	O
5	administered	O
6	i	O
7	.	O
8	v	O
9	.	O
10	showed	O
11	a	O
12	prolonged	O
13	circulation	O
14	time	O
15	compared	O
16	to	O
17	the	O
18	i	O
19	.	O
20	v	O
21	.	O
22	administered	O
23	tobramycin	O
24	solution	O
25	.	O
1	Combined	O
2	intravenous	O
3	and	O
4	intra	O
5	-	O
6	arterial	O
7	recombinant	O
8	tissue	B
9	plasminogen	I
10	activator	I
11	in	O
12	acute	O
13	ischemic	O
14	stroke	O
15	.	O
1	CONCLUSIONS	O
2	:	O
3	EBCT	O
4	technology	O
5	allows	O
6	minimally	O
7	invasive	O
8	evaluation	O
9	of	O
10	intramyocardial	O
11	microcirculatory	O
12	function	O
13	and	O
14	permits	O
15	assessment	O
16	of	O
17	microvascular	O
18	BV	O
19	distribution	O
20	in	O
21	different	O
22	functional	O
23	components	O
24	.	O
1	These	O
2	two	O
3	mAbs	O
4	used	O
5	the	O
6	same	O
7	V	O
8	(	O
9	H	O
10	)	O
11	and	O
12	J	O
13	(	O
14	H	O
15	)	O
16	gene	O
17	segments	O
18	,	O
19	but	O
20	different	O
21	D	O
22	,	O
23	Vkappa	O
24	,	O
25	and	O
26	Jkappa	O
27	genes	O
28	.	O
1	SSF	O
2	experiments	O
3	were	O
4	carried	O
5	out	O
6	in	O
7	bench	O
8	-	O
9	scale	O
10	bioreactors	O
11	(	O
12	equipped	O
13	with	O
14	CO2	O
15	and	O
16	volatile	O
17	organic	O
18	traps	O
19	)	O
20	containing	O
21	a	O
22	mixture	O
23	of	O
24	lignocellulosic	O
25	materials	O
26	and	O
27	a	O
28	radiolabeled	O
29	pesticide	O
30	.	O
1	In	O
2	15	O
3	ventilator	O
4	-	O
5	dependent	O
6	,	O
7	SB	O
8	,	O
9	and	O
10	actively	O
11	expiring	O
12	patients	O
13	,	O
14	we	O
15	found	O
16	that	O
17	the	O
18	difference	O
19	PEEP	O
20	(	O
21	i	O
22	),	O
23	dyn	O
24	-	O
25	Pga	O
26	,	O
27	total	O
28	decay	O
29	(	O
30	mean	O
31	+/-	O
32	SD	O
33	,	O
34	5	O
35	.	O
36	7	O
37	+/-	O
38	1	O
39	.	O
40	9	O
41	cm	O
42	H	O
43	(	O
44	2	O
45	)	O
46	O	O
47	)	O
48	was	O
49	quite	O
50	similar	O
51	to	O
52	PEEP	O
53	(	O
54	i	O
55	),	O
56	dyn	O
57	ref	O
58	(	O
59	5	O
60	.	O
61	3	O
62	+/-	O
63	1	O
64	.	O
65	9	O
66	cm	O
67	H	O
68	(	O
69	2	O
70	)	O
71	O	O
72	).	O
1	Transcription	O
2	of	O
3	the	O
4	six	O
5	EBNA	B
6	genes	I
7	,	O
8	which	O
9	are	O
10	expressed	O
11	in	O
12	EBV	O
13	-	O
14	immortalized	O
15	primary	O
16	B	O
17	cells	O
18	,	O
19	arises	O
20	from	O
21	one	O
22	of	O
23	two	O
24	promoters	O
25	,	O
26	Cp	B
27	and	O
28	Wp	B
29	,	O
30	located	O
31	near	O
32	the	O
33	left	O
34	end	O
35	of	O
36	the	O
37	viral	O
38	genome	O
39	.	O
1	The	O
2	QT	O
3	interval	O
4	was	O
5	related	O
6	to	O
7	various	O
8	components	O
9	of	O
10	the	O
11	insulin	B
12	resistance	O
13	syndrome	O
14	,	O
15	including	O
16	BP	O
17	and	O
18	insulin	B
19	sensitivity	O
20	.	O
1	The	O
2	wavenumbers	O
3	corresponding	O
4	to	O
5	the	O
6	normal	O
7	modes	O
8	of	O
9	vibration	O
10	were	O
11	calculated	O
12	using	O
13	the	O
14	DFT	O
15	(	O
16	B3LYP	O
17	/	O
18	6	O
19	-	O
20	31G	O
21	**)	O
22	approximation	O
23	and	O
24	their	O
25	agreement	O
26	with	O
27	the	O
28	measured	O
29	values	O
30	improved	O
31	after	O
32	scaling	O
33	of	O
34	the	O
35	associated	O
36	force	O
37	field	O
38	.	O
1	The	O
2	data	O
3	provide	O
4	strong	O
5	evidence	O
6	that	O
7	ThlA	B
8	is	O
9	involved	O
10	in	O
11	the	O
12	metabolism	O
13	of	O
14	both	O
15	acid	O
16	and	O
17	solvent	O
18	formation	O
19	,	O
20	whereas	O
21	the	O
22	physiological	O
23	function	O
24	of	O
25	ThlB	B
26	has	O
27	yet	O
28	to	O
29	be	O
30	elucidated	O
31	.	O
1	Interestingly	O
2	,	O
3	this	O
4	mutant	O
5	cell	O
6	line	O
7	lacks	O
8	expression	O
9	of	O
10	the	O
11	IKK	B
12	regulatory	I
13	protein	I
14	,	O
15	IKKgamma	B
16	.	O
1	CONCLUSION	O
2	:	O
3	SPT	O
4	is	O
5	more	O
6	useful	O
7	than	O
8	WST	O
9	in	O
10	differentiating	O
11	patients	O
12	predisposed	O
13	to	O
14	aspiration	O
15	.	O
1	Studied	O
2	groups	O
3	were	O
4	(	O
5	1	O
6	)	O
7	untreated	O
8	control	O
9	,	O
10	n	O
11	=	O
12	12	O
13	;	O
14	(	O
15	2	O
16	)	O
17	FK	O
18	-	O
19	1	O
20	,	O
21	n	O
22	=	O
23	8	O
24	;	O
25	(	O
26	3	O
27	)	O
28	FK	O
29	-	O
30	3	O
31	,	O
32	n	O
33	=	O
34	8	O
35	.	O
1	Unexpectedly	O
2	,	O
3	ALK7	B
4	signaling	O
5	produced	O
6	a	O
7	remarkable	O
8	change	O
9	in	O
10	cell	O
11	morphology	O
12	characterized	O
13	by	O
14	cell	O
15	flattening	O
16	and	O
17	elaboration	O
18	of	O
19	blunt	O
20	,	O
21	short	O
22	cell	O
23	processes	O
24	.	O
1	The	O
2	swa2	B
3	-	I
4	1	I
5	allele	I
6	recovered	O
7	from	O
8	the	O
9	original	O
10	screen	O
11	carries	O
12	a	O
13	point	O
14	mutation	O
15	in	O
16	its	O
17	tetratricopeptide	O
18	repeat	O
19	(	O
20	TPR	O
21	)	O
22	domain	O
23	,	O
24	a	O
25	motif	O
26	not	O
27	found	O
28	in	O
29	auxilin	B
30	but	O
31	known	O
32	in	O
33	other	O
34	proteins	O
35	to	O
36	mediate	O
37	interaction	O
38	with	O
39	heat	B
40	-	I
41	shock	I
42	proteins	I
43	.	O
1	In	O
2	slightly	O
3	older	O
4	embryos	O
5	,	O
6	the	O
7	expression	O
8	was	O
9	skewed	O
10	to	O
11	one	O
12	side	O
13	of	O
14	the	O
15	embryo	O
16	and	O
17	by	O
18	E6	O
19	.	O
20	5	O
21	,	O
22	at	O
23	the	O
24	onset	O
25	of	O
26	gastrulation	O
27	,	O
28	expression	O
29	was	O
30	seen	O
31	in	O
32	the	O
33	epiblast	O
34	,	O
35	visceral	O
36	endoderm	O
37	,	O
38	nascent	O
39	mesoderm	O
40	,	O
41	and	O
42	the	O
43	primitive	O
44	streak	O
45	.	O
1	Transformation	O
2	of	O
3	the	O
4	sconC3	B
5	mutant	I
6	with	O
7	sconB	B
8	+	I
9	restores	O
10	the	O
11	wild	O
12	-	O
13	type	O
14	phenotype	O
15	.	O
1	A	O
2	thermal	O
3	Kubo	O
4	-	O
5	Martin	O
6	-	O
7	Schwinger	O
8	condition	O
9	arises	O
10	due	O
11	to	O
12	the	O
13	coupling	O
14	of	O
15	a	O
16	computer	O
17	to	O
18	a	O
19	strong	O
20	periodic	O
21	source	O
22	,	O
23	namely	O
24	,	O
25	the	O
26	daily	O
27	and	O
28	weekly	O
29	usage	O
30	patterns	O
31	of	O
32	the	O
33	system	O
34	.	O
1	RESULTS	O
2	:	O
3	The	O
4	main	O
5	effect	O
6	of	O
7	muscle	O
8	pain	O
9	,	O
10	compared	O
11	to	O
12	non	O
13	-	O
14	painful	O
15	stimulation	O
16	,	O
17	was	O
18	a	O
19	significant	O
20	and	O
21	long	O
22	-	O
23	lasting	O
24	increase	O
25	of	O
26	delta	O
27	(	O
28	1	O
29	-	O
30	3	O
31	Hz	O
32	)	O
33	power	O
34	and	O
35	an	O
36	alpha	O
37	-	O
38	1	O
39	(	O
40	9	O
41	-	O
42	11	O
43	Hz	O
44	)	O
45	power	O
46	increase	O
47	over	O
48	the	O
49	contralateral	O
50	parietal	O
51	locus	O
52	.	O
1	In	O
2	addition	O
3	,	O
4	our	O
5	results	O
6	show	O
7	that	O
8	ERKs	B
9	and	O
10	PI3Ks	B
11	can	O
12	synergise	O
13	to	O
14	convert	O
15	ectoderm	O
16	into	O
17	mesoderm	O
18	.	O
1	A	O
2	recently	O
3	reported	O
4	new	O
5	member	O
6	of	O
7	the	O
8	Vav	B
9	family	I
10	proteins	I
11	,	O
12	Vav3	B
13	has	O
14	been	O
15	identified	O
16	as	O
17	a	O
18	Ros	B
19	receptor	I
20	protein	I
21	tyrosine	I
22	kinase	I
23	(	O
24	RPTK	B
25	)	O
26	interacting	O
27	protein	O
28	by	O
29	yeast	O
30	two	O
31	-	O
32	hybrid	O
33	screening	O
34	.	O
1	Induced	O
2	expression	O
3	of	O
4	Rnd3	B
5	is	O
6	associated	O
7	with	O
8	transformation	O
9	of	O
10	polarized	O
11	epithelial	O
12	cells	O
13	by	O
14	the	O
15	Raf	B
16	-	O
17	MEK	B
18	-	O
19	extracellular	O
20	signal	O
21	-	O
22	regulated	O
23	kinase	O
24	pathway	O
25	.	O
1	When	O
2	10	O
3	fields	O
4	were	O
5	analysed	O
6	,	O
7	a	O
8	strong	O
9	relationship	O
10	was	O
11	found	O
12	between	O
13	the	O
14	presence	O
15	of	O
16	bacteria	O
17	on	O
18	Gram	O
19	staining	O
20	and	O
21	the	O
22	final	O
23	diagnosis	O
24	of	O
25	VAP	O
26	(	O
27	for	O
28	PSB	O
29	and	O
30	PTC	O
31	respectively	O
32	:	O
33	sensitivity	O
34	74	O
35	and	O
36	81	O
37	%,	O
38	specificity	O
39	94	O
40	and	O
41	100	O
42	%,	O
43	positive	O
44	predictive	O
45	value	O
46	91	O
47	and	O
48	100	O
49	%,	O
50	negative	O
51	predictive	O
52	value	O
53	82	O
54	and	O
55	88	O
56	%).	O
1	The	O
2	objectives	O
3	of	O
4	the	O
5	present	O
6	study	O
7	were	O
8	to	O
9	evaluate	O
10	the	O
11	effects	O
12	of	O
13	adding	O
14	Equex	O
15	to	O
16	a	O
17	TRIS	O
18	-	O
19	extender	O
20	,	O
21	diluting	O
22	the	O
23	semen	O
24	in	O
25	1	O
26	or	O
27	2	O
28	steps	O
29	,	O
30	freezing	O
31	according	O
32	to	O
33	2	O
34	methods	O
35	,	O
36	thawing	O
37	at	O
38	2	O
39	rates	O
40	,	O
41	and	O
42	the	O
43	interactions	O
44	between	O
45	these	O
46	treatments	O
47	,	O
48	on	O
49	the	O
50	post	O
51	-	O
52	thaw	O
53	survival	O
54	of	O
55	dog	O
56	spermatozoa	O
57	at	O
58	38	O
59	degrees	O
60	C	O
61	.	O
1	CONCLUSION	O
2	:	O
3	Our	O
4	results	O
5	suggest	O
6	that	O
7	AIF	O
8	peak	O
9	saturation	O
10	leads	O
11	to	O
12	a	O
13	significant	O
14	systematic	O
15	error	O
16	in	O
17	the	O
18	determination	O
19	of	O
20	CBV	O
21	and	O
22	CBF	O
23	values	O
24	and	O
25	has	O
26	necessarily	O
27	to	O
28	be	O
29	taken	O
30	into	O
31	account	O
32	for	O
33	dynamic	O
34	contrast	O
35	-	O
36	enhanced	O
37	MR	O
38	perfusion	O
39	studies	O
40	.	O
1	MS	O
2	characteristics	O
3	of	O
4	coumarins	O
5	,	O
6	psoralens	O
7	and	O
8	polymethoxylated	O
9	flavones	O
10	with	O
11	different	O
12	substitution	O
13	patterns	O
14	were	O
15	determined	O
16	on	O
17	the	O
18	basis	O
19	of	O
20	the	O
21	response	O
22	obtained	O
23	with	O
24	the	O
25	APcI	O
26	interface	O
27	.	O
1	Ketanserin	O
2	,	O
3	a	O
4	hypotensive	O
5	drug	O
6	with	O
7	5	B
8	-	I
9	HT2	I
10	receptor	I
11	antagonism	O
12	,	O
13	when	O
14	administered	O
15	by	O
16	topical	O
17	infusion	O
18	of	O
19	a	O
20	0	O
21	.	O
22	25	O
23	%	O
24	w	O
25	/	O
26	v	O
27	solution	O
28	by	O
29	corneal	O
30	and	O
31	scleral	O
32	applications	O
33	,	O
34	was	O
35	found	O
36	to	O
37	lower	O
38	intraocular	O
39	pressure	O
40	with	O
41	four	O
42	times	O
43	more	O
44	activity	O
45	than	O
46	its	O
47	metabolite	O
48	,	O
49	ketanserinol	O
50	.	O
1	A	O
2	prospectively	O
3	gated	O
4	2D	O
5	axial	O
6	sequence	O
7	with	O
8	velocity	O
9	encoding	O
10	in	O
11	the	O
12	craniocaudal	O
13	direction	O
14	in	O
15	the	O
16	cervical	O
17	region	O
18	was	O
19	set	O
20	at	O
21	a	O
22	velocity	O
23	of	O
24	+/-	O
25	10	O
26	cm	O
27	/	O
28	s	O
29	.	O
1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	determine	O
9	the	O
10	risk	O
11	factors	O
12	for	O
13	background	O
14	diabetic	O
15	retinopathy	O
16	(	O
17	BDR	O
18	)	O
19	and	O
20	PDR	O
21	by	O
22	following	O
23	394	O
24	Japanese	O
25	patients	O
26	with	O
27	early	O
28	-	O
29	onset	O
30	type	O
31	2	O
32	diabetes	O
33	diagnosed	O
34	before	O
35	30	O
36	years	O
37	of	O
38	age	O
39	(	O
40	mean	O
41	age	O
42	27	O
43	,	O
44	mean	O
45	blood	O
46	pressure	O
47	at	O
48	entry	O
49	116	O
50	/	O
51	73	O
52	mm	O
53	Hg	O
54	).	O
1	Previous	O
2	studies	O
3	have	O
4	shown	O
5	that	O
6	the	O
7	pro	O
8	-	O
9	inflammatory	O
10	cytokines	O
11	tumor	B
12	necrosis	I
13	factor	I
14	alpha	I
15	and	O
16	interferon	B
17	gamma	I
18	reduce	O
19	the	O
20	expression	O
21	of	O
22	the	O
23	cystic	B
24	fibrosis	I
25	transmembrane	I
26	conductance	I
27	regulator	I
28	(	O
29	CFTR	B
30	)	O
31	gene	O
32	(	O
33	CFTR	B
34	)	O
35	in	O
36	HT	O
37	-	O
38	29	O
39	and	O
40	T84	O
41	cells	O
42	by	O
43	acting	O
44	post	O
45	-	O
46	transcriptionally	O
47	.	O
1	Mouse	B
2	Impact	I
3	is	O
4	a	O
5	paternally	O
6	expressed	O
7	gene	O
8	encoding	O
9	an	O
10	evolutionarily	O
11	conserved	O
12	protein	O
13	of	O
14	unknown	O
15	function	O
16	.	O
1	Among	O
2	eight	O
3	graminaceous	O
4	species	O
5	tested	O
6	,	O
7	Ids3	B
8	expression	O
9	was	O
10	observed	O
11	only	O
12	in	O
13	Fe	O
14	-	O
15	deficient	O
16	roots	O
17	of	O
18	H	O
19	.	O
20	vulgare	O
21	and	O
22	Secale	O
23	cereale	O
24	.	O
25	which	O
26	not	O
27	only	O
28	secrete	O
29	2	O
30	'-	O
31	deoxymugineic	O
32	acid	O
33	(	O
34	DMA	O
35	),	O
36	but	O
37	also	O
38	mugineic	O
39	acid	O
40	(	O
41	MA	O
42	)	O
43	and	O
44	3	O
45	-	O
46	epihydroxymugineic	O
47	acid	O
48	(	O
49	epiHMA	O
50	,	O
51	H	O
52	.	O
53	vulgare	O
54	),	O
55	and	O
56	3	O
57	-	O
58	hydroxymugineic	O
59	acid	O
60	(	O
61	HMA	O
62	,	O
63	S	O
64	.	O
65	cereale	O
66	).	O
1	In	O
2	contrast	O
3	,	O
4	high	O
5	COUP	B
6	-	I
7	TFI	I
8	expression	O
9	impeded	O
10	the	O
11	neuronal	O
12	differentiation	O
13	of	O
14	P19	O
15	cells	O
16	induced	O
17	with	O
18	RA	O
19	,	O
20	resulting	O
21	in	O
22	cell	O
23	cultures	O
24	lacking	O
25	neurons	O
26	.	O
1	Because	O
2	PET	O
3	is	O
4	also	O
5	useful	O
6	for	O
7	the	O
8	pretreatment	O
9	and	O
10	follow	O
11	-	O
12	up	O
13	evaluation	O
14	,	O
15	the	O
16	use	O
17	of	O
18	stereotactic	O
19	PET	O
20	in	O
21	these	O
22	patients	O
23	can	O
24	enable	O
25	an	O
26	accurate	O
27	comparison	O
28	of	O
29	PET	O
30	-	O
31	based	O
32	metabolic	O
33	data	O
34	with	O
35	MR	O
36	-	O
37	based	O
38	anatomical	O
39	data	O
40	.	O
1	Adjuvant	O
2	therapy	O
3	for	O
4	colon	O
5	cancer	O
6	]	O
7	Surgery	O
8	alone	O
9	may	O
10	fail	O
11	to	O
12	cure	O
13	a	O
14	considerable	O
15	number	O
16	of	O
17	locally	O
18	advanced	O
19	colon	O
20	cancers	O
21	.	O
1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	and	O
12	compare	O
13	interleukin	B
14	-	I
15	6	I
16	(	O
17	IL	B
18	-	I
19	6	I
20	)	O
21	levels	O
22	in	O
23	gingival	O
24	crevicular	O
25	fluid	O
26	(	O
27	GCF	O
28	)	O
29	and	O
30	clinical	O
31	periodontal	O
32	findings	O
33	in	O
34	patients	O
35	with	O
36	rheumatoid	O
37	arthritis	O
38	(	O
39	RA	O
40	)	O
41	and	O
42	adult	O
43	periodontitis	O
44	(	O
45	AP	O
46	).	O
1	Because	O
2	the	O
3	number	O
4	of	O
5	parameters	O
6	required	O
7	by	O
8	a	O
9	Volterra	O
10	series	O
11	grows	O
12	rapidly	O
13	with	O
14	both	O
15	the	O
16	length	O
17	of	O
18	its	O
19	memory	O
20	and	O
21	the	O
22	order	O
23	of	O
24	its	O
25	nonlinearity	O
26	,	O
27	methods	O
28	for	O
29	identifying	O
30	these	O
31	models	O
32	from	O
33	measurements	O
34	of	O
35	input	O
36	/	O
37	output	O
38	data	O
39	are	O
40	limited	O
41	to	O
42	low	O
43	-	O
44	order	O
45	systems	O
46	with	O
47	relatively	O
48	short	O
49	memories	O
50	.	O
1	Additionally	O
2	,	O
3	MIP	B
4	-	I
5	2A	I
6	antagonizes	O
7	cell	O
8	growth	O
9	regulatory	O
10	role	O
11	of	O
12	MBP	B
13	-	I
14	1	I
15	.	O
1	In	O
2	addition	O
3	,	O
4	we	O
5	identified	O
6	two	O
7	mutations	O
8	,	O
9	Delta	O
10	M1281	O
11	and	O
12	IVS51	O
13	+	O
14	5G	O
15	-->	O
16	A	O
17	,	O
18	in	O
19	a	O
20	German	O
21	USH1	B
22	patient	O
23	.	O
1	Closeup	O
2	:	O
3	a	O
4	resource	O
5	for	O
6	nurses	O
7	who	O
8	smoke	O
9	.	O
1	A	O
2	marked	O
3	decrease	O
4	in	O
5	the	O
6	type	B
7	1	I
8	insulin	I
9	-	I
10	like	I
11	growth	I
12	factor	I
13	(	I
14	IGF	I
15	)	I
16	receptor	I
17	(	O
18	IGF	B
19	-	I
20	IR	I
21	)	O
22	occurs	O
23	in	O
24	prostate	O
25	epithelial	O
26	cells	O
27	during	O
28	transformation	O
29	from	O
30	the	O
31	benign	O
32	to	O
33	the	O
34	metastatic	O
35	state	O
36	.	O
1	Because	O
2	the	O
3	high	B
4	-	I
5	density	I
6	lipoprotein	I
7	receptor	I
8	(	O
9	HDL	B
10	-	I
11	R	I
12	)	O
13	is	O
14	a	O
15	key	O
16	element	O
17	in	O
18	cholesterol	O
19	homeostasis	O
20	and	O
21	a	O
22	potential	O
23	therapeutic	O
24	target	O
25	for	O
26	hypercholesterolemic	O
27	drugs	O
28	,	O
29	an	O
30	understanding	O
31	of	O
32	HDL	B
33	-	I
34	R	I
35	regulation	O
36	is	O
37	essential	O
38	.	O
1	IFN	B
2	-	I
3	stimulated	I
4	gene	I
5	factor	I
6	-	I
7	3	I
8	and	O
9	STAT1	B
10	homodimers	I
11	formed	O
12	and	O
13	bound	O
14	an	O
15	IFN	B
16	-	I
17	stimulated	I
18	response	I
19	element	I
20	(	O
21	ISRE	B
22	)	O
23	and	O
24	gamma	B
25	-	I
26	activated	I
27	sequence	I
28	(	O
29	GAS	B
30	)	O
31	element	O
32	,	O
33	respectively	O
34	.	O
1	To	O
2	understand	O
3	the	O
4	molecular	O
5	regulation	O
6	of	O
7	these	O
8	genes	O
9	in	O
10	thyroid	O
11	cells	O
12	,	O
13	the	O
14	effect	O
15	of	O
16	thyroid	B
17	transcription	I
18	factor	I
19	1	I
20	(	O
21	TTF	B
22	-	I
23	1	I
24	)	O
25	and	O
26	the	O
27	paired	B
28	domain	I
29	-	I
30	containing	I
31	protein	I
32	8	I
33	(	O
34	Pax	B
35	-	I
36	8	I
37	)	O
38	on	O
39	the	O
40	transcriptional	O
41	activity	O
42	of	O
43	the	O
44	deiodinase	B
45	promoters	I
46	were	O
47	studied	O
48	.	O
